data_2jnz_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2jnz _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.601 HG12 ' CE1' ' A' ' 34' ' ' TYR . 2.1 t . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -112.18 120.4 41.64 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.011 -1.056 . . . . 0.0 109.539 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.8 t -128.19 139.1 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.75 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.46 HG21 ' O ' ' A' ' 15' ' ' VAL . 70.7 p -141.52 145.62 35.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.225 -0.922 . . . . 0.0 109.697 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.567 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.9 m-85 -117.05 128.97 55.69 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.248 -0.907 . . . . 0.0 109.786 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 41.3 m -128.03 128.64 45.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.162 -0.961 . . . . 0.0 109.157 179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.524 ' CG1' HD13 ' A' ' 100' ' ' ILE . 21.3 t -76.18 139.44 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.357 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.16 157.23 21.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.117 -0.989 . . . . 0.0 109.72 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -51.3 114.39 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.444 -0.785 . . . . 0.0 109.977 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.16 -1.43 2.19 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.523 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.401 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.1 t -60.01 141.24 56.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.925 -1.338 . . . . 0.0 109.175 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.537 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -136.57 176.13 3.02 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.121 -0.987 . . . . 0.0 109.664 -179.639 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.529 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 51.6 Cg_endo -71.77 -30.56 14.19 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.606 2.204 . . . . 0.0 111.816 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.4 mttm -117.21 4.99 12.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -0.886 . . . . 0.0 109.091 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.471 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 41.6 mttt -142.17 133.43 26.28 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.52 HD11 ' CD1' ' A' ' 72' ' ' LEU . 0.3 OUTLIER -127.18 133.78 50.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.034 -1.042 . . . . 0.0 110.21 -179.445 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.518 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 2.8 t -122.99 124.84 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.518 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -141.16 141.31 34.13 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.034 -1.041 . . . . 0.0 110.041 -179.526 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.438 ' OD1' HG12 ' A' ' 63' ' ' VAL . 59.7 t0 -86.11 137.34 32.74 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.567 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.1 mt -122.23 131.14 73.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 120.865 -1.147 . . . . 0.0 110.523 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.515 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 66.2 mttm -110.54 120.29 41.94 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.601 ' CE1' HG12 ' A' ' 13' ' ' VAL . 77.5 t80 -122.49 114.19 20.35 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.415 -0.803 . . . . 0.0 109.541 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.9 m -116.99 117.96 31.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.784 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.52 ' CZ ' HG21 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -135.22 132.0 19.9 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.432 -0.793 . . . . 0.0 109.21 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.433 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 49.9 Cg_endo -70.2 105.89 1.64 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.67 2.246 . . . . 0.0 112.078 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.93 -2.12 87.02 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.471 ' HB3' ' HD2' ' A' ' 36' ' ' ARG . 1.7 m-20 -135.44 173.7 11.43 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.114 -1.227 . . . . 0.0 109.673 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.52 ' O ' ' HA ' ' A' ' 82' ' ' SER . 20.6 m -153.89 161.34 42.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.439 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.608 HD13 ' CE2' ' A' ' 80' ' ' PHE . 0.2 OUTLIER -71.5 132.98 45.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.588 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -114.47 -42.47 3.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.18 -0.95 . . . . 0.0 109.499 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.404 ' C ' HG23 ' A' ' 44' ' ' VAL . 47.0 mt-10 -142.84 151.24 40.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.065 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.546 HG11 ' CE1' ' A' ' 80' ' ' PHE . 65.1 t -139.86 137.6 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.1 mt-10 -126.22 148.73 49.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.784 -1.198 . . . . 0.0 109.432 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.607 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 9.6 tp -121.44 129.58 53.07 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.491 -0.756 . . . . 0.0 110.184 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.554 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 12.1 ttp180 -115.63 131.97 56.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.199 -0.938 . . . . 0.0 108.875 179.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -73.47 155.15 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.315 -0.865 . . . . 0.0 110.021 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.509 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.1 t60 -67.29 147.83 52.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.446 -0.783 . . . . 0.0 109.357 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.83 2.12 35.67 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 32.5 t -113.21 152.46 29.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -1.214 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -117.81 17.88 14.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -0.907 . . . . 0.0 109.316 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -116.39 104.35 11.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.554 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 45.8 m95 -66.59 134.72 52.92 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.338 -0.851 . . . . 0.0 109.673 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.467 ' HG2' ' HD2' ' A' ' 56' ' ' PRO . 0.9 OUTLIER -108.71 134.27 20.37 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.345 179.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.467 ' HD2' ' HG2' ' A' ' 55' ' ' GLU . 50.5 Cg_endo -70.45 144.51 50.53 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.625 2.217 . . . . 0.0 111.961 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.58 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.3 mp -103.88 148.36 26.23 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 108.823 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 63.0 m -97.5 125.78 42.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 108.947 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 12.9 tttm -70.93 111.64 6.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.236 -0.915 . . . . 0.0 109.269 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -109.77 105.54 14.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.054 -1.029 . . . . 0.0 109.461 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.79 -96.24 0.25 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -131.04 18.83 4.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.256 -1.144 . . . . 0.0 109.451 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.438 HG12 ' OD1' ' A' ' 31' ' ' ASP . 22.5 m -132.43 177.42 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.265 -0.897 . . . . 0.0 109.437 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.425 ' CD1' HD13 ' A' ' 32' ' ' ILE . 74.5 m95 -122.58 142.67 50.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 108.961 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -129.73 145.16 51.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.805 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.58 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 3.6 p -137.62 134.11 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.351 -0.843 . . . . 0.0 109.033 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -121.17 133.4 55.19 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.227 -0.92 . . . . 0.0 109.56 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.6 t -118.04 163.88 15.94 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.445 -0.784 . . . . 0.0 109.452 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 65.1 m -87.14 -5.96 58.82 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.191 -0.943 . . . . 0.0 109.152 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.56 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.9 OUTLIER -131.99 178.44 1.75 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.385 -0.822 . . . . 0.0 109.126 179.866 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.56 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -69.18 139.52 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.395 2.063 . . . . 0.0 111.577 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.578 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -75.38 141.19 43.31 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.25 -0.906 . . . . 0.0 109.935 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.411 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 42.9 t -123.86 124.92 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.465 -0.772 . . . . 0.0 109.155 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.67 170.18 30.67 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.607 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.8 Cg_endo -69.8 147.57 85.0 Favored 'Cis proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.836 -1.735 . . . . 0.0 111.833 0.037 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.7 m-85 -91.92 151.38 20.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.473 -0.767 . . . . 0.0 110.599 -179.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.513 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 34.9 m-80 -112.15 143.45 43.17 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.607 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 95.7 m-85 -136.33 130.76 33.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.947 -1.096 . . . . 0.0 109.972 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.521 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 51.3 ttp180 -110.31 141.49 43.25 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.058 -1.026 . . . . 0.0 108.627 179.023 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.608 ' CE2' HD13 ' A' ' 41' ' ' LEU . 5.8 m-85 -120.93 142.78 49.4 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 111.021 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.558 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -127.77 125.35 39.74 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.701 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.629 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.1 p -78.0 144.48 36.66 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 110.416 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.588 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 30.8 mttm -46.21 -43.79 15.63 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.14 -2.96 0.69 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.498 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.12 22.94 26.17 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.629 ' O ' ' N ' ' A' ' 82' ' ' SER . 1.6 mmm -96.34 146.45 24.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.123 -1.221 . . . . 0.0 108.604 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 42.8 mtm180 -124.36 141.35 52.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.826 -1.172 . . . . 0.0 110.535 -178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.432 ' N ' ' O ' ' A' ' 80' ' ' PHE . 24.2 m120 -136.48 140.91 43.41 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.521 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 7.0 t -121.49 135.95 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 110.354 -179.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.54 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 41.9 m-85 -124.59 122.53 37.81 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -99.55 148.94 23.76 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.202 -0.936 . . . . 0.0 109.753 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.607 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 10.5 mt-10 51.7 51.03 17.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.53 -0.731 . . . . 0.0 110.371 179.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.539 ' CG2' ' HB3' ' A' ' 106' ' ' PRO . 39.7 t -82.83 -33.54 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.911 -1.118 . . . . 0.0 109.255 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 9.1 mt -131.62 124.3 19.88 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.113 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.54 161.04 46.65 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.494 2.129 . . . . 0.0 111.916 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.7 m -53.54 -43.96 68.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.341 -0.849 . . . . 0.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.4 99.84 12.75 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.105 -0.997 . . . . 0.0 109.568 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.401 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 45.8 p90 -108.73 146.06 34.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.627 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 16.2 m -106.54 156.68 18.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.395 -0.816 . . . . 0.0 109.183 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.524 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.2 mm -92.21 136.39 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.134 -0.979 . . . . 0.0 109.441 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.04 2.2 62.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -115.56 143.04 45.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.174 -1.192 . . . . 0.0 109.097 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.45 HG21 ' HD2' ' A' ' 105' ' ' LYS . 6.0 m -79.7 169.66 17.65 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.068 -1.02 . . . . 0.0 108.995 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.54 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.7 m-85 -154.57 100.32 2.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.714 -1.241 . . . . 0.0 109.032 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.524 ' CD ' ' N ' ' A' ' 105' ' ' LYS . 0.5 OUTLIER -95.25 158.2 35.12 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.54 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 51.2 Cg_endo . . . . . 0 C--O 1.215 -0.666 0 C-N-CA 122.743 2.296 . . . . 0.0 111.808 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.556 HG12 ' CE1' ' A' ' 34' ' ' TYR . 16.6 t . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -110.1 120.77 43.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.363 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.576 HG21 ' CD1' ' A' ' 34' ' ' TYR . 3.4 t -127.94 138.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.346 -0.846 . . . . 0.0 109.632 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.474 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.0 p -141.53 145.83 35.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.25 -0.906 . . . . 0.0 109.418 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.61 ' CD2' HG12 ' A' ' 32' ' ' ILE . 15.0 m-85 -118.46 143.98 46.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.21 -0.931 . . . . 0.0 109.781 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 21.4 m -139.39 128.05 23.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 0.0 109.136 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.491 ' CG2' HD23 ' A' ' 30' ' ' LEU . 16.7 t -76.21 130.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -108.57 152.76 24.32 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.076 -1.015 . . . . 0.0 109.695 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -45.41 114.81 0.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.416 -0.802 . . . . 0.0 109.978 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.34 -2.92 1.84 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.834 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 34.9 m -63.71 141.09 58.89 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.703 -1.469 . . . . 0.0 109.277 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.64 175.49 3.55 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.128 -0.983 . . . . 0.0 109.593 -179.697 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.0 Cg_endo -71.54 -30.82 14.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.566 2.177 . . . . 0.0 111.845 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.2 mttp -117.33 4.78 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 0.0 109.053 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.405 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 35.4 mttp -142.27 133.64 26.42 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.505 HD22 ' CD1' ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.12 132.25 50.63 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.948 -1.095 . . . . 0.0 110.347 -179.253 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.496 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.8 t -121.91 125.41 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.505 ' CD1' HD22 ' A' ' 28' ' ' LEU . 1.4 mt -141.88 141.49 33.05 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.942 -1.099 . . . . 0.0 110.142 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -86.36 137.56 32.48 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.61 HG12 ' CD2' ' A' ' 17' ' ' PHE . 88.2 mt -122.74 131.56 73.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 120.856 -1.153 . . . . 0.0 110.437 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 23.4 mttt -109.9 119.22 38.65 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.576 ' CD1' HG21 ' A' ' 15' ' ' VAL . 67.2 t80 -122.99 110.69 15.68 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.511 -0.743 . . . . 0.0 109.482 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.0 m -113.21 118.17 33.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.88 . . . . 0.0 109.68 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.541 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 1.4 ttt85 -130.15 141.81 43.22 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.277 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.12 89.29 0.46 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.572 2.181 . . . . 0.0 112.001 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.03 -32.19 6.62 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.473 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 21.1 m-20 -95.11 175.74 6.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -1.188 . . . . 0.0 109.705 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 82' ' ' SER . 51.1 m -155.01 162.56 41.04 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.404 -0.81 . . . . 0.0 109.337 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.601 HD13 ' CD2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -71.52 133.92 46.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.274 179.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.57 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.45 3.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.24 -0.912 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -140.62 149.42 42.28 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 0.0 110.205 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.545 ' CG2' HD13 ' A' ' 41' ' ' LEU . 21.6 t -139.14 136.32 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.408 -0.808 . . . . 0.0 109.455 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.466 ' HA ' HD13 ' A' ' 57' ' ' LEU . 89.1 mt-10 -129.59 152.02 49.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.903 -1.123 . . . . 0.0 109.385 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.628 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 7.3 tt -121.75 141.39 51.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.301 -0.875 . . . . 0.0 109.928 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.541 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 5.5 ttp180 -124.23 129.61 51.08 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.311 -0.868 . . . . 0.0 109.022 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -70.69 150.42 45.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.357 -0.839 . . . . 0.0 109.878 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.525 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 54.9 t60 -68.06 118.3 11.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.577 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.77 4.09 52.05 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.4 t -114.48 160.63 18.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.332 -1.099 . . . . 0.0 109.468 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.45 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 72.9 tt0 -124.56 15.23 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -0.924 . . . . 0.0 109.371 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 64.9 tt0 -118.11 81.4 1.67 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.445 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.541 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 40.8 m95 -43.28 138.86 2.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.34 -0.85 . . . . 0.0 109.778 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.28 136.68 20.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.48 -0.762 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.27 145.13 47.85 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.797 2.331 . . . . 0.0 111.898 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.535 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.3 mp -112.05 155.22 24.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.235 -0.916 . . . . 0.0 109.009 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.9 m -109.67 126.92 54.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.952 -1.092 . . . . 0.0 109.32 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 31.9 tttm -73.2 110.4 7.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.061 -1.024 . . . . 0.0 109.312 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.594 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 0.1 OUTLIER -119.31 142.83 47.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.904 -1.122 . . . . 0.0 110.126 -179.469 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.8 32.46 0.93 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 3.6 t-20 81.49 12.84 0.68 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.231 -1.158 . . . . 0.0 110.478 179.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.594 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 16.6 m -129.47 176.71 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.029 -1.044 . . . . 0.0 108.872 179.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.419 ' HB3' HD21 ' A' ' 57' ' ' LEU . 81.3 m95 -116.5 138.09 51.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 0.0 109.56 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -124.29 139.69 53.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.343 -0.848 . . . . 0.0 109.418 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.535 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 10.1 p -133.57 130.85 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.311 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -120.34 131.98 55.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.114 -0.991 . . . . 0.0 109.517 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t -118.52 145.99 44.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.502 -0.749 . . . . 0.0 109.421 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.4 m -72.3 -5.17 34.23 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.098 -1.001 . . . . 0.0 109.114 179.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.559 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.3 mtmt -130.18 177.82 2.01 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.368 -0.833 . . . . 0.0 109.11 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.559 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.5 Cg_endo -68.96 145.93 63.46 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.498 2.132 . . . . 0.0 111.765 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.596 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -83.63 138.69 33.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.797 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.0 t -123.4 124.9 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.385 -0.822 . . . . 0.0 109.484 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -94.03 169.64 29.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.622 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.51 147.52 81.73 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.903 -1.707 . . . . 0.0 112.019 -0.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.8 m-85 -91.19 151.38 20.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.556 -0.715 . . . . 0.0 110.561 -179.232 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.433 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 9.2 m-80 -112.59 143.5 43.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.342 -0.848 . . . . 0.0 108.778 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 49.7 m-85 -137.28 128.45 27.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.925 -1.109 . . . . 0.0 110.257 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.1 ttp180 -108.13 142.72 37.91 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.601 ' CD2' HD13 ' A' ' 41' ' ' LEU . 8.3 m-85 -123.16 144.04 49.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.155 -0.965 . . . . 0.0 111.373 -178.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.6 ' HA ' ' O ' ' A' ' 86' ' ' MET . 10.0 ttm -127.94 126.12 40.85 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -79.8 144.17 33.78 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 110.323 -178.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.57 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 68.6 mttm -44.71 -43.56 8.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.27 -3.11 0.78 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.67 23.43 26.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 35.6 mtp -97.59 147.25 24.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.101 -1.235 . . . . 0.0 108.716 179.433 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 20.7 mtm180 -125.53 142.78 51.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.819 -1.176 . . . . 0.0 110.505 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.0 m120 -137.38 141.52 41.74 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.4 t -121.45 136.28 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.924 -1.11 . . . . 0.0 110.252 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.467 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 43.9 m-85 -124.94 122.55 37.67 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -98.42 147.28 24.88 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.622 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 18.3 mt-10 52.83 51.9 15.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.439 -0.788 . . . . 0.0 110.284 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.74 -33.32 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.804 -1.185 . . . . 0.0 109.159 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.438 HG12 ' HB3' ' A' ' 104' ' ' TYR . 65.2 mt -138.47 126.27 13.7 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.089 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.24 162.81 40.32 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.563 2.175 . . . . 0.0 111.981 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.488 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 54.4 m -53.6 -39.76 65.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.359 -0.838 . . . . 0.0 109.924 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -92.16 99.44 12.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.064 -1.022 . . . . 0.0 109.651 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -108.28 148.01 30.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.562 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.8 t -107.24 168.96 8.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.234 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.44 HD11 HG11 ' A' ' 19' ' ' VAL . 16.3 mm -104.29 136.18 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.182 -0.949 . . . . 0.0 109.237 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.84 3.45 59.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -117.67 142.76 46.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.109 -1.23 . . . . 0.0 109.172 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.455 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.1 m -78.58 175.23 10.56 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 108.914 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.591 ' N ' ' O ' ' A' ' 17' ' ' PHE . 25.0 m-85 -159.66 97.21 1.3 Allowed 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.703 -1.248 . . . . 0.0 108.972 179.267 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.465 ' CD ' HG23 ' A' ' 16' ' ' THR . 7.2 mtmt -97.84 159.31 31.22 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.423 -0.798 . . . . 0.0 109.787 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.467 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.778 2.319 . . . . 0.0 111.681 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.592 ' CG1' ' CZ ' ' A' ' 34' ' ' TYR . 9.9 t . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -109.78 120.93 44.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.079 -1.013 . . . . 0.0 109.456 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.513 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 5.1 t -129.14 140.52 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.752 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.421 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.7 p -141.44 145.24 35.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.215 -0.928 . . . . 0.0 109.549 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.586 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.2 m-85 -116.37 135.26 54.02 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.196 -0.94 . . . . 0.0 109.609 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 25.9 m -134.84 129.02 33.83 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 109.412 179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.525 HG11 ' CE1' ' A' ' 98' ' ' PHE . 39.2 t -76.47 135.84 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 109.353 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -111.46 157.18 20.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.708 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 25.7 mtpt -50.86 113.91 1.03 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.822 . . . . 0.0 109.924 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.49 -3.92 1.92 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.58 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.476 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 40.8 m -60.68 140.28 57.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.896 -1.355 . . . . 0.0 109.258 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.545 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.24 177.09 2.4 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 109.57 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.545 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -71.22 -31.66 14.1 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.59 2.193 . . . . 0.0 111.814 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -117.14 5.11 12.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.033 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.45 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 47.0 mttp -141.37 132.98 27.06 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.53 ' CD2' HD13 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.56 132.18 51.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.069 -1.02 . . . . 0.0 110.084 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.525 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 4.7 t -121.43 124.68 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.53 HD13 ' CD2' ' A' ' 28' ' ' LEU . 0.8 OUTLIER -140.87 141.07 34.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.948 -1.095 . . . . 0.0 110.124 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -85.9 136.34 33.33 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 178.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.586 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.4 mt -121.71 131.12 73.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 120.932 -1.105 . . . . 0.0 110.236 -179.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 47.4 mttm -110.36 119.53 39.5 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.592 ' CZ ' ' CG1' ' A' ' 13' ' ' VAL . 59.0 t80 -122.85 115.76 22.51 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.536 -0.727 . . . . 0.0 109.324 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.5 m -119.32 119.59 34.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.504 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 14.0 ttt85 -137.5 138.8 25.54 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.246 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.466 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.0 Cg_endo -69.74 103.05 1.1 Allowed 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.754 2.303 . . . . 0.0 112.06 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.75 2.86 86.42 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.504 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 26.2 m-20 -137.87 175.99 9.09 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -1.194 . . . . 0.0 109.693 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.9 m -156.25 163.84 39.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.466 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.591 HD23 ' CE2' ' A' ' 80' ' ' PHE . 23.4 tp -69.18 130.16 41.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.204 -0.935 . . . . 0.0 109.229 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.606 ' HB2' ' N ' ' A' ' 83' ' ' LYS . . . -113.75 -45.69 3.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 110.148 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -137.34 147.18 45.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.102 -0.998 . . . . 0.0 110.264 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.541 ' CG2' HD11 ' A' ' 41' ' ' LEU . 94.2 t -139.35 136.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.531 -0.731 . . . . 0.0 109.334 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.527 ' O ' ' HA ' ' A' ' 78' ' ' PHE . 35.1 mt-10 -128.87 151.38 49.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.415 179.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.611 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 7.0 tt -120.83 144.35 48.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.377 -0.827 . . . . 0.0 109.865 -179.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.544 ' N ' ' CD2' ' A' ' 46' ' ' LEU . 19.5 ttp180 -126.86 108.86 11.39 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 109.037 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.484 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 39.8 mt-30 -51.97 156.1 1.63 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.858 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.538 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 86.4 t60 -69.31 118.5 12.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.472 -0.768 . . . . 0.0 109.6 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.47 3.44 55.33 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -113.76 153.27 29.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -1.156 . . . . 0.0 109.467 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.472 ' HA ' ' HD2' ' A' ' 47' ' ' ARG . 85.3 tt0 -115.66 -3.47 12.29 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.273 -0.892 . . . . 0.0 109.393 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.0 tt0 -97.25 112.34 24.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -0.908 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.536 ' CE2' ' HD3' ' A' ' 47' ' ' ARG . 78.5 m95 -74.33 129.12 37.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.326 -0.859 . . . . 0.0 109.549 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -101.66 137.19 19.51 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.874 . . . . 0.0 109.364 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -71.4 144.85 46.55 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.694 2.262 . . . . 0.0 111.937 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.559 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.1 mp -107.89 148.24 29.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 108.949 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.431 HG21 ' NZ ' ' A' ' 60' ' ' LYS . 85.6 m -102.31 127.22 49.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.894 -1.129 . . . . 0.0 109.27 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.6 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 41.2 tttm -72.44 110.05 6.57 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.243 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.578 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 17.8 mmtt -118.43 140.66 49.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.907 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.85 31.74 0.84 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.583 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 9.4 m-20 82.66 13.67 0.46 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.239 -1.154 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.578 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 21.0 m -128.43 173.36 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.014 -1.054 . . . . 0.0 108.761 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.6 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 62.3 m95 -120.2 124.98 47.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.98 -1.075 . . . . 0.0 109.657 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -114.15 150.2 34.51 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.45 -0.782 . . . . 0.0 109.491 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.559 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.4 p -137.23 134.04 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.492 -0.755 . . . . 0.0 109.248 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -120.32 131.58 54.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.167 -0.958 . . . . 0.0 109.444 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.484 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 20.2 t -117.85 157.72 26.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.416 -0.802 . . . . 0.0 109.52 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.7 t -83.94 5.83 24.06 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.256 -0.903 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.527 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -139.09 176.2 2.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.295 -0.878 . . . . 0.0 109.214 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.527 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.4 Cg_endo -70.17 126.15 12.73 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.499 2.132 . . . . 0.0 111.791 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.572 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 2.0 mt -60.63 136.93 58.21 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.243 -0.91 . . . . 0.0 109.787 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.462 HG11 ' HB3' ' A' ' 49' ' ' HIS . 95.7 t -124.23 125.44 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.444 -0.785 . . . . 0.0 109.461 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -94.9 168.74 27.73 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.572 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.73 146.87 81.02 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.83 -1.737 . . . . 0.0 112.011 0.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 90.9 m-85 -91.09 149.6 21.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.506 -0.746 . . . . 0.0 110.356 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 47' ' ' ARG . 3.4 m-80 -111.99 144.57 41.11 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.611 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 18.2 m-85 -135.84 126.06 26.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.925 -1.109 . . . . 0.0 110.127 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.548 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 18.8 ttt180 -105.81 141.34 37.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.133 -0.979 . . . . 0.0 108.662 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.591 ' CE2' HD23 ' A' ' 41' ' ' LEU . 6.9 m-85 -123.7 143.03 50.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.924 . . . . 0.0 111.402 -178.146 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.631 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.5 ttt -125.93 124.47 40.87 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.606 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.0 p -72.46 144.59 48.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.385 -0.822 . . . . 0.0 109.968 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.606 ' N ' ' HB2' ' A' ' 42' ' ' ALA . 86.4 mttt -47.19 -44.74 22.49 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.402 -0.811 . . . . 0.0 108.975 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.8 -3.7 0.77 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.71 24.53 15.4 Favored Glycine 0 N--CA 1.491 2.307 0 O-C-N 120.988 -1.301 . . . . 0.0 110.257 179.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.631 ' O ' ' HA ' ' A' ' 81' ' ' MET . 15.4 mmm -96.72 148.31 23.02 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.114 -1.227 . . . . 0.0 108.633 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 72.8 mtp180 -124.12 140.03 53.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.885 -1.134 . . . . 0.0 110.416 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 80' ' ' PHE . 28.2 m120 -136.42 141.25 43.59 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.548 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 4.3 t -122.15 136.14 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.183 -179.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.557 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 13.3 m-85 -123.77 122.6 38.48 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 63.9 t0 -98.66 145.1 27.22 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.572 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 64.5 tt0 54.76 52.54 11.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.481 -0.762 . . . . 0.0 110.377 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.541 HG13 ' CD1' ' A' ' 17' ' ' PHE . 88.8 t -81.14 -34.75 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.939 -1.101 . . . . 0.0 109.006 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.429 ' CD1' HD23 ' A' ' 30' ' ' LEU . 46.6 mt -135.42 129.4 18.63 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 121.353 -0.842 . . . . 0.0 108.95 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.88 159.52 50.25 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.483 2.122 . . . . 0.0 112.009 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.485 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 31.9 m -50.17 -36.66 31.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.677 -179.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.63 101.66 11.81 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.071 -1.018 . . . . 0.0 109.518 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.525 ' CE1' HG11 ' A' ' 19' ' ' VAL . 50.9 p90 -109.49 150.84 27.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.159 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.79 168.83 8.88 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.431 HD11 ' CG1' ' A' ' 19' ' ' VAL . 17.8 mm -101.01 136.37 32.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.226 -0.921 . . . . 0.0 109.177 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 94.69 0.79 64.16 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 15.9 mttm -114.27 144.96 42.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.245 . . . . 0.0 109.157 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.436 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 4.2 m -82.65 178.37 8.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.294 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 16.3 m-85 -161.81 92.65 0.87 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.863 -1.148 . . . . 0.0 108.859 179.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.39 155.07 71.86 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.245 -0.909 . . . . 0.0 109.783 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.557 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 50.0 Cg_endo . . . . . 0 C--O 1.216 -0.576 0 C-N-CA 122.741 2.294 . . . . 0.0 111.886 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.52 ' CG1' ' HG3' ' A' ' 36' ' ' ARG . 4.0 t . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.307 0.575 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.406 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 91.5 mt-30 -109.65 121.36 45.03 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.384 -0.823 . . . . 0.0 109.167 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.546 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.7 p -128.84 139.92 50.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.207 -0.933 . . . . 0.0 109.836 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.463 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 29.3 p -142.02 145.99 35.02 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.406 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.8 m-85 -118.31 147.48 43.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.402 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 29.9 m -141.84 127.93 19.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.112 -0.993 . . . . 0.0 109.202 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.557 ' CG1' ' OG ' ' A' ' 23' ' ' SER . 21.8 t -76.33 135.9 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.106 -0.996 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.1 mm-40 -101.44 -174.83 2.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.107 -0.996 . . . . 0.0 109.531 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.4 mttt -81.6 67.42 7.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.369 -0.832 . . . . 0.0 109.983 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -174.96 22.97 0.06 OUTLIER Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.755 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.557 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 48.9 m -75.44 142.58 42.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.777 -1.425 . . . . 0.0 109.109 179.638 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.534 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.14 171.96 7.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 109.856 -179.552 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.534 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.92 -31.05 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.869 2.38 . . . . 0.0 111.984 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -115.57 6.8 14.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.235 -0.916 . . . . 0.0 108.984 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.51 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 2.5 ttpm? -142.96 133.91 25.57 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.592 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.56 124.27 43.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.934 -1.104 . . . . 0.0 109.398 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.553 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 10.7 t -120.06 124.81 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.592 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.1 mt -145.23 145.88 31.48 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.027 -1.046 . . . . 0.0 110.147 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.446 ' HA ' HG13 ' A' ' 63' ' ' VAL . 59.2 t0 -83.86 134.92 34.67 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.576 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.5 mt -121.86 131.82 72.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 120.825 -1.172 . . . . 0.0 110.723 -178.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 24.7 mmtp -110.44 119.28 38.67 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.475 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 81.2 t80 -120.42 124.67 46.04 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.411 -0.806 . . . . 0.0 109.568 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 5.2 m -128.64 118.74 23.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.847 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.544 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 0.0 OUTLIER -128.54 167.0 20.68 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.708 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.544 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.1 Cg_endo -70.55 79.06 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.716 2.277 . . . . 0.0 111.876 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.14 -9.63 69.0 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.518 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -96.84 179.0 5.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.175 . . . . 0.0 109.422 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.5 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 12.4 m -153.02 160.68 43.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.147 -0.971 . . . . 0.0 109.712 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.591 HD23 ' CE2' ' A' ' 80' ' ' PHE . 22.4 tp -69.97 130.18 41.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.471 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.58 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -116.44 -45.65 2.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.232 -0.918 . . . . 0.0 110.127 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.449 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 43.8 mt-10 -134.66 144.57 47.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.116 -0.99 . . . . 0.0 110.335 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.575 HG11 ' CE1' ' A' ' 80' ' ' PHE . 93.8 t -137.99 135.48 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.492 -0.755 . . . . 0.0 109.217 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.49 ' HA ' ' CD1' ' A' ' 57' ' ' LEU . 25.7 mt-10 -129.04 151.05 50.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.985 -1.072 . . . . 0.0 109.395 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.578 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 5.4 tt -119.4 132.61 55.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.447 -0.783 . . . . 0.0 109.913 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.509 ' N ' HD22 ' A' ' 46' ' ' LEU . 27.0 ttp180 -118.53 128.21 54.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.225 -0.922 . . . . 0.0 108.761 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -73.13 152.24 41.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 110.195 -179.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.523 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 55.1 t-80 -63.02 147.48 50.56 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.408 -0.808 . . . . 0.0 109.137 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.92 1.0 54.57 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.6 t -112.45 150.31 31.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -1.144 . . . . 0.0 109.316 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -116.59 8.46 13.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.924 . . . . 0.0 109.517 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 64.0 mm-40 -107.01 115.42 30.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.401 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 58.3 m95 -76.08 129.03 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.326 -0.859 . . . . 0.0 109.715 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -99.94 133.38 21.68 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.432 -0.793 . . . . 0.0 109.193 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 149.03 67.25 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.689 2.259 . . . . 0.0 111.803 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.535 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 6.1 mp -111.98 158.58 19.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.194 -0.941 . . . . 0.0 109.354 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.2 m -107.48 127.72 53.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.954 -1.091 . . . . 0.0 109.279 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 47.3 tttt -70.84 112.89 7.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -0.896 . . . . 0.0 109.242 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.445 ' HE3' ' OE1' ' A' ' 65' ' ' GLU . 40.2 mttt -113.64 125.66 54.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.953 -1.092 . . . . 0.0 109.595 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 44.68 -109.54 0.29 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -117.11 17.44 14.84 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.258 -1.142 . . . . 0.0 109.564 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.446 HG13 ' HA ' ' A' ' 31' ' ' ASP . 10.9 m -131.93 -175.82 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.451 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -127.33 139.82 52.62 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' HE3' ' A' ' 67' ' ' LYS . 19.1 tt0 -121.21 135.01 55.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.215 -0.928 . . . . 0.0 109.753 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.535 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 4.6 p -131.09 129.36 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.274 -0.891 . . . . 0.0 109.304 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.51 ' HG2' ' CD ' ' A' ' 27' ' ' LYS . 88.3 mttt -120.05 131.58 55.15 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.094 -1.004 . . . . 0.0 109.529 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.5 t -117.6 138.91 51.63 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.526 -0.734 . . . . 0.0 109.288 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 79.3 p -65.56 -11.3 42.72 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.154 -0.966 . . . . 0.0 109.232 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.535 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -121.12 176.34 1.95 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.68 164.57 32.66 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.602 2.201 . . . . 0.0 111.811 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.614 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.1 mt -100.59 141.56 33.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.258 -0.901 . . . . 0.0 109.849 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 50.2 t -127.86 125.2 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.547 -0.72 . . . . 0.0 109.319 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.451 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -93.76 164.74 26.64 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.591 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.9 Cg_endo -68.84 148.15 83.97 Favored 'Cis proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.984 0.075 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.4 m-85 -92.58 149.87 21.08 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.442 -0.786 . . . . 0.0 110.476 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.483 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 14.6 m-80 -110.51 143.33 41.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 108.769 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 83.1 m-85 -134.69 126.84 29.87 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.014 -1.054 . . . . 0.0 109.737 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.527 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 53.1 ttt180 -108.35 142.51 38.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.04 -1.038 . . . . 0.0 108.753 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.591 ' CE2' HD23 ' A' ' 41' ' ' LEU . 9.1 m-85 -124.6 143.42 50.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 111.551 -178.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.596 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.6 ttm -126.38 125.95 43.06 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 178.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.608 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.9 p -74.0 145.92 44.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 110.204 -178.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.58 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 78.7 mttt -48.37 -44.22 34.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.272 -0.893 . . . . 0.0 108.934 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.44 -3.69 0.68 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.53 25.05 16.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.608 ' O ' ' N ' ' A' ' 82' ' ' SER . 13.0 mmm -97.39 148.36 23.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.172 -1.193 . . . . 0.0 108.575 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.561 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 21.6 mtm180 -124.31 140.03 53.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.843 -1.16 . . . . 0.0 110.68 -178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . 34.7 m120 -135.42 140.08 44.65 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.527 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 59.1 t -122.03 136.9 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.037 -1.039 . . . . 0.0 110.409 -179.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.516 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 15.9 m-85 -125.52 122.98 38.13 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -99.57 147.84 24.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.591 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 95.8 mt-10 53.45 51.4 15.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.338 -0.851 . . . . 0.0 110.044 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.443 HG12 HG13 ' A' ' 94' ' ' ILE . 44.1 t -81.03 -33.98 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.821 -1.174 . . . . 0.0 109.26 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.49 HD12 HD21 ' A' ' 30' ' ' LEU . 43.7 mt -138.13 125.75 13.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.139 -0.976 . . . . 0.0 109.057 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.12 161.78 44.43 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.533 2.155 . . . . 0.0 111.882 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.6 m -57.08 -39.46 75.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.376 -0.827 . . . . 0.0 109.923 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.45 70.31 9.89 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.081 -1.012 . . . . 0.0 109.492 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -81.2 148.52 29.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.936 . . . . 0.0 109.656 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 43.3 m -109.82 168.8 9.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.317 -0.865 . . . . 0.0 109.186 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.544 HD11 ' CG1' ' A' ' 19' ' ' VAL . 35.6 mm -103.4 135.71 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.137 -0.977 . . . . 0.0 109.284 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 97.01 5.88 58.17 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.463 ' HD3' ' CZ ' ' A' ' 104' ' ' TYR . 43.7 tttp -119.73 143.17 47.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.25 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.567 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.7 m -79.88 176.51 9.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 109.018 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -162.7 95.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.875 -1.141 . . . . 0.0 108.937 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.474 ' HB3' ' O ' ' A' ' 15' ' ' VAL . 0.3 OUTLIER -103.0 166.33 12.05 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.873 . . . . 0.0 109.793 -179.405 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.631 0 C-N-CA 122.588 2.192 . . . . 0.0 111.727 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.577 HG12 ' CE1' ' A' ' 34' ' ' TYR . 3.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -111.47 121.64 45.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.896 . . . . 0.0 109.244 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.566 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 14.4 t -128.95 139.68 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.202 -0.936 . . . . 0.0 109.817 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.0 p -141.99 146.15 35.26 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.328 -0.857 . . . . 0.0 109.474 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.593 ' O ' ' N ' ' A' ' 104' ' ' TYR . 91.7 m-85 -118.38 123.65 45.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 34.8 m -120.05 128.37 53.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.03 -1.044 . . . . 0.0 109.063 179.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.515 ' CG1' HD13 ' A' ' 100' ' ' ILE . 11.9 t -76.04 132.57 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 37.7 mm-40 -107.3 156.35 18.98 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.8 mttt -50.08 114.55 1.12 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.432 -0.793 . . . . 0.0 109.909 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.95 1.98 1.96 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 65.9 p -62.85 142.32 58.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.762 -1.434 . . . . 0.0 109.185 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.505 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.43 174.12 4.71 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.133 -0.98 . . . . 0.0 109.664 -179.626 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.505 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.9 Cg_endo -71.01 -29.86 17.31 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.683 2.255 . . . . 0.0 111.86 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -118.18 4.18 11.98 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.32 -0.862 . . . . 0.0 109.041 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.457 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 52.7 mttt -143.01 134.13 25.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.517 HD23 ' CD1' ' A' ' 30' ' ' LEU . 0.2 OUTLIER -128.01 134.25 49.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.984 -1.073 . . . . 0.0 110.401 -179.332 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.519 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.6 t -121.95 123.73 69.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.519 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -143.68 144.51 31.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 109.914 -179.352 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -86.3 136.13 33.27 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.581 HG12 ' CD2' ' A' ' 17' ' ' PHE . 80.1 mt -120.68 131.63 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 120.881 -1.137 . . . . 0.0 110.324 -179.163 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 mttm -111.09 118.69 36.71 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.577 ' CE1' HG12 ' A' ' 13' ' ' VAL . 67.6 t80 -121.26 109.33 14.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.489 -0.757 . . . . 0.0 109.339 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.495 ' O ' HG11 ' A' ' 13' ' ' VAL . 97.1 m -112.62 117.32 31.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.89 . . . . 0.0 109.89 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.563 ' HD3' ' CB ' ' A' ' 39' ' ' ASP . 37.8 ttt-85 -136.83 139.73 29.75 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.368 -0.833 . . . . 0.0 109.179 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.49 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.3 Cg_endo -69.75 109.35 2.29 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 112.069 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.05 4.44 88.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.563 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 4.9 m-20 -134.52 173.21 11.91 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -1.22 . . . . 0.0 109.772 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -155.53 162.61 40.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.341 -0.849 . . . . 0.0 109.502 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.561 HD23 ' CE2' ' A' ' 80' ' ' PHE . 10.7 tp -70.55 129.56 39.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.846 . . . . 0.0 109.501 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.547 ' HB2' ' N ' ' A' ' 83' ' ' LYS . . . -115.83 -42.74 3.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.161 -0.962 . . . . 0.0 109.839 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -142.62 151.09 41.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.138 -0.976 . . . . 0.0 110.002 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.569 HG13 ' CZ ' ' A' ' 80' ' ' PHE . 21.4 t -139.9 137.27 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.435 -0.791 . . . . 0.0 109.465 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 61.4 mt-10 -127.78 150.55 49.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.873 -1.142 . . . . 0.0 109.215 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.576 HD22 ' CE2' ' A' ' 78' ' ' PHE . 10.9 tp -120.87 133.0 55.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.333 -0.855 . . . . 0.0 110.243 -178.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.583 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 47.8 ttp85 -113.53 127.98 56.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.099 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.441 ' NE2' HD23 ' A' ' 72' ' ' LEU . 72.5 mm-40 -71.91 152.35 42.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.512 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 37.6 t-80 -69.31 111.3 5.12 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.382 -0.824 . . . . 0.0 109.554 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.82 2.1 36.75 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.511 ' O ' ' NH1' ' A' ' 47' ' ' ARG . 33.5 t -113.47 154.37 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.195 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 37.9 mm-40 -113.22 16.14 19.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.333 -0.854 . . . . 0.0 109.394 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -113.88 114.19 25.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.528 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.583 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.6 m95 -80.13 120.09 23.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.267 -0.895 . . . . 0.0 109.655 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -95.95 129.99 32.63 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.445 -0.784 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.32 149.48 69.74 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.561 2.174 . . . . 0.0 111.879 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.59 ' CD1' ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -101.6 149.52 24.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.149 -0.97 . . . . 0.0 108.576 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -102.46 126.54 49.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 108.941 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -70.41 109.47 4.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.168 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.618 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 37.2 mttp -121.74 139.53 53.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.797 -1.189 . . . . 0.0 109.975 -179.548 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.542 ' O ' ' HB2' ' A' ' 62' ' ' ASN . . . 38.39 48.25 2.21 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.542 ' HB2' ' O ' ' A' ' 61' ' ' GLY . 54.3 m-20 68.48 11.46 8.36 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.169 -1.195 . . . . 0.0 110.956 178.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.618 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 27.9 m -128.88 -178.61 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.858 -1.151 . . . . 0.0 108.997 179.169 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.496 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 71.1 m95 -122.8 141.27 52.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.082 . . . . 0.0 109.632 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 62.5 tt0 -128.42 142.22 51.17 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.815 . . . . 0.0 109.212 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.59 ' HB ' ' CD1' ' A' ' 57' ' ' LEU . 1.8 p -136.37 135.18 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.24 -0.913 . . . . 0.0 109.145 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.413 ' HD2' ' HE2' ' A' ' 27' ' ' LYS . 6.1 ttpm? -122.54 133.73 54.56 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.851 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.8 t -117.86 148.13 42.41 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.456 -0.778 . . . . 0.0 109.153 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 85.5 p -72.77 -4.43 31.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.988 . . . . 0.0 109.354 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.538 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -131.5 176.19 3.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.243 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.538 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.44 140.52 48.25 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.482 2.121 . . . . 0.0 111.714 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.588 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 10.5 mt -74.76 137.89 42.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.826 -179.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.9 t -123.37 125.12 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.469 -0.769 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.433 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -93.3 165.47 27.67 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.62 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 50.5 Cg_endo -70.01 145.66 80.6 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.806 -1.747 . . . . 0.0 111.883 0.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.8 m-85 -91.46 151.18 20.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.523 -0.736 . . . . 0.0 110.367 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.502 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 2.4 m-80 -110.77 142.43 42.75 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CE2' HD22 ' A' ' 46' ' ' LEU . 91.0 m-85 -133.24 127.3 33.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.913 -1.117 . . . . 0.0 109.971 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 41.4 ttt180 -110.62 143.12 41.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.006 -1.059 . . . . 0.0 108.627 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.571 ' CZ ' HG23 ' A' ' 32' ' ' ILE . 9.0 m-85 -124.86 143.81 50.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.218 -0.926 . . . . 0.0 111.632 -177.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.561 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 1.2 ttt -125.85 124.4 40.82 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 86' ' ' MET . 24.2 p -77.39 147.7 35.92 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.206 -0.934 . . . . 0.0 110.043 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.547 ' N ' ' HB2' ' A' ' 42' ' ' ALA . 32.9 mttt -46.65 -46.0 19.6 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.32 -8.19 8.65 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.41 34.53 5.28 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.539 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 44.3 mmm -103.24 110.61 22.64 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.987 -1.302 . . . . 0.0 109.011 179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.561 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 61.0 mtt180 -91.71 139.49 30.63 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.199 -0.938 . . . . 0.0 110.472 -179.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.4 m120 -137.25 141.69 42.02 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 4.2 t -122.06 136.5 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.865 -1.147 . . . . 0.0 110.471 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.523 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 55.0 m-85 -124.44 122.36 37.42 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -97.13 145.27 26.17 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.18 -0.95 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.62 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 12.8 mt-10 53.96 54.26 9.99 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.491 -0.756 . . . . 0.0 110.335 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.511 HG12 ' CD1' ' A' ' 17' ' ' PHE . 75.8 t -82.26 -34.18 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 109.074 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.433 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.7 mt -135.44 124.4 16.0 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.201 -0.937 . . . . 0.0 109.132 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.42 162.13 43.12 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.608 2.205 . . . . 0.0 111.968 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.3 m -53.3 -44.7 68.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 109.976 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.84 99.72 12.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.046 -1.034 . . . . 0.0 109.502 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -109.45 147.83 32.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.94 . . . . 0.0 109.715 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.8 m -106.09 171.15 7.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.212 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.515 HD13 ' CG1' ' A' ' 19' ' ' VAL . 27.2 mm -106.73 137.83 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.427 ' N ' HG22 ' A' ' 100' ' ' ILE . . . 92.42 9.62 61.49 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 4.6 tptp -120.57 144.18 48.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.404 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 8.6 m -77.81 170.97 15.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.038 -1.039 . . . . 0.0 108.706 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.593 ' N ' ' O ' ' A' ' 17' ' ' PHE . 24.0 m-85 -157.62 97.94 1.63 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.607 -1.308 . . . . 0.0 109.151 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.522 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -104.93 161.53 22.49 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.277 -0.889 . . . . 0.0 109.767 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.523 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.2 Cg_endo . . . . . 0 C--O 1.215 -0.639 0 C-N-CA 122.718 2.279 . . . . 0.0 111.663 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.537 ' CG2' ' HG3' ' A' ' 36' ' ' ARG . 30.3 t . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 77.9 mm-40 -106.01 120.24 41.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.027 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.1 p -128.92 139.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.232 -0.917 . . . . 0.0 110.049 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 15' ' ' VAL . 73.1 p -141.25 145.42 35.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.334 179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.646 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.8 m-85 -118.24 136.22 53.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.176 -0.953 . . . . 0.0 109.717 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 88.5 m -131.34 127.77 38.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.903 -1.123 . . . . 0.0 109.302 179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.532 ' CG2' HD22 ' A' ' 30' ' ' LEU . 30.6 t -75.02 134.01 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.216 -0.928 . . . . 0.0 109.173 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.468 ' OE1' ' O ' ' A' ' 19' ' ' VAL . 4.9 mm100 -106.57 156.34 18.69 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.174 -0.954 . . . . 0.0 109.975 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.5 mttt -51.34 115.87 1.79 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.51 -0.743 . . . . 0.0 109.947 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 137.26 -1.52 3.05 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.447 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 p -60.29 144.15 51.14 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.911 -1.347 . . . . 0.0 109.403 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.481 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.19 169.79 12.62 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.288 -0.882 . . . . 0.0 109.71 -179.779 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.481 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.4 Cg_endo -70.73 -29.34 19.39 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.806 2.337 . . . . 0.0 111.88 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -113.02 7.09 17.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.165 -0.959 . . . . 0.0 108.819 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -142.74 133.55 25.45 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.35 122.84 40.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.965 -1.085 . . . . 0.0 109.337 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.545 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 51.4 t -118.72 124.35 73.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.2 mt -144.33 144.76 31.61 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.977 -1.077 . . . . 0.0 110.253 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -85.39 137.04 33.2 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 177.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.614 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 75.7 mt -120.71 130.98 73.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 C-N-CA 118.667 -1.213 . . . . 0.0 110.786 -179.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.588 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 22.1 tttm -110.61 120.38 42.23 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.486 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 78.6 t80 -120.15 112.77 19.52 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.343 -0.848 . . . . 0.0 109.567 -178.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.461 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 31.2 m -115.71 115.79 26.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -0.851 . . . . 0.0 109.677 -179.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.539 ' CZ ' ' HE1' ' A' ' 86' ' ' MET . 28.0 ttt85 -138.68 136.29 18.62 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.526 -0.734 . . . . 0.0 109.208 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.449 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -69.88 112.57 3.13 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.1 0.69 83.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.538 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.2 m-20 -133.92 172.26 13.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.966 -1.314 . . . . 0.0 109.87 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 82' ' ' SER . 13.6 m -153.98 161.61 41.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.408 -0.807 . . . . 0.0 109.341 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.601 HD11 ' CE2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -72.28 131.27 42.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.279 -0.888 . . . . 0.0 109.845 -179.588 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.623 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -114.93 -40.24 3.54 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.619 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.45 150.41 40.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.124 -0.985 . . . . 0.0 110.187 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.553 ' CG2' HD11 ' A' ' 41' ' ' LEU . 5.9 t -139.21 136.88 41.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.581 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.469 ' HA ' HD11 ' A' ' 57' ' ' LEU . 93.9 mt-10 -129.63 150.81 50.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.935 -1.103 . . . . 0.0 109.394 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.584 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 6.7 tt -118.72 140.61 49.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.892 . . . . 0.0 109.715 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.587 ' HD3' ' CD1' ' A' ' 54' ' ' TRP . 28.3 ttp180 -126.74 129.54 48.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.293 -0.879 . . . . 0.0 109.072 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.588 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 47.8 mt-30 -72.6 144.8 47.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.343 -0.848 . . . . 0.0 109.863 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.535 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 2.0 t-160 -61.36 115.81 4.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.35 -0.844 . . . . 0.0 109.442 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.42 2.75 35.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.424 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 25.6 t -113.7 155.71 25.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -1.188 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.491 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 69.7 tt0 -116.05 1.03 13.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.583 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -108.83 92.48 4.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.587 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 46.0 m95 -51.55 138.64 22.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.356 -0.84 . . . . 0.0 109.599 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -105.05 135.19 19.33 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.375 -0.828 . . . . 0.0 109.32 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.83 145.51 51.11 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.617 2.211 . . . . 0.0 111.891 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.535 HD12 ' CB ' ' A' ' 46' ' ' LEU . 5.4 mp -107.17 146.14 31.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.032 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.2 m -94.41 126.92 39.97 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.956 -1.09 . . . . 0.0 109.176 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -70.6 111.18 5.91 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.408 -0.808 . . . . 0.0 109.033 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -111.77 113.04 25.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.982 -1.074 . . . . 0.0 109.571 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.15 -103.72 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -123.76 17.36 9.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -1.146 . . . . 0.0 109.398 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 m -130.82 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.328 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 60.9 m95 -134.1 142.06 47.38 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.155 -0.966 . . . . 0.0 109.466 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -122.48 134.79 54.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.214 -0.929 . . . . 0.0 109.766 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 28' ' ' LEU . 4.8 p -130.83 130.35 64.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -0.903 . . . . 0.0 109.217 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.7 tttm -122.17 133.85 54.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.064 -1.023 . . . . 0.0 109.75 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.588 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.3 t -117.63 154.77 31.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.437 -0.789 . . . . 0.0 109.239 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 20.4 m -80.15 -4.36 52.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.288 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.531 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.1 mttm -128.33 176.05 3.03 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.531 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.5 Cg_endo -69.52 124.19 10.94 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.508 2.138 . . . . 0.0 111.735 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.585 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.3 mt -58.53 139.67 55.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.354 -0.842 . . . . 0.0 109.79 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 46.4 t -125.14 124.68 67.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.378 -0.826 . . . . 0.0 109.543 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -95.3 166.78 25.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.599 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 45.4 Cg_endo -66.61 146.53 73.86 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 123.043 -1.649 . . . . 0.0 112.087 0.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 75.5 m-85 -90.72 150.53 21.6 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.607 -0.683 . . . . 0.0 110.405 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -111.91 143.16 43.33 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 89.3 m-85 -134.77 122.16 21.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.01 -1.056 . . . . 0.0 109.704 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.421 ' N ' ' CZ3' ' A' ' 54' ' ' TRP . 51.9 ttp180 -103.3 141.91 35.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.96 -1.087 . . . . 0.0 108.609 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.614 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 31.7 m-85 -125.51 143.91 50.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.187 -0.946 . . . . 0.0 111.595 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.54 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.8 ttm -126.65 126.82 44.19 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.537 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 19.3 p -77.52 145.62 36.85 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.203 -0.936 . . . . 0.0 110.412 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.623 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 58.6 mttt -48.7 -44.56 38.15 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.61 -6.24 6.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.26 34.34 5.9 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.539 ' HE1' ' CZ ' ' A' ' 36' ' ' ARG . 15.8 mmm -106.07 108.78 20.47 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.075 -1.25 . . . . 0.0 109.001 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.54 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 82.5 mtm180 -85.86 134.98 33.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.199 -0.938 . . . . 0.0 110.634 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 30.0 m120 -134.3 139.49 45.74 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 37.2 t -122.84 136.82 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.036 -1.04 . . . . 0.0 110.587 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.511 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 61.2 m-85 -124.16 122.09 36.88 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.518 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 21.0 p-10 -100.11 148.96 24.01 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.346 -0.846 . . . . 0.0 109.744 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 40.1 tt0 52.98 51.19 16.33 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.323 -0.86 . . . . 0.0 110.002 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.47 HG11 HG13 ' A' ' 94' ' ' ILE . 61.6 t -81.76 -33.87 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.924 -1.11 . . . . 0.0 109.116 179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.497 HD12 HD21 ' A' ' 30' ' ' LEU . 67.1 mt -138.83 127.67 14.09 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.312 -0.868 . . . . 0.0 109.074 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.45 161.37 46.14 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.611 2.208 . . . . 0.0 111.982 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.52 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 87.4 m -51.2 -45.44 61.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.394 -0.816 . . . . 0.0 109.916 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -93.07 104.01 16.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.113 -0.992 . . . . 0.0 109.688 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -111.09 151.57 27.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.359 -0.838 . . . . 0.0 109.33 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.0 m -102.64 170.18 8.18 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 30.6 mm -103.23 136.06 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.182 -0.948 . . . . 0.0 109.306 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.8 57.7 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -121.28 143.39 49.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.974 -1.309 . . . . 0.0 109.306 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.526 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.9 m -79.15 177.2 9.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.076 -1.015 . . . . 0.0 108.919 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.646 ' N ' ' O ' ' A' ' 17' ' ' PHE . 27.5 m-85 -162.23 96.27 0.97 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.769 -1.207 . . . . 0.0 109.107 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.508 ' C ' ' CD ' ' A' ' 105' ' ' LYS . 0.1 OUTLIER -102.51 164.54 15.45 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.362 -0.836 . . . . 0.0 109.724 -179.584 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.511 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.5 Cg_endo . . . . . 0 C--O 1.213 -0.727 0 C-N-CA 122.675 2.25 . . . . 0.0 111.887 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.498 HG23 ' CG ' ' A' ' 36' ' ' ARG . 60.7 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.48 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 94.7 mt-30 -112.96 121.78 45.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.274 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.606 HG12 ' CE2' ' A' ' 90' ' ' PHE . 12.5 p -128.79 139.99 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.258 -0.902 . . . . 0.0 109.668 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.446 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 17.0 p -141.6 145.72 35.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.155 -0.965 . . . . 0.0 109.515 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.576 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.7 m-85 -117.49 150.44 38.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.234 -0.916 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CG2' ' O ' ' A' ' 102' ' ' LYS . 92.2 m -144.81 127.7 16.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.069 -1.02 . . . . 0.0 109.378 179.097 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.556 ' CG2' HD23 ' A' ' 30' ' ' LEU . 4.5 t -76.29 129.1 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.885 . . . . 0.0 109.377 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 91.2 mm-40 -92.97 -175.25 3.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.609 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -81.94 62.16 5.59 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.962 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -169.05 24.49 0.1 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.71 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.537 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 26.2 m -79.95 143.64 34.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.778 -1.425 . . . . 0.0 109.252 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.501 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.71 174.19 4.6 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.101 -0.999 . . . . 0.0 109.605 -179.726 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.546 ' O ' ' N ' ' A' ' 72' ' ' LEU . 48.7 Cg_endo -70.76 -30.39 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.67 2.247 . . . . 0.0 112.045 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 88.8 mttt -115.17 5.7 14.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.067 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.8 mttt -142.18 133.38 26.21 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.31 40.95 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.042 -1.036 . . . . 0.0 109.466 -179.928 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.532 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 21.9 t -118.74 124.62 73.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -144.65 145.76 31.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.978 -1.076 . . . . 0.0 110.169 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -85.63 137.36 32.9 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.608 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 77.0 mt -120.78 130.13 74.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.755 -1.215 . . . . 0.0 110.688 -178.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.5 tttm -109.66 119.95 40.98 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.472 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 72.3 t80 -122.0 124.27 43.6 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.334 -0.853 . . . . 0.0 109.716 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.48 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 16.2 m -126.74 116.93 21.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.301 -0.874 . . . . 0.0 109.737 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.498 ' CG ' HG23 ' A' ' 13' ' ' VAL . 0.5 OUTLIER -151.27 116.66 3.19 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.416 -0.803 . . . . 0.0 109.139 179.804 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.95 126.21 13.56 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.73 2.286 . . . . 0.0 111.95 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.54 -19.48 54.5 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.492 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 1.5 m-20 -142.95 -176.35 4.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.209 -1.171 . . . . 0.0 109.814 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.437 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.9 m -156.17 163.31 39.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.36 -0.838 . . . . 0.0 109.367 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.515 HD23 ' CE2' ' A' ' 80' ' ' PHE . 29.4 tp -70.52 129.02 38.12 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.342 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.578 ' HB3' ' N ' ' A' ' 83' ' ' LYS . . . -116.65 -42.35 2.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.422 ' C ' HG22 ' A' ' 44' ' ' VAL . 86.6 mt-10 -139.59 147.89 41.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.176 -0.953 . . . . 0.0 110.218 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.585 HG12 ' CZ ' ' A' ' 80' ' ' PHE . 8.9 t -138.6 136.99 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 108.965 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.477 ' HA ' HD13 ' A' ' 57' ' ' LEU . 72.5 mt-10 -128.15 149.22 50.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.821 -1.174 . . . . 0.0 109.56 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.584 HD22 ' CZ ' ' A' ' 78' ' ' PHE . 11.2 tp -120.18 131.64 55.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.418 -0.801 . . . . 0.0 109.96 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.5 ' N ' HD12 ' A' ' 46' ' ' LEU . 7.5 ttp180 -119.82 131.94 55.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.076 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.487 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 43.2 mt-30 -72.27 149.95 44.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.738 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 10.2 t60 -68.54 113.94 6.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.746 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.48 2.42 27.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.453 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 28.1 t -115.01 154.92 27.93 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -1.172 . . . . 0.0 109.406 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -111.22 15.59 21.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.291 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -121.97 121.43 37.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.541 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.478 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 43.1 m95 -83.34 132.94 34.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.76 135.11 20.14 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.335 -0.853 . . . . 0.0 109.422 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.438 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 52.3 Cg_endo -71.11 149.49 58.39 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.606 2.204 . . . . 0.0 111.96 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.602 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.6 mp -108.4 138.46 44.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.213 -0.929 . . . . 0.0 109.07 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.3 m -90.17 127.48 36.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.99 -1.069 . . . . 0.0 109.014 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 22.7 tttt -74.48 105.68 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.265 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.487 ' O ' HG21 ' A' ' 63' ' ' VAL . 13.5 mttt -108.3 110.63 22.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.006 -1.059 . . . . 0.0 109.551 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.11 -107.73 1.93 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 35.0 p-10 -121.99 16.24 10.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -1.128 . . . . 0.0 109.345 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.487 HG21 ' O ' ' A' ' 60' ' ' LYS . 30.2 m -132.08 170.09 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.947 . . . . 0.0 109.424 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.439 ' HB3' HD23 ' A' ' 57' ' ' LEU . 55.9 m95 -116.11 142.82 46.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.169 -0.957 . . . . 0.0 109.216 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.466 ' HG3' HG23 ' A' ' 29' ' ' VAL . 75.7 tt0 -123.67 136.57 54.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 109.921 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.602 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.9 p -131.07 130.25 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.361 -0.837 . . . . 0.0 109.118 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.423 ' HE2' ' OE2' ' A' ' 65' ' ' GLU . 25.1 mttt -120.75 132.34 55.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.148 -0.97 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.487 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.4 t -118.56 145.55 45.27 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.447 -0.783 . . . . 0.0 109.217 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.3 m -66.55 -11.28 52.19 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.092 -1.005 . . . . 0.0 109.165 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.535 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -123.28 176.55 2.1 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.387 -0.821 . . . . 0.0 109.278 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.4 Cg_endo -69.74 157.62 59.8 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.454 2.102 . . . . 0.0 111.63 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.601 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 5.3 mt -87.58 138.65 31.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.798 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 73.5 t -124.85 125.26 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.416 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.544 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.3 164.96 26.08 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.61 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.93 146.48 80.48 Favored 'Cis proline' 0 C--O 1.214 -0.704 0 C-N-CA 122.761 -1.766 . . . . 0.0 111.8 0.205 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.1 m-85 -91.02 152.4 20.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.515 -0.741 . . . . 0.0 110.544 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.508 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 37.8 m-80 -112.68 141.67 46.2 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CZ ' HD22 ' A' ' 46' ' ' LEU . 86.9 m-85 -134.77 122.18 21.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.102 -0.999 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.544 ' CD ' HG21 ' A' ' 89' ' ' VAL . 70.6 ttt180 -104.2 143.32 33.1 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.997 -1.064 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.608 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 11.0 m-85 -125.29 143.15 51.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.196 -0.94 . . . . 0.0 111.402 -178.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.535 ' HA ' ' O ' ' A' ' 86' ' ' MET . 2.5 ttt -125.23 125.03 42.96 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.594 ' N ' ' O ' ' A' ' 86' ' ' MET . 14.8 p -73.7 147.12 43.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 110.267 -178.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.578 ' N ' ' HB3' ' A' ' 42' ' ' ALA . 42.1 mttp -50.03 -44.78 51.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.468 -0.77 . . . . 0.0 109.134 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.65 -4.31 0.61 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.86 27.06 11.64 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.594 ' O ' ' N ' ' A' ' 82' ' ' SER . 46.4 mtp -99.89 149.07 23.79 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -1.184 . . . . 0.0 108.627 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.517 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 17.8 mtt180 -121.87 136.92 54.95 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.871 -1.143 . . . . 0.0 110.457 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -134.1 139.79 46.17 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.544 HG21 ' CD ' ' A' ' 79' ' ' ARG . 6.4 t -123.2 136.97 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 120.952 -1.093 . . . . 0.0 110.315 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.606 ' CE2' HG12 ' A' ' 15' ' ' VAL . 18.2 m-85 -123.62 121.65 36.11 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -98.96 147.35 25.08 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.262 -0.899 . . . . 0.0 109.803 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.61 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 63.1 tt0 53.88 51.41 14.87 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.5 -0.75 . . . . 0.0 110.338 179.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.426 HG12 HG13 ' A' ' 94' ' ' ILE . 42.0 t -81.13 -34.37 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.889 -1.132 . . . . 0.0 108.905 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.426 HG13 HG12 ' A' ' 93' ' ' VAL . 40.9 mt -136.45 125.32 15.42 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.326 -0.859 . . . . 0.0 109.121 179.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.85 162.71 41.09 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.565 2.177 . . . . 0.0 112.024 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.544 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 32.2 m -49.96 -38.39 36.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.373 -0.829 . . . . 0.0 110.007 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.49 102.8 13.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.006 -1.059 . . . . 0.0 109.72 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.497 ' CE1' HG11 ' A' ' 19' ' ' VAL . 42.8 p90 -110.33 154.13 23.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.905 . . . . 0.0 109.163 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.9 t -104.32 167.51 9.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.419 ' HA ' HD13 ' A' ' 100' ' ' ILE . 28.6 mm -103.41 138.9 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -0.864 . . . . 0.0 109.29 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 90.35 16.0 56.2 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.438 ' O ' ' CG2' ' A' ' 18' ' ' THR . 18.9 mttm -119.21 -165.97 1.21 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 109.071 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.6 m -131.61 163.41 28.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.977 -1.077 . . . . 0.0 108.665 179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.576 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.8 m-85 -151.6 94.03 1.95 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.44 -1.412 . . . . 0.0 109.147 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.525 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -99.66 162.13 22.2 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.584 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.53 ' CD ' HG13 ' A' ' 15' ' ' VAL . 49.3 Cg_endo . . . . . 0 C--O 1.217 -0.555 0 C-N-CA 122.554 2.169 . . . . 0.0 111.83 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.458 HG22 ' HG2' ' A' ' 36' ' ' ARG . 47.5 t . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -111.93 121.4 44.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.48 HG13 ' CE1' ' A' ' 17' ' ' PHE . 5.1 t -128.3 138.44 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.878 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.7 p -141.44 145.5 35.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.346 -0.846 . . . . 0.0 109.146 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.576 ' CD2' HG12 ' A' ' 32' ' ' ILE . 13.6 m-85 -119.06 142.68 47.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.927 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.7 m -137.85 127.79 25.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.247 -0.908 . . . . 0.0 109.189 179.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.546 ' HB ' ' HA ' ' A' ' 100' ' ' ILE . 27.9 t -75.74 136.09 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.289 -0.882 . . . . 0.0 109.173 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -114.14 156.24 24.57 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.083 -1.011 . . . . 0.0 109.926 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.6 mttt -48.35 111.98 0.53 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.15 -6.39 1.53 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.283 -1.437 . . . . 0.0 110.784 179.251 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.452 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 3.3 m -61.41 140.26 58.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.842 -1.387 . . . . 0.0 109.192 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.553 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.95 177.47 2.2 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.207 -0.933 . . . . 0.0 109.53 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.553 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.3 Cg_endo -70.88 -31.34 15.69 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.614 2.209 . . . . 0.0 111.903 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -117.93 5.26 12.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 108.931 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.451 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 44.3 mttt -142.35 133.8 26.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.454 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.25 133.71 50.17 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 120.988 -1.07 . . . . 0.0 110.222 -179.511 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.507 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 21.2 t -122.4 124.64 71.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.544 HD23 ' CG2' ' A' ' 19' ' ' VAL . 1.0 OUTLIER -142.22 142.22 32.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.057 -1.027 . . . . 0.0 110.047 -179.372 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -86.15 136.62 33.13 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.605 HG21 ' CZ ' ' A' ' 80' ' ' PHE . 87.8 mt -121.3 131.02 74.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.339 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 60.3 tttt -109.99 118.38 36.28 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.581 ' CZ ' ' HG3' ' A' ' 36' ' ' ARG . 77.2 t80 -122.26 111.16 16.59 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.54 -0.725 . . . . 0.0 109.341 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 47.5 m -115.08 120.33 39.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.215 -0.928 . . . . 0.0 109.804 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.581 ' HG3' ' CZ ' ' A' ' 34' ' ' TYR . 2.9 mtt-85 -123.21 163.34 34.45 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.609 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -72.57 50.65 1.7 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.73 2.287 . . . . 0.0 111.864 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.94 -12.89 13.01 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.41 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.5 OUTLIER -96.83 178.78 5.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -1.169 . . . . 0.0 109.308 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.462 ' OG ' ' HG3' ' A' ' 83' ' ' LYS . 10.8 p -150.95 159.25 44.68 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.204 -0.935 . . . . 0.0 109.708 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.617 HD13 ' CE2' ' A' ' 80' ' ' PHE . 2.2 tt -71.81 134.27 46.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.538 ' N ' ' CD2' ' A' ' 41' ' ' LEU . . . -114.74 -42.35 3.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.178 -0.952 . . . . 0.0 109.848 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.453 ' OE2' ' HB3' ' A' ' 42' ' ' ALA . 14.6 mp0 -144.02 152.4 40.97 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.065 -1.022 . . . . 0.0 110.431 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' HD22 ' A' ' 41' ' ' LEU . 3.5 t -140.39 138.07 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.441 -0.787 . . . . 0.0 109.345 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.434 ' OE2' ' HB3' ' A' ' 56' ' ' PRO . 5.7 mm-40 -127.08 150.91 49.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 109.352 179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.61 HD13 ' O ' ' A' ' 77' ' ' ASN . 5.9 tp -122.99 123.82 41.76 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.321 -0.862 . . . . 0.0 110.56 -178.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.617 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.6 OUTLIER -106.25 129.41 54.29 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.935 . . . . 0.0 109.006 178.838 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.59 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 27.7 mt-30 -71.64 151.17 43.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.291 -0.881 . . . . 0.0 109.306 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.59 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 30.0 t60 -67.49 110.33 3.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.188 -0.945 . . . . 0.0 109.44 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.28 1.03 38.17 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 27.2 t -112.77 153.11 28.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.246 . . . . 0.0 109.397 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 61.8 tt0 -116.22 14.23 15.82 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.25 -0.906 . . . . 0.0 109.34 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -112.45 86.9 2.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.282 -0.886 . . . . 0.0 109.465 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.617 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 22.5 m95 -53.84 138.72 35.36 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.424 -0.798 . . . . 0.0 109.841 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.07 131.61 23.44 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.454 -0.779 . . . . 0.0 108.911 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.434 ' HB3' ' OE2' ' A' ' 45' ' ' GLU . 49.1 Cg_endo -69.91 150.09 66.84 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.56 2.173 . . . . 0.0 112.027 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.601 ' CD2' ' N ' ' A' ' 57' ' ' LEU . 0.2 OUTLIER -100.92 148.43 25.0 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.469 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 69.7 m -98.12 126.69 43.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.742 -1.224 . . . . 0.0 109.051 179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -71.38 107.58 4.4 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.26 -0.9 . . . . 0.0 109.204 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 60' ' ' LYS . 6.6 mmtp -111.75 106.79 15.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.969 -1.082 . . . . 0.0 109.581 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.35 -95.46 0.21 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -134.18 17.19 3.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -1.144 . . . . 0.0 109.453 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.01 169.85 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.305 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.457 ' HE3' ' CB ' ' A' ' 57' ' ' LEU . 70.3 m95 -116.41 131.04 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.177 -0.952 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.461 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 91.1 mt-10 -117.89 144.69 45.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.596 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.555 ' HB ' ' CD1' ' A' ' 57' ' ' LEU . 2.2 p -141.34 138.47 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -122.44 132.42 54.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 0.0 110.0 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.59 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 48.4 t -118.88 116.55 26.73 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.467 -0.771 . . . . 0.0 109.479 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 68' ' ' SER . 50.0 m -43.37 -37.71 2.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.143 -0.973 . . . . 0.0 109.085 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 5.2 ptpp? -94.72 168.44 11.28 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.159 179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.6 146.68 80.17 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.443 2.095 . . . . 0.0 111.743 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.609 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 mt -80.06 139.66 36.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.307 -0.871 . . . . 0.0 109.913 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.1 t -124.4 125.06 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.467 -0.771 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.445 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.45 166.41 26.72 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.59 ' HG2' ' CE1' ' A' ' 49' ' ' HIS . 47.9 Cg_endo -68.65 145.13 76.04 Favored 'Cis proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.846 -1.731 . . . . 0.0 112.045 0.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.1 m-85 -91.19 153.1 20.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.588 -0.695 . . . . 0.0 110.49 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.61 ' O ' HD13 ' A' ' 46' ' ' LEU . 2.7 m-80 -111.72 140.91 45.97 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.606 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 91.6 m-85 -131.65 135.76 47.18 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.886 -1.134 . . . . 0.0 109.772 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.439 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 53.3 ttt-85 -119.97 142.86 48.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.192 -0.943 . . . . 0.0 108.609 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.617 ' CE2' HD13 ' A' ' 41' ' ' LEU . 15.3 m-85 -124.77 144.18 50.39 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.183 -0.948 . . . . 0.0 111.721 -177.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.626 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.4 ttt -126.65 124.16 39.22 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 178.315 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.53 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 20.8 p -77.76 141.87 39.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.325 -0.859 . . . . 0.0 109.867 -178.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.509 ' N ' ' HB1' ' A' ' 42' ' ' ALA . 19.9 mttm -44.3 -44.02 7.81 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.21 -4.31 8.09 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.03 30.63 7.76 Favored Glycine 0 N--CA 1.491 2.319 0 O-C-N 121.256 -1.144 . . . . 0.0 110.33 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.53 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 37.0 mmm -103.45 107.85 18.86 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.02 -1.282 . . . . 0.0 108.854 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.626 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 35.7 mtm-85 -92.29 142.21 27.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 110.923 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.492 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -137.25 141.33 42.01 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 t -121.33 136.8 57.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.998 -1.064 . . . . 0.0 110.202 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.498 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 82.2 m-85 -125.05 121.65 34.97 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 55.1 t0 -97.51 147.96 23.73 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.097 -1.002 . . . . 0.0 109.662 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.57 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 35.8 mt-10 51.77 54.52 10.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.449 -0.782 . . . . 0.0 109.947 179.711 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 106' ' ' PRO . 75.1 t -83.63 -32.89 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.954 -1.091 . . . . 0.0 109.261 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.45 HD13 HG22 ' A' ' 94' ' ' ILE . 34.8 mt -138.55 126.49 13.73 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.33 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.19 163.82 37.21 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.553 2.169 . . . . 0.0 111.8 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.7 m -54.38 -37.31 64.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.309 -0.87 . . . . 0.0 110.015 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.49 96.2 10.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.008 . . . . 0.0 109.836 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -104.95 143.94 32.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.488 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 88.0 p -116.66 124.07 48.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.211 -0.931 . . . . 0.0 109.665 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.546 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 5.9 mt -64.04 138.65 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.528 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.428 ' N ' HG21 ' A' ' 100' ' ' ILE . . . 102.45 -4.19 50.88 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 37.8 tttp -118.19 142.86 47.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.108 -1.23 . . . . 0.0 109.264 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.415 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 7.3 m -76.81 173.61 11.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.033 -1.042 . . . . 0.0 108.476 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.568 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.0 m-85 -158.13 96.45 1.45 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 120.64 -1.288 . . . . 0.0 109.004 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.57 158.61 33.42 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.322 -0.861 . . . . 0.0 109.833 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.498 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.5 Cg_endo . . . . . 0 C--O 1.216 -0.586 0 C-N-CA 122.734 2.289 . . . . 0.0 111.663 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.469 HG12 ' OH ' ' A' ' 34' ' ' TYR . 3.0 t . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -111.49 120.88 43.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.145 -0.972 . . . . 0.0 109.189 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 3.0 t -127.77 137.06 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.89 . . . . 0.0 109.874 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.488 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 18.1 p -143.75 147.27 33.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.409 -0.807 . . . . 0.0 109.259 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.626 ' O ' ' N ' ' A' ' 104' ' ' TYR . 21.6 m-85 -118.55 145.46 45.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 109.786 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 62.6 m -139.59 128.12 22.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.112 -0.993 . . . . 0.0 109.201 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.497 HG22 ' CD2' ' A' ' 30' ' ' LEU . 5.2 t -76.4 133.36 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.222 -0.924 . . . . 0.0 109.53 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.3 mm-40 -109.83 156.27 20.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.526 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -49.32 113.56 0.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.39 -4.13 1.72 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.39 -1.386 . . . . 0.0 110.727 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.496 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 66.4 m -63.94 140.57 58.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.835 -1.391 . . . . 0.0 109.34 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.561 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.65 177.81 2.05 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.195 -0.941 . . . . 0.0 109.497 -179.571 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.561 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 49.9 Cg_endo -70.77 -31.08 16.63 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.516 2.144 . . . . 0.0 111.827 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -116.68 6.25 13.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.016 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.474 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 19.8 mttp -142.41 133.56 26.05 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.502 ' CD2' HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.29 132.28 51.69 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.964 -1.085 . . . . 0.0 110.002 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.545 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 45.7 t -121.8 124.25 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.545 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -141.55 142.02 33.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.947 -1.095 . . . . 0.0 110.285 -179.456 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.456 ' CB ' HG11 ' A' ' 63' ' ' VAL . 10.4 t70 -86.51 136.9 32.91 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.596 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 1.2 mt -117.06 127.96 74.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 120.712 -1.243 . . . . 0.0 111.122 -178.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 31.1 mtpt -108.06 114.97 29.28 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.52 ' CG ' ' HB2' ' A' ' 41' ' ' LEU . 84.4 t80 -124.3 108.2 11.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.71 -0.618 . . . . 0.0 109.817 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.9 m -109.52 117.3 33.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.38 -0.825 . . . . 0.0 109.523 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.528 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -139.89 121.72 9.79 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.406 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 50.4 Cg_endo -70.52 119.39 6.3 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.72 2.28 . . . . 0.0 111.929 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.39 -12.44 68.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.528 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -141.25 -178.63 5.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.141 -1.211 . . . . 0.0 109.646 -179.906 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -156.32 163.45 39.5 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.584 HD12 ' CD2' ' A' ' 80' ' ' PHE . 51.0 tp -68.96 125.94 28.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.228 -0.92 . . . . 0.0 109.195 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.565 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -113.97 -44.24 3.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 109.9 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -138.55 147.56 43.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.17 -0.956 . . . . 0.0 110.22 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.541 ' CG2' HD12 ' A' ' 41' ' ' LEU . 43.4 t -138.83 136.75 43.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.492 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 93.0 mt-10 -127.75 149.8 50.08 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.813 -1.179 . . . . 0.0 109.726 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.658 HD23 ' CZ ' ' A' ' 78' ' ' PHE . 3.2 tm? -118.73 142.72 47.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.529 -0.732 . . . . 0.0 109.642 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.558 ' N ' HD11 ' A' ' 46' ' ' LEU . 13.7 ttp180 -127.48 124.65 38.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -0.86 . . . . 0.0 108.885 179.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.454 ' NE2' ' OG ' ' A' ' 68' ' ' SER . 39.4 mt-30 -63.87 155.44 30.62 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.25 -0.906 . . . . 0.0 109.895 -179.534 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.56 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 44.1 t60 -73.19 119.19 17.08 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.348 -0.845 . . . . 0.0 109.586 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.34 6.79 50.44 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.406 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.4 t -115.52 156.28 26.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -1.136 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -114.73 14.63 17.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.266 -0.896 . . . . 0.0 109.332 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -120.62 111.93 18.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.335 -0.853 . . . . 0.0 109.629 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 44.6 m95 -70.05 135.82 49.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.732 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -105.28 133.89 19.94 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.439 -0.788 . . . . 0.0 109.427 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.492 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 52.5 Cg_endo -72.16 144.63 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.653 2.235 . . . . 0.0 112.084 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.551 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.5 mp -102.28 154.63 18.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.123 -0.986 . . . . 0.0 108.669 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 96.8 m -99.89 127.64 46.05 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.855 -1.153 . . . . 0.0 109.208 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.4 tttm -69.72 109.69 4.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.14 -0.975 . . . . 0.0 109.099 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 62' ' ' ASN . 21.5 mttp -108.96 119.15 38.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.983 -1.073 . . . . 0.0 109.725 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 47.8 -92.94 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 60' ' ' LYS . 4.8 m120 -131.8 17.05 4.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -1.131 . . . . 0.0 109.422 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.456 HG11 ' CB ' ' A' ' 31' ' ' ASP . 27.1 m -130.61 178.16 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.424 ' CD1' HG13 ' A' ' 32' ' ' ILE . 59.0 m95 -124.98 125.19 43.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.34 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.53 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 62.4 mt-10 -115.77 150.71 36.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.551 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.1 p -144.53 140.11 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.85 . . . . 0.0 109.265 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -121.87 132.88 54.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.185 -0.947 . . . . 0.0 109.606 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.454 ' OG ' ' NE2' ' A' ' 48' ' ' GLN . 8.0 t -116.92 133.9 55.44 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.421 -0.8 . . . . 0.0 109.214 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.9 m -59.94 -18.94 49.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.169 -0.957 . . . . 0.0 109.31 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.553 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.4 178.22 1.02 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.7 Cg_endo -70.85 141.18 40.2 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.573 2.182 . . . . 0.0 111.846 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 4.5 mt -76.39 139.05 40.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.457 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 20.8 t -125.01 125.12 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.465 -0.772 . . . . 0.0 109.53 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.43 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.72 169.28 28.41 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.6 Cg_endo -68.37 146.09 77.89 Favored 'Cis proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.826 -1.739 . . . . 0.0 112.021 0.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.4 m-85 -89.67 146.37 24.58 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.465 -0.772 . . . . 0.0 110.355 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.583 ' O ' ' CD2' ' A' ' 46' ' ' LEU . 7.1 m-80 -107.14 142.07 37.41 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 178.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.658 ' CZ ' HD23 ' A' ' 46' ' ' LEU . 45.6 m-85 -131.7 119.48 21.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.843 -1.161 . . . . 0.0 110.205 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.563 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 33.0 ttm180 -102.13 141.14 35.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.097 -1.002 . . . . 0.0 108.51 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.596 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 6.3 m-85 -123.01 142.6 50.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 111.403 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.591 ' HA ' ' O ' ' A' ' 86' ' ' MET . 0.0 OUTLIER -125.92 124.86 41.75 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.194 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.613 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -74.06 145.63 44.3 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 110.174 -178.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.565 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 94.5 mttt -48.14 -44.5 32.29 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.393 -0.817 . . . . 0.0 108.959 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.443 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -56.78 -3.19 0.64 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.72 24.34 18.22 Favored Glycine 0 N--CA 1.489 2.173 0 O-C-N 121.062 -1.258 . . . . 0.0 110.003 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.613 ' O ' ' N ' ' A' ' 82' ' ' SER . 15.0 mmm -96.37 146.75 24.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.071 -1.252 . . . . 0.0 108.634 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.534 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 52.9 mtm-85 -122.94 139.42 54.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.855 -1.153 . . . . 0.0 110.55 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.0 m120 -136.31 141.02 43.77 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.563 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 3.6 t -122.07 136.52 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.982 -1.074 . . . . 0.0 110.195 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.518 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 72.9 m-85 -124.23 122.58 38.15 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.16 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -100.42 147.75 25.5 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.262 -0.899 . . . . 0.0 109.775 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.608 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 78.9 mt-10 53.19 52.62 13.3 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 110.276 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.45 ' HB ' ' CD1' ' A' ' 78' ' ' PHE . 57.8 t -84.68 -34.44 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 109.332 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 44.9 mt -136.58 125.88 15.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.228 -0.92 . . . . 0.0 109.146 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.26 161.96 44.07 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.509 2.139 . . . . 0.0 111.887 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.6 m -52.89 -43.05 65.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.901 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.13 99.75 12.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.107 -0.996 . . . . 0.0 109.655 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -108.27 150.72 26.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.124 -0.985 . . . . 0.0 109.478 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 87.6 p -109.73 170.31 8.15 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.346 -0.847 . . . . 0.0 109.34 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.414 ' CD1' HG12 ' A' ' 19' ' ' VAL . 32.1 mm -104.99 136.12 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.276 -0.89 . . . . 0.0 109.254 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.07 4.66 59.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -118.87 144.27 46.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.104 -1.233 . . . . 0.0 109.362 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.547 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 3.5 m -78.73 177.15 8.89 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.115 -0.991 . . . . 0.0 109.193 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.626 ' N ' ' O ' ' A' ' 17' ' ' PHE . 30.7 m-85 -163.73 100.08 0.89 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.859 -1.151 . . . . 0.0 108.926 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.45 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -112.86 164.88 14.32 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.118 -0.989 . . . . 0.0 109.887 -179.448 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.518 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.6 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 C-N-CA 122.9 2.4 . . . . 0.0 111.771 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.503 HG12 ' CZ ' ' A' ' 34' ' ' TYR . 15.4 t . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -109.81 120.02 41.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.44 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.519 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 3.8 t -126.28 135.6 63.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.917 . . . . 0.0 109.71 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.529 ' CG2' ' HG2' ' A' ' 105' ' ' LYS . 61.0 p -141.59 146.48 36.32 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.476 -0.765 . . . . 0.0 109.279 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.58 ' O ' ' N ' ' A' ' 104' ' ' TYR . 4.0 m-85 -119.41 141.16 49.34 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 0.0 109.939 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.4 m -136.97 128.52 28.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.17 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.479 HG22 HD22 ' A' ' 30' ' ' LEU . 3.0 t -76.27 144.68 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.142 -0.974 . . . . 0.0 109.377 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -115.78 159.84 20.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.997 . . . . 0.0 109.584 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 50.6 mttt -53.61 114.3 1.48 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.926 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.7 -3.61 2.62 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.446 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -58.33 141.89 49.76 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.87 -1.371 . . . . 0.0 109.232 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.507 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.19 171.84 8.36 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.223 -0.923 . . . . 0.0 109.689 -179.705 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.507 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.79 -30.8 16.98 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.808 2.339 . . . . 0.0 111.998 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 mttt -112.76 8.82 18.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.077 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.433 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 16.9 mttp -142.17 132.82 25.43 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.555 ' CD1' ' N ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -120.88 123.05 41.59 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.979 -1.076 . . . . 0.0 109.362 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.555 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 25.1 t -120.42 125.99 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 29' ' ' VAL . 1.9 mt -144.7 144.29 31.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.046 -1.034 . . . . 0.0 110.165 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.76 138.91 31.23 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.608 HG23 ' CZ ' ' A' ' 80' ' ' PHE . 69.0 mt -122.28 131.46 73.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.489 -179.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.519 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 54.7 tttp -109.8 119.01 38.01 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.503 ' CZ ' HG12 ' A' ' 13' ' ' VAL . 78.7 t80 -122.7 113.25 18.97 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.46 -0.775 . . . . 0.0 109.748 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.9 m -115.99 118.38 32.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.32 -0.863 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.534 ' HD2' ' CB ' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -132.91 150.75 76.53 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.459 179.984 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.487 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.88 88.61 0.66 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 122.642 2.228 . . . . 0.0 112.081 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.43 -27.73 8.29 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.951 -1.259 . . . . 0.0 109.951 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.534 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -91.17 171.98 8.87 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.116 -1.226 . . . . 0.0 109.619 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 82' ' ' SER . 18.2 m -153.66 161.33 42.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.545 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.621 HD13 ' CE2' ' A' ' 80' ' ' PHE . 1.4 tt -72.56 132.84 44.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.365 -0.835 . . . . 0.0 109.695 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.621 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -116.14 -40.06 3.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 109.899 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 87.7 mt-10 -142.45 150.56 40.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.156 -0.965 . . . . 0.0 110.197 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' HD23 ' A' ' 41' ' ' LEU . 11.8 t -138.44 136.13 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 109.319 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.462 ' HA ' HD12 ' A' ' 57' ' ' LEU . 44.9 mt-10 -128.59 150.51 50.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.554 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 16.7 tp -120.25 135.36 55.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.411 -0.806 . . . . 0.0 109.888 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.461 ' HD2' ' O ' ' A' ' 51' ' ' SER . 4.0 ttp180 -121.58 130.27 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.837 . . . . 0.0 108.845 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 57.0 mt-30 -74.72 150.54 39.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.13 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.556 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 51.6 t-80 -64.45 117.75 7.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.37 1.34 44.06 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.461 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 38.3 t -113.33 153.14 28.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.188 -1.183 . . . . 0.0 109.439 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 58.0 mt-10 -118.3 20.48 13.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.321 -0.862 . . . . 0.0 109.318 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -124.23 94.08 4.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.873 . . . . 0.0 109.456 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.427 ' CZ3' ' N ' ' A' ' 79' ' ' ARG . 66.3 m95 -54.22 132.06 42.64 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 109.774 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.4 mm-40 -101.05 138.22 19.93 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.799 . . . . 0.0 109.273 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.87 143.78 46.42 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.709 2.273 . . . . 0.0 112.04 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.547 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 6.8 mp -110.63 149.85 29.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.194 -0.941 . . . . 0.0 108.931 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 11.3 m -103.31 125.33 49.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.923 -1.11 . . . . 0.0 109.154 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 12.9 tttm -73.58 109.85 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.135 -0.978 . . . . 0.0 109.275 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.573 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 66.8 mttt -120.23 144.23 47.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.906 -1.121 . . . . 0.0 110.068 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.59 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.76 29.96 0.87 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.59 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 8.0 t30 81.99 14.73 0.51 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.239 -1.153 . . . . 0.0 110.376 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.573 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 27.6 m -129.52 170.26 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.099 -1.0 . . . . 0.0 109.021 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -114.51 122.67 47.29 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.908 -1.12 . . . . 0.0 109.541 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.533 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 43.1 mt-10 -112.39 147.18 36.96 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.402 -0.811 . . . . 0.0 109.445 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.547 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.7 p -136.21 132.65 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.502 -0.749 . . . . 0.0 109.121 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.0 mttp -119.2 130.51 55.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.099 -1.001 . . . . 0.0 109.482 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.4 t -118.54 144.7 45.89 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 1.2 p -71.4 -4.18 24.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.072 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.605 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 16.2 mmtt -132.86 169.7 13.3 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.386 -0.821 . . . . 0.0 109.105 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.605 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.02 133.18 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.519 2.146 . . . . 0.0 111.776 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.582 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -68.13 146.53 53.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.346 -0.846 . . . . 0.0 109.777 -179.607 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.84 123.65 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.404 -0.81 . . . . 0.0 109.198 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.527 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.82 165.39 28.24 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.625 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.5 Cg_endo -68.78 145.17 76.46 Favored 'Cis proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.922 -1.699 . . . . 0.0 111.985 0.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -89.35 149.07 23.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.578 -0.701 . . . . 0.0 110.432 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.543 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 36.2 m-80 -109.52 141.82 41.45 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.554 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 87.1 m-85 -133.38 121.09 21.8 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.958 -1.089 . . . . 0.0 109.748 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.427 ' N ' ' CZ3' ' A' ' 54' ' ' TRP . 27.8 ttm180 -104.12 143.31 33.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.07 -1.019 . . . . 0.0 108.944 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.621 ' CE2' HD13 ' A' ' 41' ' ' LEU . 22.6 m-85 -125.53 144.22 50.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 111.676 -178.013 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.602 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -127.04 126.37 42.97 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.611 ' N ' ' O ' ' A' ' 86' ' ' MET . 25.9 p -76.33 145.98 39.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.215 -0.928 . . . . 0.0 110.387 -178.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.621 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 58.5 mttt -50.08 -42.96 51.1 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.15 -2.57 0.41 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.84 25.88 18.71 Favored Glycine 0 N--CA 1.489 2.22 0 O-C-N 121.082 -1.246 . . . . 0.0 109.991 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.611 ' O ' ' N ' ' A' ' 82' ' ' SER . 12.8 mtm -102.17 151.24 22.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.084 -1.245 . . . . 0.0 108.769 179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.602 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 67.8 mtp180 -125.47 140.89 52.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.92 -1.112 . . . . 0.0 110.567 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.416 ' N ' ' O ' ' A' ' 80' ' ' PHE . 11.9 m120 -135.23 139.95 44.88 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.3 t -122.39 137.45 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.999 -1.063 . . . . 0.0 110.364 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.507 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 95.4 m-85 -125.37 122.71 37.57 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.26 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -99.81 148.34 24.52 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.625 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 98.9 mt-10 52.76 54.06 11.14 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.408 -0.808 . . . . 0.0 110.393 179.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.453 HG22 ' HB3' ' A' ' 106' ' ' PRO . 77.8 t -85.37 -34.07 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 120.903 -1.123 . . . . 0.0 109.093 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.422 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.0 mt -136.57 125.21 15.21 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.879 . . . . 0.0 108.979 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.53 162.4 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.453 2.102 . . . . 0.0 111.871 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.527 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 39.5 m -51.48 -44.99 62.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.31 -0.869 . . . . 0.0 109.815 -179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.01 101.7 14.46 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.126 -0.983 . . . . 0.0 109.365 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -109.26 151.53 26.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.266 -0.897 . . . . 0.0 109.405 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 53.5 p -105.63 170.41 7.91 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.276 -0.89 . . . . 0.0 109.23 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 18.6 mm -105.13 136.35 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.192 -0.942 . . . . 0.0 109.374 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.26 9.46 61.88 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 52.5 tttt -118.42 143.14 46.89 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -1.197 . . . . 0.0 109.18 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 23.2 m -77.28 168.61 19.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.996 -1.065 . . . . 0.0 108.997 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.58 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.1 m-85 -154.63 96.98 1.94 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.674 -1.266 . . . . 0.0 108.918 179.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.529 ' HG2' ' CG2' ' A' ' 16' ' ' THR . 6.6 mtmm -103.15 160.28 26.65 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.266 -0.897 . . . . 0.0 109.806 -179.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.507 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.1 Cg_endo . . . . . 0 C--O 1.215 -0.656 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.551 HG13 ' CE1' ' A' ' 34' ' ' TYR . 6.2 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -109.63 121.65 45.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.546 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 10.3 p -129.28 141.4 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.353 -0.842 . . . . 0.0 109.427 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.419 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 67.9 p -141.58 145.79 35.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.139 -0.976 . . . . 0.0 109.721 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.63 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.0 m-85 -118.63 143.72 46.63 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 63.7 m -137.87 128.07 26.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.109 -0.995 . . . . 0.0 109.283 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.528 ' CG1' HD13 ' A' ' 100' ' ' ILE . 15.7 t -76.05 128.63 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.27 -0.893 . . . . 0.0 109.425 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.9 mm-40 -91.26 -178.39 5.13 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.551 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 20.2 mttt -79.91 70.14 6.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.429 ' O ' HG22 ' A' ' 29' ' ' VAL . . . -177.18 25.84 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.778 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.474 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 1.5 t -73.97 140.34 45.45 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.748 -1.442 . . . . 0.0 108.831 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.505 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.53 173.74 5.45 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.011 -1.056 . . . . 0.0 109.809 -179.532 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.505 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 52.1 Cg_endo -71.8 -32.18 11.9 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.719 2.279 . . . . 0.0 111.909 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -116.95 5.63 12.92 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.012 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.511 ' CD ' ' HE2' ' A' ' 67' ' ' LYS . 79.6 tttt -142.37 133.36 25.85 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.472 HD21 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -125.15 131.08 53.3 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.077 -1.014 . . . . 0.0 109.619 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.515 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.1 t -121.45 124.39 71.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.515 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -143.5 143.5 31.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.029 -1.044 . . . . 0.0 109.999 -179.487 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -83.99 135.16 34.55 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.574 HG22 ' CE2' ' A' ' 80' ' ' PHE . 78.3 mt -119.4 130.11 74.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.541 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 8.5 ttmm -111.19 120.39 42.13 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.584 ' CE2' ' HB2' ' A' ' 36' ' ' ARG . 87.3 t80 -120.32 119.87 34.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.391 -0.818 . . . . 0.0 109.519 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 31.1 m -122.31 115.55 22.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.298 -0.876 . . . . 0.0 109.751 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.584 ' HB2' ' CE2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -133.59 136.86 27.61 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.525 -0.734 . . . . 0.0 109.03 179.768 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.483 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 48.1 Cg_endo -69.93 104.49 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.676 2.251 . . . . 0.0 111.95 -179.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.31 3.38 87.06 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.546 ' CB ' ' CD ' ' A' ' 36' ' ' ARG . 4.2 t0 -136.38 175.05 9.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.155 -1.203 . . . . 0.0 109.758 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 p -153.05 161.02 43.0 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.337 -0.852 . . . . 0.0 109.372 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.573 ' HB2' ' CG ' ' A' ' 34' ' ' TYR . 8.1 tp -72.08 132.74 44.63 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.603 ' HB1' ' N ' ' A' ' 83' ' ' LYS . . . -117.26 -41.63 2.97 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 109.741 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -141.76 150.12 41.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.181 -0.949 . . . . 0.0 109.992 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.617 ' CG1' ' CE1' ' A' ' 80' ' ' PHE . 2.6 t -138.52 135.98 43.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.439 -0.788 . . . . 0.0 109.365 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.463 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 78.4 mt-10 -127.81 149.78 50.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.911 -1.118 . . . . 0.0 109.21 179.432 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.575 HD11 ' CZ ' ' A' ' 78' ' ' PHE . 7.0 tt -120.28 139.69 52.34 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.335 -0.853 . . . . 0.0 109.89 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.532 ' HD3' ' NE1' ' A' ' 54' ' ' TRP . 17.3 ttp180 -126.82 120.12 28.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.875 . . . . 0.0 108.82 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.511 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 32.0 mt-30 -64.39 145.05 56.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.141 -179.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.54 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 49.1 t60 -55.82 145.41 24.59 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.454 -0.779 . . . . 0.0 109.243 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.51 1.22 51.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.433 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 9.6 t -111.44 152.75 27.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.1 -1.235 . . . . 0.0 109.316 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 -119.0 7.32 11.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -104.89 97.9 7.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.532 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 51.5 m95 -63.11 132.07 50.62 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 109.779 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -105.3 136.97 19.14 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 109.391 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.463 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.9 Cg_endo -70.88 151.82 62.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.752 2.301 . . . . 0.0 112.201 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.603 ' CD2' ' N ' ' A' ' 57' ' ' LEU . 0.3 OUTLIER -110.2 154.03 23.94 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 179.6 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.444 ' O ' ' HA ' ' A' ' 64' ' ' TRP . 7.0 m -110.21 126.4 54.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.833 -1.167 . . . . 0.0 108.808 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.466 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 tttm -74.31 105.73 5.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.087 -1.008 . . . . 0.0 109.283 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.588 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 16.4 mttp -120.47 142.86 48.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.819 -1.176 . . . . 0.0 110.249 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.84 35.96 1.67 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 7.9 m-20 78.06 10.82 2.01 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.061 -1.258 . . . . 0.0 110.469 179.158 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.588 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 15.6 m -128.59 -177.96 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.977 -1.077 . . . . 0.0 108.776 179.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.475 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 66.1 m95 -123.07 141.07 52.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.05 -1.032 . . . . 0.0 109.927 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.498 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 92.1 mt-10 -127.96 142.37 51.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.473 -0.767 . . . . 0.0 109.105 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.591 ' HB ' ' CD1' ' A' ' 57' ' ' LEU . 1.9 p -139.39 137.53 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.227 -0.92 . . . . 0.0 109.377 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.511 ' HE2' ' CD ' ' A' ' 27' ' ' LYS . 28.7 mttt -122.71 134.15 54.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.463 -0.773 . . . . 0.0 109.632 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.511 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.7 t -117.46 145.3 44.26 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.488 -0.758 . . . . 0.0 109.18 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 49.5 m -68.77 -16.5 63.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.16 -0.962 . . . . 0.0 109.289 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.543 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.73 176.4 1.53 Allowed Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.543 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.8 Cg_endo -70.03 136.64 32.77 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.684 2.256 . . . . 0.0 111.726 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.573 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 6.4 mt -68.64 136.57 53.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.9 t -126.06 125.56 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.491 -0.756 . . . . 0.0 109.472 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -93.66 166.25 27.68 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.614 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.73 146.12 78.93 Favored 'Cis proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.843 -1.732 . . . . 0.0 111.99 0.032 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.9 m-85 -90.09 148.39 23.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.482 -0.761 . . . . 0.0 110.425 -179.201 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.442 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 18.9 m-80 -110.52 144.37 39.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.387 -0.821 . . . . 0.0 108.829 179.021 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CZ ' HD11 ' A' ' 46' ' ' LEU . 61.8 m-85 -135.81 125.38 25.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.89 -1.131 . . . . 0.0 110.25 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.555 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 15.2 ttp180 -105.85 141.38 37.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -0.96 . . . . 0.0 108.451 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.617 ' CE1' ' CG1' ' A' ' 44' ' ' VAL . 6.0 m-85 -122.11 142.23 50.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 111.082 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.583 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.2 ttm -125.5 123.97 40.33 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.603 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.4 p -74.43 144.19 44.38 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.386 -0.821 . . . . 0.0 110.352 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.603 ' N ' ' HB1' ' A' ' 42' ' ' ALA . 46.5 mttp -46.39 -44.76 17.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.429 -0.795 . . . . 0.0 108.946 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.47 -3.42 0.63 Allowed Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.499 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.05 24.36 20.0 Favored Glycine 0 N--CA 1.49 2.27 0 O-C-N 120.992 -1.299 . . . . 0.0 110.124 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.603 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.0 mtm -98.34 150.12 21.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.994 -1.298 . . . . 0.0 108.516 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 22.7 mtm-85 -125.58 141.59 51.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.845 -1.16 . . . . 0.0 110.636 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . 23.7 m120 -137.03 141.37 42.48 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.555 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 10.5 t -122.63 136.87 58.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.882 -1.136 . . . . 0.0 110.447 -178.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.559 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.7 m-85 -123.57 121.65 36.15 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.54 146.59 25.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.778 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 51.8 tt0 53.7 51.54 14.82 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.431 -0.793 . . . . 0.0 110.424 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.457 HG21 ' HB2' ' A' ' 90' ' ' PHE . 72.5 t -82.33 -34.18 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.88 -1.138 . . . . 0.0 108.992 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.436 HG22 HD11 ' A' ' 94' ' ' ILE . 12.2 mt -135.82 127.13 17.19 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.258 -0.902 . . . . 0.0 109.162 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.48 161.13 47.12 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.552 2.168 . . . . 0.0 112.007 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.53 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 28.0 m -52.04 -45.15 64.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.744 -179.717 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.82 102.41 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.429 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.474 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 47.1 p90 -111.1 151.75 27.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.128 -0.982 . . . . 0.0 109.504 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 33.2 m -106.36 163.11 13.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.909 . . . . 0.0 109.467 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.528 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.1 mm -98.16 137.4 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.376 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.4 7.47 58.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.9 tptt -121.1 143.56 49.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.134 -1.215 . . . . 0.0 109.362 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.573 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 7.2 m -79.29 178.79 7.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 108.764 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.63 ' N ' ' O ' ' A' ' 17' ' ' PHE . 25.3 m-85 -164.36 94.57 0.72 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.659 -1.275 . . . . 0.0 109.112 179.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.538 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -106.26 163.73 16.42 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.375 -0.828 . . . . 0.0 109.596 -179.481 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.559 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 48.5 Cg_endo . . . . . 0 C--O 1.216 -0.62 0 C-N-CA 122.496 2.13 . . . . 0.0 111.723 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.489 HG21 ' HG2' ' A' ' 36' ' ' ARG . 47.8 t . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.46 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 74.5 mt-30 -107.53 119.43 39.41 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.123 -0.985 . . . . 0.0 109.122 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.646 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.8 p -128.66 139.43 51.91 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.21 -0.931 . . . . 0.0 110.051 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.449 ' HA ' ' HG2' ' A' ' 105' ' ' LYS . 30.4 p -141.21 145.12 35.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.304 -0.873 . . . . 0.0 109.41 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.602 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.8 m-85 -117.16 136.23 53.18 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 52.3 m -131.27 127.21 37.31 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.968 -1.083 . . . . 0.0 109.326 179.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.504 ' HB ' ' HA ' ' A' ' 100' ' ' ILE . 9.0 t -75.38 128.37 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.283 -0.886 . . . . 0.0 109.274 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.412 ' O ' HG12 ' A' ' 100' ' ' ILE . 88.6 mm-40 -89.35 -178.25 5.57 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.061 -1.024 . . . . 0.0 109.843 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.2 mttp -80.23 65.38 5.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.437 -0.789 . . . . 0.0 109.975 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.28 25.9 0.08 OUTLIER Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.496 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.587 ' HB3' ' CZ ' ' A' ' 98' ' ' PHE . 3.2 m -79.72 144.04 34.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.079 -1.248 . . . . 0.0 109.337 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.504 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.4 172.06 7.48 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.121 -0.987 . . . . 0.0 109.579 -179.766 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -70.67 -28.2 21.16 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.667 2.244 . . . . 0.0 111.809 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 68' ' ' SER . 80.4 mttt -116.4 5.57 13.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.087 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.463 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 61.4 mttm -141.55 132.86 26.57 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.576 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.11 123.21 41.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.978 -1.076 . . . . 0.0 109.71 -179.6 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.544 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 13.6 t -119.58 125.09 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.576 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.3 mt -145.14 146.04 31.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.926 -1.109 . . . . 0.0 110.125 -179.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.489 ' CB ' HG11 ' A' ' 63' ' ' VAL . 62.6 t0 -86.06 136.82 33.08 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.068 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.62 HG21 ' CZ ' ' A' ' 80' ' ' PHE . 78.6 mt -121.05 130.82 74.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 C-N-CA 118.825 -1.15 . . . . 0.0 110.661 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.646 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 29.0 tttm -110.43 120.75 43.45 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.42 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 88.5 t80 -120.93 111.33 17.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.328 -0.857 . . . . 0.0 109.528 -179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.482 ' O ' HG12 ' A' ' 13' ' ' VAL . 19.9 m -113.66 114.72 26.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 109.772 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.515 ' NH1' ' O ' ' A' ' 37' ' ' PRO . 0.0 OUTLIER -152.58 113.01 2.78 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.515 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.06 128.91 17.39 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.704 2.269 . . . . 0.0 112.165 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.61 -22.46 40.42 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.491 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.82 -178.76 5.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -1.144 . . . . 0.0 109.807 -179.817 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.532 ' O ' ' HA ' ' A' ' 82' ' ' SER . 57.9 m -154.37 161.68 41.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.324 -0.86 . . . . 0.0 109.331 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.606 HD12 ' CD2' ' A' ' 80' ' ' PHE . 1.2 tt -71.51 130.19 40.64 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.255 -0.903 . . . . 0.0 109.736 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.611 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -116.4 -41.22 3.14 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.222 -0.924 . . . . 0.0 109.839 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -141.19 149.48 41.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.466 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.561 HG23 ' CE2' ' A' ' 80' ' ' PHE . 95.2 t -138.72 136.94 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -128.67 149.68 50.57 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.832 -1.168 . . . . 0.0 109.551 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.575 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 5.3 tt -119.4 135.73 54.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.443 -0.786 . . . . 0.0 109.852 -179.288 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.568 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 5.3 ttp180 -122.37 129.79 52.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -0.883 . . . . 0.0 109.051 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -72.11 145.83 47.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.751 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.57 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 38.4 t60 -64.42 112.09 2.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 109.358 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.48 1.26 24.71 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.473 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 11.0 t -114.27 153.91 28.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -1.2 . . . . 0.0 109.421 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -110.73 6.92 21.92 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.3 mt-10 -118.04 104.14 10.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.568 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 33.6 m95 -61.8 142.16 57.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.415 -0.803 . . . . 0.0 109.746 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -106.0 136.15 19.34 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.361 -0.837 . . . . 0.0 109.293 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.59 147.14 50.85 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.634 2.223 . . . . 0.0 112.198 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.653 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.0 mp -108.14 148.54 29.72 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.267 -0.896 . . . . 0.0 108.775 179.461 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 61.4 m -96.29 125.63 40.93 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.876 -1.14 . . . . 0.0 109.161 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.455 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 55.4 tttt -70.15 111.19 5.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.144 -0.972 . . . . 0.0 109.072 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -111.78 107.71 16.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.957 -1.089 . . . . 0.0 109.608 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.9 -93.15 0.12 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -134.75 20.01 3.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.206 -1.173 . . . . 0.0 109.339 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.489 HG11 ' CB ' ' A' ' 31' ' ' ASP . 27.7 m -130.86 -172.81 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.362 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.455 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 69.2 m95 -135.45 125.21 25.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.885 . . . . 0.0 109.122 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.456 ' HG3' HG21 ' A' ' 29' ' ' VAL . 60.9 tt0 -114.99 149.99 36.52 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 109.748 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.653 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 14.5 p -141.57 137.54 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.412 -0.805 . . . . 0.0 109.456 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -119.91 129.33 54.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.491 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.433 ' O ' ' HB3' ' A' ' 26' ' ' LYS . 35.6 t -118.3 131.83 56.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.602 -0.687 . . . . 0.0 109.51 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.5 t -61.26 -14.02 23.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.911 . . . . 0.0 108.973 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.54 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -116.1 167.55 10.12 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.35 -0.844 . . . . 0.0 109.208 179.9 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 46.4 Cg_endo -68.14 129.64 19.81 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.54 2.16 . . . . 0.0 111.792 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.598 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -63.41 142.5 58.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.374 -0.829 . . . . 0.0 109.648 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.03 124.25 68.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.332 -0.855 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.524 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.77 164.31 27.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.635 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.3 Cg_endo -69.0 147.31 82.79 Favored 'Cis proline' 0 C--O 1.214 -0.713 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.935 0.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -91.26 147.6 22.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.536 -0.728 . . . . 0.0 110.353 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -108.32 143.77 36.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.354 -0.841 . . . . 0.0 108.736 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 85.3 m-85 -134.17 125.66 28.35 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.062 -1.024 . . . . 0.0 109.906 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.492 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 44.2 ttt180 -108.21 142.34 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.962 -1.086 . . . . 0.0 108.834 179.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.62 ' CZ ' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -124.4 143.28 50.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.881 . . . . 0.0 111.154 -178.202 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.618 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.2 ttm -126.2 125.69 42.85 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.568 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.59 ' N ' ' O ' ' A' ' 86' ' ' MET . 20.5 p -73.99 145.85 44.29 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.284 -0.885 . . . . 0.0 110.26 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.611 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 18.8 mttm -50.55 -42.88 55.92 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.342 -0.849 . . . . 0.0 108.771 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.94 -4.5 0.72 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.89 27.21 11.42 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.59 ' O ' ' N ' ' A' ' 82' ' ' SER . 8.8 mtm -103.32 153.86 19.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.04 -1.27 . . . . 0.0 108.802 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 32.7 mtt180 -128.29 142.18 51.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.812 -1.18 . . . . 0.0 110.786 -178.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.5 m120 -134.81 140.09 45.6 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.492 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 3.9 t -122.63 137.04 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.958 -1.089 . . . . 0.0 110.498 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.531 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 56.8 m-85 -124.93 122.52 37.58 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 35.2 p-10 -98.85 147.62 24.74 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.15 -0.969 . . . . 0.0 109.645 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.635 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 32.8 mt-10 53.0 52.44 13.85 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.84 . . . . 0.0 110.277 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 90' ' ' PHE . 45.2 t -83.23 -34.41 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.789 -1.194 . . . . 0.0 109.094 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 13.4 mt -138.32 125.25 13.23 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.325 -0.859 . . . . 0.0 109.032 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.04 162.79 40.26 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.611 2.207 . . . . 0.0 111.97 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.524 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 12.3 m -54.01 -37.51 64.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.41 -0.806 . . . . 0.0 109.899 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.14 101.29 12.92 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.004 -1.06 . . . . 0.0 109.714 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.587 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 40.4 p90 -109.58 149.56 29.49 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 109.279 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ILE . 1.4 m -118.77 104.22 10.38 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.731 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.504 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 8.7 mt -43.29 139.96 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 105.0 -3.09 41.05 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.9 tptt -122.29 142.76 50.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -1.174 . . . . 0.0 109.226 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.484 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 10.9 m -79.18 175.0 10.99 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.117 -0.99 . . . . 0.0 108.619 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.602 ' N ' ' O ' ' A' ' 17' ' ' PHE . 26.8 m-85 -159.94 96.7 1.24 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.675 -1.265 . . . . 0.0 109.119 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.503 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 7.9 mtmt -97.8 163.2 20.0 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.441 -0.787 . . . . 0.0 109.635 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.531 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 48.1 Cg_endo . . . . . 0 C--O 1.216 -0.602 0 C-N-CA 122.69 2.26 . . . . 0.0 112.024 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.504 ' CG2' ' HG3' ' A' ' 36' ' ' ARG . 4.6 t . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -102.81 121.31 42.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.227 -0.92 . . . . 0.0 109.251 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 7.0 p -129.81 141.15 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.279 -0.888 . . . . 0.0 109.691 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.481 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 21.4 p -141.88 145.78 35.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.562 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.7 m-85 -117.0 150.83 37.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.412 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 42.3 m -144.48 127.26 16.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.999 -1.063 . . . . 0.0 109.373 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.491 ' CG2' HD22 ' A' ' 30' ' ' LEU . 12.2 t -75.84 135.63 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.4 mm-40 -114.62 155.18 27.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.049 -1.032 . . . . 0.0 109.885 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -47.23 109.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.495 -0.753 . . . . 0.0 109.853 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.68 -5.76 1.36 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.669 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.431 ' HB2' ' CZ ' ' A' ' 98' ' ' PHE . 7.3 p -62.39 142.94 57.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.801 -1.411 . . . . 0.0 109.361 -179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.508 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -136.43 173.83 5.15 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.6 Cg_endo -70.79 -28.75 19.9 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.667 2.245 . . . . 0.0 111.954 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -116.24 7.22 13.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.068 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.471 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 33.1 mttp -142.7 133.68 25.7 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.48 123.16 40.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.929 -1.107 . . . . 0.0 109.613 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.541 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 9.0 t -120.2 125.59 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 179.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.3 mt -144.87 144.95 31.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.893 -1.129 . . . . 0.0 110.226 -179.369 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.412 ' HB3' ' HB ' ' A' ' 18' ' ' THR . 16.2 t70 -82.4 134.43 35.24 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.614 HG22 ' CE2' ' A' ' 80' ' ' PHE . 74.9 mt -119.96 130.64 73.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.779 -1.201 . . . . 0.0 110.74 -178.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 62.8 mttm -111.49 120.15 41.16 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 178.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.533 ' CG ' ' HB2' ' A' ' 41' ' ' LEU . 90.1 t80 -120.53 112.86 19.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.425 -0.797 . . . . 0.0 109.501 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.494 ' O ' HG13 ' A' ' 13' ' ' VAL . 33.8 m -115.22 115.24 26.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 0.0 109.688 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.548 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -147.6 117.55 4.36 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.462 -0.774 . . . . 0.0 109.066 179.897 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.29 123.65 10.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.94 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.37 59.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.548 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -142.71 -176.39 4.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -1.201 . . . . 0.0 109.864 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.6 m -155.83 162.69 40.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.332 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.575 HD21 ' CE2' ' A' ' 80' ' ' PHE . 48.6 tp -69.32 126.38 29.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.964 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.568 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.83 -44.51 2.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.854 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.415 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 27.0 mt-10 -137.19 146.85 45.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.158 -0.964 . . . . 0.0 110.262 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.453 HG22 HD12 ' A' ' 41' ' ' LEU . 98.2 t -139.93 137.39 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.476 -0.765 . . . . 0.0 109.252 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.472 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.5 mt-10 -127.79 150.69 49.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.822 -1.174 . . . . 0.0 109.231 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.557 ' CD1' ' O ' ' A' ' 77' ' ' ASN . 12.1 tp -120.42 132.24 55.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 110.393 -178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.608 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.4 OUTLIER -113.19 124.88 53.56 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.292 -0.88 . . . . 0.0 108.995 179.178 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.576 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 61.1 mt-30 -65.24 159.14 24.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.252 -0.905 . . . . 0.0 109.087 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.566 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 11.4 t-80 -75.95 108.15 8.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.17 7.09 21.66 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 23.1 t -115.88 154.16 30.23 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.047 -1.267 . . . . 0.0 109.514 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mt-10 -104.9 -22.44 13.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.274 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -87.67 129.03 35.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.608 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 9.4 m95 -86.92 141.68 28.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.632 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.41 ' OE2' ' O ' ' A' ' 67' ' ' LYS . 45.4 tt0 -107.98 133.75 20.38 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.351 -0.843 . . . . 0.0 109.481 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.467 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.7 Cg_endo -70.78 151.0 62.93 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.693 2.262 . . . . 0.0 111.783 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.538 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.8 mp -109.16 143.84 38.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.206 -0.934 . . . . 0.0 109.11 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.7 m -92.7 127.44 38.2 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.99 -1.069 . . . . 0.0 109.136 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -70.49 109.99 5.13 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.164 -0.96 . . . . 0.0 109.11 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.425 ' O ' HG23 ' A' ' 63' ' ' VAL . 37.1 mttt -109.4 115.77 30.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.945 -1.097 . . . . 0.0 109.586 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 53.18 -97.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -128.12 16.58 6.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.216 -1.167 . . . . 0.0 109.466 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 60' ' ' LYS . 27.3 m -131.04 -176.94 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.32 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.48 ' CD1' HD13 ' A' ' 32' ' ' ILE . 57.9 m95 -128.33 130.35 47.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.112 -0.993 . . . . 0.0 109.332 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.415 ' OE1' ' HE3' ' A' ' 60' ' ' LYS . 78.2 tt0 -111.69 135.97 51.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.645 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.55 ' CG1' ' HB3' ' A' ' 28' ' ' LEU . 5.3 p -130.67 129.67 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.426 -0.797 . . . . 0.0 109.012 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.471 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 19.4 mtmm -121.43 133.3 55.07 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.04 -1.038 . . . . 0.0 109.692 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.576 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.1 t -118.38 153.08 34.63 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.422 -0.799 . . . . 0.0 109.305 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.1 m -78.6 -2.36 38.57 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.151 -0.968 . . . . 0.0 109.148 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.543 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 3.5 mttt -128.81 177.02 2.34 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.339 -0.851 . . . . 0.0 109.164 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.543 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.6 Cg_endo -68.54 150.3 75.02 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.495 2.13 . . . . 0.0 111.856 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.567 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 14.9 mt -85.58 137.46 32.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.33 -0.856 . . . . 0.0 109.682 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.557 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 28.9 t -127.02 125.86 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.46 -0.775 . . . . 0.0 109.475 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.523 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.94 169.19 28.03 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.633 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.2 Cg_endo -67.98 146.92 78.86 Favored 'Cis proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.912 -1.703 . . . . 0.0 112.002 0.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.567 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 86.6 m-85 -89.69 149.77 22.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.589 -0.695 . . . . 0.0 110.343 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.557 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 3.0 m-80 -112.06 142.74 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -134.85 134.84 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.999 -1.063 . . . . 0.0 109.381 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.536 ' NH1' ' CZ ' ' A' ' 87' ' ' ARG . 64.5 ttt180 -116.8 144.07 44.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.943 -1.098 . . . . 0.0 108.864 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.614 ' CE2' HG22 ' A' ' 32' ' ' ILE . 6.6 m-85 -122.89 140.79 52.6 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.157 -0.965 . . . . 0.0 111.238 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.1 ttm -123.45 124.02 41.96 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 18.8 p -72.37 142.41 48.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.455 -0.778 . . . . 0.0 110.475 -178.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.568 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 56.4 mttt -46.64 -44.18 18.18 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 108.821 178.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -57.09 -5.85 1.65 Allowed Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 97.3 25.36 11.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 55.4 mtp -99.67 152.52 19.97 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.108 -1.23 . . . . 0.0 108.473 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.597 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 33.5 mtm180 -128.39 142.13 51.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.617 -1.302 . . . . 0.0 110.918 -178.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.441 ' N ' ' O ' ' A' ' 80' ' ' PHE . 29.9 m120 -135.69 140.73 44.67 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.3 t -122.79 136.72 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.863 -1.148 . . . . 0.0 110.387 -179.026 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.548 ' CD1' ' CB ' ' A' ' 106' ' ' PRO . 55.5 m-85 -124.16 122.41 37.75 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.457 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 24.0 p-10 -99.53 147.37 25.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.209 -0.932 . . . . 0.0 109.716 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.633 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 81.3 mt-10 53.99 51.18 15.15 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.505 -0.747 . . . . 0.0 110.344 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -81.96 -34.89 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.864 -1.148 . . . . 0.0 108.938 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.427 HG23 HD13 ' A' ' 94' ' ' ILE . 13.0 mt -135.8 125.07 16.02 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.473 -0.767 . . . . 0.0 108.974 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.28 161.61 45.19 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.569 2.179 . . . . 0.0 111.977 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.523 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 29.1 m -50.09 -45.68 52.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.373 -0.83 . . . . 0.0 109.726 -179.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.06 101.18 13.89 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.053 -1.029 . . . . 0.0 109.5 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.431 ' CZ ' ' HB2' ' A' ' 23' ' ' SER . 44.8 p90 -108.26 154.12 22.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 69.4 m -110.43 170.87 7.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.39 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 HG13 ' A' ' 19' ' ' VAL . 23.2 mm -105.19 136.71 37.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 109.312 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.72 6.28 59.56 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 46.7 tttt -119.03 143.43 47.1 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.095 -1.238 . . . . 0.0 109.225 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.492 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 15.5 m -80.8 174.74 11.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.161 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.619 ' N ' ' O ' ' A' ' 17' ' ' PHE . 35.1 m-85 -160.36 102.25 1.39 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.765 -1.209 . . . . 0.0 108.772 179.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.577 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 1.7 ptpp? -114.16 166.36 11.66 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.201 -0.937 . . . . 0.0 109.776 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.577 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 48.7 Cg_endo . . . . . 0 C--O 1.216 -0.617 0 C-N-CA 122.587 2.191 . . . . 0.0 111.811 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.493 HG13 ' CZ ' ' A' ' 34' ' ' TYR . 10.9 t . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -113.31 120.96 42.95 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.7 t -127.67 137.89 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.257 -0.902 . . . . 0.0 109.823 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 32.4 p -142.31 146.09 34.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.39 -0.819 . . . . 0.0 109.231 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.603 ' O ' ' N ' ' A' ' 104' ' ' TYR . 8.7 m-85 -119.41 151.85 37.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.106 -0.996 . . . . 0.0 110.02 -179.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 27.7 m -143.18 158.86 43.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 108.71 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.533 ' CG1' HD12 ' A' ' 100' ' ' ILE . 4.3 t -107.75 127.96 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.087 -1.008 . . . . 0.0 109.433 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -101.47 149.8 23.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.897 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -44.01 114.09 0.62 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.498 -0.752 . . . . 0.0 109.94 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.16 2.19 1.4 Allowed Glycine 0 N--CA 1.49 2.264 0 C-N-CA 119.272 -1.442 . . . . 0.0 110.907 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.0 m -61.18 142.38 56.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.667 -1.49 . . . . 0.0 109.054 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -137.82 171.94 7.59 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.094 -1.004 . . . . 0.0 109.616 -179.627 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.482 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.7 Cg_endo -70.68 -29.02 20.09 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.729 2.286 . . . . 0.0 111.829 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -118.03 3.4 12.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.009 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.428 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 21.1 mttt -141.83 133.15 26.51 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.422 HD21 HD12 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.07 133.78 50.39 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.018 -1.051 . . . . 0.0 110.17 -179.374 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.483 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.3 t -121.62 124.05 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.515 HD23 ' CG2' ' A' ' 19' ' ' VAL . 1.3 mt -140.94 141.14 34.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.01 -1.056 . . . . 0.0 110.093 -179.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -85.55 134.51 34.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.621 HG23 ' CZ ' ' A' ' 80' ' ' PHE . 1.4 mt -116.12 126.89 73.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 118.922 -1.111 . . . . 0.0 110.893 -179.105 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 13.7 tttm -107.28 115.07 29.52 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.01 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.493 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 77.2 t80 -124.93 111.88 15.96 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.345 0.593 . . . . 0.0 109.634 -178.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.3 m -113.85 119.77 38.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.94 . . . . 0.0 109.691 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.471 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 29.7 ttt85 -140.91 119.58 8.2 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.7 119.29 6.26 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.714 2.276 . . . . 0.0 111.821 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.14 -14.52 60.52 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.471 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 6.2 m-20 -136.43 175.18 9.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.181 -1.188 . . . . 0.0 109.644 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.51 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 m -154.41 161.6 41.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.297 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.606 HD11 ' CE2' ' A' ' 80' ' ' PHE . 0.4 OUTLIER -71.21 130.87 42.53 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.257 -0.902 . . . . 0.0 109.385 179.947 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.585 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -112.4 -41.03 3.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -143.18 151.27 40.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 0.0 110.187 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.536 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.1 t -138.9 136.32 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.5 mt-10 -126.77 149.24 49.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.697 -1.252 . . . . 0.0 109.547 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.589 HD13 ' CZ ' ' A' ' 78' ' ' PHE . 10.4 tp -122.18 131.24 53.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.479 -0.763 . . . . 0.0 109.929 -179.106 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.606 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 41.8 ttp180 -118.92 135.04 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.088 179.354 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.603 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 78.7 mt-30 -75.05 150.72 38.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 110.034 -179.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.578 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 4.2 t-80 -67.4 112.55 4.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.41 -0.806 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.63 0.63 30.73 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.47 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 4.0 t -113.67 155.54 25.35 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.206 -1.173 . . . . 0.0 109.32 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -108.33 -14.31 14.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.243 -0.911 . . . . 0.0 109.404 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -93.17 117.92 30.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.223 -0.923 . . . . 0.0 109.736 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.606 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 25.3 m95 -75.94 140.29 42.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.419 -0.801 . . . . 0.0 109.638 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.461 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.8 OUTLIER -106.59 127.35 28.31 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.472 -0.768 . . . . 0.0 109.095 179.757 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.461 ' HD2' ' HG3' ' A' ' 55' ' ' GLU . 49.6 Cg_endo -69.67 150.42 68.71 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.586 2.191 . . . . 0.0 112.19 -179.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.579 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.8 mp -107.47 141.85 38.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 108.847 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 43.5 m -92.91 127.26 38.36 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.923 -1.11 . . . . 0.0 109.06 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tttm -73.49 109.86 7.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 109.717 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.434 ' O ' HG21 ' A' ' 63' ' ' VAL . 26.0 mttm -109.88 110.93 22.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.998 -1.064 . . . . 0.0 109.752 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.46 -90.02 0.07 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.5 p-10 -139.04 18.45 2.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.288 -1.124 . . . . 0.0 109.281 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.434 HG21 ' O ' ' A' ' 60' ' ' LYS . 16.2 m -130.66 173.4 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.283 -0.886 . . . . 0.0 109.249 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.448 ' CD1' HG13 ' A' ' 32' ' ' ILE . 66.5 m95 -123.17 128.64 50.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 109.317 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -117.85 151.38 37.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.627 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.579 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.2 p -145.38 140.9 22.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.329 -0.857 . . . . 0.0 109.308 179.784 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.428 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 34.9 mttp -122.15 132.97 54.73 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.717 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.603 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 38.8 t -116.71 121.52 41.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.454 -0.779 . . . . 0.0 109.349 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 58.8 m -49.16 -22.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.555 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -109.65 177.25 1.28 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.318 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.555 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -68.86 152.69 73.67 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.504 2.136 . . . . 0.0 111.657 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.593 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 mt -90.28 138.05 31.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 35.4 t -126.34 125.28 67.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.422 -0.798 . . . . 0.0 109.605 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.532 ' HA3' ' N ' ' A' ' 96' ' ' THR . . . -94.39 167.29 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.67 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.1 Cg_endo -68.15 147.43 80.46 Favored 'Cis proline' 0 C--O 1.213 -0.735 0 C-N-CA 122.937 -1.693 . . . . 0.0 112.034 0.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.1 m-85 -91.23 150.82 21.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.441 -0.787 . . . . 0.0 110.448 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.527 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 23.3 m-80 -111.12 142.08 43.77 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CZ ' HD13 ' A' ' 46' ' ' LEU . 41.9 m-85 -135.95 128.3 30.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.918 -1.114 . . . . 0.0 110.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.541 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 16.2 ttt180 -108.56 142.23 39.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 108.643 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.621 ' CZ ' HG23 ' A' ' 32' ' ' ILE . 9.3 m-85 -123.49 143.6 50.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.213 -0.93 . . . . 0.0 111.411 -178.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.596 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.6 ttm -127.44 125.67 40.97 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.2 p -77.39 144.94 37.54 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.89 . . . . 0.0 110.246 -178.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.585 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 60.0 mttm -47.78 -43.14 27.28 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.4 -2.71 0.74 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.37 23.98 22.87 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.8 mmm -98.64 148.39 23.86 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -1.231 . . . . 0.0 108.681 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.596 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 77.8 mtm-85 -126.84 142.58 51.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.78 -1.2 . . . . 0.0 110.586 -178.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.413 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.2 m120 -136.97 141.17 42.59 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.541 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 2.9 t -121.43 136.32 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.5 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 71.8 m-85 -124.56 122.39 37.44 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -100.06 148.62 24.36 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.244 -0.91 . . . . 0.0 109.644 -179.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.67 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 88.6 mt-10 53.28 51.87 14.66 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.369 -0.832 . . . . 0.0 110.278 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.08 -34.33 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.856 -1.153 . . . . 0.0 109.188 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.2 mt -137.53 125.56 14.33 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.325 -0.859 . . . . 0.0 109.127 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.71 163.02 39.8 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.577 2.185 . . . . 0.0 112.07 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.532 ' N ' ' HA3' ' A' ' 74' ' ' GLY . 32.3 m -54.13 -44.09 71.06 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.414 -0.804 . . . . 0.0 109.918 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.39 99.41 11.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.054 -1.029 . . . . 0.0 109.363 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -107.85 147.09 31.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 109.722 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 70.4 m -107.08 167.86 9.6 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -0.862 . . . . 0.0 109.169 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.533 HD12 ' CG1' ' A' ' 19' ' ' VAL . 29.8 mm -104.16 136.78 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 109.408 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.73 2.66 61.26 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.1 tptt -116.15 142.55 46.67 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.09 -1.241 . . . . 0.0 109.176 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 18.6 m -78.39 173.51 12.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.075 -1.016 . . . . 0.0 108.966 -179.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.603 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -156.16 105.83 2.35 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.765 -1.209 . . . . 0.0 108.831 179.187 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 1.3 ptmt -103.67 157.41 33.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.724 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.5 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 51.2 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.744 2.296 . . . . 0.0 111.734 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.527 ' CG2' ' HG2' ' A' ' 36' ' ' ARG . 40.5 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -109.4 120.35 42.24 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 109.118 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.574 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.9 p -128.35 140.53 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.314 -0.866 . . . . 0.0 109.499 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.466 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 32.0 p -143.09 146.32 33.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.187 -0.945 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.597 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.4 m-85 -117.01 148.41 41.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.251 -0.905 . . . . 0.0 109.286 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 36.0 m -143.6 128.63 18.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.929 -1.107 . . . . 0.0 109.621 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.553 ' CG2' HD23 ' A' ' 30' ' ' LEU . 3.5 t -76.7 138.52 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.157 -0.964 . . . . 0.0 109.364 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.7 mm-40 -118.66 155.66 30.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.02 -1.05 . . . . 0.0 109.612 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -47.51 112.73 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.82 . . . . 0.0 110.009 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.73 -7.96 1.99 Allowed Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.71 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 4.5 p -60.18 141.76 55.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.805 -1.409 . . . . 0.0 109.435 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.565 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.14 177.27 2.25 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.165 -0.959 . . . . 0.0 109.693 -179.594 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.565 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.8 Cg_endo -71.2 -33.93 10.77 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.784 2.322 . . . . 0.0 112.015 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.435 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -115.54 2.82 13.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 108.894 179.509 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' ASP . 27.2 mtmt -139.19 132.29 29.64 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.595 ' CD2' ' CD1' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -127.68 132.99 49.6 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.001 -1.062 . . . . 0.0 110.211 -179.086 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.6 t -119.56 122.76 69.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.595 ' CD1' ' CD2' ' A' ' 28' ' ' LEU . 16.8 mt -137.66 136.72 37.7 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.046 -1.034 . . . . 0.0 110.324 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.462 ' HB2' HG13 ' A' ' 63' ' ' VAL . 37.7 t70 -84.2 136.22 34.05 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 177.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.593 HG12 ' CD2' ' A' ' 17' ' ' PHE . 88.1 mt -121.62 131.11 73.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.688 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 44.3 tttt -110.32 119.46 39.28 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.479 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 83.5 t80 -121.44 118.15 28.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.456 -0.777 . . . . 0.0 109.355 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 17.1 m -121.16 117.81 28.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.268 -0.895 . . . . 0.0 109.923 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.56 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 0.0 OUTLIER -124.24 168.52 12.7 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.832 . . . . 0.0 109.345 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.56 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -70.07 76.96 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.634 2.223 . . . . 0.0 111.726 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.43 -5.92 75.28 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.26 179.38 4.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 109.498 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.0 m -151.08 158.37 43.97 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.302 -0.874 . . . . 0.0 109.527 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.617 HD13 ' CE2' ' A' ' 80' ' ' PHE . 1.2 tt -71.79 136.4 47.06 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.659 -0.65 . . . . 0.0 109.342 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.552 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.58 -43.13 3.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.11 -0.994 . . . . 0.0 110.238 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -139.83 148.81 42.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.004 -1.06 . . . . 0.0 110.659 -179.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.561 ' CG2' HD13 ' A' ' 41' ' ' LEU . 14.6 t -139.0 136.3 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.541 -0.725 . . . . 0.0 109.33 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.424 ' HA ' HD11 ' A' ' 57' ' ' LEU . 95.2 mt-10 -128.75 150.89 50.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.953 -1.092 . . . . 0.0 109.255 179.351 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.634 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 9.6 tt -121.61 147.32 46.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.27 -0.893 . . . . 0.0 110.045 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 51' ' ' SER . 13.4 ttp180 -131.95 128.56 38.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.87 . . . . 0.0 108.808 179.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 36.0 mt-30 -69.7 153.02 43.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 0.0 109.942 -179.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HD2' ' A' ' 75' ' ' PRO . 66.1 t60 -67.45 119.29 12.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.41 -0.806 . . . . 0.0 109.682 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.91 4.35 54.41 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.462 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 39.4 t -114.24 154.49 27.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.453 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 87.5 mt-10 -117.78 15.69 14.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.375 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -119.02 97.6 5.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.903 . . . . 0.0 109.687 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -55.84 134.56 51.91 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.36 -0.838 . . . . 0.0 109.657 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -104.26 134.79 19.51 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.348 -0.845 . . . . 0.0 109.316 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.61 145.35 52.01 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.627 2.218 . . . . 0.0 112.095 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.609 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.6 mp -110.0 151.2 27.45 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 108.871 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.1 m -100.66 125.51 47.09 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.865 -1.147 . . . . 0.0 108.851 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -72.13 108.83 5.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.202 -0.936 . . . . 0.0 109.091 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.513 ' O ' ' N ' ' A' ' 62' ' ' ASN . 15.2 mttm -107.48 126.26 52.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.986 -1.071 . . . . 0.0 109.542 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 48.67 -92.68 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 60' ' ' LYS . 31.6 p-10 -136.73 19.5 3.07 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.282 -1.128 . . . . 0.0 109.344 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.462 HG13 ' HB2' ' A' ' 31' ' ' ASP . 20.6 m -131.72 173.57 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.334 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.433 ' CH2' HG22 ' A' ' 44' ' ' VAL . 71.1 m95 -117.35 127.44 54.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.94 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.413 ' CD ' ' HD2' ' A' ' 60' ' ' LYS . 80.3 mt-10 -113.43 141.07 47.53 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.29 -0.881 . . . . 0.0 109.892 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.609 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 7.7 p -135.56 132.69 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.284 -0.885 . . . . 0.0 109.066 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.451 ' HG3' ' HG2' ' A' ' 27' ' ' LYS . 41.3 tttm -120.32 132.42 55.29 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 0.0 109.686 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 69' ' ' SER . 23.2 t -121.66 124.08 43.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.5 -0.75 . . . . 0.0 109.316 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 68' ' ' SER . 44.7 m -44.2 -29.86 0.7 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.011 -1.056 . . . . 0.0 108.461 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.697 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 0.1 OUTLIER -105.72 170.53 5.77 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.37 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.697 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.3 Cg_endo -66.6 172.18 9.67 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.115 1.876 . . . . 0.0 111.687 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.597 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.9 mt -100.59 144.53 29.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 110.122 -179.486 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.87 125.34 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.453 -0.779 . . . . 0.0 109.295 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.473 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -96.47 170.35 26.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.576 ' HD2' ' CG ' ' A' ' 49' ' ' HIS . 48.2 Cg_endo -68.62 146.6 79.94 Favored 'Cis proline' 0 C--O 1.213 -0.739 0 C-N-CA 122.837 -1.734 . . . . 0.0 111.859 -0.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.597 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 84.5 m-85 -92.48 147.22 23.07 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.447 -0.783 . . . . 0.0 110.669 -179.104 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.529 ' C ' ' CD1' ' A' ' 78' ' ' PHE . 20.5 m-80 -108.75 144.99 35.83 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.634 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 3.8 m-85 -136.99 122.56 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.855 -1.153 . . . . 0.0 110.319 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.52 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 54.2 ttt180 -101.89 142.19 33.58 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.617 ' CE2' HD13 ' A' ' 41' ' ' LEU . 8.8 m-85 -123.91 143.79 50.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 111.267 -177.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.572 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.3 ttt -126.14 124.5 40.68 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.535 ' OG ' ' HB2' ' A' ' 86' ' ' MET . 13.4 p -77.53 145.6 36.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.846 . . . . 0.0 110.157 -178.233 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.552 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -44.96 -47.28 11.39 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.156 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.52 -6.92 5.14 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 97.01 34.41 5.68 Favored Glycine 0 N--CA 1.489 2.185 0 O-C-N 121.141 -1.211 . . . . 0.0 110.111 179.352 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.535 ' HB2' ' OG ' ' A' ' 82' ' ' SER . 55.8 mtp -105.36 110.46 22.82 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.028 -1.278 . . . . 0.0 109.127 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 26.6 mtm180 -90.4 140.6 29.56 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 110.668 -179.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.1 m120 -137.61 141.84 41.26 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.52 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 3.1 t -121.24 135.57 60.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.916 -1.115 . . . . 0.0 110.299 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.504 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 13.4 m-85 -124.2 122.31 37.45 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -98.44 146.98 25.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.208 -0.933 . . . . 0.0 109.546 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.574 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 49.1 tt0 52.92 52.64 13.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.438 -0.789 . . . . 0.0 110.162 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.443 HG13 HG13 ' A' ' 94' ' ' ILE . 42.4 t -80.34 -33.38 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.882 -1.136 . . . . 0.0 108.933 179.447 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.521 HG22 HD13 ' A' ' 94' ' ' ILE . 14.0 mt -138.55 127.53 14.34 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.381 -0.824 . . . . 0.0 108.882 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.06 160.64 49.1 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.559 2.173 . . . . 0.0 112.099 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.473 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 58.6 m -50.96 -36.49 39.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.83 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.15 103.23 12.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.11 -0.994 . . . . 0.0 109.522 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.488 ' CE1' HG11 ' A' ' 19' ' ' VAL . 48.7 p90 -110.9 155.01 23.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.87 . . . . 0.0 109.219 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.5 m -105.99 172.39 6.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.145 -0.972 . . . . 0.0 109.418 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.439 HD11 ' CG1' ' A' ' 19' ' ' VAL . 28.2 mm -104.61 135.21 43.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.264 -0.898 . . . . 0.0 109.152 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 99.36 2.8 56.65 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.6 tttp -117.77 142.74 46.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.967 -1.313 . . . . 0.0 109.159 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.488 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.3 m -81.74 176.45 9.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.119 -0.988 . . . . 0.0 109.091 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.597 ' N ' ' O ' ' A' ' 17' ' ' PHE . 26.9 m-85 -160.69 98.4 1.22 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.8 -1.188 . . . . 0.0 109.064 179.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.497 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 0.2 OUTLIER -100.35 164.94 15.34 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.265 -0.897 . . . . 0.0 109.797 -179.423 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.504 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.5 Cg_endo . . . . . 0 C--O 1.215 -0.626 0 C-N-CA 122.712 2.274 . . . . 0.0 111.81 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.646 ' CG1' ' CE1' ' A' ' 34' ' ' TYR . 5.0 t . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -112.23 121.58 45.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.052 -1.03 . . . . 0.0 109.625 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.623 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 14.7 t -128.19 138.59 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.515 ' HA ' ' HB3' ' A' ' 105' ' ' LYS . 68.6 p -141.85 146.5 35.89 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.775 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.632 ' CD2' HG12 ' A' ' 32' ' ' ILE . 88.8 m-85 -119.35 118.79 32.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.3 -0.875 . . . . 0.0 109.734 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 21.9 m -108.36 158.51 17.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.922 -1.111 . . . . 0.0 108.979 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.54 ' CG1' ' OG ' ' A' ' 23' ' ' SER . 8.5 t -107.8 126.68 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.46 ' O ' HD13 ' A' ' 100' ' ' ILE . 1.7 mp0 -92.66 -173.52 3.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.146 -0.971 . . . . 0.0 109.605 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -83.65 66.01 8.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.385 -0.822 . . . . 0.0 109.937 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -172.33 22.01 0.07 OUTLIER Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.055 -1.545 . . . . 0.0 110.924 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.54 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 50.3 m -74.21 142.34 45.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.766 -1.432 . . . . 0.0 109.058 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.485 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.9 173.31 5.81 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.055 -1.028 . . . . 0.0 109.875 -179.634 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 51.8 Cg_endo -71.66 -30.56 14.52 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.793 2.329 . . . . 0.0 111.836 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -115.88 5.26 14.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 108.731 179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.472 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 72.8 mttt -142.17 133.11 25.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.441 HD21 HD12 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -127.87 135.34 49.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.067 -1.021 . . . . 0.0 110.099 -179.321 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' HD12 ' A' ' 30' ' ' LEU . 4.1 t -119.39 119.05 59.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.659 ' CD2' ' N ' ' A' ' 30' ' ' LEU . 0.4 OUTLIER -126.85 127.11 44.46 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.217 -0.927 . . . . 0.0 110.282 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.462 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 63.6 t0 -77.99 132.02 37.64 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.632 HG12 ' CD2' ' A' ' 17' ' ' PHE . 52.4 mt -118.3 128.56 75.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.157 -178.125 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.623 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 33.5 mttt -109.41 119.98 41.12 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.646 ' CE1' ' CG1' ' A' ' 13' ' ' VAL . 71.7 t80 -121.21 120.77 36.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.302 -0.874 . . . . 0.0 109.837 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -123.66 116.95 23.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.399 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.543 ' CG ' ' HB2' ' A' ' 39' ' ' ASP . 38.0 ttt85 -139.72 131.94 14.96 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.421 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.44 107.85 2.08 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.814 2.343 . . . . 0.0 111.992 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.99 -5.29 84.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.543 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 31.6 m-20 -134.71 174.28 10.74 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -1.201 . . . . 0.0 109.682 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.448 ' O ' ' HA ' ' A' ' 82' ' ' SER . 14.7 m -155.42 162.65 40.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.574 HD21 ' CE2' ' A' ' 80' ' ' PHE . 26.8 tp -71.87 129.73 39.32 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.27 -0.894 . . . . 0.0 109.649 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.587 ' HB2' ' N ' ' A' ' 83' ' ' LYS . . . -116.1 -40.29 3.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -0.934 . . . . 0.0 109.479 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -143.74 152.2 40.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.915 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.599 HG13 ' CE1' ' A' ' 80' ' ' PHE . 46.5 t -139.71 137.14 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.445 -0.785 . . . . 0.0 109.406 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.469 ' HA ' HD11 ' A' ' 57' ' ' LEU . 75.4 mt-10 -128.89 150.48 50.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.904 -1.123 . . . . 0.0 109.433 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.585 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 6.7 tt -119.03 142.22 48.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.434 -0.791 . . . . 0.0 109.805 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.531 ' N ' HD22 ' A' ' 46' ' ' LEU . 17.5 ttp180 -128.03 130.02 47.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.374 -0.829 . . . . 0.0 108.812 179.216 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.538 ' NE2' HD21 ' A' ' 46' ' ' LEU . 57.6 mm-40 -72.14 152.42 42.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 110.218 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.562 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 13.0 t-80 -68.07 131.0 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.513 -0.742 . . . . 0.0 109.461 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 87.8 3.36 80.42 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.8 t -112.23 153.04 27.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.178 -1.19 . . . . 0.0 109.189 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -113.75 21.56 14.86 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.387 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.35 124.59 43.28 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.236 -0.915 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.428 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 64.6 m95 -85.06 129.94 34.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.432 -0.793 . . . . 0.0 109.415 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.4 134.62 19.66 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.369 -0.832 . . . . 0.0 109.342 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -71.8 146.88 49.15 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.642 2.228 . . . . 0.0 112.164 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.604 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.3 mp -106.8 158.04 17.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 108.621 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 52.3 m -108.87 127.04 53.7 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.846 -1.159 . . . . 0.0 109.116 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 37.5 tttm -65.35 120.95 13.73 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 62' ' ' ASN . 2.8 mttm -109.92 -152.7 0.5 Allowed 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.167 -0.958 . . . . 0.0 109.377 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 62' ' ' ASN . . . -58.72 81.2 0.01 OUTLIER Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.518 ' N ' ' O ' ' A' ' 60' ' ' LYS . 39.2 t30 63.97 10.54 5.4 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.243 -1.151 . . . . 0.0 110.086 179.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.46 HG23 ' HB2' ' A' ' 60' ' ' LYS . 5.3 m -132.05 179.12 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.092 -1.005 . . . . 0.0 109.717 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.469 ' CG ' HD11 ' A' ' 32' ' ' ILE . 63.0 m95 -127.15 126.75 43.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.067 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.426 ' HG2' ' N ' ' A' ' 66' ' ' VAL . 62.1 tt0 -119.25 154.58 33.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.17 -0.956 . . . . 0.0 109.706 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.604 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.0 p -146.17 141.42 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.405 -0.81 . . . . 0.0 109.244 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -119.81 129.01 54.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -0.941 . . . . 0.0 109.723 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.2 t -118.6 130.36 55.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.57 -0.706 . . . . 0.0 109.578 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.0 p -61.24 -21.35 63.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.149 -0.969 . . . . 0.0 108.922 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.615 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 15.0 ptmt -106.95 166.86 10.34 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.445 -0.784 . . . . 0.0 109.332 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.615 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 45.6 Cg_endo -67.74 141.39 54.34 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.478 2.118 . . . . 0.0 111.721 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.536 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 10.6 mt -76.49 141.04 41.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.343 -0.848 . . . . 0.0 109.84 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 124.72 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.366 -0.834 . . . . 0.0 109.378 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.451 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -93.99 165.33 26.69 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.75 147.41 82.24 Favored 'Cis proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.892 -1.712 . . . . 0.0 112.077 -0.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.536 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.1 m-85 -90.9 148.03 22.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.411 -0.806 . . . . 0.0 110.339 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.457 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 26.9 m-80 -109.91 144.54 38.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.379 -0.826 . . . . 0.0 108.928 179.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 82.9 m-85 -135.13 129.23 33.56 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.029 -1.044 . . . . 0.0 110.049 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 20.3 ttt85 -110.27 141.79 42.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.061 -1.025 . . . . 0.0 108.528 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.599 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.6 m-85 -125.31 143.34 51.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 111.396 -178.116 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.573 ' HA ' ' O ' ' A' ' 86' ' ' MET . 4.7 ttm -124.8 124.57 42.4 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.591 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.9 p -72.68 145.45 47.21 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.36 -0.838 . . . . 0.0 110.145 -178.472 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.587 ' N ' ' HB2' ' A' ' 42' ' ' ALA . 90.6 mttt -47.6 -45.53 27.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 109.145 179.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.16 -5.06 0.58 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.492 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.47 25.99 12.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.591 ' O ' ' N ' ' A' ' 82' ' ' SER . 45.6 mtp -98.99 150.7 21.7 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -1.18 . . . . 0.0 108.727 179.468 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.547 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 62.3 mtm-85 -123.78 138.82 54.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.888 -1.132 . . . . 0.0 110.575 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -135.69 140.6 44.57 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 59.9 t -124.04 137.73 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.95 -1.094 . . . . 0.0 110.637 -178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.528 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.3 m-85 -123.53 121.54 35.91 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 178.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -98.11 147.05 24.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.164 -0.96 . . . . 0.0 109.58 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.608 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 65.8 tt0 53.47 52.84 12.61 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.4 -0.812 . . . . 0.0 110.03 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.407 ' CG1' ' CD1' ' A' ' 17' ' ' PHE . 70.4 t -81.51 -34.43 13.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.906 -1.121 . . . . 0.0 109.26 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.461 HG12 ' HB3' ' A' ' 104' ' ' TYR . 13.4 mt -136.91 126.43 15.57 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.149 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.26 160.88 48.12 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.603 2.202 . . . . 0.0 111.986 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -52.0 -43.13 63.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.382 -0.824 . . . . 0.0 110.192 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.0 103.64 15.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.025 -1.047 . . . . 0.0 109.83 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -111.68 152.09 28.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 109.31 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 28.2 m -102.11 164.72 11.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.423 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.533 HD12 ' CG1' ' A' ' 19' ' ' VAL . 18.4 mm -98.52 137.43 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.972 . . . . 0.0 109.381 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.44 62.74 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -121.24 146.49 46.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -1.182 . . . . 0.0 109.338 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.6 m -79.77 164.15 23.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.111 -0.993 . . . . 0.0 109.321 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.543 ' N ' ' O ' ' A' ' 17' ' ' PHE . 18.0 m-85 -150.06 92.21 1.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.74 -1.225 . . . . 0.0 109.064 179.089 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.515 ' HB3' ' HA ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -108.88 164.31 15.0 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.4 -0.813 . . . . 0.0 109.867 -179.477 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.528 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 47.7 Cg_endo . . . . . 0 C--O 1.215 -0.675 0 C-N-CA 122.843 2.362 . . . . 0.0 111.617 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.584 HG11 ' CE1' ' A' ' 34' ' ' TYR . 15.7 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 70.6 mt-30 -111.95 122.35 47.54 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.12 -0.988 . . . . 0.0 109.424 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 6.2 t -129.01 139.51 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 0.0 109.721 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.457 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 19.9 p -141.26 145.91 36.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.885 . . . . 0.0 109.237 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.61 ' CD2' HG12 ' A' ' 32' ' ' ILE . 3.9 m-85 -120.22 141.93 49.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.104 -0.998 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.41 HG22 ' NE2' ' A' ' 20' ' ' GLN . 23.9 m -134.37 127.3 31.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.915 . . . . 0.0 108.963 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.557 ' HB ' ' HA ' ' A' ' 100' ' ' ILE . 21.7 t -76.0 134.32 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.146 -0.971 . . . . 0.0 109.243 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.41 ' NE2' HG22 ' A' ' 18' ' ' THR . 85.7 mm-40 -115.29 153.29 31.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.004 -1.06 . . . . 0.0 109.897 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 57.3 mttp -44.15 113.17 0.49 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.458 -0.776 . . . . 0.0 109.988 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.12 -5.86 1.96 Allowed Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.251 -1.452 . . . . 0.0 110.771 179.186 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.575 ' OG ' ' CE1' ' A' ' 98' ' ' PHE . 26.8 t -64.24 144.35 57.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.737 -1.449 . . . . 0.0 109.635 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.511 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -138.54 174.15 4.52 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.332 -0.855 . . . . 0.0 109.561 -179.907 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.57 ' O ' ' N ' ' A' ' 72' ' ' LEU . 50.0 Cg_endo -69.89 -28.84 24.11 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.837 2.358 . . . . 0.0 112.072 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -116.35 6.22 13.68 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.087 -1.008 . . . . 0.0 109.045 179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.439 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 5.9 mtpm? -142.29 133.4 26.04 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.24 40.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.084 -1.01 . . . . 0.0 109.51 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.548 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 46.3 t -118.49 124.57 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.193 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.1 mt -145.19 146.22 31.65 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.014 -1.054 . . . . 0.0 110.37 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -86.04 138.19 32.14 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.623 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 57.8 mt -123.39 132.27 71.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.817 -1.177 . . . . 0.0 110.644 -178.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 59.5 mttm -109.85 118.07 35.51 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 178.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.584 ' CE1' HG11 ' A' ' 13' ' ' VAL . 73.1 t80 -121.69 109.04 14.25 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.505 -0.747 . . . . 0.0 109.619 -179.038 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 83.5 m -111.45 116.11 30.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.272 -0.892 . . . . 0.0 109.562 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.543 ' HD3' ' CB ' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -141.83 121.61 8.19 Favored Pre-proline 0 N--CA 1.488 1.473 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.812 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.7 117.6 5.18 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.458 2.105 . . . . 0.0 112.014 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.74 -11.31 68.28 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.543 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.27 -179.94 6.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.894 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.528 ' O ' ' HA ' ' A' ' 82' ' ' SER . 15.4 m -155.68 162.96 40.48 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.356 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.483 HD11 HG22 ' A' ' 44' ' ' VAL . 17.5 tp -70.5 127.91 34.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.266 -0.896 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.548 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.52 -41.65 3.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.218 -0.926 . . . . 0.0 109.734 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -147.15 155.11 41.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.169 -0.957 . . . . 0.0 110.176 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.569 HG22 ' CD2' ' A' ' 80' ' ' PHE . 21.4 t -142.39 141.15 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.442 -0.786 . . . . 0.0 109.33 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.455 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 88.6 mt-10 -127.61 150.52 49.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.767 -1.208 . . . . 0.0 109.434 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.588 HD11 ' CZ ' ' A' ' 78' ' ' PHE . 21.7 tp -122.2 144.21 49.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.408 -178.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.617 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.1 OUTLIER -126.17 127.85 46.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.383 -0.823 . . . . 0.0 109.012 179.243 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.474 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 74.0 mt-30 -71.06 149.77 46.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 109.315 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.584 ' CD2' ' HD2' ' A' ' 75' ' ' PRO . 47.3 t60 -64.84 109.03 1.93 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.559 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.37 2.99 24.41 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.492 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 18.1 t -114.91 154.97 27.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.013 -1.287 . . . . 0.0 109.566 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.429 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 54.7 mp0 -112.02 -12.27 13.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.187 -0.946 . . . . 0.0 109.313 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -95.43 99.7 11.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.323 -0.861 . . . . 0.0 109.559 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.617 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 24.9 m95 -59.32 141.5 54.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.302 -0.874 . . . . 0.0 109.707 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -106.63 137.0 19.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.502 -0.749 . . . . 0.0 109.599 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.455 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 53.1 Cg_endo -72.46 144.41 40.55 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.592 2.195 . . . . 0.0 111.776 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.607 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.5 mp -106.95 146.37 31.14 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.17 -0.956 . . . . 0.0 108.863 179.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 88.4 m -103.11 126.22 50.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.936 -1.103 . . . . 0.0 108.905 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 9.4 tttm -68.82 112.81 5.76 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.189 -0.944 . . . . 0.0 108.904 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mttm -120.07 80.37 1.59 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.004 -1.06 . . . . 0.0 110.702 -178.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.31 60.39 1.31 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.369 179.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 60.03 10.37 2.18 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.148 -1.207 . . . . 0.0 110.16 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 59' ' ' LYS . 13.6 m -129.51 -172.64 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.161 -0.962 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.441 ' HB2' HD12 ' A' ' 32' ' ' ILE . 78.4 m95 -139.13 125.52 20.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.924 . . . . 0.0 109.553 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.514 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 27.0 mt-10 -115.08 152.08 33.14 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.856 . . . . 0.0 109.596 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.607 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 3.1 p -138.22 134.91 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.439 -0.788 . . . . 0.0 109.304 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.439 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 26.5 mttp -120.89 133.99 55.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.346 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.474 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 9.5 t -120.66 126.84 51.26 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.37 -0.831 . . . . 0.0 109.308 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' SER . 73.4 p -45.28 -26.69 0.54 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.007 -1.058 . . . . 0.0 108.514 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.562 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -115.26 178.33 0.99 Allowed Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.1 Cg_endo -67.81 178.94 2.98 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.332 2.022 . . . . 0.0 111.846 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 25' ' ' PRO . 0.9 OUTLIER -112.09 143.48 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.199 -0.938 . . . . 0.0 109.786 -179.577 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 6.4 t -120.8 123.71 70.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.367 -0.833 . . . . 0.0 109.31 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.432 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -92.41 166.21 29.24 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.599 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.4 Cg_endo -69.62 146.76 82.78 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.783 -1.757 . . . . 0.0 112.082 0.045 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.563 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 72.1 m-85 -91.54 153.6 19.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.627 -0.671 . . . . 0.0 110.494 -179.249 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.529 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 1.8 m-80 -112.5 141.03 46.73 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CZ ' HD11 ' A' ' 46' ' ' LEU . 84.4 m-85 -132.27 128.41 37.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.997 -1.065 . . . . 0.0 109.894 -179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.447 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 16.3 ttt180 -112.41 143.68 43.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.019 -1.051 . . . . 0.0 108.732 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.623 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 24.5 m-85 -125.37 144.42 50.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.269 -0.894 . . . . 0.0 111.611 -177.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.623 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.8 ttt -127.15 126.19 42.47 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.528 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.8 p -79.06 148.87 32.31 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.284 -0.885 . . . . 0.0 110.18 -178.402 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.548 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 23.3 mttt -47.0 -46.51 21.76 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.244 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.43 ' HA3' ' OD1' ' A' ' 39' ' ' ASP . . . -59.83 -8.48 8.0 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.3 34.13 5.44 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 51.6 mmm -102.97 109.18 20.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.107 -1.231 . . . . 0.0 109.065 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.623 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 87.7 mtm-85 -91.48 141.52 28.65 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.125 -0.984 . . . . 0.0 110.704 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.565 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.1 m120 -135.88 140.08 43.85 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 4.5 t -120.57 136.48 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.022 -1.049 . . . . 0.0 110.358 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.515 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 31.6 m-85 -125.96 122.23 35.35 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -98.17 147.33 24.7 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.946 . . . . 0.0 109.655 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 41.3 mt-10 53.31 52.88 12.67 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.346 -0.846 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 40.2 t -82.94 -34.35 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.986 -1.071 . . . . 0.0 109.3 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.421 HG23 HD13 ' A' ' 94' ' ' ILE . 65.8 mt -136.83 125.15 14.89 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.347 -0.845 . . . . 0.0 109.134 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.08 162.58 41.16 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.548 2.165 . . . . 0.0 111.887 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 m -52.87 -37.11 59.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.469 -0.77 . . . . 0.0 110.016 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.74 98.34 9.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.029 -1.044 . . . . 0.0 109.717 -179.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.575 ' CE1' ' OG ' ' A' ' 23' ' ' SER . 35.4 p90 -107.0 146.61 30.89 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.125 -0.985 . . . . 0.0 109.366 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.2 m -114.53 118.37 33.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.918 . . . . 0.0 109.554 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.557 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 4.8 mt -56.76 139.37 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.392 -0.817 . . . . 0.0 109.721 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.08 5.52 54.68 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 26.4 tttt -124.13 143.46 50.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.991 -1.299 . . . . 0.0 109.379 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.4 m -78.11 158.77 28.99 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.187 -0.946 . . . . 0.0 108.908 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.8 m-85 -146.58 97.49 2.93 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.491 -1.381 . . . . 0.0 108.953 179.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.54 157.9 32.81 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 110.059 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.515 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.7 Cg_endo . . . . . 0 C--O 1.215 -0.649 0 C-N-CA 122.825 2.35 . . . . 0.0 111.822 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.592 HG13 ' CZ ' ' A' ' 34' ' ' TYR . 4.2 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 82.7 mt-30 -106.99 120.84 43.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.183 -0.948 . . . . 0.0 109.172 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.559 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.4 p -129.57 141.65 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.253 -0.904 . . . . 0.0 109.747 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.474 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 60.5 p -140.77 144.6 35.57 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.071 -1.018 . . . . 0.0 109.481 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 104' ' ' TYR . 49.7 m-85 -114.24 147.41 39.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.246 -0.909 . . . . 0.0 109.253 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 29.1 m -145.98 127.34 14.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.994 -1.066 . . . . 0.0 109.483 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.542 ' CG2' HD23 ' A' ' 30' ' ' LEU . 3.8 t -75.88 136.52 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.392 -0.818 . . . . 0.0 109.209 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.16 158.22 19.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.985 -1.072 . . . . 0.0 109.835 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -51.43 113.11 0.87 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.865 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.77 -6.91 2.68 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.516 179.384 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.523 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 10.8 m -57.46 143.51 40.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.892 -1.358 . . . . 0.0 109.39 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.508 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.69 171.45 8.83 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.707 -179.818 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 72' ' ' LEU . 51.3 Cg_endo -70.22 -31.27 18.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.861 2.374 . . . . 0.0 111.891 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.451 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 2.5 pttt -112.82 7.27 18.38 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.222 -0.923 . . . . 0.0 108.938 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.465 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 29.8 mttm -141.83 132.93 26.18 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.57 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.1 121.48 37.97 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.999 -1.063 . . . . 0.0 109.406 -179.87 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.54 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 11.9 t -119.72 125.69 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.57 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.2 mt -145.27 145.37 31.24 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.983 -1.073 . . . . 0.0 110.024 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -84.54 137.57 33.25 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.561 HG21 ' CZ ' ' A' ' 80' ' ' PHE . 53.9 mt -120.49 130.09 74.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.752 -1.217 . . . . 0.0 110.557 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.7 tttt -110.36 119.57 39.64 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.472 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.592 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 66.2 t80 -121.85 121.01 36.19 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.563 -0.711 . . . . 0.0 109.259 -179.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.7 m -122.75 115.82 22.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.128 -0.983 . . . . 0.0 110.162 -179.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.54 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 20.5 ttt85 -135.64 137.48 25.92 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.534 -0.729 . . . . 0.0 109.065 179.434 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.439 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.5 Cg_endo -69.66 99.4 0.73 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.648 2.232 . . . . 0.0 111.904 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.14 -38.0 3.25 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.54 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 53.5 m-20 -96.28 176.16 6.17 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.228 -1.16 . . . . 0.0 109.798 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -154.74 162.22 41.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.378 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.592 HD23 ' CE2' ' A' ' 80' ' ' PHE . 31.8 tp -68.11 128.74 37.66 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.061 -1.024 . . . . 0.0 109.109 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.567 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.37 -45.0 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.132 -0.98 . . . . 0.0 110.274 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.457 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 81.5 mt-10 -135.55 144.56 46.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.043 -1.036 . . . . 0.0 110.392 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.546 ' CG2' HD13 ' A' ' 41' ' ' LEU . 99.7 t -137.97 135.59 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.474 -0.766 . . . . 0.0 109.147 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -127.91 150.03 50.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.964 -1.085 . . . . 0.0 109.162 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.573 HD11 ' CZ ' ' A' ' 78' ' ' PHE . 13.5 tp -121.38 133.2 55.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.798 . . . . 0.0 110.176 -178.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.518 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 40.8 ttp180 -119.46 129.04 54.55 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 108.788 179.134 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 55.0 mt-30 -71.01 160.74 32.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.276 -0.89 . . . . 0.0 110.161 -179.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.517 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.8 t60 -70.59 145.66 50.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.42 -0.8 . . . . 0.0 109.438 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.54 2.66 44.43 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.457 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.8 t -112.83 154.25 26.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.102 -1.234 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -121.17 14.18 11.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.889 . . . . 0.0 109.417 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -111.66 98.66 7.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.344 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.518 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 65.4 m95 -59.88 134.38 56.98 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.281 -0.887 . . . . 0.0 109.737 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -111.54 130.93 22.61 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.468 -0.77 . . . . 0.0 109.095 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 141.53 46.06 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.502 2.135 . . . . 0.0 111.978 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.589 ' CD1' ' N ' ' A' ' 57' ' ' LEU . 5.9 mp -97.16 143.06 28.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 108.534 179.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -81.38 125.91 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.902 -1.123 . . . . 0.0 109.13 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -72.22 108.22 5.27 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.16 -0.962 . . . . 0.0 109.379 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.449 ' O ' ' C ' ' A' ' 61' ' ' GLY . 22.7 mttm -113.76 132.78 55.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.995 -1.065 . . . . 0.0 109.469 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 60' ' ' LYS . . . 43.17 -100.24 0.02 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.443 ' N ' ' O ' ' A' ' 60' ' ' LYS . 23.9 p-10 -130.5 24.98 5.12 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -1.148 . . . . 0.0 109.187 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.49 ' C ' ' CD1' ' A' ' 64' ' ' TRP . 35.9 m -131.62 -170.08 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.568 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.537 ' CD1' HD12 ' A' ' 32' ' ' ILE . 44.6 m95 -140.99 124.69 16.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.03 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.534 ' HG3' ' CG2' ' A' ' 29' ' ' VAL . 69.8 tt0 -115.36 151.96 33.69 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 109.71 -179.66 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.519 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.0 p -141.19 138.46 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.367 -0.833 . . . . 0.0 109.191 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.447 ' CD ' ' HD3' ' A' ' 27' ' ' LYS . 84.4 mttt -122.14 134.78 54.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.278 -0.889 . . . . 0.0 109.6 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' SER . 8.8 t -120.18 126.21 50.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.343 -0.848 . . . . 0.0 109.188 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 68' ' ' SER . 6.0 m -44.1 -29.03 0.55 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.084 -1.01 . . . . 0.0 108.83 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -112.55 178.35 0.99 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.431 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.8 Cg_endo -68.79 166.34 26.59 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.382 2.055 . . . . 0.0 111.618 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.567 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.8 mt -97.34 143.29 28.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.117 -0.989 . . . . 0.0 109.816 -179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.89 124.79 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.81 . . . . 0.0 109.307 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -95.51 169.09 27.15 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.586 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.5 Cg_endo -67.99 146.34 77.5 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.838 -1.734 . . . . 0.0 111.85 0.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.567 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 74.2 m-85 -91.34 149.84 21.56 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.532 -0.73 . . . . 0.0 110.37 -179.09 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.528 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 18.9 m-80 -111.99 143.67 42.6 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 179.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CZ ' HD11 ' A' ' 46' ' ' LEU . 96.1 m-85 -134.84 120.36 19.24 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.056 -1.028 . . . . 0.0 109.515 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.475 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 63.3 ttt180 -100.55 141.94 32.7 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.955 -1.091 . . . . 0.0 108.653 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.592 ' CE2' HD23 ' A' ' 41' ' ' LEU . 7.3 m-85 -124.96 142.95 51.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.907 . . . . 0.0 111.317 -178.256 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.518 ' HE2' ' CG ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.67 124.2 41.68 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.157 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.615 ' N ' ' O ' ' A' ' 86' ' ' MET . 13.6 p -72.16 144.85 48.43 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.408 -0.808 . . . . 0.0 110.097 -178.463 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.567 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 0.2 OUTLIER -50.24 -44.45 53.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -0.917 . . . . 0.0 108.777 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.04 -2.18 0.19 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.32 25.7 18.11 Favored Glycine 0 N--CA 1.491 2.35 0 O-C-N 121.068 -1.254 . . . . 0.0 109.978 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.615 ' O ' ' N ' ' A' ' 82' ' ' SER . 39.2 mtp -100.85 149.06 24.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.109 -1.23 . . . . 0.0 108.864 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.518 ' CG ' ' HE2' ' A' ' 81' ' ' MET . 7.6 mtt85 -120.15 135.97 54.78 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.332 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -134.57 139.91 45.72 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.475 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -123.1 136.2 60.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.043 -1.036 . . . . 0.0 110.294 -178.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.653 ' CG ' ' CB ' ' A' ' 106' ' ' PRO . 11.3 m-85 -122.45 121.04 35.67 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.59 147.62 24.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.21 -0.931 . . . . 0.0 109.707 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.586 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 48.2 mt-10 53.69 49.64 18.86 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.412 -0.805 . . . . 0.0 110.2 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.442 HG22 ' HA ' ' A' ' 106' ' ' PRO . 54.3 t -77.91 -33.71 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.867 -1.146 . . . . 0.0 108.885 179.333 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 69.8 mt -138.83 124.71 12.33 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.321 -0.862 . . . . 0.0 108.959 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -67.72 162.83 37.69 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.647 2.232 . . . . 0.0 112.161 -179.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.486 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 8.1 m -50.56 -43.87 56.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.41 -0.806 . . . . 0.0 109.829 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.03 103.77 15.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.039 -1.038 . . . . 0.0 109.528 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -111.25 158.86 18.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 109.157 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.4 m -107.92 172.48 6.81 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.256 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.6 mm -104.56 135.93 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.877 . . . . 0.0 109.253 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.75 6.77 58.1 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -117.08 141.74 47.88 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.064 -1.256 . . . . 0.0 109.337 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.451 HG21 ' O ' ' A' ' 17' ' ' PHE . 34.5 m -81.95 170.1 16.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.09 -1.007 . . . . 0.0 109.026 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.575 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.4 m-85 -151.23 99.37 2.65 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.771 -1.205 . . . . 0.0 109.261 179.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.545 ' HG2' ' O ' ' A' ' 15' ' ' VAL . 1.9 mtmt -84.43 148.95 53.75 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.467 -0.77 . . . . 0.0 109.66 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.653 ' CB ' ' CG ' ' A' ' 90' ' ' PHE . 51.1 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.254 1.969 . . . . 0.0 111.569 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.517 ' CG2' ' HG3' ' A' ' 36' ' ' ARG . 17.1 t . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.439 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 36.1 mt-30 -109.31 121.35 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.094 -1.004 . . . . 0.0 109.814 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.536 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 9.5 p -128.87 140.39 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.35 -0.844 . . . . 0.0 109.439 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.462 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 27.9 p -142.08 146.16 35.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.06 -1.025 . . . . 0.0 109.606 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.0 m-85 -118.51 143.68 46.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.581 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.442 ' CG2' ' O ' ' A' ' 102' ' ' LYS . 69.0 m -139.67 129.05 24.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.067 -1.02 . . . . 0.0 109.245 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.515 ' CG2' HD23 ' A' ' 30' ' ' LEU . 42.6 t -75.91 132.67 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.225 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -105.17 159.78 15.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.109 -0.994 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -54.35 115.22 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.388 -0.82 . . . . 0.0 109.782 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 24' ' ' ASP . . . 139.5 -0.59 2.24 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.279 179.476 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.432 ' C ' ' OD1' ' A' ' 24' ' ' ASP . 34.1 t -66.85 142.17 57.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.976 -1.308 . . . . 0.0 109.394 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.6 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -134.56 174.48 4.59 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.205 -0.935 . . . . 0.0 109.31 -179.833 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.6 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 49.3 Cg_endo -70.36 -28.71 22.05 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.612 2.208 . . . . 0.0 111.985 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.3 mttm -114.51 9.37 16.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.935 . . . . 0.0 109.127 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.484 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 31.9 mttt -142.98 133.47 24.91 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.5 122.5 39.86 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.997 -1.064 . . . . 0.0 109.571 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.558 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 22.2 t -120.2 125.6 74.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -144.89 145.69 31.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.883 -1.136 . . . . 0.0 110.248 -179.419 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.447 ' OD1' HG12 ' A' ' 63' ' ' VAL . 17.9 t70 -86.22 138.52 31.81 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.607 HG23 ' CZ ' ' A' ' 80' ' ' PHE . 70.5 mt -120.2 130.34 74.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.859 -178.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 25.1 tptt -110.55 120.26 41.83 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.115 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.501 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 79.6 t80 -121.77 123.64 42.31 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.395 -0.815 . . . . 0.0 109.915 -178.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.454 ' O ' HG12 ' A' ' 13' ' ' VAL . 56.8 m -125.11 115.13 19.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 109.484 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.538 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 29.8 ttt85 -139.79 135.37 16.6 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.448 -0.782 . . . . 0.0 109.199 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.443 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.8 Cg_endo -70.96 108.01 2.21 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.778 2.318 . . . . 0.0 112.182 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.02 -1.9 86.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.538 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.8 m-20 -134.36 173.92 11.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.075 -1.25 . . . . 0.0 109.655 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -153.45 160.85 42.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.536 HD12 ' CD2' ' A' ' 80' ' ' PHE . 7.8 tp -68.65 123.3 20.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.913 . . . . 0.0 109.212 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.563 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.36 -44.89 2.95 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.45 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 69.5 mt-10 -135.18 144.46 47.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.162 -0.961 . . . . 0.0 110.217 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 80' ' ' PHE . 12.6 t -138.36 135.96 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.445 -0.784 . . . . 0.0 109.273 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.418 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 85.0 mt-10 -128.96 150.02 50.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.878 -1.139 . . . . 0.0 109.537 179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.601 HD13 ' CZ ' ' A' ' 78' ' ' PHE . 6.7 tt -119.2 143.3 47.34 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.453 -0.779 . . . . 0.0 109.857 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.52 ' N ' HD23 ' A' ' 46' ' ' LEU . 35.8 ttp180 -131.33 126.36 35.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 108.821 179.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -66.39 156.11 35.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.159 -179.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.576 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 8.3 t-80 -71.9 117.15 13.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 109.629 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 103.53 4.07 46.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.488 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 10.1 t -114.37 159.82 19.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.28 -1.13 . . . . 0.0 109.342 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.65 14.97 9.46 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -116.36 91.45 3.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.443 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -52.79 134.37 36.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -106.78 135.16 19.57 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.313 -0.867 . . . . 0.0 109.434 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.418 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 49.5 Cg_endo -70.15 145.78 55.84 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.677 2.251 . . . . 0.0 111.733 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.562 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -110.41 150.78 28.33 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.168 -0.958 . . . . 0.0 109.052 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 m -102.36 126.74 49.47 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.993 -1.067 . . . . 0.0 109.141 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.7 tttt -77.46 101.56 6.48 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.071 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.565 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.7 mttt -115.4 150.39 36.46 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.866 -1.146 . . . . 0.0 110.083 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 43.38 32.23 1.75 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 1.5 m120 76.79 12.73 2.34 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.244 . . . . 0.0 110.126 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 3.0 m -130.17 176.9 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.136 -0.978 . . . . 0.0 108.805 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 64' ' ' TRP . 37.8 m95 -120.5 144.35 48.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.926 -1.108 . . . . 0.0 109.796 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -136.5 151.97 50.01 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.376 -0.827 . . . . 0.0 109.445 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.562 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.8 p -137.11 133.77 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.387 -0.821 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.441 ' HD3' ' NZ ' ' A' ' 27' ' ' LYS . 21.4 mttt -119.72 131.21 55.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.934 . . . . 0.0 109.398 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t -118.24 165.96 13.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.381 -0.824 . . . . 0.0 109.522 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 50.2 m -88.74 2.98 52.47 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.249 -0.907 . . . . 0.0 109.052 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.539 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.2 OUTLIER -142.14 176.78 2.18 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.476 -0.765 . . . . 0.0 109.18 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.539 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.5 Cg_endo -68.55 139.31 44.37 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.506 2.137 . . . . 0.0 111.721 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.55 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 8.8 mt -73.88 143.08 45.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.261 -0.899 . . . . 0.0 109.627 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.424 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 31.2 t -119.42 123.3 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.249 -0.907 . . . . 0.0 109.31 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.532 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -92.05 164.7 28.76 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.678 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.55 147.87 85.07 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.775 -1.761 . . . . 0.0 112.035 -0.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.55 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 58.9 m-85 -89.52 151.1 22.15 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.505 -0.747 . . . . 0.0 110.149 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.421 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 39.2 m-80 -112.68 142.9 44.75 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.823 . . . . 0.0 109.051 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.601 ' CZ ' HD13 ' A' ' 46' ' ' LEU . 89.9 m-85 -135.12 123.5 23.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 109.773 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.535 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 38.4 ttt180 -103.86 141.69 35.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.985 -1.072 . . . . 0.0 108.514 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.607 ' CZ ' HG23 ' A' ' 32' ' ' ILE . 13.3 m-85 -125.17 142.8 51.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 111.497 -178.06 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.531 ' HE1' ' CG ' ' A' ' 87' ' ' ARG . 3.5 ttm -124.46 123.75 40.82 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.621 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.6 p -70.45 143.45 51.78 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.367 -0.833 . . . . 0.0 110.302 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.563 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -48.39 -45.2 35.57 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.356 -0.84 . . . . 0.0 108.83 178.924 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.42 -2.13 0.25 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.34 24.99 20.28 Favored Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.083 -1.246 . . . . 0.0 110.025 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.621 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.6 mmm -98.95 149.17 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.011 -1.288 . . . . 0.0 108.786 179.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.531 ' CG ' ' HE1' ' A' ' 81' ' ' MET . 19.6 mtm105 -120.33 135.81 54.9 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.969 -1.082 . . . . 0.0 110.401 -179.013 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -134.32 139.44 45.67 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.535 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 6.7 t -122.82 136.42 59.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.112 -0.992 . . . . 0.0 110.316 -179.026 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.45 ' CE2' HG13 ' A' ' 15' ' ' VAL . 27.7 m-85 -123.28 121.83 36.85 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.517 -0.919 . . . . 0.0 108.517 179.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -99.35 147.49 25.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.272 -0.893 . . . . 0.0 109.643 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.678 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 25.7 mt-10 53.48 52.2 13.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.392 -0.818 . . . . 0.0 110.201 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.3 t -83.04 -34.87 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 120.889 -1.132 . . . . 0.0 109.085 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -133.63 123.78 17.54 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.334 -0.854 . . . . 0.0 109.197 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.33 161.74 44.92 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.549 2.166 . . . . 0.0 111.79 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.532 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 32.6 m -54.29 -36.07 63.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.414 -0.804 . . . . 0.0 110.055 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.43 79.19 5.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.936 -1.102 . . . . 0.0 109.702 -179.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -89.02 145.05 25.73 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.314 -0.866 . . . . 0.0 109.408 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.59 116.48 26.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.321 -0.862 . . . . 0.0 109.67 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.506 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 11.1 mt -56.82 139.95 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.292 -0.88 . . . . 0.0 109.656 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.479 ' N ' HG22 ' A' ' 100' ' ' ILE . . . 100.14 5.95 54.17 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.442 ' O ' ' CG2' ' A' ' 18' ' ' THR . 20.3 mttm -120.23 -165.82 1.23 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.009 -1.289 . . . . 0.0 109.183 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.464 HG23 ' O ' ' A' ' 17' ' ' PHE . 8.7 m -131.06 165.22 23.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.07 -1.019 . . . . 0.0 108.517 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.7 m-85 -155.53 93.45 1.49 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.428 -1.42 . . . . 0.0 109.169 179.138 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . 0.542 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 6.8 pttm -105.11 164.43 15.14 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.409 -0.807 . . . . 0.0 109.393 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.542 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 50.2 Cg_endo . . . . . 0 C--O 1.216 -0.601 0 C-N-CA 122.494 2.129 . . . . 0.0 111.739 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.451 HG22 ' HG3' ' A' ' 36' ' ' ARG . 20.1 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -111.65 121.37 44.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.157 -0.964 . . . . 0.0 109.313 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.2 t -128.16 138.09 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.814 -179.614 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.1 p -142.17 146.21 35.04 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.352 -0.842 . . . . 0.0 109.32 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.594 ' O ' ' N ' ' A' ' 104' ' ' TYR . 34.1 m-85 -118.31 142.42 47.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.673 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 61.1 m -138.18 129.2 27.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.058 -1.027 . . . . 0.0 109.329 179.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.517 ' CG1' HD12 ' A' ' 100' ' ' ILE . 24.0 t -77.29 138.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.882 . . . . 0.0 109.39 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -106.15 -177.11 3.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.107 -0.995 . . . . 0.0 109.508 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 43.0 mttt -77.67 110.29 12.38 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.369 -0.832 . . . . 0.0 109.698 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.61 -0.32 1.66 Allowed Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.558 -1.306 . . . . 0.0 110.481 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.572 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.0 t -56.4 144.82 29.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.875 -1.368 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.518 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -136.5 168.99 14.62 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.167 -0.958 . . . . 0.0 109.636 -179.833 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.491 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 48.3 Cg_endo -69.76 -27.64 26.24 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.854 2.369 . . . . 0.0 111.859 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -114.65 8.61 16.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.164 -0.96 . . . . 0.0 109.01 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 56.4 mttp -143.99 134.15 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 108.98 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.593 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.91 123.02 40.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.927 -1.108 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.548 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 5.0 t -120.36 126.07 74.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.593 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.1 mt -145.35 145.48 31.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.842 -1.161 . . . . 0.0 110.2 -179.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.437 ' HA ' HG13 ' A' ' 63' ' ' VAL . 64.2 t0 -83.88 135.01 34.66 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 178.044 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.599 HG22 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -115.53 127.07 73.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.779 -1.201 . . . . 0.0 111.154 -178.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 10.2 ttpt -108.12 115.19 29.67 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 177.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.49 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 76.7 t80 -124.05 108.16 12.06 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.682 -0.637 . . . . 0.0 109.84 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.0 m -109.6 117.56 34.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.351 -0.843 . . . . 0.0 109.446 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.512 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 9.4 ttt85 -144.65 114.49 5.14 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.405 -0.81 . . . . 0.0 109.354 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.41 120.7 7.5 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.704 2.269 . . . . 0.0 111.809 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.06 -19.54 54.38 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 5.0 m-20 -140.75 -179.09 5.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -1.126 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m -155.75 162.86 40.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.86 . . . . 0.0 109.535 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.545 HD21 ' CE2' ' A' ' 80' ' ' PHE . 25.1 tp -69.97 129.19 38.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.294 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.573 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.12 3.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -138.95 147.6 42.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.189 -0.944 . . . . 0.0 110.246 -179.543 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' CG2' HD21 ' A' ' 41' ' ' LEU . 77.6 t -138.18 136.01 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.558 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.3 mt-10 -129.76 151.63 50.13 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.88 -1.137 . . . . 0.0 109.775 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.582 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 6.9 tt -120.99 140.23 52.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 109.636 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . 0.601 ' HD3' ' CD1' ' A' ' 54' ' ' TRP . 17.8 ttp180 -125.73 128.13 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.135 179.301 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -69.58 145.5 52.51 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.594 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' HIS . . . . . 0.592 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 22.4 t60 -63.85 113.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.842 . . . . 0.0 109.421 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.78 1.97 30.49 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.435 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 29.1 t -114.02 154.92 26.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.241 . . . . 0.0 109.418 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -118.25 22.35 12.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.444 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 83.0 mt-10 -127.43 81.2 2.0 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.535 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.601 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 43.8 m95 -43.38 136.53 3.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -0.907 . . . . 0.0 109.698 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -104.91 138.48 19.52 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.84 . . . . 0.0 109.311 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.74 147.84 51.43 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.649 2.233 . . . . 0.0 112.113 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.598 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -111.48 155.78 22.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 108.958 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 m -109.7 127.14 54.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.813 -1.179 . . . . 0.0 109.078 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 41.6 tttm -71.72 110.64 6.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.145 -0.972 . . . . 0.0 109.344 -179.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.587 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.8 mttt -119.63 141.1 49.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.815 -1.178 . . . . 0.0 109.812 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.584 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.52 31.08 0.97 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.584 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER 81.88 15.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.306 -1.114 . . . . 0.0 110.362 179.292 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.587 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 27.1 m -129.86 173.42 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.986 -1.071 . . . . 0.0 108.838 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 69.3 m95 -118.96 122.75 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.875 -1.141 . . . . 0.0 109.666 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.467 ' HG2' HG11 ' A' ' 29' ' ' VAL . 5.5 mt-10 -115.88 153.71 31.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.438 -0.789 . . . . 0.0 109.511 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.598 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.9 p -138.73 135.57 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.486 -0.759 . . . . 0.0 109.432 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.3 mttm -119.8 131.36 55.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -118.41 160.28 21.98 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.466 -0.771 . . . . 0.0 109.25 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 71.1 m -80.25 -13.87 58.87 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.145 -0.972 . . . . 0.0 109.148 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.538 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.0 OUTLIER -124.09 177.2 1.85 Allowed Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.369 -0.832 . . . . 0.0 109.031 179.791 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.538 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.5 Cg_endo -69.41 138.84 39.93 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.42 2.08 . . . . 0.0 111.678 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.608 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.2 mt -69.9 140.38 53.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.328 -0.858 . . . . 0.0 109.858 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.1 t -121.55 124.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.416 -0.803 . . . . 0.0 109.213 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.444 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.52 168.64 28.17 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.592 ' O ' ' HB2' ' A' ' 49' ' ' HIS . 49.3 Cg_endo -69.08 146.1 79.78 Favored 'Cis proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.822 -1.741 . . . . 0.0 112.025 -0.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.608 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 73.0 m-85 -91.14 147.76 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -0.832 . . . . 0.0 110.422 -179.179 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.404 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 30.2 m-80 -108.38 142.88 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.414 -0.804 . . . . 0.0 108.91 179.103 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 89.1 m-85 -133.93 122.29 22.91 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.041 -1.037 . . . . 0.0 109.77 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -106.33 144.1 33.5 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.089 -1.007 . . . . 0.0 108.937 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.599 ' CE2' HG22 ' A' ' 32' ' ' ILE . 8.3 m-85 -124.69 142.76 51.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.14 -0.975 . . . . 0.0 111.502 -178.142 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.565 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.8 ttt -125.13 124.78 42.55 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' SER . . . . . 0.662 ' N ' ' O ' ' A' ' 86' ' ' MET . 21.0 p -73.59 144.43 45.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.325 -0.86 . . . . 0.0 110.544 -178.284 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' LYS . . . . . 0.573 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 47.3 mttm -47.17 -45.18 22.63 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.414 -0.804 . . . . 0.0 109.033 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.64 -5.02 1.65 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 96.61 24.72 13.11 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.662 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.1 mmm -95.96 147.62 23.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.045 -1.268 . . . . 0.0 108.503 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.533 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 24.5 mtm180 -123.29 138.39 54.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.686 -1.259 . . . . 0.0 110.794 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.1 m120 -134.97 139.94 45.3 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 4.7 t -123.01 137.34 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 120.877 -1.139 . . . . 0.0 110.461 -178.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.551 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 75.1 m-85 -124.91 123.51 40.06 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -99.8 146.73 26.25 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.805 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.582 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 79.1 tt0 53.67 53.93 10.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.411 -0.806 . . . . 0.0 110.652 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 45.5 t -83.81 -33.92 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.866 -1.146 . . . . 0.0 109.04 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 12.5 mt -135.98 125.24 15.92 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.412 -0.805 . . . . 0.0 109.017 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.78 161.98 43.83 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.563 2.175 . . . . 0.0 112.101 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.444 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 23.7 m -50.49 -46.33 56.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.451 -0.781 . . . . 0.0 109.966 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.72 102.61 15.22 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.006 . . . . 0.0 109.627 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.572 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 53.7 p90 -109.85 154.36 23.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 109.353 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 73.1 p -107.97 171.96 7.1 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.517 HD12 ' CG1' ' A' ' 19' ' ' VAL . 20.9 mm -106.26 136.77 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.266 -0.897 . . . . 0.0 109.347 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 93.25 8.13 61.61 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -119.25 143.69 47.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.243 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.467 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.9 m -77.32 174.95 10.21 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.016 -1.052 . . . . 0.0 108.827 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' TYR . . . . . 0.594 ' N ' ' O ' ' A' ' 17' ' ' PHE . 26.6 m-85 -159.49 94.65 1.18 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.737 -1.227 . . . . 0.0 109.165 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 11.8 mtmm -91.72 155.33 43.72 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.341 -0.849 . . . . 0.0 109.665 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.551 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 51.7 Cg_endo . . . . . 0 C--O 1.215 -0.626 0 C-N-CA 122.783 2.322 . . . . 0.0 111.649 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 17.8 mtt85 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -66.64 95.08 0.25 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.6 p -75.6 155.27 36.08 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.243 -1.151 . . . . 0.0 109.529 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -106.09 92.29 4.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.437 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 55.3 p-80 -93.83 8.54 40.77 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.262 -0.899 . . . . 0.0 109.539 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -50.23 -34.26 22.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.282 -0.886 . . . . 0.0 109.462 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -63.85 -32.23 73.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.467 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 33.1 t-80 -58.32 -43.17 88.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 51.6 m80 -50.18 -34.23 21.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.25 -127.29 8.86 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -118.29 157.34 27.24 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -1.14 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -148.95 150.22 32.52 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.601 HG12 ' CE1' ' A' ' 34' ' ' TYR . 2.1 t -125.71 135.58 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -112.18 120.4 41.64 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.011 -1.056 . . . . 0.0 109.539 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.8 t -128.19 139.1 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.75 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.46 HG21 ' O ' ' A' ' 15' ' ' VAL . 70.7 p -141.52 145.62 35.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.225 -0.922 . . . . 0.0 109.697 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.567 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.9 m-85 -117.05 128.97 55.69 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.248 -0.907 . . . . 0.0 109.786 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 41.3 m -128.03 128.64 45.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.162 -0.961 . . . . 0.0 109.157 179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.524 ' CG1' HD13 ' A' ' 100' ' ' ILE . 21.3 t -76.18 139.44 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.357 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.16 157.23 21.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.117 -0.989 . . . . 0.0 109.72 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -51.3 114.39 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.444 -0.785 . . . . 0.0 109.977 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.16 -1.43 2.19 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.523 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.401 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.1 t -60.01 141.24 56.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.925 -1.338 . . . . 0.0 109.175 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.537 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -136.57 176.13 3.02 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.121 -0.987 . . . . 0.0 109.664 -179.639 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.529 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 51.6 Cg_endo -71.77 -30.56 14.19 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.606 2.204 . . . . 0.0 111.816 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.4 mttm -117.21 4.99 12.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -0.886 . . . . 0.0 109.091 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.471 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 41.6 mttt -142.17 133.43 26.28 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.52 HD11 ' CD1' ' A' ' 72' ' ' LEU . 0.3 OUTLIER -127.18 133.78 50.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.034 -1.042 . . . . 0.0 110.21 -179.445 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.518 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 2.8 t -122.99 124.84 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.518 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -141.16 141.31 34.13 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.034 -1.041 . . . . 0.0 110.041 -179.526 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.438 ' OD1' HG12 ' A' ' 63' ' ' VAL . 59.7 t0 -86.11 137.34 32.74 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.567 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.1 mt -122.23 131.14 73.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 120.865 -1.147 . . . . 0.0 110.523 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.515 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 66.2 mttm -110.54 120.29 41.94 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.601 ' CE1' HG12 ' A' ' 13' ' ' VAL . 77.5 t80 -122.49 114.19 20.35 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.415 -0.803 . . . . 0.0 109.541 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.9 m -116.99 117.96 31.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.784 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.52 ' CZ ' HG21 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -135.22 132.0 19.9 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.432 -0.793 . . . . 0.0 109.21 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.433 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 49.9 Cg_endo -70.2 105.89 1.64 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.67 2.246 . . . . 0.0 112.078 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.93 -2.12 87.02 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.471 ' HB3' ' HD2' ' A' ' 36' ' ' ARG . 1.7 m-20 -135.44 173.7 11.43 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.114 -1.227 . . . . 0.0 109.673 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.52 ' O ' ' HA ' ' A' ' 82' ' ' SER . 20.6 m -153.89 161.34 42.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.439 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.608 HD13 ' CE2' ' A' ' 80' ' ' PHE . 0.2 OUTLIER -71.5 132.98 45.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.588 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -114.47 -42.47 3.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.18 -0.95 . . . . 0.0 109.499 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.404 ' C ' HG23 ' A' ' 44' ' ' VAL . 47.0 mt-10 -142.84 151.24 40.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.065 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.546 HG11 ' CE1' ' A' ' 80' ' ' PHE . 65.1 t -139.86 137.6 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.1 mt-10 -126.22 148.73 49.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.784 -1.198 . . . . 0.0 109.432 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.607 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 9.6 tp -121.44 129.58 53.07 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.491 -0.756 . . . . 0.0 110.184 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.554 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 12.1 ttp180 -115.63 131.97 56.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.199 -0.938 . . . . 0.0 108.875 179.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -73.47 155.15 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.315 -0.865 . . . . 0.0 110.021 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.509 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.1 t60 -67.29 147.83 52.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.446 -0.783 . . . . 0.0 109.357 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.83 2.12 35.67 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 32.5 t -113.21 152.46 29.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -1.214 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -117.81 17.88 14.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -0.907 . . . . 0.0 109.316 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -116.39 104.35 11.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.554 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 45.8 m95 -66.59 134.72 52.92 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.338 -0.851 . . . . 0.0 109.673 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.467 ' HG2' ' HD2' ' A' ' 56' ' ' PRO . 0.9 OUTLIER -108.71 134.27 20.37 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.345 179.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.467 ' HD2' ' HG2' ' A' ' 55' ' ' GLU . 50.5 Cg_endo -70.45 144.51 50.53 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.625 2.217 . . . . 0.0 111.961 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.58 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.3 mp -103.88 148.36 26.23 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 108.823 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 63.0 m -97.5 125.78 42.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 108.947 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 12.9 tttm -70.93 111.64 6.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.236 -0.915 . . . . 0.0 109.269 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -109.77 105.54 14.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.054 -1.029 . . . . 0.0 109.461 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.79 -96.24 0.25 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -131.04 18.83 4.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.256 -1.144 . . . . 0.0 109.451 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.438 HG12 ' OD1' ' A' ' 31' ' ' ASP . 22.5 m -132.43 177.42 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.265 -0.897 . . . . 0.0 109.437 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.425 ' CD1' HD13 ' A' ' 32' ' ' ILE . 74.5 m95 -122.58 142.67 50.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 108.961 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -129.73 145.16 51.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.805 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.58 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 3.6 p -137.62 134.11 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.351 -0.843 . . . . 0.0 109.033 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -121.17 133.4 55.19 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.227 -0.92 . . . . 0.0 109.56 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.6 t -118.04 163.88 15.94 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.445 -0.784 . . . . 0.0 109.452 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 65.1 m -87.14 -5.96 58.82 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.191 -0.943 . . . . 0.0 109.152 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.56 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.9 OUTLIER -131.99 178.44 1.75 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.385 -0.822 . . . . 0.0 109.126 179.866 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.56 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -69.18 139.52 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.395 2.063 . . . . 0.0 111.577 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.578 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -75.38 141.19 43.31 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.25 -0.906 . . . . 0.0 109.935 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.411 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 42.9 t -123.86 124.92 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.465 -0.772 . . . . 0.0 109.155 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.67 170.18 30.67 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.607 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.8 Cg_endo -69.8 147.57 85.0 Favored 'Cis proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.836 -1.735 . . . . 0.0 111.833 0.037 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.7 m-85 -91.92 151.38 20.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.473 -0.767 . . . . 0.0 110.599 -179.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.513 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 34.9 m-80 -112.15 143.45 43.17 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.607 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 95.7 m-85 -136.33 130.76 33.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.947 -1.096 . . . . 0.0 109.972 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.521 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 51.3 ttp180 -110.31 141.49 43.25 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.058 -1.026 . . . . 0.0 108.627 179.023 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.608 ' CE2' HD13 ' A' ' 41' ' ' LEU . 5.8 m-85 -120.93 142.78 49.4 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 111.021 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.558 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -127.77 125.35 39.74 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.701 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.629 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.1 p -78.0 144.48 36.66 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 110.416 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.588 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 30.8 mttm -46.21 -43.79 15.63 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.14 -2.96 0.69 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.498 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.12 22.94 26.17 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.629 ' O ' ' N ' ' A' ' 82' ' ' SER . 1.6 mmm -96.34 146.45 24.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.123 -1.221 . . . . 0.0 108.604 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 42.8 mtm180 -124.36 141.35 52.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.826 -1.172 . . . . 0.0 110.535 -178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.432 ' N ' ' O ' ' A' ' 80' ' ' PHE . 24.2 m120 -136.48 140.91 43.41 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.521 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 7.0 t -121.49 135.95 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 110.354 -179.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.54 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 41.9 m-85 -124.59 122.53 37.81 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -99.55 148.94 23.76 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.202 -0.936 . . . . 0.0 109.753 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.607 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 10.5 mt-10 51.7 51.03 17.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.53 -0.731 . . . . 0.0 110.371 179.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.539 ' CG2' ' HB3' ' A' ' 106' ' ' PRO . 39.7 t -82.83 -33.54 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.911 -1.118 . . . . 0.0 109.255 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 9.1 mt -131.62 124.3 19.88 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.113 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.54 161.04 46.65 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.494 2.129 . . . . 0.0 111.916 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.7 m -53.54 -43.96 68.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.341 -0.849 . . . . 0.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.4 99.84 12.75 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.105 -0.997 . . . . 0.0 109.568 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.401 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 45.8 p90 -108.73 146.06 34.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.627 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 16.2 m -106.54 156.68 18.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.395 -0.816 . . . . 0.0 109.183 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.524 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.2 mm -92.21 136.39 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.134 -0.979 . . . . 0.0 109.441 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.04 2.2 62.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -115.56 143.04 45.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.174 -1.192 . . . . 0.0 109.097 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.45 HG21 ' HD2' ' A' ' 105' ' ' LYS . 6.0 m -79.7 169.66 17.65 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.068 -1.02 . . . . 0.0 108.995 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.54 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.7 m-85 -154.57 100.32 2.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.714 -1.241 . . . . 0.0 109.032 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.524 ' CD ' ' N ' ' A' ' 105' ' ' LYS . 0.5 OUTLIER -95.25 158.2 35.12 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.54 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 51.2 Cg_endo -71.58 135.98 27.36 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.743 2.296 . . . . 0.0 111.808 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -90.04 161.92 15.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.31 -0.868 . . . . 0.0 109.494 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 71.2 mm-40 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.995 -1.003 . . . . 0.0 109.47 -179.95 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 54.2 mtm180 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.26 137.28 47.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 52.4 m -51.61 -31.69 26.06 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.191 -1.182 . . . . 0.0 109.465 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 -121.69 139.34 53.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.489 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.401 ' O ' ' HB2' ' A' ' 6' ' ' HIS . 13.3 p-80 -90.95 31.46 1.08 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.515 ' HA ' ' CE1' ' A' ' 9' ' ' HIS . 7.8 m-70 62.07 70.44 0.58 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.294 -0.879 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 29.2 t60 -55.12 -55.92 25.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.4 p-80 -170.42 37.17 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.418 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.515 ' CE1' ' HA ' ' A' ' 6' ' ' HIS . 72.5 m80 -49.32 -40.04 33.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.213 -0.929 . . . . 0.0 109.471 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.71 165.6 27.22 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.1 m -119.33 134.24 55.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -1.154 . . . . 0.0 109.476 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 59.47 -147.58 0.48 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.252 -0.905 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.556 HG12 ' CE1' ' A' ' 34' ' ' TYR . 16.6 t -127.14 138.36 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -0.943 . . . . 0.0 109.37 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -110.1 120.77 43.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.363 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.576 HG21 ' CD1' ' A' ' 34' ' ' TYR . 3.4 t -127.94 138.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.346 -0.846 . . . . 0.0 109.632 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.474 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.0 p -141.53 145.83 35.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.25 -0.906 . . . . 0.0 109.418 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.61 ' CD2' HG12 ' A' ' 32' ' ' ILE . 15.0 m-85 -118.46 143.98 46.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.21 -0.931 . . . . 0.0 109.781 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 21.4 m -139.39 128.05 23.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 0.0 109.136 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.491 ' CG2' HD23 ' A' ' 30' ' ' LEU . 16.7 t -76.21 130.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -108.57 152.76 24.32 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.076 -1.015 . . . . 0.0 109.695 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -45.41 114.81 0.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.416 -0.802 . . . . 0.0 109.978 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.34 -2.92 1.84 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.834 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 34.9 m -63.71 141.09 58.89 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.703 -1.469 . . . . 0.0 109.277 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.64 175.49 3.55 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.128 -0.983 . . . . 0.0 109.593 -179.697 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.0 Cg_endo -71.54 -30.82 14.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.566 2.177 . . . . 0.0 111.845 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.2 mttp -117.33 4.78 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 0.0 109.053 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.405 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 35.4 mttp -142.27 133.64 26.42 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.505 HD22 ' CD1' ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.12 132.25 50.63 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.948 -1.095 . . . . 0.0 110.347 -179.253 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.496 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.8 t -121.91 125.41 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.505 ' CD1' HD22 ' A' ' 28' ' ' LEU . 1.4 mt -141.88 141.49 33.05 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.942 -1.099 . . . . 0.0 110.142 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -86.36 137.56 32.48 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.61 HG12 ' CD2' ' A' ' 17' ' ' PHE . 88.2 mt -122.74 131.56 73.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 120.856 -1.153 . . . . 0.0 110.437 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 23.4 mttt -109.9 119.22 38.65 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.576 ' CD1' HG21 ' A' ' 15' ' ' VAL . 67.2 t80 -122.99 110.69 15.68 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.511 -0.743 . . . . 0.0 109.482 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.0 m -113.21 118.17 33.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.88 . . . . 0.0 109.68 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.541 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 1.4 ttt85 -130.15 141.81 43.22 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.277 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.12 89.29 0.46 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.572 2.181 . . . . 0.0 112.001 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.03 -32.19 6.62 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.473 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 21.1 m-20 -95.11 175.74 6.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -1.188 . . . . 0.0 109.705 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 82' ' ' SER . 51.1 m -155.01 162.56 41.04 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.404 -0.81 . . . . 0.0 109.337 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.601 HD13 ' CD2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -71.52 133.92 46.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.274 179.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.57 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.45 3.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.24 -0.912 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -140.62 149.42 42.28 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 0.0 110.205 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.545 ' CG2' HD13 ' A' ' 41' ' ' LEU . 21.6 t -139.14 136.32 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.408 -0.808 . . . . 0.0 109.455 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.466 ' HA ' HD13 ' A' ' 57' ' ' LEU . 89.1 mt-10 -129.59 152.02 49.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.903 -1.123 . . . . 0.0 109.385 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.628 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 7.3 tt -121.75 141.39 51.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.301 -0.875 . . . . 0.0 109.928 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.541 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 5.5 ttp180 -124.23 129.61 51.08 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.311 -0.868 . . . . 0.0 109.022 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -70.69 150.42 45.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.357 -0.839 . . . . 0.0 109.878 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.525 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 54.9 t60 -68.06 118.3 11.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.577 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.77 4.09 52.05 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.4 t -114.48 160.63 18.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.332 -1.099 . . . . 0.0 109.468 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.45 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 72.9 tt0 -124.56 15.23 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -0.924 . . . . 0.0 109.371 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 64.9 tt0 -118.11 81.4 1.67 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.445 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.541 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 40.8 m95 -43.28 138.86 2.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.34 -0.85 . . . . 0.0 109.778 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.28 136.68 20.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.48 -0.762 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.27 145.13 47.85 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.797 2.331 . . . . 0.0 111.898 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.535 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.3 mp -112.05 155.22 24.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.235 -0.916 . . . . 0.0 109.009 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.9 m -109.67 126.92 54.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.952 -1.092 . . . . 0.0 109.32 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 31.9 tttm -73.2 110.4 7.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.061 -1.024 . . . . 0.0 109.312 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.594 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 0.1 OUTLIER -119.31 142.83 47.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.904 -1.122 . . . . 0.0 110.126 -179.469 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.8 32.46 0.93 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 3.6 t-20 81.49 12.84 0.68 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.231 -1.158 . . . . 0.0 110.478 179.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.594 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 16.6 m -129.47 176.71 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.029 -1.044 . . . . 0.0 108.872 179.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.419 ' HB3' HD21 ' A' ' 57' ' ' LEU . 81.3 m95 -116.5 138.09 51.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 0.0 109.56 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -124.29 139.69 53.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.343 -0.848 . . . . 0.0 109.418 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.535 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 10.1 p -133.57 130.85 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.311 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -120.34 131.98 55.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.114 -0.991 . . . . 0.0 109.517 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t -118.52 145.99 44.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.502 -0.749 . . . . 0.0 109.421 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.4 m -72.3 -5.17 34.23 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.098 -1.001 . . . . 0.0 109.114 179.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.559 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.3 mtmt -130.18 177.82 2.01 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.368 -0.833 . . . . 0.0 109.11 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.559 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.5 Cg_endo -68.96 145.93 63.46 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.498 2.132 . . . . 0.0 111.765 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.596 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -83.63 138.69 33.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.797 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.0 t -123.4 124.9 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.385 -0.822 . . . . 0.0 109.484 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -94.03 169.64 29.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.622 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.51 147.52 81.73 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.903 -1.707 . . . . 0.0 112.019 -0.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.8 m-85 -91.19 151.38 20.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.556 -0.715 . . . . 0.0 110.561 -179.232 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.433 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 9.2 m-80 -112.59 143.5 43.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.342 -0.848 . . . . 0.0 108.778 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 49.7 m-85 -137.28 128.45 27.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.925 -1.109 . . . . 0.0 110.257 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 9.1 ttp180 -108.13 142.72 37.91 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.601 ' CD2' HD13 ' A' ' 41' ' ' LEU . 8.3 m-85 -123.16 144.04 49.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.155 -0.965 . . . . 0.0 111.373 -178.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.6 ' HA ' ' O ' ' A' ' 86' ' ' MET . 10.0 ttm -127.94 126.12 40.85 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -79.8 144.17 33.78 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 110.323 -178.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.57 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 68.6 mttm -44.71 -43.56 8.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.27 -3.11 0.78 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.67 23.43 26.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 35.6 mtp -97.59 147.25 24.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.101 -1.235 . . . . 0.0 108.716 179.433 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 20.7 mtm180 -125.53 142.78 51.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.819 -1.176 . . . . 0.0 110.505 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.0 m120 -137.38 141.52 41.74 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.4 t -121.45 136.28 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.924 -1.11 . . . . 0.0 110.252 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.467 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 43.9 m-85 -124.94 122.55 37.67 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -98.42 147.28 24.88 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.622 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 18.3 mt-10 52.83 51.9 15.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.439 -0.788 . . . . 0.0 110.284 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.4 t -80.74 -33.32 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.804 -1.185 . . . . 0.0 109.159 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.438 HG12 ' HB3' ' A' ' 104' ' ' TYR . 65.2 mt -138.47 126.27 13.7 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.089 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.24 162.81 40.32 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.563 2.175 . . . . 0.0 111.981 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.488 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 54.4 m -53.6 -39.76 65.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.359 -0.838 . . . . 0.0 109.924 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -92.16 99.44 12.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.064 -1.022 . . . . 0.0 109.651 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -108.28 148.01 30.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.562 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.8 t -107.24 168.96 8.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.234 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.44 HD11 HG11 ' A' ' 19' ' ' VAL . 16.3 mm -104.29 136.18 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.182 -0.949 . . . . 0.0 109.237 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.84 3.45 59.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -117.67 142.76 46.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.109 -1.23 . . . . 0.0 109.172 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.455 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.1 m -78.58 175.23 10.56 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 108.914 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.591 ' N ' ' O ' ' A' ' 17' ' ' PHE . 25.0 m-85 -159.66 97.21 1.3 Allowed 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.703 -1.248 . . . . 0.0 108.972 179.267 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.465 ' CD ' HG23 ' A' ' 16' ' ' THR . 7.2 mtmt -97.84 159.31 31.22 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.423 -0.798 . . . . 0.0 109.787 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.467 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo -71.25 159.1 52.91 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.778 2.319 . . . . 0.0 111.681 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -138.66 156.14 47.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.492 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.487 -179.956 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 81.8 mtm180 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.85 149.72 45.1 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -60.95 -32.69 72.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.208 -1.172 . . . . 0.0 109.386 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -104.04 167.34 9.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.422 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.559 ' O ' ' CB ' ' A' ' 6' ' ' HIS . 36.0 m80 -121.53 175.47 6.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.545 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.576 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 7.1 m80 79.78 -6.11 1.81 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.399 -0.813 . . . . 0.0 109.639 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.576 ' CG ' ' O ' ' A' ' 6' ' ' HIS . 98.5 m-70 -159.32 118.61 2.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.561 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -73.27 -18.59 61.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.392 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -62.77 -47.13 84.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.31 -0.869 . . . . 0.0 109.422 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.43 11.18 61.21 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -132.63 152.47 51.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -1.164 . . . . 0.0 109.528 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -146.26 142.09 28.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.23 -0.919 . . . . 0.0 109.469 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.592 ' CG1' ' CZ ' ' A' ' 34' ' ' TYR . 9.9 t -127.11 137.09 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.94 . . . . 0.0 109.548 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -109.78 120.93 44.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.079 -1.013 . . . . 0.0 109.456 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.513 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 5.1 t -129.14 140.52 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.752 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.421 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.7 p -141.44 145.24 35.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.215 -0.928 . . . . 0.0 109.549 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.586 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.2 m-85 -116.37 135.26 54.02 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.196 -0.94 . . . . 0.0 109.609 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 25.9 m -134.84 129.02 33.83 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 109.412 179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.525 HG11 ' CE1' ' A' ' 98' ' ' PHE . 39.2 t -76.47 135.84 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 109.353 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -111.46 157.18 20.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.708 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 25.7 mtpt -50.86 113.91 1.03 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.822 . . . . 0.0 109.924 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.49 -3.92 1.92 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.58 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.476 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 40.8 m -60.68 140.28 57.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.896 -1.355 . . . . 0.0 109.258 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.545 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.24 177.09 2.4 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 109.57 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.545 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -71.22 -31.66 14.1 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.59 2.193 . . . . 0.0 111.814 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -117.14 5.11 12.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.033 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.45 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 47.0 mttp -141.37 132.98 27.06 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.53 ' CD2' HD13 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.56 132.18 51.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.069 -1.02 . . . . 0.0 110.084 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.525 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 4.7 t -121.43 124.68 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.53 HD13 ' CD2' ' A' ' 28' ' ' LEU . 0.8 OUTLIER -140.87 141.07 34.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.948 -1.095 . . . . 0.0 110.124 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -85.9 136.34 33.33 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 178.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.586 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.4 mt -121.71 131.12 73.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 120.932 -1.105 . . . . 0.0 110.236 -179.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 47.4 mttm -110.36 119.53 39.5 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.592 ' CZ ' ' CG1' ' A' ' 13' ' ' VAL . 59.0 t80 -122.85 115.76 22.51 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.536 -0.727 . . . . 0.0 109.324 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.5 m -119.32 119.59 34.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.504 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 14.0 ttt85 -137.5 138.8 25.54 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.246 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.466 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.0 Cg_endo -69.74 103.05 1.1 Allowed 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.754 2.303 . . . . 0.0 112.06 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.75 2.86 86.42 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.504 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 26.2 m-20 -137.87 175.99 9.09 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -1.194 . . . . 0.0 109.693 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.9 m -156.25 163.84 39.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.466 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.591 HD23 ' CE2' ' A' ' 80' ' ' PHE . 23.4 tp -69.18 130.16 41.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.204 -0.935 . . . . 0.0 109.229 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.606 ' HB2' ' N ' ' A' ' 83' ' ' LYS . . . -113.75 -45.69 3.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 110.148 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -137.34 147.18 45.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.102 -0.998 . . . . 0.0 110.264 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.541 ' CG2' HD11 ' A' ' 41' ' ' LEU . 94.2 t -139.35 136.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.531 -0.731 . . . . 0.0 109.334 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.527 ' O ' ' HA ' ' A' ' 78' ' ' PHE . 35.1 mt-10 -128.87 151.38 49.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.415 179.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.611 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 7.0 tt -120.83 144.35 48.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.377 -0.827 . . . . 0.0 109.865 -179.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.544 ' N ' ' CD2' ' A' ' 46' ' ' LEU . 19.5 ttp180 -126.86 108.86 11.39 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 109.037 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.484 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 39.8 mt-30 -51.97 156.1 1.63 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.858 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.538 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 86.4 t60 -69.31 118.5 12.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.472 -0.768 . . . . 0.0 109.6 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.47 3.44 55.33 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -113.76 153.27 29.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -1.156 . . . . 0.0 109.467 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.472 ' HA ' ' HD2' ' A' ' 47' ' ' ARG . 85.3 tt0 -115.66 -3.47 12.29 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.273 -0.892 . . . . 0.0 109.393 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.0 tt0 -97.25 112.34 24.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -0.908 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.536 ' CE2' ' HD3' ' A' ' 47' ' ' ARG . 78.5 m95 -74.33 129.12 37.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.326 -0.859 . . . . 0.0 109.549 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -101.66 137.19 19.51 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.874 . . . . 0.0 109.364 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -71.4 144.85 46.55 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.694 2.262 . . . . 0.0 111.937 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.559 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.1 mp -107.89 148.24 29.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 108.949 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.431 HG21 ' NZ ' ' A' ' 60' ' ' LYS . 85.6 m -102.31 127.22 49.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.894 -1.129 . . . . 0.0 109.27 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.6 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 41.2 tttm -72.44 110.05 6.57 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.243 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.578 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 17.8 mmtt -118.43 140.66 49.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.907 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.85 31.74 0.84 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.583 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 9.4 m-20 82.66 13.67 0.46 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.239 -1.154 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.578 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 21.0 m -128.43 173.36 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.014 -1.054 . . . . 0.0 108.761 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.6 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 62.3 m95 -120.2 124.98 47.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.98 -1.075 . . . . 0.0 109.657 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -114.15 150.2 34.51 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.45 -0.782 . . . . 0.0 109.491 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.559 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.4 p -137.23 134.04 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.492 -0.755 . . . . 0.0 109.248 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -120.32 131.58 54.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.167 -0.958 . . . . 0.0 109.444 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.484 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 20.2 t -117.85 157.72 26.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.416 -0.802 . . . . 0.0 109.52 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.7 t -83.94 5.83 24.06 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.256 -0.903 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.527 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -139.09 176.2 2.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.295 -0.878 . . . . 0.0 109.214 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.527 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.4 Cg_endo -70.17 126.15 12.73 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.499 2.132 . . . . 0.0 111.791 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.572 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 2.0 mt -60.63 136.93 58.21 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.243 -0.91 . . . . 0.0 109.787 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.462 HG11 ' HB3' ' A' ' 49' ' ' HIS . 95.7 t -124.23 125.44 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.444 -0.785 . . . . 0.0 109.461 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -94.9 168.74 27.73 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.572 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.73 146.87 81.02 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.83 -1.737 . . . . 0.0 112.011 0.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 90.9 m-85 -91.09 149.6 21.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.506 -0.746 . . . . 0.0 110.356 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 47' ' ' ARG . 3.4 m-80 -111.99 144.57 41.11 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.611 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 18.2 m-85 -135.84 126.06 26.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.925 -1.109 . . . . 0.0 110.127 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.548 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 18.8 ttt180 -105.81 141.34 37.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.133 -0.979 . . . . 0.0 108.662 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.591 ' CE2' HD23 ' A' ' 41' ' ' LEU . 6.9 m-85 -123.7 143.03 50.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.924 . . . . 0.0 111.402 -178.146 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.631 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.5 ttt -125.93 124.47 40.87 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.606 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.0 p -72.46 144.59 48.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.385 -0.822 . . . . 0.0 109.968 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.606 ' N ' ' HB2' ' A' ' 42' ' ' ALA . 86.4 mttt -47.19 -44.74 22.49 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.402 -0.811 . . . . 0.0 108.975 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.8 -3.7 0.77 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.71 24.53 15.4 Favored Glycine 0 N--CA 1.491 2.307 0 O-C-N 120.988 -1.301 . . . . 0.0 110.257 179.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.631 ' O ' ' HA ' ' A' ' 81' ' ' MET . 15.4 mmm -96.72 148.31 23.02 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.114 -1.227 . . . . 0.0 108.633 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 72.8 mtp180 -124.12 140.03 53.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.885 -1.134 . . . . 0.0 110.416 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 80' ' ' PHE . 28.2 m120 -136.42 141.25 43.59 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.548 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 4.3 t -122.15 136.14 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.183 -179.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.557 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 13.3 m-85 -123.77 122.6 38.48 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 63.9 t0 -98.66 145.1 27.22 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.572 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 64.5 tt0 54.76 52.54 11.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.481 -0.762 . . . . 0.0 110.377 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.541 HG13 ' CD1' ' A' ' 17' ' ' PHE . 88.8 t -81.14 -34.75 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.939 -1.101 . . . . 0.0 109.006 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.429 ' CD1' HD23 ' A' ' 30' ' ' LEU . 46.6 mt -135.42 129.4 18.63 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 121.353 -0.842 . . . . 0.0 108.95 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.88 159.52 50.25 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.483 2.122 . . . . 0.0 112.009 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.485 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 31.9 m -50.17 -36.66 31.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.677 -179.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.63 101.66 11.81 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.071 -1.018 . . . . 0.0 109.518 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.525 ' CE1' HG11 ' A' ' 19' ' ' VAL . 50.9 p90 -109.49 150.84 27.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.159 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.79 168.83 8.88 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.431 HD11 ' CG1' ' A' ' 19' ' ' VAL . 17.8 mm -101.01 136.37 32.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.226 -0.921 . . . . 0.0 109.177 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 94.69 0.79 64.16 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 15.9 mttm -114.27 144.96 42.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.245 . . . . 0.0 109.157 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.436 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 4.2 m -82.65 178.37 8.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.294 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 16.3 m-85 -161.81 92.65 0.87 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.863 -1.148 . . . . 0.0 108.859 179.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.39 155.07 71.86 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.245 -0.909 . . . . 0.0 109.783 -179.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.557 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 50.0 Cg_endo -69.83 149.84 66.98 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.741 2.294 . . . . 0.0 111.886 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.433 ' O ' ' O ' ' A' ' 108' ' ' GLU . 90.5 mt-10 -81.97 138.15 34.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.228 -0.92 . . . . 0.0 109.545 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.433 ' O ' ' O ' ' A' ' 107' ' ' GLU . 94.1 mt-10 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.98 -8.53 73.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.2 m -62.88 -31.13 72.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.193 -1.181 . . . . 0.0 109.601 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 55.0 m80 -129.25 151.47 49.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.25 -0.907 . . . . 0.0 109.484 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -56.89 -39.57 74.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.29 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -106.47 -179.71 4.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.362 -0.836 . . . . 0.0 109.449 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -117.79 132.64 56.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 72.7 m-70 -109.28 100.9 9.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.414 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -131.31 149.18 52.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 109.44 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 11' ' ' SER . . . 106.5 25.41 6.32 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 10' ' ' GLY . 27.1 m -43.48 -63.61 0.8 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -1.18 . . . . 0.0 109.348 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.446 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -82.03 -154.41 0.12 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.863 . . . . 0.0 109.331 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.52 ' CG1' ' HG3' ' A' ' 36' ' ' ARG . 4.0 t -120.79 119.62 60.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.14 -0.975 . . . . 0.0 109.582 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.406 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 91.5 mt-30 -109.65 121.36 45.03 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.384 -0.823 . . . . 0.0 109.167 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.546 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.7 p -128.84 139.92 50.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.207 -0.933 . . . . 0.0 109.836 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.463 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 29.3 p -142.02 145.99 35.02 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.406 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.8 m-85 -118.31 147.48 43.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.402 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 29.9 m -141.84 127.93 19.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.112 -0.993 . . . . 0.0 109.202 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.557 ' CG1' ' OG ' ' A' ' 23' ' ' SER . 21.8 t -76.33 135.9 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.106 -0.996 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.1 mm-40 -101.44 -174.83 2.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.107 -0.996 . . . . 0.0 109.531 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.4 mttt -81.6 67.42 7.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.369 -0.832 . . . . 0.0 109.983 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -174.96 22.97 0.06 OUTLIER Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.755 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.557 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 48.9 m -75.44 142.58 42.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.777 -1.425 . . . . 0.0 109.109 179.638 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.534 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.14 171.96 7.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 109.856 -179.552 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.534 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.92 -31.05 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.869 2.38 . . . . 0.0 111.984 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -115.57 6.8 14.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.235 -0.916 . . . . 0.0 108.984 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.51 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 2.5 ttpm? -142.96 133.91 25.57 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.592 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.56 124.27 43.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.934 -1.104 . . . . 0.0 109.398 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.553 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 10.7 t -120.06 124.81 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.592 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.1 mt -145.23 145.88 31.48 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.027 -1.046 . . . . 0.0 110.147 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.446 ' HA ' HG13 ' A' ' 63' ' ' VAL . 59.2 t0 -83.86 134.92 34.67 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.576 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.5 mt -121.86 131.82 72.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 120.825 -1.172 . . . . 0.0 110.723 -178.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 24.7 mmtp -110.44 119.28 38.67 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.475 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 81.2 t80 -120.42 124.67 46.04 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.411 -0.806 . . . . 0.0 109.568 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 13' ' ' VAL . 5.2 m -128.64 118.74 23.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.847 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.544 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 0.0 OUTLIER -128.54 167.0 20.68 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.708 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.544 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.1 Cg_endo -70.55 79.06 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.716 2.277 . . . . 0.0 111.876 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.14 -9.63 69.0 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.518 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -96.84 179.0 5.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.175 . . . . 0.0 109.422 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.5 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 12.4 m -153.02 160.68 43.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.147 -0.971 . . . . 0.0 109.712 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.591 HD23 ' CE2' ' A' ' 80' ' ' PHE . 22.4 tp -69.97 130.18 41.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.471 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.58 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -116.44 -45.65 2.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.232 -0.918 . . . . 0.0 110.127 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.449 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 43.8 mt-10 -134.66 144.57 47.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.116 -0.99 . . . . 0.0 110.335 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.575 HG11 ' CE1' ' A' ' 80' ' ' PHE . 93.8 t -137.99 135.48 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.492 -0.755 . . . . 0.0 109.217 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.49 ' HA ' ' CD1' ' A' ' 57' ' ' LEU . 25.7 mt-10 -129.04 151.05 50.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.985 -1.072 . . . . 0.0 109.395 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.578 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 5.4 tt -119.4 132.61 55.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.447 -0.783 . . . . 0.0 109.913 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.509 ' N ' HD22 ' A' ' 46' ' ' LEU . 27.0 ttp180 -118.53 128.21 54.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.225 -0.922 . . . . 0.0 108.761 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -73.13 152.24 41.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 110.195 -179.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.523 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 55.1 t-80 -63.02 147.48 50.56 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.408 -0.808 . . . . 0.0 109.137 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.92 1.0 54.57 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.6 t -112.45 150.31 31.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -1.144 . . . . 0.0 109.316 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -116.59 8.46 13.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.924 . . . . 0.0 109.517 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 64.0 mm-40 -107.01 115.42 30.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.401 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 58.3 m95 -76.08 129.03 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.326 -0.859 . . . . 0.0 109.715 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -99.94 133.38 21.68 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.432 -0.793 . . . . 0.0 109.193 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 149.03 67.25 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.689 2.259 . . . . 0.0 111.803 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.535 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 6.1 mp -111.98 158.58 19.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.194 -0.941 . . . . 0.0 109.354 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.2 m -107.48 127.72 53.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.954 -1.091 . . . . 0.0 109.279 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 47.3 tttt -70.84 112.89 7.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -0.896 . . . . 0.0 109.242 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.445 ' HE3' ' OE1' ' A' ' 65' ' ' GLU . 40.2 mttt -113.64 125.66 54.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.953 -1.092 . . . . 0.0 109.595 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 44.68 -109.54 0.29 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -117.11 17.44 14.84 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.258 -1.142 . . . . 0.0 109.564 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.446 HG13 ' HA ' ' A' ' 31' ' ' ASP . 10.9 m -131.93 -175.82 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.451 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -127.33 139.82 52.62 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' HE3' ' A' ' 67' ' ' LYS . 19.1 tt0 -121.21 135.01 55.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.215 -0.928 . . . . 0.0 109.753 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.535 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 4.6 p -131.09 129.36 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.274 -0.891 . . . . 0.0 109.304 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.51 ' HG2' ' CD ' ' A' ' 27' ' ' LYS . 88.3 mttt -120.05 131.58 55.15 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.094 -1.004 . . . . 0.0 109.529 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.5 t -117.6 138.91 51.63 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.526 -0.734 . . . . 0.0 109.288 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 79.3 p -65.56 -11.3 42.72 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.154 -0.966 . . . . 0.0 109.232 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.535 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -121.12 176.34 1.95 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.68 164.57 32.66 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.602 2.201 . . . . 0.0 111.811 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.614 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.1 mt -100.59 141.56 33.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.258 -0.901 . . . . 0.0 109.849 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 50.2 t -127.86 125.2 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.547 -0.72 . . . . 0.0 109.319 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.451 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -93.76 164.74 26.64 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.591 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.9 Cg_endo -68.84 148.15 83.97 Favored 'Cis proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.984 0.075 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.4 m-85 -92.58 149.87 21.08 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.442 -0.786 . . . . 0.0 110.476 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.483 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 14.6 m-80 -110.51 143.33 41.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 108.769 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 83.1 m-85 -134.69 126.84 29.87 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.014 -1.054 . . . . 0.0 109.737 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.527 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 53.1 ttt180 -108.35 142.51 38.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.04 -1.038 . . . . 0.0 108.753 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.591 ' CE2' HD23 ' A' ' 41' ' ' LEU . 9.1 m-85 -124.6 143.42 50.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 111.551 -178.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.596 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.6 ttm -126.38 125.95 43.06 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 178.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.608 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.9 p -74.0 145.92 44.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 110.204 -178.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.58 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 78.7 mttt -48.37 -44.22 34.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.272 -0.893 . . . . 0.0 108.934 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.44 -3.69 0.68 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.53 25.05 16.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.608 ' O ' ' N ' ' A' ' 82' ' ' SER . 13.0 mmm -97.39 148.36 23.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.172 -1.193 . . . . 0.0 108.575 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.561 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 21.6 mtm180 -124.31 140.03 53.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.843 -1.16 . . . . 0.0 110.68 -178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . 34.7 m120 -135.42 140.08 44.65 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.527 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 59.1 t -122.03 136.9 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.037 -1.039 . . . . 0.0 110.409 -179.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.516 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 15.9 m-85 -125.52 122.98 38.13 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -99.57 147.84 24.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.591 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 95.8 mt-10 53.45 51.4 15.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.338 -0.851 . . . . 0.0 110.044 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.443 HG12 HG13 ' A' ' 94' ' ' ILE . 44.1 t -81.03 -33.98 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.821 -1.174 . . . . 0.0 109.26 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.49 HD12 HD21 ' A' ' 30' ' ' LEU . 43.7 mt -138.13 125.75 13.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.139 -0.976 . . . . 0.0 109.057 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.12 161.78 44.43 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.533 2.155 . . . . 0.0 111.882 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.6 m -57.08 -39.46 75.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.376 -0.827 . . . . 0.0 109.923 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.45 70.31 9.89 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.081 -1.012 . . . . 0.0 109.492 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -81.2 148.52 29.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.936 . . . . 0.0 109.656 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 43.3 m -109.82 168.8 9.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.317 -0.865 . . . . 0.0 109.186 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.544 HD11 ' CG1' ' A' ' 19' ' ' VAL . 35.6 mm -103.4 135.71 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.137 -0.977 . . . . 0.0 109.284 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 97.01 5.88 58.17 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.463 ' HD3' ' CZ ' ' A' ' 104' ' ' TYR . 43.7 tttp -119.73 143.17 47.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.25 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.567 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.7 m -79.88 176.51 9.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 109.018 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -162.7 95.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.875 -1.141 . . . . 0.0 108.937 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.474 ' HB3' ' O ' ' A' ' 15' ' ' VAL . 0.3 OUTLIER -103.0 166.33 12.05 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.873 . . . . 0.0 109.793 -179.405 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo -71.11 140.93 38.68 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.588 2.192 . . . . 0.0 111.727 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.09 -31.22 72.32 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.403 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 12.8 mp0 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.464 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.4 ptm180 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -153.69 176.65 31.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.9 m -137.92 156.0 48.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -1.13 . . . . 0.0 109.452 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -112.01 173.2 6.47 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.273 -0.892 . . . . 0.0 109.359 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -68.32 153.64 43.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.394 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 44.1 m80 -91.54 140.39 29.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.289 -0.882 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 55.0 t60 -56.69 -47.29 80.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.497 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -160.15 91.96 0.97 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.228 -0.92 . . . . 0.0 109.522 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 -64.48 -50.41 67.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.221 -0.925 . . . . 0.0 109.47 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -100.97 122.46 7.6 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.473 ' HB3' ' CG ' ' A' ' 37' ' ' PRO . 22.9 t -132.9 -158.65 0.9 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -1.116 . . . . 0.0 109.463 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.417 ' C ' HG21 ' A' ' 13' ' ' VAL . . . -101.66 162.75 12.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.547 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.577 HG12 ' CE1' ' A' ' 34' ' ' TYR . 3.6 t -129.48 145.85 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.877 . . . . 0.0 109.539 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -111.47 121.64 45.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.896 . . . . 0.0 109.244 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.566 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 14.4 t -128.95 139.68 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.202 -0.936 . . . . 0.0 109.817 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.0 p -141.99 146.15 35.26 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.328 -0.857 . . . . 0.0 109.474 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.593 ' O ' ' N ' ' A' ' 104' ' ' TYR . 91.7 m-85 -118.38 123.65 45.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 34.8 m -120.05 128.37 53.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.03 -1.044 . . . . 0.0 109.063 179.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.515 ' CG1' HD13 ' A' ' 100' ' ' ILE . 11.9 t -76.04 132.57 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 37.7 mm-40 -107.3 156.35 18.98 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.8 mttt -50.08 114.55 1.12 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.432 -0.793 . . . . 0.0 109.909 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.95 1.98 1.96 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 65.9 p -62.85 142.32 58.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.762 -1.434 . . . . 0.0 109.185 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.505 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.43 174.12 4.71 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.133 -0.98 . . . . 0.0 109.664 -179.626 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.505 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.9 Cg_endo -71.01 -29.86 17.31 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.683 2.255 . . . . 0.0 111.86 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -118.18 4.18 11.98 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.32 -0.862 . . . . 0.0 109.041 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.457 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 52.7 mttt -143.01 134.13 25.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.517 HD23 ' CD1' ' A' ' 30' ' ' LEU . 0.2 OUTLIER -128.01 134.25 49.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.984 -1.073 . . . . 0.0 110.401 -179.332 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.519 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.6 t -121.95 123.73 69.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.519 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -143.68 144.51 31.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 109.914 -179.352 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -86.3 136.13 33.27 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.581 HG12 ' CD2' ' A' ' 17' ' ' PHE . 80.1 mt -120.68 131.63 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 120.881 -1.137 . . . . 0.0 110.324 -179.163 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 mttm -111.09 118.69 36.71 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.577 ' CE1' HG12 ' A' ' 13' ' ' VAL . 67.6 t80 -121.26 109.33 14.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.489 -0.757 . . . . 0.0 109.339 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.495 ' O ' HG11 ' A' ' 13' ' ' VAL . 97.1 m -112.62 117.32 31.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.89 . . . . 0.0 109.89 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.563 ' HD3' ' CB ' ' A' ' 39' ' ' ASP . 37.8 ttt-85 -136.83 139.73 29.75 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.368 -0.833 . . . . 0.0 109.179 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.49 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.3 Cg_endo -69.75 109.35 2.29 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 112.069 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.05 4.44 88.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.563 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 4.9 m-20 -134.52 173.21 11.91 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -1.22 . . . . 0.0 109.772 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -155.53 162.61 40.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.341 -0.849 . . . . 0.0 109.502 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.561 HD23 ' CE2' ' A' ' 80' ' ' PHE . 10.7 tp -70.55 129.56 39.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.846 . . . . 0.0 109.501 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.547 ' HB2' ' N ' ' A' ' 83' ' ' LYS . . . -115.83 -42.74 3.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.161 -0.962 . . . . 0.0 109.839 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -142.62 151.09 41.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.138 -0.976 . . . . 0.0 110.002 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.569 HG13 ' CZ ' ' A' ' 80' ' ' PHE . 21.4 t -139.9 137.27 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.435 -0.791 . . . . 0.0 109.465 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 61.4 mt-10 -127.78 150.55 49.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.873 -1.142 . . . . 0.0 109.215 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.576 HD22 ' CE2' ' A' ' 78' ' ' PHE . 10.9 tp -120.87 133.0 55.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.333 -0.855 . . . . 0.0 110.243 -178.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.583 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 47.8 ttp85 -113.53 127.98 56.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.099 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.441 ' NE2' HD23 ' A' ' 72' ' ' LEU . 72.5 mm-40 -71.91 152.35 42.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.512 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 37.6 t-80 -69.31 111.3 5.12 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.382 -0.824 . . . . 0.0 109.554 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.82 2.1 36.75 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.511 ' O ' ' NH1' ' A' ' 47' ' ' ARG . 33.5 t -113.47 154.37 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.195 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 37.9 mm-40 -113.22 16.14 19.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.333 -0.854 . . . . 0.0 109.394 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -113.88 114.19 25.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.528 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.583 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.6 m95 -80.13 120.09 23.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.267 -0.895 . . . . 0.0 109.655 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -95.95 129.99 32.63 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.445 -0.784 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.32 149.48 69.74 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.561 2.174 . . . . 0.0 111.879 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.59 ' CD1' ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -101.6 149.52 24.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.149 -0.97 . . . . 0.0 108.576 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -102.46 126.54 49.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 108.941 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -70.41 109.47 4.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.168 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.618 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 37.2 mttp -121.74 139.53 53.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.797 -1.189 . . . . 0.0 109.975 -179.548 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.542 ' O ' ' HB2' ' A' ' 62' ' ' ASN . . . 38.39 48.25 2.21 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.542 ' HB2' ' O ' ' A' ' 61' ' ' GLY . 54.3 m-20 68.48 11.46 8.36 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.169 -1.195 . . . . 0.0 110.956 178.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.618 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 27.9 m -128.88 -178.61 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.858 -1.151 . . . . 0.0 108.997 179.169 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.496 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 71.1 m95 -122.8 141.27 52.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.082 . . . . 0.0 109.632 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 62.5 tt0 -128.42 142.22 51.17 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.815 . . . . 0.0 109.212 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.59 ' HB ' ' CD1' ' A' ' 57' ' ' LEU . 1.8 p -136.37 135.18 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.24 -0.913 . . . . 0.0 109.145 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.413 ' HD2' ' HE2' ' A' ' 27' ' ' LYS . 6.1 ttpm? -122.54 133.73 54.56 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.851 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.8 t -117.86 148.13 42.41 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.456 -0.778 . . . . 0.0 109.153 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 85.5 p -72.77 -4.43 31.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.988 . . . . 0.0 109.354 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.538 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -131.5 176.19 3.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.243 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.538 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.44 140.52 48.25 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.482 2.121 . . . . 0.0 111.714 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.588 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 10.5 mt -74.76 137.89 42.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.826 -179.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.9 t -123.37 125.12 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.469 -0.769 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.433 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -93.3 165.47 27.67 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.62 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 50.5 Cg_endo -70.01 145.66 80.6 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.806 -1.747 . . . . 0.0 111.883 0.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.8 m-85 -91.46 151.18 20.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.523 -0.736 . . . . 0.0 110.367 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.502 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 2.4 m-80 -110.77 142.43 42.75 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CE2' HD22 ' A' ' 46' ' ' LEU . 91.0 m-85 -133.24 127.3 33.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.913 -1.117 . . . . 0.0 109.971 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 41.4 ttt180 -110.62 143.12 41.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.006 -1.059 . . . . 0.0 108.627 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.571 ' CZ ' HG23 ' A' ' 32' ' ' ILE . 9.0 m-85 -124.86 143.81 50.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.218 -0.926 . . . . 0.0 111.632 -177.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.561 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 1.2 ttt -125.85 124.4 40.82 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 86' ' ' MET . 24.2 p -77.39 147.7 35.92 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.206 -0.934 . . . . 0.0 110.043 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.547 ' N ' ' HB2' ' A' ' 42' ' ' ALA . 32.9 mttt -46.65 -46.0 19.6 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.32 -8.19 8.65 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.41 34.53 5.28 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.539 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 44.3 mmm -103.24 110.61 22.64 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.987 -1.302 . . . . 0.0 109.011 179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.561 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 61.0 mtt180 -91.71 139.49 30.63 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.199 -0.938 . . . . 0.0 110.472 -179.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.4 m120 -137.25 141.69 42.02 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 4.2 t -122.06 136.5 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.865 -1.147 . . . . 0.0 110.471 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.523 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 55.0 m-85 -124.44 122.36 37.42 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -97.13 145.27 26.17 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.18 -0.95 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.62 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 12.8 mt-10 53.96 54.26 9.99 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.491 -0.756 . . . . 0.0 110.335 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.511 HG12 ' CD1' ' A' ' 17' ' ' PHE . 75.8 t -82.26 -34.18 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 109.074 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.433 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.7 mt -135.44 124.4 16.0 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.201 -0.937 . . . . 0.0 109.132 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.42 162.13 43.12 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.608 2.205 . . . . 0.0 111.968 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.3 m -53.3 -44.7 68.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 109.976 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.84 99.72 12.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.046 -1.034 . . . . 0.0 109.502 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -109.45 147.83 32.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.94 . . . . 0.0 109.715 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.8 m -106.09 171.15 7.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.212 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.515 HD13 ' CG1' ' A' ' 19' ' ' VAL . 27.2 mm -106.73 137.83 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.427 ' N ' HG22 ' A' ' 100' ' ' ILE . . . 92.42 9.62 61.49 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 4.6 tptp -120.57 144.18 48.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.404 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 8.6 m -77.81 170.97 15.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.038 -1.039 . . . . 0.0 108.706 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.593 ' N ' ' O ' ' A' ' 17' ' ' PHE . 24.0 m-85 -157.62 97.94 1.63 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.607 -1.308 . . . . 0.0 109.151 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.522 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -104.93 161.53 22.49 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.277 -0.889 . . . . 0.0 109.767 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.523 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.2 Cg_endo -69.08 143.2 53.27 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.718 2.279 . . . . 0.0 111.663 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -52.97 -30.97 38.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.546 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.408 ' HA ' ' OE1' ' A' ' 108' ' ' GLU . 62.3 mm-40 . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.439 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -76.78 -16.69 80.55 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.0 m -118.72 147.66 43.6 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.316 -1.108 . . . . 0.0 109.466 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -132.08 164.33 26.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 109.508 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -126.66 164.19 21.81 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.448 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.1 m80 -78.95 -12.72 60.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.507 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -53.55 -26.96 23.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.422 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 t60 -58.06 -34.5 70.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -99.87 144.17 29.24 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.397 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.27 -152.98 17.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 91.9 p -114.09 146.76 39.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.294 -1.121 . . . . 0.0 109.483 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.485 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -140.66 153.32 45.95 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.488 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.537 ' CG2' ' HG3' ' A' ' 36' ' ' ARG . 30.3 t -125.37 130.32 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.295 -0.878 . . . . 0.0 109.567 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 77.9 mm-40 -106.01 120.24 41.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.027 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.1 p -128.92 139.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.232 -0.917 . . . . 0.0 110.049 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 15' ' ' VAL . 73.1 p -141.25 145.42 35.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.334 179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.646 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.8 m-85 -118.24 136.22 53.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.176 -0.953 . . . . 0.0 109.717 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 88.5 m -131.34 127.77 38.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.903 -1.123 . . . . 0.0 109.302 179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.532 ' CG2' HD22 ' A' ' 30' ' ' LEU . 30.6 t -75.02 134.01 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.216 -0.928 . . . . 0.0 109.173 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.468 ' OE1' ' O ' ' A' ' 19' ' ' VAL . 4.9 mm100 -106.57 156.34 18.69 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.174 -0.954 . . . . 0.0 109.975 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.5 mttt -51.34 115.87 1.79 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.51 -0.743 . . . . 0.0 109.947 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 137.26 -1.52 3.05 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.447 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 p -60.29 144.15 51.14 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.911 -1.347 . . . . 0.0 109.403 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.481 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.19 169.79 12.62 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.288 -0.882 . . . . 0.0 109.71 -179.779 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.481 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.4 Cg_endo -70.73 -29.34 19.39 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.806 2.337 . . . . 0.0 111.88 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -113.02 7.09 17.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.165 -0.959 . . . . 0.0 108.819 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -142.74 133.55 25.45 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.35 122.84 40.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.965 -1.085 . . . . 0.0 109.337 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.545 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 51.4 t -118.72 124.35 73.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.2 mt -144.33 144.76 31.61 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.977 -1.077 . . . . 0.0 110.253 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -85.39 137.04 33.2 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 177.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.614 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 75.7 mt -120.71 130.98 73.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 C-N-CA 118.667 -1.213 . . . . 0.0 110.786 -179.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.588 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 22.1 tttm -110.61 120.38 42.23 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.486 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 78.6 t80 -120.15 112.77 19.52 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.343 -0.848 . . . . 0.0 109.567 -178.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.461 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 31.2 m -115.71 115.79 26.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -0.851 . . . . 0.0 109.677 -179.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.539 ' CZ ' ' HE1' ' A' ' 86' ' ' MET . 28.0 ttt85 -138.68 136.29 18.62 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.526 -0.734 . . . . 0.0 109.208 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 12' ' ' ALA . 49.2 Cg_endo -69.88 112.57 3.13 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.1 0.69 83.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.538 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.2 m-20 -133.92 172.26 13.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.966 -1.314 . . . . 0.0 109.87 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 82' ' ' SER . 13.6 m -153.98 161.61 41.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.408 -0.807 . . . . 0.0 109.341 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.601 HD11 ' CE2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -72.28 131.27 42.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.279 -0.888 . . . . 0.0 109.845 -179.588 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.623 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -114.93 -40.24 3.54 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.619 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.45 150.41 40.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.124 -0.985 . . . . 0.0 110.187 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.553 ' CG2' HD11 ' A' ' 41' ' ' LEU . 5.9 t -139.21 136.88 41.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.581 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.469 ' HA ' HD11 ' A' ' 57' ' ' LEU . 93.9 mt-10 -129.63 150.81 50.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.935 -1.103 . . . . 0.0 109.394 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.584 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 6.7 tt -118.72 140.61 49.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.892 . . . . 0.0 109.715 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.587 ' HD3' ' CD1' ' A' ' 54' ' ' TRP . 28.3 ttp180 -126.74 129.54 48.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.293 -0.879 . . . . 0.0 109.072 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.588 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 47.8 mt-30 -72.6 144.8 47.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.343 -0.848 . . . . 0.0 109.863 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.535 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 2.0 t-160 -61.36 115.81 4.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.35 -0.844 . . . . 0.0 109.442 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.42 2.75 35.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.424 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 25.6 t -113.7 155.71 25.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -1.188 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.491 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 69.7 tt0 -116.05 1.03 13.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.583 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -108.83 92.48 4.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.587 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 46.0 m95 -51.55 138.64 22.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.356 -0.84 . . . . 0.0 109.599 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -105.05 135.19 19.33 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.375 -0.828 . . . . 0.0 109.32 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.83 145.51 51.11 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.617 2.211 . . . . 0.0 111.891 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.535 HD12 ' CB ' ' A' ' 46' ' ' LEU . 5.4 mp -107.17 146.14 31.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.032 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.2 m -94.41 126.92 39.97 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.956 -1.09 . . . . 0.0 109.176 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -70.6 111.18 5.91 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.408 -0.808 . . . . 0.0 109.033 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -111.77 113.04 25.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.982 -1.074 . . . . 0.0 109.571 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.15 -103.72 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -123.76 17.36 9.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -1.146 . . . . 0.0 109.398 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 m -130.82 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.328 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 60.9 m95 -134.1 142.06 47.38 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.155 -0.966 . . . . 0.0 109.466 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -122.48 134.79 54.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.214 -0.929 . . . . 0.0 109.766 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 28' ' ' LEU . 4.8 p -130.83 130.35 64.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -0.903 . . . . 0.0 109.217 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.7 tttm -122.17 133.85 54.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.064 -1.023 . . . . 0.0 109.75 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.588 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.3 t -117.63 154.77 31.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.437 -0.789 . . . . 0.0 109.239 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 20.4 m -80.15 -4.36 52.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.288 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.531 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.1 mttm -128.33 176.05 3.03 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.531 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.5 Cg_endo -69.52 124.19 10.94 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.508 2.138 . . . . 0.0 111.735 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.585 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.3 mt -58.53 139.67 55.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.354 -0.842 . . . . 0.0 109.79 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 46.4 t -125.14 124.68 67.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.378 -0.826 . . . . 0.0 109.543 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -95.3 166.78 25.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.599 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 45.4 Cg_endo -66.61 146.53 73.86 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 123.043 -1.649 . . . . 0.0 112.087 0.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 75.5 m-85 -90.72 150.53 21.6 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.607 -0.683 . . . . 0.0 110.405 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -111.91 143.16 43.33 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 89.3 m-85 -134.77 122.16 21.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.01 -1.056 . . . . 0.0 109.704 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.421 ' N ' ' CZ3' ' A' ' 54' ' ' TRP . 51.9 ttp180 -103.3 141.91 35.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.96 -1.087 . . . . 0.0 108.609 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.614 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 31.7 m-85 -125.51 143.91 50.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.187 -0.946 . . . . 0.0 111.595 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.54 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.8 ttm -126.65 126.82 44.19 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.537 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 19.3 p -77.52 145.62 36.85 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.203 -0.936 . . . . 0.0 110.412 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.623 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 58.6 mttt -48.7 -44.56 38.15 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.61 -6.24 6.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.26 34.34 5.9 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.539 ' HE1' ' CZ ' ' A' ' 36' ' ' ARG . 15.8 mmm -106.07 108.78 20.47 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.075 -1.25 . . . . 0.0 109.001 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.54 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 82.5 mtm180 -85.86 134.98 33.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.199 -0.938 . . . . 0.0 110.634 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 30.0 m120 -134.3 139.49 45.74 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 37.2 t -122.84 136.82 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.036 -1.04 . . . . 0.0 110.587 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.511 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 61.2 m-85 -124.16 122.09 36.88 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.518 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 21.0 p-10 -100.11 148.96 24.01 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.346 -0.846 . . . . 0.0 109.744 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 40.1 tt0 52.98 51.19 16.33 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.323 -0.86 . . . . 0.0 110.002 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.47 HG11 HG13 ' A' ' 94' ' ' ILE . 61.6 t -81.76 -33.87 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.924 -1.11 . . . . 0.0 109.116 179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.497 HD12 HD21 ' A' ' 30' ' ' LEU . 67.1 mt -138.83 127.67 14.09 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.312 -0.868 . . . . 0.0 109.074 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.45 161.37 46.14 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.611 2.208 . . . . 0.0 111.982 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.52 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 87.4 m -51.2 -45.44 61.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.394 -0.816 . . . . 0.0 109.916 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -93.07 104.01 16.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.113 -0.992 . . . . 0.0 109.688 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -111.09 151.57 27.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.359 -0.838 . . . . 0.0 109.33 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.0 m -102.64 170.18 8.18 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 30.6 mm -103.23 136.06 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.182 -0.948 . . . . 0.0 109.306 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.8 57.7 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -121.28 143.39 49.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.974 -1.309 . . . . 0.0 109.306 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.526 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.9 m -79.15 177.2 9.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.076 -1.015 . . . . 0.0 108.919 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.646 ' N ' ' O ' ' A' ' 17' ' ' PHE . 27.5 m-85 -162.23 96.27 0.97 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.769 -1.207 . . . . 0.0 109.107 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.508 ' C ' ' CD ' ' A' ' 105' ' ' LYS . 0.1 OUTLIER -102.51 164.54 15.45 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.362 -0.836 . . . . 0.0 109.724 -179.584 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.511 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.5 Cg_endo -68.68 174.89 7.88 Favored 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.675 2.25 . . . . 0.0 111.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.456 ' O ' ' HG2' ' A' ' 107' ' ' GLU . 37.5 tt0 -88.59 -22.04 23.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.355 -0.841 . . . . 0.0 109.511 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.3 mt-10 . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.506 179.972 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 73.39 -125.67 9.58 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 65.3 p -139.63 168.48 19.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -1.154 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.58 99.64 9.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -0.955 . . . . 0.0 109.479 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -62.45 -41.47 98.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.903 . . . . 0.0 109.481 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -86.05 139.96 30.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.201 -0.937 . . . . 0.0 109.484 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 40.6 t-80 -64.61 -42.05 95.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.3 p80 -127.52 141.03 51.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.451 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 74.1 m80 -54.37 -35.59 62.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.287 -0.883 . . . . 0.0 109.565 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.86 -159.38 26.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.2 t -120.29 116.54 25.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -1.154 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.458 ' O ' ' HD2' ' A' ' 37' ' ' PRO . . . -149.57 176.89 10.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.278 -0.889 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.498 HG23 ' CG ' ' A' ' 36' ' ' ARG . 60.7 t -121.58 123.95 70.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.533 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.48 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 94.7 mt-30 -112.96 121.78 45.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.274 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.606 HG12 ' CE2' ' A' ' 90' ' ' PHE . 12.5 p -128.79 139.99 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.258 -0.902 . . . . 0.0 109.668 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.446 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 17.0 p -141.6 145.72 35.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.155 -0.965 . . . . 0.0 109.515 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.576 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.7 m-85 -117.49 150.44 38.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.234 -0.916 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CG2' ' O ' ' A' ' 102' ' ' LYS . 92.2 m -144.81 127.7 16.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.069 -1.02 . . . . 0.0 109.378 179.097 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.556 ' CG2' HD23 ' A' ' 30' ' ' LEU . 4.5 t -76.29 129.1 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.885 . . . . 0.0 109.377 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 91.2 mm-40 -92.97 -175.25 3.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.609 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -81.94 62.16 5.59 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.962 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -169.05 24.49 0.1 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.71 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.537 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 26.2 m -79.95 143.64 34.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.778 -1.425 . . . . 0.0 109.252 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.501 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.71 174.19 4.6 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.101 -0.999 . . . . 0.0 109.605 -179.726 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.546 ' O ' ' N ' ' A' ' 72' ' ' LEU . 48.7 Cg_endo -70.76 -30.39 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.67 2.247 . . . . 0.0 112.045 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 88.8 mttt -115.17 5.7 14.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.067 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.8 mttt -142.18 133.38 26.21 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.31 40.95 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.042 -1.036 . . . . 0.0 109.466 -179.928 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.532 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 21.9 t -118.74 124.62 73.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -144.65 145.76 31.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.978 -1.076 . . . . 0.0 110.169 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -85.63 137.36 32.9 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.608 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 77.0 mt -120.78 130.13 74.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.755 -1.215 . . . . 0.0 110.688 -178.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.5 tttm -109.66 119.95 40.98 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.472 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 72.3 t80 -122.0 124.27 43.6 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.334 -0.853 . . . . 0.0 109.716 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.48 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 16.2 m -126.74 116.93 21.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.301 -0.874 . . . . 0.0 109.737 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.498 ' CG ' HG23 ' A' ' 13' ' ' VAL . 0.5 OUTLIER -151.27 116.66 3.19 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.416 -0.803 . . . . 0.0 109.139 179.804 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.458 ' HD2' ' O ' ' A' ' 12' ' ' ALA . 48.3 Cg_endo -68.95 126.21 13.56 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.73 2.286 . . . . 0.0 111.95 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.54 -19.48 54.5 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.492 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 1.5 m-20 -142.95 -176.35 4.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.209 -1.171 . . . . 0.0 109.814 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.437 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.9 m -156.17 163.31 39.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.36 -0.838 . . . . 0.0 109.367 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.515 HD23 ' CE2' ' A' ' 80' ' ' PHE . 29.4 tp -70.52 129.02 38.12 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.342 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.578 ' HB3' ' N ' ' A' ' 83' ' ' LYS . . . -116.65 -42.35 2.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.422 ' C ' HG22 ' A' ' 44' ' ' VAL . 86.6 mt-10 -139.59 147.89 41.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.176 -0.953 . . . . 0.0 110.218 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.585 HG12 ' CZ ' ' A' ' 80' ' ' PHE . 8.9 t -138.6 136.99 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 108.965 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.477 ' HA ' HD13 ' A' ' 57' ' ' LEU . 72.5 mt-10 -128.15 149.22 50.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.821 -1.174 . . . . 0.0 109.56 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.584 HD22 ' CZ ' ' A' ' 78' ' ' PHE . 11.2 tp -120.18 131.64 55.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.418 -0.801 . . . . 0.0 109.96 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.5 ' N ' HD12 ' A' ' 46' ' ' LEU . 7.5 ttp180 -119.82 131.94 55.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.076 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.487 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 43.2 mt-30 -72.27 149.95 44.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.738 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 10.2 t60 -68.54 113.94 6.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.746 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.48 2.42 27.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.453 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 28.1 t -115.01 154.92 27.93 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -1.172 . . . . 0.0 109.406 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -111.22 15.59 21.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.291 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -121.97 121.43 37.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.541 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.478 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 43.1 m95 -83.34 132.94 34.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.76 135.11 20.14 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.335 -0.853 . . . . 0.0 109.422 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.438 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 52.3 Cg_endo -71.11 149.49 58.39 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.606 2.204 . . . . 0.0 111.96 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.602 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.6 mp -108.4 138.46 44.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.213 -0.929 . . . . 0.0 109.07 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.3 m -90.17 127.48 36.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.99 -1.069 . . . . 0.0 109.014 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 22.7 tttt -74.48 105.68 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.265 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.487 ' O ' HG21 ' A' ' 63' ' ' VAL . 13.5 mttt -108.3 110.63 22.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.006 -1.059 . . . . 0.0 109.551 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.11 -107.73 1.93 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 35.0 p-10 -121.99 16.24 10.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -1.128 . . . . 0.0 109.345 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.487 HG21 ' O ' ' A' ' 60' ' ' LYS . 30.2 m -132.08 170.09 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.947 . . . . 0.0 109.424 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.439 ' HB3' HD23 ' A' ' 57' ' ' LEU . 55.9 m95 -116.11 142.82 46.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.169 -0.957 . . . . 0.0 109.216 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.466 ' HG3' HG23 ' A' ' 29' ' ' VAL . 75.7 tt0 -123.67 136.57 54.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 109.921 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.602 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.9 p -131.07 130.25 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.361 -0.837 . . . . 0.0 109.118 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.423 ' HE2' ' OE2' ' A' ' 65' ' ' GLU . 25.1 mttt -120.75 132.34 55.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.148 -0.97 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.487 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.4 t -118.56 145.55 45.27 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.447 -0.783 . . . . 0.0 109.217 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.3 m -66.55 -11.28 52.19 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.092 -1.005 . . . . 0.0 109.165 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.535 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -123.28 176.55 2.1 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.387 -0.821 . . . . 0.0 109.278 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.4 Cg_endo -69.74 157.62 59.8 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.454 2.102 . . . . 0.0 111.63 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.601 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 5.3 mt -87.58 138.65 31.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.798 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 73.5 t -124.85 125.26 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.416 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.544 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.3 164.96 26.08 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.61 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.93 146.48 80.48 Favored 'Cis proline' 0 C--O 1.214 -0.704 0 C-N-CA 122.761 -1.766 . . . . 0.0 111.8 0.205 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.1 m-85 -91.02 152.4 20.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.515 -0.741 . . . . 0.0 110.544 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.508 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 37.8 m-80 -112.68 141.67 46.2 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CZ ' HD22 ' A' ' 46' ' ' LEU . 86.9 m-85 -134.77 122.18 21.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.102 -0.999 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.544 ' CD ' HG21 ' A' ' 89' ' ' VAL . 70.6 ttt180 -104.2 143.32 33.1 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.997 -1.064 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.608 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 11.0 m-85 -125.29 143.15 51.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.196 -0.94 . . . . 0.0 111.402 -178.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.535 ' HA ' ' O ' ' A' ' 86' ' ' MET . 2.5 ttt -125.23 125.03 42.96 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.594 ' N ' ' O ' ' A' ' 86' ' ' MET . 14.8 p -73.7 147.12 43.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 110.267 -178.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.578 ' N ' ' HB3' ' A' ' 42' ' ' ALA . 42.1 mttp -50.03 -44.78 51.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.468 -0.77 . . . . 0.0 109.134 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.65 -4.31 0.61 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.512 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.86 27.06 11.64 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.594 ' O ' ' N ' ' A' ' 82' ' ' SER . 46.4 mtp -99.89 149.07 23.79 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -1.184 . . . . 0.0 108.627 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.517 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 17.8 mtt180 -121.87 136.92 54.95 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.871 -1.143 . . . . 0.0 110.457 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -134.1 139.79 46.17 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.544 HG21 ' CD ' ' A' ' 79' ' ' ARG . 6.4 t -123.2 136.97 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 120.952 -1.093 . . . . 0.0 110.315 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.606 ' CE2' HG12 ' A' ' 15' ' ' VAL . 18.2 m-85 -123.62 121.65 36.11 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -98.96 147.35 25.08 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.262 -0.899 . . . . 0.0 109.803 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.61 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 63.1 tt0 53.88 51.41 14.87 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.5 -0.75 . . . . 0.0 110.338 179.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.426 HG12 HG13 ' A' ' 94' ' ' ILE . 42.0 t -81.13 -34.37 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.889 -1.132 . . . . 0.0 108.905 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.426 HG13 HG12 ' A' ' 93' ' ' VAL . 40.9 mt -136.45 125.32 15.42 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.326 -0.859 . . . . 0.0 109.121 179.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.85 162.71 41.09 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.565 2.177 . . . . 0.0 112.024 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.544 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 32.2 m -49.96 -38.39 36.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.373 -0.829 . . . . 0.0 110.007 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.49 102.8 13.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.006 -1.059 . . . . 0.0 109.72 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.497 ' CE1' HG11 ' A' ' 19' ' ' VAL . 42.8 p90 -110.33 154.13 23.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.905 . . . . 0.0 109.163 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.9 t -104.32 167.51 9.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.419 ' HA ' HD13 ' A' ' 100' ' ' ILE . 28.6 mm -103.41 138.9 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -0.864 . . . . 0.0 109.29 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 90.35 16.0 56.2 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.438 ' O ' ' CG2' ' A' ' 18' ' ' THR . 18.9 mttm -119.21 -165.97 1.21 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 109.071 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.6 m -131.61 163.41 28.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.977 -1.077 . . . . 0.0 108.665 179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.576 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.8 m-85 -151.6 94.03 1.95 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.44 -1.412 . . . . 0.0 109.147 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.525 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -99.66 162.13 22.2 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.584 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.53 ' CD ' HG13 ' A' ' 15' ' ' VAL . 49.3 Cg_endo -69.57 146.02 60.06 Favored 'Trans proline' 0 C--O 1.217 -0.555 0 C-N-CA 122.554 2.169 . . . . 0.0 111.83 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -75.33 -32.44 60.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.511 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.421 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.71 26.4 72.04 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.4 m -60.84 -26.11 67.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -1.127 . . . . 0.0 109.463 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -67.1 -42.58 84.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.286 -0.884 . . . . 0.0 109.532 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -118.77 120.2 36.66 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.506 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -82.37 -8.6 59.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.295 -0.878 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 80.8 m80 56.5 -177.69 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.193 -0.942 . . . . 0.0 109.431 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -119.62 137.19 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.6 p-80 -56.83 -18.8 14.3 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.282 -0.886 . . . . 0.0 109.412 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.02 -162.87 36.16 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.475 ' CB ' ' HG3' ' A' ' 37' ' ' PRO . 3.4 m -145.88 131.55 18.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.26 -1.141 . . . . 0.0 109.505 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.491 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -98.92 140.42 33.11 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.424 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.458 HG22 ' HG2' ' A' ' 36' ' ' ARG . 47.5 t -121.46 124.18 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.115 -0.991 . . . . 0.0 109.537 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -111.93 121.4 44.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.48 HG13 ' CE1' ' A' ' 17' ' ' PHE . 5.1 t -128.3 138.44 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.878 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.7 p -141.44 145.5 35.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.346 -0.846 . . . . 0.0 109.146 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.576 ' CD2' HG12 ' A' ' 32' ' ' ILE . 13.6 m-85 -119.06 142.68 47.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.927 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.7 m -137.85 127.79 25.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.247 -0.908 . . . . 0.0 109.189 179.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.546 ' HB ' ' HA ' ' A' ' 100' ' ' ILE . 27.9 t -75.74 136.09 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.289 -0.882 . . . . 0.0 109.173 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -114.14 156.24 24.57 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.083 -1.011 . . . . 0.0 109.926 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.6 mttt -48.35 111.98 0.53 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.15 -6.39 1.53 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.283 -1.437 . . . . 0.0 110.784 179.251 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.452 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 3.3 m -61.41 140.26 58.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.842 -1.387 . . . . 0.0 109.192 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.553 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.95 177.47 2.2 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.207 -0.933 . . . . 0.0 109.53 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.553 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.3 Cg_endo -70.88 -31.34 15.69 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.614 2.209 . . . . 0.0 111.903 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -117.93 5.26 12.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 108.931 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.451 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 44.3 mttt -142.35 133.8 26.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.454 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.25 133.71 50.17 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 120.988 -1.07 . . . . 0.0 110.222 -179.511 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.507 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 21.2 t -122.4 124.64 71.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.544 HD23 ' CG2' ' A' ' 19' ' ' VAL . 1.0 OUTLIER -142.22 142.22 32.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.057 -1.027 . . . . 0.0 110.047 -179.372 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -86.15 136.62 33.13 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.605 HG21 ' CZ ' ' A' ' 80' ' ' PHE . 87.8 mt -121.3 131.02 74.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.339 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 60.3 tttt -109.99 118.38 36.28 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.581 ' CZ ' ' HG3' ' A' ' 36' ' ' ARG . 77.2 t80 -122.26 111.16 16.59 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.54 -0.725 . . . . 0.0 109.341 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 47.5 m -115.08 120.33 39.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.215 -0.928 . . . . 0.0 109.804 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.581 ' HG3' ' CZ ' ' A' ' 34' ' ' TYR . 2.9 mtt-85 -123.21 163.34 34.45 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.609 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.491 ' HD3' ' O ' ' A' ' 12' ' ' ALA . 51.9 Cg_endo -72.57 50.65 1.7 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.73 2.287 . . . . 0.0 111.864 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.94 -12.89 13.01 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.41 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.5 OUTLIER -96.83 178.78 5.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -1.169 . . . . 0.0 109.308 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.462 ' OG ' ' HG3' ' A' ' 83' ' ' LYS . 10.8 p -150.95 159.25 44.68 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.204 -0.935 . . . . 0.0 109.708 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.617 HD13 ' CE2' ' A' ' 80' ' ' PHE . 2.2 tt -71.81 134.27 46.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.538 ' N ' ' CD2' ' A' ' 41' ' ' LEU . . . -114.74 -42.35 3.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.178 -0.952 . . . . 0.0 109.848 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.453 ' OE2' ' HB3' ' A' ' 42' ' ' ALA . 14.6 mp0 -144.02 152.4 40.97 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.065 -1.022 . . . . 0.0 110.431 -179.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' HD22 ' A' ' 41' ' ' LEU . 3.5 t -140.39 138.07 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.441 -0.787 . . . . 0.0 109.345 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.434 ' OE2' ' HB3' ' A' ' 56' ' ' PRO . 5.7 mm-40 -127.08 150.91 49.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 109.352 179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.61 HD13 ' O ' ' A' ' 77' ' ' ASN . 5.9 tp -122.99 123.82 41.76 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.321 -0.862 . . . . 0.0 110.56 -178.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.617 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.6 OUTLIER -106.25 129.41 54.29 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.935 . . . . 0.0 109.006 178.838 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.59 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 27.7 mt-30 -71.64 151.17 43.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.291 -0.881 . . . . 0.0 109.306 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.59 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 30.0 t60 -67.49 110.33 3.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.188 -0.945 . . . . 0.0 109.44 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.28 1.03 38.17 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 27.2 t -112.77 153.11 28.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.246 . . . . 0.0 109.397 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 61.8 tt0 -116.22 14.23 15.82 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.25 -0.906 . . . . 0.0 109.34 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -112.45 86.9 2.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.282 -0.886 . . . . 0.0 109.465 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.617 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 22.5 m95 -53.84 138.72 35.36 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.424 -0.798 . . . . 0.0 109.841 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.07 131.61 23.44 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.454 -0.779 . . . . 0.0 108.911 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.434 ' HB3' ' OE2' ' A' ' 45' ' ' GLU . 49.1 Cg_endo -69.91 150.09 66.84 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.56 2.173 . . . . 0.0 112.027 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.601 ' CD2' ' N ' ' A' ' 57' ' ' LEU . 0.2 OUTLIER -100.92 148.43 25.0 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.469 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 69.7 m -98.12 126.69 43.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.742 -1.224 . . . . 0.0 109.051 179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -71.38 107.58 4.4 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.26 -0.9 . . . . 0.0 109.204 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 60' ' ' LYS . 6.6 mmtp -111.75 106.79 15.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.969 -1.082 . . . . 0.0 109.581 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.35 -95.46 0.21 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -134.18 17.19 3.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -1.144 . . . . 0.0 109.453 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.01 169.85 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.305 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.457 ' HE3' ' CB ' ' A' ' 57' ' ' LEU . 70.3 m95 -116.41 131.04 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.177 -0.952 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.461 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 91.1 mt-10 -117.89 144.69 45.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.596 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.555 ' HB ' ' CD1' ' A' ' 57' ' ' LEU . 2.2 p -141.34 138.47 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -122.44 132.42 54.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 0.0 110.0 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.59 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 48.4 t -118.88 116.55 26.73 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.467 -0.771 . . . . 0.0 109.479 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 68' ' ' SER . 50.0 m -43.37 -37.71 2.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.143 -0.973 . . . . 0.0 109.085 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 5.2 ptpp? -94.72 168.44 11.28 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.159 179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.6 146.68 80.17 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.443 2.095 . . . . 0.0 111.743 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.609 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 mt -80.06 139.66 36.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.307 -0.871 . . . . 0.0 109.913 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.1 t -124.4 125.06 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.467 -0.771 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.445 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.45 166.41 26.72 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.59 ' HG2' ' CE1' ' A' ' 49' ' ' HIS . 47.9 Cg_endo -68.65 145.13 76.04 Favored 'Cis proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.846 -1.731 . . . . 0.0 112.045 0.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.1 m-85 -91.19 153.1 20.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.588 -0.695 . . . . 0.0 110.49 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.61 ' O ' HD13 ' A' ' 46' ' ' LEU . 2.7 m-80 -111.72 140.91 45.97 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.606 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 91.6 m-85 -131.65 135.76 47.18 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.886 -1.134 . . . . 0.0 109.772 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.439 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 53.3 ttt-85 -119.97 142.86 48.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.192 -0.943 . . . . 0.0 108.609 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.617 ' CE2' HD13 ' A' ' 41' ' ' LEU . 15.3 m-85 -124.77 144.18 50.39 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.183 -0.948 . . . . 0.0 111.721 -177.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.626 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.4 ttt -126.65 124.16 39.22 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 178.315 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.53 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 20.8 p -77.76 141.87 39.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.325 -0.859 . . . . 0.0 109.867 -178.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.509 ' N ' ' HB1' ' A' ' 42' ' ' ALA . 19.9 mttm -44.3 -44.02 7.81 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.21 -4.31 8.09 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.03 30.63 7.76 Favored Glycine 0 N--CA 1.491 2.319 0 O-C-N 121.256 -1.144 . . . . 0.0 110.33 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.53 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 37.0 mmm -103.45 107.85 18.86 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.02 -1.282 . . . . 0.0 108.854 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.626 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 35.7 mtm-85 -92.29 142.21 27.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 110.923 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.492 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -137.25 141.33 42.01 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 t -121.33 136.8 57.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.998 -1.064 . . . . 0.0 110.202 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.498 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 82.2 m-85 -125.05 121.65 34.97 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 55.1 t0 -97.51 147.96 23.73 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.097 -1.002 . . . . 0.0 109.662 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.57 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 35.8 mt-10 51.77 54.52 10.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.449 -0.782 . . . . 0.0 109.947 179.711 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 106' ' ' PRO . 75.1 t -83.63 -32.89 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.954 -1.091 . . . . 0.0 109.261 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.45 HD13 HG22 ' A' ' 94' ' ' ILE . 34.8 mt -138.55 126.49 13.73 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.33 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.19 163.82 37.21 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.553 2.169 . . . . 0.0 111.8 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.7 m -54.38 -37.31 64.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.309 -0.87 . . . . 0.0 110.015 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.49 96.2 10.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.008 . . . . 0.0 109.836 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -104.95 143.94 32.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.488 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 88.0 p -116.66 124.07 48.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.211 -0.931 . . . . 0.0 109.665 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.546 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 5.9 mt -64.04 138.65 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.528 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.428 ' N ' HG21 ' A' ' 100' ' ' ILE . . . 102.45 -4.19 50.88 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 37.8 tttp -118.19 142.86 47.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.108 -1.23 . . . . 0.0 109.264 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.415 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 7.3 m -76.81 173.61 11.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.033 -1.042 . . . . 0.0 108.476 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.568 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.0 m-85 -158.13 96.45 1.45 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 120.64 -1.288 . . . . 0.0 109.004 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.57 158.61 33.42 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.322 -0.861 . . . . 0.0 109.833 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.498 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.5 Cg_endo -70.95 149.07 58.66 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.734 2.289 . . . . 0.0 111.663 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -60.84 -37.72 83.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.17 -0.956 . . . . 0.0 109.539 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 61.9 tt0 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.488 -179.914 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . 0.43 ' O ' ' HG2' ' A' ' 1' ' ' ARG . 37.1 ttp180 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -93.05 20.22 47.25 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 84.1 p -63.56 -16.63 61.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -1.146 . . . . 0.0 109.392 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -65.99 -12.36 54.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 57.52 16.96 3.59 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -128.36 122.5 31.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 109.486 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -140.15 139.94 35.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -58.06 -21.52 45.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -107.18 141.14 38.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.461 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.03 169.81 16.17 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.7 m -109.76 166.09 11.19 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.41 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 176.05 173.21 0.35 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.213 -0.929 . . . . 0.0 109.344 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.469 HG12 ' OH ' ' A' ' 34' ' ' TYR . 3.0 t -123.47 128.09 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -111.49 120.88 43.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.145 -0.972 . . . . 0.0 109.189 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 3.0 t -127.77 137.06 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.89 . . . . 0.0 109.874 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.488 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 18.1 p -143.75 147.27 33.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.409 -0.807 . . . . 0.0 109.259 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.626 ' O ' ' N ' ' A' ' 104' ' ' TYR . 21.6 m-85 -118.55 145.46 45.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 109.786 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 62.6 m -139.59 128.12 22.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.112 -0.993 . . . . 0.0 109.201 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.497 HG22 ' CD2' ' A' ' 30' ' ' LEU . 5.2 t -76.4 133.36 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.222 -0.924 . . . . 0.0 109.53 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.3 mm-40 -109.83 156.27 20.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.526 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -49.32 113.56 0.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.39 -4.13 1.72 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.39 -1.386 . . . . 0.0 110.727 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.496 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 66.4 m -63.94 140.57 58.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.835 -1.391 . . . . 0.0 109.34 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.561 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.65 177.81 2.05 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.195 -0.941 . . . . 0.0 109.497 -179.571 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.561 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 49.9 Cg_endo -70.77 -31.08 16.63 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.516 2.144 . . . . 0.0 111.827 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -116.68 6.25 13.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.016 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.474 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 19.8 mttp -142.41 133.56 26.05 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.502 ' CD2' HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.29 132.28 51.69 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.964 -1.085 . . . . 0.0 110.002 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.545 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 45.7 t -121.8 124.25 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.545 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -141.55 142.02 33.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.947 -1.095 . . . . 0.0 110.285 -179.456 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.456 ' CB ' HG11 ' A' ' 63' ' ' VAL . 10.4 t70 -86.51 136.9 32.91 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.596 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 1.2 mt -117.06 127.96 74.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 120.712 -1.243 . . . . 0.0 111.122 -178.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 31.1 mtpt -108.06 114.97 29.28 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.52 ' CG ' ' HB2' ' A' ' 41' ' ' LEU . 84.4 t80 -124.3 108.2 11.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.71 -0.618 . . . . 0.0 109.817 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.9 m -109.52 117.3 33.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.38 -0.825 . . . . 0.0 109.523 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.528 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -139.89 121.72 9.79 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.406 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 50.4 Cg_endo -70.52 119.39 6.3 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.72 2.28 . . . . 0.0 111.929 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.39 -12.44 68.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.528 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -141.25 -178.63 5.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.141 -1.211 . . . . 0.0 109.646 -179.906 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -156.32 163.45 39.5 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.584 HD12 ' CD2' ' A' ' 80' ' ' PHE . 51.0 tp -68.96 125.94 28.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.228 -0.92 . . . . 0.0 109.195 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.565 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -113.97 -44.24 3.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 109.9 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -138.55 147.56 43.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.17 -0.956 . . . . 0.0 110.22 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.541 ' CG2' HD12 ' A' ' 41' ' ' LEU . 43.4 t -138.83 136.75 43.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.492 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 93.0 mt-10 -127.75 149.8 50.08 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.813 -1.179 . . . . 0.0 109.726 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.658 HD23 ' CZ ' ' A' ' 78' ' ' PHE . 3.2 tm? -118.73 142.72 47.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.529 -0.732 . . . . 0.0 109.642 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.558 ' N ' HD11 ' A' ' 46' ' ' LEU . 13.7 ttp180 -127.48 124.65 38.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -0.86 . . . . 0.0 108.885 179.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.454 ' NE2' ' OG ' ' A' ' 68' ' ' SER . 39.4 mt-30 -63.87 155.44 30.62 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.25 -0.906 . . . . 0.0 109.895 -179.534 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.56 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 44.1 t60 -73.19 119.19 17.08 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.348 -0.845 . . . . 0.0 109.586 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.34 6.79 50.44 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.406 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.4 t -115.52 156.28 26.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -1.136 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -114.73 14.63 17.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.266 -0.896 . . . . 0.0 109.332 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -120.62 111.93 18.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.335 -0.853 . . . . 0.0 109.629 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 44.6 m95 -70.05 135.82 49.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.732 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -105.28 133.89 19.94 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.439 -0.788 . . . . 0.0 109.427 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.492 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 52.5 Cg_endo -72.16 144.63 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.653 2.235 . . . . 0.0 112.084 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.551 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.5 mp -102.28 154.63 18.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.123 -0.986 . . . . 0.0 108.669 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 96.8 m -99.89 127.64 46.05 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.855 -1.153 . . . . 0.0 109.208 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.4 tttm -69.72 109.69 4.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.14 -0.975 . . . . 0.0 109.099 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 62' ' ' ASN . 21.5 mttp -108.96 119.15 38.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.983 -1.073 . . . . 0.0 109.725 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 47.8 -92.94 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 60' ' ' LYS . 4.8 m120 -131.8 17.05 4.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -1.131 . . . . 0.0 109.422 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.456 HG11 ' CB ' ' A' ' 31' ' ' ASP . 27.1 m -130.61 178.16 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.424 ' CD1' HG13 ' A' ' 32' ' ' ILE . 59.0 m95 -124.98 125.19 43.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.34 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.53 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 62.4 mt-10 -115.77 150.71 36.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.551 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.1 p -144.53 140.11 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.85 . . . . 0.0 109.265 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -121.87 132.88 54.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.185 -0.947 . . . . 0.0 109.606 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.454 ' OG ' ' NE2' ' A' ' 48' ' ' GLN . 8.0 t -116.92 133.9 55.44 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.421 -0.8 . . . . 0.0 109.214 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.9 m -59.94 -18.94 49.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.169 -0.957 . . . . 0.0 109.31 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.553 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.4 178.22 1.02 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.7 Cg_endo -70.85 141.18 40.2 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.573 2.182 . . . . 0.0 111.846 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 4.5 mt -76.39 139.05 40.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.457 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 20.8 t -125.01 125.12 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.465 -0.772 . . . . 0.0 109.53 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.43 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.72 169.28 28.41 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.6 Cg_endo -68.37 146.09 77.89 Favored 'Cis proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.826 -1.739 . . . . 0.0 112.021 0.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.4 m-85 -89.67 146.37 24.58 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.465 -0.772 . . . . 0.0 110.355 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.583 ' O ' ' CD2' ' A' ' 46' ' ' LEU . 7.1 m-80 -107.14 142.07 37.41 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 178.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.658 ' CZ ' HD23 ' A' ' 46' ' ' LEU . 45.6 m-85 -131.7 119.48 21.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.843 -1.161 . . . . 0.0 110.205 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.563 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 33.0 ttm180 -102.13 141.14 35.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.097 -1.002 . . . . 0.0 108.51 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.596 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 6.3 m-85 -123.01 142.6 50.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 111.403 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.591 ' HA ' ' O ' ' A' ' 86' ' ' MET . 0.0 OUTLIER -125.92 124.86 41.75 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.194 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.613 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -74.06 145.63 44.3 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 110.174 -178.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.565 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 94.5 mttt -48.14 -44.5 32.29 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.393 -0.817 . . . . 0.0 108.959 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.443 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -56.78 -3.19 0.64 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.72 24.34 18.22 Favored Glycine 0 N--CA 1.489 2.173 0 O-C-N 121.062 -1.258 . . . . 0.0 110.003 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.613 ' O ' ' N ' ' A' ' 82' ' ' SER . 15.0 mmm -96.37 146.75 24.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.071 -1.252 . . . . 0.0 108.634 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.534 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 52.9 mtm-85 -122.94 139.42 54.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.855 -1.153 . . . . 0.0 110.55 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.0 m120 -136.31 141.02 43.77 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.563 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 3.6 t -122.07 136.52 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.982 -1.074 . . . . 0.0 110.195 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.518 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 72.9 m-85 -124.23 122.58 38.15 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.16 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -100.42 147.75 25.5 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.262 -0.899 . . . . 0.0 109.775 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.608 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 78.9 mt-10 53.19 52.62 13.3 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 110.276 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.45 ' HB ' ' CD1' ' A' ' 78' ' ' PHE . 57.8 t -84.68 -34.44 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 109.332 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 44.9 mt -136.58 125.88 15.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.228 -0.92 . . . . 0.0 109.146 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.26 161.96 44.07 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.509 2.139 . . . . 0.0 111.887 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.6 m -52.89 -43.05 65.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.901 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.13 99.75 12.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.107 -0.996 . . . . 0.0 109.655 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -108.27 150.72 26.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.124 -0.985 . . . . 0.0 109.478 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 87.6 p -109.73 170.31 8.15 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.346 -0.847 . . . . 0.0 109.34 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.414 ' CD1' HG12 ' A' ' 19' ' ' VAL . 32.1 mm -104.99 136.12 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.276 -0.89 . . . . 0.0 109.254 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.07 4.66 59.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -118.87 144.27 46.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.104 -1.233 . . . . 0.0 109.362 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.547 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 3.5 m -78.73 177.15 8.89 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.115 -0.991 . . . . 0.0 109.193 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.626 ' N ' ' O ' ' A' ' 17' ' ' PHE . 30.7 m-85 -163.73 100.08 0.89 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.859 -1.151 . . . . 0.0 108.926 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.45 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -112.86 164.88 14.32 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.118 -0.989 . . . . 0.0 109.887 -179.448 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.518 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.6 Cg_endo -70.44 167.1 26.29 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.9 2.4 . . . . 0.0 111.771 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 69.7 mm-40 -102.64 142.01 34.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.368 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.978 -1.011 . . . . 0.0 109.448 -179.998 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 91.4 mtt180 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 87.99 -163.98 33.63 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 92.3 p -123.97 163.42 21.4 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -1.143 . . . . 0.0 109.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 16.7 m-70 -86.65 136.82 32.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.929 . . . . 0.0 109.457 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 86.3 m-70 -80.13 -40.01 28.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -82.37 -9.76 59.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -0.877 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 36.6 t60 -128.43 153.95 46.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.257 -0.902 . . . . 0.0 109.51 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -133.55 143.38 48.68 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.47 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 47.4 m80 -93.53 1.38 56.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.229 -0.919 . . . . 0.0 109.549 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -50.84 113.6 2.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -108.67 162.81 13.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.236 -1.155 . . . . 0.0 109.477 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.461 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -93.96 -146.84 0.25 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.503 HG12 ' CZ ' ' A' ' 34' ' ' TYR . 15.4 t -123.04 127.99 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.906 . . . . 0.0 109.259 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -109.81 120.02 41.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.44 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.519 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 3.8 t -126.28 135.6 63.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.917 . . . . 0.0 109.71 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.529 ' CG2' ' HG2' ' A' ' 105' ' ' LYS . 61.0 p -141.59 146.48 36.32 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.476 -0.765 . . . . 0.0 109.279 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.58 ' O ' ' N ' ' A' ' 104' ' ' TYR . 4.0 m-85 -119.41 141.16 49.34 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 0.0 109.939 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.4 m -136.97 128.52 28.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.17 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.479 HG22 HD22 ' A' ' 30' ' ' LEU . 3.0 t -76.27 144.68 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.142 -0.974 . . . . 0.0 109.377 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -115.78 159.84 20.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.997 . . . . 0.0 109.584 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 50.6 mttt -53.61 114.3 1.48 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.926 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.7 -3.61 2.62 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.446 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -58.33 141.89 49.76 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.87 -1.371 . . . . 0.0 109.232 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.507 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.19 171.84 8.36 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.223 -0.923 . . . . 0.0 109.689 -179.705 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.507 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.79 -30.8 16.98 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.808 2.339 . . . . 0.0 111.998 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 mttt -112.76 8.82 18.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.077 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.433 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 16.9 mttp -142.17 132.82 25.43 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.555 ' CD1' ' N ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -120.88 123.05 41.59 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.979 -1.076 . . . . 0.0 109.362 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.555 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 25.1 t -120.42 125.99 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 29' ' ' VAL . 1.9 mt -144.7 144.29 31.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.046 -1.034 . . . . 0.0 110.165 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.76 138.91 31.23 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.608 HG23 ' CZ ' ' A' ' 80' ' ' PHE . 69.0 mt -122.28 131.46 73.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.489 -179.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.519 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 54.7 tttp -109.8 119.01 38.01 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.503 ' CZ ' HG12 ' A' ' 13' ' ' VAL . 78.7 t80 -122.7 113.25 18.97 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.46 -0.775 . . . . 0.0 109.748 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.9 m -115.99 118.38 32.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.32 -0.863 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.534 ' HD2' ' CB ' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -132.91 150.75 76.53 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.459 179.984 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.487 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.88 88.61 0.66 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 122.642 2.228 . . . . 0.0 112.081 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.43 -27.73 8.29 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.951 -1.259 . . . . 0.0 109.951 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.534 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -91.17 171.98 8.87 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.116 -1.226 . . . . 0.0 109.619 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 82' ' ' SER . 18.2 m -153.66 161.33 42.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.545 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.621 HD13 ' CE2' ' A' ' 80' ' ' PHE . 1.4 tt -72.56 132.84 44.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.365 -0.835 . . . . 0.0 109.695 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.621 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -116.14 -40.06 3.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 109.899 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 87.7 mt-10 -142.45 150.56 40.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.156 -0.965 . . . . 0.0 110.197 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' HD23 ' A' ' 41' ' ' LEU . 11.8 t -138.44 136.13 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 109.319 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.462 ' HA ' HD12 ' A' ' 57' ' ' LEU . 44.9 mt-10 -128.59 150.51 50.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.554 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 16.7 tp -120.25 135.36 55.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.411 -0.806 . . . . 0.0 109.888 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.461 ' HD2' ' O ' ' A' ' 51' ' ' SER . 4.0 ttp180 -121.58 130.27 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.837 . . . . 0.0 108.845 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 57.0 mt-30 -74.72 150.54 39.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.13 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.556 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 51.6 t-80 -64.45 117.75 7.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.37 1.34 44.06 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.461 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 38.3 t -113.33 153.14 28.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.188 -1.183 . . . . 0.0 109.439 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 58.0 mt-10 -118.3 20.48 13.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.321 -0.862 . . . . 0.0 109.318 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -124.23 94.08 4.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.873 . . . . 0.0 109.456 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.427 ' CZ3' ' N ' ' A' ' 79' ' ' ARG . 66.3 m95 -54.22 132.06 42.64 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 109.774 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.4 mm-40 -101.05 138.22 19.93 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.799 . . . . 0.0 109.273 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.87 143.78 46.42 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.709 2.273 . . . . 0.0 112.04 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.547 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 6.8 mp -110.63 149.85 29.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.194 -0.941 . . . . 0.0 108.931 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 11.3 m -103.31 125.33 49.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.923 -1.11 . . . . 0.0 109.154 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 12.9 tttm -73.58 109.85 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.135 -0.978 . . . . 0.0 109.275 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.573 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 66.8 mttt -120.23 144.23 47.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.906 -1.121 . . . . 0.0 110.068 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.59 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.76 29.96 0.87 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.59 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 8.0 t30 81.99 14.73 0.51 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.239 -1.153 . . . . 0.0 110.376 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.573 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 27.6 m -129.52 170.26 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.099 -1.0 . . . . 0.0 109.021 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -114.51 122.67 47.29 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.908 -1.12 . . . . 0.0 109.541 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.533 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 43.1 mt-10 -112.39 147.18 36.96 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.402 -0.811 . . . . 0.0 109.445 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.547 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.7 p -136.21 132.65 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.502 -0.749 . . . . 0.0 109.121 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.0 mttp -119.2 130.51 55.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.099 -1.001 . . . . 0.0 109.482 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.4 t -118.54 144.7 45.89 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 1.2 p -71.4 -4.18 24.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.072 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.605 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 16.2 mmtt -132.86 169.7 13.3 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.386 -0.821 . . . . 0.0 109.105 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.605 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.02 133.18 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.519 2.146 . . . . 0.0 111.776 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.582 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -68.13 146.53 53.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.346 -0.846 . . . . 0.0 109.777 -179.607 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.84 123.65 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.404 -0.81 . . . . 0.0 109.198 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.527 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.82 165.39 28.24 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.625 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.5 Cg_endo -68.78 145.17 76.46 Favored 'Cis proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.922 -1.699 . . . . 0.0 111.985 0.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -89.35 149.07 23.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.578 -0.701 . . . . 0.0 110.432 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.543 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 36.2 m-80 -109.52 141.82 41.45 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.554 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 87.1 m-85 -133.38 121.09 21.8 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.958 -1.089 . . . . 0.0 109.748 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.427 ' N ' ' CZ3' ' A' ' 54' ' ' TRP . 27.8 ttm180 -104.12 143.31 33.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.07 -1.019 . . . . 0.0 108.944 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.621 ' CE2' HD13 ' A' ' 41' ' ' LEU . 22.6 m-85 -125.53 144.22 50.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 111.676 -178.013 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.602 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -127.04 126.37 42.97 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.611 ' N ' ' O ' ' A' ' 86' ' ' MET . 25.9 p -76.33 145.98 39.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.215 -0.928 . . . . 0.0 110.387 -178.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.621 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 58.5 mttt -50.08 -42.96 51.1 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.15 -2.57 0.41 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.84 25.88 18.71 Favored Glycine 0 N--CA 1.489 2.22 0 O-C-N 121.082 -1.246 . . . . 0.0 109.991 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.611 ' O ' ' N ' ' A' ' 82' ' ' SER . 12.8 mtm -102.17 151.24 22.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.084 -1.245 . . . . 0.0 108.769 179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.602 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 67.8 mtp180 -125.47 140.89 52.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.92 -1.112 . . . . 0.0 110.567 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.416 ' N ' ' O ' ' A' ' 80' ' ' PHE . 11.9 m120 -135.23 139.95 44.88 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.3 t -122.39 137.45 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.999 -1.063 . . . . 0.0 110.364 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.507 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 95.4 m-85 -125.37 122.71 37.57 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.26 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -99.81 148.34 24.52 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.625 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 98.9 mt-10 52.76 54.06 11.14 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.408 -0.808 . . . . 0.0 110.393 179.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.453 HG22 ' HB3' ' A' ' 106' ' ' PRO . 77.8 t -85.37 -34.07 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 120.903 -1.123 . . . . 0.0 109.093 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.422 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.0 mt -136.57 125.21 15.21 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.879 . . . . 0.0 108.979 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.53 162.4 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.453 2.102 . . . . 0.0 111.871 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.527 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 39.5 m -51.48 -44.99 62.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.31 -0.869 . . . . 0.0 109.815 -179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.01 101.7 14.46 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.126 -0.983 . . . . 0.0 109.365 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -109.26 151.53 26.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.266 -0.897 . . . . 0.0 109.405 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 53.5 p -105.63 170.41 7.91 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.276 -0.89 . . . . 0.0 109.23 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 18.6 mm -105.13 136.35 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.192 -0.942 . . . . 0.0 109.374 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.26 9.46 61.88 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 52.5 tttt -118.42 143.14 46.89 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -1.197 . . . . 0.0 109.18 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 23.2 m -77.28 168.61 19.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.996 -1.065 . . . . 0.0 108.997 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.58 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.1 m-85 -154.63 96.98 1.94 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.674 -1.266 . . . . 0.0 108.918 179.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.529 ' HG2' ' CG2' ' A' ' 16' ' ' THR . 6.6 mtmm -103.15 160.28 26.65 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.266 -0.897 . . . . 0.0 109.806 -179.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.507 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.1 Cg_endo -70.07 146.16 57.46 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -57.59 -63.38 1.26 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 109.485 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.6 mt-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.063 -0.97 . . . . 0.0 109.375 -179.948 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.56 -12.28 58.14 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.0 t -59.59 -29.63 68.1 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -1.169 . . . . 0.0 109.498 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 58.3 t60 -125.02 144.18 50.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -97.74 173.55 7.06 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.875 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -118.58 148.88 42.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -57.17 -32.38 66.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.33 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 14.2 m-70 -50.61 -49.74 55.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.432 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -70.51 -54.79 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.407 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.26 -160.67 19.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HG2' ' A' ' 37' ' ' PRO . 79.6 p -114.01 -170.24 1.67 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.312 -1.11 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.43 152.37 31.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.885 . . . . 0.0 109.61 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.551 HG13 ' CE1' ' A' ' 34' ' ' TYR . 6.2 t -126.65 136.91 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.238 -0.914 . . . . 0.0 109.507 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -109.63 121.65 45.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.546 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 10.3 p -129.28 141.4 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.353 -0.842 . . . . 0.0 109.427 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.419 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 67.9 p -141.58 145.79 35.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.139 -0.976 . . . . 0.0 109.721 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.63 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.0 m-85 -118.63 143.72 46.63 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 63.7 m -137.87 128.07 26.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.109 -0.995 . . . . 0.0 109.283 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.528 ' CG1' HD13 ' A' ' 100' ' ' ILE . 15.7 t -76.05 128.63 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.27 -0.893 . . . . 0.0 109.425 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.9 mm-40 -91.26 -178.39 5.13 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.551 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 20.2 mttt -79.91 70.14 6.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.429 ' O ' HG22 ' A' ' 29' ' ' VAL . . . -177.18 25.84 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.778 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.474 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 1.5 t -73.97 140.34 45.45 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.748 -1.442 . . . . 0.0 108.831 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.505 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.53 173.74 5.45 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.011 -1.056 . . . . 0.0 109.809 -179.532 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.505 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 52.1 Cg_endo -71.8 -32.18 11.9 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.719 2.279 . . . . 0.0 111.909 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -116.95 5.63 12.92 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.012 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.511 ' CD ' ' HE2' ' A' ' 67' ' ' LYS . 79.6 tttt -142.37 133.36 25.85 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.472 HD21 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -125.15 131.08 53.3 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.077 -1.014 . . . . 0.0 109.619 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.515 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.1 t -121.45 124.39 71.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.515 ' HG ' ' C ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -143.5 143.5 31.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.029 -1.044 . . . . 0.0 109.999 -179.487 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -83.99 135.16 34.55 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.574 HG22 ' CE2' ' A' ' 80' ' ' PHE . 78.3 mt -119.4 130.11 74.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.541 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 8.5 ttmm -111.19 120.39 42.13 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.584 ' CE2' ' HB2' ' A' ' 36' ' ' ARG . 87.3 t80 -120.32 119.87 34.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.391 -0.818 . . . . 0.0 109.519 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 31.1 m -122.31 115.55 22.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.298 -0.876 . . . . 0.0 109.751 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.584 ' HB2' ' CE2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -133.59 136.86 27.61 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.525 -0.734 . . . . 0.0 109.03 179.768 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.483 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 48.1 Cg_endo -69.93 104.49 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.676 2.251 . . . . 0.0 111.95 -179.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.31 3.38 87.06 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.546 ' CB ' ' CD ' ' A' ' 36' ' ' ARG . 4.2 t0 -136.38 175.05 9.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.155 -1.203 . . . . 0.0 109.758 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 p -153.05 161.02 43.0 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.337 -0.852 . . . . 0.0 109.372 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.573 ' HB2' ' CG ' ' A' ' 34' ' ' TYR . 8.1 tp -72.08 132.74 44.63 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.603 ' HB1' ' N ' ' A' ' 83' ' ' LYS . . . -117.26 -41.63 2.97 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 109.741 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -141.76 150.12 41.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.181 -0.949 . . . . 0.0 109.992 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.617 ' CG1' ' CE1' ' A' ' 80' ' ' PHE . 2.6 t -138.52 135.98 43.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.439 -0.788 . . . . 0.0 109.365 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.463 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 78.4 mt-10 -127.81 149.78 50.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.911 -1.118 . . . . 0.0 109.21 179.432 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.575 HD11 ' CZ ' ' A' ' 78' ' ' PHE . 7.0 tt -120.28 139.69 52.34 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.335 -0.853 . . . . 0.0 109.89 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.532 ' HD3' ' NE1' ' A' ' 54' ' ' TRP . 17.3 ttp180 -126.82 120.12 28.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.875 . . . . 0.0 108.82 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.511 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 32.0 mt-30 -64.39 145.05 56.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.141 -179.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.54 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 49.1 t60 -55.82 145.41 24.59 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.454 -0.779 . . . . 0.0 109.243 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.51 1.22 51.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.433 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 9.6 t -111.44 152.75 27.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.1 -1.235 . . . . 0.0 109.316 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 -119.0 7.32 11.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -104.89 97.9 7.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.532 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 51.5 m95 -63.11 132.07 50.62 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 109.779 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -105.3 136.97 19.14 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 109.391 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.463 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.9 Cg_endo -70.88 151.82 62.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.752 2.301 . . . . 0.0 112.201 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.603 ' CD2' ' N ' ' A' ' 57' ' ' LEU . 0.3 OUTLIER -110.2 154.03 23.94 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 179.6 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.444 ' O ' ' HA ' ' A' ' 64' ' ' TRP . 7.0 m -110.21 126.4 54.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.833 -1.167 . . . . 0.0 108.808 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.466 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 tttm -74.31 105.73 5.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.087 -1.008 . . . . 0.0 109.283 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.588 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 16.4 mttp -120.47 142.86 48.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.819 -1.176 . . . . 0.0 110.249 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.84 35.96 1.67 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 7.9 m-20 78.06 10.82 2.01 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.061 -1.258 . . . . 0.0 110.469 179.158 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.588 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 15.6 m -128.59 -177.96 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.977 -1.077 . . . . 0.0 108.776 179.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.475 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 66.1 m95 -123.07 141.07 52.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.05 -1.032 . . . . 0.0 109.927 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.498 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 92.1 mt-10 -127.96 142.37 51.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.473 -0.767 . . . . 0.0 109.105 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.591 ' HB ' ' CD1' ' A' ' 57' ' ' LEU . 1.9 p -139.39 137.53 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.227 -0.92 . . . . 0.0 109.377 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.511 ' HE2' ' CD ' ' A' ' 27' ' ' LYS . 28.7 mttt -122.71 134.15 54.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.463 -0.773 . . . . 0.0 109.632 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.511 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.7 t -117.46 145.3 44.26 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.488 -0.758 . . . . 0.0 109.18 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 49.5 m -68.77 -16.5 63.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.16 -0.962 . . . . 0.0 109.289 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.543 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.73 176.4 1.53 Allowed Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.543 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.8 Cg_endo -70.03 136.64 32.77 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.684 2.256 . . . . 0.0 111.726 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.573 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 6.4 mt -68.64 136.57 53.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.9 t -126.06 125.56 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.491 -0.756 . . . . 0.0 109.472 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -93.66 166.25 27.68 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.614 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.73 146.12 78.93 Favored 'Cis proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.843 -1.732 . . . . 0.0 111.99 0.032 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.9 m-85 -90.09 148.39 23.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.482 -0.761 . . . . 0.0 110.425 -179.201 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.442 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 18.9 m-80 -110.52 144.37 39.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.387 -0.821 . . . . 0.0 108.829 179.021 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CZ ' HD11 ' A' ' 46' ' ' LEU . 61.8 m-85 -135.81 125.38 25.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.89 -1.131 . . . . 0.0 110.25 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.555 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 15.2 ttp180 -105.85 141.38 37.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -0.96 . . . . 0.0 108.451 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.617 ' CE1' ' CG1' ' A' ' 44' ' ' VAL . 6.0 m-85 -122.11 142.23 50.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 111.082 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.583 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.2 ttm -125.5 123.97 40.33 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.603 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.4 p -74.43 144.19 44.38 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.386 -0.821 . . . . 0.0 110.352 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.603 ' N ' ' HB1' ' A' ' 42' ' ' ALA . 46.5 mttp -46.39 -44.76 17.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.429 -0.795 . . . . 0.0 108.946 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.47 -3.42 0.63 Allowed Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.499 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.05 24.36 20.0 Favored Glycine 0 N--CA 1.49 2.27 0 O-C-N 120.992 -1.299 . . . . 0.0 110.124 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.603 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.0 mtm -98.34 150.12 21.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.994 -1.298 . . . . 0.0 108.516 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 22.7 mtm-85 -125.58 141.59 51.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.845 -1.16 . . . . 0.0 110.636 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . 23.7 m120 -137.03 141.37 42.48 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.555 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 10.5 t -122.63 136.87 58.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.882 -1.136 . . . . 0.0 110.447 -178.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.559 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.7 m-85 -123.57 121.65 36.15 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.54 146.59 25.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.778 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 51.8 tt0 53.7 51.54 14.82 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.431 -0.793 . . . . 0.0 110.424 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.457 HG21 ' HB2' ' A' ' 90' ' ' PHE . 72.5 t -82.33 -34.18 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.88 -1.138 . . . . 0.0 108.992 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.436 HG22 HD11 ' A' ' 94' ' ' ILE . 12.2 mt -135.82 127.13 17.19 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.258 -0.902 . . . . 0.0 109.162 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.48 161.13 47.12 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.552 2.168 . . . . 0.0 112.007 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.53 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 28.0 m -52.04 -45.15 64.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.744 -179.717 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.82 102.41 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.429 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.474 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 47.1 p90 -111.1 151.75 27.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.128 -0.982 . . . . 0.0 109.504 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 33.2 m -106.36 163.11 13.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.909 . . . . 0.0 109.467 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.528 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.1 mm -98.16 137.4 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.376 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.4 7.47 58.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.9 tptt -121.1 143.56 49.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.134 -1.215 . . . . 0.0 109.362 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.573 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 7.2 m -79.29 178.79 7.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 108.764 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.63 ' N ' ' O ' ' A' ' 17' ' ' PHE . 25.3 m-85 -164.36 94.57 0.72 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.659 -1.275 . . . . 0.0 109.112 179.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.538 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -106.26 163.73 16.42 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.375 -0.828 . . . . 0.0 109.596 -179.481 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.559 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 48.5 Cg_endo -69.89 143.99 51.95 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.496 2.13 . . . . 0.0 111.723 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.2 mm-40 -52.95 -40.73 63.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.31 -0.868 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.02 -0.99 . . . . 0.0 109.459 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -100.87 2.54 55.59 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.1 t 57.34 79.52 0.19 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -1.167 . . . . 0.0 109.431 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -91.05 146.2 24.05 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.234 -0.916 . . . . 0.0 109.425 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 76.7 t60 -62.87 -20.11 64.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.268 -0.895 . . . . 0.0 109.426 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t60 -65.06 -12.63 52.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.469 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -57.11 -16.86 8.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.536 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 59.76 55.02 4.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.277 -0.89 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -132.74 125.74 30.87 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.925 . . . . 0.0 109.543 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.52 -174.09 46.38 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.0 p -135.43 168.48 19.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.29 -1.123 . . . . 0.0 109.421 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -151.43 152.03 32.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.424 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.489 HG21 ' HG2' ' A' ' 36' ' ' ARG . 47.8 t -125.05 130.84 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.46 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 74.5 mt-30 -107.53 119.43 39.41 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.123 -0.985 . . . . 0.0 109.122 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.646 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.8 p -128.66 139.43 51.91 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.21 -0.931 . . . . 0.0 110.051 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.449 ' HA ' ' HG2' ' A' ' 105' ' ' LYS . 30.4 p -141.21 145.12 35.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.304 -0.873 . . . . 0.0 109.41 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.602 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.8 m-85 -117.16 136.23 53.18 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 52.3 m -131.27 127.21 37.31 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.968 -1.083 . . . . 0.0 109.326 179.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.504 ' HB ' ' HA ' ' A' ' 100' ' ' ILE . 9.0 t -75.38 128.37 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.283 -0.886 . . . . 0.0 109.274 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.412 ' O ' HG12 ' A' ' 100' ' ' ILE . 88.6 mm-40 -89.35 -178.25 5.57 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.061 -1.024 . . . . 0.0 109.843 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.2 mttp -80.23 65.38 5.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.437 -0.789 . . . . 0.0 109.975 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.28 25.9 0.08 OUTLIER Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.496 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.587 ' HB3' ' CZ ' ' A' ' 98' ' ' PHE . 3.2 m -79.72 144.04 34.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.079 -1.248 . . . . 0.0 109.337 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.504 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.4 172.06 7.48 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.121 -0.987 . . . . 0.0 109.579 -179.766 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -70.67 -28.2 21.16 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.667 2.244 . . . . 0.0 111.809 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 68' ' ' SER . 80.4 mttt -116.4 5.57 13.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.087 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.463 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 61.4 mttm -141.55 132.86 26.57 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.576 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.11 123.21 41.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.978 -1.076 . . . . 0.0 109.71 -179.6 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.544 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 13.6 t -119.58 125.09 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.576 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.3 mt -145.14 146.04 31.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.926 -1.109 . . . . 0.0 110.125 -179.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.489 ' CB ' HG11 ' A' ' 63' ' ' VAL . 62.6 t0 -86.06 136.82 33.08 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.068 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.62 HG21 ' CZ ' ' A' ' 80' ' ' PHE . 78.6 mt -121.05 130.82 74.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 C-N-CA 118.825 -1.15 . . . . 0.0 110.661 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.646 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 29.0 tttm -110.43 120.75 43.45 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.42 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 88.5 t80 -120.93 111.33 17.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.328 -0.857 . . . . 0.0 109.528 -179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.482 ' O ' HG12 ' A' ' 13' ' ' VAL . 19.9 m -113.66 114.72 26.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 109.772 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.515 ' NH1' ' O ' ' A' ' 37' ' ' PRO . 0.0 OUTLIER -152.58 113.01 2.78 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.515 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.06 128.91 17.39 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.704 2.269 . . . . 0.0 112.165 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.61 -22.46 40.42 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.491 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.82 -178.76 5.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -1.144 . . . . 0.0 109.807 -179.817 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.532 ' O ' ' HA ' ' A' ' 82' ' ' SER . 57.9 m -154.37 161.68 41.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.324 -0.86 . . . . 0.0 109.331 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.606 HD12 ' CD2' ' A' ' 80' ' ' PHE . 1.2 tt -71.51 130.19 40.64 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.255 -0.903 . . . . 0.0 109.736 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.611 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -116.4 -41.22 3.14 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.222 -0.924 . . . . 0.0 109.839 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -141.19 149.48 41.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.466 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.561 HG23 ' CE2' ' A' ' 80' ' ' PHE . 95.2 t -138.72 136.94 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -128.67 149.68 50.57 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.832 -1.168 . . . . 0.0 109.551 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.575 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 5.3 tt -119.4 135.73 54.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.443 -0.786 . . . . 0.0 109.852 -179.288 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.568 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 5.3 ttp180 -122.37 129.79 52.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -0.883 . . . . 0.0 109.051 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -72.11 145.83 47.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.751 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.57 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 38.4 t60 -64.42 112.09 2.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 109.358 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.48 1.26 24.71 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.473 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 11.0 t -114.27 153.91 28.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -1.2 . . . . 0.0 109.421 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -110.73 6.92 21.92 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.3 mt-10 -118.04 104.14 10.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.568 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 33.6 m95 -61.8 142.16 57.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.415 -0.803 . . . . 0.0 109.746 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -106.0 136.15 19.34 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.361 -0.837 . . . . 0.0 109.293 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.59 147.14 50.85 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.634 2.223 . . . . 0.0 112.198 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.653 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.0 mp -108.14 148.54 29.72 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.267 -0.896 . . . . 0.0 108.775 179.461 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 61.4 m -96.29 125.63 40.93 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.876 -1.14 . . . . 0.0 109.161 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.455 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 55.4 tttt -70.15 111.19 5.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.144 -0.972 . . . . 0.0 109.072 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -111.78 107.71 16.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.957 -1.089 . . . . 0.0 109.608 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.9 -93.15 0.12 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -134.75 20.01 3.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.206 -1.173 . . . . 0.0 109.339 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.489 HG11 ' CB ' ' A' ' 31' ' ' ASP . 27.7 m -130.86 -172.81 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.362 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.455 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 69.2 m95 -135.45 125.21 25.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.885 . . . . 0.0 109.122 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.456 ' HG3' HG21 ' A' ' 29' ' ' VAL . 60.9 tt0 -114.99 149.99 36.52 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 109.748 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.653 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 14.5 p -141.57 137.54 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.412 -0.805 . . . . 0.0 109.456 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -119.91 129.33 54.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.491 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.433 ' O ' ' HB3' ' A' ' 26' ' ' LYS . 35.6 t -118.3 131.83 56.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.602 -0.687 . . . . 0.0 109.51 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.5 t -61.26 -14.02 23.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.911 . . . . 0.0 108.973 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.54 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -116.1 167.55 10.12 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.35 -0.844 . . . . 0.0 109.208 179.9 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 46.4 Cg_endo -68.14 129.64 19.81 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.54 2.16 . . . . 0.0 111.792 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.598 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -63.41 142.5 58.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.374 -0.829 . . . . 0.0 109.648 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.03 124.25 68.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.332 -0.855 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.524 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.77 164.31 27.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.635 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.3 Cg_endo -69.0 147.31 82.79 Favored 'Cis proline' 0 C--O 1.214 -0.713 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.935 0.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -91.26 147.6 22.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.536 -0.728 . . . . 0.0 110.353 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -108.32 143.77 36.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.354 -0.841 . . . . 0.0 108.736 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 85.3 m-85 -134.17 125.66 28.35 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.062 -1.024 . . . . 0.0 109.906 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.492 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 44.2 ttt180 -108.21 142.34 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.962 -1.086 . . . . 0.0 108.834 179.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.62 ' CZ ' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -124.4 143.28 50.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.881 . . . . 0.0 111.154 -178.202 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.618 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.2 ttm -126.2 125.69 42.85 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.568 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.59 ' N ' ' O ' ' A' ' 86' ' ' MET . 20.5 p -73.99 145.85 44.29 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.284 -0.885 . . . . 0.0 110.26 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.611 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 18.8 mttm -50.55 -42.88 55.92 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.342 -0.849 . . . . 0.0 108.771 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.94 -4.5 0.72 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.89 27.21 11.42 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.59 ' O ' ' N ' ' A' ' 82' ' ' SER . 8.8 mtm -103.32 153.86 19.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.04 -1.27 . . . . 0.0 108.802 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 32.7 mtt180 -128.29 142.18 51.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.812 -1.18 . . . . 0.0 110.786 -178.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.5 m120 -134.81 140.09 45.6 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.492 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 3.9 t -122.63 137.04 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.958 -1.089 . . . . 0.0 110.498 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.531 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 56.8 m-85 -124.93 122.52 37.58 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 35.2 p-10 -98.85 147.62 24.74 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.15 -0.969 . . . . 0.0 109.645 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.635 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 32.8 mt-10 53.0 52.44 13.85 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.84 . . . . 0.0 110.277 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 90' ' ' PHE . 45.2 t -83.23 -34.41 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.789 -1.194 . . . . 0.0 109.094 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 13.4 mt -138.32 125.25 13.23 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.325 -0.859 . . . . 0.0 109.032 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.04 162.79 40.26 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.611 2.207 . . . . 0.0 111.97 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.524 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 12.3 m -54.01 -37.51 64.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.41 -0.806 . . . . 0.0 109.899 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.14 101.29 12.92 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.004 -1.06 . . . . 0.0 109.714 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.587 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 40.4 p90 -109.58 149.56 29.49 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 109.279 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ILE . 1.4 m -118.77 104.22 10.38 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.731 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.504 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 8.7 mt -43.29 139.96 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 105.0 -3.09 41.05 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.9 tptt -122.29 142.76 50.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -1.174 . . . . 0.0 109.226 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.484 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 10.9 m -79.18 175.0 10.99 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.117 -0.99 . . . . 0.0 108.619 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.602 ' N ' ' O ' ' A' ' 17' ' ' PHE . 26.8 m-85 -159.94 96.7 1.24 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.675 -1.265 . . . . 0.0 109.119 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.503 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 7.9 mtmt -97.8 163.2 20.0 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.441 -0.787 . . . . 0.0 109.635 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.531 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 48.1 Cg_endo -68.41 144.48 61.74 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.69 2.26 . . . . 0.0 112.024 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.473 ' O ' ' HB2' ' A' ' 108' ' ' GLU . 96.7 mt-10 -52.5 -19.36 2.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.243 -0.911 . . . . 0.0 109.563 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.473 ' HB2' ' O ' ' A' ' 107' ' ' GLU . 79.9 mt-10 . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.536 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 48.2 mtm180 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.221 0.534 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.471 ' O ' ' CE1' ' A' ' 4' ' ' HIS . . . 94.69 7.45 60.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.408 ' O ' ' HB2' ' A' ' 4' ' ' HIS . 83.6 p -61.68 -25.61 67.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -1.15 . . . . 0.0 109.472 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . 0.471 ' CE1' ' O ' ' A' ' 2' ' ' GLY . 9.1 m-70 64.58 22.6 12.69 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.306 -0.871 . . . . 0.0 109.465 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 58.3 m-70 -121.67 125.5 46.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.425 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.8 m80 -96.16 -10.38 28.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 65.4 m-70 -124.45 136.39 54.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 82.8 t60 -61.47 -38.09 85.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.253 -0.904 . . . . 0.0 109.348 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -49.32 -29.1 5.56 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.179 -0.951 . . . . 0.0 109.401 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.8 -175.83 6.03 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HG2' ' A' ' 37' ' ' PRO . 2.3 t -158.62 157.88 32.77 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -1.204 . . . . 0.0 109.534 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -112.53 156.42 22.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.47 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.504 ' CG2' ' HG3' ' A' ' 36' ' ' ARG . 4.6 t -125.14 126.23 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.471 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -102.81 121.31 42.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.227 -0.92 . . . . 0.0 109.251 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 7.0 p -129.81 141.15 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.279 -0.888 . . . . 0.0 109.691 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.481 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 21.4 p -141.88 145.78 35.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.562 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.7 m-85 -117.0 150.83 37.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.412 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 42.3 m -144.48 127.26 16.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.999 -1.063 . . . . 0.0 109.373 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.491 ' CG2' HD22 ' A' ' 30' ' ' LEU . 12.2 t -75.84 135.63 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.4 mm-40 -114.62 155.18 27.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.049 -1.032 . . . . 0.0 109.885 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -47.23 109.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.495 -0.753 . . . . 0.0 109.853 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.68 -5.76 1.36 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.669 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.431 ' HB2' ' CZ ' ' A' ' 98' ' ' PHE . 7.3 p -62.39 142.94 57.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.801 -1.411 . . . . 0.0 109.361 -179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.508 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -136.43 173.83 5.15 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.6 Cg_endo -70.79 -28.75 19.9 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.667 2.245 . . . . 0.0 111.954 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -116.24 7.22 13.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.068 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.471 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 33.1 mttp -142.7 133.68 25.7 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.48 123.16 40.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.929 -1.107 . . . . 0.0 109.613 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.541 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 9.0 t -120.2 125.59 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 179.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.3 mt -144.87 144.95 31.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.893 -1.129 . . . . 0.0 110.226 -179.369 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.412 ' HB3' ' HB ' ' A' ' 18' ' ' THR . 16.2 t70 -82.4 134.43 35.24 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.614 HG22 ' CE2' ' A' ' 80' ' ' PHE . 74.9 mt -119.96 130.64 73.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.779 -1.201 . . . . 0.0 110.74 -178.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 62.8 mttm -111.49 120.15 41.16 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 178.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.533 ' CG ' ' HB2' ' A' ' 41' ' ' LEU . 90.1 t80 -120.53 112.86 19.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.425 -0.797 . . . . 0.0 109.501 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.494 ' O ' HG13 ' A' ' 13' ' ' VAL . 33.8 m -115.22 115.24 26.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 0.0 109.688 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.548 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -147.6 117.55 4.36 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.462 -0.774 . . . . 0.0 109.066 179.897 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.465 ' HG2' ' OG ' ' A' ' 11' ' ' SER . 49.1 Cg_endo -69.29 123.65 10.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.94 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.37 59.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.548 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -142.71 -176.39 4.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -1.201 . . . . 0.0 109.864 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.6 m -155.83 162.69 40.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.332 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.575 HD21 ' CE2' ' A' ' 80' ' ' PHE . 48.6 tp -69.32 126.38 29.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.964 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.568 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.83 -44.51 2.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.854 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.415 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 27.0 mt-10 -137.19 146.85 45.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.158 -0.964 . . . . 0.0 110.262 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.453 HG22 HD12 ' A' ' 41' ' ' LEU . 98.2 t -139.93 137.39 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.476 -0.765 . . . . 0.0 109.252 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.472 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.5 mt-10 -127.79 150.69 49.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.822 -1.174 . . . . 0.0 109.231 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.557 ' CD1' ' O ' ' A' ' 77' ' ' ASN . 12.1 tp -120.42 132.24 55.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 110.393 -178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.608 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.4 OUTLIER -113.19 124.88 53.56 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.292 -0.88 . . . . 0.0 108.995 179.178 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.576 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 61.1 mt-30 -65.24 159.14 24.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.252 -0.905 . . . . 0.0 109.087 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.566 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 11.4 t-80 -75.95 108.15 8.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.17 7.09 21.66 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 23.1 t -115.88 154.16 30.23 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.047 -1.267 . . . . 0.0 109.514 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mt-10 -104.9 -22.44 13.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.274 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -87.67 129.03 35.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.608 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 9.4 m95 -86.92 141.68 28.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.632 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.41 ' OE2' ' O ' ' A' ' 67' ' ' LYS . 45.4 tt0 -107.98 133.75 20.38 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.351 -0.843 . . . . 0.0 109.481 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.467 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.7 Cg_endo -70.78 151.0 62.93 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.693 2.262 . . . . 0.0 111.783 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.538 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.8 mp -109.16 143.84 38.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.206 -0.934 . . . . 0.0 109.11 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.7 m -92.7 127.44 38.2 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.99 -1.069 . . . . 0.0 109.136 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -70.49 109.99 5.13 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.164 -0.96 . . . . 0.0 109.11 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.425 ' O ' HG23 ' A' ' 63' ' ' VAL . 37.1 mttt -109.4 115.77 30.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.945 -1.097 . . . . 0.0 109.586 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 53.18 -97.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -128.12 16.58 6.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.216 -1.167 . . . . 0.0 109.466 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 60' ' ' LYS . 27.3 m -131.04 -176.94 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.32 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.48 ' CD1' HD13 ' A' ' 32' ' ' ILE . 57.9 m95 -128.33 130.35 47.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.112 -0.993 . . . . 0.0 109.332 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.415 ' OE1' ' HE3' ' A' ' 60' ' ' LYS . 78.2 tt0 -111.69 135.97 51.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.645 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.55 ' CG1' ' HB3' ' A' ' 28' ' ' LEU . 5.3 p -130.67 129.67 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.426 -0.797 . . . . 0.0 109.012 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.471 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 19.4 mtmm -121.43 133.3 55.07 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.04 -1.038 . . . . 0.0 109.692 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.576 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.1 t -118.38 153.08 34.63 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.422 -0.799 . . . . 0.0 109.305 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.1 m -78.6 -2.36 38.57 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.151 -0.968 . . . . 0.0 109.148 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.543 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 3.5 mttt -128.81 177.02 2.34 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.339 -0.851 . . . . 0.0 109.164 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.543 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.6 Cg_endo -68.54 150.3 75.02 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.495 2.13 . . . . 0.0 111.856 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.567 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 14.9 mt -85.58 137.46 32.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.33 -0.856 . . . . 0.0 109.682 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.557 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 28.9 t -127.02 125.86 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.46 -0.775 . . . . 0.0 109.475 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.94 169.19 28.03 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.633 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.2 Cg_endo -67.98 146.92 78.86 Favored 'Cis proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.912 -1.703 . . . . 0.0 112.002 0.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.567 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 86.6 m-85 -89.69 149.77 22.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.589 -0.695 . . . . 0.0 110.343 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.557 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 3.0 m-80 -112.06 142.74 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -134.85 134.84 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.999 -1.063 . . . . 0.0 109.381 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.536 ' NH1' ' CZ ' ' A' ' 87' ' ' ARG . 64.5 ttt180 -116.8 144.07 44.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.943 -1.098 . . . . 0.0 108.864 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.614 ' CE2' HG22 ' A' ' 32' ' ' ILE . 6.6 m-85 -122.89 140.79 52.6 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.157 -0.965 . . . . 0.0 111.238 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.1 ttm -123.45 124.02 41.96 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 18.8 p -72.37 142.41 48.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.455 -0.778 . . . . 0.0 110.475 -178.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.568 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 56.4 mttt -46.64 -44.18 18.18 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 108.821 178.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -57.09 -5.85 1.65 Allowed Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 97.3 25.36 11.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 55.4 mtp -99.67 152.52 19.97 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.108 -1.23 . . . . 0.0 108.473 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.597 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 33.5 mtm180 -128.39 142.13 51.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.617 -1.302 . . . . 0.0 110.918 -178.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.441 ' N ' ' O ' ' A' ' 80' ' ' PHE . 29.9 m120 -135.69 140.73 44.67 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.3 t -122.79 136.72 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.863 -1.148 . . . . 0.0 110.387 -179.026 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.548 ' CD1' ' CB ' ' A' ' 106' ' ' PRO . 55.5 m-85 -124.16 122.41 37.75 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.457 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 24.0 p-10 -99.53 147.37 25.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.209 -0.932 . . . . 0.0 109.716 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.633 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 81.3 mt-10 53.99 51.18 15.15 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.505 -0.747 . . . . 0.0 110.344 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -81.96 -34.89 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.864 -1.148 . . . . 0.0 108.938 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.427 HG23 HD13 ' A' ' 94' ' ' ILE . 13.0 mt -135.8 125.07 16.02 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.473 -0.767 . . . . 0.0 108.974 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.28 161.61 45.19 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.569 2.179 . . . . 0.0 111.977 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.523 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 29.1 m -50.09 -45.68 52.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.373 -0.83 . . . . 0.0 109.726 -179.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.06 101.18 13.89 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.053 -1.029 . . . . 0.0 109.5 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.431 ' CZ ' ' HB2' ' A' ' 23' ' ' SER . 44.8 p90 -108.26 154.12 22.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 69.4 m -110.43 170.87 7.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.39 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 HG13 ' A' ' 19' ' ' VAL . 23.2 mm -105.19 136.71 37.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 109.312 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.72 6.28 59.56 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 46.7 tttt -119.03 143.43 47.1 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.095 -1.238 . . . . 0.0 109.225 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.492 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 15.5 m -80.8 174.74 11.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.161 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.619 ' N ' ' O ' ' A' ' 17' ' ' PHE . 35.1 m-85 -160.36 102.25 1.39 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.765 -1.209 . . . . 0.0 108.772 179.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.577 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 1.7 ptpp? -114.16 166.36 11.66 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.201 -0.937 . . . . 0.0 109.776 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.577 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 48.7 Cg_endo -69.91 -169.56 0.34 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.587 2.191 . . . . 0.0 111.811 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -123.61 154.05 39.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.485 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.444 ' HB3' ' NE2' ' A' ' 4' ' ' HIS . 88.0 mt-10 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.521 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 72.5 mtt85 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.1 164.71 37.7 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.7 p -150.2 133.84 16.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -1.165 . . . . 0.0 109.451 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -132.95 18.75 4.13 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.204 -0.935 . . . . 0.0 109.492 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -75.15 -44.7 45.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.484 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 75.3 t60 -145.14 141.47 28.78 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.223 -0.923 . . . . 0.0 109.554 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.45 ' CE1' ' O ' ' A' ' 10' ' ' GLY . 86.4 t60 -111.38 114.17 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.244 -0.91 . . . . 0.0 109.393 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -141.34 154.52 45.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 0.0 109.592 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 62.11 29.13 17.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.216 -0.927 . . . . 0.0 109.462 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.45 ' O ' ' CE1' ' A' ' 7' ' ' HIS . . . 56.03 -123.51 31.21 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -59.15 -172.14 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -1.132 . . . . 0.0 109.548 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -143.26 165.63 26.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 109.517 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.493 HG13 ' CZ ' ' A' ' 34' ' ' TYR . 10.9 t -127.66 141.27 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.34 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -113.31 120.96 42.95 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.7 t -127.67 137.89 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.257 -0.902 . . . . 0.0 109.823 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 32.4 p -142.31 146.09 34.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.39 -0.819 . . . . 0.0 109.231 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.603 ' O ' ' N ' ' A' ' 104' ' ' TYR . 8.7 m-85 -119.41 151.85 37.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.106 -0.996 . . . . 0.0 110.02 -179.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 27.7 m -143.18 158.86 43.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 108.71 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.533 ' CG1' HD12 ' A' ' 100' ' ' ILE . 4.3 t -107.75 127.96 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.087 -1.008 . . . . 0.0 109.433 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -101.47 149.8 23.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.897 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -44.01 114.09 0.62 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.498 -0.752 . . . . 0.0 109.94 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.16 2.19 1.4 Allowed Glycine 0 N--CA 1.49 2.264 0 C-N-CA 119.272 -1.442 . . . . 0.0 110.907 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.0 m -61.18 142.38 56.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.667 -1.49 . . . . 0.0 109.054 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -137.82 171.94 7.59 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.094 -1.004 . . . . 0.0 109.616 -179.627 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.482 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.7 Cg_endo -70.68 -29.02 20.09 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.729 2.286 . . . . 0.0 111.829 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -118.03 3.4 12.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.009 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.428 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 21.1 mttt -141.83 133.15 26.51 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.422 HD21 HD12 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.07 133.78 50.39 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.018 -1.051 . . . . 0.0 110.17 -179.374 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.483 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.3 t -121.62 124.05 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.515 HD23 ' CG2' ' A' ' 19' ' ' VAL . 1.3 mt -140.94 141.14 34.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.01 -1.056 . . . . 0.0 110.093 -179.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -85.55 134.51 34.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.621 HG23 ' CZ ' ' A' ' 80' ' ' PHE . 1.4 mt -116.12 126.89 73.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 118.922 -1.111 . . . . 0.0 110.893 -179.105 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 13.7 tttm -107.28 115.07 29.52 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.01 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.493 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 77.2 t80 -124.93 111.88 15.96 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.345 0.593 . . . . 0.0 109.634 -178.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.3 m -113.85 119.77 38.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.94 . . . . 0.0 109.691 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.471 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 29.7 ttt85 -140.91 119.58 8.2 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.7 119.29 6.26 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.714 2.276 . . . . 0.0 111.821 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.14 -14.52 60.52 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.471 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 6.2 m-20 -136.43 175.18 9.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.181 -1.188 . . . . 0.0 109.644 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.51 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 m -154.41 161.6 41.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.297 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.606 HD11 ' CE2' ' A' ' 80' ' ' PHE . 0.4 OUTLIER -71.21 130.87 42.53 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.257 -0.902 . . . . 0.0 109.385 179.947 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.585 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -112.4 -41.03 3.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -143.18 151.27 40.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 0.0 110.187 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.536 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.1 t -138.9 136.32 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.5 mt-10 -126.77 149.24 49.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.697 -1.252 . . . . 0.0 109.547 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.589 HD13 ' CZ ' ' A' ' 78' ' ' PHE . 10.4 tp -122.18 131.24 53.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.479 -0.763 . . . . 0.0 109.929 -179.106 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.606 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 41.8 ttp180 -118.92 135.04 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.088 179.354 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.603 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 78.7 mt-30 -75.05 150.72 38.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 110.034 -179.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.578 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 4.2 t-80 -67.4 112.55 4.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.41 -0.806 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.63 0.63 30.73 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.47 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 4.0 t -113.67 155.54 25.35 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.206 -1.173 . . . . 0.0 109.32 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -108.33 -14.31 14.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.243 -0.911 . . . . 0.0 109.404 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -93.17 117.92 30.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.223 -0.923 . . . . 0.0 109.736 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.606 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 25.3 m95 -75.94 140.29 42.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.419 -0.801 . . . . 0.0 109.638 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.461 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.8 OUTLIER -106.59 127.35 28.31 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.472 -0.768 . . . . 0.0 109.095 179.757 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.461 ' HD2' ' HG3' ' A' ' 55' ' ' GLU . 49.6 Cg_endo -69.67 150.42 68.71 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.586 2.191 . . . . 0.0 112.19 -179.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.579 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.8 mp -107.47 141.85 38.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 108.847 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 43.5 m -92.91 127.26 38.36 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.923 -1.11 . . . . 0.0 109.06 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tttm -73.49 109.86 7.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 109.717 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.434 ' O ' HG21 ' A' ' 63' ' ' VAL . 26.0 mttm -109.88 110.93 22.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.998 -1.064 . . . . 0.0 109.752 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.46 -90.02 0.07 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.5 p-10 -139.04 18.45 2.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.288 -1.124 . . . . 0.0 109.281 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.434 HG21 ' O ' ' A' ' 60' ' ' LYS . 16.2 m -130.66 173.4 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.283 -0.886 . . . . 0.0 109.249 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.448 ' CD1' HG13 ' A' ' 32' ' ' ILE . 66.5 m95 -123.17 128.64 50.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 109.317 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -117.85 151.38 37.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.627 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.579 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.2 p -145.38 140.9 22.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.329 -0.857 . . . . 0.0 109.308 179.784 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.428 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 34.9 mttp -122.15 132.97 54.73 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.717 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.603 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 38.8 t -116.71 121.52 41.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.454 -0.779 . . . . 0.0 109.349 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 58.8 m -49.16 -22.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.555 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -109.65 177.25 1.28 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.318 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.555 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -68.86 152.69 73.67 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.504 2.136 . . . . 0.0 111.657 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.593 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 mt -90.28 138.05 31.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 35.4 t -126.34 125.28 67.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.422 -0.798 . . . . 0.0 109.605 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.532 ' HA3' ' N ' ' A' ' 96' ' ' THR . . . -94.39 167.29 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.67 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.1 Cg_endo -68.15 147.43 80.46 Favored 'Cis proline' 0 C--O 1.213 -0.735 0 C-N-CA 122.937 -1.693 . . . . 0.0 112.034 0.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.1 m-85 -91.23 150.82 21.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.441 -0.787 . . . . 0.0 110.448 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.527 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 23.3 m-80 -111.12 142.08 43.77 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CZ ' HD13 ' A' ' 46' ' ' LEU . 41.9 m-85 -135.95 128.3 30.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.918 -1.114 . . . . 0.0 110.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.541 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 16.2 ttt180 -108.56 142.23 39.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 108.643 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.621 ' CZ ' HG23 ' A' ' 32' ' ' ILE . 9.3 m-85 -123.49 143.6 50.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.213 -0.93 . . . . 0.0 111.411 -178.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.596 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.6 ttm -127.44 125.67 40.97 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.2 p -77.39 144.94 37.54 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.89 . . . . 0.0 110.246 -178.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.585 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 60.0 mttm -47.78 -43.14 27.28 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.4 -2.71 0.74 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.37 23.98 22.87 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.8 mmm -98.64 148.39 23.86 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -1.231 . . . . 0.0 108.681 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.596 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 77.8 mtm-85 -126.84 142.58 51.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.78 -1.2 . . . . 0.0 110.586 -178.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.413 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.2 m120 -136.97 141.17 42.59 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.541 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 2.9 t -121.43 136.32 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.5 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 71.8 m-85 -124.56 122.39 37.44 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -100.06 148.62 24.36 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.244 -0.91 . . . . 0.0 109.644 -179.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.67 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 88.6 mt-10 53.28 51.87 14.66 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.369 -0.832 . . . . 0.0 110.278 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.08 -34.33 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.856 -1.153 . . . . 0.0 109.188 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.2 mt -137.53 125.56 14.33 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.325 -0.859 . . . . 0.0 109.127 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.71 163.02 39.8 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.577 2.185 . . . . 0.0 112.07 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.532 ' N ' ' HA3' ' A' ' 74' ' ' GLY . 32.3 m -54.13 -44.09 71.06 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.414 -0.804 . . . . 0.0 109.918 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.39 99.41 11.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.054 -1.029 . . . . 0.0 109.363 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -107.85 147.09 31.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 109.722 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 70.4 m -107.08 167.86 9.6 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -0.862 . . . . 0.0 109.169 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.533 HD12 ' CG1' ' A' ' 19' ' ' VAL . 29.8 mm -104.16 136.78 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 109.408 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.73 2.66 61.26 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.1 tptt -116.15 142.55 46.67 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.09 -1.241 . . . . 0.0 109.176 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 18.6 m -78.39 173.51 12.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.075 -1.016 . . . . 0.0 108.966 -179.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.603 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -156.16 105.83 2.35 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.765 -1.209 . . . . 0.0 108.831 179.187 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 1.3 ptmt -103.67 157.41 33.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.724 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.5 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 51.2 Cg_endo -70.47 151.79 65.26 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.744 2.296 . . . . 0.0 111.734 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -56.49 -20.63 21.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.216 -0.927 . . . . 0.0 109.458 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.489 179.929 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 45.5 mtt85 . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.92 -179.43 51.11 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 82.7 p -79.11 -8.96 59.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.228 -1.16 . . . . 0.0 109.501 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' A' ' 6' ' ' HIS . 19.4 m-70 -48.46 -41.85 30.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.464 ' CG ' ' O ' ' A' ' 5' ' ' HIS . 74.5 t60 46.12 32.89 1.54 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.229 -0.92 . . . . 0.0 109.427 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.456 ' CE1' ' O ' ' A' ' 4' ' ' HIS . 36.6 m80 -109.75 126.27 53.56 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -0.904 . . . . 0.0 109.454 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.34 -40.37 90.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.308 -0.87 . . . . 0.0 109.367 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 30.6 m80 -132.8 150.45 52.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.528 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -60.54 -29.62 69.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.69 -153.41 28.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.9 m -114.39 159.41 20.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.253 -1.146 . . . . 0.0 109.316 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -148.39 145.02 27.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.527 ' CG2' ' HG2' ' A' ' 36' ' ' ARG . 40.5 t -124.45 129.01 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -109.4 120.35 42.24 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 109.118 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.574 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.9 p -128.35 140.53 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.314 -0.866 . . . . 0.0 109.499 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.466 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 32.0 p -143.09 146.32 33.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.187 -0.945 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.597 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.4 m-85 -117.01 148.41 41.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.251 -0.905 . . . . 0.0 109.286 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 36.0 m -143.6 128.63 18.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.929 -1.107 . . . . 0.0 109.621 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.553 ' CG2' HD23 ' A' ' 30' ' ' LEU . 3.5 t -76.7 138.52 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.157 -0.964 . . . . 0.0 109.364 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.7 mm-40 -118.66 155.66 30.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.02 -1.05 . . . . 0.0 109.612 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -47.51 112.73 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.82 . . . . 0.0 110.009 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.73 -7.96 1.99 Allowed Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.71 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 4.5 p -60.18 141.76 55.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.805 -1.409 . . . . 0.0 109.435 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.565 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.14 177.27 2.25 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.165 -0.959 . . . . 0.0 109.693 -179.594 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.565 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.8 Cg_endo -71.2 -33.93 10.77 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.784 2.322 . . . . 0.0 112.015 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.435 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -115.54 2.82 13.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 108.894 179.509 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' ASP . 27.2 mtmt -139.19 132.29 29.64 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.595 ' CD2' ' CD1' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -127.68 132.99 49.6 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.001 -1.062 . . . . 0.0 110.211 -179.086 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.6 t -119.56 122.76 69.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.595 ' CD1' ' CD2' ' A' ' 28' ' ' LEU . 16.8 mt -137.66 136.72 37.7 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.046 -1.034 . . . . 0.0 110.324 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.462 ' HB2' HG13 ' A' ' 63' ' ' VAL . 37.7 t70 -84.2 136.22 34.05 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 177.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.593 HG12 ' CD2' ' A' ' 17' ' ' PHE . 88.1 mt -121.62 131.11 73.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.688 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 44.3 tttt -110.32 119.46 39.28 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.479 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 83.5 t80 -121.44 118.15 28.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.456 -0.777 . . . . 0.0 109.355 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 17.1 m -121.16 117.81 28.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.268 -0.895 . . . . 0.0 109.923 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.56 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 0.0 OUTLIER -124.24 168.52 12.7 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.832 . . . . 0.0 109.345 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.56 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -70.07 76.96 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.634 2.223 . . . . 0.0 111.726 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.43 -5.92 75.28 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.26 179.38 4.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 109.498 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.0 m -151.08 158.37 43.97 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.302 -0.874 . . . . 0.0 109.527 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.617 HD13 ' CE2' ' A' ' 80' ' ' PHE . 1.2 tt -71.79 136.4 47.06 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.659 -0.65 . . . . 0.0 109.342 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.552 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.58 -43.13 3.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.11 -0.994 . . . . 0.0 110.238 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -139.83 148.81 42.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.004 -1.06 . . . . 0.0 110.659 -179.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.561 ' CG2' HD13 ' A' ' 41' ' ' LEU . 14.6 t -139.0 136.3 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.541 -0.725 . . . . 0.0 109.33 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.424 ' HA ' HD11 ' A' ' 57' ' ' LEU . 95.2 mt-10 -128.75 150.89 50.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.953 -1.092 . . . . 0.0 109.255 179.351 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.634 ' CD1' ' CE2' ' A' ' 78' ' ' PHE . 9.6 tt -121.61 147.32 46.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.27 -0.893 . . . . 0.0 110.045 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 51' ' ' SER . 13.4 ttp180 -131.95 128.56 38.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.87 . . . . 0.0 108.808 179.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 36.0 mt-30 -69.7 153.02 43.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 0.0 109.942 -179.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HD2' ' A' ' 75' ' ' PRO . 66.1 t60 -67.45 119.29 12.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.41 -0.806 . . . . 0.0 109.682 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.91 4.35 54.41 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.462 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 39.4 t -114.24 154.49 27.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.453 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 87.5 mt-10 -117.78 15.69 14.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.375 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -119.02 97.6 5.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.903 . . . . 0.0 109.687 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -55.84 134.56 51.91 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.36 -0.838 . . . . 0.0 109.657 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -104.26 134.79 19.51 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.348 -0.845 . . . . 0.0 109.316 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.61 145.35 52.01 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.627 2.218 . . . . 0.0 112.095 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.609 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.6 mp -110.0 151.2 27.45 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 108.871 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.1 m -100.66 125.51 47.09 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.865 -1.147 . . . . 0.0 108.851 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -72.13 108.83 5.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.202 -0.936 . . . . 0.0 109.091 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.513 ' O ' ' N ' ' A' ' 62' ' ' ASN . 15.2 mttm -107.48 126.26 52.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.986 -1.071 . . . . 0.0 109.542 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 48.67 -92.68 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 60' ' ' LYS . 31.6 p-10 -136.73 19.5 3.07 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.282 -1.128 . . . . 0.0 109.344 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.462 HG13 ' HB2' ' A' ' 31' ' ' ASP . 20.6 m -131.72 173.57 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.334 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.433 ' CH2' HG22 ' A' ' 44' ' ' VAL . 71.1 m95 -117.35 127.44 54.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.94 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.413 ' CD ' ' HD2' ' A' ' 60' ' ' LYS . 80.3 mt-10 -113.43 141.07 47.53 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.29 -0.881 . . . . 0.0 109.892 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.609 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 7.7 p -135.56 132.69 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.284 -0.885 . . . . 0.0 109.066 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.451 ' HG3' ' HG2' ' A' ' 27' ' ' LYS . 41.3 tttm -120.32 132.42 55.29 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 0.0 109.686 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 69' ' ' SER . 23.2 t -121.66 124.08 43.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.5 -0.75 . . . . 0.0 109.316 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 68' ' ' SER . 44.7 m -44.2 -29.86 0.7 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.011 -1.056 . . . . 0.0 108.461 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.697 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 0.1 OUTLIER -105.72 170.53 5.77 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.37 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.697 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.3 Cg_endo -66.6 172.18 9.67 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.115 1.876 . . . . 0.0 111.687 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.597 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.9 mt -100.59 144.53 29.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 110.122 -179.486 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.87 125.34 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.453 -0.779 . . . . 0.0 109.295 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.473 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -96.47 170.35 26.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.576 ' HD2' ' CG ' ' A' ' 49' ' ' HIS . 48.2 Cg_endo -68.62 146.6 79.94 Favored 'Cis proline' 0 C--O 1.213 -0.739 0 C-N-CA 122.837 -1.734 . . . . 0.0 111.859 -0.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.597 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 84.5 m-85 -92.48 147.22 23.07 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.447 -0.783 . . . . 0.0 110.669 -179.104 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.529 ' C ' ' CD1' ' A' ' 78' ' ' PHE . 20.5 m-80 -108.75 144.99 35.83 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.634 ' CE2' ' CD1' ' A' ' 46' ' ' LEU . 3.8 m-85 -136.99 122.56 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.855 -1.153 . . . . 0.0 110.319 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.52 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 54.2 ttt180 -101.89 142.19 33.58 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.617 ' CE2' HD13 ' A' ' 41' ' ' LEU . 8.8 m-85 -123.91 143.79 50.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 111.267 -177.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.572 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.3 ttt -126.14 124.5 40.68 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.535 ' OG ' ' HB2' ' A' ' 86' ' ' MET . 13.4 p -77.53 145.6 36.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.846 . . . . 0.0 110.157 -178.233 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.552 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -44.96 -47.28 11.39 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.156 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.52 -6.92 5.14 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 97.01 34.41 5.68 Favored Glycine 0 N--CA 1.489 2.185 0 O-C-N 121.141 -1.211 . . . . 0.0 110.111 179.352 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.535 ' HB2' ' OG ' ' A' ' 82' ' ' SER . 55.8 mtp -105.36 110.46 22.82 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.028 -1.278 . . . . 0.0 109.127 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 26.6 mtm180 -90.4 140.6 29.56 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 110.668 -179.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.1 m120 -137.61 141.84 41.26 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.52 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 3.1 t -121.24 135.57 60.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.916 -1.115 . . . . 0.0 110.299 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.504 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 13.4 m-85 -124.2 122.31 37.45 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -98.44 146.98 25.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.208 -0.933 . . . . 0.0 109.546 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.574 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 49.1 tt0 52.92 52.64 13.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.438 -0.789 . . . . 0.0 110.162 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.443 HG13 HG13 ' A' ' 94' ' ' ILE . 42.4 t -80.34 -33.38 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.882 -1.136 . . . . 0.0 108.933 179.447 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.521 HG22 HD13 ' A' ' 94' ' ' ILE . 14.0 mt -138.55 127.53 14.34 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.381 -0.824 . . . . 0.0 108.882 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.06 160.64 49.1 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.559 2.173 . . . . 0.0 112.099 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.473 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 58.6 m -50.96 -36.49 39.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.83 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.15 103.23 12.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.11 -0.994 . . . . 0.0 109.522 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.488 ' CE1' HG11 ' A' ' 19' ' ' VAL . 48.7 p90 -110.9 155.01 23.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.87 . . . . 0.0 109.219 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.5 m -105.99 172.39 6.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.145 -0.972 . . . . 0.0 109.418 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.439 HD11 ' CG1' ' A' ' 19' ' ' VAL . 28.2 mm -104.61 135.21 43.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.264 -0.898 . . . . 0.0 109.152 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 99.36 2.8 56.65 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.6 tttp -117.77 142.74 46.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.967 -1.313 . . . . 0.0 109.159 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.488 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.3 m -81.74 176.45 9.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.119 -0.988 . . . . 0.0 109.091 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.597 ' N ' ' O ' ' A' ' 17' ' ' PHE . 26.9 m-85 -160.69 98.4 1.22 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.8 -1.188 . . . . 0.0 109.064 179.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.497 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 0.2 OUTLIER -100.35 164.94 15.34 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.265 -0.897 . . . . 0.0 109.797 -179.423 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.504 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.5 Cg_endo -69.91 164.93 32.86 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.712 2.274 . . . . 0.0 111.81 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 108' ' ' GLU . 80.5 tt0 -56.36 -26.78 53.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.536 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 107' ' ' GLU . 36.4 tp10 . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.441 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 110.71 34.35 2.25 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.8 p -73.78 -8.46 56.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -1.164 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -109.47 128.56 55.25 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.39 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 87.5 m-70 -121.93 123.6 42.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.21 -0.931 . . . . 0.0 109.614 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -133.2 167.87 19.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.297 -0.877 . . . . 0.0 109.409 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 81.3 m-70 -123.1 90.46 3.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -52.35 -24.88 8.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.457 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -130.85 144.09 51.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.551 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.452 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . 119.81 -16.96 10.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -63.46 -11.44 23.6 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.203 -1.175 . . . . 0.0 109.436 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -116.71 -146.97 0.41 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.646 ' CG1' ' CE1' ' A' ' 34' ' ' TYR . 5.0 t -122.64 128.45 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.255 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -112.23 121.58 45.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.052 -1.03 . . . . 0.0 109.625 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.623 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 14.7 t -128.19 138.59 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.515 ' HA ' ' HB3' ' A' ' 105' ' ' LYS . 68.6 p -141.85 146.5 35.89 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.775 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.632 ' CD2' HG12 ' A' ' 32' ' ' ILE . 88.8 m-85 -119.35 118.79 32.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.3 -0.875 . . . . 0.0 109.734 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 21.9 m -108.36 158.51 17.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.922 -1.111 . . . . 0.0 108.979 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.54 ' CG1' ' OG ' ' A' ' 23' ' ' SER . 8.5 t -107.8 126.68 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.46 ' O ' HD13 ' A' ' 100' ' ' ILE . 1.7 mp0 -92.66 -173.52 3.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.146 -0.971 . . . . 0.0 109.605 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -83.65 66.01 8.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.385 -0.822 . . . . 0.0 109.937 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -172.33 22.01 0.07 OUTLIER Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.055 -1.545 . . . . 0.0 110.924 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.54 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 50.3 m -74.21 142.34 45.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.766 -1.432 . . . . 0.0 109.058 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.485 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.9 173.31 5.81 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.055 -1.028 . . . . 0.0 109.875 -179.634 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 51.8 Cg_endo -71.66 -30.56 14.52 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.793 2.329 . . . . 0.0 111.836 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -115.88 5.26 14.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 108.731 179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.472 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 72.8 mttt -142.17 133.11 25.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.441 HD21 HD12 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -127.87 135.34 49.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.067 -1.021 . . . . 0.0 110.099 -179.321 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' HD12 ' A' ' 30' ' ' LEU . 4.1 t -119.39 119.05 59.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.659 ' CD2' ' N ' ' A' ' 30' ' ' LEU . 0.4 OUTLIER -126.85 127.11 44.46 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.217 -0.927 . . . . 0.0 110.282 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.462 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 63.6 t0 -77.99 132.02 37.64 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.632 HG12 ' CD2' ' A' ' 17' ' ' PHE . 52.4 mt -118.3 128.56 75.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.157 -178.125 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.623 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 33.5 mttt -109.41 119.98 41.12 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.646 ' CE1' ' CG1' ' A' ' 13' ' ' VAL . 71.7 t80 -121.21 120.77 36.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.302 -0.874 . . . . 0.0 109.837 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -123.66 116.95 23.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.399 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.543 ' CG ' ' HB2' ' A' ' 39' ' ' ASP . 38.0 ttt85 -139.72 131.94 14.96 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 10' ' ' GLY . 50.3 Cg_endo -70.44 107.85 2.08 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.814 2.343 . . . . 0.0 111.992 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.99 -5.29 84.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.543 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 31.6 m-20 -134.71 174.28 10.74 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -1.201 . . . . 0.0 109.682 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.448 ' O ' ' HA ' ' A' ' 82' ' ' SER . 14.7 m -155.42 162.65 40.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.574 HD21 ' CE2' ' A' ' 80' ' ' PHE . 26.8 tp -71.87 129.73 39.32 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.27 -0.894 . . . . 0.0 109.649 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.587 ' HB2' ' N ' ' A' ' 83' ' ' LYS . . . -116.1 -40.29 3.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -0.934 . . . . 0.0 109.479 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -143.74 152.2 40.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.915 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.599 HG13 ' CE1' ' A' ' 80' ' ' PHE . 46.5 t -139.71 137.14 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.445 -0.785 . . . . 0.0 109.406 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.469 ' HA ' HD11 ' A' ' 57' ' ' LEU . 75.4 mt-10 -128.89 150.48 50.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.904 -1.123 . . . . 0.0 109.433 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.585 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 6.7 tt -119.03 142.22 48.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.434 -0.791 . . . . 0.0 109.805 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.531 ' N ' HD22 ' A' ' 46' ' ' LEU . 17.5 ttp180 -128.03 130.02 47.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.374 -0.829 . . . . 0.0 108.812 179.216 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.538 ' NE2' HD21 ' A' ' 46' ' ' LEU . 57.6 mm-40 -72.14 152.42 42.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 110.218 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.562 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 13.0 t-80 -68.07 131.0 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.513 -0.742 . . . . 0.0 109.461 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 87.8 3.36 80.42 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.8 t -112.23 153.04 27.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.178 -1.19 . . . . 0.0 109.189 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -113.75 21.56 14.86 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.387 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.35 124.59 43.28 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.236 -0.915 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.428 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 64.6 m95 -85.06 129.94 34.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.432 -0.793 . . . . 0.0 109.415 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.4 134.62 19.66 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.369 -0.832 . . . . 0.0 109.342 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -71.8 146.88 49.15 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.642 2.228 . . . . 0.0 112.164 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.604 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.3 mp -106.8 158.04 17.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 108.621 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 52.3 m -108.87 127.04 53.7 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.846 -1.159 . . . . 0.0 109.116 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 37.5 tttm -65.35 120.95 13.73 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 62' ' ' ASN . 2.8 mttm -109.92 -152.7 0.5 Allowed 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.167 -0.958 . . . . 0.0 109.377 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 62' ' ' ASN . . . -58.72 81.2 0.01 OUTLIER Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.518 ' N ' ' O ' ' A' ' 60' ' ' LYS . 39.2 t30 63.97 10.54 5.4 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.243 -1.151 . . . . 0.0 110.086 179.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.46 HG23 ' HB2' ' A' ' 60' ' ' LYS . 5.3 m -132.05 179.12 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.092 -1.005 . . . . 0.0 109.717 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.469 ' CG ' HD11 ' A' ' 32' ' ' ILE . 63.0 m95 -127.15 126.75 43.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.067 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.426 ' HG2' ' N ' ' A' ' 66' ' ' VAL . 62.1 tt0 -119.25 154.58 33.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.17 -0.956 . . . . 0.0 109.706 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.604 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.0 p -146.17 141.42 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.405 -0.81 . . . . 0.0 109.244 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -119.81 129.01 54.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -0.941 . . . . 0.0 109.723 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.2 t -118.6 130.36 55.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.57 -0.706 . . . . 0.0 109.578 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.0 p -61.24 -21.35 63.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.149 -0.969 . . . . 0.0 108.922 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.615 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 15.0 ptmt -106.95 166.86 10.34 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.445 -0.784 . . . . 0.0 109.332 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.615 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 45.6 Cg_endo -67.74 141.39 54.34 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.478 2.118 . . . . 0.0 111.721 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.536 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 10.6 mt -76.49 141.04 41.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.343 -0.848 . . . . 0.0 109.84 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 124.72 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.366 -0.834 . . . . 0.0 109.378 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.451 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -93.99 165.33 26.69 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.75 147.41 82.24 Favored 'Cis proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.892 -1.712 . . . . 0.0 112.077 -0.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.536 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.1 m-85 -90.9 148.03 22.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.411 -0.806 . . . . 0.0 110.339 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.457 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 26.9 m-80 -109.91 144.54 38.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.379 -0.826 . . . . 0.0 108.928 179.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 82.9 m-85 -135.13 129.23 33.56 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.029 -1.044 . . . . 0.0 110.049 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 20.3 ttt85 -110.27 141.79 42.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.061 -1.025 . . . . 0.0 108.528 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.599 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.6 m-85 -125.31 143.34 51.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 111.396 -178.116 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.573 ' HA ' ' O ' ' A' ' 86' ' ' MET . 4.7 ttm -124.8 124.57 42.4 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.591 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.9 p -72.68 145.45 47.21 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.36 -0.838 . . . . 0.0 110.145 -178.472 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.587 ' N ' ' HB2' ' A' ' 42' ' ' ALA . 90.6 mttt -47.6 -45.53 27.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 109.145 179.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.16 -5.06 0.58 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.492 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.47 25.99 12.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.591 ' O ' ' N ' ' A' ' 82' ' ' SER . 45.6 mtp -98.99 150.7 21.7 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -1.18 . . . . 0.0 108.727 179.468 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.547 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 62.3 mtm-85 -123.78 138.82 54.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.888 -1.132 . . . . 0.0 110.575 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -135.69 140.6 44.57 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 59.9 t -124.04 137.73 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.95 -1.094 . . . . 0.0 110.637 -178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.528 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.3 m-85 -123.53 121.54 35.91 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 178.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -98.11 147.05 24.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.164 -0.96 . . . . 0.0 109.58 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.608 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 65.8 tt0 53.47 52.84 12.61 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.4 -0.812 . . . . 0.0 110.03 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.407 ' CG1' ' CD1' ' A' ' 17' ' ' PHE . 70.4 t -81.51 -34.43 13.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.906 -1.121 . . . . 0.0 109.26 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.461 HG12 ' HB3' ' A' ' 104' ' ' TYR . 13.4 mt -136.91 126.43 15.57 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.149 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.26 160.88 48.12 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.603 2.202 . . . . 0.0 111.986 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -52.0 -43.13 63.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.382 -0.824 . . . . 0.0 110.192 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.0 103.64 15.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.025 -1.047 . . . . 0.0 109.83 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -111.68 152.09 28.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 109.31 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 28.2 m -102.11 164.72 11.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.423 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.533 HD12 ' CG1' ' A' ' 19' ' ' VAL . 18.4 mm -98.52 137.43 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.972 . . . . 0.0 109.381 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.44 62.74 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -121.24 146.49 46.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -1.182 . . . . 0.0 109.338 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.6 m -79.77 164.15 23.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.111 -0.993 . . . . 0.0 109.321 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.543 ' N ' ' O ' ' A' ' 17' ' ' PHE . 18.0 m-85 -150.06 92.21 1.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.74 -1.225 . . . . 0.0 109.064 179.089 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.515 ' HB3' ' HA ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -108.88 164.31 15.0 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.4 -0.813 . . . . 0.0 109.867 -179.477 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.528 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 47.7 Cg_endo -69.16 174.88 8.35 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.843 2.362 . . . . 0.0 111.617 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -127.4 138.79 53.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.632 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.503 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 83.4 mtp180 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.44 -176.49 38.79 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.8 m -53.55 141.04 26.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 109.415 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -46.41 -69.0 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.466 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.0 p-80 -172.07 62.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.508 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -159.59 143.8 14.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.258 -0.901 . . . . 0.0 109.482 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 38.2 m170 -100.86 159.9 14.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.384 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 53.9 m80 -120.82 134.43 55.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.18 -0.95 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -117.24 125.16 50.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.223 -0.923 . . . . 0.0 109.353 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.71 121.86 0.6 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.2 t -111.31 169.37 8.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.224 -1.162 . . . . 0.0 109.482 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.79 139.67 58.35 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.584 HG11 ' CE1' ' A' ' 34' ' ' TYR . 15.7 t -126.27 135.63 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 70.6 mt-30 -111.95 122.35 47.54 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.12 -0.988 . . . . 0.0 109.424 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 6.2 t -129.01 139.51 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 0.0 109.721 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.457 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 19.9 p -141.26 145.91 36.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.885 . . . . 0.0 109.237 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.61 ' CD2' HG12 ' A' ' 32' ' ' ILE . 3.9 m-85 -120.22 141.93 49.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.104 -0.998 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.41 HG22 ' NE2' ' A' ' 20' ' ' GLN . 23.9 m -134.37 127.3 31.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.915 . . . . 0.0 108.963 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.557 ' HB ' ' HA ' ' A' ' 100' ' ' ILE . 21.7 t -76.0 134.32 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.146 -0.971 . . . . 0.0 109.243 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.41 ' NE2' HG22 ' A' ' 18' ' ' THR . 85.7 mm-40 -115.29 153.29 31.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.004 -1.06 . . . . 0.0 109.897 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 57.3 mttp -44.15 113.17 0.49 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.458 -0.776 . . . . 0.0 109.988 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.12 -5.86 1.96 Allowed Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.251 -1.452 . . . . 0.0 110.771 179.186 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.575 ' OG ' ' CE1' ' A' ' 98' ' ' PHE . 26.8 t -64.24 144.35 57.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.737 -1.449 . . . . 0.0 109.635 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.511 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -138.54 174.15 4.52 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.332 -0.855 . . . . 0.0 109.561 -179.907 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.57 ' O ' ' N ' ' A' ' 72' ' ' LEU . 50.0 Cg_endo -69.89 -28.84 24.11 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.837 2.358 . . . . 0.0 112.072 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -116.35 6.22 13.68 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.087 -1.008 . . . . 0.0 109.045 179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.439 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 5.9 mtpm? -142.29 133.4 26.04 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.24 40.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.084 -1.01 . . . . 0.0 109.51 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.548 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 46.3 t -118.49 124.57 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.193 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.585 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.1 mt -145.19 146.22 31.65 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.014 -1.054 . . . . 0.0 110.37 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -86.04 138.19 32.14 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.623 HG22 ' CZ ' ' A' ' 80' ' ' PHE . 57.8 mt -123.39 132.27 71.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.817 -1.177 . . . . 0.0 110.644 -178.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 59.5 mttm -109.85 118.07 35.51 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 178.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.584 ' CE1' HG11 ' A' ' 13' ' ' VAL . 73.1 t80 -121.69 109.04 14.25 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.505 -0.747 . . . . 0.0 109.619 -179.038 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 83.5 m -111.45 116.11 30.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.272 -0.892 . . . . 0.0 109.562 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.543 ' HD3' ' CB ' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -141.83 121.61 8.19 Favored Pre-proline 0 N--CA 1.488 1.473 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.812 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.7 117.6 5.18 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.458 2.105 . . . . 0.0 112.014 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.74 -11.31 68.28 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.543 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.27 -179.94 6.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.894 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.528 ' O ' ' HA ' ' A' ' 82' ' ' SER . 15.4 m -155.68 162.96 40.48 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.356 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.483 HD11 HG22 ' A' ' 44' ' ' VAL . 17.5 tp -70.5 127.91 34.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.266 -0.896 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.548 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.52 -41.65 3.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.218 -0.926 . . . . 0.0 109.734 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -147.15 155.11 41.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.169 -0.957 . . . . 0.0 110.176 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.569 HG22 ' CD2' ' A' ' 80' ' ' PHE . 21.4 t -142.39 141.15 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.442 -0.786 . . . . 0.0 109.33 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.455 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 88.6 mt-10 -127.61 150.52 49.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.767 -1.208 . . . . 0.0 109.434 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.588 HD11 ' CZ ' ' A' ' 78' ' ' PHE . 21.7 tp -122.2 144.21 49.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.408 -178.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.617 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.1 OUTLIER -126.17 127.85 46.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.383 -0.823 . . . . 0.0 109.012 179.243 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.474 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 74.0 mt-30 -71.06 149.77 46.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 109.315 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.584 ' CD2' ' HD2' ' A' ' 75' ' ' PRO . 47.3 t60 -64.84 109.03 1.93 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.559 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.37 2.99 24.41 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.492 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 18.1 t -114.91 154.97 27.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.013 -1.287 . . . . 0.0 109.566 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.429 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 54.7 mp0 -112.02 -12.27 13.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.187 -0.946 . . . . 0.0 109.313 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -95.43 99.7 11.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.323 -0.861 . . . . 0.0 109.559 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.617 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 24.9 m95 -59.32 141.5 54.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.302 -0.874 . . . . 0.0 109.707 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -106.63 137.0 19.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.502 -0.749 . . . . 0.0 109.599 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.455 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 53.1 Cg_endo -72.46 144.41 40.55 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.592 2.195 . . . . 0.0 111.776 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.607 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 7.5 mp -106.95 146.37 31.14 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.17 -0.956 . . . . 0.0 108.863 179.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 88.4 m -103.11 126.22 50.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.936 -1.103 . . . . 0.0 108.905 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 9.4 tttm -68.82 112.81 5.76 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.189 -0.944 . . . . 0.0 108.904 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mttm -120.07 80.37 1.59 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.004 -1.06 . . . . 0.0 110.702 -178.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.31 60.39 1.31 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.369 179.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 60.03 10.37 2.18 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.148 -1.207 . . . . 0.0 110.16 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 59' ' ' LYS . 13.6 m -129.51 -172.64 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.161 -0.962 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.441 ' HB2' HD12 ' A' ' 32' ' ' ILE . 78.4 m95 -139.13 125.52 20.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.924 . . . . 0.0 109.553 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.514 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 27.0 mt-10 -115.08 152.08 33.14 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.856 . . . . 0.0 109.596 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.607 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 3.1 p -138.22 134.91 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.439 -0.788 . . . . 0.0 109.304 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.439 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 26.5 mttp -120.89 133.99 55.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.346 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.474 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 9.5 t -120.66 126.84 51.26 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.37 -0.831 . . . . 0.0 109.308 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' SER . 73.4 p -45.28 -26.69 0.54 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.007 -1.058 . . . . 0.0 108.514 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.562 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -115.26 178.33 0.99 Allowed Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.1 Cg_endo -67.81 178.94 2.98 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.332 2.022 . . . . 0.0 111.846 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 25' ' ' PRO . 0.9 OUTLIER -112.09 143.48 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.199 -0.938 . . . . 0.0 109.786 -179.577 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 6.4 t -120.8 123.71 70.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.367 -0.833 . . . . 0.0 109.31 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.432 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -92.41 166.21 29.24 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.599 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.4 Cg_endo -69.62 146.76 82.78 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.783 -1.757 . . . . 0.0 112.082 0.045 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.563 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 72.1 m-85 -91.54 153.6 19.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.627 -0.671 . . . . 0.0 110.494 -179.249 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.529 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 1.8 m-80 -112.5 141.03 46.73 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CZ ' HD11 ' A' ' 46' ' ' LEU . 84.4 m-85 -132.27 128.41 37.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.997 -1.065 . . . . 0.0 109.894 -179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.447 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 16.3 ttt180 -112.41 143.68 43.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.019 -1.051 . . . . 0.0 108.732 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.623 ' CZ ' HG22 ' A' ' 32' ' ' ILE . 24.5 m-85 -125.37 144.42 50.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.269 -0.894 . . . . 0.0 111.611 -177.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.623 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.8 ttt -127.15 126.19 42.47 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.528 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.8 p -79.06 148.87 32.31 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.284 -0.885 . . . . 0.0 110.18 -178.402 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.548 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 23.3 mttt -47.0 -46.51 21.76 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.244 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.43 ' HA3' ' OD1' ' A' ' 39' ' ' ASP . . . -59.83 -8.48 8.0 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.3 34.13 5.44 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 51.6 mmm -102.97 109.18 20.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.107 -1.231 . . . . 0.0 109.065 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.623 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 87.7 mtm-85 -91.48 141.52 28.65 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.125 -0.984 . . . . 0.0 110.704 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.565 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.1 m120 -135.88 140.08 43.85 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 4.5 t -120.57 136.48 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.022 -1.049 . . . . 0.0 110.358 -178.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.515 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 31.6 m-85 -125.96 122.23 35.35 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -98.17 147.33 24.7 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.946 . . . . 0.0 109.655 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 41.3 mt-10 53.31 52.88 12.67 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.346 -0.846 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 40.2 t -82.94 -34.35 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.986 -1.071 . . . . 0.0 109.3 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.421 HG23 HD13 ' A' ' 94' ' ' ILE . 65.8 mt -136.83 125.15 14.89 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.347 -0.845 . . . . 0.0 109.134 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.08 162.58 41.16 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.548 2.165 . . . . 0.0 111.887 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 m -52.87 -37.11 59.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.469 -0.77 . . . . 0.0 110.016 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.74 98.34 9.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.029 -1.044 . . . . 0.0 109.717 -179.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.575 ' CE1' ' OG ' ' A' ' 23' ' ' SER . 35.4 p90 -107.0 146.61 30.89 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.125 -0.985 . . . . 0.0 109.366 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.2 m -114.53 118.37 33.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.918 . . . . 0.0 109.554 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.557 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 4.8 mt -56.76 139.37 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.392 -0.817 . . . . 0.0 109.721 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.08 5.52 54.68 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 26.4 tttt -124.13 143.46 50.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.991 -1.299 . . . . 0.0 109.379 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.4 m -78.11 158.77 28.99 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.187 -0.946 . . . . 0.0 108.908 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.8 m-85 -146.58 97.49 2.93 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.491 -1.381 . . . . 0.0 108.953 179.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.54 157.9 32.81 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 110.059 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.515 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.7 Cg_endo -70.72 174.58 10.13 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.825 2.35 . . . . 0.0 111.822 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.406 ' O ' ' CB ' ' A' ' 108' ' ' GLU . 96.8 mt-10 -87.51 161.11 17.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.527 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 107' ' ' GLU . 36.7 tt0 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.415 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 25.9 mtm180 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 121.283 0.563 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.33 -48.25 2.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 92.1 p -126.61 131.2 51.55 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.468 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -56.49 -43.56 79.81 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.288 -0.883 . . . . 0.0 109.56 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.566 ' HB2' ' CE1' ' A' ' 7' ' ' HIS . 48.4 m80 -126.04 175.21 7.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.292 -0.88 . . . . 0.0 109.529 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -84.72 -15.44 45.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.566 ' CE1' ' HB2' ' A' ' 5' ' ' HIS . 2.2 p-80 -56.87 121.94 11.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.294 -0.879 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 9' ' ' HIS . 88.1 m-70 -90.37 -10.4 44.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.267 -0.895 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER -55.05 -167.02 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.32 -0.862 . . . . 0.0 109.547 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.469 ' O ' ' HG3' ' A' ' 37' ' ' PRO . . . 97.15 0.39 59.92 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -93.63 18.72 9.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.47 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -82.94 149.13 27.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.334 -0.854 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.592 HG13 ' CZ ' ' A' ' 34' ' ' TYR . 4.2 t -127.23 137.25 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.848 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 82.7 mt-30 -106.99 120.84 43.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.183 -0.948 . . . . 0.0 109.172 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.559 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.4 p -129.57 141.65 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.253 -0.904 . . . . 0.0 109.747 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.474 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 60.5 p -140.77 144.6 35.57 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.071 -1.018 . . . . 0.0 109.481 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 104' ' ' TYR . 49.7 m-85 -114.24 147.41 39.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.246 -0.909 . . . . 0.0 109.253 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 29.1 m -145.98 127.34 14.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.994 -1.066 . . . . 0.0 109.483 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.542 ' CG2' HD23 ' A' ' 30' ' ' LEU . 3.8 t -75.88 136.52 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.392 -0.818 . . . . 0.0 109.209 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.16 158.22 19.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.985 -1.072 . . . . 0.0 109.835 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -51.43 113.11 0.87 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.865 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.77 -6.91 2.68 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.516 179.384 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.523 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 10.8 m -57.46 143.51 40.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.892 -1.358 . . . . 0.0 109.39 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.508 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.69 171.45 8.83 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.707 -179.818 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 72' ' ' LEU . 51.3 Cg_endo -70.22 -31.27 18.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.861 2.374 . . . . 0.0 111.891 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.451 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 2.5 pttt -112.82 7.27 18.38 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.222 -0.923 . . . . 0.0 108.938 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.465 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 29.8 mttm -141.83 132.93 26.18 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.57 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.1 121.48 37.97 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.999 -1.063 . . . . 0.0 109.406 -179.87 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.54 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 11.9 t -119.72 125.69 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.57 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.2 mt -145.27 145.37 31.24 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.983 -1.073 . . . . 0.0 110.024 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -84.54 137.57 33.25 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.561 HG21 ' CZ ' ' A' ' 80' ' ' PHE . 53.9 mt -120.49 130.09 74.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.752 -1.217 . . . . 0.0 110.557 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.7 tttt -110.36 119.57 39.64 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.472 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.592 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 66.2 t80 -121.85 121.01 36.19 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.563 -0.711 . . . . 0.0 109.259 -179.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.7 m -122.75 115.82 22.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.128 -0.983 . . . . 0.0 110.162 -179.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.54 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 20.5 ttt85 -135.64 137.48 25.92 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.534 -0.729 . . . . 0.0 109.065 179.434 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.469 ' HG3' ' O ' ' A' ' 10' ' ' GLY . 48.5 Cg_endo -69.66 99.4 0.73 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.648 2.232 . . . . 0.0 111.904 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.14 -38.0 3.25 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.54 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 53.5 m-20 -96.28 176.16 6.17 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.228 -1.16 . . . . 0.0 109.798 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -154.74 162.22 41.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.378 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.592 HD23 ' CE2' ' A' ' 80' ' ' PHE . 31.8 tp -68.11 128.74 37.66 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.061 -1.024 . . . . 0.0 109.109 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.567 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.37 -45.0 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.132 -0.98 . . . . 0.0 110.274 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.457 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 81.5 mt-10 -135.55 144.56 46.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.043 -1.036 . . . . 0.0 110.392 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.546 ' CG2' HD13 ' A' ' 41' ' ' LEU . 99.7 t -137.97 135.59 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.474 -0.766 . . . . 0.0 109.147 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -127.91 150.03 50.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.964 -1.085 . . . . 0.0 109.162 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.573 HD11 ' CZ ' ' A' ' 78' ' ' PHE . 13.5 tp -121.38 133.2 55.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.798 . . . . 0.0 110.176 -178.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.518 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 40.8 ttp180 -119.46 129.04 54.55 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 108.788 179.134 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 55.0 mt-30 -71.01 160.74 32.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.276 -0.89 . . . . 0.0 110.161 -179.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.517 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.8 t60 -70.59 145.66 50.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.42 -0.8 . . . . 0.0 109.438 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.54 2.66 44.43 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.457 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.8 t -112.83 154.25 26.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.102 -1.234 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -121.17 14.18 11.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.889 . . . . 0.0 109.417 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -111.66 98.66 7.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.344 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.518 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 65.4 m95 -59.88 134.38 56.98 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.281 -0.887 . . . . 0.0 109.737 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -111.54 130.93 22.61 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.468 -0.77 . . . . 0.0 109.095 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 141.53 46.06 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.502 2.135 . . . . 0.0 111.978 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.589 ' CD1' ' N ' ' A' ' 57' ' ' LEU . 5.9 mp -97.16 143.06 28.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 108.534 179.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -81.38 125.91 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.902 -1.123 . . . . 0.0 109.13 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -72.22 108.22 5.27 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.16 -0.962 . . . . 0.0 109.379 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.449 ' O ' ' C ' ' A' ' 61' ' ' GLY . 22.7 mttm -113.76 132.78 55.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.995 -1.065 . . . . 0.0 109.469 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 60' ' ' LYS . . . 43.17 -100.24 0.02 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.443 ' N ' ' O ' ' A' ' 60' ' ' LYS . 23.9 p-10 -130.5 24.98 5.12 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -1.148 . . . . 0.0 109.187 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.49 ' C ' ' CD1' ' A' ' 64' ' ' TRP . 35.9 m -131.62 -170.08 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.568 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.537 ' CD1' HD12 ' A' ' 32' ' ' ILE . 44.6 m95 -140.99 124.69 16.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.03 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.534 ' HG3' ' CG2' ' A' ' 29' ' ' VAL . 69.8 tt0 -115.36 151.96 33.69 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 109.71 -179.66 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.519 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.0 p -141.19 138.46 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.367 -0.833 . . . . 0.0 109.191 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.447 ' CD ' ' HD3' ' A' ' 27' ' ' LYS . 84.4 mttt -122.14 134.78 54.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.278 -0.889 . . . . 0.0 109.6 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' SER . 8.8 t -120.18 126.21 50.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.343 -0.848 . . . . 0.0 109.188 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 68' ' ' SER . 6.0 m -44.1 -29.03 0.55 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.084 -1.01 . . . . 0.0 108.83 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -112.55 178.35 0.99 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.431 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.8 Cg_endo -68.79 166.34 26.59 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.382 2.055 . . . . 0.0 111.618 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.567 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.8 mt -97.34 143.29 28.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.117 -0.989 . . . . 0.0 109.816 -179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.89 124.79 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.81 . . . . 0.0 109.307 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -95.51 169.09 27.15 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.586 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.5 Cg_endo -67.99 146.34 77.5 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.838 -1.734 . . . . 0.0 111.85 0.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.567 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 74.2 m-85 -91.34 149.84 21.56 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.532 -0.73 . . . . 0.0 110.37 -179.09 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.528 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 18.9 m-80 -111.99 143.67 42.6 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 179.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CZ ' HD11 ' A' ' 46' ' ' LEU . 96.1 m-85 -134.84 120.36 19.24 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.056 -1.028 . . . . 0.0 109.515 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.475 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 63.3 ttt180 -100.55 141.94 32.7 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.955 -1.091 . . . . 0.0 108.653 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.592 ' CE2' HD23 ' A' ' 41' ' ' LEU . 7.3 m-85 -124.96 142.95 51.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.907 . . . . 0.0 111.317 -178.256 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.518 ' HE2' ' CG ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.67 124.2 41.68 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.157 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.615 ' N ' ' O ' ' A' ' 86' ' ' MET . 13.6 p -72.16 144.85 48.43 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.408 -0.808 . . . . 0.0 110.097 -178.463 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.567 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 0.2 OUTLIER -50.24 -44.45 53.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -0.917 . . . . 0.0 108.777 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.04 -2.18 0.19 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.32 25.7 18.11 Favored Glycine 0 N--CA 1.491 2.35 0 O-C-N 121.068 -1.254 . . . . 0.0 109.978 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.615 ' O ' ' N ' ' A' ' 82' ' ' SER . 39.2 mtp -100.85 149.06 24.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.109 -1.23 . . . . 0.0 108.864 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.518 ' CG ' ' HE2' ' A' ' 81' ' ' MET . 7.6 mtt85 -120.15 135.97 54.78 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.332 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -134.57 139.91 45.72 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.475 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -123.1 136.2 60.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.043 -1.036 . . . . 0.0 110.294 -178.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.653 ' CG ' ' CB ' ' A' ' 106' ' ' PRO . 11.3 m-85 -122.45 121.04 35.67 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.59 147.62 24.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.21 -0.931 . . . . 0.0 109.707 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.586 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 48.2 mt-10 53.69 49.64 18.86 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.412 -0.805 . . . . 0.0 110.2 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.442 HG22 ' HA ' ' A' ' 106' ' ' PRO . 54.3 t -77.91 -33.71 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.867 -1.146 . . . . 0.0 108.885 179.333 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 69.8 mt -138.83 124.71 12.33 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.321 -0.862 . . . . 0.0 108.959 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -67.72 162.83 37.69 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.647 2.232 . . . . 0.0 112.161 -179.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.486 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 8.1 m -50.56 -43.87 56.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.41 -0.806 . . . . 0.0 109.829 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.03 103.77 15.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.039 -1.038 . . . . 0.0 109.528 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -111.25 158.86 18.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 109.157 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.4 m -107.92 172.48 6.81 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.256 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.6 mm -104.56 135.93 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.877 . . . . 0.0 109.253 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.75 6.77 58.1 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -117.08 141.74 47.88 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.064 -1.256 . . . . 0.0 109.337 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.451 HG21 ' O ' ' A' ' 17' ' ' PHE . 34.5 m -81.95 170.1 16.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.09 -1.007 . . . . 0.0 109.026 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.575 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.4 m-85 -151.23 99.37 2.65 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.771 -1.205 . . . . 0.0 109.261 179.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.545 ' HG2' ' O ' ' A' ' 15' ' ' VAL . 1.9 mtmt -84.43 148.95 53.75 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.467 -0.77 . . . . 0.0 109.66 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.653 ' CB ' ' CG ' ' A' ' 90' ' ' PHE . 51.1 Cg_endo -72.22 120.4 6.76 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.254 1.969 . . . . 0.0 111.569 179.635 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.16 -76.83 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.242 -0.911 . . . . 0.0 109.584 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.522 -179.915 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 29.8 mtm180 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.17 138.32 45.73 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.3 t -80.41 152.37 28.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -1.169 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 37.3 p-80 -117.62 8.19 12.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 36.0 t60 -53.75 -48.85 69.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.189 -0.945 . . . . 0.0 109.427 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 63.9 m80 -55.1 -29.32 57.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.423 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.543 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 74.1 t60 -113.76 22.0 14.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.447 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -98.29 144.53 27.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.922 . . . . 0.0 109.505 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -138.97 168.6 19.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.891 . . . . 0.0 109.499 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.35 169.76 39.28 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HB3' ' A' ' 12' ' ' ALA . 69.0 m -100.9 151.09 22.15 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.262 -1.14 . . . . 0.0 109.328 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 11' ' ' SER . . . 177.81 -142.3 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.195 -0.941 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.517 ' CG2' ' HG3' ' A' ' 36' ' ' ARG . 17.1 t -123.89 132.76 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 108.855 179.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.439 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 36.1 mt-30 -109.31 121.35 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.094 -1.004 . . . . 0.0 109.814 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.536 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 9.5 p -128.87 140.39 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.35 -0.844 . . . . 0.0 109.439 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.462 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 27.9 p -142.08 146.16 35.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.06 -1.025 . . . . 0.0 109.606 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.0 m-85 -118.51 143.68 46.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.581 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.442 ' CG2' ' O ' ' A' ' 102' ' ' LYS . 69.0 m -139.67 129.05 24.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.067 -1.02 . . . . 0.0 109.245 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.515 ' CG2' HD23 ' A' ' 30' ' ' LEU . 42.6 t -75.91 132.67 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.225 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -105.17 159.78 15.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.109 -0.994 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -54.35 115.22 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.388 -0.82 . . . . 0.0 109.782 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 24' ' ' ASP . . . 139.5 -0.59 2.24 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.279 179.476 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.432 ' C ' ' OD1' ' A' ' 24' ' ' ASP . 34.1 t -66.85 142.17 57.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.976 -1.308 . . . . 0.0 109.394 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.6 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -134.56 174.48 4.59 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.205 -0.935 . . . . 0.0 109.31 -179.833 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.6 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 49.3 Cg_endo -70.36 -28.71 22.05 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.612 2.208 . . . . 0.0 111.985 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.3 mttm -114.51 9.37 16.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.935 . . . . 0.0 109.127 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.484 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 31.9 mttt -142.98 133.47 24.91 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.5 122.5 39.86 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.997 -1.064 . . . . 0.0 109.571 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.558 ' N ' ' CD1' ' A' ' 28' ' ' LEU . 22.2 t -120.2 125.6 74.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -144.89 145.69 31.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.883 -1.136 . . . . 0.0 110.248 -179.419 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.447 ' OD1' HG12 ' A' ' 63' ' ' VAL . 17.9 t70 -86.22 138.52 31.81 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.607 HG23 ' CZ ' ' A' ' 80' ' ' PHE . 70.5 mt -120.2 130.34 74.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.859 -178.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 25.1 tptt -110.55 120.26 41.83 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.115 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.501 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 79.6 t80 -121.77 123.64 42.31 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.395 -0.815 . . . . 0.0 109.915 -178.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.454 ' O ' HG12 ' A' ' 13' ' ' VAL . 56.8 m -125.11 115.13 19.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 109.484 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.538 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 29.8 ttt85 -139.79 135.37 16.6 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.448 -0.782 . . . . 0.0 109.199 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.443 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.8 Cg_endo -70.96 108.01 2.21 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.778 2.318 . . . . 0.0 112.182 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.02 -1.9 86.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.538 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.8 m-20 -134.36 173.92 11.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.075 -1.25 . . . . 0.0 109.655 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -153.45 160.85 42.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.536 HD12 ' CD2' ' A' ' 80' ' ' PHE . 7.8 tp -68.65 123.3 20.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.913 . . . . 0.0 109.212 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.563 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.36 -44.89 2.95 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.45 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 69.5 mt-10 -135.18 144.46 47.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.162 -0.961 . . . . 0.0 110.217 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 80' ' ' PHE . 12.6 t -138.36 135.96 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.445 -0.784 . . . . 0.0 109.273 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.418 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 85.0 mt-10 -128.96 150.02 50.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.878 -1.139 . . . . 0.0 109.537 179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.601 HD13 ' CZ ' ' A' ' 78' ' ' PHE . 6.7 tt -119.2 143.3 47.34 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.453 -0.779 . . . . 0.0 109.857 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.52 ' N ' HD23 ' A' ' 46' ' ' LEU . 35.8 ttp180 -131.33 126.36 35.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 108.821 179.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -66.39 156.11 35.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.159 -179.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.576 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 8.3 t-80 -71.9 117.15 13.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 109.629 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 103.53 4.07 46.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.488 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 10.1 t -114.37 159.82 19.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.28 -1.13 . . . . 0.0 109.342 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.65 14.97 9.46 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -116.36 91.45 3.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.443 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -52.79 134.37 36.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -106.78 135.16 19.57 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.313 -0.867 . . . . 0.0 109.434 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.418 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 49.5 Cg_endo -70.15 145.78 55.84 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.677 2.251 . . . . 0.0 111.733 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.562 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -110.41 150.78 28.33 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.168 -0.958 . . . . 0.0 109.052 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 m -102.36 126.74 49.47 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.993 -1.067 . . . . 0.0 109.141 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.7 tttt -77.46 101.56 6.48 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.071 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.565 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.7 mttt -115.4 150.39 36.46 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.866 -1.146 . . . . 0.0 110.083 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 43.38 32.23 1.75 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 1.5 m120 76.79 12.73 2.34 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.244 . . . . 0.0 110.126 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 3.0 m -130.17 176.9 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.136 -0.978 . . . . 0.0 108.805 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 64' ' ' TRP . 37.8 m95 -120.5 144.35 48.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.926 -1.108 . . . . 0.0 109.796 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -136.5 151.97 50.01 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.376 -0.827 . . . . 0.0 109.445 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.562 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.8 p -137.11 133.77 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.387 -0.821 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.441 ' HD3' ' NZ ' ' A' ' 27' ' ' LYS . 21.4 mttt -119.72 131.21 55.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.934 . . . . 0.0 109.398 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t -118.24 165.96 13.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.381 -0.824 . . . . 0.0 109.522 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 50.2 m -88.74 2.98 52.47 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.249 -0.907 . . . . 0.0 109.052 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.539 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.2 OUTLIER -142.14 176.78 2.18 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.476 -0.765 . . . . 0.0 109.18 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.539 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.5 Cg_endo -68.55 139.31 44.37 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.506 2.137 . . . . 0.0 111.721 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.55 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 8.8 mt -73.88 143.08 45.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.261 -0.899 . . . . 0.0 109.627 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.424 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 31.2 t -119.42 123.3 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.249 -0.907 . . . . 0.0 109.31 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.532 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -92.05 164.7 28.76 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.678 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.55 147.87 85.07 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.775 -1.761 . . . . 0.0 112.035 -0.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.55 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 58.9 m-85 -89.52 151.1 22.15 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.505 -0.747 . . . . 0.0 110.149 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.421 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 39.2 m-80 -112.68 142.9 44.75 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.823 . . . . 0.0 109.051 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.601 ' CZ ' HD13 ' A' ' 46' ' ' LEU . 89.9 m-85 -135.12 123.5 23.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 109.773 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.535 ' HG3' ' CG2' ' A' ' 89' ' ' VAL . 38.4 ttt180 -103.86 141.69 35.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.985 -1.072 . . . . 0.0 108.514 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.607 ' CZ ' HG23 ' A' ' 32' ' ' ILE . 13.3 m-85 -125.17 142.8 51.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 111.497 -178.06 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.531 ' HE1' ' CG ' ' A' ' 87' ' ' ARG . 3.5 ttm -124.46 123.75 40.82 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.621 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.6 p -70.45 143.45 51.78 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.367 -0.833 . . . . 0.0 110.302 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.563 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -48.39 -45.2 35.57 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.356 -0.84 . . . . 0.0 108.83 178.924 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.42 -2.13 0.25 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.34 24.99 20.28 Favored Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.083 -1.246 . . . . 0.0 110.025 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.621 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.6 mmm -98.95 149.17 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.011 -1.288 . . . . 0.0 108.786 179.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.531 ' CG ' ' HE1' ' A' ' 81' ' ' MET . 19.6 mtm105 -120.33 135.81 54.9 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.969 -1.082 . . . . 0.0 110.401 -179.013 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -134.32 139.44 45.67 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.535 ' CG2' ' HG3' ' A' ' 79' ' ' ARG . 6.7 t -122.82 136.42 59.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.112 -0.992 . . . . 0.0 110.316 -179.026 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.45 ' CE2' HG13 ' A' ' 15' ' ' VAL . 27.7 m-85 -123.28 121.83 36.85 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.517 -0.919 . . . . 0.0 108.517 179.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -99.35 147.49 25.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.272 -0.893 . . . . 0.0 109.643 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.678 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 25.7 mt-10 53.48 52.2 13.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.392 -0.818 . . . . 0.0 110.201 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.3 t -83.04 -34.87 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 120.889 -1.132 . . . . 0.0 109.085 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -133.63 123.78 17.54 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.334 -0.854 . . . . 0.0 109.197 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.33 161.74 44.92 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.549 2.166 . . . . 0.0 111.79 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.532 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 32.6 m -54.29 -36.07 63.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.414 -0.804 . . . . 0.0 110.055 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.43 79.19 5.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.936 -1.102 . . . . 0.0 109.702 -179.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -89.02 145.05 25.73 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.314 -0.866 . . . . 0.0 109.408 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.59 116.48 26.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.321 -0.862 . . . . 0.0 109.67 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.506 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 11.1 mt -56.82 139.95 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.292 -0.88 . . . . 0.0 109.656 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.479 ' N ' HG22 ' A' ' 100' ' ' ILE . . . 100.14 5.95 54.17 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.442 ' O ' ' CG2' ' A' ' 18' ' ' THR . 20.3 mttm -120.23 -165.82 1.23 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.009 -1.289 . . . . 0.0 109.183 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.464 HG23 ' O ' ' A' ' 17' ' ' PHE . 8.7 m -131.06 165.22 23.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.07 -1.019 . . . . 0.0 108.517 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.7 m-85 -155.53 93.45 1.49 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.428 -1.42 . . . . 0.0 109.169 179.138 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.542 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 6.8 pttm -105.11 164.43 15.14 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.409 -0.807 . . . . 0.0 109.393 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.542 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 50.2 Cg_endo -71.28 147.72 53.89 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.494 2.129 . . . . 0.0 111.739 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 107' ' ' GLU . 69.5 mm-40 -91.93 145.67 24.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.212 -0.93 . . . . 0.0 109.458 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.457 179.961 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -51.8 114.1 2.9 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.99 -44.11 96.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.231 -1.158 . . . . 0.0 109.433 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . 0.437 ' HA ' ' HB2' ' A' ' 7' ' ' HIS . 1.6 m80 -54.41 -33.15 58.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 69.6 t60 -54.49 -33.38 59.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.396 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -98.74 -34.7 10.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.313 -0.867 . . . . 0.0 109.465 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.437 ' HB2' ' HA ' ' A' ' 4' ' ' HIS . 65.6 m-70 -65.9 -38.32 88.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.951 . . . . 0.0 109.478 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.5 m-70 -119.04 140.27 50.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.382 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -103.66 -7.43 20.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.567 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 72.57 -167.27 53.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.9 t -103.14 153.68 20.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.233 -1.157 . . . . 0.0 109.527 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -137.46 138.92 40.26 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.396 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.451 HG22 ' HG3' ' A' ' 36' ' ' ARG . 20.1 t -124.35 129.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.286 -0.884 . . . . 0.0 109.655 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -111.65 121.37 44.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.157 -0.964 . . . . 0.0 109.313 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.2 t -128.16 138.09 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.814 -179.614 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.1 p -142.17 146.21 35.04 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.352 -0.842 . . . . 0.0 109.32 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.594 ' O ' ' N ' ' A' ' 104' ' ' TYR . 34.1 m-85 -118.31 142.42 47.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.673 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 61.1 m -138.18 129.2 27.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.058 -1.027 . . . . 0.0 109.329 179.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.517 ' CG1' HD12 ' A' ' 100' ' ' ILE . 24.0 t -77.29 138.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.882 . . . . 0.0 109.39 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -106.15 -177.11 3.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.107 -0.995 . . . . 0.0 109.508 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 43.0 mttt -77.67 110.29 12.38 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.369 -0.832 . . . . 0.0 109.698 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.61 -0.32 1.66 Allowed Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.558 -1.306 . . . . 0.0 110.481 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.572 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.0 t -56.4 144.82 29.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.875 -1.368 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.518 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -136.5 168.99 14.62 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.167 -0.958 . . . . 0.0 109.636 -179.833 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.491 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 48.3 Cg_endo -69.76 -27.64 26.24 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.854 2.369 . . . . 0.0 111.859 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -114.65 8.61 16.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.164 -0.96 . . . . 0.0 109.01 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 56.4 mttp -143.99 134.15 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 108.98 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.593 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.91 123.02 40.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.927 -1.108 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.548 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 5.0 t -120.36 126.07 74.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.593 ' CD1' ' CD1' ' A' ' 28' ' ' LEU . 1.1 mt -145.35 145.48 31.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.842 -1.161 . . . . 0.0 110.2 -179.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.437 ' HA ' HG13 ' A' ' 63' ' ' VAL . 64.2 t0 -83.88 135.01 34.66 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 178.044 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.599 HG22 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -115.53 127.07 73.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.779 -1.201 . . . . 0.0 111.154 -178.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 10.2 ttpt -108.12 115.19 29.67 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 177.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.49 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 76.7 t80 -124.05 108.16 12.06 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.682 -0.637 . . . . 0.0 109.84 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.0 m -109.6 117.56 34.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.351 -0.843 . . . . 0.0 109.446 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.512 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 9.4 ttt85 -144.65 114.49 5.14 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.405 -0.81 . . . . 0.0 109.354 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.41 120.7 7.5 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.704 2.269 . . . . 0.0 111.809 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.06 -19.54 54.38 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 5.0 m-20 -140.75 -179.09 5.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -1.126 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m -155.75 162.86 40.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.86 . . . . 0.0 109.535 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.545 HD21 ' CE2' ' A' ' 80' ' ' PHE . 25.1 tp -69.97 129.19 38.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.294 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.573 ' CB ' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.12 3.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -138.95 147.6 42.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.189 -0.944 . . . . 0.0 110.246 -179.543 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' CG2' HD21 ' A' ' 41' ' ' LEU . 77.6 t -138.18 136.01 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.558 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.3 mt-10 -129.76 151.63 50.13 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.88 -1.137 . . . . 0.0 109.775 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.582 HD12 ' CZ ' ' A' ' 78' ' ' PHE . 6.9 tt -120.99 140.23 52.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 109.636 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.601 ' HD3' ' CD1' ' A' ' 54' ' ' TRP . 17.8 ttp180 -125.73 128.13 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.135 179.301 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -69.58 145.5 52.51 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.594 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' HIS . . . . . 0.592 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 22.4 t60 -63.85 113.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.842 . . . . 0.0 109.421 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.78 1.97 30.49 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.435 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 29.1 t -114.02 154.92 26.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.241 . . . . 0.0 109.418 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -118.25 22.35 12.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.444 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 83.0 mt-10 -127.43 81.2 2.0 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.535 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.601 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 43.8 m95 -43.38 136.53 3.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -0.907 . . . . 0.0 109.698 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -104.91 138.48 19.52 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.84 . . . . 0.0 109.311 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.74 147.84 51.43 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.649 2.233 . . . . 0.0 112.113 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.598 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -111.48 155.78 22.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 108.958 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 m -109.7 127.14 54.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.813 -1.179 . . . . 0.0 109.078 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 41.6 tttm -71.72 110.64 6.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.145 -0.972 . . . . 0.0 109.344 -179.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.587 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.8 mttt -119.63 141.1 49.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.815 -1.178 . . . . 0.0 109.812 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.584 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.52 31.08 0.97 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.584 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER 81.88 15.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.306 -1.114 . . . . 0.0 110.362 179.292 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.587 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 27.1 m -129.86 173.42 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.986 -1.071 . . . . 0.0 108.838 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 69.3 m95 -118.96 122.75 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.875 -1.141 . . . . 0.0 109.666 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.467 ' HG2' HG11 ' A' ' 29' ' ' VAL . 5.5 mt-10 -115.88 153.71 31.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.438 -0.789 . . . . 0.0 109.511 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.598 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.9 p -138.73 135.57 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.486 -0.759 . . . . 0.0 109.432 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.3 mttm -119.8 131.36 55.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -118.41 160.28 21.98 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.466 -0.771 . . . . 0.0 109.25 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 71.1 m -80.25 -13.87 58.87 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.145 -0.972 . . . . 0.0 109.148 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.538 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.0 OUTLIER -124.09 177.2 1.85 Allowed Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.369 -0.832 . . . . 0.0 109.031 179.791 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.538 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.5 Cg_endo -69.41 138.84 39.93 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.42 2.08 . . . . 0.0 111.678 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.608 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.2 mt -69.9 140.38 53.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.328 -0.858 . . . . 0.0 109.858 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.1 t -121.55 124.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.416 -0.803 . . . . 0.0 109.213 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.444 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.52 168.64 28.17 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.592 ' O ' ' HB2' ' A' ' 49' ' ' HIS . 49.3 Cg_endo -69.08 146.1 79.78 Favored 'Cis proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.822 -1.741 . . . . 0.0 112.025 -0.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.608 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 73.0 m-85 -91.14 147.76 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -0.832 . . . . 0.0 110.422 -179.179 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.404 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 30.2 m-80 -108.38 142.88 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.414 -0.804 . . . . 0.0 108.91 179.103 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CZ ' HD12 ' A' ' 46' ' ' LEU . 89.1 m-85 -133.93 122.29 22.91 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.041 -1.037 . . . . 0.0 109.77 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -106.33 144.1 33.5 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.089 -1.007 . . . . 0.0 108.937 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.599 ' CE2' HG22 ' A' ' 32' ' ' ILE . 8.3 m-85 -124.69 142.76 51.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.14 -0.975 . . . . 0.0 111.502 -178.142 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.565 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.8 ttt -125.13 124.78 42.55 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' SER . . . . . 0.662 ' N ' ' O ' ' A' ' 86' ' ' MET . 21.0 p -73.59 144.43 45.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.325 -0.86 . . . . 0.0 110.544 -178.284 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.573 ' HA ' ' CB ' ' A' ' 42' ' ' ALA . 47.3 mttm -47.17 -45.18 22.63 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.414 -0.804 . . . . 0.0 109.033 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.64 -5.02 1.65 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 96.61 24.72 13.11 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.662 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.1 mmm -95.96 147.62 23.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.045 -1.268 . . . . 0.0 108.503 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.533 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 24.5 mtm180 -123.29 138.39 54.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.686 -1.259 . . . . 0.0 110.794 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.1 m120 -134.97 139.94 45.3 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 4.7 t -123.01 137.34 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 120.877 -1.139 . . . . 0.0 110.461 -178.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.551 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 75.1 m-85 -124.91 123.51 40.06 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -99.8 146.73 26.25 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.805 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.582 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 79.1 tt0 53.67 53.93 10.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.411 -0.806 . . . . 0.0 110.652 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 45.5 t -83.81 -33.92 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.866 -1.146 . . . . 0.0 109.04 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 12.5 mt -135.98 125.24 15.92 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.412 -0.805 . . . . 0.0 109.017 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.78 161.98 43.83 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.563 2.175 . . . . 0.0 112.101 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.444 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 23.7 m -50.49 -46.33 56.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.451 -0.781 . . . . 0.0 109.966 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.72 102.61 15.22 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.006 . . . . 0.0 109.627 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.572 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 53.7 p90 -109.85 154.36 23.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 109.353 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 73.1 p -107.97 171.96 7.1 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.517 HD12 ' CG1' ' A' ' 19' ' ' VAL . 20.9 mm -106.26 136.77 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.266 -0.897 . . . . 0.0 109.347 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 93.25 8.13 61.61 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -119.25 143.69 47.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.243 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.467 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 6.9 m -77.32 174.95 10.21 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.016 -1.052 . . . . 0.0 108.827 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.594 ' N ' ' O ' ' A' ' 17' ' ' PHE . 26.6 m-85 -159.49 94.65 1.18 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.737 -1.227 . . . . 0.0 109.165 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 11.8 mtmm -91.72 155.33 43.72 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.341 -0.849 . . . . 0.0 109.665 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.551 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 51.7 Cg_endo -71.83 52.02 1.67 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.783 2.322 . . . . 0.0 111.649 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 108' ' ' GLU . 35.7 tt0 -96.3 -51.97 4.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 107' ' ' GLU . 77.0 tt0 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.493 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.757 HG13 ' HG3' ' A' ' 36' ' ' ARG . 2.1 t . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -112.18 120.4 41.64 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.011 -1.056 . . . . 0.0 109.539 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.8 t -128.19 139.1 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.75 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.442 ' HA ' ' HG3' ' A' ' 105' ' ' LYS . 70.7 p -141.52 145.62 35.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.225 -0.922 . . . . 0.0 109.697 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.803 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.9 m-85 -117.05 128.97 55.69 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.248 -0.907 . . . . 0.0 109.786 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.462 ' O ' ' N ' ' A' ' 31' ' ' ASP . 41.3 m -128.03 128.64 45.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.162 -0.961 . . . . 0.0 109.157 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.848 HG22 HD23 ' A' ' 30' ' ' LEU . 21.3 t -76.18 139.44 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.357 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.16 157.23 21.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.117 -0.989 . . . . 0.0 109.72 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -51.3 114.39 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.444 -0.785 . . . . 0.0 109.977 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.16 -1.43 2.19 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.523 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.1 t -60.01 141.24 56.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.925 -1.338 . . . . 0.0 109.175 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.57 176.13 3.02 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.121 -0.987 . . . . 0.0 109.664 -179.639 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.6 Cg_endo -71.77 -30.56 14.19 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.606 2.204 . . . . 0.0 111.816 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.4 mttm -117.21 4.99 12.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -0.886 . . . . 0.0 109.091 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.488 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 41.6 mttt -142.17 133.43 26.28 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.15 HD12 HD13 ' A' ' 72' ' ' LEU . 0.3 OUTLIER -127.18 133.78 50.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.034 -1.042 . . . . 0.0 110.21 -179.445 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 2.8 t -122.99 124.84 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.038 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -141.16 141.31 34.13 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.034 -1.041 . . . . 0.0 110.041 -179.526 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.602 ' CB ' HG12 ' A' ' 63' ' ' VAL . 59.7 t0 -86.11 137.34 32.74 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.575 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.1 mt -122.23 131.14 73.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 120.865 -1.147 . . . . 0.0 110.523 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 66.2 mttm -110.54 120.29 41.94 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.604 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.5 t80 -122.49 114.19 20.35 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.415 -0.803 . . . . 0.0 109.541 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.9 m -116.99 117.96 31.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.784 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.757 ' HG3' HG13 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -135.22 132.0 19.9 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.432 -0.793 . . . . 0.0 109.21 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.453 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 49.9 Cg_endo -70.2 105.89 1.64 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.67 2.246 . . . . 0.0 112.078 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.93 -2.12 87.02 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.523 ' HB3' ' HD2' ' A' ' 36' ' ' ARG . 1.7 m-20 -135.44 173.7 11.43 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.114 -1.227 . . . . 0.0 109.673 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 82' ' ' SER . 20.6 m -153.89 161.34 42.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.439 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.735 HD11 ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -71.5 132.98 45.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.947 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.47 -42.47 3.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.18 -0.95 . . . . 0.0 109.499 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -142.84 151.24 40.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.065 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.735 ' CG2' HD11 ' A' ' 41' ' ' LEU . 65.1 t -139.86 137.6 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.1 mt-10 -126.22 148.73 49.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.784 -1.198 . . . . 0.0 109.432 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.017 HD13 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tp -121.44 129.58 53.07 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.491 -0.756 . . . . 0.0 110.184 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.688 ' N ' HD12 ' A' ' 46' ' ' LEU . 12.1 ttp180 -115.63 131.97 56.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.199 -0.938 . . . . 0.0 108.875 179.238 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 13.1 mt-30 -73.47 155.15 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.315 -0.865 . . . . 0.0 110.021 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.1 t60 -67.29 147.83 52.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.446 -0.783 . . . . 0.0 109.357 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.83 2.12 35.67 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 32.5 t -113.21 152.46 29.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -1.214 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -117.81 17.88 14.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -0.907 . . . . 0.0 109.316 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -116.39 104.35 11.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.58 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 45.8 m95 -66.59 134.72 52.92 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.338 -0.851 . . . . 0.0 109.673 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.486 ' HG2' ' HD2' ' A' ' 56' ' ' PRO . 0.9 OUTLIER -108.71 134.27 20.37 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.345 179.912 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.535 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.5 Cg_endo -70.45 144.51 50.53 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.625 2.217 . . . . 0.0 111.961 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.73 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -103.88 148.36 26.23 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 108.823 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 63.0 m -97.5 125.78 42.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 108.947 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 12.9 tttm -70.93 111.64 6.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.236 -0.915 . . . . 0.0 109.269 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -109.77 105.54 14.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.054 -1.029 . . . . 0.0 109.461 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.79 -96.24 0.25 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -131.04 18.83 4.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.256 -1.144 . . . . 0.0 109.451 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.602 HG12 ' CB ' ' A' ' 31' ' ' ASP . 22.5 m -132.43 177.42 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.265 -0.897 . . . . 0.0 109.437 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.572 ' CD1' HD12 ' A' ' 32' ' ' ILE . 74.5 m95 -122.58 142.67 50.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 108.961 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -129.73 145.16 51.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.805 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.977 HG11 HD23 ' A' ' 46' ' ' LEU . 3.6 p -137.62 134.11 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.351 -0.843 . . . . 0.0 109.033 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -121.17 133.4 55.19 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.227 -0.92 . . . . 0.0 109.56 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.6 t -118.04 163.88 15.94 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.445 -0.784 . . . . 0.0 109.452 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 65.1 m -87.14 -5.96 58.82 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.191 -0.943 . . . . 0.0 109.152 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.9 OUTLIER -131.99 178.44 1.75 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.385 -0.822 . . . . 0.0 109.126 179.866 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -69.18 139.52 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.395 2.063 . . . . 0.0 111.577 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.15 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -75.38 141.19 43.31 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.25 -0.906 . . . . 0.0 109.935 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 42.9 t -123.86 124.92 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.465 -0.772 . . . . 0.0 109.155 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.585 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.67 170.18 30.67 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.63 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.8 Cg_endo -69.8 147.57 85.0 Favored 'Cis proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.836 -1.735 . . . . 0.0 111.833 0.037 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.591 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.7 m-85 -91.92 151.38 20.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.473 -0.767 . . . . 0.0 110.599 -179.108 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.746 ' O ' HD12 ' A' ' 46' ' ' LEU . 34.9 m-80 -112.15 143.45 43.17 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 1.017 ' CE2' HD13 ' A' ' 46' ' ' LEU . 95.7 m-85 -136.33 130.76 33.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.947 -1.096 . . . . 0.0 109.972 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.993 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.3 ttp180 -110.31 141.49 43.25 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.058 -1.026 . . . . 0.0 108.627 179.023 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.568 ' CE2' HG21 ' A' ' 32' ' ' ILE . 5.8 m-85 -120.93 142.78 49.4 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 111.021 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.591 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -127.77 125.35 39.74 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.701 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.629 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.1 p -78.0 144.48 36.66 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 110.416 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.947 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 30.8 mttm -46.21 -43.79 15.63 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.14 -2.96 0.69 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.12 22.94 26.17 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.629 ' O ' ' N ' ' A' ' 82' ' ' SER . 1.6 mmm -96.34 146.45 24.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.123 -1.221 . . . . 0.0 108.604 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 42.8 mtm180 -124.36 141.35 52.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.826 -1.172 . . . . 0.0 110.535 -178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.432 ' N ' ' O ' ' A' ' 80' ' ' PHE . 24.2 m120 -136.48 140.91 43.41 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.993 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.0 t -121.49 135.95 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 110.354 -179.081 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.552 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 41.9 m-85 -124.59 122.53 37.81 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -99.55 148.94 23.76 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.202 -0.936 . . . . 0.0 109.753 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.63 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 10.5 mt-10 51.7 51.03 17.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.53 -0.731 . . . . 0.0 110.371 179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.803 HG11 ' CE1' ' A' ' 17' ' ' PHE . 39.7 t -82.83 -33.54 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.911 -1.118 . . . . 0.0 109.255 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 9.1 mt -131.62 124.3 19.88 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.113 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.54 161.04 46.65 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.494 2.129 . . . . 0.0 111.916 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.585 HG23 ' H ' ' A' ' 74' ' ' GLY . 7.7 m -53.54 -43.96 68.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.341 -0.849 . . . . 0.0 109.95 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.4 99.84 12.75 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.105 -0.997 . . . . 0.0 109.568 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.73 146.06 34.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.627 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 16.2 m -106.54 156.68 18.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.395 -0.816 . . . . 0.0 109.183 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.575 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.2 mm -92.21 136.39 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.134 -0.979 . . . . 0.0 109.441 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.04 2.2 62.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -115.56 143.04 45.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.174 -1.192 . . . . 0.0 109.097 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.0 m -79.7 169.66 17.65 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.068 -1.02 . . . . 0.0 108.995 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.7 m-85 -154.57 100.32 2.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.714 -1.241 . . . . 0.0 109.032 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.524 ' CD ' ' N ' ' A' ' 105' ' ' LYS . 0.5 OUTLIER -95.25 158.2 35.12 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.718 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo . . . . . 0 C--O 1.215 -0.666 0 C-N-CA 122.743 2.296 . . . . 0.0 111.808 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.734 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 16.6 t . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -110.1 120.77 43.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.363 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.517 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.4 t -127.94 138.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.346 -0.846 . . . . 0.0 109.632 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.0 p -141.53 145.83 35.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.25 -0.906 . . . . 0.0 109.418 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.621 ' CD2' HG12 ' A' ' 32' ' ' ILE . 15.0 m-85 -118.46 143.98 46.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.21 -0.931 . . . . 0.0 109.781 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 21.4 m -139.39 128.05 23.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 0.0 109.136 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.829 HG22 ' CD2' ' A' ' 30' ' ' LEU . 16.7 t -76.21 130.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -108.57 152.76 24.32 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.076 -1.015 . . . . 0.0 109.695 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -45.41 114.81 0.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.416 -0.802 . . . . 0.0 109.978 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.34 -2.92 1.84 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.834 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 34.9 m -63.71 141.09 58.89 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.703 -1.469 . . . . 0.0 109.277 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.534 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.64 175.49 3.55 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.128 -0.983 . . . . 0.0 109.593 -179.697 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.0 Cg_endo -71.54 -30.82 14.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.566 2.177 . . . . 0.0 111.845 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.2 mttp -117.33 4.78 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 0.0 109.053 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.426 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 35.4 mttp -142.27 133.64 26.42 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.074 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.12 132.25 50.63 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.948 -1.095 . . . . 0.0 110.347 -179.253 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.614 HG13 ' HG2' ' A' ' 65' ' ' GLU . 8.8 t -121.91 125.41 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.074 HD11 HD22 ' A' ' 28' ' ' LEU . 1.4 mt -141.88 141.49 33.05 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.942 -1.099 . . . . 0.0 110.142 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.438 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.0 t0 -86.36 137.56 32.48 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.396 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.742 HG21 ' CE2' ' A' ' 80' ' ' PHE . 88.2 mt -122.74 131.56 73.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 120.856 -1.153 . . . . 0.0 110.437 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 23.4 mttt -109.9 119.22 38.65 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.734 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.2 t80 -122.99 110.69 15.68 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.511 -0.743 . . . . 0.0 109.482 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.0 m -113.21 118.17 33.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.88 . . . . 0.0 109.68 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.551 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 1.4 ttt85 -130.15 141.81 43.22 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.277 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.12 89.29 0.46 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.572 2.181 . . . . 0.0 112.001 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.03 -32.19 6.62 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.492 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 21.1 m-20 -95.11 175.74 6.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -1.188 . . . . 0.0 109.705 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 82' ' ' SER . 51.1 m -155.01 162.56 41.04 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.404 -0.81 . . . . 0.0 109.337 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.739 HD11 ' CD2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -71.52 133.92 46.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.274 179.944 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.917 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.45 3.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.24 -0.912 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -140.62 149.42 42.28 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 0.0 110.205 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' CG2' HD11 ' A' ' 41' ' ' LEU . 21.6 t -139.14 136.32 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.408 -0.808 . . . . 0.0 109.455 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -129.59 152.02 49.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.903 -1.123 . . . . 0.0 109.385 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.88 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.3 tt -121.75 141.39 51.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.301 -0.875 . . . . 0.0 109.928 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.878 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.5 ttp180 -124.23 129.61 51.08 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.311 -0.868 . . . . 0.0 109.022 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -70.69 150.42 45.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.357 -0.839 . . . . 0.0 109.878 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.521 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 54.9 t60 -68.06 118.3 11.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.577 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.77 4.09 52.05 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.4 t -114.48 160.63 18.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.332 -1.099 . . . . 0.0 109.468 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 72.9 tt0 -124.56 15.23 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -0.924 . . . . 0.0 109.371 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 64.9 tt0 -118.11 81.4 1.67 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.445 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.563 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 40.8 m95 -43.28 138.86 2.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.34 -0.85 . . . . 0.0 109.778 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.28 136.68 20.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.48 -0.762 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.27 145.13 47.85 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.797 2.331 . . . . 0.0 111.898 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.839 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.3 mp -112.05 155.22 24.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.235 -0.916 . . . . 0.0 109.009 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.9 m -109.67 126.92 54.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.952 -1.092 . . . . 0.0 109.32 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 31.9 tttm -73.2 110.4 7.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.061 -1.024 . . . . 0.0 109.312 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.837 ' O ' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -119.31 142.83 47.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.904 -1.122 . . . . 0.0 110.126 -179.469 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.8 32.46 0.93 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 3.6 t-20 81.49 12.84 0.68 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.231 -1.158 . . . . 0.0 110.478 179.209 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.837 HG22 ' O ' ' A' ' 60' ' ' LYS . 16.6 m -129.47 176.71 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.029 -1.044 . . . . 0.0 108.872 179.386 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.719 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.3 m95 -116.5 138.09 51.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 0.0 109.56 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.614 ' HG2' HG13 ' A' ' 29' ' ' VAL . 38.3 mt-10 -124.29 139.69 53.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.343 -0.848 . . . . 0.0 109.418 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 46' ' ' LEU . 10.1 p -133.57 130.85 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.311 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -120.34 131.98 55.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.114 -0.991 . . . . 0.0 109.517 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t -118.52 145.99 44.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.502 -0.749 . . . . 0.0 109.421 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.4 m -72.3 -5.17 34.23 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.098 -1.001 . . . . 0.0 109.114 179.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.577 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.3 mtmt -130.18 177.82 2.01 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.368 -0.833 . . . . 0.0 109.11 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.5 Cg_endo -68.96 145.93 63.46 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.498 2.132 . . . . 0.0 111.765 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.99 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -83.63 138.69 33.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.797 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.0 t -123.4 124.9 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.385 -0.822 . . . . 0.0 109.484 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -94.03 169.64 29.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.51 147.52 81.73 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.903 -1.707 . . . . 0.0 112.019 -0.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.8 m-85 -91.19 151.38 20.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.556 -0.715 . . . . 0.0 110.561 -179.232 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.445 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 9.2 m-80 -112.59 143.5 43.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.342 -0.848 . . . . 0.0 108.778 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.88 ' CE2' HD12 ' A' ' 46' ' ' LEU . 49.7 m-85 -137.28 128.45 27.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.925 -1.109 . . . . 0.0 110.257 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.609 ' HG3' HG22 ' A' ' 89' ' ' VAL . 9.1 ttp180 -108.13 142.72 37.91 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.742 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -123.16 144.04 49.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.155 -0.965 . . . . 0.0 111.373 -178.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' O ' ' A' ' 86' ' ' MET . 10.0 ttm -127.94 126.12 40.85 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -79.8 144.17 33.78 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 110.323 -178.451 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.917 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 68.6 mttm -44.71 -43.56 8.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.27 -3.11 0.78 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.454 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.67 23.43 26.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 35.6 mtp -97.59 147.25 24.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.101 -1.235 . . . . 0.0 108.716 179.433 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.6 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 20.7 mtm180 -125.53 142.78 51.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.819 -1.176 . . . . 0.0 110.505 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.0 m120 -137.38 141.52 41.74 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.4 t -121.45 136.28 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.924 -1.11 . . . . 0.0 110.252 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.512 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 43.9 m-85 -124.94 122.55 37.67 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -98.42 147.28 24.88 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 18.3 mt-10 52.83 51.9 15.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.439 -0.788 . . . . 0.0 110.284 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.444 HG21 ' HB2' ' A' ' 90' ' ' PHE . 58.4 t -80.74 -33.32 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.804 -1.185 . . . . 0.0 109.159 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.474 HG12 ' HB3' ' A' ' 104' ' ' TYR . 65.2 mt -138.47 126.27 13.7 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.089 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.24 162.81 40.32 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.563 2.175 . . . . 0.0 111.981 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.488 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 54.4 m -53.6 -39.76 65.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.359 -0.838 . . . . 0.0 109.924 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -92.16 99.44 12.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.064 -1.022 . . . . 0.0 109.651 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -108.28 148.01 30.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.562 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.8 t -107.24 168.96 8.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.234 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.616 HD13 ' CG1' ' A' ' 19' ' ' VAL . 16.3 mm -104.29 136.18 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.182 -0.949 . . . . 0.0 109.237 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.84 3.45 59.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -117.67 142.76 46.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.109 -1.23 . . . . 0.0 109.172 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.1 m -78.58 175.23 10.56 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 108.914 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.611 ' H ' HG22 ' A' ' 103' ' ' THR . 25.0 m-85 -159.66 97.21 1.3 Allowed 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.703 -1.248 . . . . 0.0 108.972 179.267 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -97.84 159.31 31.22 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.423 -0.798 . . . . 0.0 109.787 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.512 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.778 2.319 . . . . 0.0 111.681 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.81 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 9.9 t . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -109.78 120.93 44.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.079 -1.013 . . . . 0.0 109.456 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.564 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -129.14 140.52 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.752 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 105' ' ' LYS . 34.7 p -141.44 145.24 35.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.215 -0.928 . . . . 0.0 109.549 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.596 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.2 m-85 -116.37 135.26 54.02 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.196 -0.94 . . . . 0.0 109.609 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.428 ' O ' ' N ' ' A' ' 31' ' ' ASP . 25.9 m -134.84 129.02 33.83 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 109.412 179.558 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 HD23 ' A' ' 30' ' ' LEU . 39.2 t -76.47 135.84 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 109.353 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -111.46 157.18 20.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.708 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 25.7 mtpt -50.86 113.91 1.03 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.822 . . . . 0.0 109.924 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.49 -3.92 1.92 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.58 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.476 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 40.8 m -60.68 140.28 57.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.896 -1.355 . . . . 0.0 109.258 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.562 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.24 177.09 2.4 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 109.57 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -71.22 -31.66 14.1 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.59 2.193 . . . . 0.0 111.814 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -117.14 5.11 12.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.033 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.473 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 47.0 mttp -141.37 132.98 27.06 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.041 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.56 132.18 51.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.069 -1.02 . . . . 0.0 110.084 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.533 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 4.7 t -121.43 124.68 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.041 HD11 HD22 ' A' ' 28' ' ' LEU . 0.8 OUTLIER -140.87 141.07 34.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.948 -1.095 . . . . 0.0 110.124 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.428 ' N ' ' O ' ' A' ' 18' ' ' THR . 63.6 t0 -85.9 136.34 33.33 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 178.439 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.672 HD13 ' HZ ' ' A' ' 80' ' ' PHE . 82.4 mt -121.71 131.12 73.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 120.932 -1.105 . . . . 0.0 110.236 -179.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 47.4 mttm -110.36 119.53 39.5 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.81 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 59.0 t80 -122.85 115.76 22.51 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.536 -0.727 . . . . 0.0 109.324 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.5 m -119.32 119.59 34.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.527 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 14.0 ttt85 -137.5 138.8 25.54 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.246 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.507 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.0 Cg_endo -69.74 103.05 1.1 Allowed 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.754 2.303 . . . . 0.0 112.06 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.75 2.86 86.42 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.527 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 26.2 m-20 -137.87 175.99 9.09 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -1.194 . . . . 0.0 109.693 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.9 m -156.25 163.84 39.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.466 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.74 HD21 HG21 ' A' ' 44' ' ' VAL . 23.4 tp -69.18 130.16 41.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.204 -0.935 . . . . 0.0 109.229 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.641 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -113.75 -45.69 3.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 110.148 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 77.9 mt-10 -137.34 147.18 45.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.102 -0.998 . . . . 0.0 110.264 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.74 HG21 HD21 ' A' ' 41' ' ' LEU . 94.2 t -139.35 136.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.531 -0.731 . . . . 0.0 109.334 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.531 ' O ' ' HA ' ' A' ' 78' ' ' PHE . 35.1 mt-10 -128.87 151.38 49.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.415 179.387 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.04 HD23 ' N ' ' A' ' 47' ' ' ARG . 7.0 tt -120.83 144.35 48.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.377 -0.827 . . . . 0.0 109.865 -179.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 1.04 ' N ' HD23 ' A' ' 46' ' ' LEU . 19.5 ttp180 -126.86 108.86 11.39 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 109.037 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.406 HE21 ' HB3' ' A' ' 48' ' ' GLN . 10.8 mt-30 -51.97 156.1 1.63 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.858 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB3' HG12 ' A' ' 73' ' ' VAL . 86.4 t60 -69.31 118.5 12.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.472 -0.768 . . . . 0.0 109.6 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.47 3.44 55.33 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -113.76 153.27 29.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -1.156 . . . . 0.0 109.467 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.48 ' HA ' ' HD2' ' A' ' 47' ' ' ARG . 85.3 tt0 -115.66 -3.47 12.29 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.273 -0.892 . . . . 0.0 109.393 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.0 tt0 -97.25 112.34 24.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -0.908 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.539 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 78.5 m95 -74.33 129.12 37.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.326 -0.859 . . . . 0.0 109.549 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -101.66 137.19 19.51 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.874 . . . . 0.0 109.364 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -71.4 144.85 46.55 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.694 2.262 . . . . 0.0 111.937 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.575 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.1 mp -107.89 148.24 29.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 108.949 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.418 HG21 ' NZ ' ' A' ' 60' ' ' LYS . 85.6 m -102.31 127.22 49.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.894 -1.129 . . . . 0.0 109.27 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.605 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 41.2 tttm -72.44 110.05 6.57 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.243 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.905 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.8 mmtt -118.43 140.66 49.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.907 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.85 31.74 0.84 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.583 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 9.4 m-20 82.66 13.67 0.46 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.239 -1.154 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.905 HG22 ' O ' ' A' ' 60' ' ' LYS . 21.0 m -128.43 173.36 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.014 -1.054 . . . . 0.0 108.761 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.605 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 62.3 m95 -120.2 124.98 47.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.98 -1.075 . . . . 0.0 109.657 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -114.15 150.2 34.51 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.45 -0.782 . . . . 0.0 109.491 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.575 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.4 p -137.23 134.04 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.492 -0.755 . . . . 0.0 109.248 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -120.32 131.58 54.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.167 -0.958 . . . . 0.0 109.444 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.2 t -117.85 157.72 26.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.416 -0.802 . . . . 0.0 109.52 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.7 t -83.94 5.83 24.06 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.256 -0.903 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -139.09 176.2 2.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.295 -0.878 . . . . 0.0 109.214 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.4 Cg_endo -70.17 126.15 12.73 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.499 2.132 . . . . 0.0 111.791 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.938 HD13 HD12 ' A' ' 28' ' ' LEU . 2.0 mt -60.63 136.93 58.21 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.243 -0.91 . . . . 0.0 109.787 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.594 HG12 ' HB3' ' A' ' 49' ' ' HIS . 95.7 t -124.23 125.44 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.444 -0.785 . . . . 0.0 109.461 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.9 168.74 27.73 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.6 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.73 146.87 81.02 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.83 -1.737 . . . . 0.0 112.011 0.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 90.9 m-85 -91.09 149.6 21.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.506 -0.746 . . . . 0.0 110.356 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 47' ' ' ARG . 3.4 m-80 -111.99 144.57 41.11 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.845 ' CE2' HD12 ' A' ' 46' ' ' LEU . 18.2 m-85 -135.84 126.06 26.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.925 -1.109 . . . . 0.0 110.127 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.986 ' HG3' HG22 ' A' ' 89' ' ' VAL . 18.8 ttt180 -105.81 141.34 37.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.133 -0.979 . . . . 0.0 108.662 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.734 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.9 m-85 -123.7 143.03 50.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.924 . . . . 0.0 111.402 -178.146 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.638 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.5 ttt -125.93 124.47 40.87 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.0 p -72.46 144.59 48.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.385 -0.822 . . . . 0.0 109.968 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.641 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 86.4 mttt -47.19 -44.74 22.49 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.402 -0.811 . . . . 0.0 108.975 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.8 -3.7 0.77 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.71 24.53 15.4 Favored Glycine 0 N--CA 1.491 2.307 0 O-C-N 120.988 -1.301 . . . . 0.0 110.257 179.348 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.638 ' O ' ' HA ' ' A' ' 81' ' ' MET . 15.4 mmm -96.72 148.31 23.02 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.114 -1.227 . . . . 0.0 108.633 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.582 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 72.8 mtp180 -124.12 140.03 53.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.885 -1.134 . . . . 0.0 110.416 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 28.2 m120 -136.42 141.25 43.59 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.986 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.3 t -122.15 136.14 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.183 -179.049 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.565 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 13.3 m-85 -123.77 122.6 38.48 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 63.9 t0 -98.66 145.1 27.22 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.6 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 64.5 tt0 54.76 52.54 11.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.481 -0.762 . . . . 0.0 110.377 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 ' CD1' ' A' ' 17' ' ' PHE . 88.8 t -81.14 -34.75 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.939 -1.101 . . . . 0.0 109.006 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 46.6 mt -135.42 129.4 18.63 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 121.353 -0.842 . . . . 0.0 108.95 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.88 159.52 50.25 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.483 2.122 . . . . 0.0 112.009 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.541 HG23 ' H ' ' A' ' 74' ' ' GLY . 31.9 m -50.17 -36.66 31.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.677 -179.781 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.63 101.66 11.81 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.071 -1.018 . . . . 0.0 109.518 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.5 ' CE1' HG11 ' A' ' 19' ' ' VAL . 50.9 p90 -109.49 150.84 27.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.159 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.79 168.83 8.88 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 ' CG1' ' A' ' 19' ' ' VAL . 17.8 mm -101.01 136.37 32.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.226 -0.921 . . . . 0.0 109.177 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 94.69 0.79 64.16 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 15.9 mttm -114.27 144.96 42.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.245 . . . . 0.0 109.157 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.683 HG22 ' H ' ' A' ' 104' ' ' TYR . 4.2 m -82.65 178.37 8.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.294 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.683 ' H ' HG22 ' A' ' 103' ' ' THR . 16.3 m-85 -161.81 92.65 0.87 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.863 -1.148 . . . . 0.0 108.859 179.115 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.488 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.2 OUTLIER -81.39 155.07 71.86 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.245 -0.909 . . . . 0.0 109.783 -179.415 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.565 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 50.0 Cg_endo . . . . . 0 C--O 1.216 -0.576 0 C-N-CA 122.741 2.294 . . . . 0.0 111.886 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.932 HG22 ' HG2' ' A' ' 36' ' ' ARG . 4.0 t . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.307 0.575 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.418 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 91.5 mt-30 -109.65 121.36 45.03 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.384 -0.823 . . . . 0.0 109.167 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.7 p -128.84 139.92 50.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.207 -0.933 . . . . 0.0 109.836 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.764 HG22 ' HD2' ' A' ' 105' ' ' LYS . 29.3 p -142.02 145.99 35.02 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.406 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.8 m-85 -118.31 147.48 43.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 31' ' ' ASP . 29.9 m -141.84 127.93 19.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.112 -0.993 . . . . 0.0 109.202 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.938 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.8 t -76.33 135.9 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.106 -0.996 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.418 ' O ' HD12 ' A' ' 100' ' ' ILE . 76.1 mm-40 -101.44 -174.83 2.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.107 -0.996 . . . . 0.0 109.531 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.4 mttt -81.6 67.42 7.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.369 -0.832 . . . . 0.0 109.983 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -174.96 22.97 0.06 OUTLIER Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.755 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.557 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 48.9 m -75.44 142.58 42.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.777 -1.425 . . . . 0.0 109.109 179.638 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.574 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.14 171.96 7.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 109.856 -179.552 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.574 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.92 -31.05 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.869 2.38 . . . . 0.0 111.984 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -115.57 6.8 14.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.235 -0.916 . . . . 0.0 108.984 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.525 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 2.5 ttpm? -142.96 133.91 25.57 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.76 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.56 124.27 43.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.934 -1.104 . . . . 0.0 109.398 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.563 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 10.7 t -120.06 124.81 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.938 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.23 145.88 31.48 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.027 -1.046 . . . . 0.0 110.147 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.714 ' HA ' HG12 ' A' ' 63' ' ' VAL . 59.2 t0 -83.86 134.92 34.67 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.777 HG21 ' CE2' ' A' ' 80' ' ' PHE . 82.5 mt -121.86 131.82 72.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 120.825 -1.172 . . . . 0.0 110.723 -178.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 24.7 mmtp -110.44 119.28 38.67 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.471 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 81.2 t80 -120.42 124.67 46.04 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.411 -0.806 . . . . 0.0 109.568 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 5.2 m -128.64 118.74 23.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.847 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.932 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -128.54 167.0 20.68 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.708 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.1 Cg_endo -70.55 79.06 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.716 2.277 . . . . 0.0 111.876 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.14 -9.63 69.0 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.531 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -96.84 179.0 5.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.175 . . . . 0.0 109.422 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.503 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 12.4 m -153.02 160.68 43.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.147 -0.971 . . . . 0.0 109.712 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.815 HD21 HG21 ' A' ' 44' ' ' VAL . 22.4 tp -69.97 130.18 41.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.471 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.795 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.44 -45.65 2.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.232 -0.918 . . . . 0.0 110.127 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.468 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 43.8 mt-10 -134.66 144.57 47.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.116 -0.99 . . . . 0.0 110.335 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.815 HG21 HD21 ' A' ' 41' ' ' LEU . 93.8 t -137.99 135.48 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.492 -0.755 . . . . 0.0 109.217 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.48 ' HA ' ' CD1' ' A' ' 57' ' ' LEU . 25.7 mt-10 -129.04 151.05 50.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.985 -1.072 . . . . 0.0 109.395 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.945 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.4 tt -119.4 132.61 55.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.447 -0.783 . . . . 0.0 109.913 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.945 ' N ' HD23 ' A' ' 46' ' ' LEU . 27.0 ttp180 -118.53 128.21 54.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.225 -0.922 . . . . 0.0 108.761 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -73.13 152.24 41.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 110.195 -179.273 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.527 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 55.1 t-80 -63.02 147.48 50.56 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.408 -0.808 . . . . 0.0 109.137 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.92 1.0 54.57 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.6 t -112.45 150.31 31.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -1.144 . . . . 0.0 109.316 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -116.59 8.46 13.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.924 . . . . 0.0 109.517 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 64.0 mm-40 -107.01 115.42 30.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.401 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 58.3 m95 -76.08 129.03 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.326 -0.859 . . . . 0.0 109.715 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -99.94 133.38 21.68 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.432 -0.793 . . . . 0.0 109.193 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 149.03 67.25 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.689 2.259 . . . . 0.0 111.803 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.673 HD11 ' HB2' ' A' ' 46' ' ' LEU . 6.1 mp -111.98 158.58 19.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.194 -0.941 . . . . 0.0 109.354 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.2 m -107.48 127.72 53.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.954 -1.091 . . . . 0.0 109.279 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 47.3 tttt -70.84 112.89 7.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -0.896 . . . . 0.0 109.242 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.451 ' HE3' ' HB3' ' A' ' 65' ' ' GLU . 40.2 mttt -113.64 125.66 54.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.953 -1.092 . . . . 0.0 109.595 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 44.68 -109.54 0.29 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -117.11 17.44 14.84 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.258 -1.142 . . . . 0.0 109.564 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 31' ' ' ASP . 10.9 m -131.93 -175.82 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.451 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -127.33 139.82 52.62 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 67' ' ' LYS . 19.1 tt0 -121.21 135.01 55.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.215 -0.928 . . . . 0.0 109.753 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.603 HG12 ' HB3' ' A' ' 28' ' ' LEU . 4.6 p -131.09 129.36 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.274 -0.891 . . . . 0.0 109.304 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG2' ' CD ' ' A' ' 27' ' ' LYS . 88.3 mttt -120.05 131.58 55.15 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.094 -1.004 . . . . 0.0 109.529 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.5 t -117.6 138.91 51.63 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.526 -0.734 . . . . 0.0 109.288 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 79.3 p -65.56 -11.3 42.72 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.154 -0.966 . . . . 0.0 109.232 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -121.12 176.34 1.95 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.68 164.57 32.66 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.602 2.201 . . . . 0.0 111.811 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.626 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.1 mt -100.59 141.56 33.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.258 -0.901 . . . . 0.0 109.849 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 50.2 t -127.86 125.2 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.547 -0.72 . . . . 0.0 109.319 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.671 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.76 164.74 26.64 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.614 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.9 Cg_endo -68.84 148.15 83.97 Favored 'Cis proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.984 0.075 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.4 m-85 -92.58 149.87 21.08 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.442 -0.786 . . . . 0.0 110.476 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.495 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 14.6 m-80 -110.51 143.33 41.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 108.769 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 46' ' ' LEU . 83.1 m-85 -134.69 126.84 29.87 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.014 -1.054 . . . . 0.0 109.737 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 89' ' ' VAL . 53.1 ttt180 -108.35 142.51 38.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.04 -1.038 . . . . 0.0 108.753 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.777 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.1 m-85 -124.6 143.42 50.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 111.551 -178.079 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.6 ttm -126.38 125.95 43.06 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 178.478 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.632 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.9 p -74.0 145.92 44.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 110.204 -178.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.795 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 78.7 mttt -48.37 -44.22 34.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.272 -0.893 . . . . 0.0 108.934 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.44 -3.69 0.68 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.53 25.05 16.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.582 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.632 ' O ' ' N ' ' A' ' 82' ' ' SER . 13.0 mmm -97.39 148.36 23.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.172 -1.193 . . . . 0.0 108.575 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 21.6 mtm180 -124.31 140.03 53.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.843 -1.16 . . . . 0.0 110.68 -178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . 34.7 m120 -135.42 140.08 44.65 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.1 t -122.03 136.9 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.037 -1.039 . . . . 0.0 110.409 -179.079 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.541 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 15.9 m-85 -125.52 122.98 38.13 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -99.57 147.84 24.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 95.8 mt-10 53.45 51.4 15.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.338 -0.851 . . . . 0.0 110.044 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.536 HG12 HG13 ' A' ' 94' ' ' ILE . 44.1 t -81.03 -33.98 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.821 -1.174 . . . . 0.0 109.26 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 93' ' ' VAL . 43.7 mt -138.13 125.75 13.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.139 -0.976 . . . . 0.0 109.057 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.12 161.78 44.43 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.533 2.155 . . . . 0.0 111.882 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.671 HG23 ' H ' ' A' ' 74' ' ' GLY . 2.6 m -57.08 -39.46 75.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.376 -0.827 . . . . 0.0 109.923 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.45 70.31 9.89 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.081 -1.012 . . . . 0.0 109.492 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -81.2 148.52 29.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.936 . . . . 0.0 109.656 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 43.3 m -109.82 168.8 9.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.317 -0.865 . . . . 0.0 109.186 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.521 HD13 ' CG1' ' A' ' 19' ' ' VAL . 35.6 mm -103.4 135.71 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.137 -0.977 . . . . 0.0 109.284 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 97.01 5.88 58.17 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.471 ' HD3' ' CZ ' ' A' ' 104' ' ' TYR . 43.7 tttp -119.73 143.17 47.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.25 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.652 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.7 m -79.88 176.51 9.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 109.018 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.652 ' H ' HG22 ' A' ' 103' ' ' THR . 32.5 m-85 -162.7 95.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.875 -1.141 . . . . 0.0 108.937 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.764 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.3 OUTLIER -103.0 166.33 12.05 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.873 . . . . 0.0 109.793 -179.405 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.631 0 C-N-CA 122.588 2.192 . . . . 0.0 111.727 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.954 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 3.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -111.47 121.64 45.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.896 . . . . 0.0 109.244 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.4 t -128.95 139.68 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.202 -0.936 . . . . 0.0 109.817 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.0 p -141.99 146.15 35.26 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.328 -0.857 . . . . 0.0 109.474 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.7 m-85 -118.38 123.65 45.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.425 ' O ' ' N ' ' A' ' 31' ' ' ASP . 34.8 m -120.05 128.37 53.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.03 -1.044 . . . . 0.0 109.063 179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' CD2' ' A' ' 30' ' ' LEU . 11.9 t -76.04 132.57 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 37.7 mm-40 -107.3 156.35 18.98 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.8 mttt -50.08 114.55 1.12 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.432 -0.793 . . . . 0.0 109.909 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.95 1.98 1.96 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 65.9 p -62.85 142.32 58.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.762 -1.434 . . . . 0.0 109.185 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.521 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.43 174.12 4.71 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.133 -0.98 . . . . 0.0 109.664 -179.626 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.9 Cg_endo -71.01 -29.86 17.31 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.683 2.255 . . . . 0.0 111.86 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -118.18 4.18 11.98 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.32 -0.862 . . . . 0.0 109.041 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.47 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 52.7 mttt -143.01 134.13 25.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.994 HD12 HD13 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -128.01 134.25 49.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.984 -1.073 . . . . 0.0 110.401 -179.332 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.6 t -121.95 123.73 69.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.966 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.68 144.51 31.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 109.914 -179.352 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 18' ' ' THR . 57.0 t0 -86.3 136.13 33.27 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.334 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.701 HG21 ' CE2' ' A' ' 80' ' ' PHE . 80.1 mt -120.68 131.63 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 120.881 -1.137 . . . . 0.0 110.324 -179.163 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 mttm -111.09 118.69 36.71 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.954 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.6 t80 -121.26 109.33 14.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.489 -0.757 . . . . 0.0 109.339 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.1 m -112.62 117.32 31.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.89 . . . . 0.0 109.89 -179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.625 ' HG3' HG22 ' A' ' 13' ' ' VAL . 37.8 ttt-85 -136.83 139.73 29.75 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.368 -0.833 . . . . 0.0 109.179 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.525 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.3 Cg_endo -69.75 109.35 2.29 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 112.069 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.05 4.44 88.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.561 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 4.9 m-20 -134.52 173.21 11.91 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -1.22 . . . . 0.0 109.772 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.9 m -155.53 162.61 40.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.341 -0.849 . . . . 0.0 109.502 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.701 HD21 ' CG2' ' A' ' 44' ' ' VAL . 10.7 tp -70.55 129.56 39.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.846 . . . . 0.0 109.501 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.741 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -115.83 -42.74 3.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.161 -0.962 . . . . 0.0 109.839 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -142.62 151.09 41.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.138 -0.976 . . . . 0.0 110.002 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.701 ' CG2' HD21 ' A' ' 41' ' ' LEU . 21.4 t -139.9 137.27 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.435 -0.791 . . . . 0.0 109.465 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 56' ' ' PRO . 61.4 mt-10 -127.78 150.55 49.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.873 -1.142 . . . . 0.0 109.215 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.776 HD12 ' O ' ' A' ' 77' ' ' ASN . 10.9 tp -120.87 133.0 55.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.333 -0.855 . . . . 0.0 110.243 -178.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.693 ' N ' HD12 ' A' ' 46' ' ' LEU . 47.8 ttp85 -113.53 127.98 56.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.099 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -71.91 152.35 42.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.512 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 85.6 t60 -69.31 111.3 5.12 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.382 -0.824 . . . . 0.0 109.554 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.82 2.1 36.75 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.511 ' O ' ' NH1' ' A' ' 47' ' ' ARG . 33.5 t -113.47 154.37 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.195 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 37.9 mm-40 -113.22 16.14 19.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.333 -0.854 . . . . 0.0 109.394 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -113.88 114.19 25.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.528 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.594 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.6 m95 -80.13 120.09 23.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.267 -0.895 . . . . 0.0 109.655 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.445 ' O ' ' N ' ' A' ' 46' ' ' LEU . 11.6 mm-40 -95.95 129.99 32.63 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.445 -0.784 . . . . 0.0 109.344 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 48.2 Cg_endo -69.32 149.48 69.74 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.561 2.174 . . . . 0.0 111.879 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.618 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -101.6 149.52 24.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.149 -0.97 . . . . 0.0 108.576 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -102.46 126.54 49.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 108.941 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -70.41 109.47 4.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.168 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.877 ' O ' HG22 ' A' ' 63' ' ' VAL . 37.2 mttp -121.74 139.53 53.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.797 -1.189 . . . . 0.0 109.975 -179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.531 ' O ' ' HB2' ' A' ' 62' ' ' ASN . . . 38.39 48.25 2.21 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.531 ' HB2' ' O ' ' A' ' 61' ' ' GLY . 54.3 m-20 68.48 11.46 8.36 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.169 -1.195 . . . . 0.0 110.956 178.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.9 m -128.88 -178.61 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.858 -1.151 . . . . 0.0 108.997 179.169 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.506 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 71.1 m95 -122.8 141.27 52.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.082 . . . . 0.0 109.632 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 62.5 tt0 -128.42 142.22 51.17 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.815 . . . . 0.0 109.212 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.645 HG11 HD23 ' A' ' 46' ' ' LEU . 1.8 p -136.37 135.18 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.24 -0.913 . . . . 0.0 109.145 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.433 ' HD2' ' HE2' ' A' ' 27' ' ' LYS . 6.1 ttpm? -122.54 133.73 54.56 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.851 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.8 t -117.86 148.13 42.41 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.456 -0.778 . . . . 0.0 109.153 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 85.5 p -72.77 -4.43 31.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.988 . . . . 0.0 109.354 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -131.5 176.19 3.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.243 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.44 140.52 48.25 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.482 2.121 . . . . 0.0 111.714 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.994 HD13 HD12 ' A' ' 28' ' ' LEU . 10.5 mt -74.76 137.89 42.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.826 -179.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.9 t -123.37 125.12 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.469 -0.769 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.665 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.3 165.47 27.67 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 50.5 Cg_endo -70.01 145.66 80.6 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.806 -1.747 . . . . 0.0 111.883 0.03 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.667 ' HB3' HD11 ' A' ' 46' ' ' LEU . 76.8 m-85 -91.46 151.18 20.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.523 -0.736 . . . . 0.0 110.367 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.776 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.5 m120 -110.77 142.43 42.75 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.767 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.0 m-85 -133.24 127.3 33.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.913 -1.117 . . . . 0.0 109.971 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.686 ' HG3' HG22 ' A' ' 89' ' ' VAL . 41.4 ttt180 -110.62 143.12 41.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.006 -1.059 . . . . 0.0 108.627 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.701 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.0 m-85 -124.86 143.81 50.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.218 -0.926 . . . . 0.0 111.632 -177.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 1.2 ttt -125.85 124.4 40.82 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.537 ' CB ' ' HB2' ' A' ' 86' ' ' MET . 24.2 p -77.39 147.7 35.92 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.206 -0.934 . . . . 0.0 110.043 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.741 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 32.9 mttt -46.65 -46.0 19.6 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.32 -8.19 8.65 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.41 34.53 5.28 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.537 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 44.3 mmm -103.24 110.61 22.64 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.987 -1.302 . . . . 0.0 109.011 179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 61.0 mtt180 -91.71 139.49 30.63 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.199 -0.938 . . . . 0.0 110.472 -179.148 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.4 m120 -137.25 141.69 42.02 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.686 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.2 t -122.06 136.5 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.865 -1.147 . . . . 0.0 110.471 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.567 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 55.0 m-85 -124.44 122.36 37.42 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -97.13 145.27 26.17 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.18 -0.95 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 12.8 mt-10 53.96 54.26 9.99 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.491 -0.756 . . . . 0.0 110.335 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.779 HG11 ' CE1' ' A' ' 17' ' ' PHE . 75.8 t -82.26 -34.18 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 109.074 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.464 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.7 mt -135.44 124.4 16.0 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.201 -0.937 . . . . 0.0 109.132 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.42 162.13 43.12 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.608 2.205 . . . . 0.0 111.968 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.665 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.3 m -53.3 -44.7 68.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 109.976 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.84 99.72 12.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.046 -1.034 . . . . 0.0 109.502 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -109.45 147.83 32.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.94 . . . . 0.0 109.715 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.8 m -106.09 171.15 7.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.212 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.552 HD13 ' CG1' ' A' ' 19' ' ' VAL . 27.2 mm -106.73 137.83 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.42 9.62 61.49 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 4.6 tptp -120.57 144.18 48.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.495 HG22 ' H ' ' A' ' 104' ' ' TYR . 8.6 m -77.81 170.97 15.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.038 -1.039 . . . . 0.0 108.706 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.593 ' N ' ' O ' ' A' ' 17' ' ' PHE . 24.0 m-85 -157.62 97.94 1.63 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.607 -1.308 . . . . 0.0 109.151 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.529 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -104.93 161.53 22.49 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.277 -0.889 . . . . 0.0 109.767 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.2 Cg_endo . . . . . 0 C--O 1.215 -0.639 0 C-N-CA 122.718 2.279 . . . . 0.0 111.663 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.989 HG22 ' HG3' ' A' ' 36' ' ' ARG . 30.3 t . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.47 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 77.9 mm-40 -106.01 120.24 41.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.027 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.601 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.1 p -128.92 139.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.232 -0.917 . . . . 0.0 110.049 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 73.1 p -141.25 145.42 35.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.334 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.646 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.8 m-85 -118.24 136.22 53.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.176 -0.953 . . . . 0.0 109.717 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 88.5 m -131.34 127.77 38.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.903 -1.123 . . . . 0.0 109.302 179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.898 HG22 ' CD2' ' A' ' 30' ' ' LEU . 30.6 t -75.02 134.01 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.216 -0.928 . . . . 0.0 109.173 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.468 ' OE1' ' O ' ' A' ' 19' ' ' VAL . 4.9 mm100 -106.57 156.34 18.69 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.174 -0.954 . . . . 0.0 109.975 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.5 mttt -51.34 115.87 1.79 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.51 -0.743 . . . . 0.0 109.947 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 137.26 -1.52 3.05 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.447 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 p -60.29 144.15 51.14 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.911 -1.347 . . . . 0.0 109.403 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.19 169.79 12.62 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.288 -0.882 . . . . 0.0 109.71 -179.779 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.4 Cg_endo -70.73 -29.34 19.39 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.806 2.337 . . . . 0.0 111.88 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -113.02 7.09 17.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.165 -0.959 . . . . 0.0 108.819 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -142.74 133.55 25.45 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.72 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.35 122.84 40.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.965 -1.085 . . . . 0.0 109.337 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.549 HG13 ' HG2' ' A' ' 65' ' ' GLU . 51.4 t -118.72 124.35 73.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.898 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -144.33 144.76 31.61 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.977 -1.077 . . . . 0.0 110.253 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.635 ' OD1' HG12 ' A' ' 63' ' ' VAL . 20.9 t70 -85.39 137.04 33.2 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 177.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.897 HG21 ' CE2' ' A' ' 80' ' ' PHE . 75.7 mt -120.71 130.98 73.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 C-N-CA 118.667 -1.213 . . . . 0.0 110.786 -179.033 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.601 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 22.1 tttm -110.61 120.38 42.23 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.094 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.51 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 78.6 t80 -120.15 112.77 19.52 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.343 -0.848 . . . . 0.0 109.567 -178.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 31.2 m -115.71 115.79 26.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -0.851 . . . . 0.0 109.677 -179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.989 ' HG3' HG22 ' A' ' 13' ' ' VAL . 28.0 ttt85 -138.68 136.29 18.62 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.526 -0.734 . . . . 0.0 109.208 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.484 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -69.88 112.57 3.13 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.1 0.69 83.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.563 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.2 m-20 -133.92 172.26 13.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.966 -1.314 . . . . 0.0 109.87 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 82' ' ' SER . 13.6 m -153.98 161.61 41.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.408 -0.807 . . . . 0.0 109.341 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.864 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.7 OUTLIER -72.28 131.27 42.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.279 -0.888 . . . . 0.0 109.845 -179.588 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.936 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.93 -40.24 3.54 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.619 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.45 150.41 40.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.124 -0.985 . . . . 0.0 110.187 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.679 ' CG2' HD11 ' A' ' 41' ' ' LEU . 5.9 t -139.21 136.88 41.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.581 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -129.63 150.81 50.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.935 -1.103 . . . . 0.0 109.394 179.412 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.0 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -118.72 140.61 49.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.892 . . . . 0.0 109.715 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 1.0 ' N ' HD23 ' A' ' 46' ' ' LEU . 28.3 ttp180 -126.74 129.54 48.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.293 -0.879 . . . . 0.0 109.072 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.438 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 14.9 mt-30 -72.6 144.8 47.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.343 -0.848 . . . . 0.0 109.863 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.537 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 2.0 t-160 -61.36 115.81 4.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.35 -0.844 . . . . 0.0 109.442 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.42 2.75 35.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.417 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 25.6 t -113.7 155.71 25.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -1.188 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.495 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 69.7 tt0 -116.05 1.03 13.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.583 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -108.83 92.48 4.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.602 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.0 m95 -51.55 138.64 22.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.356 -0.84 . . . . 0.0 109.599 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -105.05 135.19 19.33 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.375 -0.828 . . . . 0.0 109.32 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.83 145.51 51.11 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.617 2.211 . . . . 0.0 111.891 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.869 HD11 ' HB2' ' A' ' 46' ' ' LEU . 5.4 mp -107.17 146.14 31.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.032 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.2 m -94.41 126.92 39.97 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.956 -1.09 . . . . 0.0 109.176 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -70.6 111.18 5.91 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.408 -0.808 . . . . 0.0 109.033 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -111.77 113.04 25.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.982 -1.074 . . . . 0.0 109.571 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.15 -103.72 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -123.76 17.36 9.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -1.146 . . . . 0.0 109.398 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.635 HG12 ' OD1' ' A' ' 31' ' ' ASP . 17.8 m -130.82 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.328 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 60.9 m95 -134.1 142.06 47.38 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.155 -0.966 . . . . 0.0 109.466 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG2' HG13 ' A' ' 29' ' ' VAL . 30.2 mt-10 -122.48 134.79 54.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.214 -0.929 . . . . 0.0 109.766 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.855 HG11 HD13 ' A' ' 46' ' ' LEU . 4.8 p -130.83 130.35 64.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -0.903 . . . . 0.0 109.217 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.7 tttm -122.17 133.85 54.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.064 -1.023 . . . . 0.0 109.75 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.438 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 8.3 t -117.63 154.77 31.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.437 -0.789 . . . . 0.0 109.239 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 20.4 m -80.15 -4.36 52.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.288 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.546 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.1 mttm -128.33 176.05 3.03 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.5 Cg_endo -69.52 124.19 10.94 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.508 2.138 . . . . 0.0 111.735 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.598 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.3 mt -58.53 139.67 55.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.354 -0.842 . . . . 0.0 109.79 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 46.4 t -125.14 124.68 67.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.378 -0.826 . . . . 0.0 109.543 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -95.3 166.78 25.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 45.4 Cg_endo -66.61 146.53 73.86 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 123.043 -1.649 . . . . 0.0 112.087 0.185 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 75.5 m-85 -90.72 150.53 21.6 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.607 -0.683 . . . . 0.0 110.405 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.41 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 10.0 m-80 -111.91 143.16 43.33 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.805 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.3 m-85 -134.77 122.16 21.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.01 -1.056 . . . . 0.0 109.704 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.571 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.9 ttp180 -103.3 141.91 35.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.96 -1.087 . . . . 0.0 108.609 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.897 ' CE2' HG21 ' A' ' 32' ' ' ILE . 31.7 m-85 -125.51 143.91 50.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.187 -0.946 . . . . 0.0 111.595 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.588 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.8 ttm -126.65 126.82 44.19 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.3 p -77.52 145.62 36.85 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.203 -0.936 . . . . 0.0 110.412 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.936 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.6 mttt -48.7 -44.56 38.15 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.61 -6.24 6.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.26 34.34 5.9 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.537 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 15.8 mmm -106.07 108.78 20.47 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.075 -1.25 . . . . 0.0 109.001 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.588 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 82.5 mtm180 -85.86 134.98 33.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.199 -0.938 . . . . 0.0 110.634 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.446 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -134.3 139.49 45.74 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.571 HG22 ' HG3' ' A' ' 79' ' ' ARG . 37.2 t -122.84 136.82 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.036 -1.04 . . . . 0.0 110.587 -178.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.532 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 61.2 m-85 -124.16 122.09 36.88 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 21.0 p-10 -100.11 148.96 24.01 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.346 -0.846 . . . . 0.0 109.744 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 40.1 tt0 52.98 51.19 16.33 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.323 -0.86 . . . . 0.0 110.002 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 94' ' ' ILE . 61.6 t -81.76 -33.87 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.924 -1.11 . . . . 0.0 109.116 179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.5 HG13 HG12 ' A' ' 93' ' ' VAL . 67.1 mt -138.83 127.67 14.09 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.312 -0.868 . . . . 0.0 109.074 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.45 161.37 46.14 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.611 2.208 . . . . 0.0 111.982 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.52 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 87.4 m -51.2 -45.44 61.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.394 -0.816 . . . . 0.0 109.916 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -93.07 104.01 16.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.113 -0.992 . . . . 0.0 109.688 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -111.09 151.57 27.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.359 -0.838 . . . . 0.0 109.33 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.0 m -102.64 170.18 8.18 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 30.6 mm -103.23 136.06 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.182 -0.948 . . . . 0.0 109.306 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.8 57.7 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -121.28 143.39 49.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.974 -1.309 . . . . 0.0 109.306 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.667 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -79.15 177.2 9.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.076 -1.015 . . . . 0.0 108.919 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.667 ' H ' HG22 ' A' ' 103' ' ' THR . 27.5 m-85 -162.23 96.27 0.97 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.769 -1.207 . . . . 0.0 109.107 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.521 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -102.51 164.54 15.45 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.362 -0.836 . . . . 0.0 109.724 -179.584 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.532 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.5 Cg_endo . . . . . 0 C--O 1.213 -0.727 0 C-N-CA 122.675 2.25 . . . . 0.0 111.887 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 36' ' ' ARG . 60.7 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.498 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 94.7 mt-30 -112.96 121.78 45.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.274 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.639 HG11 ' CE2' ' A' ' 90' ' ' PHE . 12.5 p -128.79 139.99 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.258 -0.902 . . . . 0.0 109.668 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.469 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 17.0 p -141.6 145.72 35.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.155 -0.965 . . . . 0.0 109.515 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.576 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.7 m-85 -117.49 150.44 38.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.234 -0.916 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.973 HG23 ' O ' ' A' ' 102' ' ' LYS . 92.2 m -144.81 127.7 16.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.069 -1.02 . . . . 0.0 109.378 179.097 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.813 HG22 ' CD2' ' A' ' 30' ' ' LEU . 4.5 t -76.29 129.1 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.885 . . . . 0.0 109.377 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.49 ' O ' HD12 ' A' ' 100' ' ' ILE . 91.2 mm-40 -92.97 -175.25 3.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.609 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -81.94 62.16 5.59 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.962 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -169.05 24.49 0.1 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.71 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.537 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 26.2 m -79.95 143.64 34.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.778 -1.425 . . . . 0.0 109.252 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.632 ' O ' HD12 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -137.71 174.19 4.6 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.101 -0.999 . . . . 0.0 109.605 -179.726 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.546 ' O ' ' N ' ' A' ' 72' ' ' LEU . 48.7 Cg_endo -70.76 -30.39 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.67 2.247 . . . . 0.0 112.045 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 88.8 mttt -115.17 5.7 14.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.067 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.42 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 81.8 mttt -142.18 133.38 26.21 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.31 40.95 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.042 -1.036 . . . . 0.0 109.466 -179.928 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 65' ' ' GLU . 21.9 t -118.74 124.62 73.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.813 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.0 OUTLIER -144.65 145.76 31.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.978 -1.076 . . . . 0.0 110.169 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -85.63 137.36 32.9 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.787 HG21 ' CE2' ' A' ' 80' ' ' PHE . 77.0 mt -120.78 130.13 74.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.755 -1.215 . . . . 0.0 110.688 -178.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.55 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.5 tttm -109.66 119.95 40.98 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 72.3 t80 -122.0 124.27 43.6 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.334 -0.853 . . . . 0.0 109.716 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 16.2 m -126.74 116.93 21.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.301 -0.874 . . . . 0.0 109.737 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.606 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.5 OUTLIER -151.27 116.66 3.19 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.416 -0.803 . . . . 0.0 109.139 179.804 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.95 126.21 13.56 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.73 2.286 . . . . 0.0 111.95 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.54 -19.48 54.5 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 1.5 m-20 -142.95 -176.35 4.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.209 -1.171 . . . . 0.0 109.814 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' LYS . 5.9 m -156.17 163.31 39.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.36 -0.838 . . . . 0.0 109.367 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.672 HD11 HG22 ' A' ' 44' ' ' VAL . 29.4 tp -70.52 129.02 38.12 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.342 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.893 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.65 -42.35 2.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.418 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 86.6 mt-10 -139.59 147.89 41.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.176 -0.953 . . . . 0.0 110.218 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.672 HG22 HD11 ' A' ' 41' ' ' LEU . 8.9 t -138.6 136.99 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 108.965 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.406 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 72.5 mt-10 -128.15 149.22 50.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.821 -1.174 . . . . 0.0 109.56 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.099 HD23 HG11 ' A' ' 66' ' ' VAL . 11.2 tp -120.18 131.64 55.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.418 -0.801 . . . . 0.0 109.96 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.65 ' N ' HD12 ' A' ' 46' ' ' LEU . 7.5 ttp180 -119.82 131.94 55.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.076 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 12.3 mt-30 -72.27 149.95 44.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.738 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.507 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 1.9 t-80 -68.54 113.94 6.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.746 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.48 2.42 27.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.45 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 28.1 t -115.01 154.92 27.93 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -1.172 . . . . 0.0 109.406 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -111.22 15.59 21.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.291 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -121.97 121.43 37.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.541 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.506 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 43.1 m95 -83.34 132.94 34.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.431 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.0 OUTLIER -100.76 135.11 20.14 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.335 -0.853 . . . . 0.0 109.422 179.975 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.431 ' HD2' ' HG3' ' A' ' 55' ' ' GLU . 52.3 Cg_endo -71.11 149.49 58.39 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.606 2.204 . . . . 0.0 111.96 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.623 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.6 mp -108.4 138.46 44.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.213 -0.929 . . . . 0.0 109.07 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.3 m -90.17 127.48 36.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.99 -1.069 . . . . 0.0 109.014 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 22.7 tttt -74.48 105.68 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.265 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -108.3 110.63 22.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.006 -1.059 . . . . 0.0 109.551 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.11 -107.73 1.93 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 35.0 p-10 -121.99 16.24 10.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -1.128 . . . . 0.0 109.345 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.2 m -132.08 170.09 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.947 . . . . 0.0 109.424 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.445 ' CD1' HD12 ' A' ' 32' ' ' ILE . 55.9 m95 -116.11 142.82 46.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.169 -0.957 . . . . 0.0 109.216 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 29' ' ' VAL . 75.7 tt0 -123.67 136.57 54.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 109.921 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 1.099 HG11 HD23 ' A' ' 46' ' ' LEU . 11.9 p -131.07 130.25 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.361 -0.837 . . . . 0.0 109.118 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.424 ' HE2' ' OE2' ' A' ' 65' ' ' GLU . 25.1 mttt -120.75 132.34 55.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.148 -0.97 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.4 t -118.56 145.55 45.27 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.447 -0.783 . . . . 0.0 109.217 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.3 m -66.55 -11.28 52.19 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.092 -1.005 . . . . 0.0 109.165 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.55 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -123.28 176.55 2.1 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.387 -0.821 . . . . 0.0 109.278 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.4 Cg_endo -69.74 157.62 59.8 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.454 2.102 . . . . 0.0 111.63 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.632 HD12 ' O ' ' A' ' 24' ' ' ASP . 5.3 mt -87.58 138.65 31.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.798 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 73.5 t -124.85 125.26 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.416 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.542 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.3 164.96 26.08 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.93 146.48 80.48 Favored 'Cis proline' 0 C--O 1.214 -0.704 0 C-N-CA 122.761 -1.766 . . . . 0.0 111.8 0.205 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.615 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.1 m-85 -91.02 152.4 20.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.515 -0.741 . . . . 0.0 110.544 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.773 ' O ' HD12 ' A' ' 46' ' ' LEU . 37.8 m-80 -112.68 141.67 46.2 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.856 ' CE1' HD13 ' A' ' 46' ' ' LEU . 86.9 m-85 -134.77 122.18 21.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.102 -0.999 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.987 ' HG3' HG22 ' A' ' 89' ' ' VAL . 70.6 ttt180 -104.2 143.32 33.1 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.997 -1.064 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.787 ' CE2' HG21 ' A' ' 32' ' ' ILE . 11.0 m-85 -125.29 143.15 51.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.196 -0.94 . . . . 0.0 111.402 -178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.559 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.5 ttt -125.23 125.03 42.96 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.594 ' N ' ' O ' ' A' ' 86' ' ' MET . 14.8 p -73.7 147.12 43.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 110.267 -178.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.893 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 42.1 mttp -50.03 -44.78 51.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.468 -0.77 . . . . 0.0 109.134 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.65 -4.31 0.61 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.86 27.06 11.64 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.594 ' O ' ' N ' ' A' ' 82' ' ' SER . 46.4 mtp -99.89 149.07 23.79 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -1.184 . . . . 0.0 108.627 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.559 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 17.8 mtt180 -121.87 136.92 54.95 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.871 -1.143 . . . . 0.0 110.457 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -134.1 139.79 46.17 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.987 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.4 t -123.2 136.97 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 120.952 -1.093 . . . . 0.0 110.315 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.639 ' CE2' HG11 ' A' ' 15' ' ' VAL . 18.2 m-85 -123.62 121.65 36.11 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -98.96 147.35 25.08 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.262 -0.899 . . . . 0.0 109.803 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 63.1 tt0 53.88 51.41 14.87 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.5 -0.75 . . . . 0.0 110.338 179.512 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.563 HG12 HG13 ' A' ' 94' ' ' ILE . 42.0 t -81.13 -34.37 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.889 -1.132 . . . . 0.0 108.905 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.563 HG13 HG12 ' A' ' 93' ' ' VAL . 40.9 mt -136.45 125.32 15.42 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.326 -0.859 . . . . 0.0 109.121 179.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.85 162.71 41.09 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.565 2.177 . . . . 0.0 112.024 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.542 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 32.2 m -49.96 -38.39 36.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.373 -0.829 . . . . 0.0 110.007 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.49 102.8 13.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.006 -1.059 . . . . 0.0 109.72 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CE1' HG11 ' A' ' 19' ' ' VAL . 42.8 p90 -110.33 154.13 23.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.905 . . . . 0.0 109.163 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.9 t -104.32 167.51 9.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 20' ' ' GLN . 28.6 mm -103.41 138.9 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -0.864 . . . . 0.0 109.29 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 90.35 16.0 56.2 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.973 ' O ' HG23 ' A' ' 18' ' ' THR . 18.9 mttm -119.21 -165.97 1.21 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 109.071 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.6 m -131.61 163.41 28.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.977 -1.077 . . . . 0.0 108.665 179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.576 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.8 m-85 -151.6 94.03 1.95 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.44 -1.412 . . . . 0.0 109.147 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.54 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -99.66 162.13 22.2 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.584 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.548 ' CD ' HG13 ' A' ' 15' ' ' VAL . 49.3 Cg_endo . . . . . 0 C--O 1.217 -0.555 0 C-N-CA 122.554 2.169 . . . . 0.0 111.83 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 36' ' ' ARG . 47.5 t . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -111.93 121.4 44.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.611 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -128.3 138.44 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.878 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.41 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 36.7 p -141.44 145.5 35.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.346 -0.846 . . . . 0.0 109.146 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.587 ' CD2' HG12 ' A' ' 32' ' ' ILE . 13.6 m-85 -119.06 142.68 47.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.927 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.7 m -137.85 127.79 25.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.247 -0.908 . . . . 0.0 109.189 179.291 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.876 HG22 ' CD2' ' A' ' 30' ' ' LEU . 27.9 t -75.74 136.09 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.289 -0.882 . . . . 0.0 109.173 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -114.14 156.24 24.57 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.083 -1.011 . . . . 0.0 109.926 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.6 mttt -48.35 111.98 0.53 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.15 -6.39 1.53 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.283 -1.437 . . . . 0.0 110.784 179.251 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.452 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 3.3 m -61.41 140.26 58.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.842 -1.387 . . . . 0.0 109.192 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.57 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.95 177.47 2.2 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.207 -0.933 . . . . 0.0 109.53 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.57 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.3 Cg_endo -70.88 -31.34 15.69 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.614 2.209 . . . . 0.0 111.903 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -117.93 5.26 12.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 108.931 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.472 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 44.3 mttt -142.35 133.8 26.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.039 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.25 133.71 50.17 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 120.988 -1.07 . . . . 0.0 110.222 -179.511 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.972 HG13 ' HG2' ' A' ' 65' ' ' GLU . 21.2 t -122.4 124.64 71.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.039 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -142.22 142.22 32.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.057 -1.027 . . . . 0.0 110.047 -179.372 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -86.15 136.62 33.13 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.849 HG21 ' CE2' ' A' ' 80' ' ' PHE . 87.8 mt -121.3 131.02 74.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.339 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 60.3 tttt -109.99 118.38 36.28 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.611 ' CD1' HG22 ' A' ' 15' ' ' VAL . 77.2 t80 -122.26 111.16 16.59 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.54 -0.725 . . . . 0.0 109.341 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 47.5 m -115.08 120.33 39.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.215 -0.928 . . . . 0.0 109.804 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 34' ' ' TYR . 2.9 mtt-85 -123.21 163.34 34.45 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.609 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -72.57 50.65 1.7 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.73 2.287 . . . . 0.0 111.864 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.94 -12.89 13.01 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.433 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.5 OUTLIER -96.83 178.78 5.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -1.169 . . . . 0.0 109.308 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.8 p -150.95 159.25 44.68 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.204 -0.935 . . . . 0.0 109.708 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.955 HD23 ' N ' ' A' ' 42' ' ' ALA . 2.2 tt -71.81 134.27 46.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.955 ' N ' HD23 ' A' ' 41' ' ' LEU . . . -114.74 -42.35 3.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.178 -0.952 . . . . 0.0 109.848 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -144.02 152.4 40.97 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.065 -1.022 . . . . 0.0 110.431 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.498 HG13 ' CE1' ' A' ' 80' ' ' PHE . 3.5 t -140.39 138.07 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.441 -0.787 . . . . 0.0 109.345 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.424 ' OE2' ' HB3' ' A' ' 56' ' ' PRO . 5.7 mm-40 -127.08 150.91 49.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 109.352 179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.724 HD23 HG11 ' A' ' 66' ' ' VAL . 5.9 tp -122.99 123.82 41.76 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.321 -0.862 . . . . 0.0 110.56 -178.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.709 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.6 OUTLIER -106.25 129.41 54.29 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.935 . . . . 0.0 109.006 178.838 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.44 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 8.3 mt-30 -71.64 151.17 43.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.291 -0.881 . . . . 0.0 109.306 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.608 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 30.0 t60 -67.49 110.33 3.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.188 -0.945 . . . . 0.0 109.44 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.28 1.03 38.17 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 27.2 t -112.77 153.11 28.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.246 . . . . 0.0 109.397 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 61.8 tt0 -116.22 14.23 15.82 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.25 -0.906 . . . . 0.0 109.34 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -112.45 86.9 2.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.282 -0.886 . . . . 0.0 109.465 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.628 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 22.5 m95 -53.84 138.72 35.36 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.424 -0.798 . . . . 0.0 109.841 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.07 131.61 23.44 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.454 -0.779 . . . . 0.0 108.911 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.424 ' HB3' ' OE2' ' A' ' 45' ' ' GLU . 49.1 Cg_endo -69.91 150.09 66.84 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.56 2.173 . . . . 0.0 112.027 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.712 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -100.92 148.43 25.0 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.469 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 69.7 m -98.12 126.69 43.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.742 -1.224 . . . . 0.0 109.051 179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -71.38 107.58 4.4 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.26 -0.9 . . . . 0.0 109.204 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.426 ' HD3' ' HA ' ' A' ' 60' ' ' LYS . 6.6 mmtp -111.75 106.79 15.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.969 -1.082 . . . . 0.0 109.581 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.35 -95.46 0.21 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -134.18 17.19 3.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -1.144 . . . . 0.0 109.453 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.01 169.85 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.305 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.459 ' HE3' ' CB ' ' A' ' 57' ' ' LEU . 70.3 m95 -116.41 131.04 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.177 -0.952 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.972 ' HG2' HG13 ' A' ' 29' ' ' VAL . 91.1 mt-10 -117.89 144.69 45.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.596 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.724 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -141.34 138.47 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -122.44 132.42 54.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 0.0 110.0 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.44 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 48.4 t -118.88 116.55 26.73 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.467 -0.771 . . . . 0.0 109.479 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 68' ' ' SER . 50.0 m -43.37 -37.71 2.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.143 -0.973 . . . . 0.0 109.085 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.618 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 5.2 ptpp? -94.72 168.44 11.28 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.159 179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.618 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.6 146.68 80.17 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.443 2.095 . . . . 0.0 111.743 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.006 HD13 HD12 ' A' ' 28' ' ' LEU . 1.6 mt -80.06 139.66 36.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.307 -0.871 . . . . 0.0 109.913 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.1 t -124.4 125.06 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.467 -0.771 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.495 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.45 166.41 26.72 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HG2' ' CE1' ' A' ' 49' ' ' HIS . 47.9 Cg_endo -68.65 145.13 76.04 Favored 'Cis proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.846 -1.731 . . . . 0.0 112.045 0.011 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.1 m-85 -91.19 153.1 20.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.588 -0.695 . . . . 0.0 110.49 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.484 ' ND2' ' OD1' ' A' ' 91' ' ' ASP . 2.7 m120 -111.72 140.91 45.97 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.6 m-85 -131.65 135.76 47.18 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.886 -1.134 . . . . 0.0 109.772 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.442 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 53.3 ttt-85 -119.97 142.86 48.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.192 -0.943 . . . . 0.0 108.609 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.849 ' CE2' HG21 ' A' ' 32' ' ' ILE . 15.3 m-85 -124.77 144.18 50.39 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.183 -0.948 . . . . 0.0 111.721 -177.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.654 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.4 ttt -126.65 124.16 39.22 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 178.315 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.53 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 20.8 p -77.76 141.87 39.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.325 -0.859 . . . . 0.0 109.867 -178.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.804 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 19.9 mttm -44.3 -44.02 7.81 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.21 -4.31 8.09 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.03 30.63 7.76 Favored Glycine 0 N--CA 1.491 2.319 0 O-C-N 121.256 -1.144 . . . . 0.0 110.33 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.53 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 37.0 mmm -103.45 107.85 18.86 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.02 -1.282 . . . . 0.0 108.854 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 35.7 mtm-85 -92.29 142.21 27.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 110.923 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -137.25 141.33 42.01 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.582 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 t -121.33 136.8 57.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.998 -1.064 . . . . 0.0 110.202 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 82.2 m-85 -125.05 121.65 34.97 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.484 ' OD1' ' ND2' ' A' ' 77' ' ' ASN . 55.1 t0 -97.51 147.96 23.73 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.097 -1.002 . . . . 0.0 109.662 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 35.8 mt-10 51.77 54.52 10.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.449 -0.782 . . . . 0.0 109.947 179.711 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' A' ' 106' ' ' PRO . 75.1 t -83.63 -32.89 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.954 -1.091 . . . . 0.0 109.261 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.45 HG12 ' HB3' ' A' ' 104' ' ' TYR . 34.8 mt -138.55 126.49 13.73 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.33 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.19 163.82 37.21 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.553 2.169 . . . . 0.0 111.8 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.495 HG23 ' H ' ' A' ' 74' ' ' GLY . 5.7 m -54.38 -37.31 64.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.309 -0.87 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.49 96.2 10.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.008 . . . . 0.0 109.836 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -104.95 143.94 32.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.488 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 88.0 p -116.66 124.07 48.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.211 -0.931 . . . . 0.0 109.665 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.567 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 5.9 mt -64.04 138.65 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.528 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.45 -4.19 50.88 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 37.8 tttp -118.19 142.86 47.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.108 -1.23 . . . . 0.0 109.264 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.562 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.3 m -76.81 173.61 11.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.033 -1.042 . . . . 0.0 108.476 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.568 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.0 m-85 -158.13 96.45 1.45 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 120.64 -1.288 . . . . 0.0 109.004 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.57 158.61 33.42 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.322 -0.861 . . . . 0.0 109.833 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HB3' HG22 ' A' ' 93' ' ' VAL . 49.5 Cg_endo . . . . . 0 C--O 1.216 -0.586 0 C-N-CA 122.734 2.289 . . . . 0.0 111.663 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 36' ' ' ARG . 3.0 t . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -111.49 120.88 43.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.145 -0.972 . . . . 0.0 109.189 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.58 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.0 t -127.77 137.06 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.89 . . . . 0.0 109.874 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.495 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 18.1 p -143.75 147.27 33.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.409 -0.807 . . . . 0.0 109.259 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.626 ' O ' ' N ' ' A' ' 104' ' ' TYR . 21.6 m-85 -118.55 145.46 45.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 109.786 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 62.6 m -139.59 128.12 22.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.112 -0.993 . . . . 0.0 109.201 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 HD23 ' A' ' 30' ' ' LEU . 5.2 t -76.4 133.36 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.222 -0.924 . . . . 0.0 109.53 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.3 mm-40 -109.83 156.27 20.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.526 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -49.32 113.56 0.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.39 -4.13 1.72 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.39 -1.386 . . . . 0.0 110.727 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.496 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 66.4 m -63.94 140.57 58.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.835 -1.391 . . . . 0.0 109.34 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.58 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.65 177.81 2.05 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.195 -0.941 . . . . 0.0 109.497 -179.571 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 49.9 Cg_endo -70.77 -31.08 16.63 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.516 2.144 . . . . 0.0 111.827 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -116.68 6.25 13.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.016 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 19.8 mttp -142.41 133.56 26.05 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.084 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.29 132.28 51.69 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.964 -1.085 . . . . 0.0 110.002 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.929 HG13 ' HG2' ' A' ' 65' ' ' GLU . 45.7 t -121.8 124.25 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.084 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -141.55 142.02 33.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.947 -1.095 . . . . 0.0 110.285 -179.456 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD2' HG12 ' A' ' 63' ' ' VAL . 10.4 t70 -86.51 136.9 32.91 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.599 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.2 mt -117.06 127.96 74.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 120.712 -1.243 . . . . 0.0 111.122 -178.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 31.1 mtpt -108.06 114.97 29.28 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.58 ' CD1' HG22 ' A' ' 15' ' ' VAL . 84.4 t80 -124.3 108.2 11.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.71 -0.618 . . . . 0.0 109.817 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.9 m -109.52 117.3 33.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.38 -0.825 . . . . 0.0 109.523 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.554 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -139.89 121.72 9.79 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.406 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 50.4 Cg_endo -70.52 119.39 6.3 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.72 2.28 . . . . 0.0 111.929 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.39 -12.44 68.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -141.25 -178.63 5.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.141 -1.211 . . . . 0.0 109.646 -179.906 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -156.32 163.45 39.5 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.748 HD13 ' HD2' ' A' ' 80' ' ' PHE . 51.0 tp -68.96 125.94 28.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.228 -0.92 . . . . 0.0 109.195 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.828 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -113.97 -44.24 3.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 109.9 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -138.55 147.56 43.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.17 -0.956 . . . . 0.0 110.22 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.738 HG22 HD11 ' A' ' 41' ' ' LEU . 43.4 t -138.83 136.75 43.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.458 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 93.0 mt-10 -127.75 149.8 50.08 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.813 -1.179 . . . . 0.0 109.726 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.984 HD13 ' N ' ' A' ' 47' ' ' ARG . 3.2 tm? -118.73 142.72 47.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.529 -0.732 . . . . 0.0 109.642 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.984 ' N ' HD13 ' A' ' 46' ' ' LEU . 13.7 ttp180 -127.48 124.65 38.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -0.86 . . . . 0.0 108.885 179.217 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 11.7 mt-30 -63.87 155.44 30.62 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.25 -0.906 . . . . 0.0 109.895 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.569 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 44.1 t60 -73.19 119.19 17.08 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.348 -0.845 . . . . 0.0 109.586 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.34 6.79 50.44 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.402 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.4 t -115.52 156.28 26.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -1.136 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -114.73 14.63 17.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.266 -0.896 . . . . 0.0 109.332 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -120.62 111.93 18.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.335 -0.853 . . . . 0.0 109.629 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.4 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 44.6 m95 -70.05 135.82 49.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -105.28 133.89 19.94 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.439 -0.788 . . . . 0.0 109.427 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.557 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.5 Cg_endo -72.16 144.63 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.653 2.235 . . . . 0.0 112.084 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.717 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.5 mp -102.28 154.63 18.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.123 -0.986 . . . . 0.0 108.669 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 96.8 m -99.89 127.64 46.05 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.855 -1.153 . . . . 0.0 109.208 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.4 tttm -69.72 109.69 4.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.14 -0.975 . . . . 0.0 109.099 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 62' ' ' ASN . 21.5 mttp -108.96 119.15 38.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.983 -1.073 . . . . 0.0 109.725 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 47.8 -92.94 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 60' ' ' LYS . 4.8 m120 -131.8 17.05 4.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -1.131 . . . . 0.0 109.422 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.487 HG12 ' OD2' ' A' ' 31' ' ' ASP . 27.1 m -130.61 178.16 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.413 ' CD1' HG13 ' A' ' 32' ' ' ILE . 59.0 m95 -124.98 125.19 43.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.34 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.929 ' HG2' HG13 ' A' ' 29' ' ' VAL . 62.4 mt-10 -115.77 150.71 36.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.57 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.1 p -144.53 140.11 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.85 . . . . 0.0 109.265 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -121.87 132.88 54.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.185 -0.947 . . . . 0.0 109.606 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.0 t -116.92 133.9 55.44 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.421 -0.8 . . . . 0.0 109.214 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.9 m -59.94 -18.94 49.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.169 -0.957 . . . . 0.0 109.31 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.573 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.4 178.22 1.02 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.573 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.7 Cg_endo -70.85 141.18 40.2 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.573 2.182 . . . . 0.0 111.846 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.956 HD13 HD12 ' A' ' 28' ' ' LEU . 4.5 mt -76.39 139.05 40.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.475 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 20.8 t -125.01 125.12 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.465 -0.772 . . . . 0.0 109.53 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.438 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.72 169.28 28.41 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.646 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.6 Cg_endo -68.37 146.09 77.89 Favored 'Cis proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.826 -1.739 . . . . 0.0 112.021 0.101 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.835 ' HB3' HD21 ' A' ' 46' ' ' LEU . 83.4 m-85 -89.67 146.37 24.58 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.465 -0.772 . . . . 0.0 110.355 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.943 ' O ' HD22 ' A' ' 46' ' ' LEU . 7.1 m-80 -107.14 142.07 37.41 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 178.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.833 ' CE2' HD23 ' A' ' 46' ' ' LEU . 45.6 m-85 -131.7 119.48 21.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.843 -1.161 . . . . 0.0 110.205 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.99 ' HG3' HG22 ' A' ' 89' ' ' VAL . 33.0 ttm180 -102.13 141.14 35.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.097 -1.002 . . . . 0.0 108.51 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.748 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.3 m-85 -123.01 142.6 50.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 111.403 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' O ' ' A' ' 86' ' ' MET . 0.0 OUTLIER -125.92 124.86 41.75 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.194 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.613 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -74.06 145.63 44.3 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 110.174 -178.413 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.828 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 94.5 mttt -48.14 -44.5 32.29 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.393 -0.817 . . . . 0.0 108.959 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.443 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -56.78 -3.19 0.64 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.72 24.34 18.22 Favored Glycine 0 N--CA 1.489 2.173 0 O-C-N 121.062 -1.258 . . . . 0.0 110.003 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.613 ' O ' ' N ' ' A' ' 82' ' ' SER . 15.0 mmm -96.37 146.75 24.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.071 -1.252 . . . . 0.0 108.634 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 52.9 mtm-85 -122.94 139.42 54.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.855 -1.153 . . . . 0.0 110.55 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.0 m120 -136.31 141.02 43.77 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.99 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.6 t -122.07 136.52 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.982 -1.074 . . . . 0.0 110.195 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.547 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 72.9 m-85 -124.23 122.58 38.15 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.16 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -100.42 147.75 25.5 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.262 -0.899 . . . . 0.0 109.775 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 78.9 mt-10 53.19 52.62 13.3 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 110.276 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.459 ' HB ' ' CD1' ' A' ' 78' ' ' PHE . 57.8 t -84.68 -34.44 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 109.332 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.429 HG13 HG12 ' A' ' 93' ' ' VAL . 44.9 mt -136.58 125.88 15.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.228 -0.92 . . . . 0.0 109.146 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.26 161.96 44.07 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.509 2.139 . . . . 0.0 111.887 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.6 m -52.89 -43.05 65.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.901 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.13 99.75 12.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.107 -0.996 . . . . 0.0 109.655 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -108.27 150.72 26.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.124 -0.985 . . . . 0.0 109.478 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 87.6 p -109.73 170.31 8.15 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.346 -0.847 . . . . 0.0 109.34 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.493 HD13 ' CG1' ' A' ' 19' ' ' VAL . 32.1 mm -104.99 136.12 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.276 -0.89 . . . . 0.0 109.254 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.07 4.66 59.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -118.87 144.27 46.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.104 -1.233 . . . . 0.0 109.362 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.634 HG22 ' H ' ' A' ' 104' ' ' TYR . 3.5 m -78.73 177.15 8.89 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.115 -0.991 . . . . 0.0 109.193 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.634 ' H ' HG22 ' A' ' 103' ' ' THR . 30.7 m-85 -163.73 100.08 0.89 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.859 -1.151 . . . . 0.0 108.926 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -112.86 164.88 14.32 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.118 -0.989 . . . . 0.0 109.887 -179.448 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.547 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.6 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 C-N-CA 122.9 2.4 . . . . 0.0 111.771 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.755 HG22 ' HG2' ' A' ' 36' ' ' ARG . 15.4 t . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -109.81 120.02 41.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.44 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.8 t -126.28 135.6 63.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.917 . . . . 0.0 109.71 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.84 HG22 ' HG2' ' A' ' 105' ' ' LYS . 61.0 p -141.59 146.48 36.32 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.476 -0.765 . . . . 0.0 109.279 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.58 ' O ' ' N ' ' A' ' 104' ' ' TYR . 4.0 m-85 -119.41 141.16 49.34 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 0.0 109.939 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.4 m -136.97 128.52 28.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.17 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.909 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.0 t -76.27 144.68 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.142 -0.974 . . . . 0.0 109.377 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -115.78 159.84 20.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.997 . . . . 0.0 109.584 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 50.6 mttt -53.61 114.3 1.48 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.926 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.7 -3.61 2.62 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.446 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -58.33 141.89 49.76 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.87 -1.371 . . . . 0.0 109.232 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.551 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.19 171.84 8.36 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.223 -0.923 . . . . 0.0 109.689 -179.705 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.79 -30.8 16.98 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.808 2.339 . . . . 0.0 111.998 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 mttt -112.76 8.82 18.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.077 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.453 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 16.9 mttp -142.17 132.82 25.43 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.612 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.1 OUTLIER -120.88 123.05 41.59 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.979 -1.076 . . . . 0.0 109.362 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.985 HG13 ' HG2' ' A' ' 65' ' ' GLU . 25.1 t -120.42 125.99 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.909 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.9 mt -144.7 144.29 31.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.046 -1.034 . . . . 0.0 110.165 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.76 138.91 31.23 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.148 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.936 HG21 ' CE2' ' A' ' 80' ' ' PHE . 69.0 mt -122.28 131.46 73.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.489 -179.193 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 54.7 tttp -109.8 119.01 38.01 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.336 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.575 ' CD1' HG22 ' A' ' 15' ' ' VAL . 78.7 t80 -122.7 113.25 18.97 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.46 -0.775 . . . . 0.0 109.748 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.9 m -115.99 118.38 32.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.32 -0.863 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.755 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -132.91 150.75 76.53 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.459 179.984 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.88 88.61 0.66 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 122.642 2.228 . . . . 0.0 112.081 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.43 -27.73 8.29 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.951 -1.259 . . . . 0.0 109.951 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.56 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -91.17 171.98 8.87 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.116 -1.226 . . . . 0.0 109.619 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.534 ' O ' ' HA ' ' A' ' 82' ' ' SER . 18.2 m -153.66 161.33 42.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.545 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.901 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.4 tt -72.56 132.84 44.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.365 -0.835 . . . . 0.0 109.695 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.952 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.14 -40.06 3.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 109.899 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 87.7 mt-10 -142.45 150.56 40.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.156 -0.965 . . . . 0.0 110.197 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.491 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.8 t -138.44 136.13 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 109.319 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.59 150.51 50.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.002 HD23 HG11 ' A' ' 66' ' ' VAL . 16.7 tp -120.25 135.36 55.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.411 -0.806 . . . . 0.0 109.888 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.598 ' H ' HD12 ' A' ' 46' ' ' LEU . 4.0 ttp180 -121.58 130.27 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.837 . . . . 0.0 108.845 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -74.72 150.54 39.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.13 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.567 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 51.6 t-80 -64.45 117.75 7.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.37 1.34 44.06 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.455 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 38.3 t -113.33 153.14 28.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.188 -1.183 . . . . 0.0 109.439 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 58.0 mt-10 -118.3 20.48 13.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.321 -0.862 . . . . 0.0 109.318 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -124.23 94.08 4.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.873 . . . . 0.0 109.456 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.427 ' CZ3' ' N ' ' A' ' 79' ' ' ARG . 66.3 m95 -54.22 132.06 42.64 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 109.774 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.4 mm-40 -101.05 138.22 19.93 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.799 . . . . 0.0 109.273 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.87 143.78 46.42 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.709 2.273 . . . . 0.0 112.04 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.785 HD11 ' CB ' ' A' ' 46' ' ' LEU . 6.8 mp -110.63 149.85 29.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.194 -0.941 . . . . 0.0 108.931 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 11.3 m -103.31 125.33 49.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.923 -1.11 . . . . 0.0 109.154 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 12.9 tttm -73.58 109.85 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.135 -0.978 . . . . 0.0 109.275 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.898 ' O ' HG22 ' A' ' 63' ' ' VAL . 66.8 mttt -120.23 144.23 47.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.906 -1.121 . . . . 0.0 110.068 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.59 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.76 29.96 0.87 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.59 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 8.0 t30 81.99 14.73 0.51 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.239 -1.153 . . . . 0.0 110.376 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.898 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.6 m -129.52 170.26 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.099 -1.0 . . . . 0.0 109.021 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.678 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.6 m95 -114.51 122.67 47.29 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.908 -1.12 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.985 ' HG2' HG13 ' A' ' 29' ' ' VAL . 43.1 mt-10 -112.39 147.18 36.96 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.402 -0.811 . . . . 0.0 109.445 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 1.002 HG11 HD23 ' A' ' 46' ' ' LEU . 9.7 p -136.21 132.65 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.502 -0.749 . . . . 0.0 109.121 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.0 mttp -119.2 130.51 55.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.099 -1.001 . . . . 0.0 109.482 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.4 t -118.54 144.7 45.89 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 1.2 p -71.4 -4.18 24.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.072 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 16.2 mmtt -132.86 169.7 13.3 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.386 -0.821 . . . . 0.0 109.105 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.02 133.18 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.519 2.146 . . . . 0.0 111.776 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.605 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -68.13 146.53 53.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.346 -0.846 . . . . 0.0 109.777 -179.607 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.84 123.65 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.404 -0.81 . . . . 0.0 109.198 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.82 165.39 28.24 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.653 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.5 Cg_endo -68.78 145.17 76.46 Favored 'Cis proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.922 -1.699 . . . . 0.0 111.985 0.048 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.605 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -89.35 149.07 23.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.578 -0.701 . . . . 0.0 110.432 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.861 ' O ' HD12 ' A' ' 46' ' ' LEU . 36.2 m-80 -109.52 141.82 41.45 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.875 ' CE1' HD13 ' A' ' 46' ' ' LEU . 87.1 m-85 -133.38 121.09 21.8 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.958 -1.089 . . . . 0.0 109.748 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.646 ' HG3' HG22 ' A' ' 89' ' ' VAL . 27.8 ttm180 -104.12 143.31 33.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.07 -1.019 . . . . 0.0 108.944 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.936 ' CE2' HG21 ' A' ' 32' ' ' ILE . 22.6 m-85 -125.53 144.22 50.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 111.676 -178.013 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.637 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -127.04 126.37 42.97 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.611 ' N ' ' O ' ' A' ' 86' ' ' MET . 25.9 p -76.33 145.98 39.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.215 -0.928 . . . . 0.0 110.387 -178.336 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.952 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.5 mttt -50.08 -42.96 51.1 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.15 -2.57 0.41 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.84 25.88 18.71 Favored Glycine 0 N--CA 1.489 2.22 0 O-C-N 121.082 -1.246 . . . . 0.0 109.991 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.611 ' O ' ' N ' ' A' ' 82' ' ' SER . 12.8 mtm -102.17 151.24 22.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.084 -1.245 . . . . 0.0 108.769 179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.637 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 67.8 mtp180 -125.47 140.89 52.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.92 -1.112 . . . . 0.0 110.567 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 80' ' ' PHE . 11.9 m120 -135.23 139.95 44.88 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 79' ' ' ARG . 26.3 t -122.39 137.45 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.999 -1.063 . . . . 0.0 110.364 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 95.4 m-85 -125.37 122.71 37.57 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.26 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -99.81 148.34 24.52 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 98.9 mt-10 52.76 54.06 11.14 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.408 -0.808 . . . . 0.0 110.393 179.493 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 106' ' ' PRO . 77.8 t -85.37 -34.07 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 120.903 -1.123 . . . . 0.0 109.093 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.456 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.0 mt -136.57 125.21 15.21 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.879 . . . . 0.0 108.979 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.53 162.4 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.453 2.102 . . . . 0.0 111.871 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.525 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 39.5 m -51.48 -44.99 62.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.31 -0.869 . . . . 0.0 109.815 -179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.01 101.7 14.46 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.126 -0.983 . . . . 0.0 109.365 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -109.26 151.53 26.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.266 -0.897 . . . . 0.0 109.405 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 53.5 p -105.63 170.41 7.91 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.276 -0.89 . . . . 0.0 109.23 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 18.6 mm -105.13 136.35 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.192 -0.942 . . . . 0.0 109.374 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.26 9.46 61.88 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 52.5 tttt -118.42 143.14 46.89 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -1.197 . . . . 0.0 109.18 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.513 HG22 ' N ' ' A' ' 104' ' ' TYR . 23.2 m -77.28 168.61 19.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.996 -1.065 . . . . 0.0 108.997 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.58 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.1 m-85 -154.63 96.98 1.94 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.674 -1.266 . . . . 0.0 108.918 179.238 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.84 ' HG2' HG22 ' A' ' 16' ' ' THR . 6.6 mtmm -103.15 160.28 26.65 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.266 -0.897 . . . . 0.0 109.806 -179.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.536 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.1 Cg_endo . . . . . 0 C--O 1.215 -0.656 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.974 HG22 ' HG2' ' A' ' 36' ' ' ARG . 6.2 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -109.63 121.65 45.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.546 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 10.3 p -129.28 141.4 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.353 -0.842 . . . . 0.0 109.427 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.442 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 67.9 p -141.58 145.79 35.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.139 -0.976 . . . . 0.0 109.721 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.63 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.0 m-85 -118.63 143.72 46.63 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 31' ' ' ASP . 63.7 m -137.87 128.07 26.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.109 -0.995 . . . . 0.0 109.283 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 ' CD2' ' A' ' 30' ' ' LEU . 15.7 t -76.05 128.63 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.27 -0.893 . . . . 0.0 109.425 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.417 ' O ' HD12 ' A' ' 100' ' ' ILE . 89.9 mm-40 -91.26 -178.39 5.13 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.551 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 20.2 mttt -79.91 70.14 6.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.18 25.84 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.423 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 1.5 t -73.97 140.34 45.45 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.748 -1.442 . . . . 0.0 108.831 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.53 173.74 5.45 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.011 -1.056 . . . . 0.0 109.809 -179.532 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 52.1 Cg_endo -71.8 -32.18 11.9 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.719 2.279 . . . . 0.0 111.909 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -116.95 5.63 12.92 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.012 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.508 ' CD ' ' HE2' ' A' ' 67' ' ' LYS . 79.6 tttt -142.37 133.36 25.85 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.997 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -125.15 131.08 53.3 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.077 -1.014 . . . . 0.0 109.619 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 1.059 HG13 ' HG2' ' A' ' 65' ' ' GLU . 3.1 t -121.45 124.39 71.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.532 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.997 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.5 143.5 31.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.029 -1.044 . . . . 0.0 109.999 -179.487 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HA ' HG12 ' A' ' 63' ' ' VAL . 60.1 t0 -83.99 135.16 34.55 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.577 HG21 ' CE2' ' A' ' 80' ' ' PHE . 78.3 mt -119.4 130.11 74.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.541 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 8.5 ttmm -111.19 120.39 42.13 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.6 ' CE2' ' HB2' ' A' ' 36' ' ' ARG . 87.3 t80 -120.32 119.87 34.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.391 -0.818 . . . . 0.0 109.519 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 31.1 m -122.31 115.55 22.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.298 -0.876 . . . . 0.0 109.751 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.974 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -133.59 136.86 27.61 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.525 -0.734 . . . . 0.0 109.03 179.768 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 48.1 Cg_endo -69.93 104.49 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.676 2.251 . . . . 0.0 111.95 -179.747 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.31 3.38 87.06 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.562 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 4.2 t0 -136.38 175.05 9.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.155 -1.203 . . . . 0.0 109.758 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.511 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 p -153.05 161.02 43.0 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.337 -0.852 . . . . 0.0 109.372 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.803 HD21 ' CG2' ' A' ' 44' ' ' VAL . 8.1 tp -72.08 132.74 44.63 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.789 ' N ' HD12 ' A' ' 41' ' ' LEU . . . -117.26 -41.63 2.97 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 109.741 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -141.76 150.12 41.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.181 -0.949 . . . . 0.0 109.992 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.803 ' CG2' HD21 ' A' ' 41' ' ' LEU . 2.6 t -138.52 135.98 43.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.439 -0.788 . . . . 0.0 109.365 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.451 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 78.4 mt-10 -127.81 149.78 50.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.911 -1.118 . . . . 0.0 109.21 179.432 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.889 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.0 tt -120.28 139.69 52.34 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.335 -0.853 . . . . 0.0 109.89 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.883 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.3 ttp180 -126.82 120.12 28.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.875 . . . . 0.0 108.82 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -64.39 145.05 56.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.141 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.552 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 49.1 t60 -55.82 145.41 24.59 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.454 -0.779 . . . . 0.0 109.243 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.51 1.22 51.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.419 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 9.6 t -111.44 152.75 27.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.1 -1.235 . . . . 0.0 109.316 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 -119.0 7.32 11.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -104.89 97.9 7.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.543 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 51.5 m95 -63.11 132.07 50.62 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 109.779 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -105.3 136.97 19.14 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 109.391 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD22 ' A' ' 57' ' ' LEU . 50.9 Cg_endo -70.88 151.82 62.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.752 2.301 . . . . 0.0 112.201 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.744 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.3 OUTLIER -110.2 154.03 23.94 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 179.6 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' TRP . 7.0 m -110.21 126.4 54.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.833 -1.167 . . . . 0.0 108.808 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 tttm -74.31 105.73 5.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.087 -1.008 . . . . 0.0 109.283 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.77 ' O ' HG22 ' A' ' 63' ' ' VAL . 16.4 mttp -120.47 142.86 48.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.819 -1.176 . . . . 0.0 110.249 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.84 35.96 1.67 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 7.9 m-20 78.06 10.82 2.01 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.061 -1.258 . . . . 0.0 110.469 179.158 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 60' ' ' LYS . 15.6 m -128.59 -177.96 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.977 -1.077 . . . . 0.0 108.776 179.241 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 66.1 m95 -123.07 141.07 52.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.05 -1.032 . . . . 0.0 109.927 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 1.059 ' HG2' HG13 ' A' ' 29' ' ' VAL . 92.1 mt-10 -127.96 142.37 51.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.473 -0.767 . . . . 0.0 109.105 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.744 ' HB ' HD13 ' A' ' 57' ' ' LEU . 1.9 p -139.39 137.53 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.227 -0.92 . . . . 0.0 109.377 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.508 ' HE2' ' CD ' ' A' ' 27' ' ' LYS . 28.7 mttt -122.71 134.15 54.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.463 -0.773 . . . . 0.0 109.632 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.7 t -117.46 145.3 44.26 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.488 -0.758 . . . . 0.0 109.18 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 49.5 m -68.77 -16.5 63.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.16 -0.962 . . . . 0.0 109.289 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.557 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.73 176.4 1.53 Allowed Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.557 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.8 Cg_endo -70.03 136.64 32.77 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.684 2.256 . . . . 0.0 111.726 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.946 HD13 HD12 ' A' ' 28' ' ' LEU . 6.4 mt -68.64 136.57 53.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.9 t -126.06 125.56 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.491 -0.756 . . . . 0.0 109.472 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.529 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -93.66 166.25 27.68 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.64 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.73 146.12 78.93 Favored 'Cis proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.843 -1.732 . . . . 0.0 111.99 0.032 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.9 m-85 -90.09 148.39 23.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.482 -0.761 . . . . 0.0 110.425 -179.201 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.455 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 18.9 m-80 -110.52 144.37 39.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.387 -0.821 . . . . 0.0 108.829 179.021 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.889 ' CE2' HD12 ' A' ' 46' ' ' LEU . 61.8 m-85 -135.81 125.38 25.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.89 -1.131 . . . . 0.0 110.25 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.955 ' HG3' HG22 ' A' ' 89' ' ' VAL . 15.2 ttp180 -105.85 141.38 37.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -0.96 . . . . 0.0 108.451 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.766 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.0 m-85 -122.11 142.23 50.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 111.082 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -125.5 123.97 40.33 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.448 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.603 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.4 p -74.43 144.19 44.38 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.386 -0.821 . . . . 0.0 110.352 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.774 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 46.5 mttp -46.39 -44.76 17.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.429 -0.795 . . . . 0.0 108.946 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.47 -3.42 0.63 Allowed Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.462 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.05 24.36 20.0 Favored Glycine 0 N--CA 1.49 2.27 0 O-C-N 120.992 -1.299 . . . . 0.0 110.124 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.603 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.0 mtm -98.34 150.12 21.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.994 -1.298 . . . . 0.0 108.516 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.597 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 22.7 mtm-85 -125.58 141.59 51.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.845 -1.16 . . . . 0.0 110.636 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . 23.7 m120 -137.03 141.37 42.48 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.955 HG22 ' HG3' ' A' ' 79' ' ' ARG . 10.5 t -122.63 136.87 58.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.882 -1.136 . . . . 0.0 110.447 -178.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.557 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.7 m-85 -123.57 121.65 36.15 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.54 146.59 25.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.778 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.64 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 51.8 tt0 53.7 51.54 14.82 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.431 -0.793 . . . . 0.0 110.424 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.453 HG21 ' HB2' ' A' ' 90' ' ' PHE . 72.5 t -82.33 -34.18 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.88 -1.138 . . . . 0.0 108.992 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.4 HG12 ' HB3' ' A' ' 104' ' ' TYR . 12.2 mt -135.82 127.13 17.19 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.258 -0.902 . . . . 0.0 109.162 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.48 161.13 47.12 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.552 2.168 . . . . 0.0 112.007 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.529 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 28.0 m -52.04 -45.15 64.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.744 -179.717 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.82 102.41 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.429 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 47.1 p90 -111.1 151.75 27.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.128 -0.982 . . . . 0.0 109.504 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 33.2 m -106.36 163.11 13.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.909 . . . . 0.0 109.467 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.531 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.1 mm -98.16 137.4 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.376 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.4 7.47 58.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.9 tptt -121.1 143.56 49.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.134 -1.215 . . . . 0.0 109.362 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.7 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.2 m -79.29 178.79 7.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 108.764 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.7 ' H ' HG22 ' A' ' 103' ' ' THR . 25.3 m-85 -164.36 94.57 0.72 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.659 -1.275 . . . . 0.0 109.112 179.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -106.26 163.73 16.42 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.375 -0.828 . . . . 0.0 109.596 -179.481 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 48.5 Cg_endo . . . . . 0 C--O 1.216 -0.62 0 C-N-CA 122.496 2.13 . . . . 0.0 111.723 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.81 HG22 ' CG ' ' A' ' 36' ' ' ARG . 47.8 t . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 74.5 mt-30 -107.53 119.43 39.41 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.123 -0.985 . . . . 0.0 109.122 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.661 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.8 p -128.66 139.43 51.91 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.21 -0.931 . . . . 0.0 110.051 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.513 HG22 ' HG2' ' A' ' 105' ' ' LYS . 30.4 p -141.21 145.12 35.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.304 -0.873 . . . . 0.0 109.41 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.602 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.8 m-85 -117.16 136.23 53.18 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 52.3 m -131.27 127.21 37.31 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.968 -1.083 . . . . 0.0 109.326 179.402 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.96 HG22 ' CD2' ' A' ' 30' ' ' LEU . 9.0 t -75.38 128.37 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.283 -0.886 . . . . 0.0 109.274 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.414 ' O ' HG12 ' A' ' 100' ' ' ILE . 88.6 mm-40 -89.35 -178.25 5.57 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.061 -1.024 . . . . 0.0 109.843 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.2 mttp -80.23 65.38 5.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.437 -0.789 . . . . 0.0 109.975 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.28 25.9 0.08 OUTLIER Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.496 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.608 ' HB3' ' CZ ' ' A' ' 98' ' ' PHE . 3.2 m -79.72 144.04 34.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.079 -1.248 . . . . 0.0 109.337 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.4 172.06 7.48 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.121 -0.987 . . . . 0.0 109.579 -179.766 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -70.67 -28.2 21.16 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.667 2.244 . . . . 0.0 111.809 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.44 ' HB3' ' O ' ' A' ' 68' ' ' SER . 80.4 mttt -116.4 5.57 13.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.087 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 61.4 mttm -141.55 132.86 26.57 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.682 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.11 123.21 41.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.978 -1.076 . . . . 0.0 109.71 -179.6 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.787 HG22 ' HG3' ' A' ' 65' ' ' GLU . 13.6 t -119.58 125.09 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.96 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -145.14 146.04 31.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.926 -1.109 . . . . 0.0 110.125 -179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.469 ' HA ' HG12 ' A' ' 63' ' ' VAL . 62.6 t0 -86.06 136.82 33.08 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.068 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.869 HG21 ' HE2' ' A' ' 80' ' ' PHE . 78.6 mt -121.05 130.82 74.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 C-N-CA 118.825 -1.15 . . . . 0.0 110.661 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.661 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 29.0 tttm -110.43 120.75 43.45 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.533 ' CE1' HG11 ' A' ' 13' ' ' VAL . 88.5 t80 -120.93 111.33 17.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.328 -0.857 . . . . 0.0 109.528 -179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 19.9 m -113.66 114.72 26.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 109.772 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.81 ' CG ' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -152.58 113.01 2.78 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.515 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.06 128.91 17.39 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.704 2.269 . . . . 0.0 112.165 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.61 -22.46 40.42 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.82 -178.76 5.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -1.144 . . . . 0.0 109.807 -179.817 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.561 ' O ' ' HA ' ' A' ' 82' ' ' SER . 57.9 m -154.37 161.68 41.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.324 -0.86 . . . . 0.0 109.331 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.51 130.19 40.64 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.255 -0.903 . . . . 0.0 109.736 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.937 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.4 -41.22 3.14 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.222 -0.924 . . . . 0.0 109.839 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -141.19 149.48 41.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.466 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.638 ' CG2' HD11 ' A' ' 41' ' ' LEU . 95.2 t -138.72 136.94 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -128.67 149.68 50.57 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.832 -1.168 . . . . 0.0 109.551 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.006 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.3 tt -119.4 135.73 54.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.443 -0.786 . . . . 0.0 109.852 -179.288 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 1.006 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.3 ttp180 -122.37 129.79 52.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -0.883 . . . . 0.0 109.051 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 16.0 mt-30 -72.11 145.83 47.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.751 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.593 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 38.4 t60 -64.42 112.09 2.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 109.358 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.48 1.26 24.71 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 11.0 t -114.27 153.91 28.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -1.2 . . . . 0.0 109.421 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -110.73 6.92 21.92 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.3 mt-10 -118.04 104.14 10.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.593 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 33.6 m95 -61.8 142.16 57.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.415 -0.803 . . . . 0.0 109.746 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -106.0 136.15 19.34 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.361 -0.837 . . . . 0.0 109.293 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.8 Cg_endo -71.59 147.14 50.85 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.634 2.223 . . . . 0.0 112.198 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.81 HD11 ' HB2' ' A' ' 46' ' ' LEU . 9.0 mp -108.14 148.54 29.72 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.267 -0.896 . . . . 0.0 108.775 179.461 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 61.4 m -96.29 125.63 40.93 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.876 -1.14 . . . . 0.0 109.161 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.441 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 55.4 tttt -70.15 111.19 5.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.144 -0.972 . . . . 0.0 109.072 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.438 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.5 mttt -111.78 107.71 16.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.957 -1.089 . . . . 0.0 109.608 -179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.9 -93.15 0.12 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -134.75 20.01 3.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.206 -1.173 . . . . 0.0 109.339 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.469 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.7 m -130.86 -172.81 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.362 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.441 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 69.2 m95 -135.45 125.21 25.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.885 . . . . 0.0 109.122 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.787 ' HG3' HG22 ' A' ' 29' ' ' VAL . 60.9 tt0 -114.99 149.99 36.52 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 109.748 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.677 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 14.5 p -141.57 137.54 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.412 -0.805 . . . . 0.0 109.456 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -119.91 129.33 54.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.491 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.44 ' O ' ' HB3' ' A' ' 26' ' ' LYS . 35.6 t -118.3 131.83 56.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.602 -0.687 . . . . 0.0 109.51 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.5 t -61.26 -14.02 23.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.911 . . . . 0.0 108.973 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -116.1 167.55 10.12 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.35 -0.844 . . . . 0.0 109.208 179.9 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 46.4 Cg_endo -68.14 129.64 19.81 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.54 2.16 . . . . 0.0 111.792 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.617 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -63.41 142.5 58.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.374 -0.829 . . . . 0.0 109.648 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.03 124.25 68.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.332 -0.855 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.523 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.77 164.31 27.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.67 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.3 Cg_endo -69.0 147.31 82.79 Favored 'Cis proline' 0 C--O 1.214 -0.713 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.935 0.072 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.617 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -91.26 147.6 22.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.536 -0.728 . . . . 0.0 110.353 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -108.32 143.77 36.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.354 -0.841 . . . . 0.0 108.736 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.697 ' CE2' HD12 ' A' ' 46' ' ' LEU . 85.3 m-85 -134.17 125.66 28.35 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.062 -1.024 . . . . 0.0 109.906 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.943 ' HG3' HG22 ' A' ' 89' ' ' VAL . 44.2 ttt180 -108.21 142.34 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.962 -1.086 . . . . 0.0 108.834 179.15 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.869 ' HE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -124.4 143.28 50.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.881 . . . . 0.0 111.154 -178.202 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.65 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.2 ttm -126.2 125.69 42.85 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.568 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 20.5 p -73.99 145.85 44.29 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.284 -0.885 . . . . 0.0 110.26 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.937 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 18.8 mttm -50.55 -42.88 55.92 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.342 -0.849 . . . . 0.0 108.771 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.94 -4.5 0.72 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.89 27.21 11.42 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 8.8 mtm -103.32 153.86 19.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.04 -1.27 . . . . 0.0 108.802 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.65 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 32.7 mtt180 -128.29 142.18 51.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.812 -1.18 . . . . 0.0 110.786 -178.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.5 m120 -134.81 140.09 45.6 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.943 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.9 t -122.63 137.04 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.958 -1.089 . . . . 0.0 110.498 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 56.8 m-85 -124.93 122.52 37.58 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.204 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 35.2 p-10 -98.85 147.62 24.74 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.15 -0.969 . . . . 0.0 109.645 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.67 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 32.8 mt-10 53.0 52.44 13.85 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.84 . . . . 0.0 110.277 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.413 HG21 ' HB2' ' A' ' 90' ' ' PHE . 45.2 t -83.23 -34.41 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.789 -1.194 . . . . 0.0 109.094 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.406 HG13 HG12 ' A' ' 93' ' ' VAL . 13.4 mt -138.32 125.25 13.23 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.325 -0.859 . . . . 0.0 109.032 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.04 162.79 40.26 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.611 2.207 . . . . 0.0 111.97 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.523 HG23 ' H ' ' A' ' 74' ' ' GLY . 12.3 m -54.01 -37.51 64.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.41 -0.806 . . . . 0.0 109.899 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.14 101.29 12.92 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.004 -1.06 . . . . 0.0 109.714 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.608 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 40.4 p90 -109.58 149.56 29.49 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 109.279 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ILE . 1.4 m -118.77 104.22 10.38 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.731 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.525 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 8.7 mt -43.29 139.96 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 105.0 -3.09 41.05 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.9 tptt -122.29 142.76 50.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -1.174 . . . . 0.0 109.226 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.612 HG22 ' H ' ' A' ' 104' ' ' TYR . 10.9 m -79.18 175.0 10.99 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.117 -0.99 . . . . 0.0 108.619 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.612 ' H ' HG22 ' A' ' 103' ' ' THR . 26.8 m-85 -159.94 96.7 1.24 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.675 -1.265 . . . . 0.0 109.119 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.517 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 7.9 mtmt -97.8 163.2 20.0 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.441 -0.787 . . . . 0.0 109.635 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 48.1 Cg_endo . . . . . 0 C--O 1.216 -0.602 0 C-N-CA 122.69 2.26 . . . . 0.0 112.024 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.777 HG13 ' HB2' ' A' ' 36' ' ' ARG . 4.6 t . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 88.4 mm-40 -102.81 121.31 42.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.227 -0.92 . . . . 0.0 109.251 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 7.0 p -129.81 141.15 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.279 -0.888 . . . . 0.0 109.691 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.486 ' HA ' ' HB3' ' A' ' 105' ' ' LYS . 21.4 p -141.88 145.78 35.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.562 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.7 m-85 -117.0 150.83 37.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.436 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 42.3 m -144.48 127.26 16.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.999 -1.063 . . . . 0.0 109.373 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.919 HG22 ' CD2' ' A' ' 30' ' ' LEU . 12.2 t -75.84 135.63 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.4 mm-40 -114.62 155.18 27.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.049 -1.032 . . . . 0.0 109.885 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -47.23 109.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.495 -0.753 . . . . 0.0 109.853 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.68 -5.76 1.36 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.669 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 98' ' ' PHE . 7.3 p -62.39 142.94 57.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.801 -1.411 . . . . 0.0 109.361 -179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.535 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.43 173.83 5.15 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.6 Cg_endo -70.79 -28.75 19.9 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.667 2.245 . . . . 0.0 111.954 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -116.24 7.22 13.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.068 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.491 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 33.1 mttp -142.7 133.68 25.7 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.687 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.48 123.16 40.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.929 -1.107 . . . . 0.0 109.613 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.549 HG22 ' HG3' ' A' ' 65' ' ' GLU . 9.0 t -120.2 125.59 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 179.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.919 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -144.87 144.95 31.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.893 -1.129 . . . . 0.0 110.226 -179.369 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.562 ' HA ' HG12 ' A' ' 63' ' ' VAL . 16.2 t70 -82.4 134.43 35.24 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.625 HG21 ' CE2' ' A' ' 80' ' ' PHE . 74.9 mt -119.96 130.64 73.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.779 -1.201 . . . . 0.0 110.74 -178.574 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 62.8 mttm -111.49 120.15 41.16 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 178.652 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.545 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 90.1 t80 -120.53 112.86 19.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.425 -0.797 . . . . 0.0 109.501 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 33.8 m -115.22 115.24 26.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 0.0 109.688 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.777 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -147.6 117.55 4.36 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.462 -0.774 . . . . 0.0 109.066 179.897 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.29 123.65 10.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.94 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.37 59.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.572 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -142.71 -176.39 4.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -1.201 . . . . 0.0 109.864 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.6 m -155.83 162.69 40.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.332 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.759 HD21 HG21 ' A' ' 44' ' ' VAL . 48.6 tp -69.32 126.38 29.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.964 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.855 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.83 -44.51 2.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.854 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.433 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 27.0 mt-10 -137.19 146.85 45.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.158 -0.964 . . . . 0.0 110.262 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 HD21 ' A' ' 41' ' ' LEU . 98.2 t -139.93 137.39 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.476 -0.765 . . . . 0.0 109.252 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.432 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 94.5 mt-10 -127.79 150.69 49.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.822 -1.174 . . . . 0.0 109.231 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.035 HD23 HG11 ' A' ' 66' ' ' VAL . 12.1 tp -120.42 132.24 55.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 110.393 -178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.647 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.4 OUTLIER -113.19 124.88 53.56 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.292 -0.88 . . . . 0.0 108.995 179.178 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.429 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 19.7 mt-30 -65.24 159.14 24.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.252 -0.905 . . . . 0.0 109.087 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.583 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 11.4 t-80 -75.95 108.15 8.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.17 7.09 21.66 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 23.1 t -115.88 154.16 30.23 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.047 -1.267 . . . . 0.0 109.514 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mt-10 -104.9 -22.44 13.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.274 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -87.67 129.03 35.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.62 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 9.4 m95 -86.92 141.68 28.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.632 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.41 ' OE2' ' O ' ' A' ' 67' ' ' LYS . 45.4 tt0 -107.98 133.75 20.38 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.351 -0.843 . . . . 0.0 109.481 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.7 Cg_endo -70.78 151.0 62.93 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.693 2.262 . . . . 0.0 111.783 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.809 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.8 mp -109.16 143.84 38.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.206 -0.934 . . . . 0.0 109.11 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.7 m -92.7 127.44 38.2 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.99 -1.069 . . . . 0.0 109.136 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -70.49 109.99 5.13 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.164 -0.96 . . . . 0.0 109.11 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -109.4 115.77 30.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.945 -1.097 . . . . 0.0 109.586 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 53.18 -97.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -128.12 16.58 6.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.216 -1.167 . . . . 0.0 109.466 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.562 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.3 m -131.04 -176.94 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.32 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.477 ' CD1' HD12 ' A' ' 32' ' ' ILE . 57.9 m95 -128.33 130.35 47.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.112 -0.993 . . . . 0.0 109.332 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.2 tt0 -111.69 135.97 51.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.645 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 1.035 HG11 HD23 ' A' ' 46' ' ' LEU . 5.3 p -130.67 129.67 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.426 -0.797 . . . . 0.0 109.012 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.449 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 19.4 mtmm -121.43 133.3 55.07 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.04 -1.038 . . . . 0.0 109.692 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.429 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 3.1 t -118.38 153.08 34.63 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.422 -0.799 . . . . 0.0 109.305 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.1 m -78.6 -2.36 38.57 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.151 -0.968 . . . . 0.0 109.148 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.561 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 3.5 mttt -128.81 177.02 2.34 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.339 -0.851 . . . . 0.0 109.164 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.6 Cg_endo -68.54 150.3 75.02 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.495 2.13 . . . . 0.0 111.856 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.579 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 14.9 mt -85.58 137.46 32.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.33 -0.856 . . . . 0.0 109.682 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.557 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 28.9 t -127.02 125.86 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.46 -0.775 . . . . 0.0 109.475 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.522 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.94 169.19 28.03 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.664 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.2 Cg_endo -67.98 146.92 78.86 Favored 'Cis proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.912 -1.703 . . . . 0.0 112.002 0.122 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 86.6 m-85 -89.69 149.77 22.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.589 -0.695 . . . . 0.0 110.343 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.809 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.9 m120 -112.06 142.74 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.78 ' CE1' HD13 ' A' ' 46' ' ' LEU . 96.5 m-85 -134.85 134.84 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.999 -1.063 . . . . 0.0 109.381 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.536 ' NH1' ' CZ ' ' A' ' 87' ' ' ARG . 64.5 ttt180 -116.8 144.07 44.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.943 -1.098 . . . . 0.0 108.864 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.732 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.6 m-85 -122.89 140.79 52.6 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.157 -0.965 . . . . 0.0 111.238 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.624 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.1 ttm -123.45 124.02 41.96 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.027 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 18.8 p -72.37 142.41 48.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.455 -0.778 . . . . 0.0 110.475 -178.164 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.855 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 56.4 mttt -46.64 -44.18 18.18 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 108.821 178.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -57.09 -5.85 1.65 Allowed Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 97.3 25.36 11.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 55.4 mtp -99.67 152.52 19.97 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.108 -1.23 . . . . 0.0 108.473 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.624 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 33.5 mtm180 -128.39 142.13 51.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.617 -1.302 . . . . 0.0 110.918 -178.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.535 ' N ' ' O ' ' A' ' 80' ' ' PHE . 29.9 m120 -135.69 140.73 44.67 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.3 t -122.79 136.72 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.863 -1.148 . . . . 0.0 110.387 -179.026 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.548 ' CD1' ' CB ' ' A' ' 106' ' ' PRO . 55.5 m-85 -124.16 122.41 37.75 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.107 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -99.53 147.37 25.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.209 -0.932 . . . . 0.0 109.716 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.664 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 81.3 mt-10 53.99 51.18 15.15 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.505 -0.747 . . . . 0.0 110.344 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 94' ' ' ILE . 43.5 t -81.96 -34.89 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.864 -1.148 . . . . 0.0 108.938 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 93' ' ' VAL . 13.0 mt -135.8 125.07 16.02 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.473 -0.767 . . . . 0.0 108.974 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.28 161.61 45.19 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.569 2.179 . . . . 0.0 111.977 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.522 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 29.1 m -50.09 -45.68 52.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.373 -0.83 . . . . 0.0 109.726 -179.713 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.06 101.18 13.89 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.053 -1.029 . . . . 0.0 109.5 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.509 ' CE1' HG11 ' A' ' 19' ' ' VAL . 44.8 p90 -108.26 154.12 22.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 69.4 m -110.43 170.87 7.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.39 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 23.2 mm -105.19 136.71 37.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 109.312 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.72 6.28 59.56 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 46.7 tttt -119.03 143.43 47.1 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.095 -1.238 . . . . 0.0 109.225 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.622 HG22 ' H ' ' A' ' 104' ' ' TYR . 15.5 m -80.8 174.74 11.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.161 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.622 ' H ' HG22 ' A' ' 103' ' ' THR . 35.1 m-85 -160.36 102.25 1.39 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.765 -1.209 . . . . 0.0 108.772 179.231 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.597 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 1.7 ptpp? -114.16 166.36 11.66 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.201 -0.937 . . . . 0.0 109.776 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.597 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 48.7 Cg_endo . . . . . 0 C--O 1.216 -0.617 0 C-N-CA 122.587 2.191 . . . . 0.0 111.811 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.624 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 10.9 t . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -113.31 120.96 42.95 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.6 HG22 ' CD1' ' A' ' 34' ' ' TYR . 2.7 t -127.67 137.89 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.257 -0.902 . . . . 0.0 109.823 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 32.4 p -142.31 146.09 34.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.39 -0.819 . . . . 0.0 109.231 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.603 ' O ' ' N ' ' A' ' 104' ' ' TYR . 8.7 m-85 -119.41 151.85 37.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.106 -0.996 . . . . 0.0 110.02 -179.757 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 27.7 m -143.18 158.86 43.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 108.71 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.845 HG22 HD23 ' A' ' 30' ' ' LEU . 4.3 t -107.75 127.96 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.087 -1.008 . . . . 0.0 109.433 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -101.47 149.8 23.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.897 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -44.01 114.09 0.62 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.498 -0.752 . . . . 0.0 109.94 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.16 2.19 1.4 Allowed Glycine 0 N--CA 1.49 2.264 0 C-N-CA 119.272 -1.442 . . . . 0.0 110.907 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.0 m -61.18 142.38 56.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.667 -1.49 . . . . 0.0 109.054 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.82 171.94 7.59 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.094 -1.004 . . . . 0.0 109.616 -179.627 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.7 Cg_endo -70.68 -29.02 20.09 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.729 2.286 . . . . 0.0 111.829 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -118.03 3.4 12.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.009 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 21.1 mttt -141.83 133.15 26.51 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.049 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.07 133.78 50.39 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.018 -1.051 . . . . 0.0 110.17 -179.374 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.492 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.3 t -121.62 124.05 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.049 HD11 HD22 ' A' ' 28' ' ' LEU . 1.3 mt -140.94 141.14 34.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.01 -1.056 . . . . 0.0 110.093 -179.428 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.72 ' CG ' HG12 ' A' ' 63' ' ' VAL . 18.2 t0 -85.55 134.51 34.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.461 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.654 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -116.12 126.89 73.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 118.922 -1.111 . . . . 0.0 110.893 -179.105 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 13.7 tttm -107.28 115.07 29.52 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.01 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.624 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.2 t80 -124.93 111.88 15.96 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.345 0.593 . . . . 0.0 109.634 -178.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.3 m -113.85 119.77 38.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.94 . . . . 0.0 109.691 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.488 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 29.7 ttt85 -140.91 119.58 8.2 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.7 119.29 6.26 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.714 2.276 . . . . 0.0 111.821 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.14 -14.52 60.52 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.488 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 6.2 m-20 -136.43 175.18 9.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.181 -1.188 . . . . 0.0 109.644 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 m -154.41 161.6 41.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.297 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.718 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.4 OUTLIER -71.21 130.87 42.53 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.257 -0.902 . . . . 0.0 109.385 179.947 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.93 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -112.4 -41.03 3.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.466 ' O ' HD21 ' A' ' 41' ' ' LEU . 90.4 mt-10 -143.18 151.27 40.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 0.0 110.187 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.693 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.1 t -138.9 136.32 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.5 mt-10 -126.77 149.24 49.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.697 -1.252 . . . . 0.0 109.547 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.908 HD13 ' CE2' ' A' ' 78' ' ' PHE . 10.4 tp -122.18 131.24 53.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.479 -0.763 . . . . 0.0 109.929 -179.106 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.646 ' N ' HD12 ' A' ' 46' ' ' LEU . 41.8 ttp180 -118.92 135.04 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.088 179.354 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.453 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 24.7 mt-30 -75.05 150.72 38.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 110.034 -179.311 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 4.2 t-80 -67.4 112.55 4.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.41 -0.806 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.63 0.63 30.73 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.464 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 4.0 t -113.67 155.54 25.35 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.206 -1.173 . . . . 0.0 109.32 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -108.33 -14.31 14.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.243 -0.911 . . . . 0.0 109.404 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -93.17 117.92 30.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.223 -0.923 . . . . 0.0 109.736 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.631 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 25.3 m95 -75.94 140.29 42.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.419 -0.801 . . . . 0.0 109.638 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.469 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.8 OUTLIER -106.59 127.35 28.31 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.472 -0.768 . . . . 0.0 109.095 179.757 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.617 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.6 Cg_endo -69.67 150.42 68.71 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.586 2.191 . . . . 0.0 112.19 -179.623 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.8 mp -107.47 141.85 38.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 108.847 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 43.5 m -92.91 127.26 38.36 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.923 -1.11 . . . . 0.0 109.06 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tttm -73.49 109.86 7.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 109.717 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.0 mttm -109.88 110.93 22.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.998 -1.064 . . . . 0.0 109.752 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.46 -90.02 0.07 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.431 ' OD1' HG13 ' A' ' 63' ' ' VAL . 49.5 p-10 -139.04 18.45 2.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.288 -1.124 . . . . 0.0 109.281 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.72 HG12 ' CG ' ' A' ' 31' ' ' ASP . 16.2 m -130.66 173.4 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.283 -0.886 . . . . 0.0 109.249 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.434 ' CD1' HG13 ' A' ' 32' ' ' ILE . 66.5 m95 -123.17 128.64 50.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 109.317 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.461 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.7 tt0 -117.85 151.38 37.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.627 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.882 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -145.38 140.9 22.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.329 -0.857 . . . . 0.0 109.308 179.784 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 34.9 mttp -122.15 132.97 54.73 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.717 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.453 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 38.8 t -116.71 121.52 41.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.454 -0.779 . . . . 0.0 109.349 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 58.8 m -49.16 -22.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.571 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -109.65 177.25 1.28 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.318 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.571 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -68.86 152.69 73.67 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.504 2.136 . . . . 0.0 111.657 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.732 HD13 HD12 ' A' ' 28' ' ' LEU . 1.5 mt -90.28 138.05 31.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 35.4 t -126.34 125.28 67.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.422 -0.798 . . . . 0.0 109.605 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA3' ' N ' ' A' ' 96' ' ' THR . . . -94.39 167.29 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.713 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.1 Cg_endo -68.15 147.43 80.46 Favored 'Cis proline' 0 C--O 1.213 -0.735 0 C-N-CA 122.937 -1.693 . . . . 0.0 112.034 0.218 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.604 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.1 m-85 -91.23 150.82 21.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.441 -0.787 . . . . 0.0 110.448 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.784 ' O ' HD12 ' A' ' 46' ' ' LEU . 23.3 m-80 -111.12 142.08 43.77 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.908 ' CE2' HD13 ' A' ' 46' ' ' LEU . 41.9 m-85 -135.95 128.3 30.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.918 -1.114 . . . . 0.0 110.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.875 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.2 ttt180 -108.56 142.23 39.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 108.643 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.654 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.3 m-85 -123.49 143.6 50.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.213 -0.93 . . . . 0.0 111.411 -178.079 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.621 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.6 ttm -127.44 125.67 40.97 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.727 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.2 p -77.39 144.94 37.54 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.89 . . . . 0.0 110.246 -178.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.93 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 60.0 mttm -47.78 -43.14 27.28 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.4 -2.71 0.74 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.37 23.98 22.87 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.8 mmm -98.64 148.39 23.86 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -1.231 . . . . 0.0 108.681 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 77.8 mtm-85 -126.84 142.58 51.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.78 -1.2 . . . . 0.0 110.586 -178.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.413 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.2 m120 -136.97 141.17 42.59 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.875 HG22 ' HG3' ' A' ' 79' ' ' ARG . 2.9 t -121.43 136.32 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 71.8 m-85 -124.56 122.39 37.44 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.267 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -100.06 148.62 24.36 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.244 -0.91 . . . . 0.0 109.644 -179.699 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.713 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 88.6 mt-10 53.28 51.87 14.66 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.369 -0.832 . . . . 0.0 110.278 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.648 HG22 ' HB3' ' A' ' 106' ' ' PRO . 97.6 t -84.08 -34.33 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.856 -1.153 . . . . 0.0 109.188 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.2 mt -137.53 125.56 14.33 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.325 -0.859 . . . . 0.0 109.127 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.71 163.02 39.8 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.577 2.185 . . . . 0.0 112.07 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.535 ' N ' ' HA3' ' A' ' 74' ' ' GLY . 32.3 m -54.13 -44.09 71.06 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.414 -0.804 . . . . 0.0 109.918 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.39 99.41 11.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.054 -1.029 . . . . 0.0 109.363 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -107.85 147.09 31.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 109.722 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 70.4 m -107.08 167.86 9.6 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -0.862 . . . . 0.0 109.169 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.502 HD13 ' CG1' ' A' ' 19' ' ' VAL . 29.8 mm -104.16 136.78 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 109.408 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.73 2.66 61.26 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.1 tptt -116.15 142.55 46.67 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.09 -1.241 . . . . 0.0 109.176 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.573 HG22 ' H ' ' A' ' 104' ' ' TYR . 18.6 m -78.39 173.51 12.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.075 -1.016 . . . . 0.0 108.966 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.603 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -156.16 105.83 2.35 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.765 -1.209 . . . . 0.0 108.831 179.187 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 105' ' ' LYS . 1.3 ptmt -103.67 157.41 33.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.724 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.648 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.744 2.296 . . . . 0.0 111.734 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.959 HG22 ' HG2' ' A' ' 36' ' ' ARG . 40.5 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 97.2 mm-40 -109.4 120.35 42.24 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 109.118 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.9 p -128.35 140.53 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.314 -0.866 . . . . 0.0 109.499 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.49 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 32.0 p -143.09 146.32 33.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.187 -0.945 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.606 ' CD2' HG12 ' A' ' 32' ' ' ILE . 7.4 m-85 -117.01 148.41 41.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.251 -0.905 . . . . 0.0 109.286 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 36.0 m -143.6 128.63 18.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.929 -1.107 . . . . 0.0 109.621 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.935 HG22 HD21 ' A' ' 30' ' ' LEU . 3.5 t -76.7 138.52 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.157 -0.964 . . . . 0.0 109.364 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.7 mm-40 -118.66 155.66 30.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.02 -1.05 . . . . 0.0 109.612 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -47.51 112.73 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.82 . . . . 0.0 110.009 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.73 -7.96 1.99 Allowed Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.71 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 4.5 p -60.18 141.76 55.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.805 -1.409 . . . . 0.0 109.435 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.584 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.14 177.27 2.25 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.165 -0.959 . . . . 0.0 109.693 -179.594 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.584 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.8 Cg_endo -71.2 -33.93 10.77 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.784 2.322 . . . . 0.0 112.015 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.443 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -115.54 2.82 13.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 108.894 179.509 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 27.2 mtmt -139.19 132.29 29.64 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 1.116 HD21 ' CD1' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -127.68 132.99 49.6 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.001 -1.062 . . . . 0.0 110.211 -179.086 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.854 HG13 ' HG2' ' A' ' 65' ' ' GLU . 13.6 t -119.56 122.76 69.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.116 ' CD1' HD21 ' A' ' 28' ' ' LEU . 16.8 mt -137.66 136.72 37.7 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.046 -1.034 . . . . 0.0 110.324 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.563 ' HA ' HG12 ' A' ' 63' ' ' VAL . 37.7 t70 -84.2 136.22 34.05 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 177.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.854 HD12 ' CD1' ' A' ' 64' ' ' TRP . 88.1 mt -121.62 131.11 73.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.688 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.589 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 44.3 tttt -110.32 119.46 39.28 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.294 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 83.5 t80 -121.44 118.15 28.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.456 -0.777 . . . . 0.0 109.355 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 17.1 m -121.16 117.81 28.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.268 -0.895 . . . . 0.0 109.923 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.959 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -124.24 168.52 12.7 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.832 . . . . 0.0 109.345 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.582 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -70.07 76.96 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.634 2.223 . . . . 0.0 111.726 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.43 -5.92 75.28 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.44 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -97.26 179.38 4.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 109.498 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.0 m -151.08 158.37 43.97 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.302 -0.874 . . . . 0.0 109.527 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.847 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.79 136.4 47.06 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.659 -0.65 . . . . 0.0 109.342 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.928 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.58 -43.13 3.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.11 -0.994 . . . . 0.0 110.238 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -139.83 148.81 42.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.004 -1.06 . . . . 0.0 110.659 -179.215 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.615 HG13 ' CE1' ' A' ' 80' ' ' PHE . 14.6 t -139.0 136.3 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.541 -0.725 . . . . 0.0 109.33 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.508 ' HA ' HD13 ' A' ' 57' ' ' LEU . 95.2 mt-10 -128.75 150.89 50.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.953 -1.092 . . . . 0.0 109.255 179.351 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.95 HD12 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tt -121.61 147.32 46.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.27 -0.893 . . . . 0.0 110.045 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.799 ' N ' HD23 ' A' ' 46' ' ' LEU . 13.4 ttp180 -131.95 128.56 38.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.87 . . . . 0.0 108.808 179.302 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.414 ' NE2' HD23 ' A' ' 72' ' ' LEU . 36.0 mt-30 -69.7 153.02 43.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 0.0 109.942 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.573 ' CG ' ' HD2' ' A' ' 75' ' ' PRO . 66.1 t60 -67.45 119.29 12.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.41 -0.806 . . . . 0.0 109.682 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.91 4.35 54.41 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.452 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 39.4 t -114.24 154.49 27.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.453 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 87.5 mt-10 -117.78 15.69 14.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.375 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -119.02 97.6 5.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.903 . . . . 0.0 109.687 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -55.84 134.56 51.91 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.36 -0.838 . . . . 0.0 109.657 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -104.26 134.79 19.51 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.348 -0.845 . . . . 0.0 109.316 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.606 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.1 Cg_endo -70.61 145.35 52.01 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.627 2.218 . . . . 0.0 112.095 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.631 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.6 mp -110.0 151.2 27.45 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 108.871 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.1 m -100.66 125.51 47.09 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.865 -1.147 . . . . 0.0 108.851 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -72.13 108.83 5.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.202 -0.936 . . . . 0.0 109.091 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.513 ' O ' ' N ' ' A' ' 62' ' ' ASN . 15.2 mttm -107.48 126.26 52.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.986 -1.071 . . . . 0.0 109.542 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 48.67 -92.68 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 60' ' ' LYS . 31.6 p-10 -136.73 19.5 3.07 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.282 -1.128 . . . . 0.0 109.344 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.563 HG12 ' HA ' ' A' ' 31' ' ' ASP . 20.6 m -131.72 173.57 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.334 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.854 ' CD1' HD12 ' A' ' 32' ' ' ILE . 71.1 m95 -117.35 127.44 54.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.94 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.854 ' HG2' HG13 ' A' ' 29' ' ' VAL . 80.3 mt-10 -113.43 141.07 47.53 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.29 -0.881 . . . . 0.0 109.892 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.631 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 7.7 p -135.56 132.69 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.284 -0.885 . . . . 0.0 109.066 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.457 ' HG3' ' HG2' ' A' ' 27' ' ' LYS . 41.3 tttm -120.32 132.42 55.29 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 0.0 109.686 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 69' ' ' SER . 23.2 t -121.66 124.08 43.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.5 -0.75 . . . . 0.0 109.316 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 68' ' ' SER . 44.7 m -44.2 -29.86 0.7 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.011 -1.056 . . . . 0.0 108.461 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.713 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 0.1 OUTLIER -105.72 170.53 5.77 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.37 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.713 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.3 Cg_endo -66.6 172.18 9.67 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.115 1.876 . . . . 0.0 111.687 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.609 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.9 mt -100.59 144.53 29.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 110.122 -179.486 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.87 125.34 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.453 -0.779 . . . . 0.0 109.295 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -96.47 170.35 26.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.602 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.2 Cg_endo -68.62 146.6 79.94 Favored 'Cis proline' 0 C--O 1.213 -0.739 0 C-N-CA 122.837 -1.734 . . . . 0.0 111.859 -0.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 84.5 m-85 -92.48 147.22 23.07 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.447 -0.783 . . . . 0.0 110.669 -179.104 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.529 ' C ' ' CD1' ' A' ' 78' ' ' PHE . 20.5 m-80 -108.75 144.99 35.83 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.79 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.95 ' CE2' HD12 ' A' ' 46' ' ' LEU . 3.8 m-85 -136.99 122.56 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.855 -1.153 . . . . 0.0 110.319 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 89' ' ' VAL . 54.2 ttt180 -101.89 142.19 33.58 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.818 ' CD2' HD11 ' A' ' 41' ' ' LEU . 8.8 m-85 -123.91 143.79 50.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 111.267 -177.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.3 ttt -126.14 124.5 40.68 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.519 ' OG ' ' HB2' ' A' ' 86' ' ' MET . 13.4 p -77.53 145.6 36.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.846 . . . . 0.0 110.157 -178.233 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.928 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -44.96 -47.28 11.39 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.156 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.52 -6.92 5.14 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 97.01 34.41 5.68 Favored Glycine 0 N--CA 1.489 2.185 0 O-C-N 121.141 -1.211 . . . . 0.0 110.111 179.352 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.519 ' HB2' ' OG ' ' A' ' 82' ' ' SER . 55.8 mtp -105.36 110.46 22.82 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.028 -1.278 . . . . 0.0 109.127 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 26.6 mtm180 -90.4 140.6 29.56 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 110.668 -179.169 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.1 m120 -137.61 141.84 41.26 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.1 t -121.24 135.57 60.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.916 -1.115 . . . . 0.0 110.299 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.515 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 13.4 m-85 -124.2 122.31 37.45 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -98.44 146.98 25.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.208 -0.933 . . . . 0.0 109.546 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.602 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 49.1 tt0 52.92 52.64 13.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.438 -0.789 . . . . 0.0 110.162 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 94' ' ' ILE . 42.4 t -80.34 -33.38 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.882 -1.136 . . . . 0.0 108.933 179.447 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.484 HG13 HG12 ' A' ' 93' ' ' VAL . 14.0 mt -138.55 127.53 14.34 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.381 -0.824 . . . . 0.0 108.882 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.06 160.64 49.1 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.559 2.173 . . . . 0.0 112.099 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.474 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 58.6 m -50.96 -36.49 39.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.83 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.15 103.23 12.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.11 -0.994 . . . . 0.0 109.522 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.481 ' CE1' HG11 ' A' ' 19' ' ' VAL . 48.7 p90 -110.9 155.01 23.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.87 . . . . 0.0 109.219 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.5 m -105.99 172.39 6.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.145 -0.972 . . . . 0.0 109.418 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.433 HD13 ' CG1' ' A' ' 19' ' ' VAL . 28.2 mm -104.61 135.21 43.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.264 -0.898 . . . . 0.0 109.152 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 99.36 2.8 56.65 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.6 tttp -117.77 142.74 46.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.967 -1.313 . . . . 0.0 109.159 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.642 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.3 m -81.74 176.45 9.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.119 -0.988 . . . . 0.0 109.091 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.642 ' H ' HG22 ' A' ' 103' ' ' THR . 26.9 m-85 -160.69 98.4 1.22 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.8 -1.188 . . . . 0.0 109.064 179.417 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.53 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 0.2 OUTLIER -100.35 164.94 15.34 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.265 -0.897 . . . . 0.0 109.797 -179.423 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.53 ' HD2' ' HB3' ' A' ' 105' ' ' LYS . 50.5 Cg_endo . . . . . 0 C--O 1.215 -0.626 0 C-N-CA 122.712 2.274 . . . . 0.0 111.81 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.646 ' CG1' ' CE1' ' A' ' 34' ' ' TYR . 5.0 t . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -112.23 121.58 45.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.052 -1.03 . . . . 0.0 109.625 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.753 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.7 t -128.19 138.59 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.606 HG22 ' HB3' ' A' ' 105' ' ' LYS . 68.6 p -141.85 146.5 35.89 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.775 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.715 ' CD1' HG11 ' A' ' 93' ' ' VAL . 88.8 m-85 -119.35 118.79 32.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.3 -0.875 . . . . 0.0 109.734 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 21.9 m -108.36 158.51 17.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.922 -1.111 . . . . 0.0 108.979 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.702 ' CG1' HD13 ' A' ' 100' ' ' ILE . 8.5 t -107.8 126.68 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' HD12 ' A' ' 100' ' ' ILE . 1.7 mp0 -92.66 -173.52 3.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.146 -0.971 . . . . 0.0 109.605 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -83.65 66.01 8.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.385 -0.822 . . . . 0.0 109.937 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -172.33 22.01 0.07 OUTLIER Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.055 -1.545 . . . . 0.0 110.924 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.54 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 50.3 m -74.21 142.34 45.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.766 -1.432 . . . . 0.0 109.058 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.9 173.31 5.81 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.055 -1.028 . . . . 0.0 109.875 -179.634 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.8 Cg_endo -71.66 -30.56 14.52 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.793 2.329 . . . . 0.0 111.836 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -115.88 5.26 14.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 108.731 179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 72.8 mttt -142.17 133.11 25.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.949 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -127.87 135.34 49.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.067 -1.021 . . . . 0.0 110.099 -179.321 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.92 ' O ' HD13 ' A' ' 30' ' ' LEU . 4.1 t -119.39 119.05 59.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.949 HD11 HD22 ' A' ' 28' ' ' LEU . 0.4 OUTLIER -126.85 127.11 44.46 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.217 -0.927 . . . . 0.0 110.282 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.58 ' CB ' HG12 ' A' ' 63' ' ' VAL . 63.6 t0 -77.99 132.02 37.64 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.722 HG21 ' CE2' ' A' ' 80' ' ' PHE . 52.4 mt -118.3 128.56 75.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.157 -178.125 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.637 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 33.5 mttt -109.41 119.98 41.12 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.753 ' CD1' HG22 ' A' ' 15' ' ' VAL . 71.7 t80 -121.21 120.77 36.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.302 -0.874 . . . . 0.0 109.837 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -123.66 116.95 23.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.399 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CG ' ' HB2' ' A' ' 39' ' ' ASP . 38.0 ttt85 -139.72 131.94 14.96 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.452 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.44 107.85 2.08 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.814 2.343 . . . . 0.0 111.992 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.99 -5.29 84.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.556 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 31.6 m-20 -134.71 174.28 10.74 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -1.201 . . . . 0.0 109.682 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 82' ' ' SER . 14.7 m -155.42 162.65 40.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.74 HD13 ' HD2' ' A' ' 80' ' ' PHE . 26.8 tp -71.87 129.73 39.32 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.27 -0.894 . . . . 0.0 109.649 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.787 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -116.1 -40.29 3.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -0.934 . . . . 0.0 109.479 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -143.74 152.2 40.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.915 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.829 HG13 ' CE1' ' A' ' 80' ' ' PHE . 46.5 t -139.71 137.14 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.445 -0.785 . . . . 0.0 109.406 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.509 ' HA ' HD13 ' A' ' 57' ' ' LEU . 75.4 mt-10 -128.89 150.48 50.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.904 -1.123 . . . . 0.0 109.433 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.989 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.03 142.22 48.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.434 -0.791 . . . . 0.0 109.805 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.989 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.5 ttp180 -128.03 130.02 47.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.374 -0.829 . . . . 0.0 108.812 179.216 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.614 ' NE2' ' HA ' ' A' ' 48' ' ' GLN . 8.3 mm100 -72.14 152.42 42.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 110.218 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.574 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 13.0 t-80 -68.07 131.0 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.513 -0.742 . . . . 0.0 109.461 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 87.8 3.36 80.42 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.8 t -112.23 153.04 27.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.178 -1.19 . . . . 0.0 109.189 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -113.75 21.56 14.86 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.387 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.35 124.59 43.28 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.236 -0.915 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.452 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 64.6 m95 -85.06 129.94 34.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.432 -0.793 . . . . 0.0 109.415 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.4 134.62 19.66 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.369 -0.832 . . . . 0.0 109.342 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.663 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.3 Cg_endo -71.8 146.88 49.15 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.642 2.228 . . . . 0.0 112.164 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.676 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -106.8 158.04 17.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 108.621 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 52.3 m -108.87 127.04 53.7 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.846 -1.159 . . . . 0.0 109.116 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 37.5 tttm -65.35 120.95 13.73 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 63' ' ' VAL . 2.8 mttm -109.92 -152.7 0.5 Allowed 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.167 -0.958 . . . . 0.0 109.377 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 62' ' ' ASN . . . -58.72 81.2 0.01 OUTLIER Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.518 ' N ' ' O ' ' A' ' 60' ' ' LYS . 39.2 t30 63.97 10.54 5.4 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.243 -1.151 . . . . 0.0 110.086 179.501 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.582 HG23 ' HB2' ' A' ' 60' ' ' LYS . 5.3 m -132.05 179.12 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.092 -1.005 . . . . 0.0 109.717 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.507 ' CD1' HD12 ' A' ' 32' ' ' ILE . 63.0 m95 -127.15 126.75 43.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.067 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.443 ' HG2' ' N ' ' A' ' 66' ' ' VAL . 62.1 tt0 -119.25 154.58 33.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.17 -0.956 . . . . 0.0 109.706 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.627 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.0 p -146.17 141.42 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.405 -0.81 . . . . 0.0 109.244 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -119.81 129.01 54.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -0.941 . . . . 0.0 109.723 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.2 t -118.6 130.36 55.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.57 -0.706 . . . . 0.0 109.578 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.0 p -61.24 -21.35 63.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.149 -0.969 . . . . 0.0 108.922 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 15.0 ptmt -106.95 166.86 10.34 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.445 -0.784 . . . . 0.0 109.332 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.633 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 45.6 Cg_endo -67.74 141.39 54.34 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.478 2.118 . . . . 0.0 111.721 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.92 HD13 HD12 ' A' ' 28' ' ' LEU . 10.6 mt -76.49 141.04 41.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.343 -0.848 . . . . 0.0 109.84 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 124.72 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.366 -0.834 . . . . 0.0 109.378 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.505 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.99 165.33 26.69 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.75 147.41 82.24 Favored 'Cis proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.892 -1.712 . . . . 0.0 112.077 -0.024 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.558 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.1 m-85 -90.9 148.03 22.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.411 -0.806 . . . . 0.0 110.339 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.469 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 26.9 m-80 -109.91 144.54 38.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.379 -0.826 . . . . 0.0 108.928 179.171 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.864 ' CE2' HD12 ' A' ' 46' ' ' LEU . 82.9 m-85 -135.13 129.23 33.56 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.029 -1.044 . . . . 0.0 110.049 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.618 ' HG3' HG22 ' A' ' 89' ' ' VAL . 20.3 ttt85 -110.27 141.79 42.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.061 -1.025 . . . . 0.0 108.528 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.829 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.6 m-85 -125.31 143.34 51.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 111.396 -178.116 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.8 124.57 42.4 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.224 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.591 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.9 p -72.68 145.45 47.21 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.36 -0.838 . . . . 0.0 110.145 -178.472 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.787 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 90.6 mttt -47.6 -45.53 27.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 109.145 179.21 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.16 -5.06 0.58 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.47 25.99 12.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.591 ' O ' ' N ' ' A' ' 82' ' ' SER . 45.6 mtp -98.99 150.7 21.7 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -1.18 . . . . 0.0 108.727 179.468 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 62.3 mtm-85 -123.78 138.82 54.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.888 -1.132 . . . . 0.0 110.575 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 31.1 m120 -135.69 140.6 44.57 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.618 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.9 t -124.04 137.73 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.95 -1.094 . . . . 0.0 110.637 -178.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.529 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.3 m-85 -123.53 121.54 35.91 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 178.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -98.11 147.05 24.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.164 -0.96 . . . . 0.0 109.58 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 65.8 tt0 53.47 52.84 12.61 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.4 -0.812 . . . . 0.0 110.03 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.715 HG11 ' CD1' ' A' ' 17' ' ' PHE . 70.4 t -81.51 -34.43 13.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.906 -1.121 . . . . 0.0 109.26 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.483 HG12 ' HB3' ' A' ' 104' ' ' TYR . 13.4 mt -136.91 126.43 15.57 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.149 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.26 160.88 48.12 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.603 2.202 . . . . 0.0 111.986 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.505 HG23 ' H ' ' A' ' 74' ' ' GLY . 9.2 m -52.0 -43.13 63.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.382 -0.824 . . . . 0.0 110.192 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.0 103.64 15.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.025 -1.047 . . . . 0.0 109.83 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.414 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 52.4 p90 -111.68 152.09 28.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 28.2 m -102.11 164.72 11.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.423 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.702 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.4 mm -98.52 137.43 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.972 . . . . 0.0 109.381 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.44 62.74 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -121.24 146.49 46.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -1.182 . . . . 0.0 109.338 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.6 m -79.77 164.15 23.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.111 -0.993 . . . . 0.0 109.321 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.543 ' N ' ' O ' ' A' ' 17' ' ' PHE . 18.0 m-85 -150.06 92.21 1.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.74 -1.225 . . . . 0.0 109.064 179.089 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.606 ' HB3' HG22 ' A' ' 16' ' ' THR . 0.0 OUTLIER -108.88 164.31 15.0 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.4 -0.813 . . . . 0.0 109.867 -179.477 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.529 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 47.7 Cg_endo . . . . . 0 C--O 1.215 -0.675 0 C-N-CA 122.843 2.362 . . . . 0.0 111.617 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 36' ' ' ARG . 15.7 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 70.6 mt-30 -111.95 122.35 47.54 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.12 -0.988 . . . . 0.0 109.424 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 6.2 t -129.01 139.51 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 0.0 109.721 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.452 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 19.9 p -141.26 145.91 36.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.885 . . . . 0.0 109.237 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.624 ' CD2' HG12 ' A' ' 32' ' ' ILE . 3.9 m-85 -120.22 141.93 49.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.104 -0.998 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 23.9 m -134.37 127.3 31.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.915 . . . . 0.0 108.963 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.0 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.7 t -76.0 134.32 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.146 -0.971 . . . . 0.0 109.243 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.7 mm-40 -115.29 153.29 31.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.004 -1.06 . . . . 0.0 109.897 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 57.3 mttp -44.15 113.17 0.49 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.458 -0.776 . . . . 0.0 109.988 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.12 -5.86 1.96 Allowed Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.251 -1.452 . . . . 0.0 110.771 179.186 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.572 ' OG ' ' CE1' ' A' ' 98' ' ' PHE . 26.8 t -64.24 144.35 57.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.737 -1.449 . . . . 0.0 109.635 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.539 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -138.54 174.15 4.52 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.332 -0.855 . . . . 0.0 109.561 -179.907 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.57 ' O ' ' N ' ' A' ' 72' ' ' LEU . 50.0 Cg_endo -69.89 -28.84 24.11 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.837 2.358 . . . . 0.0 112.072 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -116.35 6.22 13.68 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.087 -1.008 . . . . 0.0 109.045 179.611 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.448 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 5.9 mtpm? -142.29 133.4 26.04 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.24 40.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.084 -1.01 . . . . 0.0 109.51 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 1.015 HG13 ' HG2' ' A' ' 65' ' ' GLU . 46.3 t -118.49 124.57 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.193 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.0 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.19 146.22 31.65 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.014 -1.054 . . . . 0.0 110.37 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.543 ' OD1' HG12 ' A' ' 63' ' ' VAL . 48.4 t0 -86.04 138.19 32.14 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.99 HG21 ' CE2' ' A' ' 80' ' ' PHE . 57.8 mt -123.39 132.27 71.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.817 -1.177 . . . . 0.0 110.644 -178.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 59.5 mttm -109.85 118.07 35.51 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 178.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.645 ' CD1' HG22 ' A' ' 15' ' ' VAL . 73.1 t80 -121.69 109.04 14.25 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.505 -0.747 . . . . 0.0 109.619 -179.038 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 83.5 m -111.45 116.11 30.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.272 -0.892 . . . . 0.0 109.562 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -141.83 121.61 8.19 Favored Pre-proline 0 N--CA 1.488 1.473 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.812 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.7 117.6 5.18 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.458 2.105 . . . . 0.0 112.014 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.74 -11.31 68.28 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.544 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.27 -179.94 6.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.894 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 82' ' ' SER . 15.4 m -155.68 162.96 40.48 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.356 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.485 HD21 HG21 ' A' ' 44' ' ' VAL . 17.5 tp -70.5 127.91 34.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.266 -0.896 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.853 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.52 -41.65 3.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.218 -0.926 . . . . 0.0 109.734 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -147.15 155.11 41.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.169 -0.957 . . . . 0.0 110.176 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.57 HG22 ' CD2' ' A' ' 80' ' ' PHE . 21.4 t -142.39 141.15 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.442 -0.786 . . . . 0.0 109.33 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.435 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 88.6 mt-10 -127.61 150.52 49.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.767 -1.208 . . . . 0.0 109.434 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.955 HD12 ' O ' ' A' ' 77' ' ' ASN . 21.7 tp -122.2 144.21 49.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.408 -178.836 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.627 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.1 OUTLIER -126.17 127.85 46.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.383 -0.823 . . . . 0.0 109.012 179.243 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -71.06 149.77 46.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 109.315 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.592 ' CD2' ' HD2' ' A' ' 75' ' ' PRO . 47.3 t60 -64.84 109.03 1.93 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.559 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.37 2.99 24.41 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.518 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 18.1 t -114.91 154.97 27.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.013 -1.287 . . . . 0.0 109.566 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.429 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 54.7 mp0 -112.02 -12.27 13.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.187 -0.946 . . . . 0.0 109.313 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -95.43 99.7 11.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.323 -0.861 . . . . 0.0 109.559 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.627 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 24.9 m95 -59.32 141.5 54.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.302 -0.874 . . . . 0.0 109.707 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -106.63 137.0 19.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.502 -0.749 . . . . 0.0 109.599 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.435 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 53.1 Cg_endo -72.46 144.41 40.55 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.592 2.195 . . . . 0.0 111.776 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.704 HD11 ' CB ' ' A' ' 46' ' ' LEU . 7.5 mp -106.95 146.37 31.14 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.17 -0.956 . . . . 0.0 108.863 179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 88.4 m -103.11 126.22 50.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.936 -1.103 . . . . 0.0 108.905 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 9.4 tttm -68.82 112.81 5.76 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.189 -0.944 . . . . 0.0 108.904 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mttm -120.07 80.37 1.59 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.004 -1.06 . . . . 0.0 110.702 -178.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.31 60.39 1.31 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.369 179.164 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 60.03 10.37 2.18 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.148 -1.207 . . . . 0.0 110.16 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 59' ' ' LYS . 13.6 m -129.51 -172.64 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.161 -0.962 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.409 ' CD1' HD12 ' A' ' 32' ' ' ILE . 78.4 m95 -139.13 125.52 20.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.924 . . . . 0.0 109.553 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 1.015 ' HG2' HG13 ' A' ' 29' ' ' VAL . 27.0 mt-10 -115.08 152.08 33.14 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.856 . . . . 0.0 109.596 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.704 HG11 HD23 ' A' ' 46' ' ' LEU . 3.1 p -138.22 134.91 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.439 -0.788 . . . . 0.0 109.304 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 26.5 mttp -120.89 133.99 55.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.346 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 69' ' ' SER . 9.5 t -120.66 126.84 51.26 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.37 -0.831 . . . . 0.0 109.308 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' SER . 73.4 p -45.28 -26.69 0.54 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.007 -1.058 . . . . 0.0 108.514 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -115.26 178.33 0.99 Allowed Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.1 Cg_endo -67.81 178.94 2.98 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.332 2.022 . . . . 0.0 111.846 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.583 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -112.09 143.48 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.199 -0.938 . . . . 0.0 109.786 -179.577 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 6.4 t -120.8 123.71 70.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.367 -0.833 . . . . 0.0 109.31 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.729 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.41 166.21 29.24 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.4 Cg_endo -69.62 146.76 82.78 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.783 -1.757 . . . . 0.0 112.082 0.045 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 46' ' ' LEU . 72.1 m-85 -91.54 153.6 19.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.627 -0.671 . . . . 0.0 110.494 -179.249 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.955 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.5 m120 -112.5 141.03 46.73 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.91 ' CE1' HD13 ' A' ' 46' ' ' LEU . 84.4 m-85 -132.27 128.41 37.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.997 -1.065 . . . . 0.0 109.894 -179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.772 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.3 ttt180 -112.41 143.68 43.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.019 -1.051 . . . . 0.0 108.732 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.99 ' CE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -125.37 144.42 50.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.269 -0.894 . . . . 0.0 111.611 -177.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.8 ttt -127.15 126.19 42.47 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.458 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.552 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.8 p -79.06 148.87 32.31 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.284 -0.885 . . . . 0.0 110.18 -178.402 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.853 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 23.3 mttt -47.0 -46.51 21.76 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.244 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.422 ' HA3' ' OD1' ' A' ' 39' ' ' ASP . . . -59.83 -8.48 8.0 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.3 34.13 5.44 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 51.6 mmm -102.97 109.18 20.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.107 -1.231 . . . . 0.0 109.065 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 87.7 mtm-85 -91.48 141.52 28.65 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.125 -0.984 . . . . 0.0 110.704 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.565 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.1 m120 -135.88 140.08 43.85 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.772 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -120.57 136.48 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.022 -1.049 . . . . 0.0 110.358 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.55 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 31.6 m-85 -125.96 122.23 35.35 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -98.17 147.33 24.7 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.946 . . . . 0.0 109.655 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 41.3 mt-10 53.31 52.88 12.67 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.346 -0.846 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.687 HG12 HG13 ' A' ' 94' ' ' ILE . 40.2 t -82.94 -34.35 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.986 -1.071 . . . . 0.0 109.3 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.687 HG13 HG12 ' A' ' 93' ' ' VAL . 65.8 mt -136.83 125.15 14.89 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.347 -0.845 . . . . 0.0 109.134 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.08 162.58 41.16 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.548 2.165 . . . . 0.0 111.887 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.729 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.7 m -52.87 -37.11 59.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.469 -0.77 . . . . 0.0 110.016 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.74 98.34 9.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.029 -1.044 . . . . 0.0 109.717 -179.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.572 ' CE1' ' OG ' ' A' ' 23' ' ' SER . 35.4 p90 -107.0 146.61 30.89 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.125 -0.985 . . . . 0.0 109.366 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.2 m -114.53 118.37 33.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.918 . . . . 0.0 109.554 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.576 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 4.8 mt -56.76 139.37 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.392 -0.817 . . . . 0.0 109.721 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.08 5.52 54.68 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 26.4 tttt -124.13 143.46 50.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.991 -1.299 . . . . 0.0 109.379 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.4 m -78.11 158.77 28.99 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.187 -0.946 . . . . 0.0 108.908 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.8 m-85 -146.58 97.49 2.93 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.491 -1.381 . . . . 0.0 108.953 179.272 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.54 157.9 32.81 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 110.059 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.55 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.7 Cg_endo . . . . . 0 C--O 1.215 -0.649 0 C-N-CA 122.825 2.35 . . . . 0.0 111.822 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.778 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 4.2 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.408 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 82.7 mt-30 -106.99 120.84 43.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.183 -0.948 . . . . 0.0 109.172 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.619 HG11 ' HG3' ' A' ' 106' ' ' PRO . 11.4 p -129.57 141.65 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.253 -0.904 . . . . 0.0 109.747 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.498 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 60.5 p -140.77 144.6 35.57 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.071 -1.018 . . . . 0.0 109.481 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 104' ' ' TYR . 49.7 m-85 -114.24 147.41 39.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.246 -0.909 . . . . 0.0 109.253 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 29.1 m -145.98 127.34 14.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.994 -1.066 . . . . 0.0 109.483 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.91 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.8 t -75.88 136.52 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.392 -0.818 . . . . 0.0 109.209 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.16 158.22 19.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.985 -1.072 . . . . 0.0 109.835 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -51.43 113.11 0.87 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.865 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.77 -6.91 2.68 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.516 179.384 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.523 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 10.8 m -57.46 143.51 40.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.892 -1.358 . . . . 0.0 109.39 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.553 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.69 171.45 8.83 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.707 -179.818 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.3 Cg_endo -70.22 -31.27 18.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.861 2.374 . . . . 0.0 111.891 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.455 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 2.5 pttt -112.82 7.27 18.38 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.222 -0.923 . . . . 0.0 108.938 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.487 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 29.8 mttm -141.83 132.93 26.18 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.709 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.1 121.48 37.97 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.999 -1.063 . . . . 0.0 109.406 -179.87 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 1.025 HG22 ' HG3' ' A' ' 65' ' ' GLU . 11.9 t -119.72 125.69 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.91 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -145.27 145.37 31.24 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.983 -1.073 . . . . 0.0 110.024 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.508 ' HA ' HG12 ' A' ' 63' ' ' VAL . 67.7 t0 -84.54 137.57 33.25 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.665 HG21 ' HE2' ' A' ' 80' ' ' PHE . 53.9 mt -120.49 130.09 74.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.752 -1.217 . . . . 0.0 110.557 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.7 tttt -110.36 119.57 39.64 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.472 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.778 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 66.2 t80 -121.85 121.01 36.19 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.563 -0.711 . . . . 0.0 109.259 -179.321 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 91.7 m -122.75 115.82 22.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.128 -0.983 . . . . 0.0 110.162 -179.531 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.623 ' HG3' HG22 ' A' ' 13' ' ' VAL . 20.5 ttt85 -135.64 137.48 25.92 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.534 -0.729 . . . . 0.0 109.065 179.434 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.48 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.5 Cg_endo -69.66 99.4 0.73 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.648 2.232 . . . . 0.0 111.904 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.14 -38.0 3.25 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.565 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 53.5 m-20 -96.28 176.16 6.17 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.228 -1.16 . . . . 0.0 109.798 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -154.74 162.22 41.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.378 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.789 HD21 HG21 ' A' ' 44' ' ' VAL . 31.8 tp -68.11 128.74 37.66 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.061 -1.024 . . . . 0.0 109.109 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.837 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.37 -45.0 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.132 -0.98 . . . . 0.0 110.274 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.473 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 81.5 mt-10 -135.55 144.56 46.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.043 -1.036 . . . . 0.0 110.392 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.789 HG21 HD21 ' A' ' 41' ' ' LEU . 99.7 t -137.97 135.59 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.474 -0.766 . . . . 0.0 109.147 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -127.91 150.03 50.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.964 -1.085 . . . . 0.0 109.162 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.96 HD13 ' CE2' ' A' ' 78' ' ' PHE . 13.5 tp -121.38 133.2 55.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.798 . . . . 0.0 110.176 -178.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.618 ' N ' HD12 ' A' ' 46' ' ' LEU . 40.8 ttp180 -119.46 129.04 54.55 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 108.788 179.134 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.452 ' OE1' HD23 ' A' ' 72' ' ' LEU . 14.5 mt-30 -71.01 160.74 32.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.276 -0.89 . . . . 0.0 110.161 -179.216 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.8 t60 -70.59 145.66 50.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.42 -0.8 . . . . 0.0 109.438 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.54 2.66 44.43 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.462 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.8 t -112.83 154.25 26.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.102 -1.234 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -121.17 14.18 11.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.889 . . . . 0.0 109.417 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -111.66 98.66 7.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.344 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.541 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 65.4 m95 -59.88 134.38 56.98 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.281 -0.887 . . . . 0.0 109.737 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -111.54 130.93 22.61 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.468 -0.77 . . . . 0.0 109.095 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.506 ' C ' HD12 ' A' ' 57' ' ' LEU . 48.5 Cg_endo -69.62 141.53 46.06 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.502 2.135 . . . . 0.0 111.978 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.804 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.9 mp -97.16 143.06 28.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 108.534 179.332 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -81.38 125.91 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.902 -1.123 . . . . 0.0 109.13 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -72.22 108.22 5.27 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.16 -0.962 . . . . 0.0 109.379 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.449 ' O ' ' C ' ' A' ' 61' ' ' GLY . 22.7 mttm -113.76 132.78 55.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.995 -1.065 . . . . 0.0 109.469 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 60' ' ' LYS . . . 43.17 -100.24 0.02 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.443 ' N ' ' O ' ' A' ' 60' ' ' LYS . 23.9 p-10 -130.5 24.98 5.12 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -1.148 . . . . 0.0 109.187 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.508 HG12 ' HA ' ' A' ' 31' ' ' ASP . 35.9 m -131.62 -170.08 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.568 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.566 ' CD1' HD12 ' A' ' 32' ' ' ILE . 44.6 m95 -140.99 124.69 16.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.03 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 1.025 ' HG3' HG22 ' A' ' 29' ' ' VAL . 69.8 tt0 -115.36 151.96 33.69 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 109.71 -179.66 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.92 HG11 HD23 ' A' ' 46' ' ' LEU . 2.0 p -141.19 138.46 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.367 -0.833 . . . . 0.0 109.191 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.441 ' CD ' ' HD3' ' A' ' 27' ' ' LYS . 84.4 mttt -122.14 134.78 54.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.278 -0.889 . . . . 0.0 109.6 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' SER . 8.8 t -120.18 126.21 50.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.343 -0.848 . . . . 0.0 109.188 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 68' ' ' SER . 6.0 m -44.1 -29.03 0.55 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.084 -1.01 . . . . 0.0 108.83 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.567 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -112.55 178.35 0.99 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.431 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.8 Cg_endo -68.79 166.34 26.59 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.382 2.055 . . . . 0.0 111.618 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.587 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.8 mt -97.34 143.29 28.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.117 -0.989 . . . . 0.0 109.816 -179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.419 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 22.9 t -119.89 124.79 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.81 . . . . 0.0 109.307 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.763 ' H ' HG23 ' A' ' 96' ' ' THR . . . -95.51 169.09 27.15 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.615 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.5 Cg_endo -67.99 146.34 77.5 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.838 -1.734 . . . . 0.0 111.85 0.111 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.611 ' HB3' HD11 ' A' ' 46' ' ' LEU . 74.2 m-85 -91.34 149.84 21.56 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.532 -0.73 . . . . 0.0 110.37 -179.09 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.874 ' O ' HD12 ' A' ' 46' ' ' LEU . 18.9 m-80 -111.99 143.67 42.6 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 179.137 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.96 ' CE2' HD13 ' A' ' 46' ' ' LEU . 96.1 m-85 -134.84 120.36 19.24 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.056 -1.028 . . . . 0.0 109.515 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.934 ' HG3' HG22 ' A' ' 89' ' ' VAL . 63.3 ttt180 -100.55 141.94 32.7 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.955 -1.091 . . . . 0.0 108.653 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.74 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.3 m-85 -124.96 142.95 51.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.907 . . . . 0.0 111.317 -178.256 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.67 124.2 41.68 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.157 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.615 ' N ' ' O ' ' A' ' 86' ' ' MET . 13.6 p -72.16 144.85 48.43 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.408 -0.808 . . . . 0.0 110.097 -178.463 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.837 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.2 OUTLIER -50.24 -44.45 53.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -0.917 . . . . 0.0 108.777 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.04 -2.18 0.19 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.32 25.7 18.11 Favored Glycine 0 N--CA 1.491 2.35 0 O-C-N 121.068 -1.254 . . . . 0.0 109.978 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.615 ' O ' ' N ' ' A' ' 82' ' ' SER . 39.2 mtp -100.85 149.06 24.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.109 -1.23 . . . . 0.0 108.864 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 7.6 mtt85 -120.15 135.97 54.78 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.332 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -134.57 139.91 45.72 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.934 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -123.1 136.2 60.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.043 -1.036 . . . . 0.0 110.294 -178.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.653 ' CG ' ' CB ' ' A' ' 106' ' ' PRO . 11.3 m-85 -122.45 121.04 35.67 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.59 147.62 24.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.21 -0.931 . . . . 0.0 109.707 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.615 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 48.2 mt-10 53.69 49.64 18.86 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.412 -0.805 . . . . 0.0 110.2 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.611 HG12 HG13 ' A' ' 94' ' ' ILE . 54.3 t -77.91 -33.71 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.867 -1.146 . . . . 0.0 108.885 179.333 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.611 HG13 HG12 ' A' ' 93' ' ' VAL . 69.8 mt -138.83 124.71 12.33 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.321 -0.862 . . . . 0.0 108.959 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -67.72 162.83 37.69 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.647 2.232 . . . . 0.0 112.161 -179.237 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.763 HG23 ' H ' ' A' ' 74' ' ' GLY . 8.1 m -50.56 -43.87 56.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.41 -0.806 . . . . 0.0 109.829 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.03 103.77 15.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.039 -1.038 . . . . 0.0 109.528 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.582 ' CE2' HG11 ' A' ' 19' ' ' VAL . 43.0 p90 -111.25 158.86 18.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 109.157 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.4 m -107.92 172.48 6.81 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.256 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.6 mm -104.56 135.93 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.877 . . . . 0.0 109.253 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.75 6.77 58.1 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -117.08 141.74 47.88 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.064 -1.256 . . . . 0.0 109.337 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.57 HG22 ' N ' ' A' ' 104' ' ' TYR . 34.5 m -81.95 170.1 16.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.09 -1.007 . . . . 0.0 109.026 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.575 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.4 m-85 -151.23 99.37 2.65 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.771 -1.205 . . . . 0.0 109.261 179.416 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.571 ' HG2' ' O ' ' A' ' 15' ' ' VAL . 1.9 mtmt -84.43 148.95 53.75 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.467 -0.77 . . . . 0.0 109.66 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.653 ' CB ' ' CG ' ' A' ' 90' ' ' PHE . 51.1 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.254 1.969 . . . . 0.0 111.569 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 36' ' ' ARG . 17.1 t . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.457 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 36.1 mt-30 -109.31 121.35 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.094 -1.004 . . . . 0.0 109.814 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 9.5 p -128.87 140.39 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.35 -0.844 . . . . 0.0 109.439 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.484 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 27.9 p -142.08 146.16 35.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.06 -1.025 . . . . 0.0 109.606 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.0 m-85 -118.51 143.68 46.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.581 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . 1.005 HG23 ' O ' ' A' ' 102' ' ' LYS . 69.0 m -139.67 129.05 24.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.067 -1.02 . . . . 0.0 109.245 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.904 HG22 HD23 ' A' ' 30' ' ' LEU . 42.6 t -75.91 132.67 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.225 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -105.17 159.78 15.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.109 -0.994 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -54.35 115.22 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.388 -0.82 . . . . 0.0 109.782 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 24' ' ' ASP . . . 139.5 -0.59 2.24 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.279 179.476 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.432 ' C ' ' OD1' ' A' ' 24' ' ' ASP . 34.1 t -66.85 142.17 57.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.976 -1.308 . . . . 0.0 109.394 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.648 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -134.56 174.48 4.59 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.205 -0.935 . . . . 0.0 109.31 -179.833 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.648 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 49.3 Cg_endo -70.36 -28.71 22.05 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.612 2.208 . . . . 0.0 111.985 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.3 mttm -114.51 9.37 16.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.935 . . . . 0.0 109.127 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.505 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 31.9 mttt -142.98 133.47 24.91 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.731 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.5 122.5 39.86 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.997 -1.064 . . . . 0.0 109.571 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.647 HG22 ' CG ' ' A' ' 65' ' ' GLU . 22.2 t -120.2 125.6 74.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.904 HD23 HG22 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -144.89 145.69 31.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.883 -1.136 . . . . 0.0 110.248 -179.419 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.494 ' HA ' HG12 ' A' ' 63' ' ' VAL . 17.9 t70 -86.22 138.52 31.81 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.824 HG21 ' HE2' ' A' ' 80' ' ' PHE . 70.5 mt -120.2 130.34 74.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.859 -178.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 25.1 tptt -110.55 120.26 41.83 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.115 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.504 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 79.6 t80 -121.77 123.64 42.31 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.395 -0.815 . . . . 0.0 109.915 -178.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.457 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 56.8 m -125.11 115.13 19.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 109.484 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 13' ' ' VAL . 29.8 ttt85 -139.79 135.37 16.6 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.448 -0.782 . . . . 0.0 109.199 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.481 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.8 Cg_endo -70.96 108.01 2.21 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.778 2.318 . . . . 0.0 112.182 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.02 -1.9 86.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.56 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.8 m-20 -134.36 173.92 11.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.075 -1.25 . . . . 0.0 109.655 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -153.45 160.85 42.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.81 HD11 ' CG2' ' A' ' 44' ' ' VAL . 7.8 tp -68.65 123.3 20.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.913 . . . . 0.0 109.212 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.794 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.36 -44.89 2.95 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.469 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 69.5 mt-10 -135.18 144.46 47.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.162 -0.961 . . . . 0.0 110.217 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.81 ' CG2' HD11 ' A' ' 41' ' ' LEU . 12.6 t -138.36 135.96 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.445 -0.784 . . . . 0.0 109.273 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -128.96 150.02 50.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.878 -1.139 . . . . 0.0 109.537 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.942 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.2 143.3 47.34 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.453 -0.779 . . . . 0.0 109.857 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.942 ' N ' HD23 ' A' ' 46' ' ' LEU . 35.8 ttp180 -131.33 126.36 35.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 108.821 179.297 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.439 ' OE1' HD23 ' A' ' 72' ' ' LEU . 16.3 mt-30 -66.39 156.11 35.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.159 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.59 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 8.3 t-80 -71.9 117.15 13.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 109.629 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 103.53 4.07 46.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.486 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 10.1 t -114.37 159.82 19.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.28 -1.13 . . . . 0.0 109.342 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.65 14.97 9.46 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -116.36 91.45 3.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.443 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -52.79 134.37 36.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -106.78 135.16 19.57 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.313 -0.867 . . . . 0.0 109.434 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.485 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.5 Cg_endo -70.15 145.78 55.84 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.677 2.251 . . . . 0.0 111.733 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.682 HD11 ' CB ' ' A' ' 46' ' ' LEU . 8.2 mp -110.41 150.78 28.33 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.168 -0.958 . . . . 0.0 109.052 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 m -102.36 126.74 49.47 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.993 -1.067 . . . . 0.0 109.141 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.7 tttt -77.46 101.56 6.48 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.071 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.565 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.7 mttt -115.4 150.39 36.46 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.866 -1.146 . . . . 0.0 110.083 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 43.38 32.23 1.75 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 1.5 m120 76.79 12.73 2.34 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.244 . . . . 0.0 110.126 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 3.0 m -130.17 176.9 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.136 -0.978 . . . . 0.0 108.805 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 64' ' ' TRP . 37.8 m95 -120.5 144.35 48.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.926 -1.108 . . . . 0.0 109.796 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.647 ' CG ' HG22 ' A' ' 29' ' ' VAL . 51.3 tt0 -136.5 151.97 50.01 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.376 -0.827 . . . . 0.0 109.445 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.813 HG11 HD13 ' A' ' 46' ' ' LEU . 9.8 p -137.11 133.77 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.387 -0.821 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' NZ ' ' A' ' 27' ' ' LYS . 21.4 mttt -119.72 131.21 55.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.934 . . . . 0.0 109.398 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t -118.24 165.96 13.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.381 -0.824 . . . . 0.0 109.522 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 50.2 m -88.74 2.98 52.47 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.249 -0.907 . . . . 0.0 109.052 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.558 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.2 OUTLIER -142.14 176.78 2.18 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.476 -0.765 . . . . 0.0 109.18 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.558 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.5 Cg_endo -68.55 139.31 44.37 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.506 2.137 . . . . 0.0 111.721 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.573 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 8.8 mt -73.88 143.08 45.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.261 -0.899 . . . . 0.0 109.627 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.424 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 31.2 t -119.42 123.3 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.249 -0.907 . . . . 0.0 109.31 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.532 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -92.05 164.7 28.76 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.701 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.55 147.87 85.07 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.775 -1.761 . . . . 0.0 112.035 -0.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 58.9 m-85 -89.52 151.1 22.15 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.505 -0.747 . . . . 0.0 110.149 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.432 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 39.2 m-80 -112.68 142.9 44.75 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.823 . . . . 0.0 109.051 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.874 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.9 m-85 -135.12 123.5 23.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 109.773 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.999 ' HG3' HG22 ' A' ' 89' ' ' VAL . 38.4 ttt180 -103.86 141.69 35.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.985 -1.072 . . . . 0.0 108.514 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.824 ' HE2' HG21 ' A' ' 32' ' ' ILE . 13.3 m-85 -125.17 142.8 51.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 111.497 -178.06 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.5 ttm -124.46 123.75 40.82 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.167 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.621 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.6 p -70.45 143.45 51.78 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.367 -0.833 . . . . 0.0 110.302 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.794 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -48.39 -45.2 35.57 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.356 -0.84 . . . . 0.0 108.83 178.924 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.42 -2.13 0.25 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.499 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.34 24.99 20.28 Favored Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.083 -1.246 . . . . 0.0 110.025 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.621 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.6 mmm -98.95 149.17 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.011 -1.288 . . . . 0.0 108.786 179.29 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.538 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 19.6 mtm105 -120.33 135.81 54.9 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.969 -1.082 . . . . 0.0 110.401 -179.013 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -134.32 139.44 45.67 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.999 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.7 t -122.82 136.42 59.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.112 -0.992 . . . . 0.0 110.316 -179.026 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 15' ' ' VAL . 27.7 m-85 -123.28 121.83 36.85 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.517 -0.919 . . . . 0.0 108.517 179.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -99.35 147.49 25.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.272 -0.893 . . . . 0.0 109.643 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.701 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 25.7 mt-10 53.48 52.2 13.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.392 -0.818 . . . . 0.0 110.201 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.3 t -83.04 -34.87 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 120.889 -1.132 . . . . 0.0 109.085 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -133.63 123.78 17.54 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.334 -0.854 . . . . 0.0 109.197 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.33 161.74 44.92 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.549 2.166 . . . . 0.0 111.79 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.532 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 32.6 m -54.29 -36.07 63.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.414 -0.804 . . . . 0.0 110.055 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.43 79.19 5.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.936 -1.102 . . . . 0.0 109.702 -179.513 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -89.02 145.05 25.73 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.314 -0.866 . . . . 0.0 109.408 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.59 116.48 26.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.321 -0.862 . . . . 0.0 109.67 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.59 HG12 HG12 ' A' ' 19' ' ' VAL . 11.1 mt -56.82 139.95 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.292 -0.88 . . . . 0.0 109.656 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.14 5.95 54.17 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 1.005 ' O ' HG23 ' A' ' 18' ' ' THR . 20.3 mttm -120.23 -165.82 1.23 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.009 -1.289 . . . . 0.0 109.183 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 8.7 m -131.06 165.22 23.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.07 -1.019 . . . . 0.0 108.517 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.7 m-85 -155.53 93.45 1.49 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.428 -1.42 . . . . 0.0 109.169 179.138 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 6.8 pttm -105.11 164.43 15.14 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.409 -0.807 . . . . 0.0 109.393 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 50.2 Cg_endo . . . . . 0 C--O 1.216 -0.601 0 C-N-CA 122.494 2.129 . . . . 0.0 111.739 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.645 HG22 ' HG3' ' A' ' 36' ' ' ARG . 20.1 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -111.65 121.37 44.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.157 -0.964 . . . . 0.0 109.313 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.2 t -128.16 138.09 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.814 -179.614 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.472 HG22 ' HD3' ' A' ' 105' ' ' LYS . 28.1 p -142.17 146.21 35.04 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.352 -0.842 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.594 ' O ' ' N ' ' A' ' 104' ' ' TYR . 34.1 m-85 -118.31 142.42 47.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.673 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 61.1 m -138.18 129.2 27.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.058 -1.027 . . . . 0.0 109.329 179.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.901 HG22 ' CD2' ' A' ' 30' ' ' LEU . 24.0 t -77.29 138.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.882 . . . . 0.0 109.39 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -106.15 -177.11 3.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.107 -0.995 . . . . 0.0 109.508 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 43.0 mttt -77.67 110.29 12.38 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.369 -0.832 . . . . 0.0 109.698 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.61 -0.32 1.66 Allowed Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.558 -1.306 . . . . 0.0 110.481 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.0 t -56.4 144.82 29.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.875 -1.368 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.5 168.99 14.62 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.167 -0.958 . . . . 0.0 109.636 -179.833 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.527 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 48.3 Cg_endo -69.76 -27.64 26.24 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.854 2.369 . . . . 0.0 111.859 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -114.65 8.61 16.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.164 -0.96 . . . . 0.0 109.01 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.443 ' C ' HD11 ' A' ' 72' ' ' LEU . 56.4 mttp -143.99 134.15 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 108.98 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.91 123.02 40.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.927 -1.108 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.735 HG13 ' HG2' ' A' ' 65' ' ' GLU . 5.0 t -120.36 126.07 74.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.901 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.35 145.48 31.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.842 -1.161 . . . . 0.0 110.2 -179.567 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.423 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.2 t0 -83.88 135.01 34.66 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 178.044 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.633 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -115.53 127.07 73.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.779 -1.201 . . . . 0.0 111.154 -178.641 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 10.2 ttpt -108.12 115.19 29.67 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 177.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.514 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 76.7 t80 -124.05 108.16 12.06 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.682 -0.637 . . . . 0.0 109.84 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.0 m -109.6 117.56 34.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.351 -0.843 . . . . 0.0 109.446 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.645 ' HG3' HG22 ' A' ' 13' ' ' VAL . 9.4 ttt85 -144.65 114.49 5.14 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.405 -0.81 . . . . 0.0 109.354 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.41 120.7 7.5 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.704 2.269 . . . . 0.0 111.809 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.06 -19.54 54.38 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.531 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 5.0 m-20 -140.75 -179.09 5.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -1.126 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.412 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 18.6 m -155.75 162.86 40.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.86 . . . . 0.0 109.535 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.778 HD21 ' CG2' ' A' ' 44' ' ' VAL . 25.1 tp -69.97 129.19 38.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.294 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.884 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.12 3.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -138.95 147.6 42.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.189 -0.944 . . . . 0.0 110.246 -179.543 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.778 ' CG2' HD21 ' A' ' 41' ' ' LEU . 77.6 t -138.18 136.01 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.488 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.3 mt-10 -129.76 151.63 50.13 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.88 -1.137 . . . . 0.0 109.775 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.943 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.9 tt -120.99 140.23 52.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 109.636 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ARG . . . . . 0.943 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.8 ttp180 -125.73 128.13 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.135 179.301 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.469 ' NE2' HD23 ' A' ' 72' ' ' LEU . 28.2 mt-30 -69.58 145.5 52.51 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.594 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' HIS . . . . . 0.609 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 22.4 t60 -63.85 113.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.842 . . . . 0.0 109.421 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.78 1.97 30.49 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.425 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 29.1 t -114.02 154.92 26.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.241 . . . . 0.0 109.418 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -118.25 22.35 12.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.444 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 83.0 mt-10 -127.43 81.2 2.0 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.535 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.612 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 43.8 m95 -43.38 136.53 3.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -0.907 . . . . 0.0 109.698 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -104.91 138.48 19.52 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.84 . . . . 0.0 109.311 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.497 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.7 Cg_endo -71.74 147.84 51.43 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.649 2.233 . . . . 0.0 112.113 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.62 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -111.48 155.78 22.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 108.958 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 m -109.7 127.14 54.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.813 -1.179 . . . . 0.0 109.078 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 41.6 tttm -71.72 110.64 6.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.145 -0.972 . . . . 0.0 109.344 -179.549 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.965 ' O ' HG22 ' A' ' 63' ' ' VAL . 20.8 mttt -119.63 141.1 49.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.815 -1.178 . . . . 0.0 109.812 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.584 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.52 31.08 0.97 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.584 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER 81.88 15.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.306 -1.114 . . . . 0.0 110.362 179.292 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.1 m -129.86 173.42 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.986 -1.071 . . . . 0.0 108.838 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 69.3 m95 -118.96 122.75 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.875 -1.141 . . . . 0.0 109.666 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.735 ' HG2' HG13 ' A' ' 29' ' ' VAL . 5.5 mt-10 -115.88 153.71 31.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.438 -0.789 . . . . 0.0 109.511 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.736 HG11 HD13 ' A' ' 46' ' ' LEU . 2.9 p -138.73 135.57 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.486 -0.759 . . . . 0.0 109.432 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.3 mttm -119.8 131.36 55.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -118.41 160.28 21.98 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.466 -0.771 . . . . 0.0 109.25 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 71.1 m -80.25 -13.87 58.87 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.145 -0.972 . . . . 0.0 109.148 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.556 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.0 OUTLIER -124.09 177.2 1.85 Allowed Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.369 -0.832 . . . . 0.0 109.031 179.791 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.556 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.5 Cg_endo -69.41 138.84 39.93 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.42 2.08 . . . . 0.0 111.678 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.675 HD13 ' HB2' ' A' ' 28' ' ' LEU . 16.2 mt -69.9 140.38 53.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.328 -0.858 . . . . 0.0 109.858 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.1 t -121.55 124.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.416 -0.803 . . . . 0.0 109.213 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.52 168.64 28.17 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.611 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.08 146.1 79.78 Favored 'Cis proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.822 -1.741 . . . . 0.0 112.025 -0.085 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 73.0 m-85 -91.14 147.76 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -0.832 . . . . 0.0 110.422 -179.179 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.418 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 30.2 m-80 -108.38 142.88 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.414 -0.804 . . . . 0.0 108.91 179.103 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.872 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.1 m-85 -133.93 122.29 22.91 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.041 -1.037 . . . . 0.0 109.77 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.584 ' HG3' HG22 ' A' ' 89' ' ' VAL . 57.9 ttp180 -106.33 144.1 33.5 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.089 -1.007 . . . . 0.0 108.937 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.633 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -124.69 142.76 51.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.14 -0.975 . . . . 0.0 111.502 -178.142 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.568 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.8 ttt -125.13 124.78 42.55 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' SER . . . . . 0.662 ' N ' ' O ' ' A' ' 86' ' ' MET . 21.0 p -73.59 144.43 45.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.325 -0.86 . . . . 0.0 110.544 -178.284 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' LYS . . . . . 0.884 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 47.3 mttm -47.17 -45.18 22.63 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.414 -0.804 . . . . 0.0 109.033 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.64 -5.02 1.65 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 96.61 24.72 13.11 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.662 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.1 mmm -95.96 147.62 23.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.045 -1.268 . . . . 0.0 108.503 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 24.5 mtm180 -123.29 138.39 54.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.686 -1.259 . . . . 0.0 110.794 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.428 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.1 m120 -134.97 139.94 45.3 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.527 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.584 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.7 t -123.01 137.34 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 120.877 -1.139 . . . . 0.0 110.461 -178.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.561 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 75.1 m-85 -124.91 123.51 40.06 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -99.8 146.73 26.25 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.805 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.611 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 79.1 tt0 53.67 53.93 10.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.411 -0.806 . . . . 0.0 110.652 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.606 HG22 ' HB3' ' A' ' 106' ' ' PRO . 45.5 t -83.81 -33.92 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.866 -1.146 . . . . 0.0 109.04 179.366 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 12.5 mt -135.98 125.24 15.92 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.412 -0.805 . . . . 0.0 109.017 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.78 161.98 43.83 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.563 2.175 . . . . 0.0 112.101 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.52 HG23 ' H ' ' A' ' 74' ' ' GLY . 23.7 m -50.49 -46.33 56.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.451 -0.781 . . . . 0.0 109.966 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.72 102.61 15.22 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.006 . . . . 0.0 109.627 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 53.7 p90 -109.85 154.36 23.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 109.353 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 73.1 p -107.97 171.96 7.1 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.545 HD13 ' CG1' ' A' ' 19' ' ' VAL . 20.9 mm -106.26 136.77 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.266 -0.897 . . . . 0.0 109.347 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 93.25 8.13 61.61 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -119.25 143.69 47.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.243 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -77.32 174.95 10.21 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.016 -1.052 . . . . 0.0 108.827 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' TYR . . . . . 0.616 ' H ' HG22 ' A' ' 103' ' ' THR . 26.6 m-85 -159.49 94.65 1.18 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.737 -1.227 . . . . 0.0 109.165 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' LYS . . . . . 0.472 ' HD3' HG22 ' A' ' 16' ' ' THR . 11.8 mtmm -91.72 155.33 43.72 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.341 -0.849 . . . . 0.0 109.665 -179.5 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.606 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.7 Cg_endo . . . . . 0 C--O 1.215 -0.626 0 C-N-CA 122.783 2.322 . . . . 0.0 111.649 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 17.8 mtt85 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -66.64 95.08 0.25 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.6 p -75.6 155.27 36.08 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.243 -1.151 . . . . 0.0 109.529 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -106.09 92.29 4.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.437 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 55.3 p-80 -93.83 8.54 40.77 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.262 -0.899 . . . . 0.0 109.539 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -50.23 -34.26 22.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.282 -0.886 . . . . 0.0 109.462 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -63.85 -32.23 73.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.467 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 33.1 t-80 -58.32 -43.17 88.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 51.6 m80 -50.18 -34.23 21.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.25 -127.29 8.86 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -118.29 157.34 27.24 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -1.14 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -148.95 150.22 32.52 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.757 HG13 ' HG3' ' A' ' 36' ' ' ARG . 2.1 t -125.71 135.58 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -112.18 120.4 41.64 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.011 -1.056 . . . . 0.0 109.539 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.8 t -128.19 139.1 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.75 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.442 ' HA ' ' HG3' ' A' ' 105' ' ' LYS . 70.7 p -141.52 145.62 35.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.225 -0.922 . . . . 0.0 109.697 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.803 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.9 m-85 -117.05 128.97 55.69 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.248 -0.907 . . . . 0.0 109.786 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.462 ' O ' ' N ' ' A' ' 31' ' ' ASP . 41.3 m -128.03 128.64 45.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.162 -0.961 . . . . 0.0 109.157 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.848 HG22 HD23 ' A' ' 30' ' ' LEU . 21.3 t -76.18 139.44 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.357 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.16 157.23 21.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.117 -0.989 . . . . 0.0 109.72 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -51.3 114.39 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.444 -0.785 . . . . 0.0 109.977 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.16 -1.43 2.19 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.523 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.1 t -60.01 141.24 56.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.925 -1.338 . . . . 0.0 109.175 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.57 176.13 3.02 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.121 -0.987 . . . . 0.0 109.664 -179.639 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.6 Cg_endo -71.77 -30.56 14.19 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.606 2.204 . . . . 0.0 111.816 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.4 mttm -117.21 4.99 12.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -0.886 . . . . 0.0 109.091 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.488 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 41.6 mttt -142.17 133.43 26.28 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.15 HD12 HD13 ' A' ' 72' ' ' LEU . 0.3 OUTLIER -127.18 133.78 50.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.034 -1.042 . . . . 0.0 110.21 -179.445 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 2.8 t -122.99 124.84 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.038 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -141.16 141.31 34.13 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.034 -1.041 . . . . 0.0 110.041 -179.526 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.602 ' CB ' HG12 ' A' ' 63' ' ' VAL . 59.7 t0 -86.11 137.34 32.74 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.575 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.1 mt -122.23 131.14 73.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 120.865 -1.147 . . . . 0.0 110.523 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 66.2 mttm -110.54 120.29 41.94 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.604 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.5 t80 -122.49 114.19 20.35 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.415 -0.803 . . . . 0.0 109.541 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.9 m -116.99 117.96 31.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.784 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.757 ' HG3' HG13 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -135.22 132.0 19.9 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.432 -0.793 . . . . 0.0 109.21 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.453 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 49.9 Cg_endo -70.2 105.89 1.64 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.67 2.246 . . . . 0.0 112.078 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.93 -2.12 87.02 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.523 ' HB3' ' HD2' ' A' ' 36' ' ' ARG . 1.7 m-20 -135.44 173.7 11.43 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.114 -1.227 . . . . 0.0 109.673 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 82' ' ' SER . 20.6 m -153.89 161.34 42.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.439 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.735 HD11 ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -71.5 132.98 45.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.947 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.47 -42.47 3.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.18 -0.95 . . . . 0.0 109.499 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -142.84 151.24 40.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.065 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.735 ' CG2' HD11 ' A' ' 41' ' ' LEU . 65.1 t -139.86 137.6 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.1 mt-10 -126.22 148.73 49.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.784 -1.198 . . . . 0.0 109.432 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.017 HD13 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tp -121.44 129.58 53.07 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.491 -0.756 . . . . 0.0 110.184 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.688 ' N ' HD12 ' A' ' 46' ' ' LEU . 12.1 ttp180 -115.63 131.97 56.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.199 -0.938 . . . . 0.0 108.875 179.238 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 13.1 mt-30 -73.47 155.15 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.315 -0.865 . . . . 0.0 110.021 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.1 t60 -67.29 147.83 52.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.446 -0.783 . . . . 0.0 109.357 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.83 2.12 35.67 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 32.5 t -113.21 152.46 29.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -1.214 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -117.81 17.88 14.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -0.907 . . . . 0.0 109.316 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -116.39 104.35 11.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.58 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 45.8 m95 -66.59 134.72 52.92 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.338 -0.851 . . . . 0.0 109.673 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.486 ' HG2' ' HD2' ' A' ' 56' ' ' PRO . 0.9 OUTLIER -108.71 134.27 20.37 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.345 179.912 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.535 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.5 Cg_endo -70.45 144.51 50.53 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.625 2.217 . . . . 0.0 111.961 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.73 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -103.88 148.36 26.23 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 108.823 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 63.0 m -97.5 125.78 42.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 108.947 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 12.9 tttm -70.93 111.64 6.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.236 -0.915 . . . . 0.0 109.269 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -109.77 105.54 14.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.054 -1.029 . . . . 0.0 109.461 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.79 -96.24 0.25 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -131.04 18.83 4.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.256 -1.144 . . . . 0.0 109.451 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.602 HG12 ' CB ' ' A' ' 31' ' ' ASP . 22.5 m -132.43 177.42 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.265 -0.897 . . . . 0.0 109.437 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.572 ' CD1' HD12 ' A' ' 32' ' ' ILE . 74.5 m95 -122.58 142.67 50.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 108.961 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -129.73 145.16 51.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.805 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.977 HG11 HD23 ' A' ' 46' ' ' LEU . 3.6 p -137.62 134.11 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.351 -0.843 . . . . 0.0 109.033 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -121.17 133.4 55.19 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.227 -0.92 . . . . 0.0 109.56 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.6 t -118.04 163.88 15.94 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.445 -0.784 . . . . 0.0 109.452 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 65.1 m -87.14 -5.96 58.82 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.191 -0.943 . . . . 0.0 109.152 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.9 OUTLIER -131.99 178.44 1.75 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.385 -0.822 . . . . 0.0 109.126 179.866 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -69.18 139.52 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.395 2.063 . . . . 0.0 111.577 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.15 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -75.38 141.19 43.31 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.25 -0.906 . . . . 0.0 109.935 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 42.9 t -123.86 124.92 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.465 -0.772 . . . . 0.0 109.155 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.585 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.67 170.18 30.67 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.63 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.8 Cg_endo -69.8 147.57 85.0 Favored 'Cis proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.836 -1.735 . . . . 0.0 111.833 0.037 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.591 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.7 m-85 -91.92 151.38 20.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.473 -0.767 . . . . 0.0 110.599 -179.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.746 ' O ' HD12 ' A' ' 46' ' ' LEU . 34.9 m-80 -112.15 143.45 43.17 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 1.017 ' CE2' HD13 ' A' ' 46' ' ' LEU . 95.7 m-85 -136.33 130.76 33.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.947 -1.096 . . . . 0.0 109.972 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.993 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.3 ttp180 -110.31 141.49 43.25 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.058 -1.026 . . . . 0.0 108.627 179.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.568 ' CE2' HG21 ' A' ' 32' ' ' ILE . 5.8 m-85 -120.93 142.78 49.4 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 111.021 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.591 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -127.77 125.35 39.74 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.701 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.629 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.1 p -78.0 144.48 36.66 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 110.416 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.947 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 30.8 mttm -46.21 -43.79 15.63 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.14 -2.96 0.69 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.12 22.94 26.17 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.629 ' O ' ' N ' ' A' ' 82' ' ' SER . 1.6 mmm -96.34 146.45 24.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.123 -1.221 . . . . 0.0 108.604 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 42.8 mtm180 -124.36 141.35 52.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.826 -1.172 . . . . 0.0 110.535 -178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.432 ' N ' ' O ' ' A' ' 80' ' ' PHE . 24.2 m120 -136.48 140.91 43.41 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.993 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.0 t -121.49 135.95 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 110.354 -179.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.552 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 41.9 m-85 -124.59 122.53 37.81 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -99.55 148.94 23.76 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.202 -0.936 . . . . 0.0 109.753 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.63 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 10.5 mt-10 51.7 51.03 17.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.53 -0.731 . . . . 0.0 110.371 179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.803 HG11 ' CE1' ' A' ' 17' ' ' PHE . 39.7 t -82.83 -33.54 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.911 -1.118 . . . . 0.0 109.255 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 9.1 mt -131.62 124.3 19.88 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.113 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.54 161.04 46.65 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.494 2.129 . . . . 0.0 111.916 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.585 HG23 ' H ' ' A' ' 74' ' ' GLY . 7.7 m -53.54 -43.96 68.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.341 -0.849 . . . . 0.0 109.95 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.4 99.84 12.75 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.105 -0.997 . . . . 0.0 109.568 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.73 146.06 34.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.627 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 16.2 m -106.54 156.68 18.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.395 -0.816 . . . . 0.0 109.183 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.575 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.2 mm -92.21 136.39 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.134 -0.979 . . . . 0.0 109.441 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.04 2.2 62.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -115.56 143.04 45.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.174 -1.192 . . . . 0.0 109.097 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.0 m -79.7 169.66 17.65 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.068 -1.02 . . . . 0.0 108.995 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.7 m-85 -154.57 100.32 2.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.714 -1.241 . . . . 0.0 109.032 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.524 ' CD ' ' N ' ' A' ' 105' ' ' LYS . 0.5 OUTLIER -95.25 158.2 35.12 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.718 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo -71.58 135.98 27.36 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.743 2.296 . . . . 0.0 111.808 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -90.04 161.92 15.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.31 -0.868 . . . . 0.0 109.494 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 71.2 mm-40 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.995 -1.003 . . . . 0.0 109.47 -179.95 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 54.2 mtm180 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.26 137.28 47.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 52.4 m -51.61 -31.69 26.06 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.191 -1.182 . . . . 0.0 109.465 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 -121.69 139.34 53.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.489 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -90.95 31.46 1.08 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.421 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . 0.524 ' HA ' ' CE1' ' A' ' 9' ' ' HIS . 7.8 m-70 62.07 70.44 0.58 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.294 -0.879 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 29.2 t60 -55.12 -55.92 25.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.4 p-80 -170.42 37.17 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.418 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.524 ' CE1' ' HA ' ' A' ' 6' ' ' HIS . 72.5 m80 -49.32 -40.04 33.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.213 -0.929 . . . . 0.0 109.471 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.71 165.6 27.22 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.1 m -119.33 134.24 55.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -1.154 . . . . 0.0 109.476 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 59.47 -147.58 0.48 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.252 -0.905 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.734 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 16.6 t -127.14 138.36 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -0.943 . . . . 0.0 109.37 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -110.1 120.77 43.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.363 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.517 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.4 t -127.94 138.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.346 -0.846 . . . . 0.0 109.632 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.0 p -141.53 145.83 35.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.25 -0.906 . . . . 0.0 109.418 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.621 ' CD2' HG12 ' A' ' 32' ' ' ILE . 15.0 m-85 -118.46 143.98 46.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.21 -0.931 . . . . 0.0 109.781 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 21.4 m -139.39 128.05 23.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 0.0 109.136 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.829 HG22 ' CD2' ' A' ' 30' ' ' LEU . 16.7 t -76.21 130.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -108.57 152.76 24.32 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.076 -1.015 . . . . 0.0 109.695 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -45.41 114.81 0.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.416 -0.802 . . . . 0.0 109.978 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.34 -2.92 1.84 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.834 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 34.9 m -63.71 141.09 58.89 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.703 -1.469 . . . . 0.0 109.277 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.534 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.64 175.49 3.55 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.128 -0.983 . . . . 0.0 109.593 -179.697 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.0 Cg_endo -71.54 -30.82 14.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.566 2.177 . . . . 0.0 111.845 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.2 mttp -117.33 4.78 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 0.0 109.053 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.426 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 35.4 mttp -142.27 133.64 26.42 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.074 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.12 132.25 50.63 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.948 -1.095 . . . . 0.0 110.347 -179.253 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.614 HG13 ' HG2' ' A' ' 65' ' ' GLU . 8.8 t -121.91 125.41 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.074 HD11 HD22 ' A' ' 28' ' ' LEU . 1.4 mt -141.88 141.49 33.05 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.942 -1.099 . . . . 0.0 110.142 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.438 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.0 t0 -86.36 137.56 32.48 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.396 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.742 HG21 ' CE2' ' A' ' 80' ' ' PHE . 88.2 mt -122.74 131.56 73.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 120.856 -1.153 . . . . 0.0 110.437 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 23.4 mttt -109.9 119.22 38.65 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.734 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.2 t80 -122.99 110.69 15.68 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.511 -0.743 . . . . 0.0 109.482 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.0 m -113.21 118.17 33.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.88 . . . . 0.0 109.68 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.551 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 1.4 ttt85 -130.15 141.81 43.22 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.277 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.12 89.29 0.46 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.572 2.181 . . . . 0.0 112.001 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.03 -32.19 6.62 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.492 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 21.1 m-20 -95.11 175.74 6.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -1.188 . . . . 0.0 109.705 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 82' ' ' SER . 51.1 m -155.01 162.56 41.04 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.404 -0.81 . . . . 0.0 109.337 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.739 HD11 ' CD2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -71.52 133.92 46.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.274 179.944 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.917 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.45 3.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.24 -0.912 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -140.62 149.42 42.28 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 0.0 110.205 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' CG2' HD11 ' A' ' 41' ' ' LEU . 21.6 t -139.14 136.32 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.408 -0.808 . . . . 0.0 109.455 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -129.59 152.02 49.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.903 -1.123 . . . . 0.0 109.385 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.88 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.3 tt -121.75 141.39 51.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.301 -0.875 . . . . 0.0 109.928 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.878 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.5 ttp180 -124.23 129.61 51.08 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.311 -0.868 . . . . 0.0 109.022 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -70.69 150.42 45.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.357 -0.839 . . . . 0.0 109.878 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.521 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 54.9 t60 -68.06 118.3 11.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.577 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.77 4.09 52.05 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.4 t -114.48 160.63 18.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.332 -1.099 . . . . 0.0 109.468 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 72.9 tt0 -124.56 15.23 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -0.924 . . . . 0.0 109.371 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 64.9 tt0 -118.11 81.4 1.67 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.445 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.563 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 40.8 m95 -43.28 138.86 2.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.34 -0.85 . . . . 0.0 109.778 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.28 136.68 20.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.48 -0.762 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.27 145.13 47.85 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.797 2.331 . . . . 0.0 111.898 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.839 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.3 mp -112.05 155.22 24.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.235 -0.916 . . . . 0.0 109.009 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.9 m -109.67 126.92 54.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.952 -1.092 . . . . 0.0 109.32 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 31.9 tttm -73.2 110.4 7.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.061 -1.024 . . . . 0.0 109.312 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.837 ' O ' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -119.31 142.83 47.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.904 -1.122 . . . . 0.0 110.126 -179.469 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.8 32.46 0.93 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 3.6 t-20 81.49 12.84 0.68 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.231 -1.158 . . . . 0.0 110.478 179.209 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.837 HG22 ' O ' ' A' ' 60' ' ' LYS . 16.6 m -129.47 176.71 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.029 -1.044 . . . . 0.0 108.872 179.386 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.719 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.3 m95 -116.5 138.09 51.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 0.0 109.56 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.614 ' HG2' HG13 ' A' ' 29' ' ' VAL . 38.3 mt-10 -124.29 139.69 53.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.343 -0.848 . . . . 0.0 109.418 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 46' ' ' LEU . 10.1 p -133.57 130.85 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.311 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -120.34 131.98 55.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.114 -0.991 . . . . 0.0 109.517 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t -118.52 145.99 44.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.502 -0.749 . . . . 0.0 109.421 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.4 m -72.3 -5.17 34.23 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.098 -1.001 . . . . 0.0 109.114 179.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.577 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.3 mtmt -130.18 177.82 2.01 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.368 -0.833 . . . . 0.0 109.11 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.5 Cg_endo -68.96 145.93 63.46 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.498 2.132 . . . . 0.0 111.765 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.99 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -83.63 138.69 33.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.797 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.0 t -123.4 124.9 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.385 -0.822 . . . . 0.0 109.484 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -94.03 169.64 29.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.51 147.52 81.73 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.903 -1.707 . . . . 0.0 112.019 -0.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.8 m-85 -91.19 151.38 20.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.556 -0.715 . . . . 0.0 110.561 -179.232 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.445 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 9.2 m-80 -112.59 143.5 43.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.342 -0.848 . . . . 0.0 108.778 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.88 ' CE2' HD12 ' A' ' 46' ' ' LEU . 49.7 m-85 -137.28 128.45 27.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.925 -1.109 . . . . 0.0 110.257 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.609 ' HG3' HG22 ' A' ' 89' ' ' VAL . 9.1 ttp180 -108.13 142.72 37.91 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.742 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -123.16 144.04 49.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.155 -0.965 . . . . 0.0 111.373 -178.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' O ' ' A' ' 86' ' ' MET . 10.0 ttm -127.94 126.12 40.85 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -79.8 144.17 33.78 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 110.323 -178.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.917 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 68.6 mttm -44.71 -43.56 8.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.27 -3.11 0.78 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.454 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.67 23.43 26.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 35.6 mtp -97.59 147.25 24.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.101 -1.235 . . . . 0.0 108.716 179.433 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.6 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 20.7 mtm180 -125.53 142.78 51.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.819 -1.176 . . . . 0.0 110.505 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.0 m120 -137.38 141.52 41.74 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.4 t -121.45 136.28 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.924 -1.11 . . . . 0.0 110.252 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.512 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 43.9 m-85 -124.94 122.55 37.67 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -98.42 147.28 24.88 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 18.3 mt-10 52.83 51.9 15.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.439 -0.788 . . . . 0.0 110.284 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.444 HG21 ' HB2' ' A' ' 90' ' ' PHE . 58.4 t -80.74 -33.32 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.804 -1.185 . . . . 0.0 109.159 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.474 HG12 ' HB3' ' A' ' 104' ' ' TYR . 65.2 mt -138.47 126.27 13.7 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.089 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.24 162.81 40.32 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.563 2.175 . . . . 0.0 111.981 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.488 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 54.4 m -53.6 -39.76 65.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.359 -0.838 . . . . 0.0 109.924 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -92.16 99.44 12.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.064 -1.022 . . . . 0.0 109.651 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -108.28 148.01 30.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.562 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.8 t -107.24 168.96 8.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.234 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.616 HD13 ' CG1' ' A' ' 19' ' ' VAL . 16.3 mm -104.29 136.18 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.182 -0.949 . . . . 0.0 109.237 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.84 3.45 59.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -117.67 142.76 46.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.109 -1.23 . . . . 0.0 109.172 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.1 m -78.58 175.23 10.56 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 108.914 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.611 ' H ' HG22 ' A' ' 103' ' ' THR . 25.0 m-85 -159.66 97.21 1.3 Allowed 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.703 -1.248 . . . . 0.0 108.972 179.267 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -97.84 159.31 31.22 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.423 -0.798 . . . . 0.0 109.787 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.512 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo -71.25 159.1 52.91 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.778 2.319 . . . . 0.0 111.681 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -138.66 156.14 47.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.492 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.487 -179.956 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 81.8 mtm180 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.85 149.72 45.1 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -60.95 -32.69 72.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.208 -1.172 . . . . 0.0 109.386 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -104.04 167.34 9.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.422 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.559 ' O ' ' CB ' ' A' ' 6' ' ' HIS . 36.0 m80 -121.53 175.47 6.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.545 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . 0.576 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 7.1 m80 79.78 -6.11 1.81 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.399 -0.813 . . . . 0.0 109.639 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.576 ' CG ' ' O ' ' A' ' 6' ' ' HIS . 98.5 m-70 -159.32 118.61 2.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.561 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -73.27 -18.59 61.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.392 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 18.2 t-80 -62.77 -47.13 84.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.31 -0.869 . . . . 0.0 109.422 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.43 11.18 61.21 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -132.63 152.47 51.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -1.164 . . . . 0.0 109.528 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -146.26 142.09 28.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.23 -0.919 . . . . 0.0 109.469 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.81 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 9.9 t -127.11 137.09 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.94 . . . . 0.0 109.548 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -109.78 120.93 44.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.079 -1.013 . . . . 0.0 109.456 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.564 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -129.14 140.52 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.752 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 105' ' ' LYS . 34.7 p -141.44 145.24 35.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.215 -0.928 . . . . 0.0 109.549 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.596 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.2 m-85 -116.37 135.26 54.02 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.196 -0.94 . . . . 0.0 109.609 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.428 ' O ' ' N ' ' A' ' 31' ' ' ASP . 25.9 m -134.84 129.02 33.83 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 109.412 179.558 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 HD23 ' A' ' 30' ' ' LEU . 39.2 t -76.47 135.84 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 109.353 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -111.46 157.18 20.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.708 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 25.7 mtpt -50.86 113.91 1.03 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.822 . . . . 0.0 109.924 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.49 -3.92 1.92 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.58 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.476 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 40.8 m -60.68 140.28 57.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.896 -1.355 . . . . 0.0 109.258 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.562 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.24 177.09 2.4 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 109.57 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -71.22 -31.66 14.1 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.59 2.193 . . . . 0.0 111.814 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -117.14 5.11 12.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.033 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.473 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 47.0 mttp -141.37 132.98 27.06 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.041 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.56 132.18 51.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.069 -1.02 . . . . 0.0 110.084 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.533 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 4.7 t -121.43 124.68 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.041 HD11 HD22 ' A' ' 28' ' ' LEU . 0.8 OUTLIER -140.87 141.07 34.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.948 -1.095 . . . . 0.0 110.124 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.428 ' N ' ' O ' ' A' ' 18' ' ' THR . 63.6 t0 -85.9 136.34 33.33 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 178.439 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.672 HD13 ' HZ ' ' A' ' 80' ' ' PHE . 82.4 mt -121.71 131.12 73.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 120.932 -1.105 . . . . 0.0 110.236 -179.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 47.4 mttm -110.36 119.53 39.5 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.81 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 59.0 t80 -122.85 115.76 22.51 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.536 -0.727 . . . . 0.0 109.324 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.5 m -119.32 119.59 34.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.527 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 14.0 ttt85 -137.5 138.8 25.54 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.246 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.507 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.0 Cg_endo -69.74 103.05 1.1 Allowed 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.754 2.303 . . . . 0.0 112.06 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.75 2.86 86.42 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.527 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 26.2 m-20 -137.87 175.99 9.09 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -1.194 . . . . 0.0 109.693 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.9 m -156.25 163.84 39.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.466 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.74 HD21 HG21 ' A' ' 44' ' ' VAL . 23.4 tp -69.18 130.16 41.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.204 -0.935 . . . . 0.0 109.229 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.641 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -113.75 -45.69 3.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 110.148 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 77.9 mt-10 -137.34 147.18 45.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.102 -0.998 . . . . 0.0 110.264 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.74 HG21 HD21 ' A' ' 41' ' ' LEU . 94.2 t -139.35 136.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.531 -0.731 . . . . 0.0 109.334 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.531 ' O ' ' HA ' ' A' ' 78' ' ' PHE . 35.1 mt-10 -128.87 151.38 49.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.415 179.387 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.04 HD23 ' N ' ' A' ' 47' ' ' ARG . 7.0 tt -120.83 144.35 48.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.377 -0.827 . . . . 0.0 109.865 -179.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 1.04 ' N ' HD23 ' A' ' 46' ' ' LEU . 19.5 ttp180 -126.86 108.86 11.39 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 109.037 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.406 HE21 ' HB3' ' A' ' 48' ' ' GLN . 10.8 mt-30 -51.97 156.1 1.63 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.858 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB3' HG12 ' A' ' 73' ' ' VAL . 86.4 t60 -69.31 118.5 12.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.472 -0.768 . . . . 0.0 109.6 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.47 3.44 55.33 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -113.76 153.27 29.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -1.156 . . . . 0.0 109.467 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.48 ' HA ' ' HD2' ' A' ' 47' ' ' ARG . 85.3 tt0 -115.66 -3.47 12.29 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.273 -0.892 . . . . 0.0 109.393 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.0 tt0 -97.25 112.34 24.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -0.908 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.539 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 78.5 m95 -74.33 129.12 37.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.326 -0.859 . . . . 0.0 109.549 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -101.66 137.19 19.51 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.874 . . . . 0.0 109.364 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -71.4 144.85 46.55 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.694 2.262 . . . . 0.0 111.937 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.575 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.1 mp -107.89 148.24 29.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 108.949 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.418 HG21 ' NZ ' ' A' ' 60' ' ' LYS . 85.6 m -102.31 127.22 49.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.894 -1.129 . . . . 0.0 109.27 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.605 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 41.2 tttm -72.44 110.05 6.57 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.243 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.905 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.8 mmtt -118.43 140.66 49.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.907 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.85 31.74 0.84 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.583 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 9.4 m-20 82.66 13.67 0.46 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.239 -1.154 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.905 HG22 ' O ' ' A' ' 60' ' ' LYS . 21.0 m -128.43 173.36 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.014 -1.054 . . . . 0.0 108.761 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.605 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 62.3 m95 -120.2 124.98 47.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.98 -1.075 . . . . 0.0 109.657 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -114.15 150.2 34.51 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.45 -0.782 . . . . 0.0 109.491 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.575 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.4 p -137.23 134.04 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.492 -0.755 . . . . 0.0 109.248 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -120.32 131.58 54.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.167 -0.958 . . . . 0.0 109.444 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.2 t -117.85 157.72 26.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.416 -0.802 . . . . 0.0 109.52 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.7 t -83.94 5.83 24.06 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.256 -0.903 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -139.09 176.2 2.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.295 -0.878 . . . . 0.0 109.214 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.4 Cg_endo -70.17 126.15 12.73 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.499 2.132 . . . . 0.0 111.791 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.938 HD13 HD12 ' A' ' 28' ' ' LEU . 2.0 mt -60.63 136.93 58.21 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.243 -0.91 . . . . 0.0 109.787 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.594 HG12 ' HB3' ' A' ' 49' ' ' HIS . 95.7 t -124.23 125.44 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.444 -0.785 . . . . 0.0 109.461 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.9 168.74 27.73 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.6 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.73 146.87 81.02 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.83 -1.737 . . . . 0.0 112.011 0.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 90.9 m-85 -91.09 149.6 21.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.506 -0.746 . . . . 0.0 110.356 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 47' ' ' ARG . 3.4 m-80 -111.99 144.57 41.11 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.845 ' CE2' HD12 ' A' ' 46' ' ' LEU . 18.2 m-85 -135.84 126.06 26.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.925 -1.109 . . . . 0.0 110.127 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.986 ' HG3' HG22 ' A' ' 89' ' ' VAL . 18.8 ttt180 -105.81 141.34 37.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.133 -0.979 . . . . 0.0 108.662 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.734 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.9 m-85 -123.7 143.03 50.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.924 . . . . 0.0 111.402 -178.146 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.638 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.5 ttt -125.93 124.47 40.87 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.0 p -72.46 144.59 48.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.385 -0.822 . . . . 0.0 109.968 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.641 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 86.4 mttt -47.19 -44.74 22.49 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.402 -0.811 . . . . 0.0 108.975 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.8 -3.7 0.77 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.71 24.53 15.4 Favored Glycine 0 N--CA 1.491 2.307 0 O-C-N 120.988 -1.301 . . . . 0.0 110.257 179.348 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.638 ' O ' ' HA ' ' A' ' 81' ' ' MET . 15.4 mmm -96.72 148.31 23.02 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.114 -1.227 . . . . 0.0 108.633 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.582 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 72.8 mtp180 -124.12 140.03 53.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.885 -1.134 . . . . 0.0 110.416 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 28.2 m120 -136.42 141.25 43.59 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.986 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.3 t -122.15 136.14 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.183 -179.049 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.565 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 13.3 m-85 -123.77 122.6 38.48 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 63.9 t0 -98.66 145.1 27.22 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.6 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 64.5 tt0 54.76 52.54 11.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.481 -0.762 . . . . 0.0 110.377 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 ' CD1' ' A' ' 17' ' ' PHE . 88.8 t -81.14 -34.75 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.939 -1.101 . . . . 0.0 109.006 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 46.6 mt -135.42 129.4 18.63 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 121.353 -0.842 . . . . 0.0 108.95 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.88 159.52 50.25 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.483 2.122 . . . . 0.0 112.009 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.541 HG23 ' H ' ' A' ' 74' ' ' GLY . 31.9 m -50.17 -36.66 31.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.677 -179.781 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.63 101.66 11.81 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.071 -1.018 . . . . 0.0 109.518 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.5 ' CE1' HG11 ' A' ' 19' ' ' VAL . 50.9 p90 -109.49 150.84 27.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.159 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.79 168.83 8.88 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 ' CG1' ' A' ' 19' ' ' VAL . 17.8 mm -101.01 136.37 32.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.226 -0.921 . . . . 0.0 109.177 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 94.69 0.79 64.16 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 15.9 mttm -114.27 144.96 42.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.245 . . . . 0.0 109.157 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.683 HG22 ' H ' ' A' ' 104' ' ' TYR . 4.2 m -82.65 178.37 8.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.294 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.683 ' H ' HG22 ' A' ' 103' ' ' THR . 16.3 m-85 -161.81 92.65 0.87 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.863 -1.148 . . . . 0.0 108.859 179.115 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.488 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.2 OUTLIER -81.39 155.07 71.86 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.245 -0.909 . . . . 0.0 109.783 -179.415 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.565 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 50.0 Cg_endo -69.83 149.84 66.98 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.741 2.294 . . . . 0.0 111.886 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.433 ' O ' ' O ' ' A' ' 108' ' ' GLU . 90.5 mt-10 -81.97 138.15 34.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.228 -0.92 . . . . 0.0 109.545 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.433 ' O ' ' O ' ' A' ' 107' ' ' GLU . 94.1 mt-10 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.98 -8.53 73.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.2 m -62.88 -31.13 72.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.193 -1.181 . . . . 0.0 109.601 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 55.0 m80 -129.25 151.47 49.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.25 -0.907 . . . . 0.0 109.484 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -56.89 -39.57 74.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.29 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -106.47 -179.71 4.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.362 -0.836 . . . . 0.0 109.449 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -117.79 132.64 56.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 72.7 m-70 -109.28 100.9 9.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.414 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -131.31 149.18 52.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 109.44 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 11' ' ' SER . . . 106.5 25.41 6.32 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 10' ' ' GLY . 27.1 m -43.48 -63.61 0.8 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -1.18 . . . . 0.0 109.348 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.46 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -82.03 -154.41 0.12 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.863 . . . . 0.0 109.331 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.932 HG22 ' HG2' ' A' ' 36' ' ' ARG . 4.0 t -120.79 119.62 60.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.14 -0.975 . . . . 0.0 109.582 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.418 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 91.5 mt-30 -109.65 121.36 45.03 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.384 -0.823 . . . . 0.0 109.167 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.7 p -128.84 139.92 50.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.207 -0.933 . . . . 0.0 109.836 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.764 HG22 ' HD2' ' A' ' 105' ' ' LYS . 29.3 p -142.02 145.99 35.02 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.406 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.8 m-85 -118.31 147.48 43.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 31' ' ' ASP . 29.9 m -141.84 127.93 19.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.112 -0.993 . . . . 0.0 109.202 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.938 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.8 t -76.33 135.9 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.106 -0.996 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.418 ' O ' HD12 ' A' ' 100' ' ' ILE . 76.1 mm-40 -101.44 -174.83 2.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.107 -0.996 . . . . 0.0 109.531 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.4 mttt -81.6 67.42 7.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.369 -0.832 . . . . 0.0 109.983 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -174.96 22.97 0.06 OUTLIER Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.755 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.557 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 48.9 m -75.44 142.58 42.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.777 -1.425 . . . . 0.0 109.109 179.638 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.574 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.14 171.96 7.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 109.856 -179.552 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.574 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.92 -31.05 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.869 2.38 . . . . 0.0 111.984 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -115.57 6.8 14.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.235 -0.916 . . . . 0.0 108.984 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.525 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 2.5 ttpm? -142.96 133.91 25.57 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.76 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.56 124.27 43.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.934 -1.104 . . . . 0.0 109.398 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.563 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 10.7 t -120.06 124.81 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.938 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.23 145.88 31.48 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.027 -1.046 . . . . 0.0 110.147 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.714 ' HA ' HG12 ' A' ' 63' ' ' VAL . 59.2 t0 -83.86 134.92 34.67 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.777 HG21 ' CE2' ' A' ' 80' ' ' PHE . 82.5 mt -121.86 131.82 72.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 120.825 -1.172 . . . . 0.0 110.723 -178.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 24.7 mmtp -110.44 119.28 38.67 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.471 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 81.2 t80 -120.42 124.67 46.04 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.411 -0.806 . . . . 0.0 109.568 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 5.2 m -128.64 118.74 23.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.847 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.932 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -128.54 167.0 20.68 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.708 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.1 Cg_endo -70.55 79.06 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.716 2.277 . . . . 0.0 111.876 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.14 -9.63 69.0 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.531 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -96.84 179.0 5.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.175 . . . . 0.0 109.422 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.503 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 12.4 m -153.02 160.68 43.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.147 -0.971 . . . . 0.0 109.712 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.815 HD21 HG21 ' A' ' 44' ' ' VAL . 22.4 tp -69.97 130.18 41.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.471 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.795 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.44 -45.65 2.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.232 -0.918 . . . . 0.0 110.127 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.468 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 43.8 mt-10 -134.66 144.57 47.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.116 -0.99 . . . . 0.0 110.335 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.815 HG21 HD21 ' A' ' 41' ' ' LEU . 93.8 t -137.99 135.48 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.492 -0.755 . . . . 0.0 109.217 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.48 ' HA ' ' CD1' ' A' ' 57' ' ' LEU . 25.7 mt-10 -129.04 151.05 50.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.985 -1.072 . . . . 0.0 109.395 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.945 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.4 tt -119.4 132.61 55.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.447 -0.783 . . . . 0.0 109.913 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.945 ' N ' HD23 ' A' ' 46' ' ' LEU . 27.0 ttp180 -118.53 128.21 54.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.225 -0.922 . . . . 0.0 108.761 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -73.13 152.24 41.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 110.195 -179.273 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.527 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 55.1 t-80 -63.02 147.48 50.56 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.408 -0.808 . . . . 0.0 109.137 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.92 1.0 54.57 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.6 t -112.45 150.31 31.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -1.144 . . . . 0.0 109.316 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -116.59 8.46 13.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.924 . . . . 0.0 109.517 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 64.0 mm-40 -107.01 115.42 30.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.401 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 58.3 m95 -76.08 129.03 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.326 -0.859 . . . . 0.0 109.715 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -99.94 133.38 21.68 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.432 -0.793 . . . . 0.0 109.193 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 149.03 67.25 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.689 2.259 . . . . 0.0 111.803 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.673 HD11 ' HB2' ' A' ' 46' ' ' LEU . 6.1 mp -111.98 158.58 19.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.194 -0.941 . . . . 0.0 109.354 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.2 m -107.48 127.72 53.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.954 -1.091 . . . . 0.0 109.279 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 47.3 tttt -70.84 112.89 7.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -0.896 . . . . 0.0 109.242 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.451 ' HE3' ' HB3' ' A' ' 65' ' ' GLU . 40.2 mttt -113.64 125.66 54.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.953 -1.092 . . . . 0.0 109.595 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 44.68 -109.54 0.29 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -117.11 17.44 14.84 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.258 -1.142 . . . . 0.0 109.564 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 31' ' ' ASP . 10.9 m -131.93 -175.82 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.451 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -127.33 139.82 52.62 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 67' ' ' LYS . 19.1 tt0 -121.21 135.01 55.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.215 -0.928 . . . . 0.0 109.753 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.603 HG12 ' HB3' ' A' ' 28' ' ' LEU . 4.6 p -131.09 129.36 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.274 -0.891 . . . . 0.0 109.304 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG2' ' CD ' ' A' ' 27' ' ' LYS . 88.3 mttt -120.05 131.58 55.15 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.094 -1.004 . . . . 0.0 109.529 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.5 t -117.6 138.91 51.63 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.526 -0.734 . . . . 0.0 109.288 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 79.3 p -65.56 -11.3 42.72 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.154 -0.966 . . . . 0.0 109.232 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -121.12 176.34 1.95 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.68 164.57 32.66 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.602 2.201 . . . . 0.0 111.811 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.626 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.1 mt -100.59 141.56 33.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.258 -0.901 . . . . 0.0 109.849 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 50.2 t -127.86 125.2 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.547 -0.72 . . . . 0.0 109.319 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.671 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.76 164.74 26.64 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.614 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.9 Cg_endo -68.84 148.15 83.97 Favored 'Cis proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.984 0.075 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.4 m-85 -92.58 149.87 21.08 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.442 -0.786 . . . . 0.0 110.476 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.495 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 14.6 m-80 -110.51 143.33 41.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 108.769 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 46' ' ' LEU . 83.1 m-85 -134.69 126.84 29.87 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.014 -1.054 . . . . 0.0 109.737 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 89' ' ' VAL . 53.1 ttt180 -108.35 142.51 38.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.04 -1.038 . . . . 0.0 108.753 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.777 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.1 m-85 -124.6 143.42 50.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 111.551 -178.079 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.6 ttm -126.38 125.95 43.06 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 178.478 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.632 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.9 p -74.0 145.92 44.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 110.204 -178.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.795 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 78.7 mttt -48.37 -44.22 34.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.272 -0.893 . . . . 0.0 108.934 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.44 -3.69 0.68 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.53 25.05 16.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.582 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.632 ' O ' ' N ' ' A' ' 82' ' ' SER . 13.0 mmm -97.39 148.36 23.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.172 -1.193 . . . . 0.0 108.575 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 21.6 mtm180 -124.31 140.03 53.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.843 -1.16 . . . . 0.0 110.68 -178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . 34.7 m120 -135.42 140.08 44.65 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.1 t -122.03 136.9 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.037 -1.039 . . . . 0.0 110.409 -179.079 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.541 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 15.9 m-85 -125.52 122.98 38.13 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -99.57 147.84 24.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 95.8 mt-10 53.45 51.4 15.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.338 -0.851 . . . . 0.0 110.044 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.536 HG12 HG13 ' A' ' 94' ' ' ILE . 44.1 t -81.03 -33.98 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.821 -1.174 . . . . 0.0 109.26 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 93' ' ' VAL . 43.7 mt -138.13 125.75 13.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.139 -0.976 . . . . 0.0 109.057 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.12 161.78 44.43 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.533 2.155 . . . . 0.0 111.882 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.671 HG23 ' H ' ' A' ' 74' ' ' GLY . 2.6 m -57.08 -39.46 75.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.376 -0.827 . . . . 0.0 109.923 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.45 70.31 9.89 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.081 -1.012 . . . . 0.0 109.492 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -81.2 148.52 29.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.936 . . . . 0.0 109.656 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 43.3 m -109.82 168.8 9.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.317 -0.865 . . . . 0.0 109.186 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.521 HD13 ' CG1' ' A' ' 19' ' ' VAL . 35.6 mm -103.4 135.71 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.137 -0.977 . . . . 0.0 109.284 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 97.01 5.88 58.17 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.471 ' HD3' ' CZ ' ' A' ' 104' ' ' TYR . 43.7 tttp -119.73 143.17 47.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.25 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.652 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.7 m -79.88 176.51 9.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 109.018 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.652 ' H ' HG22 ' A' ' 103' ' ' THR . 32.5 m-85 -162.7 95.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.875 -1.141 . . . . 0.0 108.937 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.764 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.3 OUTLIER -103.0 166.33 12.05 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.873 . . . . 0.0 109.793 -179.405 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo -71.11 140.93 38.68 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.588 2.192 . . . . 0.0 111.727 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.09 -31.22 72.32 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.403 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 12.8 mp0 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.464 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.4 ptm180 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -153.69 176.65 31.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.9 m -137.92 156.0 48.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -1.13 . . . . 0.0 109.452 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -112.01 173.2 6.47 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.273 -0.892 . . . . 0.0 109.359 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -68.32 153.64 43.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.394 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 44.1 m80 -91.54 140.39 29.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.289 -0.882 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 55.0 t60 -56.69 -47.29 80.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.497 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -160.15 91.96 0.97 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.228 -0.92 . . . . 0.0 109.522 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 -64.48 -50.41 67.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.221 -0.925 . . . . 0.0 109.47 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -100.97 122.46 7.6 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.511 ' HB3' ' HG3' ' A' ' 37' ' ' PRO . 22.9 t -132.9 -158.65 0.9 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -1.116 . . . . 0.0 109.463 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.66 162.75 12.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.547 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.954 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 3.6 t -129.48 145.85 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.877 . . . . 0.0 109.539 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -111.47 121.64 45.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.896 . . . . 0.0 109.244 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.4 t -128.95 139.68 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.202 -0.936 . . . . 0.0 109.817 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.0 p -141.99 146.15 35.26 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.328 -0.857 . . . . 0.0 109.474 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.7 m-85 -118.38 123.65 45.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.425 ' O ' ' N ' ' A' ' 31' ' ' ASP . 34.8 m -120.05 128.37 53.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.03 -1.044 . . . . 0.0 109.063 179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' CD2' ' A' ' 30' ' ' LEU . 11.9 t -76.04 132.57 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 37.7 mm-40 -107.3 156.35 18.98 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.8 mttt -50.08 114.55 1.12 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.432 -0.793 . . . . 0.0 109.909 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.95 1.98 1.96 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 65.9 p -62.85 142.32 58.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.762 -1.434 . . . . 0.0 109.185 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.43 174.12 4.71 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.133 -0.98 . . . . 0.0 109.664 -179.626 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.9 Cg_endo -71.01 -29.86 17.31 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.683 2.255 . . . . 0.0 111.86 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -118.18 4.18 11.98 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.32 -0.862 . . . . 0.0 109.041 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.47 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 52.7 mttt -143.01 134.13 25.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.994 HD12 HD13 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -128.01 134.25 49.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.984 -1.073 . . . . 0.0 110.401 -179.332 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.6 t -121.95 123.73 69.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.966 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.68 144.51 31.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 109.914 -179.352 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 18' ' ' THR . 57.0 t0 -86.3 136.13 33.27 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.334 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.701 HG21 ' CE2' ' A' ' 80' ' ' PHE . 80.1 mt -120.68 131.63 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 120.881 -1.137 . . . . 0.0 110.324 -179.163 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 mttm -111.09 118.69 36.71 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.954 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.6 t80 -121.26 109.33 14.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.489 -0.757 . . . . 0.0 109.339 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.1 m -112.62 117.32 31.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.89 . . . . 0.0 109.89 -179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.625 ' HG3' HG22 ' A' ' 13' ' ' VAL . 37.8 ttt-85 -136.83 139.73 29.75 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.368 -0.833 . . . . 0.0 109.179 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.525 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.3 Cg_endo -69.75 109.35 2.29 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 112.069 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.05 4.44 88.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.561 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 4.9 m-20 -134.52 173.21 11.91 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -1.22 . . . . 0.0 109.772 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.9 m -155.53 162.61 40.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.341 -0.849 . . . . 0.0 109.502 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.701 HD21 ' CG2' ' A' ' 44' ' ' VAL . 10.7 tp -70.55 129.56 39.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.846 . . . . 0.0 109.501 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.741 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -115.83 -42.74 3.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.161 -0.962 . . . . 0.0 109.839 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -142.62 151.09 41.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.138 -0.976 . . . . 0.0 110.002 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.701 ' CG2' HD21 ' A' ' 41' ' ' LEU . 21.4 t -139.9 137.27 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.435 -0.791 . . . . 0.0 109.465 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 56' ' ' PRO . 61.4 mt-10 -127.78 150.55 49.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.873 -1.142 . . . . 0.0 109.215 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.776 HD12 ' O ' ' A' ' 77' ' ' ASN . 10.9 tp -120.87 133.0 55.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.333 -0.855 . . . . 0.0 110.243 -178.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.693 ' N ' HD12 ' A' ' 46' ' ' LEU . 47.8 ttp85 -113.53 127.98 56.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.099 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -71.91 152.35 42.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.512 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 85.6 t60 -69.31 111.3 5.12 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.382 -0.824 . . . . 0.0 109.554 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.82 2.1 36.75 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.511 ' O ' ' NH1' ' A' ' 47' ' ' ARG . 33.5 t -113.47 154.37 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.195 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 37.9 mm-40 -113.22 16.14 19.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.333 -0.854 . . . . 0.0 109.394 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -113.88 114.19 25.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.528 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.594 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.6 m95 -80.13 120.09 23.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.267 -0.895 . . . . 0.0 109.655 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.445 ' O ' ' N ' ' A' ' 46' ' ' LEU . 11.6 mm-40 -95.95 129.99 32.63 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.445 -0.784 . . . . 0.0 109.344 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 48.2 Cg_endo -69.32 149.48 69.74 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.561 2.174 . . . . 0.0 111.879 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.618 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -101.6 149.52 24.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.149 -0.97 . . . . 0.0 108.576 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -102.46 126.54 49.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 108.941 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -70.41 109.47 4.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.168 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.877 ' O ' HG22 ' A' ' 63' ' ' VAL . 37.2 mttp -121.74 139.53 53.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.797 -1.189 . . . . 0.0 109.975 -179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.531 ' O ' ' HB2' ' A' ' 62' ' ' ASN . . . 38.39 48.25 2.21 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.531 ' HB2' ' O ' ' A' ' 61' ' ' GLY . 54.3 m-20 68.48 11.46 8.36 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.169 -1.195 . . . . 0.0 110.956 178.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.9 m -128.88 -178.61 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.858 -1.151 . . . . 0.0 108.997 179.169 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.506 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 71.1 m95 -122.8 141.27 52.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.082 . . . . 0.0 109.632 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 62.5 tt0 -128.42 142.22 51.17 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.815 . . . . 0.0 109.212 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.645 HG11 HD23 ' A' ' 46' ' ' LEU . 1.8 p -136.37 135.18 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.24 -0.913 . . . . 0.0 109.145 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.433 ' HD2' ' HE2' ' A' ' 27' ' ' LYS . 6.1 ttpm? -122.54 133.73 54.56 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.851 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.8 t -117.86 148.13 42.41 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.456 -0.778 . . . . 0.0 109.153 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 85.5 p -72.77 -4.43 31.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.988 . . . . 0.0 109.354 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -131.5 176.19 3.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.243 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.44 140.52 48.25 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.482 2.121 . . . . 0.0 111.714 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.994 HD13 HD12 ' A' ' 28' ' ' LEU . 10.5 mt -74.76 137.89 42.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.826 -179.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.9 t -123.37 125.12 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.469 -0.769 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.665 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.3 165.47 27.67 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 50.5 Cg_endo -70.01 145.66 80.6 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.806 -1.747 . . . . 0.0 111.883 0.03 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.667 ' HB3' HD11 ' A' ' 46' ' ' LEU . 76.8 m-85 -91.46 151.18 20.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.523 -0.736 . . . . 0.0 110.367 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.776 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.5 m120 -110.77 142.43 42.75 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.767 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.0 m-85 -133.24 127.3 33.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.913 -1.117 . . . . 0.0 109.971 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.686 ' HG3' HG22 ' A' ' 89' ' ' VAL . 41.4 ttt180 -110.62 143.12 41.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.006 -1.059 . . . . 0.0 108.627 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.701 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.0 m-85 -124.86 143.81 50.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.218 -0.926 . . . . 0.0 111.632 -177.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 1.2 ttt -125.85 124.4 40.82 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.537 ' CB ' ' HB2' ' A' ' 86' ' ' MET . 24.2 p -77.39 147.7 35.92 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.206 -0.934 . . . . 0.0 110.043 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.741 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 32.9 mttt -46.65 -46.0 19.6 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.32 -8.19 8.65 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.41 34.53 5.28 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.537 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 44.3 mmm -103.24 110.61 22.64 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.987 -1.302 . . . . 0.0 109.011 179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 61.0 mtt180 -91.71 139.49 30.63 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.199 -0.938 . . . . 0.0 110.472 -179.148 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.4 m120 -137.25 141.69 42.02 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.686 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.2 t -122.06 136.5 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.865 -1.147 . . . . 0.0 110.471 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.567 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 55.0 m-85 -124.44 122.36 37.42 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -97.13 145.27 26.17 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.18 -0.95 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 12.8 mt-10 53.96 54.26 9.99 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.491 -0.756 . . . . 0.0 110.335 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.779 HG11 ' CE1' ' A' ' 17' ' ' PHE . 75.8 t -82.26 -34.18 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 109.074 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.464 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.7 mt -135.44 124.4 16.0 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.201 -0.937 . . . . 0.0 109.132 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.42 162.13 43.12 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.608 2.205 . . . . 0.0 111.968 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.665 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.3 m -53.3 -44.7 68.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 109.976 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.84 99.72 12.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.046 -1.034 . . . . 0.0 109.502 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -109.45 147.83 32.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.94 . . . . 0.0 109.715 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.8 m -106.09 171.15 7.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.212 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.552 HD13 ' CG1' ' A' ' 19' ' ' VAL . 27.2 mm -106.73 137.83 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.42 9.62 61.49 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 4.6 tptp -120.57 144.18 48.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.495 HG22 ' H ' ' A' ' 104' ' ' TYR . 8.6 m -77.81 170.97 15.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.038 -1.039 . . . . 0.0 108.706 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.593 ' N ' ' O ' ' A' ' 17' ' ' PHE . 24.0 m-85 -157.62 97.94 1.63 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.607 -1.308 . . . . 0.0 109.151 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.529 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -104.93 161.53 22.49 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.277 -0.889 . . . . 0.0 109.767 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.2 Cg_endo -69.08 143.2 53.27 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.718 2.279 . . . . 0.0 111.663 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -52.97 -30.97 38.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.546 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.417 ' HA ' ' OE1' ' A' ' 108' ' ' GLU . 62.3 mm-40 . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.439 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -76.78 -16.69 80.55 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.0 m -118.72 147.66 43.6 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.316 -1.108 . . . . 0.0 109.466 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -132.08 164.33 26.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 109.508 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -126.66 164.19 21.81 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.448 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.1 m80 -78.95 -12.72 60.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.507 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -53.55 -26.96 23.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.422 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 t60 -58.06 -34.5 70.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -99.87 144.17 29.24 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.397 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.27 -152.98 17.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 91.9 p -114.09 146.76 39.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.294 -1.121 . . . . 0.0 109.483 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.506 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -140.66 153.32 45.95 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.488 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.989 HG22 ' HG3' ' A' ' 36' ' ' ARG . 30.3 t -125.37 130.32 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.295 -0.878 . . . . 0.0 109.567 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.47 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 77.9 mm-40 -106.01 120.24 41.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.027 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.601 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.1 p -128.92 139.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.232 -0.917 . . . . 0.0 110.049 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 73.1 p -141.25 145.42 35.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.334 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.646 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.8 m-85 -118.24 136.22 53.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.176 -0.953 . . . . 0.0 109.717 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 88.5 m -131.34 127.77 38.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.903 -1.123 . . . . 0.0 109.302 179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.898 HG22 ' CD2' ' A' ' 30' ' ' LEU . 30.6 t -75.02 134.01 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.216 -0.928 . . . . 0.0 109.173 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.468 ' OE1' ' O ' ' A' ' 19' ' ' VAL . 4.9 mm100 -106.57 156.34 18.69 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.174 -0.954 . . . . 0.0 109.975 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.5 mttt -51.34 115.87 1.79 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.51 -0.743 . . . . 0.0 109.947 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 137.26 -1.52 3.05 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.447 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 p -60.29 144.15 51.14 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.911 -1.347 . . . . 0.0 109.403 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.19 169.79 12.62 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.288 -0.882 . . . . 0.0 109.71 -179.779 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.4 Cg_endo -70.73 -29.34 19.39 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.806 2.337 . . . . 0.0 111.88 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -113.02 7.09 17.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.165 -0.959 . . . . 0.0 108.819 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -142.74 133.55 25.45 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.72 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.35 122.84 40.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.965 -1.085 . . . . 0.0 109.337 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.549 HG13 ' HG2' ' A' ' 65' ' ' GLU . 51.4 t -118.72 124.35 73.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.898 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -144.33 144.76 31.61 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.977 -1.077 . . . . 0.0 110.253 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.635 ' OD1' HG12 ' A' ' 63' ' ' VAL . 20.9 t70 -85.39 137.04 33.2 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 177.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.897 HG21 ' CE2' ' A' ' 80' ' ' PHE . 75.7 mt -120.71 130.98 73.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 C-N-CA 118.667 -1.213 . . . . 0.0 110.786 -179.033 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.601 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 22.1 tttm -110.61 120.38 42.23 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.094 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.51 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 78.6 t80 -120.15 112.77 19.52 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.343 -0.848 . . . . 0.0 109.567 -178.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 31.2 m -115.71 115.79 26.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -0.851 . . . . 0.0 109.677 -179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.989 ' HG3' HG22 ' A' ' 13' ' ' VAL . 28.0 ttt85 -138.68 136.29 18.62 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.526 -0.734 . . . . 0.0 109.208 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 12' ' ' ALA . 49.2 Cg_endo -69.88 112.57 3.13 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.1 0.69 83.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.563 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.2 m-20 -133.92 172.26 13.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.966 -1.314 . . . . 0.0 109.87 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 82' ' ' SER . 13.6 m -153.98 161.61 41.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.408 -0.807 . . . . 0.0 109.341 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.864 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.7 OUTLIER -72.28 131.27 42.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.279 -0.888 . . . . 0.0 109.845 -179.588 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.936 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.93 -40.24 3.54 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.619 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.45 150.41 40.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.124 -0.985 . . . . 0.0 110.187 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.679 ' CG2' HD11 ' A' ' 41' ' ' LEU . 5.9 t -139.21 136.88 41.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.581 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -129.63 150.81 50.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.935 -1.103 . . . . 0.0 109.394 179.412 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.0 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -118.72 140.61 49.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.892 . . . . 0.0 109.715 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 1.0 ' N ' HD23 ' A' ' 46' ' ' LEU . 28.3 ttp180 -126.74 129.54 48.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.293 -0.879 . . . . 0.0 109.072 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.438 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 14.9 mt-30 -72.6 144.8 47.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.343 -0.848 . . . . 0.0 109.863 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.537 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 2.0 t-160 -61.36 115.81 4.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.35 -0.844 . . . . 0.0 109.442 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.42 2.75 35.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.417 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 25.6 t -113.7 155.71 25.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -1.188 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 69.7 tt0 -116.05 1.03 13.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.583 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -108.83 92.48 4.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.602 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.0 m95 -51.55 138.64 22.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.356 -0.84 . . . . 0.0 109.599 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -105.05 135.19 19.33 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.375 -0.828 . . . . 0.0 109.32 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.83 145.51 51.11 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.617 2.211 . . . . 0.0 111.891 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.869 HD11 ' HB2' ' A' ' 46' ' ' LEU . 5.4 mp -107.17 146.14 31.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.032 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.2 m -94.41 126.92 39.97 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.956 -1.09 . . . . 0.0 109.176 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -70.6 111.18 5.91 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.408 -0.808 . . . . 0.0 109.033 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -111.77 113.04 25.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.982 -1.074 . . . . 0.0 109.571 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.15 -103.72 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -123.76 17.36 9.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -1.146 . . . . 0.0 109.398 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.635 HG12 ' OD1' ' A' ' 31' ' ' ASP . 17.8 m -130.82 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.328 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 60.9 m95 -134.1 142.06 47.38 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.155 -0.966 . . . . 0.0 109.466 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG2' HG13 ' A' ' 29' ' ' VAL . 30.2 mt-10 -122.48 134.79 54.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.214 -0.929 . . . . 0.0 109.766 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.855 HG11 HD13 ' A' ' 46' ' ' LEU . 4.8 p -130.83 130.35 64.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -0.903 . . . . 0.0 109.217 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.7 tttm -122.17 133.85 54.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.064 -1.023 . . . . 0.0 109.75 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.438 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 8.3 t -117.63 154.77 31.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.437 -0.789 . . . . 0.0 109.239 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 20.4 m -80.15 -4.36 52.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.288 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.546 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.1 mttm -128.33 176.05 3.03 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.5 Cg_endo -69.52 124.19 10.94 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.508 2.138 . . . . 0.0 111.735 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.598 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.3 mt -58.53 139.67 55.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.354 -0.842 . . . . 0.0 109.79 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 46.4 t -125.14 124.68 67.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.378 -0.826 . . . . 0.0 109.543 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -95.3 166.78 25.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 45.4 Cg_endo -66.61 146.53 73.86 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 123.043 -1.649 . . . . 0.0 112.087 0.185 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 75.5 m-85 -90.72 150.53 21.6 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.607 -0.683 . . . . 0.0 110.405 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.41 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 10.0 m-80 -111.91 143.16 43.33 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.805 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.3 m-85 -134.77 122.16 21.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.01 -1.056 . . . . 0.0 109.704 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.571 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.9 ttp180 -103.3 141.91 35.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.96 -1.087 . . . . 0.0 108.609 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.897 ' CE2' HG21 ' A' ' 32' ' ' ILE . 31.7 m-85 -125.51 143.91 50.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.187 -0.946 . . . . 0.0 111.595 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.588 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.8 ttm -126.65 126.82 44.19 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.3 p -77.52 145.62 36.85 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.203 -0.936 . . . . 0.0 110.412 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.936 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.6 mttt -48.7 -44.56 38.15 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.61 -6.24 6.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.26 34.34 5.9 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.537 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 15.8 mmm -106.07 108.78 20.47 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.075 -1.25 . . . . 0.0 109.001 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.588 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 82.5 mtm180 -85.86 134.98 33.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.199 -0.938 . . . . 0.0 110.634 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.446 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -134.3 139.49 45.74 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.571 HG22 ' HG3' ' A' ' 79' ' ' ARG . 37.2 t -122.84 136.82 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.036 -1.04 . . . . 0.0 110.587 -178.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.532 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 61.2 m-85 -124.16 122.09 36.88 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 21.0 p-10 -100.11 148.96 24.01 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.346 -0.846 . . . . 0.0 109.744 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 40.1 tt0 52.98 51.19 16.33 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.323 -0.86 . . . . 0.0 110.002 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 94' ' ' ILE . 61.6 t -81.76 -33.87 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.924 -1.11 . . . . 0.0 109.116 179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.5 HG13 HG12 ' A' ' 93' ' ' VAL . 67.1 mt -138.83 127.67 14.09 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.312 -0.868 . . . . 0.0 109.074 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.45 161.37 46.14 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.611 2.208 . . . . 0.0 111.982 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.52 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 87.4 m -51.2 -45.44 61.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.394 -0.816 . . . . 0.0 109.916 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -93.07 104.01 16.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.113 -0.992 . . . . 0.0 109.688 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -111.09 151.57 27.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.359 -0.838 . . . . 0.0 109.33 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.0 m -102.64 170.18 8.18 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 30.6 mm -103.23 136.06 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.182 -0.948 . . . . 0.0 109.306 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.8 57.7 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -121.28 143.39 49.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.974 -1.309 . . . . 0.0 109.306 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.667 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -79.15 177.2 9.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.076 -1.015 . . . . 0.0 108.919 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.667 ' H ' HG22 ' A' ' 103' ' ' THR . 27.5 m-85 -162.23 96.27 0.97 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.769 -1.207 . . . . 0.0 109.107 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.521 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -102.51 164.54 15.45 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.362 -0.836 . . . . 0.0 109.724 -179.584 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.532 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.5 Cg_endo -68.68 174.89 7.88 Favored 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.675 2.25 . . . . 0.0 111.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 37.5 tt0 -88.59 -22.04 23.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.355 -0.841 . . . . 0.0 109.511 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.3 mt-10 . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.506 179.972 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 73.39 -125.67 9.58 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 65.3 p -139.63 168.48 19.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -1.154 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.58 99.64 9.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -0.955 . . . . 0.0 109.479 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -62.45 -41.47 98.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.903 . . . . 0.0 109.481 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -86.05 139.96 30.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.201 -0.937 . . . . 0.0 109.484 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 40.6 t-80 -64.61 -42.05 95.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.3 p80 -127.52 141.03 51.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.451 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 74.1 m80 -54.37 -35.59 62.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.287 -0.883 . . . . 0.0 109.565 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.86 -159.38 26.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.2 t -120.29 116.54 25.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -1.154 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.474 ' O ' ' HD2' ' A' ' 37' ' ' PRO . . . -149.57 176.89 10.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.278 -0.889 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 36' ' ' ARG . 60.7 t -121.58 123.95 70.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.533 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.498 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 94.7 mt-30 -112.96 121.78 45.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.274 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.639 HG11 ' CE2' ' A' ' 90' ' ' PHE . 12.5 p -128.79 139.99 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.258 -0.902 . . . . 0.0 109.668 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.469 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 17.0 p -141.6 145.72 35.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.155 -0.965 . . . . 0.0 109.515 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.576 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.7 m-85 -117.49 150.44 38.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.234 -0.916 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.973 HG23 ' O ' ' A' ' 102' ' ' LYS . 92.2 m -144.81 127.7 16.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.069 -1.02 . . . . 0.0 109.378 179.097 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.813 HG22 ' CD2' ' A' ' 30' ' ' LEU . 4.5 t -76.29 129.1 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.885 . . . . 0.0 109.377 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.49 ' O ' HD12 ' A' ' 100' ' ' ILE . 91.2 mm-40 -92.97 -175.25 3.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.609 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -81.94 62.16 5.59 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.962 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -169.05 24.49 0.1 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.71 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.537 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 26.2 m -79.95 143.64 34.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.778 -1.425 . . . . 0.0 109.252 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.632 ' O ' HD12 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -137.71 174.19 4.6 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.101 -0.999 . . . . 0.0 109.605 -179.726 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.546 ' O ' ' N ' ' A' ' 72' ' ' LEU . 48.7 Cg_endo -70.76 -30.39 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.67 2.247 . . . . 0.0 112.045 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 88.8 mttt -115.17 5.7 14.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.067 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.42 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 81.8 mttt -142.18 133.38 26.21 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.31 40.95 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.042 -1.036 . . . . 0.0 109.466 -179.928 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 65' ' ' GLU . 21.9 t -118.74 124.62 73.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.813 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.0 OUTLIER -144.65 145.76 31.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.978 -1.076 . . . . 0.0 110.169 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -85.63 137.36 32.9 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.787 HG21 ' CE2' ' A' ' 80' ' ' PHE . 77.0 mt -120.78 130.13 74.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.755 -1.215 . . . . 0.0 110.688 -178.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.55 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.5 tttm -109.66 119.95 40.98 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 72.3 t80 -122.0 124.27 43.6 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.334 -0.853 . . . . 0.0 109.716 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 16.2 m -126.74 116.93 21.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.301 -0.874 . . . . 0.0 109.737 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.606 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.5 OUTLIER -151.27 116.66 3.19 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.416 -0.803 . . . . 0.0 109.139 179.804 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.474 ' HD2' ' O ' ' A' ' 12' ' ' ALA . 48.3 Cg_endo -68.95 126.21 13.56 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.73 2.286 . . . . 0.0 111.95 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.54 -19.48 54.5 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 1.5 m-20 -142.95 -176.35 4.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.209 -1.171 . . . . 0.0 109.814 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' LYS . 5.9 m -156.17 163.31 39.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.36 -0.838 . . . . 0.0 109.367 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.672 HD11 HG22 ' A' ' 44' ' ' VAL . 29.4 tp -70.52 129.02 38.12 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.342 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.893 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.65 -42.35 2.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.418 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 86.6 mt-10 -139.59 147.89 41.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.176 -0.953 . . . . 0.0 110.218 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.672 HG22 HD11 ' A' ' 41' ' ' LEU . 8.9 t -138.6 136.99 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 108.965 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.406 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 72.5 mt-10 -128.15 149.22 50.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.821 -1.174 . . . . 0.0 109.56 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.099 HD23 HG11 ' A' ' 66' ' ' VAL . 11.2 tp -120.18 131.64 55.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.418 -0.801 . . . . 0.0 109.96 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.65 ' N ' HD12 ' A' ' 46' ' ' LEU . 7.5 ttp180 -119.82 131.94 55.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.076 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 12.3 mt-30 -72.27 149.95 44.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.738 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.507 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 1.9 t-80 -68.54 113.94 6.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.746 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.48 2.42 27.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.45 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 28.1 t -115.01 154.92 27.93 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -1.172 . . . . 0.0 109.406 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -111.22 15.59 21.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.291 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -121.97 121.43 37.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.541 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.506 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 43.1 m95 -83.34 132.94 34.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.431 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.0 OUTLIER -100.76 135.11 20.14 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.335 -0.853 . . . . 0.0 109.422 179.975 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.431 ' HD2' ' HG3' ' A' ' 55' ' ' GLU . 52.3 Cg_endo -71.11 149.49 58.39 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.606 2.204 . . . . 0.0 111.96 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.623 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.6 mp -108.4 138.46 44.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.213 -0.929 . . . . 0.0 109.07 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.3 m -90.17 127.48 36.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.99 -1.069 . . . . 0.0 109.014 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 22.7 tttt -74.48 105.68 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.265 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -108.3 110.63 22.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.006 -1.059 . . . . 0.0 109.551 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.11 -107.73 1.93 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 35.0 p-10 -121.99 16.24 10.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -1.128 . . . . 0.0 109.345 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.2 m -132.08 170.09 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.947 . . . . 0.0 109.424 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.445 ' CD1' HD12 ' A' ' 32' ' ' ILE . 55.9 m95 -116.11 142.82 46.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.169 -0.957 . . . . 0.0 109.216 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 29' ' ' VAL . 75.7 tt0 -123.67 136.57 54.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 109.921 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 1.099 HG11 HD23 ' A' ' 46' ' ' LEU . 11.9 p -131.07 130.25 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.361 -0.837 . . . . 0.0 109.118 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.424 ' HE2' ' OE2' ' A' ' 65' ' ' GLU . 25.1 mttt -120.75 132.34 55.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.148 -0.97 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.4 t -118.56 145.55 45.27 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.447 -0.783 . . . . 0.0 109.217 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.3 m -66.55 -11.28 52.19 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.092 -1.005 . . . . 0.0 109.165 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.55 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -123.28 176.55 2.1 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.387 -0.821 . . . . 0.0 109.278 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.4 Cg_endo -69.74 157.62 59.8 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.454 2.102 . . . . 0.0 111.63 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.632 HD12 ' O ' ' A' ' 24' ' ' ASP . 5.3 mt -87.58 138.65 31.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.798 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 73.5 t -124.85 125.26 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.416 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.542 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.3 164.96 26.08 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.93 146.48 80.48 Favored 'Cis proline' 0 C--O 1.214 -0.704 0 C-N-CA 122.761 -1.766 . . . . 0.0 111.8 0.205 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.615 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.1 m-85 -91.02 152.4 20.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.515 -0.741 . . . . 0.0 110.544 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.773 ' O ' HD12 ' A' ' 46' ' ' LEU . 37.8 m-80 -112.68 141.67 46.2 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.856 ' CE1' HD13 ' A' ' 46' ' ' LEU . 86.9 m-85 -134.77 122.18 21.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.102 -0.999 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.987 ' HG3' HG22 ' A' ' 89' ' ' VAL . 70.6 ttt180 -104.2 143.32 33.1 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.997 -1.064 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.787 ' CE2' HG21 ' A' ' 32' ' ' ILE . 11.0 m-85 -125.29 143.15 51.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.196 -0.94 . . . . 0.0 111.402 -178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.559 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.5 ttt -125.23 125.03 42.96 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.594 ' N ' ' O ' ' A' ' 86' ' ' MET . 14.8 p -73.7 147.12 43.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 110.267 -178.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.893 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 42.1 mttp -50.03 -44.78 51.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.468 -0.77 . . . . 0.0 109.134 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.65 -4.31 0.61 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.86 27.06 11.64 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.594 ' O ' ' N ' ' A' ' 82' ' ' SER . 46.4 mtp -99.89 149.07 23.79 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -1.184 . . . . 0.0 108.627 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.559 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 17.8 mtt180 -121.87 136.92 54.95 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.871 -1.143 . . . . 0.0 110.457 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -134.1 139.79 46.17 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.987 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.4 t -123.2 136.97 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 120.952 -1.093 . . . . 0.0 110.315 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.639 ' CE2' HG11 ' A' ' 15' ' ' VAL . 18.2 m-85 -123.62 121.65 36.11 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -98.96 147.35 25.08 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.262 -0.899 . . . . 0.0 109.803 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 63.1 tt0 53.88 51.41 14.87 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.5 -0.75 . . . . 0.0 110.338 179.512 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.563 HG12 HG13 ' A' ' 94' ' ' ILE . 42.0 t -81.13 -34.37 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.889 -1.132 . . . . 0.0 108.905 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.563 HG13 HG12 ' A' ' 93' ' ' VAL . 40.9 mt -136.45 125.32 15.42 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.326 -0.859 . . . . 0.0 109.121 179.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.85 162.71 41.09 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.565 2.177 . . . . 0.0 112.024 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.542 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 32.2 m -49.96 -38.39 36.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.373 -0.829 . . . . 0.0 110.007 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.49 102.8 13.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.006 -1.059 . . . . 0.0 109.72 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CE1' HG11 ' A' ' 19' ' ' VAL . 42.8 p90 -110.33 154.13 23.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.905 . . . . 0.0 109.163 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.9 t -104.32 167.51 9.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 20' ' ' GLN . 28.6 mm -103.41 138.9 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -0.864 . . . . 0.0 109.29 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 90.35 16.0 56.2 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.973 ' O ' HG23 ' A' ' 18' ' ' THR . 18.9 mttm -119.21 -165.97 1.21 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 109.071 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.6 m -131.61 163.41 28.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.977 -1.077 . . . . 0.0 108.665 179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.576 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.8 m-85 -151.6 94.03 1.95 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.44 -1.412 . . . . 0.0 109.147 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.54 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -99.66 162.13 22.2 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.584 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.548 ' CD ' HG13 ' A' ' 15' ' ' VAL . 49.3 Cg_endo -69.57 146.02 60.06 Favored 'Trans proline' 0 C--O 1.217 -0.555 0 C-N-CA 122.554 2.169 . . . . 0.0 111.83 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -75.33 -32.44 60.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.511 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.421 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.71 26.4 72.04 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.4 m -60.84 -26.11 67.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -1.127 . . . . 0.0 109.463 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -67.1 -42.58 84.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.286 -0.884 . . . . 0.0 109.532 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -118.77 120.2 36.66 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.506 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -82.37 -8.6 59.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.295 -0.878 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 80.8 m80 56.5 -177.69 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.193 -0.942 . . . . 0.0 109.431 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -119.62 137.19 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.6 p-80 -56.83 -18.8 14.3 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.282 -0.886 . . . . 0.0 109.412 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.02 -162.87 36.16 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HG3' ' A' ' 37' ' ' PRO . 3.4 m -145.88 131.55 18.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.26 -1.141 . . . . 0.0 109.505 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.5 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -98.92 140.42 33.11 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.424 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 36' ' ' ARG . 47.5 t -121.46 124.18 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.115 -0.991 . . . . 0.0 109.537 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -111.93 121.4 44.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.611 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -128.3 138.44 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.878 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.41 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 36.7 p -141.44 145.5 35.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.346 -0.846 . . . . 0.0 109.146 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.587 ' CD2' HG12 ' A' ' 32' ' ' ILE . 13.6 m-85 -119.06 142.68 47.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.927 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.7 m -137.85 127.79 25.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.247 -0.908 . . . . 0.0 109.189 179.291 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.876 HG22 ' CD2' ' A' ' 30' ' ' LEU . 27.9 t -75.74 136.09 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.289 -0.882 . . . . 0.0 109.173 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -114.14 156.24 24.57 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.083 -1.011 . . . . 0.0 109.926 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.6 mttt -48.35 111.98 0.53 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.15 -6.39 1.53 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.283 -1.437 . . . . 0.0 110.784 179.251 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.452 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 3.3 m -61.41 140.26 58.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.842 -1.387 . . . . 0.0 109.192 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.57 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.95 177.47 2.2 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.207 -0.933 . . . . 0.0 109.53 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.57 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.3 Cg_endo -70.88 -31.34 15.69 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.614 2.209 . . . . 0.0 111.903 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -117.93 5.26 12.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 108.931 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.472 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 44.3 mttt -142.35 133.8 26.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.039 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.25 133.71 50.17 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 120.988 -1.07 . . . . 0.0 110.222 -179.511 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.972 HG13 ' HG2' ' A' ' 65' ' ' GLU . 21.2 t -122.4 124.64 71.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.039 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -142.22 142.22 32.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.057 -1.027 . . . . 0.0 110.047 -179.372 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -86.15 136.62 33.13 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.849 HG21 ' CE2' ' A' ' 80' ' ' PHE . 87.8 mt -121.3 131.02 74.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.339 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 60.3 tttt -109.99 118.38 36.28 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.611 ' CD1' HG22 ' A' ' 15' ' ' VAL . 77.2 t80 -122.26 111.16 16.59 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.54 -0.725 . . . . 0.0 109.341 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 47.5 m -115.08 120.33 39.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.215 -0.928 . . . . 0.0 109.804 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 34' ' ' TYR . 2.9 mtt-85 -123.21 163.34 34.45 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.609 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.502 ' HG3' ' CB ' ' A' ' 11' ' ' SER . 51.9 Cg_endo -72.57 50.65 1.7 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.73 2.287 . . . . 0.0 111.864 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.94 -12.89 13.01 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.433 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.5 OUTLIER -96.83 178.78 5.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -1.169 . . . . 0.0 109.308 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.8 p -150.95 159.25 44.68 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.204 -0.935 . . . . 0.0 109.708 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.955 HD23 ' N ' ' A' ' 42' ' ' ALA . 2.2 tt -71.81 134.27 46.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.955 ' N ' HD23 ' A' ' 41' ' ' LEU . . . -114.74 -42.35 3.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.178 -0.952 . . . . 0.0 109.848 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -144.02 152.4 40.97 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.065 -1.022 . . . . 0.0 110.431 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.498 HG13 ' CE1' ' A' ' 80' ' ' PHE . 3.5 t -140.39 138.07 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.441 -0.787 . . . . 0.0 109.345 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.424 ' OE2' ' HB3' ' A' ' 56' ' ' PRO . 5.7 mm-40 -127.08 150.91 49.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 109.352 179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.724 HD23 HG11 ' A' ' 66' ' ' VAL . 5.9 tp -122.99 123.82 41.76 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.321 -0.862 . . . . 0.0 110.56 -178.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.709 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.6 OUTLIER -106.25 129.41 54.29 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.935 . . . . 0.0 109.006 178.838 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.44 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 8.3 mt-30 -71.64 151.17 43.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.291 -0.881 . . . . 0.0 109.306 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.608 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 30.0 t60 -67.49 110.33 3.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.188 -0.945 . . . . 0.0 109.44 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.28 1.03 38.17 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 27.2 t -112.77 153.11 28.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.246 . . . . 0.0 109.397 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 61.8 tt0 -116.22 14.23 15.82 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.25 -0.906 . . . . 0.0 109.34 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -112.45 86.9 2.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.282 -0.886 . . . . 0.0 109.465 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.628 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 22.5 m95 -53.84 138.72 35.36 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.424 -0.798 . . . . 0.0 109.841 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.07 131.61 23.44 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.454 -0.779 . . . . 0.0 108.911 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.424 ' HB3' ' OE2' ' A' ' 45' ' ' GLU . 49.1 Cg_endo -69.91 150.09 66.84 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.56 2.173 . . . . 0.0 112.027 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.712 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -100.92 148.43 25.0 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.469 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 69.7 m -98.12 126.69 43.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.742 -1.224 . . . . 0.0 109.051 179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -71.38 107.58 4.4 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.26 -0.9 . . . . 0.0 109.204 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.426 ' HD3' ' HA ' ' A' ' 60' ' ' LYS . 6.6 mmtp -111.75 106.79 15.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.969 -1.082 . . . . 0.0 109.581 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.35 -95.46 0.21 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -134.18 17.19 3.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -1.144 . . . . 0.0 109.453 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.01 169.85 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.305 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.459 ' HE3' ' CB ' ' A' ' 57' ' ' LEU . 70.3 m95 -116.41 131.04 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.177 -0.952 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.972 ' HG2' HG13 ' A' ' 29' ' ' VAL . 91.1 mt-10 -117.89 144.69 45.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.596 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.724 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -141.34 138.47 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -122.44 132.42 54.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 0.0 110.0 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.44 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 48.4 t -118.88 116.55 26.73 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.467 -0.771 . . . . 0.0 109.479 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 68' ' ' SER . 50.0 m -43.37 -37.71 2.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.143 -0.973 . . . . 0.0 109.085 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.618 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 5.2 ptpp? -94.72 168.44 11.28 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.159 179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.618 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.6 146.68 80.17 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.443 2.095 . . . . 0.0 111.743 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.006 HD13 HD12 ' A' ' 28' ' ' LEU . 1.6 mt -80.06 139.66 36.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.307 -0.871 . . . . 0.0 109.913 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.1 t -124.4 125.06 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.467 -0.771 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.495 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.45 166.41 26.72 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HG2' ' CE1' ' A' ' 49' ' ' HIS . 47.9 Cg_endo -68.65 145.13 76.04 Favored 'Cis proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.846 -1.731 . . . . 0.0 112.045 0.011 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.1 m-85 -91.19 153.1 20.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.588 -0.695 . . . . 0.0 110.49 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.484 ' ND2' ' OD1' ' A' ' 91' ' ' ASP . 2.7 m120 -111.72 140.91 45.97 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.6 m-85 -131.65 135.76 47.18 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.886 -1.134 . . . . 0.0 109.772 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.442 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 53.3 ttt-85 -119.97 142.86 48.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.192 -0.943 . . . . 0.0 108.609 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.849 ' CE2' HG21 ' A' ' 32' ' ' ILE . 15.3 m-85 -124.77 144.18 50.39 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.183 -0.948 . . . . 0.0 111.721 -177.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.654 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.4 ttt -126.65 124.16 39.22 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 178.315 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.53 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 20.8 p -77.76 141.87 39.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.325 -0.859 . . . . 0.0 109.867 -178.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.804 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 19.9 mttm -44.3 -44.02 7.81 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.21 -4.31 8.09 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.03 30.63 7.76 Favored Glycine 0 N--CA 1.491 2.319 0 O-C-N 121.256 -1.144 . . . . 0.0 110.33 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.53 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 37.0 mmm -103.45 107.85 18.86 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.02 -1.282 . . . . 0.0 108.854 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 35.7 mtm-85 -92.29 142.21 27.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 110.923 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -137.25 141.33 42.01 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.582 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 t -121.33 136.8 57.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.998 -1.064 . . . . 0.0 110.202 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 82.2 m-85 -125.05 121.65 34.97 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.484 ' OD1' ' ND2' ' A' ' 77' ' ' ASN . 55.1 t0 -97.51 147.96 23.73 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.097 -1.002 . . . . 0.0 109.662 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 35.8 mt-10 51.77 54.52 10.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.449 -0.782 . . . . 0.0 109.947 179.711 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' A' ' 106' ' ' PRO . 75.1 t -83.63 -32.89 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.954 -1.091 . . . . 0.0 109.261 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.45 HG12 ' HB3' ' A' ' 104' ' ' TYR . 34.8 mt -138.55 126.49 13.73 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.33 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.19 163.82 37.21 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.553 2.169 . . . . 0.0 111.8 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.495 HG23 ' H ' ' A' ' 74' ' ' GLY . 5.7 m -54.38 -37.31 64.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.309 -0.87 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.49 96.2 10.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.008 . . . . 0.0 109.836 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -104.95 143.94 32.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.488 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 88.0 p -116.66 124.07 48.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.211 -0.931 . . . . 0.0 109.665 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.567 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 5.9 mt -64.04 138.65 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.528 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.45 -4.19 50.88 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 37.8 tttp -118.19 142.86 47.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.108 -1.23 . . . . 0.0 109.264 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.562 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.3 m -76.81 173.61 11.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.033 -1.042 . . . . 0.0 108.476 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.568 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.0 m-85 -158.13 96.45 1.45 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 120.64 -1.288 . . . . 0.0 109.004 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.57 158.61 33.42 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.322 -0.861 . . . . 0.0 109.833 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HB3' HG22 ' A' ' 93' ' ' VAL . 49.5 Cg_endo -70.95 149.07 58.66 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.734 2.289 . . . . 0.0 111.663 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -60.84 -37.72 83.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.17 -0.956 . . . . 0.0 109.539 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 61.9 tt0 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.488 -179.914 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ARG . . . . . 0.428 ' O ' ' HG2' ' A' ' 1' ' ' ARG . 37.1 ttp180 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -93.05 20.22 47.25 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 84.1 p -63.56 -16.63 61.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -1.146 . . . . 0.0 109.392 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -65.99 -12.36 54.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 57.52 16.96 3.59 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -128.36 122.5 31.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 109.486 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 28.8 m80 -140.15 139.94 35.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -58.06 -21.52 45.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -107.18 141.14 38.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.461 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.03 169.81 16.17 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HB2' ' A' ' 12' ' ' ALA . 15.7 m -109.76 166.09 11.19 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.41 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 11' ' ' SER . . . 176.05 173.21 0.35 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.213 -0.929 . . . . 0.0 109.344 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 36' ' ' ARG . 3.0 t -123.47 128.09 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -111.49 120.88 43.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.145 -0.972 . . . . 0.0 109.189 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.58 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.0 t -127.77 137.06 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.89 . . . . 0.0 109.874 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.495 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 18.1 p -143.75 147.27 33.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.409 -0.807 . . . . 0.0 109.259 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.626 ' O ' ' N ' ' A' ' 104' ' ' TYR . 21.6 m-85 -118.55 145.46 45.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 109.786 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 62.6 m -139.59 128.12 22.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.112 -0.993 . . . . 0.0 109.201 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 HD23 ' A' ' 30' ' ' LEU . 5.2 t -76.4 133.36 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.222 -0.924 . . . . 0.0 109.53 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.3 mm-40 -109.83 156.27 20.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.526 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -49.32 113.56 0.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.39 -4.13 1.72 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.39 -1.386 . . . . 0.0 110.727 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.496 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 66.4 m -63.94 140.57 58.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.835 -1.391 . . . . 0.0 109.34 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.58 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.65 177.81 2.05 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.195 -0.941 . . . . 0.0 109.497 -179.571 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 49.9 Cg_endo -70.77 -31.08 16.63 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.516 2.144 . . . . 0.0 111.827 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -116.68 6.25 13.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.016 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 19.8 mttp -142.41 133.56 26.05 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.084 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.29 132.28 51.69 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.964 -1.085 . . . . 0.0 110.002 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.929 HG13 ' HG2' ' A' ' 65' ' ' GLU . 45.7 t -121.8 124.25 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.084 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -141.55 142.02 33.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.947 -1.095 . . . . 0.0 110.285 -179.456 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD2' HG12 ' A' ' 63' ' ' VAL . 10.4 t70 -86.51 136.9 32.91 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.599 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.2 mt -117.06 127.96 74.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 120.712 -1.243 . . . . 0.0 111.122 -178.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 31.1 mtpt -108.06 114.97 29.28 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.58 ' CD1' HG22 ' A' ' 15' ' ' VAL . 84.4 t80 -124.3 108.2 11.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.71 -0.618 . . . . 0.0 109.817 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.9 m -109.52 117.3 33.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.38 -0.825 . . . . 0.0 109.523 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.554 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -139.89 121.72 9.79 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.406 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 50.4 Cg_endo -70.52 119.39 6.3 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.72 2.28 . . . . 0.0 111.929 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.39 -12.44 68.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -141.25 -178.63 5.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.141 -1.211 . . . . 0.0 109.646 -179.906 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -156.32 163.45 39.5 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.748 HD13 ' HD2' ' A' ' 80' ' ' PHE . 51.0 tp -68.96 125.94 28.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.228 -0.92 . . . . 0.0 109.195 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.828 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -113.97 -44.24 3.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 109.9 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -138.55 147.56 43.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.17 -0.956 . . . . 0.0 110.22 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.738 HG22 HD11 ' A' ' 41' ' ' LEU . 43.4 t -138.83 136.75 43.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.458 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 93.0 mt-10 -127.75 149.8 50.08 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.813 -1.179 . . . . 0.0 109.726 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.984 HD13 ' N ' ' A' ' 47' ' ' ARG . 3.2 tm? -118.73 142.72 47.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.529 -0.732 . . . . 0.0 109.642 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.984 ' N ' HD13 ' A' ' 46' ' ' LEU . 13.7 ttp180 -127.48 124.65 38.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -0.86 . . . . 0.0 108.885 179.217 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 11.7 mt-30 -63.87 155.44 30.62 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.25 -0.906 . . . . 0.0 109.895 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.569 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 44.1 t60 -73.19 119.19 17.08 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.348 -0.845 . . . . 0.0 109.586 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.34 6.79 50.44 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.402 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.4 t -115.52 156.28 26.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -1.136 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -114.73 14.63 17.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.266 -0.896 . . . . 0.0 109.332 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -120.62 111.93 18.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.335 -0.853 . . . . 0.0 109.629 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.4 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 44.6 m95 -70.05 135.82 49.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -105.28 133.89 19.94 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.439 -0.788 . . . . 0.0 109.427 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.557 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.5 Cg_endo -72.16 144.63 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.653 2.235 . . . . 0.0 112.084 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.717 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.5 mp -102.28 154.63 18.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.123 -0.986 . . . . 0.0 108.669 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 96.8 m -99.89 127.64 46.05 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.855 -1.153 . . . . 0.0 109.208 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.4 tttm -69.72 109.69 4.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.14 -0.975 . . . . 0.0 109.099 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 62' ' ' ASN . 21.5 mttp -108.96 119.15 38.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.983 -1.073 . . . . 0.0 109.725 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 47.8 -92.94 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 60' ' ' LYS . 4.8 m120 -131.8 17.05 4.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -1.131 . . . . 0.0 109.422 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.487 HG12 ' OD2' ' A' ' 31' ' ' ASP . 27.1 m -130.61 178.16 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.413 ' CD1' HG13 ' A' ' 32' ' ' ILE . 59.0 m95 -124.98 125.19 43.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.34 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.929 ' HG2' HG13 ' A' ' 29' ' ' VAL . 62.4 mt-10 -115.77 150.71 36.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.57 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.1 p -144.53 140.11 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.85 . . . . 0.0 109.265 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -121.87 132.88 54.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.185 -0.947 . . . . 0.0 109.606 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.0 t -116.92 133.9 55.44 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.421 -0.8 . . . . 0.0 109.214 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.9 m -59.94 -18.94 49.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.169 -0.957 . . . . 0.0 109.31 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.573 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.4 178.22 1.02 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.573 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.7 Cg_endo -70.85 141.18 40.2 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.573 2.182 . . . . 0.0 111.846 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.956 HD13 HD12 ' A' ' 28' ' ' LEU . 4.5 mt -76.39 139.05 40.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.475 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 20.8 t -125.01 125.12 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.465 -0.772 . . . . 0.0 109.53 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.438 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.72 169.28 28.41 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.646 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.6 Cg_endo -68.37 146.09 77.89 Favored 'Cis proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.826 -1.739 . . . . 0.0 112.021 0.101 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.835 ' HB3' HD21 ' A' ' 46' ' ' LEU . 83.4 m-85 -89.67 146.37 24.58 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.465 -0.772 . . . . 0.0 110.355 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.943 ' O ' HD22 ' A' ' 46' ' ' LEU . 7.1 m-80 -107.14 142.07 37.41 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 178.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.833 ' CE2' HD23 ' A' ' 46' ' ' LEU . 45.6 m-85 -131.7 119.48 21.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.843 -1.161 . . . . 0.0 110.205 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.99 ' HG3' HG22 ' A' ' 89' ' ' VAL . 33.0 ttm180 -102.13 141.14 35.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.097 -1.002 . . . . 0.0 108.51 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.748 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.3 m-85 -123.01 142.6 50.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 111.403 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' O ' ' A' ' 86' ' ' MET . 0.0 OUTLIER -125.92 124.86 41.75 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.194 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.613 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -74.06 145.63 44.3 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 110.174 -178.413 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.828 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 94.5 mttt -48.14 -44.5 32.29 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.393 -0.817 . . . . 0.0 108.959 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.443 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -56.78 -3.19 0.64 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.72 24.34 18.22 Favored Glycine 0 N--CA 1.489 2.173 0 O-C-N 121.062 -1.258 . . . . 0.0 110.003 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.613 ' O ' ' N ' ' A' ' 82' ' ' SER . 15.0 mmm -96.37 146.75 24.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.071 -1.252 . . . . 0.0 108.634 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 52.9 mtm-85 -122.94 139.42 54.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.855 -1.153 . . . . 0.0 110.55 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.0 m120 -136.31 141.02 43.77 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.99 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.6 t -122.07 136.52 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.982 -1.074 . . . . 0.0 110.195 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.547 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 72.9 m-85 -124.23 122.58 38.15 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.16 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -100.42 147.75 25.5 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.262 -0.899 . . . . 0.0 109.775 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 78.9 mt-10 53.19 52.62 13.3 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 110.276 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.459 ' HB ' ' CD1' ' A' ' 78' ' ' PHE . 57.8 t -84.68 -34.44 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 109.332 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.429 HG13 HG12 ' A' ' 93' ' ' VAL . 44.9 mt -136.58 125.88 15.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.228 -0.92 . . . . 0.0 109.146 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.26 161.96 44.07 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.509 2.139 . . . . 0.0 111.887 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.6 m -52.89 -43.05 65.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.901 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.13 99.75 12.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.107 -0.996 . . . . 0.0 109.655 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -108.27 150.72 26.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.124 -0.985 . . . . 0.0 109.478 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 87.6 p -109.73 170.31 8.15 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.346 -0.847 . . . . 0.0 109.34 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.493 HD13 ' CG1' ' A' ' 19' ' ' VAL . 32.1 mm -104.99 136.12 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.276 -0.89 . . . . 0.0 109.254 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.07 4.66 59.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -118.87 144.27 46.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.104 -1.233 . . . . 0.0 109.362 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.634 HG22 ' H ' ' A' ' 104' ' ' TYR . 3.5 m -78.73 177.15 8.89 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.115 -0.991 . . . . 0.0 109.193 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.634 ' H ' HG22 ' A' ' 103' ' ' THR . 30.7 m-85 -163.73 100.08 0.89 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.859 -1.151 . . . . 0.0 108.926 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -112.86 164.88 14.32 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.118 -0.989 . . . . 0.0 109.887 -179.448 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.547 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.6 Cg_endo -70.44 167.1 26.29 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.9 2.4 . . . . 0.0 111.771 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 69.7 mm-40 -102.64 142.01 34.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.368 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.978 -1.011 . . . . 0.0 109.448 -179.998 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 91.4 mtt180 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 87.99 -163.98 33.63 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 92.3 p -123.97 163.42 21.4 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -1.143 . . . . 0.0 109.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 16.7 m-70 -86.65 136.82 32.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.929 . . . . 0.0 109.457 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 86.3 m-70 -80.13 -40.01 28.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -82.37 -9.76 59.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -0.877 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 36.6 t60 -128.43 153.95 46.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.257 -0.902 . . . . 0.0 109.51 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -133.55 143.38 48.68 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.47 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 47.4 m80 -93.53 1.38 56.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.229 -0.919 . . . . 0.0 109.549 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -50.84 113.6 2.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -108.67 162.81 13.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.236 -1.155 . . . . 0.0 109.477 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.479 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -93.96 -146.84 0.25 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.755 HG22 ' HG2' ' A' ' 36' ' ' ARG . 15.4 t -123.04 127.99 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.906 . . . . 0.0 109.259 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -109.81 120.02 41.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.44 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.8 t -126.28 135.6 63.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.917 . . . . 0.0 109.71 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.84 HG22 ' HG2' ' A' ' 105' ' ' LYS . 61.0 p -141.59 146.48 36.32 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.476 -0.765 . . . . 0.0 109.279 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.58 ' O ' ' N ' ' A' ' 104' ' ' TYR . 4.0 m-85 -119.41 141.16 49.34 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 0.0 109.939 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.4 m -136.97 128.52 28.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.17 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.909 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.0 t -76.27 144.68 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.142 -0.974 . . . . 0.0 109.377 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -115.78 159.84 20.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.997 . . . . 0.0 109.584 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 50.6 mttt -53.61 114.3 1.48 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.926 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.7 -3.61 2.62 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.446 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -58.33 141.89 49.76 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.87 -1.371 . . . . 0.0 109.232 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.551 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.19 171.84 8.36 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.223 -0.923 . . . . 0.0 109.689 -179.705 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.79 -30.8 16.98 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.808 2.339 . . . . 0.0 111.998 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 mttt -112.76 8.82 18.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.077 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.453 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 16.9 mttp -142.17 132.82 25.43 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.612 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.1 OUTLIER -120.88 123.05 41.59 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.979 -1.076 . . . . 0.0 109.362 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.985 HG13 ' HG2' ' A' ' 65' ' ' GLU . 25.1 t -120.42 125.99 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.909 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.9 mt -144.7 144.29 31.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.046 -1.034 . . . . 0.0 110.165 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.76 138.91 31.23 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.148 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.936 HG21 ' CE2' ' A' ' 80' ' ' PHE . 69.0 mt -122.28 131.46 73.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.489 -179.193 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 54.7 tttp -109.8 119.01 38.01 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.336 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.575 ' CD1' HG22 ' A' ' 15' ' ' VAL . 78.7 t80 -122.7 113.25 18.97 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.46 -0.775 . . . . 0.0 109.748 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.9 m -115.99 118.38 32.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.32 -0.863 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.755 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -132.91 150.75 76.53 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.459 179.984 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.88 88.61 0.66 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 122.642 2.228 . . . . 0.0 112.081 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.43 -27.73 8.29 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.951 -1.259 . . . . 0.0 109.951 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.56 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -91.17 171.98 8.87 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.116 -1.226 . . . . 0.0 109.619 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.534 ' O ' ' HA ' ' A' ' 82' ' ' SER . 18.2 m -153.66 161.33 42.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.545 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.901 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.4 tt -72.56 132.84 44.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.365 -0.835 . . . . 0.0 109.695 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.952 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.14 -40.06 3.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 109.899 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 87.7 mt-10 -142.45 150.56 40.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.156 -0.965 . . . . 0.0 110.197 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.491 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.8 t -138.44 136.13 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 109.319 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.59 150.51 50.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.002 HD23 HG11 ' A' ' 66' ' ' VAL . 16.7 tp -120.25 135.36 55.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.411 -0.806 . . . . 0.0 109.888 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.598 ' H ' HD12 ' A' ' 46' ' ' LEU . 4.0 ttp180 -121.58 130.27 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.837 . . . . 0.0 108.845 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -74.72 150.54 39.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.13 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.567 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 51.6 t-80 -64.45 117.75 7.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.37 1.34 44.06 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.455 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 38.3 t -113.33 153.14 28.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.188 -1.183 . . . . 0.0 109.439 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 58.0 mt-10 -118.3 20.48 13.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.321 -0.862 . . . . 0.0 109.318 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -124.23 94.08 4.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.873 . . . . 0.0 109.456 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.427 ' CZ3' ' N ' ' A' ' 79' ' ' ARG . 66.3 m95 -54.22 132.06 42.64 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 109.774 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.4 mm-40 -101.05 138.22 19.93 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.799 . . . . 0.0 109.273 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.87 143.78 46.42 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.709 2.273 . . . . 0.0 112.04 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.785 HD11 ' CB ' ' A' ' 46' ' ' LEU . 6.8 mp -110.63 149.85 29.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.194 -0.941 . . . . 0.0 108.931 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 11.3 m -103.31 125.33 49.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.923 -1.11 . . . . 0.0 109.154 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 12.9 tttm -73.58 109.85 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.135 -0.978 . . . . 0.0 109.275 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.898 ' O ' HG22 ' A' ' 63' ' ' VAL . 66.8 mttt -120.23 144.23 47.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.906 -1.121 . . . . 0.0 110.068 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.59 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.76 29.96 0.87 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.59 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 8.0 t30 81.99 14.73 0.51 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.239 -1.153 . . . . 0.0 110.376 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.898 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.6 m -129.52 170.26 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.099 -1.0 . . . . 0.0 109.021 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.678 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.6 m95 -114.51 122.67 47.29 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.908 -1.12 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.985 ' HG2' HG13 ' A' ' 29' ' ' VAL . 43.1 mt-10 -112.39 147.18 36.96 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.402 -0.811 . . . . 0.0 109.445 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 1.002 HG11 HD23 ' A' ' 46' ' ' LEU . 9.7 p -136.21 132.65 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.502 -0.749 . . . . 0.0 109.121 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.0 mttp -119.2 130.51 55.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.099 -1.001 . . . . 0.0 109.482 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.4 t -118.54 144.7 45.89 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 1.2 p -71.4 -4.18 24.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.072 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 16.2 mmtt -132.86 169.7 13.3 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.386 -0.821 . . . . 0.0 109.105 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.02 133.18 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.519 2.146 . . . . 0.0 111.776 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.605 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -68.13 146.53 53.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.346 -0.846 . . . . 0.0 109.777 -179.607 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.84 123.65 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.404 -0.81 . . . . 0.0 109.198 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.82 165.39 28.24 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.653 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.5 Cg_endo -68.78 145.17 76.46 Favored 'Cis proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.922 -1.699 . . . . 0.0 111.985 0.048 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.605 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -89.35 149.07 23.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.578 -0.701 . . . . 0.0 110.432 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.861 ' O ' HD12 ' A' ' 46' ' ' LEU . 36.2 m-80 -109.52 141.82 41.45 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.875 ' CE1' HD13 ' A' ' 46' ' ' LEU . 87.1 m-85 -133.38 121.09 21.8 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.958 -1.089 . . . . 0.0 109.748 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.646 ' HG3' HG22 ' A' ' 89' ' ' VAL . 27.8 ttm180 -104.12 143.31 33.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.07 -1.019 . . . . 0.0 108.944 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.936 ' CE2' HG21 ' A' ' 32' ' ' ILE . 22.6 m-85 -125.53 144.22 50.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 111.676 -178.013 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.637 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -127.04 126.37 42.97 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.611 ' N ' ' O ' ' A' ' 86' ' ' MET . 25.9 p -76.33 145.98 39.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.215 -0.928 . . . . 0.0 110.387 -178.336 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.952 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.5 mttt -50.08 -42.96 51.1 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.15 -2.57 0.41 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.84 25.88 18.71 Favored Glycine 0 N--CA 1.489 2.22 0 O-C-N 121.082 -1.246 . . . . 0.0 109.991 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.611 ' O ' ' N ' ' A' ' 82' ' ' SER . 12.8 mtm -102.17 151.24 22.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.084 -1.245 . . . . 0.0 108.769 179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.637 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 67.8 mtp180 -125.47 140.89 52.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.92 -1.112 . . . . 0.0 110.567 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 80' ' ' PHE . 11.9 m120 -135.23 139.95 44.88 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 79' ' ' ARG . 26.3 t -122.39 137.45 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.999 -1.063 . . . . 0.0 110.364 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 95.4 m-85 -125.37 122.71 37.57 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.26 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -99.81 148.34 24.52 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 98.9 mt-10 52.76 54.06 11.14 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.408 -0.808 . . . . 0.0 110.393 179.493 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 106' ' ' PRO . 77.8 t -85.37 -34.07 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 120.903 -1.123 . . . . 0.0 109.093 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.456 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.0 mt -136.57 125.21 15.21 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.879 . . . . 0.0 108.979 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.53 162.4 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.453 2.102 . . . . 0.0 111.871 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.525 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 39.5 m -51.48 -44.99 62.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.31 -0.869 . . . . 0.0 109.815 -179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.01 101.7 14.46 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.126 -0.983 . . . . 0.0 109.365 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -109.26 151.53 26.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.266 -0.897 . . . . 0.0 109.405 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 53.5 p -105.63 170.41 7.91 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.276 -0.89 . . . . 0.0 109.23 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 18.6 mm -105.13 136.35 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.192 -0.942 . . . . 0.0 109.374 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.26 9.46 61.88 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 52.5 tttt -118.42 143.14 46.89 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -1.197 . . . . 0.0 109.18 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.513 HG22 ' N ' ' A' ' 104' ' ' TYR . 23.2 m -77.28 168.61 19.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.996 -1.065 . . . . 0.0 108.997 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.58 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.1 m-85 -154.63 96.98 1.94 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.674 -1.266 . . . . 0.0 108.918 179.238 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.84 ' HG2' HG22 ' A' ' 16' ' ' THR . 6.6 mtmm -103.15 160.28 26.65 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.266 -0.897 . . . . 0.0 109.806 -179.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.536 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.1 Cg_endo -70.07 146.16 57.46 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -57.59 -63.38 1.26 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 109.485 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.6 mt-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.063 -0.97 . . . . 0.0 109.375 -179.948 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.56 -12.28 58.14 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.0 t -59.59 -29.63 68.1 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -1.169 . . . . 0.0 109.498 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 58.3 t60 -125.02 144.18 50.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -97.74 173.55 7.06 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.875 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -118.58 148.88 42.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -57.17 -32.38 66.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.33 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 14.2 m-70 -50.61 -49.74 55.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.432 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -70.51 -54.79 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.407 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.26 -160.67 19.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.494 ' OG ' ' HG2' ' A' ' 37' ' ' PRO . 79.6 p -114.01 -170.24 1.67 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.312 -1.11 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.43 152.37 31.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.885 . . . . 0.0 109.61 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.974 HG22 ' HG2' ' A' ' 36' ' ' ARG . 6.2 t -126.65 136.91 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.238 -0.914 . . . . 0.0 109.507 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -109.63 121.65 45.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.546 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 10.3 p -129.28 141.4 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.353 -0.842 . . . . 0.0 109.427 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.442 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 67.9 p -141.58 145.79 35.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.139 -0.976 . . . . 0.0 109.721 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.63 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.0 m-85 -118.63 143.72 46.63 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 31' ' ' ASP . 63.7 m -137.87 128.07 26.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.109 -0.995 . . . . 0.0 109.283 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 ' CD2' ' A' ' 30' ' ' LEU . 15.7 t -76.05 128.63 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.27 -0.893 . . . . 0.0 109.425 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.417 ' O ' HD12 ' A' ' 100' ' ' ILE . 89.9 mm-40 -91.26 -178.39 5.13 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.551 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 20.2 mttt -79.91 70.14 6.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.18 25.84 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.423 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 1.5 t -73.97 140.34 45.45 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.748 -1.442 . . . . 0.0 108.831 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.53 173.74 5.45 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.011 -1.056 . . . . 0.0 109.809 -179.532 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 52.1 Cg_endo -71.8 -32.18 11.9 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.719 2.279 . . . . 0.0 111.909 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -116.95 5.63 12.92 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.012 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.508 ' CD ' ' HE2' ' A' ' 67' ' ' LYS . 79.6 tttt -142.37 133.36 25.85 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.997 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -125.15 131.08 53.3 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.077 -1.014 . . . . 0.0 109.619 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 1.059 HG13 ' HG2' ' A' ' 65' ' ' GLU . 3.1 t -121.45 124.39 71.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.532 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.997 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.5 143.5 31.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.029 -1.044 . . . . 0.0 109.999 -179.487 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HA ' HG12 ' A' ' 63' ' ' VAL . 60.1 t0 -83.99 135.16 34.55 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.577 HG21 ' CE2' ' A' ' 80' ' ' PHE . 78.3 mt -119.4 130.11 74.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.541 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 8.5 ttmm -111.19 120.39 42.13 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.6 ' CE2' ' HB2' ' A' ' 36' ' ' ARG . 87.3 t80 -120.32 119.87 34.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.391 -0.818 . . . . 0.0 109.519 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 31.1 m -122.31 115.55 22.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.298 -0.876 . . . . 0.0 109.751 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.974 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -133.59 136.86 27.61 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.525 -0.734 . . . . 0.0 109.03 179.768 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.494 ' HG2' ' OG ' ' A' ' 11' ' ' SER . 48.1 Cg_endo -69.93 104.49 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.676 2.251 . . . . 0.0 111.95 -179.747 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.31 3.38 87.06 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.562 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 4.2 t0 -136.38 175.05 9.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.155 -1.203 . . . . 0.0 109.758 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.511 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 p -153.05 161.02 43.0 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.337 -0.852 . . . . 0.0 109.372 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.803 HD21 ' CG2' ' A' ' 44' ' ' VAL . 8.1 tp -72.08 132.74 44.63 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.789 ' N ' HD12 ' A' ' 41' ' ' LEU . . . -117.26 -41.63 2.97 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 109.741 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -141.76 150.12 41.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.181 -0.949 . . . . 0.0 109.992 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.803 ' CG2' HD21 ' A' ' 41' ' ' LEU . 2.6 t -138.52 135.98 43.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.439 -0.788 . . . . 0.0 109.365 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.451 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 78.4 mt-10 -127.81 149.78 50.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.911 -1.118 . . . . 0.0 109.21 179.432 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.889 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.0 tt -120.28 139.69 52.34 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.335 -0.853 . . . . 0.0 109.89 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.883 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.3 ttp180 -126.82 120.12 28.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.875 . . . . 0.0 108.82 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -64.39 145.05 56.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.141 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.552 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 49.1 t60 -55.82 145.41 24.59 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.454 -0.779 . . . . 0.0 109.243 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.51 1.22 51.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.419 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 9.6 t -111.44 152.75 27.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.1 -1.235 . . . . 0.0 109.316 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 -119.0 7.32 11.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -104.89 97.9 7.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.543 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 51.5 m95 -63.11 132.07 50.62 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 109.779 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -105.3 136.97 19.14 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 109.391 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD22 ' A' ' 57' ' ' LEU . 50.9 Cg_endo -70.88 151.82 62.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.752 2.301 . . . . 0.0 112.201 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.744 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.3 OUTLIER -110.2 154.03 23.94 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 179.6 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' TRP . 7.0 m -110.21 126.4 54.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.833 -1.167 . . . . 0.0 108.808 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 tttm -74.31 105.73 5.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.087 -1.008 . . . . 0.0 109.283 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.77 ' O ' HG22 ' A' ' 63' ' ' VAL . 16.4 mttp -120.47 142.86 48.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.819 -1.176 . . . . 0.0 110.249 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.84 35.96 1.67 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 7.9 m-20 78.06 10.82 2.01 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.061 -1.258 . . . . 0.0 110.469 179.158 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 60' ' ' LYS . 15.6 m -128.59 -177.96 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.977 -1.077 . . . . 0.0 108.776 179.241 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 66.1 m95 -123.07 141.07 52.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.05 -1.032 . . . . 0.0 109.927 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 1.059 ' HG2' HG13 ' A' ' 29' ' ' VAL . 92.1 mt-10 -127.96 142.37 51.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.473 -0.767 . . . . 0.0 109.105 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.744 ' HB ' HD13 ' A' ' 57' ' ' LEU . 1.9 p -139.39 137.53 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.227 -0.92 . . . . 0.0 109.377 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.508 ' HE2' ' CD ' ' A' ' 27' ' ' LYS . 28.7 mttt -122.71 134.15 54.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.463 -0.773 . . . . 0.0 109.632 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.7 t -117.46 145.3 44.26 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.488 -0.758 . . . . 0.0 109.18 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 49.5 m -68.77 -16.5 63.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.16 -0.962 . . . . 0.0 109.289 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.557 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.73 176.4 1.53 Allowed Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.557 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.8 Cg_endo -70.03 136.64 32.77 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.684 2.256 . . . . 0.0 111.726 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.946 HD13 HD12 ' A' ' 28' ' ' LEU . 6.4 mt -68.64 136.57 53.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.9 t -126.06 125.56 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.491 -0.756 . . . . 0.0 109.472 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -93.66 166.25 27.68 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.64 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.73 146.12 78.93 Favored 'Cis proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.843 -1.732 . . . . 0.0 111.99 0.032 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.9 m-85 -90.09 148.39 23.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.482 -0.761 . . . . 0.0 110.425 -179.201 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.455 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 18.9 m-80 -110.52 144.37 39.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.387 -0.821 . . . . 0.0 108.829 179.021 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.889 ' CE2' HD12 ' A' ' 46' ' ' LEU . 61.8 m-85 -135.81 125.38 25.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.89 -1.131 . . . . 0.0 110.25 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.955 ' HG3' HG22 ' A' ' 89' ' ' VAL . 15.2 ttp180 -105.85 141.38 37.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -0.96 . . . . 0.0 108.451 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.766 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.0 m-85 -122.11 142.23 50.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 111.082 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -125.5 123.97 40.33 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.448 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.603 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.4 p -74.43 144.19 44.38 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.386 -0.821 . . . . 0.0 110.352 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.774 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 46.5 mttp -46.39 -44.76 17.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.429 -0.795 . . . . 0.0 108.946 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.47 -3.42 0.63 Allowed Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.462 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.05 24.36 20.0 Favored Glycine 0 N--CA 1.49 2.27 0 O-C-N 120.992 -1.299 . . . . 0.0 110.124 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.603 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.0 mtm -98.34 150.12 21.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.994 -1.298 . . . . 0.0 108.516 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.597 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 22.7 mtm-85 -125.58 141.59 51.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.845 -1.16 . . . . 0.0 110.636 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . 23.7 m120 -137.03 141.37 42.48 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.955 HG22 ' HG3' ' A' ' 79' ' ' ARG . 10.5 t -122.63 136.87 58.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.882 -1.136 . . . . 0.0 110.447 -178.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.557 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.7 m-85 -123.57 121.65 36.15 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.54 146.59 25.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.778 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.64 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 51.8 tt0 53.7 51.54 14.82 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.431 -0.793 . . . . 0.0 110.424 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.453 HG21 ' HB2' ' A' ' 90' ' ' PHE . 72.5 t -82.33 -34.18 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.88 -1.138 . . . . 0.0 108.992 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.4 HG12 ' HB3' ' A' ' 104' ' ' TYR . 12.2 mt -135.82 127.13 17.19 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.258 -0.902 . . . . 0.0 109.162 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.48 161.13 47.12 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.552 2.168 . . . . 0.0 112.007 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.529 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 28.0 m -52.04 -45.15 64.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.744 -179.717 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.82 102.41 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.429 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 47.1 p90 -111.1 151.75 27.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.128 -0.982 . . . . 0.0 109.504 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 33.2 m -106.36 163.11 13.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.909 . . . . 0.0 109.467 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.531 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.1 mm -98.16 137.4 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.376 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.4 7.47 58.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.9 tptt -121.1 143.56 49.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.134 -1.215 . . . . 0.0 109.362 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.7 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.2 m -79.29 178.79 7.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 108.764 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.7 ' H ' HG22 ' A' ' 103' ' ' THR . 25.3 m-85 -164.36 94.57 0.72 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.659 -1.275 . . . . 0.0 109.112 179.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -106.26 163.73 16.42 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.375 -0.828 . . . . 0.0 109.596 -179.481 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 48.5 Cg_endo -69.89 143.99 51.95 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.496 2.13 . . . . 0.0 111.723 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.2 mm-40 -52.95 -40.73 63.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.31 -0.868 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.02 -0.99 . . . . 0.0 109.459 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -100.87 2.54 55.59 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.1 t 57.34 79.52 0.19 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -1.167 . . . . 0.0 109.431 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -91.05 146.2 24.05 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.234 -0.916 . . . . 0.0 109.425 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 76.7 t60 -62.87 -20.11 64.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.268 -0.895 . . . . 0.0 109.426 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t60 -65.06 -12.63 52.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.469 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -57.11 -16.86 8.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.536 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 59.76 55.02 4.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.277 -0.89 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -132.74 125.74 30.87 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.925 . . . . 0.0 109.543 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.52 -174.09 46.38 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.0 p -135.43 168.48 19.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.29 -1.123 . . . . 0.0 109.421 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -151.43 152.03 32.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.424 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.81 HG22 ' CG ' ' A' ' 36' ' ' ARG . 47.8 t -125.05 130.84 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 74.5 mt-30 -107.53 119.43 39.41 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.123 -0.985 . . . . 0.0 109.122 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.661 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.8 p -128.66 139.43 51.91 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.21 -0.931 . . . . 0.0 110.051 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.513 HG22 ' HG2' ' A' ' 105' ' ' LYS . 30.4 p -141.21 145.12 35.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.304 -0.873 . . . . 0.0 109.41 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.602 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.8 m-85 -117.16 136.23 53.18 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 52.3 m -131.27 127.21 37.31 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.968 -1.083 . . . . 0.0 109.326 179.402 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.96 HG22 ' CD2' ' A' ' 30' ' ' LEU . 9.0 t -75.38 128.37 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.283 -0.886 . . . . 0.0 109.274 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.414 ' O ' HG12 ' A' ' 100' ' ' ILE . 88.6 mm-40 -89.35 -178.25 5.57 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.061 -1.024 . . . . 0.0 109.843 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.2 mttp -80.23 65.38 5.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.437 -0.789 . . . . 0.0 109.975 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.28 25.9 0.08 OUTLIER Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.496 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.608 ' HB3' ' CZ ' ' A' ' 98' ' ' PHE . 3.2 m -79.72 144.04 34.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.079 -1.248 . . . . 0.0 109.337 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.4 172.06 7.48 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.121 -0.987 . . . . 0.0 109.579 -179.766 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -70.67 -28.2 21.16 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.667 2.244 . . . . 0.0 111.809 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.44 ' HB3' ' O ' ' A' ' 68' ' ' SER . 80.4 mttt -116.4 5.57 13.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.087 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 61.4 mttm -141.55 132.86 26.57 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.682 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.11 123.21 41.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.978 -1.076 . . . . 0.0 109.71 -179.6 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.787 HG22 ' HG3' ' A' ' 65' ' ' GLU . 13.6 t -119.58 125.09 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.96 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -145.14 146.04 31.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.926 -1.109 . . . . 0.0 110.125 -179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.469 ' HA ' HG12 ' A' ' 63' ' ' VAL . 62.6 t0 -86.06 136.82 33.08 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.068 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.869 HG21 ' HE2' ' A' ' 80' ' ' PHE . 78.6 mt -121.05 130.82 74.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 C-N-CA 118.825 -1.15 . . . . 0.0 110.661 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.661 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 29.0 tttm -110.43 120.75 43.45 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.533 ' CE1' HG11 ' A' ' 13' ' ' VAL . 88.5 t80 -120.93 111.33 17.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.328 -0.857 . . . . 0.0 109.528 -179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 19.9 m -113.66 114.72 26.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 109.772 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.81 ' CG ' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -152.58 113.01 2.78 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.515 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.06 128.91 17.39 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.704 2.269 . . . . 0.0 112.165 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.61 -22.46 40.42 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.82 -178.76 5.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -1.144 . . . . 0.0 109.807 -179.817 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.561 ' O ' ' HA ' ' A' ' 82' ' ' SER . 57.9 m -154.37 161.68 41.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.324 -0.86 . . . . 0.0 109.331 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.51 130.19 40.64 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.255 -0.903 . . . . 0.0 109.736 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.937 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.4 -41.22 3.14 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.222 -0.924 . . . . 0.0 109.839 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -141.19 149.48 41.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.466 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.638 ' CG2' HD11 ' A' ' 41' ' ' LEU . 95.2 t -138.72 136.94 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -128.67 149.68 50.57 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.832 -1.168 . . . . 0.0 109.551 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.006 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.3 tt -119.4 135.73 54.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.443 -0.786 . . . . 0.0 109.852 -179.288 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 1.006 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.3 ttp180 -122.37 129.79 52.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -0.883 . . . . 0.0 109.051 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 16.0 mt-30 -72.11 145.83 47.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.751 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.593 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 38.4 t60 -64.42 112.09 2.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 109.358 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.48 1.26 24.71 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 11.0 t -114.27 153.91 28.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -1.2 . . . . 0.0 109.421 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -110.73 6.92 21.92 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.3 mt-10 -118.04 104.14 10.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.593 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 33.6 m95 -61.8 142.16 57.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.415 -0.803 . . . . 0.0 109.746 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -106.0 136.15 19.34 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.361 -0.837 . . . . 0.0 109.293 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.8 Cg_endo -71.59 147.14 50.85 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.634 2.223 . . . . 0.0 112.198 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.81 HD11 ' HB2' ' A' ' 46' ' ' LEU . 9.0 mp -108.14 148.54 29.72 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.267 -0.896 . . . . 0.0 108.775 179.461 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 61.4 m -96.29 125.63 40.93 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.876 -1.14 . . . . 0.0 109.161 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.441 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 55.4 tttt -70.15 111.19 5.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.144 -0.972 . . . . 0.0 109.072 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.438 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.5 mttt -111.78 107.71 16.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.957 -1.089 . . . . 0.0 109.608 -179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.9 -93.15 0.12 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -134.75 20.01 3.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.206 -1.173 . . . . 0.0 109.339 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.469 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.7 m -130.86 -172.81 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.362 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.441 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 69.2 m95 -135.45 125.21 25.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.885 . . . . 0.0 109.122 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.787 ' HG3' HG22 ' A' ' 29' ' ' VAL . 60.9 tt0 -114.99 149.99 36.52 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 109.748 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.677 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 14.5 p -141.57 137.54 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.412 -0.805 . . . . 0.0 109.456 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -119.91 129.33 54.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.491 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.44 ' O ' ' HB3' ' A' ' 26' ' ' LYS . 35.6 t -118.3 131.83 56.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.602 -0.687 . . . . 0.0 109.51 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.5 t -61.26 -14.02 23.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.911 . . . . 0.0 108.973 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -116.1 167.55 10.12 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.35 -0.844 . . . . 0.0 109.208 179.9 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 46.4 Cg_endo -68.14 129.64 19.81 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.54 2.16 . . . . 0.0 111.792 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.617 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -63.41 142.5 58.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.374 -0.829 . . . . 0.0 109.648 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.03 124.25 68.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.332 -0.855 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.77 164.31 27.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.67 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.3 Cg_endo -69.0 147.31 82.79 Favored 'Cis proline' 0 C--O 1.214 -0.713 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.935 0.072 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.617 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -91.26 147.6 22.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.536 -0.728 . . . . 0.0 110.353 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -108.32 143.77 36.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.354 -0.841 . . . . 0.0 108.736 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.697 ' CE2' HD12 ' A' ' 46' ' ' LEU . 85.3 m-85 -134.17 125.66 28.35 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.062 -1.024 . . . . 0.0 109.906 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.943 ' HG3' HG22 ' A' ' 89' ' ' VAL . 44.2 ttt180 -108.21 142.34 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.962 -1.086 . . . . 0.0 108.834 179.15 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.869 ' HE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -124.4 143.28 50.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.881 . . . . 0.0 111.154 -178.202 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.65 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.2 ttm -126.2 125.69 42.85 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.568 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 20.5 p -73.99 145.85 44.29 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.284 -0.885 . . . . 0.0 110.26 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.937 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 18.8 mttm -50.55 -42.88 55.92 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.342 -0.849 . . . . 0.0 108.771 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.94 -4.5 0.72 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.89 27.21 11.42 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 8.8 mtm -103.32 153.86 19.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.04 -1.27 . . . . 0.0 108.802 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.65 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 32.7 mtt180 -128.29 142.18 51.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.812 -1.18 . . . . 0.0 110.786 -178.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.5 m120 -134.81 140.09 45.6 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.943 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.9 t -122.63 137.04 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.958 -1.089 . . . . 0.0 110.498 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 56.8 m-85 -124.93 122.52 37.58 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.204 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 35.2 p-10 -98.85 147.62 24.74 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.15 -0.969 . . . . 0.0 109.645 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.67 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 32.8 mt-10 53.0 52.44 13.85 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.84 . . . . 0.0 110.277 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.413 HG21 ' HB2' ' A' ' 90' ' ' PHE . 45.2 t -83.23 -34.41 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.789 -1.194 . . . . 0.0 109.094 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.406 HG13 HG12 ' A' ' 93' ' ' VAL . 13.4 mt -138.32 125.25 13.23 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.325 -0.859 . . . . 0.0 109.032 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.04 162.79 40.26 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.611 2.207 . . . . 0.0 111.97 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.523 HG23 ' H ' ' A' ' 74' ' ' GLY . 12.3 m -54.01 -37.51 64.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.41 -0.806 . . . . 0.0 109.899 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.14 101.29 12.92 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.004 -1.06 . . . . 0.0 109.714 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.608 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 40.4 p90 -109.58 149.56 29.49 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 109.279 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ILE . 1.4 m -118.77 104.22 10.38 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.731 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.525 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 8.7 mt -43.29 139.96 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 105.0 -3.09 41.05 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.9 tptt -122.29 142.76 50.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -1.174 . . . . 0.0 109.226 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.612 HG22 ' H ' ' A' ' 104' ' ' TYR . 10.9 m -79.18 175.0 10.99 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.117 -0.99 . . . . 0.0 108.619 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.612 ' H ' HG22 ' A' ' 103' ' ' THR . 26.8 m-85 -159.94 96.7 1.24 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.675 -1.265 . . . . 0.0 109.119 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.517 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 7.9 mtmt -97.8 163.2 20.0 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.441 -0.787 . . . . 0.0 109.635 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 48.1 Cg_endo -68.41 144.48 61.74 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.69 2.26 . . . . 0.0 112.024 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.469 ' O ' ' HB2' ' A' ' 108' ' ' GLU . 96.7 mt-10 -52.5 -19.36 2.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.243 -0.911 . . . . 0.0 109.563 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 107' ' ' GLU . 79.9 mt-10 . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.536 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 48.2 mtm180 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.221 0.534 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.471 ' O ' ' CE1' ' A' ' 4' ' ' HIS . . . 94.69 7.45 60.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 83.6 p -61.68 -25.61 67.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -1.15 . . . . 0.0 109.472 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' HIS . . . . . 0.471 ' CE1' ' O ' ' A' ' 2' ' ' GLY . 9.1 m-70 64.58 22.6 12.69 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.306 -0.871 . . . . 0.0 109.465 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 58.3 m-70 -121.67 125.5 46.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.425 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.8 m80 -96.16 -10.38 28.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 65.4 m-70 -124.45 136.39 54.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 82.8 t60 -61.47 -38.09 85.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.253 -0.904 . . . . 0.0 109.348 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -49.32 -29.1 5.56 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.179 -0.951 . . . . 0.0 109.401 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.8 -175.83 6.03 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HG2' ' A' ' 37' ' ' PRO . 2.3 t -158.62 157.88 32.77 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -1.204 . . . . 0.0 109.534 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -112.53 156.42 22.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.47 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.777 HG13 ' HB2' ' A' ' 36' ' ' ARG . 4.6 t -125.14 126.23 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.471 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 88.4 mm-40 -102.81 121.31 42.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.227 -0.92 . . . . 0.0 109.251 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 7.0 p -129.81 141.15 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.279 -0.888 . . . . 0.0 109.691 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.486 ' HA ' ' HB3' ' A' ' 105' ' ' LYS . 21.4 p -141.88 145.78 35.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.562 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.7 m-85 -117.0 150.83 37.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.436 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 42.3 m -144.48 127.26 16.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.999 -1.063 . . . . 0.0 109.373 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.919 HG22 ' CD2' ' A' ' 30' ' ' LEU . 12.2 t -75.84 135.63 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.4 mm-40 -114.62 155.18 27.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.049 -1.032 . . . . 0.0 109.885 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -47.23 109.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.495 -0.753 . . . . 0.0 109.853 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.68 -5.76 1.36 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.669 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 98' ' ' PHE . 7.3 p -62.39 142.94 57.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.801 -1.411 . . . . 0.0 109.361 -179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.535 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.43 173.83 5.15 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.6 Cg_endo -70.79 -28.75 19.9 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.667 2.245 . . . . 0.0 111.954 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -116.24 7.22 13.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.068 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.491 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 33.1 mttp -142.7 133.68 25.7 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.687 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.48 123.16 40.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.929 -1.107 . . . . 0.0 109.613 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.549 HG22 ' HG3' ' A' ' 65' ' ' GLU . 9.0 t -120.2 125.59 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 179.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.919 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -144.87 144.95 31.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.893 -1.129 . . . . 0.0 110.226 -179.369 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.562 ' HA ' HG12 ' A' ' 63' ' ' VAL . 16.2 t70 -82.4 134.43 35.24 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.625 HG21 ' CE2' ' A' ' 80' ' ' PHE . 74.9 mt -119.96 130.64 73.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.779 -1.201 . . . . 0.0 110.74 -178.574 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 62.8 mttm -111.49 120.15 41.16 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 178.652 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.545 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 90.1 t80 -120.53 112.86 19.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.425 -0.797 . . . . 0.0 109.501 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 33.8 m -115.22 115.24 26.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 0.0 109.688 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.777 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -147.6 117.55 4.36 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.462 -0.774 . . . . 0.0 109.066 179.897 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.489 ' HG2' ' OG ' ' A' ' 11' ' ' SER . 49.1 Cg_endo -69.29 123.65 10.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.94 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.37 59.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.572 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -142.71 -176.39 4.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -1.201 . . . . 0.0 109.864 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.6 m -155.83 162.69 40.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.332 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.759 HD21 HG21 ' A' ' 44' ' ' VAL . 48.6 tp -69.32 126.38 29.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.964 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.855 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.83 -44.51 2.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.854 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.433 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 27.0 mt-10 -137.19 146.85 45.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.158 -0.964 . . . . 0.0 110.262 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 HD21 ' A' ' 41' ' ' LEU . 98.2 t -139.93 137.39 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.476 -0.765 . . . . 0.0 109.252 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.432 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 94.5 mt-10 -127.79 150.69 49.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.822 -1.174 . . . . 0.0 109.231 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.035 HD23 HG11 ' A' ' 66' ' ' VAL . 12.1 tp -120.42 132.24 55.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 110.393 -178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.647 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.4 OUTLIER -113.19 124.88 53.56 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.292 -0.88 . . . . 0.0 108.995 179.178 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.429 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 19.7 mt-30 -65.24 159.14 24.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.252 -0.905 . . . . 0.0 109.087 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.583 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 11.4 t-80 -75.95 108.15 8.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.17 7.09 21.66 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 23.1 t -115.88 154.16 30.23 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.047 -1.267 . . . . 0.0 109.514 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mt-10 -104.9 -22.44 13.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.274 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -87.67 129.03 35.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.62 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 9.4 m95 -86.92 141.68 28.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.632 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.41 ' OE2' ' O ' ' A' ' 67' ' ' LYS . 45.4 tt0 -107.98 133.75 20.38 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.351 -0.843 . . . . 0.0 109.481 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.7 Cg_endo -70.78 151.0 62.93 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.693 2.262 . . . . 0.0 111.783 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.809 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.8 mp -109.16 143.84 38.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.206 -0.934 . . . . 0.0 109.11 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.7 m -92.7 127.44 38.2 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.99 -1.069 . . . . 0.0 109.136 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -70.49 109.99 5.13 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.164 -0.96 . . . . 0.0 109.11 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -109.4 115.77 30.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.945 -1.097 . . . . 0.0 109.586 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 53.18 -97.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -128.12 16.58 6.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.216 -1.167 . . . . 0.0 109.466 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.562 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.3 m -131.04 -176.94 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.32 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.477 ' CD1' HD12 ' A' ' 32' ' ' ILE . 57.9 m95 -128.33 130.35 47.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.112 -0.993 . . . . 0.0 109.332 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.2 tt0 -111.69 135.97 51.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.645 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 1.035 HG11 HD23 ' A' ' 46' ' ' LEU . 5.3 p -130.67 129.67 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.426 -0.797 . . . . 0.0 109.012 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.449 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 19.4 mtmm -121.43 133.3 55.07 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.04 -1.038 . . . . 0.0 109.692 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.429 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 3.1 t -118.38 153.08 34.63 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.422 -0.799 . . . . 0.0 109.305 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.1 m -78.6 -2.36 38.57 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.151 -0.968 . . . . 0.0 109.148 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.561 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 3.5 mttt -128.81 177.02 2.34 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.339 -0.851 . . . . 0.0 109.164 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.6 Cg_endo -68.54 150.3 75.02 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.495 2.13 . . . . 0.0 111.856 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.579 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 14.9 mt -85.58 137.46 32.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.33 -0.856 . . . . 0.0 109.682 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.557 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 28.9 t -127.02 125.86 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.46 -0.775 . . . . 0.0 109.475 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.522 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.94 169.19 28.03 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.664 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.2 Cg_endo -67.98 146.92 78.86 Favored 'Cis proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.912 -1.703 . . . . 0.0 112.002 0.122 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 86.6 m-85 -89.69 149.77 22.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.589 -0.695 . . . . 0.0 110.343 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.809 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.9 m120 -112.06 142.74 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.78 ' CE1' HD13 ' A' ' 46' ' ' LEU . 96.5 m-85 -134.85 134.84 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.999 -1.063 . . . . 0.0 109.381 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.536 ' NH1' ' CZ ' ' A' ' 87' ' ' ARG . 64.5 ttt180 -116.8 144.07 44.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.943 -1.098 . . . . 0.0 108.864 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.732 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.6 m-85 -122.89 140.79 52.6 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.157 -0.965 . . . . 0.0 111.238 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.624 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.1 ttm -123.45 124.02 41.96 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.027 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 18.8 p -72.37 142.41 48.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.455 -0.778 . . . . 0.0 110.475 -178.164 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.855 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 56.4 mttt -46.64 -44.18 18.18 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 108.821 178.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -57.09 -5.85 1.65 Allowed Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 97.3 25.36 11.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 55.4 mtp -99.67 152.52 19.97 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.108 -1.23 . . . . 0.0 108.473 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.624 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 33.5 mtm180 -128.39 142.13 51.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.617 -1.302 . . . . 0.0 110.918 -178.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.535 ' N ' ' O ' ' A' ' 80' ' ' PHE . 29.9 m120 -135.69 140.73 44.67 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.3 t -122.79 136.72 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.863 -1.148 . . . . 0.0 110.387 -179.026 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.548 ' CD1' ' CB ' ' A' ' 106' ' ' PRO . 55.5 m-85 -124.16 122.41 37.75 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.107 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -99.53 147.37 25.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.209 -0.932 . . . . 0.0 109.716 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.664 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 81.3 mt-10 53.99 51.18 15.15 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.505 -0.747 . . . . 0.0 110.344 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 94' ' ' ILE . 43.5 t -81.96 -34.89 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.864 -1.148 . . . . 0.0 108.938 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 93' ' ' VAL . 13.0 mt -135.8 125.07 16.02 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.473 -0.767 . . . . 0.0 108.974 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.28 161.61 45.19 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.569 2.179 . . . . 0.0 111.977 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.522 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 29.1 m -50.09 -45.68 52.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.373 -0.83 . . . . 0.0 109.726 -179.713 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.06 101.18 13.89 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.053 -1.029 . . . . 0.0 109.5 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.509 ' CE1' HG11 ' A' ' 19' ' ' VAL . 44.8 p90 -108.26 154.12 22.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 69.4 m -110.43 170.87 7.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.39 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 23.2 mm -105.19 136.71 37.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 109.312 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.72 6.28 59.56 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 46.7 tttt -119.03 143.43 47.1 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.095 -1.238 . . . . 0.0 109.225 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.622 HG22 ' H ' ' A' ' 104' ' ' TYR . 15.5 m -80.8 174.74 11.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.161 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.622 ' H ' HG22 ' A' ' 103' ' ' THR . 35.1 m-85 -160.36 102.25 1.39 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.765 -1.209 . . . . 0.0 108.772 179.231 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.597 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 1.7 ptpp? -114.16 166.36 11.66 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.201 -0.937 . . . . 0.0 109.776 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.597 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 48.7 Cg_endo -69.91 -169.56 0.34 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.587 2.191 . . . . 0.0 111.811 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -123.61 154.05 39.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.485 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.464 ' HB3' ' NE2' ' A' ' 4' ' ' HIS . 88.0 mt-10 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.521 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 72.5 mtt85 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.1 164.71 37.7 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.7 p -150.2 133.84 16.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -1.165 . . . . 0.0 109.451 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -132.95 18.75 4.13 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.204 -0.935 . . . . 0.0 109.492 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -75.15 -44.7 45.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.484 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 75.3 t60 -145.14 141.47 28.78 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.223 -0.923 . . . . 0.0 109.554 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.45 ' CE1' ' O ' ' A' ' 10' ' ' GLY . 86.4 t60 -111.38 114.17 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.244 -0.91 . . . . 0.0 109.393 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -141.34 154.52 45.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 0.0 109.592 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 62.11 29.13 17.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.216 -0.927 . . . . 0.0 109.462 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.45 ' O ' ' CE1' ' A' ' 7' ' ' HIS . . . 56.03 -123.51 31.21 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -59.15 -172.14 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -1.132 . . . . 0.0 109.548 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -143.26 165.63 26.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 109.517 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.624 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 10.9 t -127.66 141.27 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.34 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -113.31 120.96 42.95 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.6 HG22 ' CD1' ' A' ' 34' ' ' TYR . 2.7 t -127.67 137.89 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.257 -0.902 . . . . 0.0 109.823 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 32.4 p -142.31 146.09 34.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.39 -0.819 . . . . 0.0 109.231 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.603 ' O ' ' N ' ' A' ' 104' ' ' TYR . 8.7 m-85 -119.41 151.85 37.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.106 -0.996 . . . . 0.0 110.02 -179.757 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 27.7 m -143.18 158.86 43.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 108.71 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.845 HG22 HD23 ' A' ' 30' ' ' LEU . 4.3 t -107.75 127.96 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.087 -1.008 . . . . 0.0 109.433 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -101.47 149.8 23.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.897 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -44.01 114.09 0.62 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.498 -0.752 . . . . 0.0 109.94 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.16 2.19 1.4 Allowed Glycine 0 N--CA 1.49 2.264 0 C-N-CA 119.272 -1.442 . . . . 0.0 110.907 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.0 m -61.18 142.38 56.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.667 -1.49 . . . . 0.0 109.054 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.82 171.94 7.59 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.094 -1.004 . . . . 0.0 109.616 -179.627 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.7 Cg_endo -70.68 -29.02 20.09 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.729 2.286 . . . . 0.0 111.829 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -118.03 3.4 12.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.009 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 21.1 mttt -141.83 133.15 26.51 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.049 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.07 133.78 50.39 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.018 -1.051 . . . . 0.0 110.17 -179.374 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.492 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.3 t -121.62 124.05 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.049 HD11 HD22 ' A' ' 28' ' ' LEU . 1.3 mt -140.94 141.14 34.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.01 -1.056 . . . . 0.0 110.093 -179.428 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.72 ' CG ' HG12 ' A' ' 63' ' ' VAL . 18.2 t0 -85.55 134.51 34.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.461 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.654 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -116.12 126.89 73.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 118.922 -1.111 . . . . 0.0 110.893 -179.105 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 13.7 tttm -107.28 115.07 29.52 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.01 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.624 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.2 t80 -124.93 111.88 15.96 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.345 0.593 . . . . 0.0 109.634 -178.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.3 m -113.85 119.77 38.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.94 . . . . 0.0 109.691 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.488 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 29.7 ttt85 -140.91 119.58 8.2 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.7 119.29 6.26 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.714 2.276 . . . . 0.0 111.821 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.14 -14.52 60.52 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.488 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 6.2 m-20 -136.43 175.18 9.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.181 -1.188 . . . . 0.0 109.644 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 m -154.41 161.6 41.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.297 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.718 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.4 OUTLIER -71.21 130.87 42.53 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.257 -0.902 . . . . 0.0 109.385 179.947 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.93 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -112.4 -41.03 3.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.466 ' O ' HD21 ' A' ' 41' ' ' LEU . 90.4 mt-10 -143.18 151.27 40.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 0.0 110.187 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.693 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.1 t -138.9 136.32 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.5 mt-10 -126.77 149.24 49.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.697 -1.252 . . . . 0.0 109.547 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.908 HD13 ' CE2' ' A' ' 78' ' ' PHE . 10.4 tp -122.18 131.24 53.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.479 -0.763 . . . . 0.0 109.929 -179.106 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.646 ' N ' HD12 ' A' ' 46' ' ' LEU . 41.8 ttp180 -118.92 135.04 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.088 179.354 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.453 ' OE1' ' CB ' ' A' ' 68' ' ' SER . 24.7 mt-30 -75.05 150.72 38.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 110.034 -179.311 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 4.2 t-80 -67.4 112.55 4.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.41 -0.806 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.63 0.63 30.73 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.464 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 4.0 t -113.67 155.54 25.35 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.206 -1.173 . . . . 0.0 109.32 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -108.33 -14.31 14.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.243 -0.911 . . . . 0.0 109.404 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -93.17 117.92 30.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.223 -0.923 . . . . 0.0 109.736 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.631 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 25.3 m95 -75.94 140.29 42.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.419 -0.801 . . . . 0.0 109.638 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.469 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.8 OUTLIER -106.59 127.35 28.31 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.472 -0.768 . . . . 0.0 109.095 179.757 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.617 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.6 Cg_endo -69.67 150.42 68.71 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.586 2.191 . . . . 0.0 112.19 -179.623 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.8 mp -107.47 141.85 38.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 108.847 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 43.5 m -92.91 127.26 38.36 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.923 -1.11 . . . . 0.0 109.06 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tttm -73.49 109.86 7.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 109.717 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.0 mttm -109.88 110.93 22.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.998 -1.064 . . . . 0.0 109.752 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.46 -90.02 0.07 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.431 ' OD1' HG13 ' A' ' 63' ' ' VAL . 49.5 p-10 -139.04 18.45 2.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.288 -1.124 . . . . 0.0 109.281 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.72 HG12 ' CG ' ' A' ' 31' ' ' ASP . 16.2 m -130.66 173.4 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.283 -0.886 . . . . 0.0 109.249 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.434 ' CD1' HG13 ' A' ' 32' ' ' ILE . 66.5 m95 -123.17 128.64 50.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 109.317 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.461 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.7 tt0 -117.85 151.38 37.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.627 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.882 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -145.38 140.9 22.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.329 -0.857 . . . . 0.0 109.308 179.784 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 34.9 mttp -122.15 132.97 54.73 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.717 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.453 ' CB ' ' OE1' ' A' ' 48' ' ' GLN . 38.8 t -116.71 121.52 41.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.454 -0.779 . . . . 0.0 109.349 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 58.8 m -49.16 -22.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.571 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -109.65 177.25 1.28 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.318 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.571 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -68.86 152.69 73.67 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.504 2.136 . . . . 0.0 111.657 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.732 HD13 HD12 ' A' ' 28' ' ' LEU . 1.5 mt -90.28 138.05 31.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 35.4 t -126.34 125.28 67.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.422 -0.798 . . . . 0.0 109.605 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA3' ' N ' ' A' ' 96' ' ' THR . . . -94.39 167.29 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.713 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.1 Cg_endo -68.15 147.43 80.46 Favored 'Cis proline' 0 C--O 1.213 -0.735 0 C-N-CA 122.937 -1.693 . . . . 0.0 112.034 0.218 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.604 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.1 m-85 -91.23 150.82 21.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.441 -0.787 . . . . 0.0 110.448 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.784 ' O ' HD12 ' A' ' 46' ' ' LEU . 23.3 m-80 -111.12 142.08 43.77 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.908 ' CE2' HD13 ' A' ' 46' ' ' LEU . 41.9 m-85 -135.95 128.3 30.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.918 -1.114 . . . . 0.0 110.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.875 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.2 ttt180 -108.56 142.23 39.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 108.643 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.654 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.3 m-85 -123.49 143.6 50.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.213 -0.93 . . . . 0.0 111.411 -178.079 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.621 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.6 ttm -127.44 125.67 40.97 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.727 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.2 p -77.39 144.94 37.54 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.89 . . . . 0.0 110.246 -178.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.93 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 60.0 mttm -47.78 -43.14 27.28 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.4 -2.71 0.74 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.37 23.98 22.87 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.8 mmm -98.64 148.39 23.86 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -1.231 . . . . 0.0 108.681 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 77.8 mtm-85 -126.84 142.58 51.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.78 -1.2 . . . . 0.0 110.586 -178.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.413 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.2 m120 -136.97 141.17 42.59 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.875 HG22 ' HG3' ' A' ' 79' ' ' ARG . 2.9 t -121.43 136.32 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 71.8 m-85 -124.56 122.39 37.44 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.267 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -100.06 148.62 24.36 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.244 -0.91 . . . . 0.0 109.644 -179.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.713 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 88.6 mt-10 53.28 51.87 14.66 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.369 -0.832 . . . . 0.0 110.278 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.648 HG22 ' HB3' ' A' ' 106' ' ' PRO . 97.6 t -84.08 -34.33 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.856 -1.153 . . . . 0.0 109.188 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.2 mt -137.53 125.56 14.33 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.325 -0.859 . . . . 0.0 109.127 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.71 163.02 39.8 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.577 2.185 . . . . 0.0 112.07 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.535 ' N ' ' HA3' ' A' ' 74' ' ' GLY . 32.3 m -54.13 -44.09 71.06 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.414 -0.804 . . . . 0.0 109.918 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.39 99.41 11.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.054 -1.029 . . . . 0.0 109.363 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -107.85 147.09 31.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 109.722 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 70.4 m -107.08 167.86 9.6 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -0.862 . . . . 0.0 109.169 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.502 HD13 ' CG1' ' A' ' 19' ' ' VAL . 29.8 mm -104.16 136.78 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 109.408 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.73 2.66 61.26 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.1 tptt -116.15 142.55 46.67 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.09 -1.241 . . . . 0.0 109.176 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.573 HG22 ' H ' ' A' ' 104' ' ' TYR . 18.6 m -78.39 173.51 12.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.075 -1.016 . . . . 0.0 108.966 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.603 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -156.16 105.83 2.35 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.765 -1.209 . . . . 0.0 108.831 179.187 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 105' ' ' LYS . 1.3 ptmt -103.67 157.41 33.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.724 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.648 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo -70.47 151.79 65.26 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.744 2.296 . . . . 0.0 111.734 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -56.49 -20.63 21.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.216 -0.927 . . . . 0.0 109.458 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.489 179.929 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 45.5 mtt85 . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.92 -179.43 51.11 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 82.7 p -79.11 -8.96 59.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.228 -1.16 . . . . 0.0 109.501 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' A' ' 6' ' ' HIS . 19.4 m-70 -48.46 -41.85 30.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.464 ' CG ' ' O ' ' A' ' 5' ' ' HIS . 74.5 t60 46.12 32.89 1.54 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.229 -0.92 . . . . 0.0 109.427 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HIS . . . . . 0.456 ' CE1' ' O ' ' A' ' 4' ' ' HIS . 36.6 m80 -109.75 126.27 53.56 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -0.904 . . . . 0.0 109.454 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.34 -40.37 90.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.308 -0.87 . . . . 0.0 109.367 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 30.6 m80 -132.8 150.45 52.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.528 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -60.54 -29.62 69.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.69 -153.41 28.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.9 m -114.39 159.41 20.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.253 -1.146 . . . . 0.0 109.316 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -148.39 145.02 27.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.959 HG22 ' HG2' ' A' ' 36' ' ' ARG . 40.5 t -124.45 129.01 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 97.2 mm-40 -109.4 120.35 42.24 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 109.118 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.9 p -128.35 140.53 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.314 -0.866 . . . . 0.0 109.499 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.49 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 32.0 p -143.09 146.32 33.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.187 -0.945 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.606 ' CD2' HG12 ' A' ' 32' ' ' ILE . 7.4 m-85 -117.01 148.41 41.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.251 -0.905 . . . . 0.0 109.286 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 36.0 m -143.6 128.63 18.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.929 -1.107 . . . . 0.0 109.621 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.935 HG22 HD21 ' A' ' 30' ' ' LEU . 3.5 t -76.7 138.52 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.157 -0.964 . . . . 0.0 109.364 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.7 mm-40 -118.66 155.66 30.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.02 -1.05 . . . . 0.0 109.612 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -47.51 112.73 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.82 . . . . 0.0 110.009 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.73 -7.96 1.99 Allowed Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.71 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 4.5 p -60.18 141.76 55.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.805 -1.409 . . . . 0.0 109.435 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.584 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.14 177.27 2.25 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.165 -0.959 . . . . 0.0 109.693 -179.594 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.584 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.8 Cg_endo -71.2 -33.93 10.77 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.784 2.322 . . . . 0.0 112.015 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.443 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -115.54 2.82 13.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 108.894 179.509 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 27.2 mtmt -139.19 132.29 29.64 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 1.116 HD21 ' CD1' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -127.68 132.99 49.6 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.001 -1.062 . . . . 0.0 110.211 -179.086 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.854 HG13 ' HG2' ' A' ' 65' ' ' GLU . 13.6 t -119.56 122.76 69.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.116 ' CD1' HD21 ' A' ' 28' ' ' LEU . 16.8 mt -137.66 136.72 37.7 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.046 -1.034 . . . . 0.0 110.324 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.563 ' HA ' HG12 ' A' ' 63' ' ' VAL . 37.7 t70 -84.2 136.22 34.05 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 177.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.854 HD12 ' CD1' ' A' ' 64' ' ' TRP . 88.1 mt -121.62 131.11 73.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.688 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.589 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 44.3 tttt -110.32 119.46 39.28 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.294 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 83.5 t80 -121.44 118.15 28.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.456 -0.777 . . . . 0.0 109.355 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 17.1 m -121.16 117.81 28.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.268 -0.895 . . . . 0.0 109.923 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.959 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -124.24 168.52 12.7 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.832 . . . . 0.0 109.345 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.582 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -70.07 76.96 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.634 2.223 . . . . 0.0 111.726 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.43 -5.92 75.28 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.44 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -97.26 179.38 4.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 109.498 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.0 m -151.08 158.37 43.97 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.302 -0.874 . . . . 0.0 109.527 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.847 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.79 136.4 47.06 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.659 -0.65 . . . . 0.0 109.342 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.928 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.58 -43.13 3.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.11 -0.994 . . . . 0.0 110.238 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -139.83 148.81 42.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.004 -1.06 . . . . 0.0 110.659 -179.215 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.615 HG13 ' CE1' ' A' ' 80' ' ' PHE . 14.6 t -139.0 136.3 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.541 -0.725 . . . . 0.0 109.33 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.508 ' HA ' HD13 ' A' ' 57' ' ' LEU . 95.2 mt-10 -128.75 150.89 50.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.953 -1.092 . . . . 0.0 109.255 179.351 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.95 HD12 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tt -121.61 147.32 46.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.27 -0.893 . . . . 0.0 110.045 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.799 ' N ' HD23 ' A' ' 46' ' ' LEU . 13.4 ttp180 -131.95 128.56 38.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.87 . . . . 0.0 108.808 179.302 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' NE2' HD23 ' A' ' 72' ' ' LEU . 36.0 mt-30 -69.7 153.02 43.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 0.0 109.942 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.573 ' CG ' ' HD2' ' A' ' 75' ' ' PRO . 66.1 t60 -67.45 119.29 12.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.41 -0.806 . . . . 0.0 109.682 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.91 4.35 54.41 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.452 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 39.4 t -114.24 154.49 27.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.453 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 87.5 mt-10 -117.78 15.69 14.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.375 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -119.02 97.6 5.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.903 . . . . 0.0 109.687 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -55.84 134.56 51.91 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.36 -0.838 . . . . 0.0 109.657 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -104.26 134.79 19.51 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.348 -0.845 . . . . 0.0 109.316 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.606 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.1 Cg_endo -70.61 145.35 52.01 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.627 2.218 . . . . 0.0 112.095 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.631 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.6 mp -110.0 151.2 27.45 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 108.871 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.1 m -100.66 125.51 47.09 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.865 -1.147 . . . . 0.0 108.851 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -72.13 108.83 5.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.202 -0.936 . . . . 0.0 109.091 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.513 ' O ' ' N ' ' A' ' 62' ' ' ASN . 15.2 mttm -107.48 126.26 52.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.986 -1.071 . . . . 0.0 109.542 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 48.67 -92.68 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 60' ' ' LYS . 31.6 p-10 -136.73 19.5 3.07 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.282 -1.128 . . . . 0.0 109.344 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.563 HG12 ' HA ' ' A' ' 31' ' ' ASP . 20.6 m -131.72 173.57 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.334 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.854 ' CD1' HD12 ' A' ' 32' ' ' ILE . 71.1 m95 -117.35 127.44 54.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.94 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.854 ' HG2' HG13 ' A' ' 29' ' ' VAL . 80.3 mt-10 -113.43 141.07 47.53 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.29 -0.881 . . . . 0.0 109.892 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.631 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 7.7 p -135.56 132.69 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.284 -0.885 . . . . 0.0 109.066 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.457 ' HG3' ' HG2' ' A' ' 27' ' ' LYS . 41.3 tttm -120.32 132.42 55.29 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 0.0 109.686 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 69' ' ' SER . 23.2 t -121.66 124.08 43.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.5 -0.75 . . . . 0.0 109.316 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 68' ' ' SER . 44.7 m -44.2 -29.86 0.7 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.011 -1.056 . . . . 0.0 108.461 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.713 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 0.1 OUTLIER -105.72 170.53 5.77 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.37 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.713 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.3 Cg_endo -66.6 172.18 9.67 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.115 1.876 . . . . 0.0 111.687 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.609 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.9 mt -100.59 144.53 29.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 110.122 -179.486 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.87 125.34 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.453 -0.779 . . . . 0.0 109.295 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -96.47 170.35 26.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.602 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.2 Cg_endo -68.62 146.6 79.94 Favored 'Cis proline' 0 C--O 1.213 -0.739 0 C-N-CA 122.837 -1.734 . . . . 0.0 111.859 -0.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 84.5 m-85 -92.48 147.22 23.07 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.447 -0.783 . . . . 0.0 110.669 -179.104 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.529 ' C ' ' CD1' ' A' ' 78' ' ' PHE . 20.5 m-80 -108.75 144.99 35.83 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.79 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.95 ' CE2' HD12 ' A' ' 46' ' ' LEU . 3.8 m-85 -136.99 122.56 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.855 -1.153 . . . . 0.0 110.319 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 89' ' ' VAL . 54.2 ttt180 -101.89 142.19 33.58 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.818 ' CD2' HD11 ' A' ' 41' ' ' LEU . 8.8 m-85 -123.91 143.79 50.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 111.267 -177.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.3 ttt -126.14 124.5 40.68 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.519 ' OG ' ' HB2' ' A' ' 86' ' ' MET . 13.4 p -77.53 145.6 36.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.846 . . . . 0.0 110.157 -178.233 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.928 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -44.96 -47.28 11.39 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.156 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.52 -6.92 5.14 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 97.01 34.41 5.68 Favored Glycine 0 N--CA 1.489 2.185 0 O-C-N 121.141 -1.211 . . . . 0.0 110.111 179.352 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.519 ' HB2' ' OG ' ' A' ' 82' ' ' SER . 55.8 mtp -105.36 110.46 22.82 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.028 -1.278 . . . . 0.0 109.127 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 26.6 mtm180 -90.4 140.6 29.56 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 110.668 -179.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.1 m120 -137.61 141.84 41.26 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.1 t -121.24 135.57 60.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.916 -1.115 . . . . 0.0 110.299 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.515 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 13.4 m-85 -124.2 122.31 37.45 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -98.44 146.98 25.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.208 -0.933 . . . . 0.0 109.546 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.602 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 49.1 tt0 52.92 52.64 13.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.438 -0.789 . . . . 0.0 110.162 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 94' ' ' ILE . 42.4 t -80.34 -33.38 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.882 -1.136 . . . . 0.0 108.933 179.447 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.484 HG13 HG12 ' A' ' 93' ' ' VAL . 14.0 mt -138.55 127.53 14.34 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.381 -0.824 . . . . 0.0 108.882 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.06 160.64 49.1 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.559 2.173 . . . . 0.0 112.099 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.474 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 58.6 m -50.96 -36.49 39.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.83 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.15 103.23 12.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.11 -0.994 . . . . 0.0 109.522 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.481 ' CE1' HG11 ' A' ' 19' ' ' VAL . 48.7 p90 -110.9 155.01 23.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.87 . . . . 0.0 109.219 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.5 m -105.99 172.39 6.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.145 -0.972 . . . . 0.0 109.418 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.433 HD13 ' CG1' ' A' ' 19' ' ' VAL . 28.2 mm -104.61 135.21 43.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.264 -0.898 . . . . 0.0 109.152 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 99.36 2.8 56.65 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.6 tttp -117.77 142.74 46.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.967 -1.313 . . . . 0.0 109.159 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.642 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.3 m -81.74 176.45 9.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.119 -0.988 . . . . 0.0 109.091 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.642 ' H ' HG22 ' A' ' 103' ' ' THR . 26.9 m-85 -160.69 98.4 1.22 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.8 -1.188 . . . . 0.0 109.064 179.417 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.53 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 0.2 OUTLIER -100.35 164.94 15.34 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.265 -0.897 . . . . 0.0 109.797 -179.423 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.53 ' HD2' ' HB3' ' A' ' 105' ' ' LYS . 50.5 Cg_endo -69.91 164.93 32.86 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.712 2.274 . . . . 0.0 111.81 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 108' ' ' GLU . 80.5 tt0 -56.36 -26.78 53.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.536 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 107' ' ' GLU . 36.4 tp10 . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.441 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 110.71 34.35 2.25 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.8 p -73.78 -8.46 56.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -1.164 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -109.47 128.56 55.25 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.39 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 87.5 m-70 -121.93 123.6 42.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.21 -0.931 . . . . 0.0 109.614 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -133.2 167.87 19.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.297 -0.877 . . . . 0.0 109.409 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 81.3 m-70 -123.1 90.46 3.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -52.35 -24.88 8.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.457 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -130.85 144.09 51.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.551 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.44 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . 119.81 -16.96 10.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -63.46 -11.44 23.6 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.203 -1.175 . . . . 0.0 109.436 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -116.71 -146.97 0.41 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.646 ' CG1' ' CE1' ' A' ' 34' ' ' TYR . 5.0 t -122.64 128.45 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.255 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -112.23 121.58 45.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.052 -1.03 . . . . 0.0 109.625 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.753 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.7 t -128.19 138.59 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.606 HG22 ' HB3' ' A' ' 105' ' ' LYS . 68.6 p -141.85 146.5 35.89 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.775 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.715 ' CD1' HG11 ' A' ' 93' ' ' VAL . 88.8 m-85 -119.35 118.79 32.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.3 -0.875 . . . . 0.0 109.734 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 21.9 m -108.36 158.51 17.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.922 -1.111 . . . . 0.0 108.979 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.702 ' CG1' HD13 ' A' ' 100' ' ' ILE . 8.5 t -107.8 126.68 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' HD12 ' A' ' 100' ' ' ILE . 1.7 mp0 -92.66 -173.52 3.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.146 -0.971 . . . . 0.0 109.605 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -83.65 66.01 8.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.385 -0.822 . . . . 0.0 109.937 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -172.33 22.01 0.07 OUTLIER Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.055 -1.545 . . . . 0.0 110.924 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.54 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 50.3 m -74.21 142.34 45.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.766 -1.432 . . . . 0.0 109.058 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.9 173.31 5.81 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.055 -1.028 . . . . 0.0 109.875 -179.634 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.8 Cg_endo -71.66 -30.56 14.52 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.793 2.329 . . . . 0.0 111.836 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -115.88 5.26 14.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 108.731 179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 72.8 mttt -142.17 133.11 25.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.949 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -127.87 135.34 49.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.067 -1.021 . . . . 0.0 110.099 -179.321 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.92 ' O ' HD13 ' A' ' 30' ' ' LEU . 4.1 t -119.39 119.05 59.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.949 HD11 HD22 ' A' ' 28' ' ' LEU . 0.4 OUTLIER -126.85 127.11 44.46 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.217 -0.927 . . . . 0.0 110.282 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.58 ' CB ' HG12 ' A' ' 63' ' ' VAL . 63.6 t0 -77.99 132.02 37.64 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.722 HG21 ' CE2' ' A' ' 80' ' ' PHE . 52.4 mt -118.3 128.56 75.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.157 -178.125 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.637 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 33.5 mttt -109.41 119.98 41.12 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.753 ' CD1' HG22 ' A' ' 15' ' ' VAL . 71.7 t80 -121.21 120.77 36.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.302 -0.874 . . . . 0.0 109.837 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -123.66 116.95 23.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.399 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CG ' ' HB2' ' A' ' 39' ' ' ASP . 38.0 ttt85 -139.72 131.94 14.96 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.452 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.44 107.85 2.08 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.814 2.343 . . . . 0.0 111.992 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.99 -5.29 84.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.556 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 31.6 m-20 -134.71 174.28 10.74 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -1.201 . . . . 0.0 109.682 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 82' ' ' SER . 14.7 m -155.42 162.65 40.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.74 HD13 ' HD2' ' A' ' 80' ' ' PHE . 26.8 tp -71.87 129.73 39.32 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.27 -0.894 . . . . 0.0 109.649 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.787 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -116.1 -40.29 3.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -0.934 . . . . 0.0 109.479 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -143.74 152.2 40.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.915 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.829 HG13 ' CE1' ' A' ' 80' ' ' PHE . 46.5 t -139.71 137.14 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.445 -0.785 . . . . 0.0 109.406 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.509 ' HA ' HD13 ' A' ' 57' ' ' LEU . 75.4 mt-10 -128.89 150.48 50.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.904 -1.123 . . . . 0.0 109.433 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.989 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.03 142.22 48.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.434 -0.791 . . . . 0.0 109.805 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.989 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.5 ttp180 -128.03 130.02 47.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.374 -0.829 . . . . 0.0 108.812 179.216 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.614 ' NE2' ' HA ' ' A' ' 48' ' ' GLN . 8.3 mm100 -72.14 152.42 42.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 110.218 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.574 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 13.0 t-80 -68.07 131.0 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.513 -0.742 . . . . 0.0 109.461 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 87.8 3.36 80.42 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.8 t -112.23 153.04 27.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.178 -1.19 . . . . 0.0 109.189 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -113.75 21.56 14.86 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.387 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.35 124.59 43.28 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.236 -0.915 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.452 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 64.6 m95 -85.06 129.94 34.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.432 -0.793 . . . . 0.0 109.415 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.4 134.62 19.66 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.369 -0.832 . . . . 0.0 109.342 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.663 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.3 Cg_endo -71.8 146.88 49.15 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.642 2.228 . . . . 0.0 112.164 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.676 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -106.8 158.04 17.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 108.621 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 52.3 m -108.87 127.04 53.7 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.846 -1.159 . . . . 0.0 109.116 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 37.5 tttm -65.35 120.95 13.73 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 63' ' ' VAL . 2.8 mttm -109.92 -152.7 0.5 Allowed 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.167 -0.958 . . . . 0.0 109.377 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 62' ' ' ASN . . . -58.72 81.2 0.01 OUTLIER Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.518 ' N ' ' O ' ' A' ' 60' ' ' LYS . 39.2 t30 63.97 10.54 5.4 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.243 -1.151 . . . . 0.0 110.086 179.501 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.582 HG23 ' HB2' ' A' ' 60' ' ' LYS . 5.3 m -132.05 179.12 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.092 -1.005 . . . . 0.0 109.717 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.507 ' CD1' HD12 ' A' ' 32' ' ' ILE . 63.0 m95 -127.15 126.75 43.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.067 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.443 ' HG2' ' N ' ' A' ' 66' ' ' VAL . 62.1 tt0 -119.25 154.58 33.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.17 -0.956 . . . . 0.0 109.706 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.627 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.0 p -146.17 141.42 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.405 -0.81 . . . . 0.0 109.244 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -119.81 129.01 54.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -0.941 . . . . 0.0 109.723 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.2 t -118.6 130.36 55.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.57 -0.706 . . . . 0.0 109.578 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.0 p -61.24 -21.35 63.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.149 -0.969 . . . . 0.0 108.922 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 15.0 ptmt -106.95 166.86 10.34 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.445 -0.784 . . . . 0.0 109.332 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.633 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 45.6 Cg_endo -67.74 141.39 54.34 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.478 2.118 . . . . 0.0 111.721 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.92 HD13 HD12 ' A' ' 28' ' ' LEU . 10.6 mt -76.49 141.04 41.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.343 -0.848 . . . . 0.0 109.84 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 124.72 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.366 -0.834 . . . . 0.0 109.378 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.505 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.99 165.33 26.69 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.75 147.41 82.24 Favored 'Cis proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.892 -1.712 . . . . 0.0 112.077 -0.024 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.558 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.1 m-85 -90.9 148.03 22.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.411 -0.806 . . . . 0.0 110.339 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.469 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 26.9 m-80 -109.91 144.54 38.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.379 -0.826 . . . . 0.0 108.928 179.171 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.864 ' CE2' HD12 ' A' ' 46' ' ' LEU . 82.9 m-85 -135.13 129.23 33.56 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.029 -1.044 . . . . 0.0 110.049 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.618 ' HG3' HG22 ' A' ' 89' ' ' VAL . 20.3 ttt85 -110.27 141.79 42.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.061 -1.025 . . . . 0.0 108.528 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.829 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.6 m-85 -125.31 143.34 51.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 111.396 -178.116 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.8 124.57 42.4 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.224 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.591 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.9 p -72.68 145.45 47.21 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.36 -0.838 . . . . 0.0 110.145 -178.472 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.787 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 90.6 mttt -47.6 -45.53 27.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 109.145 179.21 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.16 -5.06 0.58 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.47 25.99 12.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.591 ' O ' ' N ' ' A' ' 82' ' ' SER . 45.6 mtp -98.99 150.7 21.7 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -1.18 . . . . 0.0 108.727 179.468 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 62.3 mtm-85 -123.78 138.82 54.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.888 -1.132 . . . . 0.0 110.575 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 31.1 m120 -135.69 140.6 44.57 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.618 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.9 t -124.04 137.73 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.95 -1.094 . . . . 0.0 110.637 -178.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.529 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.3 m-85 -123.53 121.54 35.91 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 178.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -98.11 147.05 24.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.164 -0.96 . . . . 0.0 109.58 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 65.8 tt0 53.47 52.84 12.61 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.4 -0.812 . . . . 0.0 110.03 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.715 HG11 ' CD1' ' A' ' 17' ' ' PHE . 70.4 t -81.51 -34.43 13.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.906 -1.121 . . . . 0.0 109.26 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.483 HG12 ' HB3' ' A' ' 104' ' ' TYR . 13.4 mt -136.91 126.43 15.57 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.149 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.26 160.88 48.12 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.603 2.202 . . . . 0.0 111.986 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.505 HG23 ' H ' ' A' ' 74' ' ' GLY . 9.2 m -52.0 -43.13 63.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.382 -0.824 . . . . 0.0 110.192 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.0 103.64 15.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.025 -1.047 . . . . 0.0 109.83 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.414 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 52.4 p90 -111.68 152.09 28.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 28.2 m -102.11 164.72 11.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.423 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.702 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.4 mm -98.52 137.43 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.972 . . . . 0.0 109.381 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.44 62.74 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -121.24 146.49 46.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -1.182 . . . . 0.0 109.338 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.6 m -79.77 164.15 23.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.111 -0.993 . . . . 0.0 109.321 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.543 ' N ' ' O ' ' A' ' 17' ' ' PHE . 18.0 m-85 -150.06 92.21 1.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.74 -1.225 . . . . 0.0 109.064 179.089 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.606 ' HB3' HG22 ' A' ' 16' ' ' THR . 0.0 OUTLIER -108.88 164.31 15.0 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.4 -0.813 . . . . 0.0 109.867 -179.477 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.529 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 47.7 Cg_endo -69.16 174.88 8.35 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.843 2.362 . . . . 0.0 111.617 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -127.4 138.79 53.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.632 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.503 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 83.4 mtp180 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.44 -176.49 38.79 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.8 m -53.55 141.04 26.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 109.415 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -46.41 -69.0 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.466 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.0 p-80 -172.07 62.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.508 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -159.59 143.8 14.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.258 -0.901 . . . . 0.0 109.482 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 38.2 m170 -100.86 159.9 14.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.384 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 53.9 m80 -120.82 134.43 55.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.18 -0.95 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -117.24 125.16 50.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.223 -0.923 . . . . 0.0 109.353 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.71 121.86 0.6 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.2 t -111.31 169.37 8.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.224 -1.162 . . . . 0.0 109.482 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.79 139.67 58.35 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 36' ' ' ARG . 15.7 t -126.27 135.63 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 70.6 mt-30 -111.95 122.35 47.54 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.12 -0.988 . . . . 0.0 109.424 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 6.2 t -129.01 139.51 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 0.0 109.721 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.452 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 19.9 p -141.26 145.91 36.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.885 . . . . 0.0 109.237 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.624 ' CD2' HG12 ' A' ' 32' ' ' ILE . 3.9 m-85 -120.22 141.93 49.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.104 -0.998 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 23.9 m -134.37 127.3 31.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.915 . . . . 0.0 108.963 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.0 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.7 t -76.0 134.32 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.146 -0.971 . . . . 0.0 109.243 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.7 mm-40 -115.29 153.29 31.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.004 -1.06 . . . . 0.0 109.897 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 57.3 mttp -44.15 113.17 0.49 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.458 -0.776 . . . . 0.0 109.988 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.12 -5.86 1.96 Allowed Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.251 -1.452 . . . . 0.0 110.771 179.186 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.572 ' OG ' ' CE1' ' A' ' 98' ' ' PHE . 26.8 t -64.24 144.35 57.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.737 -1.449 . . . . 0.0 109.635 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.539 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -138.54 174.15 4.52 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.332 -0.855 . . . . 0.0 109.561 -179.907 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.57 ' O ' ' N ' ' A' ' 72' ' ' LEU . 50.0 Cg_endo -69.89 -28.84 24.11 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.837 2.358 . . . . 0.0 112.072 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -116.35 6.22 13.68 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.087 -1.008 . . . . 0.0 109.045 179.611 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.448 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 5.9 mtpm? -142.29 133.4 26.04 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.24 40.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.084 -1.01 . . . . 0.0 109.51 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 1.015 HG13 ' HG2' ' A' ' 65' ' ' GLU . 46.3 t -118.49 124.57 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.193 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.0 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.19 146.22 31.65 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.014 -1.054 . . . . 0.0 110.37 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.543 ' OD1' HG12 ' A' ' 63' ' ' VAL . 48.4 t0 -86.04 138.19 32.14 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.99 HG21 ' CE2' ' A' ' 80' ' ' PHE . 57.8 mt -123.39 132.27 71.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.817 -1.177 . . . . 0.0 110.644 -178.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 59.5 mttm -109.85 118.07 35.51 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 178.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.645 ' CD1' HG22 ' A' ' 15' ' ' VAL . 73.1 t80 -121.69 109.04 14.25 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.505 -0.747 . . . . 0.0 109.619 -179.038 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 83.5 m -111.45 116.11 30.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.272 -0.892 . . . . 0.0 109.562 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -141.83 121.61 8.19 Favored Pre-proline 0 N--CA 1.488 1.473 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.812 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.7 117.6 5.18 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.458 2.105 . . . . 0.0 112.014 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.74 -11.31 68.28 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.544 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.27 -179.94 6.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.894 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 82' ' ' SER . 15.4 m -155.68 162.96 40.48 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.356 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.485 HD21 HG21 ' A' ' 44' ' ' VAL . 17.5 tp -70.5 127.91 34.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.266 -0.896 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.853 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.52 -41.65 3.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.218 -0.926 . . . . 0.0 109.734 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -147.15 155.11 41.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.169 -0.957 . . . . 0.0 110.176 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.57 HG22 ' CD2' ' A' ' 80' ' ' PHE . 21.4 t -142.39 141.15 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.442 -0.786 . . . . 0.0 109.33 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.435 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 88.6 mt-10 -127.61 150.52 49.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.767 -1.208 . . . . 0.0 109.434 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.955 HD12 ' O ' ' A' ' 77' ' ' ASN . 21.7 tp -122.2 144.21 49.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.408 -178.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.627 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.1 OUTLIER -126.17 127.85 46.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.383 -0.823 . . . . 0.0 109.012 179.243 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -71.06 149.77 46.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 109.315 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.592 ' CD2' ' HD2' ' A' ' 75' ' ' PRO . 47.3 t60 -64.84 109.03 1.93 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.559 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.37 2.99 24.41 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.518 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 18.1 t -114.91 154.97 27.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.013 -1.287 . . . . 0.0 109.566 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.429 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 54.7 mp0 -112.02 -12.27 13.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.187 -0.946 . . . . 0.0 109.313 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -95.43 99.7 11.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.323 -0.861 . . . . 0.0 109.559 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.627 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 24.9 m95 -59.32 141.5 54.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.302 -0.874 . . . . 0.0 109.707 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -106.63 137.0 19.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.502 -0.749 . . . . 0.0 109.599 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.435 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 53.1 Cg_endo -72.46 144.41 40.55 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.592 2.195 . . . . 0.0 111.776 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.704 HD11 ' CB ' ' A' ' 46' ' ' LEU . 7.5 mp -106.95 146.37 31.14 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.17 -0.956 . . . . 0.0 108.863 179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 88.4 m -103.11 126.22 50.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.936 -1.103 . . . . 0.0 108.905 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 9.4 tttm -68.82 112.81 5.76 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.189 -0.944 . . . . 0.0 108.904 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mttm -120.07 80.37 1.59 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.004 -1.06 . . . . 0.0 110.702 -178.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.31 60.39 1.31 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.369 179.164 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 60.03 10.37 2.18 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.148 -1.207 . . . . 0.0 110.16 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 59' ' ' LYS . 13.6 m -129.51 -172.64 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.161 -0.962 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.409 ' CD1' HD12 ' A' ' 32' ' ' ILE . 78.4 m95 -139.13 125.52 20.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.924 . . . . 0.0 109.553 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 1.015 ' HG2' HG13 ' A' ' 29' ' ' VAL . 27.0 mt-10 -115.08 152.08 33.14 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.856 . . . . 0.0 109.596 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.704 HG11 HD23 ' A' ' 46' ' ' LEU . 3.1 p -138.22 134.91 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.439 -0.788 . . . . 0.0 109.304 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 26.5 mttp -120.89 133.99 55.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.346 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 69' ' ' SER . 9.5 t -120.66 126.84 51.26 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.37 -0.831 . . . . 0.0 109.308 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' SER . 73.4 p -45.28 -26.69 0.54 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.007 -1.058 . . . . 0.0 108.514 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -115.26 178.33 0.99 Allowed Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.1 Cg_endo -67.81 178.94 2.98 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.332 2.022 . . . . 0.0 111.846 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.583 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -112.09 143.48 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.199 -0.938 . . . . 0.0 109.786 -179.577 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 6.4 t -120.8 123.71 70.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.367 -0.833 . . . . 0.0 109.31 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.729 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.41 166.21 29.24 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.4 Cg_endo -69.62 146.76 82.78 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.783 -1.757 . . . . 0.0 112.082 0.045 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 46' ' ' LEU . 72.1 m-85 -91.54 153.6 19.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.627 -0.671 . . . . 0.0 110.494 -179.249 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.955 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.5 m120 -112.5 141.03 46.73 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.91 ' CE1' HD13 ' A' ' 46' ' ' LEU . 84.4 m-85 -132.27 128.41 37.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.997 -1.065 . . . . 0.0 109.894 -179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.772 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.3 ttt180 -112.41 143.68 43.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.019 -1.051 . . . . 0.0 108.732 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.99 ' CE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -125.37 144.42 50.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.269 -0.894 . . . . 0.0 111.611 -177.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.8 ttt -127.15 126.19 42.47 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.458 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.552 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.8 p -79.06 148.87 32.31 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.284 -0.885 . . . . 0.0 110.18 -178.402 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.853 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 23.3 mttt -47.0 -46.51 21.76 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.244 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.422 ' HA3' ' OD1' ' A' ' 39' ' ' ASP . . . -59.83 -8.48 8.0 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.3 34.13 5.44 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 51.6 mmm -102.97 109.18 20.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.107 -1.231 . . . . 0.0 109.065 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 87.7 mtm-85 -91.48 141.52 28.65 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.125 -0.984 . . . . 0.0 110.704 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.565 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.1 m120 -135.88 140.08 43.85 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.772 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -120.57 136.48 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.022 -1.049 . . . . 0.0 110.358 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.55 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 31.6 m-85 -125.96 122.23 35.35 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -98.17 147.33 24.7 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.946 . . . . 0.0 109.655 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 41.3 mt-10 53.31 52.88 12.67 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.346 -0.846 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.687 HG12 HG13 ' A' ' 94' ' ' ILE . 40.2 t -82.94 -34.35 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.986 -1.071 . . . . 0.0 109.3 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.687 HG13 HG12 ' A' ' 93' ' ' VAL . 65.8 mt -136.83 125.15 14.89 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.347 -0.845 . . . . 0.0 109.134 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.08 162.58 41.16 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.548 2.165 . . . . 0.0 111.887 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.729 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.7 m -52.87 -37.11 59.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.469 -0.77 . . . . 0.0 110.016 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.74 98.34 9.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.029 -1.044 . . . . 0.0 109.717 -179.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.572 ' CE1' ' OG ' ' A' ' 23' ' ' SER . 35.4 p90 -107.0 146.61 30.89 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.125 -0.985 . . . . 0.0 109.366 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.2 m -114.53 118.37 33.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.918 . . . . 0.0 109.554 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.576 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 4.8 mt -56.76 139.37 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.392 -0.817 . . . . 0.0 109.721 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.08 5.52 54.68 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 26.4 tttt -124.13 143.46 50.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.991 -1.299 . . . . 0.0 109.379 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.4 m -78.11 158.77 28.99 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.187 -0.946 . . . . 0.0 108.908 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.8 m-85 -146.58 97.49 2.93 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.491 -1.381 . . . . 0.0 108.953 179.272 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.54 157.9 32.81 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 110.059 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.55 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.7 Cg_endo -70.72 174.58 10.13 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.825 2.35 . . . . 0.0 111.822 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.406 ' O ' ' CB ' ' A' ' 108' ' ' GLU . 96.8 mt-10 -87.51 161.11 17.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.527 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 107' ' ' GLU . 36.7 tt0 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.415 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 25.9 mtm180 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 121.283 0.563 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.33 -48.25 2.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 92.1 p -126.61 131.2 51.55 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.468 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -56.49 -43.56 79.81 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.288 -0.883 . . . . 0.0 109.56 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.581 ' HB2' ' CE1' ' A' ' 7' ' ' HIS . 48.4 m80 -126.04 175.21 7.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.292 -0.88 . . . . 0.0 109.529 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -84.72 -15.44 45.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.581 ' CE1' ' HB2' ' A' ' 5' ' ' HIS . 2.2 p-80 -56.87 121.94 11.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.294 -0.879 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 9' ' ' HIS . 88.1 m-70 -90.37 -10.4 44.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.267 -0.895 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER -55.05 -167.02 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.32 -0.862 . . . . 0.0 109.547 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.494 ' O ' ' HG3' ' A' ' 37' ' ' PRO . . . 97.15 0.39 59.92 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -93.63 18.72 9.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.47 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -82.94 149.13 27.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.334 -0.854 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.778 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 4.2 t -127.23 137.25 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.848 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.408 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 82.7 mt-30 -106.99 120.84 43.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.183 -0.948 . . . . 0.0 109.172 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.619 HG11 ' HG3' ' A' ' 106' ' ' PRO . 11.4 p -129.57 141.65 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.253 -0.904 . . . . 0.0 109.747 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.498 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 60.5 p -140.77 144.6 35.57 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.071 -1.018 . . . . 0.0 109.481 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 104' ' ' TYR . 49.7 m-85 -114.24 147.41 39.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.246 -0.909 . . . . 0.0 109.253 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 29.1 m -145.98 127.34 14.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.994 -1.066 . . . . 0.0 109.483 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.91 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.8 t -75.88 136.52 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.392 -0.818 . . . . 0.0 109.209 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.16 158.22 19.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.985 -1.072 . . . . 0.0 109.835 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -51.43 113.11 0.87 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.865 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.77 -6.91 2.68 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.516 179.384 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.523 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 10.8 m -57.46 143.51 40.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.892 -1.358 . . . . 0.0 109.39 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.553 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.69 171.45 8.83 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.707 -179.818 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.3 Cg_endo -70.22 -31.27 18.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.861 2.374 . . . . 0.0 111.891 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.455 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 2.5 pttt -112.82 7.27 18.38 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.222 -0.923 . . . . 0.0 108.938 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.487 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 29.8 mttm -141.83 132.93 26.18 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.709 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.1 121.48 37.97 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.999 -1.063 . . . . 0.0 109.406 -179.87 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 1.025 HG22 ' HG3' ' A' ' 65' ' ' GLU . 11.9 t -119.72 125.69 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.91 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -145.27 145.37 31.24 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.983 -1.073 . . . . 0.0 110.024 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.508 ' HA ' HG12 ' A' ' 63' ' ' VAL . 67.7 t0 -84.54 137.57 33.25 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.665 HG21 ' HE2' ' A' ' 80' ' ' PHE . 53.9 mt -120.49 130.09 74.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.752 -1.217 . . . . 0.0 110.557 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.7 tttt -110.36 119.57 39.64 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.472 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.778 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 66.2 t80 -121.85 121.01 36.19 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.563 -0.711 . . . . 0.0 109.259 -179.321 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 91.7 m -122.75 115.82 22.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.128 -0.983 . . . . 0.0 110.162 -179.531 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.623 ' HG3' HG22 ' A' ' 13' ' ' VAL . 20.5 ttt85 -135.64 137.48 25.92 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.534 -0.729 . . . . 0.0 109.065 179.434 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.494 ' HG3' ' O ' ' A' ' 10' ' ' GLY . 48.5 Cg_endo -69.66 99.4 0.73 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.648 2.232 . . . . 0.0 111.904 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.14 -38.0 3.25 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.565 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 53.5 m-20 -96.28 176.16 6.17 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.228 -1.16 . . . . 0.0 109.798 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -154.74 162.22 41.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.378 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.789 HD21 HG21 ' A' ' 44' ' ' VAL . 31.8 tp -68.11 128.74 37.66 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.061 -1.024 . . . . 0.0 109.109 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.837 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.37 -45.0 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.132 -0.98 . . . . 0.0 110.274 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.473 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 81.5 mt-10 -135.55 144.56 46.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.043 -1.036 . . . . 0.0 110.392 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.789 HG21 HD21 ' A' ' 41' ' ' LEU . 99.7 t -137.97 135.59 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.474 -0.766 . . . . 0.0 109.147 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -127.91 150.03 50.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.964 -1.085 . . . . 0.0 109.162 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.96 HD13 ' CE2' ' A' ' 78' ' ' PHE . 13.5 tp -121.38 133.2 55.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.798 . . . . 0.0 110.176 -178.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.618 ' N ' HD12 ' A' ' 46' ' ' LEU . 40.8 ttp180 -119.46 129.04 54.55 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 108.788 179.134 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.452 ' OE1' HD23 ' A' ' 72' ' ' LEU . 14.5 mt-30 -71.01 160.74 32.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.276 -0.89 . . . . 0.0 110.161 -179.216 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.8 t60 -70.59 145.66 50.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.42 -0.8 . . . . 0.0 109.438 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.54 2.66 44.43 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.462 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.8 t -112.83 154.25 26.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.102 -1.234 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -121.17 14.18 11.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.889 . . . . 0.0 109.417 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -111.66 98.66 7.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.344 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.541 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 65.4 m95 -59.88 134.38 56.98 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.281 -0.887 . . . . 0.0 109.737 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -111.54 130.93 22.61 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.468 -0.77 . . . . 0.0 109.095 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.506 ' C ' HD12 ' A' ' 57' ' ' LEU . 48.5 Cg_endo -69.62 141.53 46.06 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.502 2.135 . . . . 0.0 111.978 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.804 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.9 mp -97.16 143.06 28.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 108.534 179.332 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -81.38 125.91 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.902 -1.123 . . . . 0.0 109.13 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -72.22 108.22 5.27 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.16 -0.962 . . . . 0.0 109.379 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.449 ' O ' ' C ' ' A' ' 61' ' ' GLY . 22.7 mttm -113.76 132.78 55.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.995 -1.065 . . . . 0.0 109.469 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 60' ' ' LYS . . . 43.17 -100.24 0.02 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.443 ' N ' ' O ' ' A' ' 60' ' ' LYS . 23.9 p-10 -130.5 24.98 5.12 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -1.148 . . . . 0.0 109.187 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.508 HG12 ' HA ' ' A' ' 31' ' ' ASP . 35.9 m -131.62 -170.08 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.568 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.566 ' CD1' HD12 ' A' ' 32' ' ' ILE . 44.6 m95 -140.99 124.69 16.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.03 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 1.025 ' HG3' HG22 ' A' ' 29' ' ' VAL . 69.8 tt0 -115.36 151.96 33.69 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 109.71 -179.66 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.92 HG11 HD23 ' A' ' 46' ' ' LEU . 2.0 p -141.19 138.46 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.367 -0.833 . . . . 0.0 109.191 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.441 ' CD ' ' HD3' ' A' ' 27' ' ' LYS . 84.4 mttt -122.14 134.78 54.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.278 -0.889 . . . . 0.0 109.6 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' SER . 8.8 t -120.18 126.21 50.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.343 -0.848 . . . . 0.0 109.188 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 68' ' ' SER . 6.0 m -44.1 -29.03 0.55 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.084 -1.01 . . . . 0.0 108.83 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.567 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -112.55 178.35 0.99 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.431 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.8 Cg_endo -68.79 166.34 26.59 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.382 2.055 . . . . 0.0 111.618 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.587 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 1.8 mt -97.34 143.29 28.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.117 -0.989 . . . . 0.0 109.816 -179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.419 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 22.9 t -119.89 124.79 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.81 . . . . 0.0 109.307 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.763 ' H ' HG23 ' A' ' 96' ' ' THR . . . -95.51 169.09 27.15 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.615 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.5 Cg_endo -67.99 146.34 77.5 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.838 -1.734 . . . . 0.0 111.85 0.111 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.611 ' HB3' HD11 ' A' ' 46' ' ' LEU . 74.2 m-85 -91.34 149.84 21.56 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.532 -0.73 . . . . 0.0 110.37 -179.09 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.874 ' O ' HD12 ' A' ' 46' ' ' LEU . 18.9 m-80 -111.99 143.67 42.6 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 179.137 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.96 ' CE2' HD13 ' A' ' 46' ' ' LEU . 96.1 m-85 -134.84 120.36 19.24 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.056 -1.028 . . . . 0.0 109.515 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.934 ' HG3' HG22 ' A' ' 89' ' ' VAL . 63.3 ttt180 -100.55 141.94 32.7 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.955 -1.091 . . . . 0.0 108.653 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.74 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.3 m-85 -124.96 142.95 51.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.907 . . . . 0.0 111.317 -178.256 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.67 124.2 41.68 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.157 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.615 ' N ' ' O ' ' A' ' 86' ' ' MET . 13.6 p -72.16 144.85 48.43 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.408 -0.808 . . . . 0.0 110.097 -178.463 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.837 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.2 OUTLIER -50.24 -44.45 53.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -0.917 . . . . 0.0 108.777 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.04 -2.18 0.19 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.32 25.7 18.11 Favored Glycine 0 N--CA 1.491 2.35 0 O-C-N 121.068 -1.254 . . . . 0.0 109.978 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.615 ' O ' ' N ' ' A' ' 82' ' ' SER . 39.2 mtp -100.85 149.06 24.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.109 -1.23 . . . . 0.0 108.864 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 7.6 mtt85 -120.15 135.97 54.78 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.332 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -134.57 139.91 45.72 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.934 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -123.1 136.2 60.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.043 -1.036 . . . . 0.0 110.294 -178.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.653 ' CG ' ' CB ' ' A' ' 106' ' ' PRO . 11.3 m-85 -122.45 121.04 35.67 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.59 147.62 24.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.21 -0.931 . . . . 0.0 109.707 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.615 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 48.2 mt-10 53.69 49.64 18.86 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.412 -0.805 . . . . 0.0 110.2 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.611 HG12 HG13 ' A' ' 94' ' ' ILE . 54.3 t -77.91 -33.71 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.867 -1.146 . . . . 0.0 108.885 179.333 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.611 HG13 HG12 ' A' ' 93' ' ' VAL . 69.8 mt -138.83 124.71 12.33 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.321 -0.862 . . . . 0.0 108.959 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -67.72 162.83 37.69 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.647 2.232 . . . . 0.0 112.161 -179.237 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.763 HG23 ' H ' ' A' ' 74' ' ' GLY . 8.1 m -50.56 -43.87 56.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.41 -0.806 . . . . 0.0 109.829 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.03 103.77 15.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.039 -1.038 . . . . 0.0 109.528 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.582 ' CE2' HG11 ' A' ' 19' ' ' VAL . 43.0 p90 -111.25 158.86 18.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 109.157 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.4 m -107.92 172.48 6.81 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.256 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.6 mm -104.56 135.93 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.877 . . . . 0.0 109.253 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.75 6.77 58.1 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -117.08 141.74 47.88 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.064 -1.256 . . . . 0.0 109.337 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.57 HG22 ' N ' ' A' ' 104' ' ' TYR . 34.5 m -81.95 170.1 16.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.09 -1.007 . . . . 0.0 109.026 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.575 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.4 m-85 -151.23 99.37 2.65 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.771 -1.205 . . . . 0.0 109.261 179.416 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.571 ' HG2' ' O ' ' A' ' 15' ' ' VAL . 1.9 mtmt -84.43 148.95 53.75 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.467 -0.77 . . . . 0.0 109.66 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.653 ' CB ' ' CG ' ' A' ' 90' ' ' PHE . 51.1 Cg_endo -72.22 120.4 6.76 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.254 1.969 . . . . 0.0 111.569 179.635 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.16 -76.83 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.242 -0.911 . . . . 0.0 109.584 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 90' ' ' PHE . 32.8 tt0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.522 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 29.8 mtm180 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.17 138.32 45.73 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.3 t -80.41 152.37 28.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -1.169 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 37.3 p-80 -117.62 8.19 12.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 36.0 t60 -53.75 -48.85 69.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.189 -0.945 . . . . 0.0 109.427 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 63.9 m80 -55.1 -29.32 57.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.423 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.543 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 74.1 t60 -113.76 22.0 14.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.447 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -98.29 144.53 27.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.922 . . . . 0.0 109.505 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -138.97 168.6 19.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.891 . . . . 0.0 109.499 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.35 169.76 39.28 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.453 ' O ' ' HB2' ' A' ' 12' ' ' ALA . 69.0 m -100.9 151.09 22.15 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.262 -1.14 . . . . 0.0 109.328 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.453 ' HB2' ' O ' ' A' ' 11' ' ' SER . . . 177.81 -142.3 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.195 -0.941 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 36' ' ' ARG . 17.1 t -123.89 132.76 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 108.855 179.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.457 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 36.1 mt-30 -109.31 121.35 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.094 -1.004 . . . . 0.0 109.814 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 9.5 p -128.87 140.39 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.35 -0.844 . . . . 0.0 109.439 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.484 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 27.9 p -142.08 146.16 35.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.06 -1.025 . . . . 0.0 109.606 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.0 m-85 -118.51 143.68 46.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.581 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . 1.005 HG23 ' O ' ' A' ' 102' ' ' LYS . 69.0 m -139.67 129.05 24.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.067 -1.02 . . . . 0.0 109.245 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.904 HG22 HD23 ' A' ' 30' ' ' LEU . 42.6 t -75.91 132.67 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.225 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -105.17 159.78 15.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.109 -0.994 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -54.35 115.22 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.388 -0.82 . . . . 0.0 109.782 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 24' ' ' ASP . . . 139.5 -0.59 2.24 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.279 179.476 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.432 ' C ' ' OD1' ' A' ' 24' ' ' ASP . 34.1 t -66.85 142.17 57.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.976 -1.308 . . . . 0.0 109.394 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.648 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -134.56 174.48 4.59 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.205 -0.935 . . . . 0.0 109.31 -179.833 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.648 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 49.3 Cg_endo -70.36 -28.71 22.05 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.612 2.208 . . . . 0.0 111.985 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.3 mttm -114.51 9.37 16.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.935 . . . . 0.0 109.127 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.505 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 31.9 mttt -142.98 133.47 24.91 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.731 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.5 122.5 39.86 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.997 -1.064 . . . . 0.0 109.571 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.647 HG22 ' CG ' ' A' ' 65' ' ' GLU . 22.2 t -120.2 125.6 74.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.904 HD23 HG22 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -144.89 145.69 31.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.883 -1.136 . . . . 0.0 110.248 -179.419 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.494 ' HA ' HG12 ' A' ' 63' ' ' VAL . 17.9 t70 -86.22 138.52 31.81 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.824 HG21 ' HE2' ' A' ' 80' ' ' PHE . 70.5 mt -120.2 130.34 74.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.859 -178.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 25.1 tptt -110.55 120.26 41.83 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.115 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.504 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 79.6 t80 -121.77 123.64 42.31 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.395 -0.815 . . . . 0.0 109.915 -178.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.457 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 56.8 m -125.11 115.13 19.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 109.484 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 13' ' ' VAL . 29.8 ttt85 -139.79 135.37 16.6 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.448 -0.782 . . . . 0.0 109.199 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.481 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.8 Cg_endo -70.96 108.01 2.21 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.778 2.318 . . . . 0.0 112.182 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.02 -1.9 86.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.56 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.8 m-20 -134.36 173.92 11.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.075 -1.25 . . . . 0.0 109.655 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -153.45 160.85 42.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.81 HD11 ' CG2' ' A' ' 44' ' ' VAL . 7.8 tp -68.65 123.3 20.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.913 . . . . 0.0 109.212 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.794 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.36 -44.89 2.95 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.469 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 69.5 mt-10 -135.18 144.46 47.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.162 -0.961 . . . . 0.0 110.217 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.81 ' CG2' HD11 ' A' ' 41' ' ' LEU . 12.6 t -138.36 135.96 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.445 -0.784 . . . . 0.0 109.273 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -128.96 150.02 50.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.878 -1.139 . . . . 0.0 109.537 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.942 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.2 143.3 47.34 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.453 -0.779 . . . . 0.0 109.857 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.942 ' N ' HD23 ' A' ' 46' ' ' LEU . 35.8 ttp180 -131.33 126.36 35.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 108.821 179.297 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.439 ' OE1' HD23 ' A' ' 72' ' ' LEU . 16.3 mt-30 -66.39 156.11 35.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.159 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.59 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 8.3 t-80 -71.9 117.15 13.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 109.629 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 103.53 4.07 46.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.486 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 10.1 t -114.37 159.82 19.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.28 -1.13 . . . . 0.0 109.342 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.65 14.97 9.46 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -116.36 91.45 3.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.443 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -52.79 134.37 36.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -106.78 135.16 19.57 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.313 -0.867 . . . . 0.0 109.434 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.485 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.5 Cg_endo -70.15 145.78 55.84 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.677 2.251 . . . . 0.0 111.733 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.682 HD11 ' CB ' ' A' ' 46' ' ' LEU . 8.2 mp -110.41 150.78 28.33 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.168 -0.958 . . . . 0.0 109.052 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 m -102.36 126.74 49.47 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.993 -1.067 . . . . 0.0 109.141 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.7 tttt -77.46 101.56 6.48 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.071 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.565 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.7 mttt -115.4 150.39 36.46 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.866 -1.146 . . . . 0.0 110.083 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 43.38 32.23 1.75 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 1.5 m120 76.79 12.73 2.34 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.244 . . . . 0.0 110.126 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 3.0 m -130.17 176.9 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.136 -0.978 . . . . 0.0 108.805 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 64' ' ' TRP . 37.8 m95 -120.5 144.35 48.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.926 -1.108 . . . . 0.0 109.796 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.647 ' CG ' HG22 ' A' ' 29' ' ' VAL . 51.3 tt0 -136.5 151.97 50.01 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.376 -0.827 . . . . 0.0 109.445 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.813 HG11 HD13 ' A' ' 46' ' ' LEU . 9.8 p -137.11 133.77 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.387 -0.821 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' NZ ' ' A' ' 27' ' ' LYS . 21.4 mttt -119.72 131.21 55.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.934 . . . . 0.0 109.398 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t -118.24 165.96 13.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.381 -0.824 . . . . 0.0 109.522 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 50.2 m -88.74 2.98 52.47 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.249 -0.907 . . . . 0.0 109.052 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.558 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.2 OUTLIER -142.14 176.78 2.18 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.476 -0.765 . . . . 0.0 109.18 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.558 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.5 Cg_endo -68.55 139.31 44.37 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.506 2.137 . . . . 0.0 111.721 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.573 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 8.8 mt -73.88 143.08 45.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.261 -0.899 . . . . 0.0 109.627 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.424 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 31.2 t -119.42 123.3 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.249 -0.907 . . . . 0.0 109.31 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.532 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -92.05 164.7 28.76 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.701 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.55 147.87 85.07 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.775 -1.761 . . . . 0.0 112.035 -0.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 58.9 m-85 -89.52 151.1 22.15 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.505 -0.747 . . . . 0.0 110.149 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.432 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 39.2 m-80 -112.68 142.9 44.75 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.823 . . . . 0.0 109.051 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.874 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.9 m-85 -135.12 123.5 23.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 109.773 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.999 ' HG3' HG22 ' A' ' 89' ' ' VAL . 38.4 ttt180 -103.86 141.69 35.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.985 -1.072 . . . . 0.0 108.514 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.824 ' HE2' HG21 ' A' ' 32' ' ' ILE . 13.3 m-85 -125.17 142.8 51.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 111.497 -178.06 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.5 ttm -124.46 123.75 40.82 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.167 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.621 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.6 p -70.45 143.45 51.78 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.367 -0.833 . . . . 0.0 110.302 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.794 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -48.39 -45.2 35.57 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.356 -0.84 . . . . 0.0 108.83 178.924 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.42 -2.13 0.25 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.499 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.34 24.99 20.28 Favored Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.083 -1.246 . . . . 0.0 110.025 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.621 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.6 mmm -98.95 149.17 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.011 -1.288 . . . . 0.0 108.786 179.29 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.538 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 19.6 mtm105 -120.33 135.81 54.9 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.969 -1.082 . . . . 0.0 110.401 -179.013 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -134.32 139.44 45.67 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.999 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.7 t -122.82 136.42 59.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.112 -0.992 . . . . 0.0 110.316 -179.026 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 15' ' ' VAL . 27.7 m-85 -123.28 121.83 36.85 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.517 -0.919 . . . . 0.0 108.517 179.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -99.35 147.49 25.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.272 -0.893 . . . . 0.0 109.643 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.701 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 25.7 mt-10 53.48 52.2 13.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.392 -0.818 . . . . 0.0 110.201 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.3 t -83.04 -34.87 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 120.889 -1.132 . . . . 0.0 109.085 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -133.63 123.78 17.54 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.334 -0.854 . . . . 0.0 109.197 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.33 161.74 44.92 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.549 2.166 . . . . 0.0 111.79 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.532 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 32.6 m -54.29 -36.07 63.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.414 -0.804 . . . . 0.0 110.055 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.43 79.19 5.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.936 -1.102 . . . . 0.0 109.702 -179.513 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -89.02 145.05 25.73 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.314 -0.866 . . . . 0.0 109.408 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.59 116.48 26.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.321 -0.862 . . . . 0.0 109.67 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.59 HG12 HG12 ' A' ' 19' ' ' VAL . 11.1 mt -56.82 139.95 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.292 -0.88 . . . . 0.0 109.656 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.14 5.95 54.17 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 1.005 ' O ' HG23 ' A' ' 18' ' ' THR . 20.3 mttm -120.23 -165.82 1.23 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.009 -1.289 . . . . 0.0 109.183 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 8.7 m -131.06 165.22 23.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.07 -1.019 . . . . 0.0 108.517 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.7 m-85 -155.53 93.45 1.49 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.428 -1.42 . . . . 0.0 109.169 179.138 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 6.8 pttm -105.11 164.43 15.14 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.409 -0.807 . . . . 0.0 109.393 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 50.2 Cg_endo -71.28 147.72 53.89 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.494 2.129 . . . . 0.0 111.739 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.427 ' OE1' ' HA ' ' A' ' 107' ' ' GLU . 69.5 mm-40 -91.93 145.67 24.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.212 -0.93 . . . . 0.0 109.458 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.457 179.961 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -51.8 114.1 2.9 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.99 -44.11 96.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.231 -1.158 . . . . 0.0 109.433 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' HIS . . . . . 0.453 ' HA ' ' HB2' ' A' ' 7' ' ' HIS . 1.6 m80 -54.41 -33.15 58.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 69.6 t60 -54.49 -33.38 59.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.396 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -98.74 -34.7 10.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.313 -0.867 . . . . 0.0 109.465 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.453 ' HB2' ' HA ' ' A' ' 4' ' ' HIS . 65.6 m-70 -65.9 -38.32 88.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.951 . . . . 0.0 109.478 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -119.04 140.27 50.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.382 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -103.66 -7.43 20.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.567 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 72.57 -167.27 53.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.9 t -103.14 153.68 20.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.233 -1.157 . . . . 0.0 109.527 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -137.46 138.92 40.26 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.396 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.645 HG22 ' HG3' ' A' ' 36' ' ' ARG . 20.1 t -124.35 129.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.286 -0.884 . . . . 0.0 109.655 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -111.65 121.37 44.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.157 -0.964 . . . . 0.0 109.313 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.2 t -128.16 138.09 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.814 -179.614 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.472 HG22 ' HD3' ' A' ' 105' ' ' LYS . 28.1 p -142.17 146.21 35.04 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.352 -0.842 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.594 ' O ' ' N ' ' A' ' 104' ' ' TYR . 34.1 m-85 -118.31 142.42 47.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.673 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 61.1 m -138.18 129.2 27.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.058 -1.027 . . . . 0.0 109.329 179.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.901 HG22 ' CD2' ' A' ' 30' ' ' LEU . 24.0 t -77.29 138.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.882 . . . . 0.0 109.39 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -106.15 -177.11 3.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.107 -0.995 . . . . 0.0 109.508 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 43.0 mttt -77.67 110.29 12.38 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.369 -0.832 . . . . 0.0 109.698 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.61 -0.32 1.66 Allowed Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.558 -1.306 . . . . 0.0 110.481 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.0 t -56.4 144.82 29.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.875 -1.368 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.5 168.99 14.62 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.167 -0.958 . . . . 0.0 109.636 -179.833 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.527 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 48.3 Cg_endo -69.76 -27.64 26.24 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.854 2.369 . . . . 0.0 111.859 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -114.65 8.61 16.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.164 -0.96 . . . . 0.0 109.01 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.443 ' C ' HD11 ' A' ' 72' ' ' LEU . 56.4 mttp -143.99 134.15 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 108.98 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.91 123.02 40.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.927 -1.108 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.735 HG13 ' HG2' ' A' ' 65' ' ' GLU . 5.0 t -120.36 126.07 74.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.901 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.35 145.48 31.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.842 -1.161 . . . . 0.0 110.2 -179.567 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.423 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.2 t0 -83.88 135.01 34.66 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 178.044 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.633 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -115.53 127.07 73.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.779 -1.201 . . . . 0.0 111.154 -178.641 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 10.2 ttpt -108.12 115.19 29.67 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 177.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.514 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 76.7 t80 -124.05 108.16 12.06 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.682 -0.637 . . . . 0.0 109.84 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.0 m -109.6 117.56 34.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.351 -0.843 . . . . 0.0 109.446 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.645 ' HG3' HG22 ' A' ' 13' ' ' VAL . 9.4 ttt85 -144.65 114.49 5.14 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.405 -0.81 . . . . 0.0 109.354 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.41 120.7 7.5 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.704 2.269 . . . . 0.0 111.809 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.06 -19.54 54.38 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.531 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 5.0 m-20 -140.75 -179.09 5.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -1.126 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.412 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 18.6 m -155.75 162.86 40.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.86 . . . . 0.0 109.535 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.778 HD21 ' CG2' ' A' ' 44' ' ' VAL . 25.1 tp -69.97 129.19 38.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.294 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.884 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.12 3.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -138.95 147.6 42.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.189 -0.944 . . . . 0.0 110.246 -179.543 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.778 ' CG2' HD21 ' A' ' 41' ' ' LEU . 77.6 t -138.18 136.01 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.488 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.3 mt-10 -129.76 151.63 50.13 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.88 -1.137 . . . . 0.0 109.775 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.943 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.9 tt -120.99 140.23 52.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 109.636 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.943 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.8 ttp180 -125.73 128.13 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.135 179.301 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.469 ' NE2' HD23 ' A' ' 72' ' ' LEU . 28.2 mt-30 -69.58 145.5 52.51 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.594 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' HIS . . . . . 0.609 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 22.4 t60 -63.85 113.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.842 . . . . 0.0 109.421 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.78 1.97 30.49 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.425 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 29.1 t -114.02 154.92 26.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.241 . . . . 0.0 109.418 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -118.25 22.35 12.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.444 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 83.0 mt-10 -127.43 81.2 2.0 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.535 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.612 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 43.8 m95 -43.38 136.53 3.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -0.907 . . . . 0.0 109.698 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -104.91 138.48 19.52 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.84 . . . . 0.0 109.311 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.497 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.7 Cg_endo -71.74 147.84 51.43 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.649 2.233 . . . . 0.0 112.113 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.62 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -111.48 155.78 22.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 108.958 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 m -109.7 127.14 54.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.813 -1.179 . . . . 0.0 109.078 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 41.6 tttm -71.72 110.64 6.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.145 -0.972 . . . . 0.0 109.344 -179.549 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.965 ' O ' HG22 ' A' ' 63' ' ' VAL . 20.8 mttt -119.63 141.1 49.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.815 -1.178 . . . . 0.0 109.812 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.584 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.52 31.08 0.97 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.584 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER 81.88 15.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.306 -1.114 . . . . 0.0 110.362 179.292 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.1 m -129.86 173.42 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.986 -1.071 . . . . 0.0 108.838 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 69.3 m95 -118.96 122.75 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.875 -1.141 . . . . 0.0 109.666 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.735 ' HG2' HG13 ' A' ' 29' ' ' VAL . 5.5 mt-10 -115.88 153.71 31.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.438 -0.789 . . . . 0.0 109.511 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.736 HG11 HD13 ' A' ' 46' ' ' LEU . 2.9 p -138.73 135.57 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.486 -0.759 . . . . 0.0 109.432 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.3 mttm -119.8 131.36 55.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -118.41 160.28 21.98 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.466 -0.771 . . . . 0.0 109.25 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 71.1 m -80.25 -13.87 58.87 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.145 -0.972 . . . . 0.0 109.148 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.556 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.0 OUTLIER -124.09 177.2 1.85 Allowed Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.369 -0.832 . . . . 0.0 109.031 179.791 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.556 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.5 Cg_endo -69.41 138.84 39.93 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.42 2.08 . . . . 0.0 111.678 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.675 HD13 ' HB2' ' A' ' 28' ' ' LEU . 16.2 mt -69.9 140.38 53.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.328 -0.858 . . . . 0.0 109.858 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.1 t -121.55 124.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.416 -0.803 . . . . 0.0 109.213 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.52 168.64 28.17 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.611 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.08 146.1 79.78 Favored 'Cis proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.822 -1.741 . . . . 0.0 112.025 -0.085 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 73.0 m-85 -91.14 147.76 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -0.832 . . . . 0.0 110.422 -179.179 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.418 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 30.2 m-80 -108.38 142.88 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.414 -0.804 . . . . 0.0 108.91 179.103 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.872 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.1 m-85 -133.93 122.29 22.91 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.041 -1.037 . . . . 0.0 109.77 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.584 ' HG3' HG22 ' A' ' 89' ' ' VAL . 57.9 ttp180 -106.33 144.1 33.5 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.089 -1.007 . . . . 0.0 108.937 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.633 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -124.69 142.76 51.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.14 -0.975 . . . . 0.0 111.502 -178.142 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.568 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.8 ttt -125.13 124.78 42.55 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' SER . . . . . 0.662 ' N ' ' O ' ' A' ' 86' ' ' MET . 21.0 p -73.59 144.43 45.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.325 -0.86 . . . . 0.0 110.544 -178.284 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.884 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 47.3 mttm -47.17 -45.18 22.63 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.414 -0.804 . . . . 0.0 109.033 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.64 -5.02 1.65 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 96.61 24.72 13.11 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.662 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.1 mmm -95.96 147.62 23.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.045 -1.268 . . . . 0.0 108.503 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 24.5 mtm180 -123.29 138.39 54.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.686 -1.259 . . . . 0.0 110.794 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.428 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.1 m120 -134.97 139.94 45.3 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.527 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.584 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.7 t -123.01 137.34 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 120.877 -1.139 . . . . 0.0 110.461 -178.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.561 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 75.1 m-85 -124.91 123.51 40.06 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -99.8 146.73 26.25 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.805 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.611 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 79.1 tt0 53.67 53.93 10.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.411 -0.806 . . . . 0.0 110.652 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.606 HG22 ' HB3' ' A' ' 106' ' ' PRO . 45.5 t -83.81 -33.92 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.866 -1.146 . . . . 0.0 109.04 179.366 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 12.5 mt -135.98 125.24 15.92 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.412 -0.805 . . . . 0.0 109.017 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.78 161.98 43.83 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.563 2.175 . . . . 0.0 112.101 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.52 HG23 ' H ' ' A' ' 74' ' ' GLY . 23.7 m -50.49 -46.33 56.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.451 -0.781 . . . . 0.0 109.966 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.72 102.61 15.22 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.006 . . . . 0.0 109.627 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 53.7 p90 -109.85 154.36 23.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 109.353 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 73.1 p -107.97 171.96 7.1 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.545 HD13 ' CG1' ' A' ' 19' ' ' VAL . 20.9 mm -106.26 136.77 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.266 -0.897 . . . . 0.0 109.347 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 93.25 8.13 61.61 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -119.25 143.69 47.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.243 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -77.32 174.95 10.21 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.016 -1.052 . . . . 0.0 108.827 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.616 ' H ' HG22 ' A' ' 103' ' ' THR . 26.6 m-85 -159.49 94.65 1.18 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.737 -1.227 . . . . 0.0 109.165 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.472 ' HD3' HG22 ' A' ' 16' ' ' THR . 11.8 mtmm -91.72 155.33 43.72 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.341 -0.849 . . . . 0.0 109.665 -179.5 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.606 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.7 Cg_endo -71.83 52.02 1.67 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.783 2.322 . . . . 0.0 111.649 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 108' ' ' GLU . 35.7 tt0 -96.3 -51.97 4.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 107' ' ' GLU . 77.0 tt0 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.493 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.757 HG13 ' HG3' ' A' ' 36' ' ' ARG . 2.1 t . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -112.18 120.4 41.64 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.011 -1.056 . . . . 0.0 109.539 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.8 t -128.19 139.1 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.75 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.442 ' HA ' ' HG3' ' A' ' 105' ' ' LYS . 70.7 p -141.52 145.62 35.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.225 -0.922 . . . . 0.0 109.697 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.803 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.9 m-85 -117.05 128.97 55.69 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.248 -0.907 . . . . 0.0 109.786 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.462 ' O ' ' N ' ' A' ' 31' ' ' ASP . 41.3 m -128.03 128.64 45.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.162 -0.961 . . . . 0.0 109.157 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.848 HG22 HD23 ' A' ' 30' ' ' LEU . 21.3 t -76.18 139.44 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.357 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.16 157.23 21.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.117 -0.989 . . . . 0.0 109.72 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -51.3 114.39 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.444 -0.785 . . . . 0.0 109.977 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.16 -1.43 2.19 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.523 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.1 t -60.01 141.24 56.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.925 -1.338 . . . . 0.0 109.175 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.57 176.13 3.02 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.121 -0.987 . . . . 0.0 109.664 -179.639 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.6 Cg_endo -71.77 -30.56 14.19 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.606 2.204 . . . . 0.0 111.816 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.4 mttm -117.21 4.99 12.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -0.886 . . . . 0.0 109.091 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.488 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 41.6 mttt -142.17 133.43 26.28 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.15 HD12 HD13 ' A' ' 72' ' ' LEU . 0.3 OUTLIER -127.18 133.78 50.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.034 -1.042 . . . . 0.0 110.21 -179.445 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 2.8 t -122.99 124.84 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.038 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -141.16 141.31 34.13 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.034 -1.041 . . . . 0.0 110.041 -179.526 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.602 ' CB ' HG12 ' A' ' 63' ' ' VAL . 59.7 t0 -86.11 137.34 32.74 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.575 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.1 mt -122.23 131.14 73.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 120.865 -1.147 . . . . 0.0 110.523 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 66.2 mttm -110.54 120.29 41.94 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.604 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.5 t80 -122.49 114.19 20.35 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.415 -0.803 . . . . 0.0 109.541 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.9 m -116.99 117.96 31.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.784 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.757 ' HG3' HG13 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -135.22 132.0 19.9 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.432 -0.793 . . . . 0.0 109.21 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.453 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 49.9 Cg_endo -70.2 105.89 1.64 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.67 2.246 . . . . 0.0 112.078 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.93 -2.12 87.02 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.523 ' HB3' ' HD2' ' A' ' 36' ' ' ARG . 1.7 m-20 -135.44 173.7 11.43 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.114 -1.227 . . . . 0.0 109.673 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 82' ' ' SER . 20.6 m -153.89 161.34 42.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.439 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.735 HD11 ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -71.5 132.98 45.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.947 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.47 -42.47 3.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.18 -0.95 . . . . 0.0 109.499 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -142.84 151.24 40.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.065 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.735 ' CG2' HD11 ' A' ' 41' ' ' LEU . 65.1 t -139.86 137.6 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.1 mt-10 -126.22 148.73 49.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.784 -1.198 . . . . 0.0 109.432 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.017 HD13 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tp -121.44 129.58 53.07 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.491 -0.756 . . . . 0.0 110.184 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.688 ' N ' HD12 ' A' ' 46' ' ' LEU . 12.1 ttp180 -115.63 131.97 56.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.199 -0.938 . . . . 0.0 108.875 179.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.588 HE21 HD23 ' A' ' 72' ' ' LEU . 44.5 mt-30 -73.47 155.15 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.315 -0.865 . . . . 0.0 110.021 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.1 t60 -67.29 147.83 52.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.446 -0.783 . . . . 0.0 109.357 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.83 2.12 35.67 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 32.5 t -113.21 152.46 29.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -1.214 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -117.81 17.88 14.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -0.907 . . . . 0.0 109.316 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -116.39 104.35 11.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.58 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 45.8 m95 -66.59 134.72 52.92 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.338 -0.851 . . . . 0.0 109.673 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.486 ' HG2' ' HD2' ' A' ' 56' ' ' PRO . 0.9 OUTLIER -108.71 134.27 20.37 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.345 179.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.535 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.5 Cg_endo -70.45 144.51 50.53 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.625 2.217 . . . . 0.0 111.961 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.73 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -103.88 148.36 26.23 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 108.823 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 63.0 m -97.5 125.78 42.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 108.947 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 12.9 tttm -70.93 111.64 6.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.236 -0.915 . . . . 0.0 109.269 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -109.77 105.54 14.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.054 -1.029 . . . . 0.0 109.461 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.79 -96.24 0.25 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -131.04 18.83 4.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.256 -1.144 . . . . 0.0 109.451 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.602 HG12 ' CB ' ' A' ' 31' ' ' ASP . 22.5 m -132.43 177.42 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.265 -0.897 . . . . 0.0 109.437 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.572 ' CD1' HD12 ' A' ' 32' ' ' ILE . 74.5 m95 -122.58 142.67 50.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 108.961 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -129.73 145.16 51.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.805 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.977 HG11 HD23 ' A' ' 46' ' ' LEU . 3.6 p -137.62 134.11 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.351 -0.843 . . . . 0.0 109.033 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -121.17 133.4 55.19 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.227 -0.92 . . . . 0.0 109.56 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.6 t -118.04 163.88 15.94 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.445 -0.784 . . . . 0.0 109.452 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 65.1 m -87.14 -5.96 58.82 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.191 -0.943 . . . . 0.0 109.152 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.9 OUTLIER -131.99 178.44 1.75 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.385 -0.822 . . . . 0.0 109.126 179.866 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -69.18 139.52 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.395 2.063 . . . . 0.0 111.577 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.15 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -75.38 141.19 43.31 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.25 -0.906 . . . . 0.0 109.935 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 42.9 t -123.86 124.92 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.465 -0.772 . . . . 0.0 109.155 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.585 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.67 170.18 30.67 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.63 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.8 Cg_endo -69.8 147.57 85.0 Favored 'Cis proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.836 -1.735 . . . . 0.0 111.833 0.037 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.591 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.7 m-85 -91.92 151.38 20.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.473 -0.767 . . . . 0.0 110.599 -179.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.746 ' O ' HD12 ' A' ' 46' ' ' LEU . 34.9 m-80 -112.15 143.45 43.17 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 1.017 ' CE2' HD13 ' A' ' 46' ' ' LEU . 95.7 m-85 -136.33 130.76 33.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.947 -1.096 . . . . 0.0 109.972 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.993 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.3 ttp180 -110.31 141.49 43.25 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.058 -1.026 . . . . 0.0 108.627 179.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.568 ' CE2' HG21 ' A' ' 32' ' ' ILE . 5.8 m-85 -120.93 142.78 49.4 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 111.021 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.591 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -127.77 125.35 39.74 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.701 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.629 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.1 p -78.0 144.48 36.66 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 110.416 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.947 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 30.8 mttm -46.21 -43.79 15.63 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.14 -2.96 0.69 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.12 22.94 26.17 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.629 ' O ' ' N ' ' A' ' 82' ' ' SER . 1.6 mmm -96.34 146.45 24.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.123 -1.221 . . . . 0.0 108.604 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 42.8 mtm180 -124.36 141.35 52.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.826 -1.172 . . . . 0.0 110.535 -178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.432 ' N ' ' O ' ' A' ' 80' ' ' PHE . 24.2 m120 -136.48 140.91 43.41 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.993 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.0 t -121.49 135.95 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 110.354 -179.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.552 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 41.9 m-85 -124.59 122.53 37.81 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -99.55 148.94 23.76 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.202 -0.936 . . . . 0.0 109.753 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.63 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 10.5 mt-10 51.7 51.03 17.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.53 -0.731 . . . . 0.0 110.371 179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.803 HG11 ' CE1' ' A' ' 17' ' ' PHE . 39.7 t -82.83 -33.54 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.911 -1.118 . . . . 0.0 109.255 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 9.1 mt -131.62 124.3 19.88 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.113 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.54 161.04 46.65 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.494 2.129 . . . . 0.0 111.916 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.585 HG23 ' H ' ' A' ' 74' ' ' GLY . 7.7 m -53.54 -43.96 68.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.341 -0.849 . . . . 0.0 109.95 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.4 99.84 12.75 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.105 -0.997 . . . . 0.0 109.568 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.73 146.06 34.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.627 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 16.2 m -106.54 156.68 18.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.395 -0.816 . . . . 0.0 109.183 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.575 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.2 mm -92.21 136.39 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.134 -0.979 . . . . 0.0 109.441 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.04 2.2 62.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -115.56 143.04 45.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.174 -1.192 . . . . 0.0 109.097 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.0 m -79.7 169.66 17.65 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.068 -1.02 . . . . 0.0 108.995 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.7 m-85 -154.57 100.32 2.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.714 -1.241 . . . . 0.0 109.032 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.524 ' CD ' ' N ' ' A' ' 105' ' ' LYS . 0.5 OUTLIER -95.25 158.2 35.12 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.718 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo . . . . . 0 C--O 1.215 -0.666 0 C-N-CA 122.743 2.296 . . . . 0.0 111.808 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.734 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 16.6 t . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -110.1 120.77 43.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.363 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.517 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.4 t -127.94 138.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.346 -0.846 . . . . 0.0 109.632 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.0 p -141.53 145.83 35.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.25 -0.906 . . . . 0.0 109.418 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.621 ' CD2' HG12 ' A' ' 32' ' ' ILE . 15.0 m-85 -118.46 143.98 46.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.21 -0.931 . . . . 0.0 109.781 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 21.4 m -139.39 128.05 23.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 0.0 109.136 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.829 HG22 ' CD2' ' A' ' 30' ' ' LEU . 16.7 t -76.21 130.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -108.57 152.76 24.32 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.076 -1.015 . . . . 0.0 109.695 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -45.41 114.81 0.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.416 -0.802 . . . . 0.0 109.978 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.34 -2.92 1.84 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.834 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 34.9 m -63.71 141.09 58.89 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.703 -1.469 . . . . 0.0 109.277 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.534 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.64 175.49 3.55 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.128 -0.983 . . . . 0.0 109.593 -179.697 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.0 Cg_endo -71.54 -30.82 14.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.566 2.177 . . . . 0.0 111.845 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.2 mttp -117.33 4.78 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 0.0 109.053 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.426 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 35.4 mttp -142.27 133.64 26.42 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.074 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.12 132.25 50.63 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.948 -1.095 . . . . 0.0 110.347 -179.253 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.614 HG13 ' HG2' ' A' ' 65' ' ' GLU . 8.8 t -121.91 125.41 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.074 HD11 HD22 ' A' ' 28' ' ' LEU . 1.4 mt -141.88 141.49 33.05 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.942 -1.099 . . . . 0.0 110.142 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.438 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.0 t0 -86.36 137.56 32.48 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.742 HG21 ' CE2' ' A' ' 80' ' ' PHE . 88.2 mt -122.74 131.56 73.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 120.856 -1.153 . . . . 0.0 110.437 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 23.4 mttt -109.9 119.22 38.65 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.734 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.2 t80 -122.99 110.69 15.68 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.511 -0.743 . . . . 0.0 109.482 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.0 m -113.21 118.17 33.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.88 . . . . 0.0 109.68 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.551 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 1.4 ttt85 -130.15 141.81 43.22 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.277 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.12 89.29 0.46 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.572 2.181 . . . . 0.0 112.001 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.03 -32.19 6.62 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.492 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 21.1 m-20 -95.11 175.74 6.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -1.188 . . . . 0.0 109.705 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 82' ' ' SER . 51.1 m -155.01 162.56 41.04 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.404 -0.81 . . . . 0.0 109.337 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.739 HD11 ' CD2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -71.52 133.92 46.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.274 179.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.917 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.45 3.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.24 -0.912 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -140.62 149.42 42.28 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 0.0 110.205 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' CG2' HD11 ' A' ' 41' ' ' LEU . 21.6 t -139.14 136.32 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.408 -0.808 . . . . 0.0 109.455 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -129.59 152.02 49.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.903 -1.123 . . . . 0.0 109.385 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.88 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.3 tt -121.75 141.39 51.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.301 -0.875 . . . . 0.0 109.928 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.878 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.5 ttp180 -124.23 129.61 51.08 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.311 -0.868 . . . . 0.0 109.022 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' HD23 ' A' ' 72' ' ' LEU . 37.1 mt-30 -70.69 150.42 45.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.357 -0.839 . . . . 0.0 109.878 -179.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.521 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 54.9 t60 -68.06 118.3 11.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.577 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.77 4.09 52.05 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.4 t -114.48 160.63 18.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.332 -1.099 . . . . 0.0 109.468 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 72.9 tt0 -124.56 15.23 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -0.924 . . . . 0.0 109.371 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 64.9 tt0 -118.11 81.4 1.67 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.445 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.563 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 40.8 m95 -43.28 138.86 2.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.34 -0.85 . . . . 0.0 109.778 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.28 136.68 20.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.48 -0.762 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.27 145.13 47.85 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.797 2.331 . . . . 0.0 111.898 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.839 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.3 mp -112.05 155.22 24.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.235 -0.916 . . . . 0.0 109.009 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.9 m -109.67 126.92 54.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.952 -1.092 . . . . 0.0 109.32 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 31.9 tttm -73.2 110.4 7.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.061 -1.024 . . . . 0.0 109.312 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.837 ' O ' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -119.31 142.83 47.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.904 -1.122 . . . . 0.0 110.126 -179.469 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.8 32.46 0.93 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 3.6 t-20 81.49 12.84 0.68 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.231 -1.158 . . . . 0.0 110.478 179.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.837 HG22 ' O ' ' A' ' 60' ' ' LYS . 16.6 m -129.47 176.71 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.029 -1.044 . . . . 0.0 108.872 179.386 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.719 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.3 m95 -116.5 138.09 51.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 0.0 109.56 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.614 ' HG2' HG13 ' A' ' 29' ' ' VAL . 38.3 mt-10 -124.29 139.69 53.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.343 -0.848 . . . . 0.0 109.418 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 46' ' ' LEU . 10.1 p -133.57 130.85 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.311 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -120.34 131.98 55.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.114 -0.991 . . . . 0.0 109.517 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t -118.52 145.99 44.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.502 -0.749 . . . . 0.0 109.421 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.4 m -72.3 -5.17 34.23 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.098 -1.001 . . . . 0.0 109.114 179.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.577 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.3 mtmt -130.18 177.82 2.01 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.368 -0.833 . . . . 0.0 109.11 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.5 Cg_endo -68.96 145.93 63.46 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.498 2.132 . . . . 0.0 111.765 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.99 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -83.63 138.69 33.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.797 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.0 t -123.4 124.9 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.385 -0.822 . . . . 0.0 109.484 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -94.03 169.64 29.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.51 147.52 81.73 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.903 -1.707 . . . . 0.0 112.019 -0.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.8 m-85 -91.19 151.38 20.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.556 -0.715 . . . . 0.0 110.561 -179.232 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.445 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 9.2 m-80 -112.59 143.5 43.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.342 -0.848 . . . . 0.0 108.778 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.88 ' CE2' HD12 ' A' ' 46' ' ' LEU . 49.7 m-85 -137.28 128.45 27.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.925 -1.109 . . . . 0.0 110.257 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.609 ' HG3' HG22 ' A' ' 89' ' ' VAL . 9.1 ttp180 -108.13 142.72 37.91 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.742 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -123.16 144.04 49.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.155 -0.965 . . . . 0.0 111.373 -178.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' O ' ' A' ' 86' ' ' MET . 10.0 ttm -127.94 126.12 40.85 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -79.8 144.17 33.78 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 110.323 -178.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.917 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 68.6 mttm -44.71 -43.56 8.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.27 -3.11 0.78 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.454 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.67 23.43 26.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 35.6 mtp -97.59 147.25 24.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.101 -1.235 . . . . 0.0 108.716 179.433 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.6 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 20.7 mtm180 -125.53 142.78 51.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.819 -1.176 . . . . 0.0 110.505 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.0 m120 -137.38 141.52 41.74 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.4 t -121.45 136.28 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.924 -1.11 . . . . 0.0 110.252 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.512 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 43.9 m-85 -124.94 122.55 37.67 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -98.42 147.28 24.88 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 18.3 mt-10 52.83 51.9 15.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.439 -0.788 . . . . 0.0 110.284 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.444 HG21 ' HB2' ' A' ' 90' ' ' PHE . 58.4 t -80.74 -33.32 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.804 -1.185 . . . . 0.0 109.159 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.474 HG12 ' HB3' ' A' ' 104' ' ' TYR . 65.2 mt -138.47 126.27 13.7 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.089 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.24 162.81 40.32 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.563 2.175 . . . . 0.0 111.981 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.488 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 54.4 m -53.6 -39.76 65.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.359 -0.838 . . . . 0.0 109.924 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -92.16 99.44 12.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.064 -1.022 . . . . 0.0 109.651 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -108.28 148.01 30.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.562 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.8 t -107.24 168.96 8.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.234 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.616 HD13 ' CG1' ' A' ' 19' ' ' VAL . 16.3 mm -104.29 136.18 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.182 -0.949 . . . . 0.0 109.237 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.84 3.45 59.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -117.67 142.76 46.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.109 -1.23 . . . . 0.0 109.172 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.1 m -78.58 175.23 10.56 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 108.914 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.611 ' H ' HG22 ' A' ' 103' ' ' THR . 25.0 m-85 -159.66 97.21 1.3 Allowed 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.703 -1.248 . . . . 0.0 108.972 179.267 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -97.84 159.31 31.22 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.423 -0.798 . . . . 0.0 109.787 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.512 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.778 2.319 . . . . 0.0 111.681 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.81 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 9.9 t . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -109.78 120.93 44.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.079 -1.013 . . . . 0.0 109.456 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.564 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -129.14 140.52 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.752 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 105' ' ' LYS . 34.7 p -141.44 145.24 35.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.215 -0.928 . . . . 0.0 109.549 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.596 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.2 m-85 -116.37 135.26 54.02 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.196 -0.94 . . . . 0.0 109.609 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.428 ' O ' ' N ' ' A' ' 31' ' ' ASP . 25.9 m -134.84 129.02 33.83 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 109.412 179.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 HD23 ' A' ' 30' ' ' LEU . 39.2 t -76.47 135.84 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 109.353 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -111.46 157.18 20.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.708 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 25.7 mtpt -50.86 113.91 1.03 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.822 . . . . 0.0 109.924 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.49 -3.92 1.92 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.58 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.476 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 40.8 m -60.68 140.28 57.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.896 -1.355 . . . . 0.0 109.258 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.562 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.24 177.09 2.4 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 109.57 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -71.22 -31.66 14.1 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.59 2.193 . . . . 0.0 111.814 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -117.14 5.11 12.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.033 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.473 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 47.0 mttp -141.37 132.98 27.06 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.041 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.56 132.18 51.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.069 -1.02 . . . . 0.0 110.084 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.533 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 4.7 t -121.43 124.68 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.041 HD11 HD22 ' A' ' 28' ' ' LEU . 0.8 OUTLIER -140.87 141.07 34.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.948 -1.095 . . . . 0.0 110.124 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.428 ' N ' ' O ' ' A' ' 18' ' ' THR . 63.6 t0 -85.9 136.34 33.33 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 178.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.672 HD13 ' HZ ' ' A' ' 80' ' ' PHE . 82.4 mt -121.71 131.12 73.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 120.932 -1.105 . . . . 0.0 110.236 -179.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 47.4 mttm -110.36 119.53 39.5 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.81 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 59.0 t80 -122.85 115.76 22.51 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.536 -0.727 . . . . 0.0 109.324 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.5 m -119.32 119.59 34.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.527 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 14.0 ttt85 -137.5 138.8 25.54 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.246 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.507 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.0 Cg_endo -69.74 103.05 1.1 Allowed 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.754 2.303 . . . . 0.0 112.06 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.75 2.86 86.42 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.527 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 26.2 m-20 -137.87 175.99 9.09 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -1.194 . . . . 0.0 109.693 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.9 m -156.25 163.84 39.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.466 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.74 HD21 HG21 ' A' ' 44' ' ' VAL . 23.4 tp -69.18 130.16 41.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.204 -0.935 . . . . 0.0 109.229 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.641 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -113.75 -45.69 3.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 110.148 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 77.9 mt-10 -137.34 147.18 45.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.102 -0.998 . . . . 0.0 110.264 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.74 HG21 HD21 ' A' ' 41' ' ' LEU . 94.2 t -139.35 136.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.531 -0.731 . . . . 0.0 109.334 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.531 ' O ' ' HA ' ' A' ' 78' ' ' PHE . 35.1 mt-10 -128.87 151.38 49.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.415 179.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.04 HD23 ' N ' ' A' ' 47' ' ' ARG . 7.0 tt -120.83 144.35 48.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.377 -0.827 . . . . 0.0 109.865 -179.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 1.04 ' N ' HD23 ' A' ' 46' ' ' LEU . 19.5 ttp180 -126.86 108.86 11.39 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 109.037 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.484 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 39.8 mt-30 -51.97 156.1 1.63 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.858 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB3' HG12 ' A' ' 73' ' ' VAL . 86.4 t60 -69.31 118.5 12.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.472 -0.768 . . . . 0.0 109.6 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.47 3.44 55.33 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -113.76 153.27 29.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -1.156 . . . . 0.0 109.467 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.48 ' HA ' ' HD2' ' A' ' 47' ' ' ARG . 85.3 tt0 -115.66 -3.47 12.29 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.273 -0.892 . . . . 0.0 109.393 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.0 tt0 -97.25 112.34 24.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -0.908 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.539 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 78.5 m95 -74.33 129.12 37.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.326 -0.859 . . . . 0.0 109.549 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -101.66 137.19 19.51 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.874 . . . . 0.0 109.364 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -71.4 144.85 46.55 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.694 2.262 . . . . 0.0 111.937 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.575 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.1 mp -107.89 148.24 29.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 108.949 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.418 HG21 ' NZ ' ' A' ' 60' ' ' LYS . 85.6 m -102.31 127.22 49.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.894 -1.129 . . . . 0.0 109.27 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.605 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 41.2 tttm -72.44 110.05 6.57 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.243 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.905 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.8 mmtt -118.43 140.66 49.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.907 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.85 31.74 0.84 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.583 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 9.4 m-20 82.66 13.67 0.46 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.239 -1.154 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.905 HG22 ' O ' ' A' ' 60' ' ' LYS . 21.0 m -128.43 173.36 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.014 -1.054 . . . . 0.0 108.761 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.605 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 62.3 m95 -120.2 124.98 47.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.98 -1.075 . . . . 0.0 109.657 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -114.15 150.2 34.51 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.45 -0.782 . . . . 0.0 109.491 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.575 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.4 p -137.23 134.04 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.492 -0.755 . . . . 0.0 109.248 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -120.32 131.58 54.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.167 -0.958 . . . . 0.0 109.444 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.484 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 20.2 t -117.85 157.72 26.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.416 -0.802 . . . . 0.0 109.52 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.7 t -83.94 5.83 24.06 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.256 -0.903 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -139.09 176.2 2.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.295 -0.878 . . . . 0.0 109.214 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.4 Cg_endo -70.17 126.15 12.73 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.499 2.132 . . . . 0.0 111.791 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.938 HD13 HD12 ' A' ' 28' ' ' LEU . 2.0 mt -60.63 136.93 58.21 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.243 -0.91 . . . . 0.0 109.787 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.594 HG12 ' HB3' ' A' ' 49' ' ' HIS . 95.7 t -124.23 125.44 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.444 -0.785 . . . . 0.0 109.461 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.9 168.74 27.73 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.6 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.73 146.87 81.02 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.83 -1.737 . . . . 0.0 112.011 0.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 90.9 m-85 -91.09 149.6 21.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.506 -0.746 . . . . 0.0 110.356 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 47' ' ' ARG . 3.4 m-80 -111.99 144.57 41.11 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.845 ' CE2' HD12 ' A' ' 46' ' ' LEU . 18.2 m-85 -135.84 126.06 26.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.925 -1.109 . . . . 0.0 110.127 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.986 ' HG3' HG22 ' A' ' 89' ' ' VAL . 18.8 ttt180 -105.81 141.34 37.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.133 -0.979 . . . . 0.0 108.662 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.734 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.9 m-85 -123.7 143.03 50.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.924 . . . . 0.0 111.402 -178.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.638 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.5 ttt -125.93 124.47 40.87 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.0 p -72.46 144.59 48.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.385 -0.822 . . . . 0.0 109.968 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.641 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 86.4 mttt -47.19 -44.74 22.49 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.402 -0.811 . . . . 0.0 108.975 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.8 -3.7 0.77 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.71 24.53 15.4 Favored Glycine 0 N--CA 1.491 2.307 0 O-C-N 120.988 -1.301 . . . . 0.0 110.257 179.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.638 ' O ' ' HA ' ' A' ' 81' ' ' MET . 15.4 mmm -96.72 148.31 23.02 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.114 -1.227 . . . . 0.0 108.633 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.582 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 72.8 mtp180 -124.12 140.03 53.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.885 -1.134 . . . . 0.0 110.416 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 28.2 m120 -136.42 141.25 43.59 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.986 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.3 t -122.15 136.14 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.183 -179.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.565 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 13.3 m-85 -123.77 122.6 38.48 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 63.9 t0 -98.66 145.1 27.22 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.6 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 64.5 tt0 54.76 52.54 11.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.481 -0.762 . . . . 0.0 110.377 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 ' CD1' ' A' ' 17' ' ' PHE . 88.8 t -81.14 -34.75 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.939 -1.101 . . . . 0.0 109.006 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 46.6 mt -135.42 129.4 18.63 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 121.353 -0.842 . . . . 0.0 108.95 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.88 159.52 50.25 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.483 2.122 . . . . 0.0 112.009 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.541 HG23 ' H ' ' A' ' 74' ' ' GLY . 31.9 m -50.17 -36.66 31.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.677 -179.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.63 101.66 11.81 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.071 -1.018 . . . . 0.0 109.518 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.5 ' CE1' HG11 ' A' ' 19' ' ' VAL . 50.9 p90 -109.49 150.84 27.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.159 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.79 168.83 8.88 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 ' CG1' ' A' ' 19' ' ' VAL . 17.8 mm -101.01 136.37 32.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.226 -0.921 . . . . 0.0 109.177 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 94.69 0.79 64.16 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 15.9 mttm -114.27 144.96 42.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.245 . . . . 0.0 109.157 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.683 HG22 ' H ' ' A' ' 104' ' ' TYR . 4.2 m -82.65 178.37 8.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.294 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.683 ' H ' HG22 ' A' ' 103' ' ' THR . 16.3 m-85 -161.81 92.65 0.87 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.863 -1.148 . . . . 0.0 108.859 179.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.488 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.2 OUTLIER -81.39 155.07 71.86 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.245 -0.909 . . . . 0.0 109.783 -179.415 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.565 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 50.0 Cg_endo . . . . . 0 C--O 1.216 -0.576 0 C-N-CA 122.741 2.294 . . . . 0.0 111.886 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.932 HG22 ' HG2' ' A' ' 36' ' ' ARG . 4.0 t . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.307 0.575 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.418 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 91.5 mt-30 -109.65 121.36 45.03 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.384 -0.823 . . . . 0.0 109.167 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.7 p -128.84 139.92 50.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.207 -0.933 . . . . 0.0 109.836 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.764 HG22 ' HD2' ' A' ' 105' ' ' LYS . 29.3 p -142.02 145.99 35.02 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.406 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.8 m-85 -118.31 147.48 43.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 31' ' ' ASP . 29.9 m -141.84 127.93 19.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.112 -0.993 . . . . 0.0 109.202 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.938 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.8 t -76.33 135.9 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.106 -0.996 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.418 ' O ' HD12 ' A' ' 100' ' ' ILE . 76.1 mm-40 -101.44 -174.83 2.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.107 -0.996 . . . . 0.0 109.531 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.4 mttt -81.6 67.42 7.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.369 -0.832 . . . . 0.0 109.983 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -174.96 22.97 0.06 OUTLIER Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.755 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.557 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 48.9 m -75.44 142.58 42.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.777 -1.425 . . . . 0.0 109.109 179.638 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.574 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.14 171.96 7.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 109.856 -179.552 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.574 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.92 -31.05 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.869 2.38 . . . . 0.0 111.984 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -115.57 6.8 14.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.235 -0.916 . . . . 0.0 108.984 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.525 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 2.5 ttpm? -142.96 133.91 25.57 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.76 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.56 124.27 43.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.934 -1.104 . . . . 0.0 109.398 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.563 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 10.7 t -120.06 124.81 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.938 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.23 145.88 31.48 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.027 -1.046 . . . . 0.0 110.147 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.714 ' HA ' HG12 ' A' ' 63' ' ' VAL . 59.2 t0 -83.86 134.92 34.67 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.777 HG21 ' CE2' ' A' ' 80' ' ' PHE . 82.5 mt -121.86 131.82 72.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 120.825 -1.172 . . . . 0.0 110.723 -178.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 24.7 mmtp -110.44 119.28 38.67 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.471 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 81.2 t80 -120.42 124.67 46.04 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.411 -0.806 . . . . 0.0 109.568 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 5.2 m -128.64 118.74 23.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.847 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.932 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -128.54 167.0 20.68 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.708 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.1 Cg_endo -70.55 79.06 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.716 2.277 . . . . 0.0 111.876 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.14 -9.63 69.0 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.531 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -96.84 179.0 5.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.175 . . . . 0.0 109.422 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.503 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 12.4 m -153.02 160.68 43.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.147 -0.971 . . . . 0.0 109.712 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.815 HD21 HG21 ' A' ' 44' ' ' VAL . 22.4 tp -69.97 130.18 41.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.471 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.795 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.44 -45.65 2.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.232 -0.918 . . . . 0.0 110.127 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.468 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 43.8 mt-10 -134.66 144.57 47.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.116 -0.99 . . . . 0.0 110.335 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.815 HG21 HD21 ' A' ' 41' ' ' LEU . 93.8 t -137.99 135.48 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.492 -0.755 . . . . 0.0 109.217 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.48 ' HA ' ' CD1' ' A' ' 57' ' ' LEU . 25.7 mt-10 -129.04 151.05 50.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.985 -1.072 . . . . 0.0 109.395 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.945 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.4 tt -119.4 132.61 55.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.447 -0.783 . . . . 0.0 109.913 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.945 ' N ' HD23 ' A' ' 46' ' ' LEU . 27.0 ttp180 -118.53 128.21 54.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.225 -0.922 . . . . 0.0 108.761 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -73.13 152.24 41.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 110.195 -179.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.527 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 55.1 t-80 -63.02 147.48 50.56 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.408 -0.808 . . . . 0.0 109.137 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.92 1.0 54.57 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.6 t -112.45 150.31 31.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -1.144 . . . . 0.0 109.316 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -116.59 8.46 13.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.924 . . . . 0.0 109.517 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 64.0 mm-40 -107.01 115.42 30.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.401 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 58.3 m95 -76.08 129.03 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.326 -0.859 . . . . 0.0 109.715 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -99.94 133.38 21.68 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.432 -0.793 . . . . 0.0 109.193 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 149.03 67.25 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.689 2.259 . . . . 0.0 111.803 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.673 HD11 ' HB2' ' A' ' 46' ' ' LEU . 6.1 mp -111.98 158.58 19.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.194 -0.941 . . . . 0.0 109.354 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.2 m -107.48 127.72 53.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.954 -1.091 . . . . 0.0 109.279 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 47.3 tttt -70.84 112.89 7.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -0.896 . . . . 0.0 109.242 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.451 ' HE3' ' HB3' ' A' ' 65' ' ' GLU . 40.2 mttt -113.64 125.66 54.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.953 -1.092 . . . . 0.0 109.595 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 44.68 -109.54 0.29 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -117.11 17.44 14.84 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.258 -1.142 . . . . 0.0 109.564 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 31' ' ' ASP . 10.9 m -131.93 -175.82 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.451 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -127.33 139.82 52.62 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 67' ' ' LYS . 19.1 tt0 -121.21 135.01 55.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.215 -0.928 . . . . 0.0 109.753 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.603 HG12 ' HB3' ' A' ' 28' ' ' LEU . 4.6 p -131.09 129.36 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.274 -0.891 . . . . 0.0 109.304 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG2' ' CD ' ' A' ' 27' ' ' LYS . 88.3 mttt -120.05 131.58 55.15 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.094 -1.004 . . . . 0.0 109.529 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.5 t -117.6 138.91 51.63 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.526 -0.734 . . . . 0.0 109.288 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 79.3 p -65.56 -11.3 42.72 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.154 -0.966 . . . . 0.0 109.232 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -121.12 176.34 1.95 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.68 164.57 32.66 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.602 2.201 . . . . 0.0 111.811 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.626 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.1 mt -100.59 141.56 33.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.258 -0.901 . . . . 0.0 109.849 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 50.2 t -127.86 125.2 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.547 -0.72 . . . . 0.0 109.319 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.671 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.76 164.74 26.64 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.614 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.9 Cg_endo -68.84 148.15 83.97 Favored 'Cis proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.984 0.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.4 m-85 -92.58 149.87 21.08 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.442 -0.786 . . . . 0.0 110.476 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.495 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 14.6 m-80 -110.51 143.33 41.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 108.769 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 46' ' ' LEU . 83.1 m-85 -134.69 126.84 29.87 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.014 -1.054 . . . . 0.0 109.737 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 89' ' ' VAL . 53.1 ttt180 -108.35 142.51 38.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.04 -1.038 . . . . 0.0 108.753 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.777 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.1 m-85 -124.6 143.42 50.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 111.551 -178.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.6 ttm -126.38 125.95 43.06 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 178.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.632 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.9 p -74.0 145.92 44.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 110.204 -178.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.795 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 78.7 mttt -48.37 -44.22 34.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.272 -0.893 . . . . 0.0 108.934 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.44 -3.69 0.68 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.53 25.05 16.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.632 ' O ' ' N ' ' A' ' 82' ' ' SER . 13.0 mmm -97.39 148.36 23.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.172 -1.193 . . . . 0.0 108.575 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 21.6 mtm180 -124.31 140.03 53.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.843 -1.16 . . . . 0.0 110.68 -178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . 34.7 m120 -135.42 140.08 44.65 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.1 t -122.03 136.9 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.037 -1.039 . . . . 0.0 110.409 -179.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.541 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 15.9 m-85 -125.52 122.98 38.13 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -99.57 147.84 24.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 95.8 mt-10 53.45 51.4 15.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.338 -0.851 . . . . 0.0 110.044 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.536 HG12 HG13 ' A' ' 94' ' ' ILE . 44.1 t -81.03 -33.98 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.821 -1.174 . . . . 0.0 109.26 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 93' ' ' VAL . 43.7 mt -138.13 125.75 13.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.139 -0.976 . . . . 0.0 109.057 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.12 161.78 44.43 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.533 2.155 . . . . 0.0 111.882 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.671 HG23 ' H ' ' A' ' 74' ' ' GLY . 2.6 m -57.08 -39.46 75.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.376 -0.827 . . . . 0.0 109.923 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.45 70.31 9.89 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.081 -1.012 . . . . 0.0 109.492 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -81.2 148.52 29.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.936 . . . . 0.0 109.656 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 43.3 m -109.82 168.8 9.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.317 -0.865 . . . . 0.0 109.186 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.521 HD13 ' CG1' ' A' ' 19' ' ' VAL . 35.6 mm -103.4 135.71 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.137 -0.977 . . . . 0.0 109.284 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 97.01 5.88 58.17 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.471 ' HD3' ' CZ ' ' A' ' 104' ' ' TYR . 43.7 tttp -119.73 143.17 47.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.25 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.652 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.7 m -79.88 176.51 9.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 109.018 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.652 ' H ' HG22 ' A' ' 103' ' ' THR . 32.5 m-85 -162.7 95.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.875 -1.141 . . . . 0.0 108.937 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.764 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.3 OUTLIER -103.0 166.33 12.05 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.873 . . . . 0.0 109.793 -179.405 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.631 0 C-N-CA 122.588 2.192 . . . . 0.0 111.727 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.954 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 3.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -111.47 121.64 45.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.896 . . . . 0.0 109.244 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.4 t -128.95 139.68 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.202 -0.936 . . . . 0.0 109.817 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.0 p -141.99 146.15 35.26 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.328 -0.857 . . . . 0.0 109.474 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.7 m-85 -118.38 123.65 45.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.425 ' O ' ' N ' ' A' ' 31' ' ' ASP . 34.8 m -120.05 128.37 53.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.03 -1.044 . . . . 0.0 109.063 179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' CD2' ' A' ' 30' ' ' LEU . 11.9 t -76.04 132.57 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 37.7 mm-40 -107.3 156.35 18.98 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.8 mttt -50.08 114.55 1.12 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.432 -0.793 . . . . 0.0 109.909 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.95 1.98 1.96 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 65.9 p -62.85 142.32 58.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.762 -1.434 . . . . 0.0 109.185 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.521 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.43 174.12 4.71 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.133 -0.98 . . . . 0.0 109.664 -179.626 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.9 Cg_endo -71.01 -29.86 17.31 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.683 2.255 . . . . 0.0 111.86 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -118.18 4.18 11.98 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.32 -0.862 . . . . 0.0 109.041 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.47 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 52.7 mttt -143.01 134.13 25.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.994 HD12 HD13 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -128.01 134.25 49.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.984 -1.073 . . . . 0.0 110.401 -179.332 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.6 t -121.95 123.73 69.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.966 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.68 144.51 31.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 109.914 -179.352 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 18' ' ' THR . 57.0 t0 -86.3 136.13 33.27 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.334 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.701 HG21 ' CE2' ' A' ' 80' ' ' PHE . 80.1 mt -120.68 131.63 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 120.881 -1.137 . . . . 0.0 110.324 -179.163 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 mttm -111.09 118.69 36.71 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.954 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.6 t80 -121.26 109.33 14.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.489 -0.757 . . . . 0.0 109.339 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.1 m -112.62 117.32 31.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.89 . . . . 0.0 109.89 -179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.625 ' HG3' HG22 ' A' ' 13' ' ' VAL . 37.8 ttt-85 -136.83 139.73 29.75 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.368 -0.833 . . . . 0.0 109.179 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.525 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.3 Cg_endo -69.75 109.35 2.29 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 112.069 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.05 4.44 88.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.561 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 4.9 m-20 -134.52 173.21 11.91 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -1.22 . . . . 0.0 109.772 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.9 m -155.53 162.61 40.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.341 -0.849 . . . . 0.0 109.502 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.701 HD21 ' CG2' ' A' ' 44' ' ' VAL . 10.7 tp -70.55 129.56 39.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.846 . . . . 0.0 109.501 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.741 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -115.83 -42.74 3.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.161 -0.962 . . . . 0.0 109.839 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -142.62 151.09 41.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.138 -0.976 . . . . 0.0 110.002 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.701 ' CG2' HD21 ' A' ' 41' ' ' LEU . 21.4 t -139.9 137.27 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.435 -0.791 . . . . 0.0 109.465 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 56' ' ' PRO . 61.4 mt-10 -127.78 150.55 49.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.873 -1.142 . . . . 0.0 109.215 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.776 HD12 ' O ' ' A' ' 77' ' ' ASN . 10.9 tp -120.87 133.0 55.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.333 -0.855 . . . . 0.0 110.243 -178.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.693 ' N ' HD12 ' A' ' 46' ' ' LEU . 47.8 ttp85 -113.53 127.98 56.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.099 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -71.91 152.35 42.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.512 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 37.6 t-80 -69.31 111.3 5.12 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.382 -0.824 . . . . 0.0 109.554 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.82 2.1 36.75 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.511 ' O ' ' NH1' ' A' ' 47' ' ' ARG . 33.5 t -113.47 154.37 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.195 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 37.9 mm-40 -113.22 16.14 19.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.333 -0.854 . . . . 0.0 109.394 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -113.88 114.19 25.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.528 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.594 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.6 m95 -80.13 120.09 23.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.267 -0.895 . . . . 0.0 109.655 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.445 ' O ' ' N ' ' A' ' 46' ' ' LEU . 11.6 mm-40 -95.95 129.99 32.63 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.445 -0.784 . . . . 0.0 109.344 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 48.2 Cg_endo -69.32 149.48 69.74 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.561 2.174 . . . . 0.0 111.879 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.618 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -101.6 149.52 24.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.149 -0.97 . . . . 0.0 108.576 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -102.46 126.54 49.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 108.941 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -70.41 109.47 4.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.168 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.877 ' O ' HG22 ' A' ' 63' ' ' VAL . 37.2 mttp -121.74 139.53 53.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.797 -1.189 . . . . 0.0 109.975 -179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.531 ' O ' ' HB2' ' A' ' 62' ' ' ASN . . . 38.39 48.25 2.21 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.531 ' HB2' ' O ' ' A' ' 61' ' ' GLY . 54.3 m-20 68.48 11.46 8.36 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.169 -1.195 . . . . 0.0 110.956 178.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.9 m -128.88 -178.61 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.858 -1.151 . . . . 0.0 108.997 179.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.506 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 71.1 m95 -122.8 141.27 52.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.082 . . . . 0.0 109.632 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 62.5 tt0 -128.42 142.22 51.17 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.815 . . . . 0.0 109.212 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.645 HG11 HD23 ' A' ' 46' ' ' LEU . 1.8 p -136.37 135.18 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.24 -0.913 . . . . 0.0 109.145 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.433 ' HD2' ' HE2' ' A' ' 27' ' ' LYS . 6.1 ttpm? -122.54 133.73 54.56 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.851 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.8 t -117.86 148.13 42.41 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.456 -0.778 . . . . 0.0 109.153 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 85.5 p -72.77 -4.43 31.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.988 . . . . 0.0 109.354 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -131.5 176.19 3.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.243 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.44 140.52 48.25 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.482 2.121 . . . . 0.0 111.714 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.994 HD13 HD12 ' A' ' 28' ' ' LEU . 10.5 mt -74.76 137.89 42.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.826 -179.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.9 t -123.37 125.12 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.469 -0.769 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.665 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.3 165.47 27.67 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 50.5 Cg_endo -70.01 145.66 80.6 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.806 -1.747 . . . . 0.0 111.883 0.03 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.667 ' HB3' HD11 ' A' ' 46' ' ' LEU . 76.8 m-85 -91.46 151.18 20.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.523 -0.736 . . . . 0.0 110.367 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.776 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.4 m-80 -110.77 142.43 42.75 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.767 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.0 m-85 -133.24 127.3 33.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.913 -1.117 . . . . 0.0 109.971 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.686 ' HG3' HG22 ' A' ' 89' ' ' VAL . 41.4 ttt180 -110.62 143.12 41.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.006 -1.059 . . . . 0.0 108.627 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.701 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.0 m-85 -124.86 143.81 50.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.218 -0.926 . . . . 0.0 111.632 -177.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 1.2 ttt -125.85 124.4 40.82 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.537 ' CB ' ' HB2' ' A' ' 86' ' ' MET . 24.2 p -77.39 147.7 35.92 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.206 -0.934 . . . . 0.0 110.043 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.741 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 32.9 mttt -46.65 -46.0 19.6 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.32 -8.19 8.65 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.41 34.53 5.28 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.537 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 44.3 mmm -103.24 110.61 22.64 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.987 -1.302 . . . . 0.0 109.011 179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 61.0 mtt180 -91.71 139.49 30.63 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.199 -0.938 . . . . 0.0 110.472 -179.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.4 m120 -137.25 141.69 42.02 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.686 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.2 t -122.06 136.5 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.865 -1.147 . . . . 0.0 110.471 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.567 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 55.0 m-85 -124.44 122.36 37.42 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -97.13 145.27 26.17 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.18 -0.95 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 12.8 mt-10 53.96 54.26 9.99 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.491 -0.756 . . . . 0.0 110.335 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.779 HG11 ' CE1' ' A' ' 17' ' ' PHE . 75.8 t -82.26 -34.18 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 109.074 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.464 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.7 mt -135.44 124.4 16.0 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.201 -0.937 . . . . 0.0 109.132 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.42 162.13 43.12 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.608 2.205 . . . . 0.0 111.968 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.665 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.3 m -53.3 -44.7 68.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 109.976 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.84 99.72 12.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.046 -1.034 . . . . 0.0 109.502 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -109.45 147.83 32.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.94 . . . . 0.0 109.715 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.8 m -106.09 171.15 7.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.212 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.552 HD13 ' CG1' ' A' ' 19' ' ' VAL . 27.2 mm -106.73 137.83 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.42 9.62 61.49 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 4.6 tptp -120.57 144.18 48.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.495 HG22 ' H ' ' A' ' 104' ' ' TYR . 8.6 m -77.81 170.97 15.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.038 -1.039 . . . . 0.0 108.706 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.593 ' N ' ' O ' ' A' ' 17' ' ' PHE . 24.0 m-85 -157.62 97.94 1.63 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.607 -1.308 . . . . 0.0 109.151 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.529 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -104.93 161.53 22.49 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.277 -0.889 . . . . 0.0 109.767 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.2 Cg_endo . . . . . 0 C--O 1.215 -0.639 0 C-N-CA 122.718 2.279 . . . . 0.0 111.663 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.989 HG22 ' HG3' ' A' ' 36' ' ' ARG . 30.3 t . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.47 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 77.9 mm-40 -106.01 120.24 41.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.027 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.601 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.1 p -128.92 139.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.232 -0.917 . . . . 0.0 110.049 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 73.1 p -141.25 145.42 35.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.334 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.646 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.8 m-85 -118.24 136.22 53.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.176 -0.953 . . . . 0.0 109.717 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 88.5 m -131.34 127.77 38.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.903 -1.123 . . . . 0.0 109.302 179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.898 HG22 ' CD2' ' A' ' 30' ' ' LEU . 30.6 t -75.02 134.01 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.216 -0.928 . . . . 0.0 109.173 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.468 ' OE1' ' O ' ' A' ' 19' ' ' VAL . 4.9 mm100 -106.57 156.34 18.69 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.174 -0.954 . . . . 0.0 109.975 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.5 mttt -51.34 115.87 1.79 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.51 -0.743 . . . . 0.0 109.947 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 137.26 -1.52 3.05 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.447 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 p -60.29 144.15 51.14 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.911 -1.347 . . . . 0.0 109.403 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.19 169.79 12.62 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.288 -0.882 . . . . 0.0 109.71 -179.779 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.4 Cg_endo -70.73 -29.34 19.39 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.806 2.337 . . . . 0.0 111.88 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -113.02 7.09 17.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.165 -0.959 . . . . 0.0 108.819 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -142.74 133.55 25.45 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.72 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.35 122.84 40.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.965 -1.085 . . . . 0.0 109.337 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.549 HG13 ' HG2' ' A' ' 65' ' ' GLU . 51.4 t -118.72 124.35 73.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.898 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -144.33 144.76 31.61 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.977 -1.077 . . . . 0.0 110.253 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.635 ' OD1' HG12 ' A' ' 63' ' ' VAL . 20.9 t70 -85.39 137.04 33.2 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 177.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.897 HG21 ' CE2' ' A' ' 80' ' ' PHE . 75.7 mt -120.71 130.98 73.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 C-N-CA 118.667 -1.213 . . . . 0.0 110.786 -179.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.601 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 22.1 tttm -110.61 120.38 42.23 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.094 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.51 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 78.6 t80 -120.15 112.77 19.52 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.343 -0.848 . . . . 0.0 109.567 -178.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 31.2 m -115.71 115.79 26.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -0.851 . . . . 0.0 109.677 -179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.989 ' HG3' HG22 ' A' ' 13' ' ' VAL . 28.0 ttt85 -138.68 136.29 18.62 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.526 -0.734 . . . . 0.0 109.208 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.484 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -69.88 112.57 3.13 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.1 0.69 83.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.563 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.2 m-20 -133.92 172.26 13.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.966 -1.314 . . . . 0.0 109.87 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 82' ' ' SER . 13.6 m -153.98 161.61 41.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.408 -0.807 . . . . 0.0 109.341 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.864 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.7 OUTLIER -72.28 131.27 42.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.279 -0.888 . . . . 0.0 109.845 -179.588 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.936 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.93 -40.24 3.54 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.619 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.45 150.41 40.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.124 -0.985 . . . . 0.0 110.187 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.679 ' CG2' HD11 ' A' ' 41' ' ' LEU . 5.9 t -139.21 136.88 41.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.581 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -129.63 150.81 50.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.935 -1.103 . . . . 0.0 109.394 179.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.0 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -118.72 140.61 49.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.892 . . . . 0.0 109.715 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 1.0 ' N ' HD23 ' A' ' 46' ' ' LEU . 28.3 ttp180 -126.74 129.54 48.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.293 -0.879 . . . . 0.0 109.072 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.588 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 47.8 mt-30 -72.6 144.8 47.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.343 -0.848 . . . . 0.0 109.863 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.537 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 2.0 t-160 -61.36 115.81 4.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.35 -0.844 . . . . 0.0 109.442 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.42 2.75 35.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.417 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 25.6 t -113.7 155.71 25.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -1.188 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.495 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 69.7 tt0 -116.05 1.03 13.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.583 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -108.83 92.48 4.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.602 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.0 m95 -51.55 138.64 22.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.356 -0.84 . . . . 0.0 109.599 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -105.05 135.19 19.33 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.375 -0.828 . . . . 0.0 109.32 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.83 145.51 51.11 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.617 2.211 . . . . 0.0 111.891 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.869 HD11 ' HB2' ' A' ' 46' ' ' LEU . 5.4 mp -107.17 146.14 31.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.032 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.2 m -94.41 126.92 39.97 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.956 -1.09 . . . . 0.0 109.176 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -70.6 111.18 5.91 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.408 -0.808 . . . . 0.0 109.033 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -111.77 113.04 25.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.982 -1.074 . . . . 0.0 109.571 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.15 -103.72 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -123.76 17.36 9.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -1.146 . . . . 0.0 109.398 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.635 HG12 ' OD1' ' A' ' 31' ' ' ASP . 17.8 m -130.82 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.328 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 60.9 m95 -134.1 142.06 47.38 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.155 -0.966 . . . . 0.0 109.466 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG2' HG13 ' A' ' 29' ' ' VAL . 30.2 mt-10 -122.48 134.79 54.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.214 -0.929 . . . . 0.0 109.766 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.855 HG11 HD13 ' A' ' 46' ' ' LEU . 4.8 p -130.83 130.35 64.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -0.903 . . . . 0.0 109.217 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.7 tttm -122.17 133.85 54.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.064 -1.023 . . . . 0.0 109.75 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.588 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.3 t -117.63 154.77 31.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.437 -0.789 . . . . 0.0 109.239 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 20.4 m -80.15 -4.36 52.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.288 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.546 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.1 mttm -128.33 176.05 3.03 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.5 Cg_endo -69.52 124.19 10.94 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.508 2.138 . . . . 0.0 111.735 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.598 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.3 mt -58.53 139.67 55.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.354 -0.842 . . . . 0.0 109.79 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 46.4 t -125.14 124.68 67.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.378 -0.826 . . . . 0.0 109.543 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -95.3 166.78 25.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 45.4 Cg_endo -66.61 146.53 73.86 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 123.043 -1.649 . . . . 0.0 112.087 0.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 75.5 m-85 -90.72 150.53 21.6 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.607 -0.683 . . . . 0.0 110.405 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.41 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 10.0 m-80 -111.91 143.16 43.33 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.805 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.3 m-85 -134.77 122.16 21.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.01 -1.056 . . . . 0.0 109.704 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.571 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.9 ttp180 -103.3 141.91 35.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.96 -1.087 . . . . 0.0 108.609 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.897 ' CE2' HG21 ' A' ' 32' ' ' ILE . 31.7 m-85 -125.51 143.91 50.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.187 -0.946 . . . . 0.0 111.595 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.588 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.8 ttm -126.65 126.82 44.19 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.3 p -77.52 145.62 36.85 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.203 -0.936 . . . . 0.0 110.412 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.936 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.6 mttt -48.7 -44.56 38.15 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.61 -6.24 6.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.26 34.34 5.9 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.537 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 15.8 mmm -106.07 108.78 20.47 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.075 -1.25 . . . . 0.0 109.001 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.588 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 82.5 mtm180 -85.86 134.98 33.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.199 -0.938 . . . . 0.0 110.634 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.446 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -134.3 139.49 45.74 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.571 HG22 ' HG3' ' A' ' 79' ' ' ARG . 37.2 t -122.84 136.82 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.036 -1.04 . . . . 0.0 110.587 -178.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.532 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 61.2 m-85 -124.16 122.09 36.88 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 21.0 p-10 -100.11 148.96 24.01 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.346 -0.846 . . . . 0.0 109.744 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 40.1 tt0 52.98 51.19 16.33 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.323 -0.86 . . . . 0.0 110.002 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 94' ' ' ILE . 61.6 t -81.76 -33.87 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.924 -1.11 . . . . 0.0 109.116 179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.5 HG13 HG12 ' A' ' 93' ' ' VAL . 67.1 mt -138.83 127.67 14.09 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.312 -0.868 . . . . 0.0 109.074 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.45 161.37 46.14 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.611 2.208 . . . . 0.0 111.982 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.52 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 87.4 m -51.2 -45.44 61.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.394 -0.816 . . . . 0.0 109.916 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -93.07 104.01 16.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.113 -0.992 . . . . 0.0 109.688 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -111.09 151.57 27.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.359 -0.838 . . . . 0.0 109.33 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.0 m -102.64 170.18 8.18 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 30.6 mm -103.23 136.06 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.182 -0.948 . . . . 0.0 109.306 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.8 57.7 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -121.28 143.39 49.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.974 -1.309 . . . . 0.0 109.306 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.667 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -79.15 177.2 9.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.076 -1.015 . . . . 0.0 108.919 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.667 ' H ' HG22 ' A' ' 103' ' ' THR . 27.5 m-85 -162.23 96.27 0.97 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.769 -1.207 . . . . 0.0 109.107 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.521 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -102.51 164.54 15.45 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.362 -0.836 . . . . 0.0 109.724 -179.584 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.532 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.5 Cg_endo . . . . . 0 C--O 1.213 -0.727 0 C-N-CA 122.675 2.25 . . . . 0.0 111.887 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 36' ' ' ARG . 60.7 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.498 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 94.7 mt-30 -112.96 121.78 45.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.274 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.639 HG11 ' CE2' ' A' ' 90' ' ' PHE . 12.5 p -128.79 139.99 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.258 -0.902 . . . . 0.0 109.668 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.469 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 17.0 p -141.6 145.72 35.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.155 -0.965 . . . . 0.0 109.515 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.576 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.7 m-85 -117.49 150.44 38.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.234 -0.916 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.973 HG23 ' O ' ' A' ' 102' ' ' LYS . 92.2 m -144.81 127.7 16.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.069 -1.02 . . . . 0.0 109.378 179.097 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.813 HG22 ' CD2' ' A' ' 30' ' ' LEU . 4.5 t -76.29 129.1 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.885 . . . . 0.0 109.377 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.49 ' O ' HD12 ' A' ' 100' ' ' ILE . 91.2 mm-40 -92.97 -175.25 3.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.609 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -81.94 62.16 5.59 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.962 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -169.05 24.49 0.1 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.71 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.537 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 26.2 m -79.95 143.64 34.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.778 -1.425 . . . . 0.0 109.252 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.632 ' O ' HD12 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -137.71 174.19 4.6 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.101 -0.999 . . . . 0.0 109.605 -179.726 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.546 ' O ' ' N ' ' A' ' 72' ' ' LEU . 48.7 Cg_endo -70.76 -30.39 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.67 2.247 . . . . 0.0 112.045 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 88.8 mttt -115.17 5.7 14.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.067 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.42 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 81.8 mttt -142.18 133.38 26.21 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.31 40.95 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.042 -1.036 . . . . 0.0 109.466 -179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 65' ' ' GLU . 21.9 t -118.74 124.62 73.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.813 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.0 OUTLIER -144.65 145.76 31.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.978 -1.076 . . . . 0.0 110.169 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -85.63 137.36 32.9 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.787 HG21 ' CE2' ' A' ' 80' ' ' PHE . 77.0 mt -120.78 130.13 74.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.755 -1.215 . . . . 0.0 110.688 -178.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.55 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.5 tttm -109.66 119.95 40.98 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 72.3 t80 -122.0 124.27 43.6 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.334 -0.853 . . . . 0.0 109.716 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 16.2 m -126.74 116.93 21.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.301 -0.874 . . . . 0.0 109.737 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.606 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.5 OUTLIER -151.27 116.66 3.19 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.416 -0.803 . . . . 0.0 109.139 179.804 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.95 126.21 13.56 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.73 2.286 . . . . 0.0 111.95 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.54 -19.48 54.5 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 1.5 m-20 -142.95 -176.35 4.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.209 -1.171 . . . . 0.0 109.814 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' LYS . 5.9 m -156.17 163.31 39.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.36 -0.838 . . . . 0.0 109.367 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.672 HD11 HG22 ' A' ' 44' ' ' VAL . 29.4 tp -70.52 129.02 38.12 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.342 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.893 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.65 -42.35 2.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.418 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 86.6 mt-10 -139.59 147.89 41.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.176 -0.953 . . . . 0.0 110.218 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.672 HG22 HD11 ' A' ' 41' ' ' LEU . 8.9 t -138.6 136.99 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 108.965 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.406 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 72.5 mt-10 -128.15 149.22 50.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.821 -1.174 . . . . 0.0 109.56 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.099 HD23 HG11 ' A' ' 66' ' ' VAL . 11.2 tp -120.18 131.64 55.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.418 -0.801 . . . . 0.0 109.96 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.65 ' N ' HD12 ' A' ' 46' ' ' LEU . 7.5 ttp180 -119.82 131.94 55.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.076 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.487 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 43.2 mt-30 -72.27 149.95 44.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.738 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 10.2 t60 -68.54 113.94 6.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.746 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.48 2.42 27.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.45 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 28.1 t -115.01 154.92 27.93 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -1.172 . . . . 0.0 109.406 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -111.22 15.59 21.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.291 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -121.97 121.43 37.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.541 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.506 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 43.1 m95 -83.34 132.94 34.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.431 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.0 OUTLIER -100.76 135.11 20.14 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.335 -0.853 . . . . 0.0 109.422 179.975 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.431 ' HD2' ' HG3' ' A' ' 55' ' ' GLU . 52.3 Cg_endo -71.11 149.49 58.39 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.606 2.204 . . . . 0.0 111.96 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.623 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.6 mp -108.4 138.46 44.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.213 -0.929 . . . . 0.0 109.07 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.3 m -90.17 127.48 36.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.99 -1.069 . . . . 0.0 109.014 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 22.7 tttt -74.48 105.68 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.265 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -108.3 110.63 22.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.006 -1.059 . . . . 0.0 109.551 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.11 -107.73 1.93 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 35.0 p-10 -121.99 16.24 10.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -1.128 . . . . 0.0 109.345 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.2 m -132.08 170.09 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.947 . . . . 0.0 109.424 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.445 ' CD1' HD12 ' A' ' 32' ' ' ILE . 55.9 m95 -116.11 142.82 46.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.169 -0.957 . . . . 0.0 109.216 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 29' ' ' VAL . 75.7 tt0 -123.67 136.57 54.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 109.921 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 1.099 HG11 HD23 ' A' ' 46' ' ' LEU . 11.9 p -131.07 130.25 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.361 -0.837 . . . . 0.0 109.118 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.424 ' HE2' ' OE2' ' A' ' 65' ' ' GLU . 25.1 mttt -120.75 132.34 55.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.148 -0.97 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.487 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.4 t -118.56 145.55 45.27 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.447 -0.783 . . . . 0.0 109.217 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.3 m -66.55 -11.28 52.19 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.092 -1.005 . . . . 0.0 109.165 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.55 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -123.28 176.55 2.1 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.387 -0.821 . . . . 0.0 109.278 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.4 Cg_endo -69.74 157.62 59.8 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.454 2.102 . . . . 0.0 111.63 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.632 HD12 ' O ' ' A' ' 24' ' ' ASP . 5.3 mt -87.58 138.65 31.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.798 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 73.5 t -124.85 125.26 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.416 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.542 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.3 164.96 26.08 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.93 146.48 80.48 Favored 'Cis proline' 0 C--O 1.214 -0.704 0 C-N-CA 122.761 -1.766 . . . . 0.0 111.8 0.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.615 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.1 m-85 -91.02 152.4 20.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.515 -0.741 . . . . 0.0 110.544 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.773 ' O ' HD12 ' A' ' 46' ' ' LEU . 37.8 m-80 -112.68 141.67 46.2 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.856 ' CE1' HD13 ' A' ' 46' ' ' LEU . 86.9 m-85 -134.77 122.18 21.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.102 -0.999 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.987 ' HG3' HG22 ' A' ' 89' ' ' VAL . 70.6 ttt180 -104.2 143.32 33.1 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.997 -1.064 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.787 ' CE2' HG21 ' A' ' 32' ' ' ILE . 11.0 m-85 -125.29 143.15 51.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.196 -0.94 . . . . 0.0 111.402 -178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.559 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.5 ttt -125.23 125.03 42.96 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.594 ' N ' ' O ' ' A' ' 86' ' ' MET . 14.8 p -73.7 147.12 43.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 110.267 -178.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.893 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 42.1 mttp -50.03 -44.78 51.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.468 -0.77 . . . . 0.0 109.134 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.65 -4.31 0.61 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.86 27.06 11.64 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.594 ' O ' ' N ' ' A' ' 82' ' ' SER . 46.4 mtp -99.89 149.07 23.79 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -1.184 . . . . 0.0 108.627 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.559 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 17.8 mtt180 -121.87 136.92 54.95 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.871 -1.143 . . . . 0.0 110.457 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -134.1 139.79 46.17 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.987 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.4 t -123.2 136.97 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 120.952 -1.093 . . . . 0.0 110.315 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.639 ' CE2' HG11 ' A' ' 15' ' ' VAL . 18.2 m-85 -123.62 121.65 36.11 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -98.96 147.35 25.08 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.262 -0.899 . . . . 0.0 109.803 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 63.1 tt0 53.88 51.41 14.87 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.5 -0.75 . . . . 0.0 110.338 179.512 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.563 HG12 HG13 ' A' ' 94' ' ' ILE . 42.0 t -81.13 -34.37 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.889 -1.132 . . . . 0.0 108.905 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.563 HG13 HG12 ' A' ' 93' ' ' VAL . 40.9 mt -136.45 125.32 15.42 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.326 -0.859 . . . . 0.0 109.121 179.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.85 162.71 41.09 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.565 2.177 . . . . 0.0 112.024 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.542 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 32.2 m -49.96 -38.39 36.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.373 -0.829 . . . . 0.0 110.007 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.49 102.8 13.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.006 -1.059 . . . . 0.0 109.72 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CE1' HG11 ' A' ' 19' ' ' VAL . 42.8 p90 -110.33 154.13 23.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.905 . . . . 0.0 109.163 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.9 t -104.32 167.51 9.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 20' ' ' GLN . 28.6 mm -103.41 138.9 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -0.864 . . . . 0.0 109.29 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 90.35 16.0 56.2 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.973 ' O ' HG23 ' A' ' 18' ' ' THR . 18.9 mttm -119.21 -165.97 1.21 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 109.071 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.6 m -131.61 163.41 28.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.977 -1.077 . . . . 0.0 108.665 179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.576 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.8 m-85 -151.6 94.03 1.95 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.44 -1.412 . . . . 0.0 109.147 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.54 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -99.66 162.13 22.2 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.584 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.548 ' CD ' HG13 ' A' ' 15' ' ' VAL . 49.3 Cg_endo . . . . . 0 C--O 1.217 -0.555 0 C-N-CA 122.554 2.169 . . . . 0.0 111.83 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 36' ' ' ARG . 47.5 t . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -111.93 121.4 44.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.611 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -128.3 138.44 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.878 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.41 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 36.7 p -141.44 145.5 35.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.346 -0.846 . . . . 0.0 109.146 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.587 ' CD2' HG12 ' A' ' 32' ' ' ILE . 13.6 m-85 -119.06 142.68 47.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.927 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.7 m -137.85 127.79 25.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.247 -0.908 . . . . 0.0 109.189 179.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.876 HG22 ' CD2' ' A' ' 30' ' ' LEU . 27.9 t -75.74 136.09 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.289 -0.882 . . . . 0.0 109.173 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -114.14 156.24 24.57 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.083 -1.011 . . . . 0.0 109.926 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.6 mttt -48.35 111.98 0.53 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.15 -6.39 1.53 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.283 -1.437 . . . . 0.0 110.784 179.251 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.452 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 3.3 m -61.41 140.26 58.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.842 -1.387 . . . . 0.0 109.192 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.57 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.95 177.47 2.2 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.207 -0.933 . . . . 0.0 109.53 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.57 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.3 Cg_endo -70.88 -31.34 15.69 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.614 2.209 . . . . 0.0 111.903 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -117.93 5.26 12.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 108.931 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.472 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 44.3 mttt -142.35 133.8 26.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.039 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.25 133.71 50.17 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 120.988 -1.07 . . . . 0.0 110.222 -179.511 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.972 HG13 ' HG2' ' A' ' 65' ' ' GLU . 21.2 t -122.4 124.64 71.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.039 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -142.22 142.22 32.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.057 -1.027 . . . . 0.0 110.047 -179.372 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -86.15 136.62 33.13 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.849 HG21 ' CE2' ' A' ' 80' ' ' PHE . 87.8 mt -121.3 131.02 74.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.339 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 60.3 tttt -109.99 118.38 36.28 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.611 ' CD1' HG22 ' A' ' 15' ' ' VAL . 77.2 t80 -122.26 111.16 16.59 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.54 -0.725 . . . . 0.0 109.341 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 47.5 m -115.08 120.33 39.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.215 -0.928 . . . . 0.0 109.804 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 34' ' ' TYR . 2.9 mtt-85 -123.21 163.34 34.45 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.609 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -72.57 50.65 1.7 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.73 2.287 . . . . 0.0 111.864 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.94 -12.89 13.01 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.433 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.5 OUTLIER -96.83 178.78 5.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -1.169 . . . . 0.0 109.308 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.8 p -150.95 159.25 44.68 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.204 -0.935 . . . . 0.0 109.708 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.955 HD23 ' N ' ' A' ' 42' ' ' ALA . 2.2 tt -71.81 134.27 46.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.955 ' N ' HD23 ' A' ' 41' ' ' LEU . . . -114.74 -42.35 3.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.178 -0.952 . . . . 0.0 109.848 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -144.02 152.4 40.97 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.065 -1.022 . . . . 0.0 110.431 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.498 HG13 ' CE1' ' A' ' 80' ' ' PHE . 3.5 t -140.39 138.07 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.441 -0.787 . . . . 0.0 109.345 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.424 ' OE2' ' HB3' ' A' ' 56' ' ' PRO . 5.7 mm-40 -127.08 150.91 49.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 109.352 179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.724 HD23 HG11 ' A' ' 66' ' ' VAL . 5.9 tp -122.99 123.82 41.76 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.321 -0.862 . . . . 0.0 110.56 -178.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.709 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.6 OUTLIER -106.25 129.41 54.29 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.935 . . . . 0.0 109.006 178.838 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.59 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 27.7 mt-30 -71.64 151.17 43.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.291 -0.881 . . . . 0.0 109.306 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.608 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 30.0 t60 -67.49 110.33 3.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.188 -0.945 . . . . 0.0 109.44 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.28 1.03 38.17 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 27.2 t -112.77 153.11 28.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.246 . . . . 0.0 109.397 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 61.8 tt0 -116.22 14.23 15.82 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.25 -0.906 . . . . 0.0 109.34 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -112.45 86.9 2.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.282 -0.886 . . . . 0.0 109.465 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.628 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 22.5 m95 -53.84 138.72 35.36 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.424 -0.798 . . . . 0.0 109.841 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.07 131.61 23.44 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.454 -0.779 . . . . 0.0 108.911 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.424 ' HB3' ' OE2' ' A' ' 45' ' ' GLU . 49.1 Cg_endo -69.91 150.09 66.84 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.56 2.173 . . . . 0.0 112.027 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.712 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -100.92 148.43 25.0 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.469 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 69.7 m -98.12 126.69 43.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.742 -1.224 . . . . 0.0 109.051 179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -71.38 107.58 4.4 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.26 -0.9 . . . . 0.0 109.204 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.426 ' HD3' ' HA ' ' A' ' 60' ' ' LYS . 6.6 mmtp -111.75 106.79 15.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.969 -1.082 . . . . 0.0 109.581 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.35 -95.46 0.21 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -134.18 17.19 3.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -1.144 . . . . 0.0 109.453 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.01 169.85 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.305 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.459 ' HE3' ' CB ' ' A' ' 57' ' ' LEU . 70.3 m95 -116.41 131.04 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.177 -0.952 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.972 ' HG2' HG13 ' A' ' 29' ' ' VAL . 91.1 mt-10 -117.89 144.69 45.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.596 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.724 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -141.34 138.47 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -122.44 132.42 54.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 0.0 110.0 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.59 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 48.4 t -118.88 116.55 26.73 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.467 -0.771 . . . . 0.0 109.479 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 68' ' ' SER . 50.0 m -43.37 -37.71 2.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.143 -0.973 . . . . 0.0 109.085 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.618 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 5.2 ptpp? -94.72 168.44 11.28 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.159 179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.618 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.6 146.68 80.17 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.443 2.095 . . . . 0.0 111.743 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.006 HD13 HD12 ' A' ' 28' ' ' LEU . 1.6 mt -80.06 139.66 36.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.307 -0.871 . . . . 0.0 109.913 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.1 t -124.4 125.06 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.467 -0.771 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.495 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.45 166.41 26.72 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HG2' ' CE1' ' A' ' 49' ' ' HIS . 47.9 Cg_endo -68.65 145.13 76.04 Favored 'Cis proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.846 -1.731 . . . . 0.0 112.045 0.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.1 m-85 -91.19 153.1 20.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.588 -0.695 . . . . 0.0 110.49 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.477 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.7 m-80 -111.72 140.91 45.97 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.6 m-85 -131.65 135.76 47.18 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.886 -1.134 . . . . 0.0 109.772 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.442 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 53.3 ttt-85 -119.97 142.86 48.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.192 -0.943 . . . . 0.0 108.609 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.849 ' CE2' HG21 ' A' ' 32' ' ' ILE . 15.3 m-85 -124.77 144.18 50.39 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.183 -0.948 . . . . 0.0 111.721 -177.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.654 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.4 ttt -126.65 124.16 39.22 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 178.315 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.53 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 20.8 p -77.76 141.87 39.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.325 -0.859 . . . . 0.0 109.867 -178.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.804 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 19.9 mttm -44.3 -44.02 7.81 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.21 -4.31 8.09 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.03 30.63 7.76 Favored Glycine 0 N--CA 1.491 2.319 0 O-C-N 121.256 -1.144 . . . . 0.0 110.33 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.53 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 37.0 mmm -103.45 107.85 18.86 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.02 -1.282 . . . . 0.0 108.854 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 35.7 mtm-85 -92.29 142.21 27.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 110.923 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -137.25 141.33 42.01 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 t -121.33 136.8 57.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.998 -1.064 . . . . 0.0 110.202 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 82.2 m-85 -125.05 121.65 34.97 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 55.1 t0 -97.51 147.96 23.73 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.097 -1.002 . . . . 0.0 109.662 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 35.8 mt-10 51.77 54.52 10.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.449 -0.782 . . . . 0.0 109.947 179.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' A' ' 106' ' ' PRO . 75.1 t -83.63 -32.89 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.954 -1.091 . . . . 0.0 109.261 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.45 HG12 ' HB3' ' A' ' 104' ' ' TYR . 34.8 mt -138.55 126.49 13.73 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.33 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.19 163.82 37.21 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.553 2.169 . . . . 0.0 111.8 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.495 HG23 ' H ' ' A' ' 74' ' ' GLY . 5.7 m -54.38 -37.31 64.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.309 -0.87 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.49 96.2 10.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.008 . . . . 0.0 109.836 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -104.95 143.94 32.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.488 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 88.0 p -116.66 124.07 48.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.211 -0.931 . . . . 0.0 109.665 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.567 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 5.9 mt -64.04 138.65 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.528 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.45 -4.19 50.88 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 37.8 tttp -118.19 142.86 47.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.108 -1.23 . . . . 0.0 109.264 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.562 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.3 m -76.81 173.61 11.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.033 -1.042 . . . . 0.0 108.476 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.568 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.0 m-85 -158.13 96.45 1.45 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 120.64 -1.288 . . . . 0.0 109.004 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.57 158.61 33.42 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.322 -0.861 . . . . 0.0 109.833 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HB3' HG22 ' A' ' 93' ' ' VAL . 49.5 Cg_endo . . . . . 0 C--O 1.216 -0.586 0 C-N-CA 122.734 2.289 . . . . 0.0 111.663 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 36' ' ' ARG . 3.0 t . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -111.49 120.88 43.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.145 -0.972 . . . . 0.0 109.189 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.58 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.0 t -127.77 137.06 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.89 . . . . 0.0 109.874 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.495 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 18.1 p -143.75 147.27 33.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.409 -0.807 . . . . 0.0 109.259 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.626 ' O ' ' N ' ' A' ' 104' ' ' TYR . 21.6 m-85 -118.55 145.46 45.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 109.786 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 62.6 m -139.59 128.12 22.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.112 -0.993 . . . . 0.0 109.201 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 HD23 ' A' ' 30' ' ' LEU . 5.2 t -76.4 133.36 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.222 -0.924 . . . . 0.0 109.53 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.3 mm-40 -109.83 156.27 20.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.526 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -49.32 113.56 0.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.39 -4.13 1.72 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.39 -1.386 . . . . 0.0 110.727 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.496 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 66.4 m -63.94 140.57 58.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.835 -1.391 . . . . 0.0 109.34 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.58 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.65 177.81 2.05 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.195 -0.941 . . . . 0.0 109.497 -179.571 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 49.9 Cg_endo -70.77 -31.08 16.63 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.516 2.144 . . . . 0.0 111.827 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -116.68 6.25 13.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.016 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 19.8 mttp -142.41 133.56 26.05 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.084 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.29 132.28 51.69 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.964 -1.085 . . . . 0.0 110.002 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.929 HG13 ' HG2' ' A' ' 65' ' ' GLU . 45.7 t -121.8 124.25 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.084 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -141.55 142.02 33.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.947 -1.095 . . . . 0.0 110.285 -179.456 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD2' HG12 ' A' ' 63' ' ' VAL . 10.4 t70 -86.51 136.9 32.91 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.599 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.2 mt -117.06 127.96 74.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 120.712 -1.243 . . . . 0.0 111.122 -178.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 31.1 mtpt -108.06 114.97 29.28 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.58 ' CD1' HG22 ' A' ' 15' ' ' VAL . 84.4 t80 -124.3 108.2 11.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.71 -0.618 . . . . 0.0 109.817 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.9 m -109.52 117.3 33.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.38 -0.825 . . . . 0.0 109.523 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.554 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -139.89 121.72 9.79 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.406 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 50.4 Cg_endo -70.52 119.39 6.3 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.72 2.28 . . . . 0.0 111.929 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.39 -12.44 68.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -141.25 -178.63 5.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.141 -1.211 . . . . 0.0 109.646 -179.906 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -156.32 163.45 39.5 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.748 HD13 ' HD2' ' A' ' 80' ' ' PHE . 51.0 tp -68.96 125.94 28.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.228 -0.92 . . . . 0.0 109.195 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.828 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -113.97 -44.24 3.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 109.9 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -138.55 147.56 43.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.17 -0.956 . . . . 0.0 110.22 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.738 HG22 HD11 ' A' ' 41' ' ' LEU . 43.4 t -138.83 136.75 43.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.458 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 93.0 mt-10 -127.75 149.8 50.08 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.813 -1.179 . . . . 0.0 109.726 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.984 HD13 ' N ' ' A' ' 47' ' ' ARG . 3.2 tm? -118.73 142.72 47.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.529 -0.732 . . . . 0.0 109.642 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.984 ' N ' HD13 ' A' ' 46' ' ' LEU . 13.7 ttp180 -127.48 124.65 38.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -0.86 . . . . 0.0 108.885 179.217 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.454 ' NE2' ' OG ' ' A' ' 68' ' ' SER . 39.4 mt-30 -63.87 155.44 30.62 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.25 -0.906 . . . . 0.0 109.895 -179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.569 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 44.1 t60 -73.19 119.19 17.08 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.348 -0.845 . . . . 0.0 109.586 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.34 6.79 50.44 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.402 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.4 t -115.52 156.28 26.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -1.136 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -114.73 14.63 17.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.266 -0.896 . . . . 0.0 109.332 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -120.62 111.93 18.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.335 -0.853 . . . . 0.0 109.629 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.4 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 44.6 m95 -70.05 135.82 49.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -105.28 133.89 19.94 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.439 -0.788 . . . . 0.0 109.427 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.557 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.5 Cg_endo -72.16 144.63 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.653 2.235 . . . . 0.0 112.084 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.717 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.5 mp -102.28 154.63 18.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.123 -0.986 . . . . 0.0 108.669 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 96.8 m -99.89 127.64 46.05 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.855 -1.153 . . . . 0.0 109.208 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.4 tttm -69.72 109.69 4.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.14 -0.975 . . . . 0.0 109.099 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 62' ' ' ASN . 21.5 mttp -108.96 119.15 38.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.983 -1.073 . . . . 0.0 109.725 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 47.8 -92.94 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 60' ' ' LYS . 4.8 m120 -131.8 17.05 4.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -1.131 . . . . 0.0 109.422 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.487 HG12 ' OD2' ' A' ' 31' ' ' ASP . 27.1 m -130.61 178.16 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.413 ' CD1' HG13 ' A' ' 32' ' ' ILE . 59.0 m95 -124.98 125.19 43.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.34 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.929 ' HG2' HG13 ' A' ' 29' ' ' VAL . 62.4 mt-10 -115.77 150.71 36.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.57 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.1 p -144.53 140.11 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.85 . . . . 0.0 109.265 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -121.87 132.88 54.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.185 -0.947 . . . . 0.0 109.606 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.454 ' OG ' ' NE2' ' A' ' 48' ' ' GLN . 8.0 t -116.92 133.9 55.44 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.421 -0.8 . . . . 0.0 109.214 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.9 m -59.94 -18.94 49.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.169 -0.957 . . . . 0.0 109.31 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.573 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.4 178.22 1.02 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.573 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.7 Cg_endo -70.85 141.18 40.2 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.573 2.182 . . . . 0.0 111.846 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.956 HD13 HD12 ' A' ' 28' ' ' LEU . 4.5 mt -76.39 139.05 40.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.475 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 20.8 t -125.01 125.12 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.465 -0.772 . . . . 0.0 109.53 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.438 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.72 169.28 28.41 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.646 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.6 Cg_endo -68.37 146.09 77.89 Favored 'Cis proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.826 -1.739 . . . . 0.0 112.021 0.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.835 ' HB3' HD21 ' A' ' 46' ' ' LEU . 83.4 m-85 -89.67 146.37 24.58 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.465 -0.772 . . . . 0.0 110.355 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.943 ' O ' HD22 ' A' ' 46' ' ' LEU . 7.1 m-80 -107.14 142.07 37.41 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 178.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.833 ' CE2' HD23 ' A' ' 46' ' ' LEU . 45.6 m-85 -131.7 119.48 21.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.843 -1.161 . . . . 0.0 110.205 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.99 ' HG3' HG22 ' A' ' 89' ' ' VAL . 33.0 ttm180 -102.13 141.14 35.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.097 -1.002 . . . . 0.0 108.51 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.748 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.3 m-85 -123.01 142.6 50.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 111.403 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' O ' ' A' ' 86' ' ' MET . 0.0 OUTLIER -125.92 124.86 41.75 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.194 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.613 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -74.06 145.63 44.3 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 110.174 -178.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.828 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 94.5 mttt -48.14 -44.5 32.29 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.393 -0.817 . . . . 0.0 108.959 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.443 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -56.78 -3.19 0.64 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.72 24.34 18.22 Favored Glycine 0 N--CA 1.489 2.173 0 O-C-N 121.062 -1.258 . . . . 0.0 110.003 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.613 ' O ' ' N ' ' A' ' 82' ' ' SER . 15.0 mmm -96.37 146.75 24.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.071 -1.252 . . . . 0.0 108.634 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 52.9 mtm-85 -122.94 139.42 54.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.855 -1.153 . . . . 0.0 110.55 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.0 m120 -136.31 141.02 43.77 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.99 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.6 t -122.07 136.52 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.982 -1.074 . . . . 0.0 110.195 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.547 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 72.9 m-85 -124.23 122.58 38.15 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.16 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -100.42 147.75 25.5 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.262 -0.899 . . . . 0.0 109.775 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 78.9 mt-10 53.19 52.62 13.3 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 110.276 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.459 ' HB ' ' CD1' ' A' ' 78' ' ' PHE . 57.8 t -84.68 -34.44 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 109.332 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.429 HG13 HG12 ' A' ' 93' ' ' VAL . 44.9 mt -136.58 125.88 15.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.228 -0.92 . . . . 0.0 109.146 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.26 161.96 44.07 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.509 2.139 . . . . 0.0 111.887 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.6 m -52.89 -43.05 65.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.901 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.13 99.75 12.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.107 -0.996 . . . . 0.0 109.655 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -108.27 150.72 26.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.124 -0.985 . . . . 0.0 109.478 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 87.6 p -109.73 170.31 8.15 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.346 -0.847 . . . . 0.0 109.34 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.493 HD13 ' CG1' ' A' ' 19' ' ' VAL . 32.1 mm -104.99 136.12 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.276 -0.89 . . . . 0.0 109.254 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.07 4.66 59.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -118.87 144.27 46.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.104 -1.233 . . . . 0.0 109.362 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.634 HG22 ' H ' ' A' ' 104' ' ' TYR . 3.5 m -78.73 177.15 8.89 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.115 -0.991 . . . . 0.0 109.193 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.634 ' H ' HG22 ' A' ' 103' ' ' THR . 30.7 m-85 -163.73 100.08 0.89 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.859 -1.151 . . . . 0.0 108.926 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -112.86 164.88 14.32 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.118 -0.989 . . . . 0.0 109.887 -179.448 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.547 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.6 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 C-N-CA 122.9 2.4 . . . . 0.0 111.771 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.755 HG22 ' HG2' ' A' ' 36' ' ' ARG . 15.4 t . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -109.81 120.02 41.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.44 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.8 t -126.28 135.6 63.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.917 . . . . 0.0 109.71 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.84 HG22 ' HG2' ' A' ' 105' ' ' LYS . 61.0 p -141.59 146.48 36.32 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.476 -0.765 . . . . 0.0 109.279 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.58 ' O ' ' N ' ' A' ' 104' ' ' TYR . 4.0 m-85 -119.41 141.16 49.34 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 0.0 109.939 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.4 m -136.97 128.52 28.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.17 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.909 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.0 t -76.27 144.68 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.142 -0.974 . . . . 0.0 109.377 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -115.78 159.84 20.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.997 . . . . 0.0 109.584 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 50.6 mttt -53.61 114.3 1.48 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.926 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.7 -3.61 2.62 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.446 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -58.33 141.89 49.76 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.87 -1.371 . . . . 0.0 109.232 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.551 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.19 171.84 8.36 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.223 -0.923 . . . . 0.0 109.689 -179.705 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.79 -30.8 16.98 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.808 2.339 . . . . 0.0 111.998 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 mttt -112.76 8.82 18.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.077 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.453 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 16.9 mttp -142.17 132.82 25.43 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.612 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.1 OUTLIER -120.88 123.05 41.59 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.979 -1.076 . . . . 0.0 109.362 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.985 HG13 ' HG2' ' A' ' 65' ' ' GLU . 25.1 t -120.42 125.99 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.909 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.9 mt -144.7 144.29 31.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.046 -1.034 . . . . 0.0 110.165 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.76 138.91 31.23 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.936 HG21 ' CE2' ' A' ' 80' ' ' PHE . 69.0 mt -122.28 131.46 73.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.489 -179.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 54.7 tttp -109.8 119.01 38.01 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.575 ' CD1' HG22 ' A' ' 15' ' ' VAL . 78.7 t80 -122.7 113.25 18.97 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.46 -0.775 . . . . 0.0 109.748 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.9 m -115.99 118.38 32.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.32 -0.863 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.755 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -132.91 150.75 76.53 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.459 179.984 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.88 88.61 0.66 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 122.642 2.228 . . . . 0.0 112.081 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.43 -27.73 8.29 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.951 -1.259 . . . . 0.0 109.951 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.56 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -91.17 171.98 8.87 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.116 -1.226 . . . . 0.0 109.619 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.534 ' O ' ' HA ' ' A' ' 82' ' ' SER . 18.2 m -153.66 161.33 42.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.545 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.901 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.4 tt -72.56 132.84 44.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.365 -0.835 . . . . 0.0 109.695 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.952 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.14 -40.06 3.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 109.899 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 87.7 mt-10 -142.45 150.56 40.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.156 -0.965 . . . . 0.0 110.197 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.491 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.8 t -138.44 136.13 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 109.319 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.59 150.51 50.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.002 HD23 HG11 ' A' ' 66' ' ' VAL . 16.7 tp -120.25 135.36 55.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.411 -0.806 . . . . 0.0 109.888 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.598 ' H ' HD12 ' A' ' 46' ' ' LEU . 4.0 ttp180 -121.58 130.27 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.837 . . . . 0.0 108.845 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 57.0 mt-30 -74.72 150.54 39.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.13 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.567 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 51.6 t-80 -64.45 117.75 7.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.37 1.34 44.06 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.455 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 38.3 t -113.33 153.14 28.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.188 -1.183 . . . . 0.0 109.439 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 58.0 mt-10 -118.3 20.48 13.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.321 -0.862 . . . . 0.0 109.318 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -124.23 94.08 4.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.873 . . . . 0.0 109.456 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.427 ' CZ3' ' N ' ' A' ' 79' ' ' ARG . 66.3 m95 -54.22 132.06 42.64 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 109.774 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.4 mm-40 -101.05 138.22 19.93 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.799 . . . . 0.0 109.273 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.87 143.78 46.42 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.709 2.273 . . . . 0.0 112.04 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.785 HD11 ' CB ' ' A' ' 46' ' ' LEU . 6.8 mp -110.63 149.85 29.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.194 -0.941 . . . . 0.0 108.931 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 11.3 m -103.31 125.33 49.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.923 -1.11 . . . . 0.0 109.154 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 12.9 tttm -73.58 109.85 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.135 -0.978 . . . . 0.0 109.275 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.898 ' O ' HG22 ' A' ' 63' ' ' VAL . 66.8 mttt -120.23 144.23 47.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.906 -1.121 . . . . 0.0 110.068 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.59 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.76 29.96 0.87 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.59 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 8.0 t30 81.99 14.73 0.51 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.239 -1.153 . . . . 0.0 110.376 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.898 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.6 m -129.52 170.26 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.099 -1.0 . . . . 0.0 109.021 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.678 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.6 m95 -114.51 122.67 47.29 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.908 -1.12 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.985 ' HG2' HG13 ' A' ' 29' ' ' VAL . 43.1 mt-10 -112.39 147.18 36.96 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.402 -0.811 . . . . 0.0 109.445 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 1.002 HG11 HD23 ' A' ' 46' ' ' LEU . 9.7 p -136.21 132.65 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.502 -0.749 . . . . 0.0 109.121 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.0 mttp -119.2 130.51 55.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.099 -1.001 . . . . 0.0 109.482 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.4 t -118.54 144.7 45.89 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 1.2 p -71.4 -4.18 24.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.072 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 16.2 mmtt -132.86 169.7 13.3 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.386 -0.821 . . . . 0.0 109.105 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.02 133.18 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.519 2.146 . . . . 0.0 111.776 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.605 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -68.13 146.53 53.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.346 -0.846 . . . . 0.0 109.777 -179.607 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.84 123.65 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.404 -0.81 . . . . 0.0 109.198 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.82 165.39 28.24 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.653 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.5 Cg_endo -68.78 145.17 76.46 Favored 'Cis proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.922 -1.699 . . . . 0.0 111.985 0.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.605 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -89.35 149.07 23.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.578 -0.701 . . . . 0.0 110.432 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.861 ' O ' HD12 ' A' ' 46' ' ' LEU . 36.2 m-80 -109.52 141.82 41.45 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.875 ' CE1' HD13 ' A' ' 46' ' ' LEU . 87.1 m-85 -133.38 121.09 21.8 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.958 -1.089 . . . . 0.0 109.748 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.646 ' HG3' HG22 ' A' ' 89' ' ' VAL . 27.8 ttm180 -104.12 143.31 33.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.07 -1.019 . . . . 0.0 108.944 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.936 ' CE2' HG21 ' A' ' 32' ' ' ILE . 22.6 m-85 -125.53 144.22 50.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 111.676 -178.013 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.637 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -127.04 126.37 42.97 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.611 ' N ' ' O ' ' A' ' 86' ' ' MET . 25.9 p -76.33 145.98 39.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.215 -0.928 . . . . 0.0 110.387 -178.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.952 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.5 mttt -50.08 -42.96 51.1 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.15 -2.57 0.41 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.84 25.88 18.71 Favored Glycine 0 N--CA 1.489 2.22 0 O-C-N 121.082 -1.246 . . . . 0.0 109.991 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.611 ' O ' ' N ' ' A' ' 82' ' ' SER . 12.8 mtm -102.17 151.24 22.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.084 -1.245 . . . . 0.0 108.769 179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.637 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 67.8 mtp180 -125.47 140.89 52.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.92 -1.112 . . . . 0.0 110.567 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 80' ' ' PHE . 11.9 m120 -135.23 139.95 44.88 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 79' ' ' ARG . 26.3 t -122.39 137.45 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.999 -1.063 . . . . 0.0 110.364 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 95.4 m-85 -125.37 122.71 37.57 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.26 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -99.81 148.34 24.52 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 98.9 mt-10 52.76 54.06 11.14 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.408 -0.808 . . . . 0.0 110.393 179.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 106' ' ' PRO . 77.8 t -85.37 -34.07 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 120.903 -1.123 . . . . 0.0 109.093 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.456 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.0 mt -136.57 125.21 15.21 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.879 . . . . 0.0 108.979 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.53 162.4 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.453 2.102 . . . . 0.0 111.871 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.525 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 39.5 m -51.48 -44.99 62.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.31 -0.869 . . . . 0.0 109.815 -179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.01 101.7 14.46 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.126 -0.983 . . . . 0.0 109.365 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -109.26 151.53 26.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.266 -0.897 . . . . 0.0 109.405 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 53.5 p -105.63 170.41 7.91 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.276 -0.89 . . . . 0.0 109.23 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 18.6 mm -105.13 136.35 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.192 -0.942 . . . . 0.0 109.374 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.26 9.46 61.88 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 52.5 tttt -118.42 143.14 46.89 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -1.197 . . . . 0.0 109.18 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.513 HG22 ' N ' ' A' ' 104' ' ' TYR . 23.2 m -77.28 168.61 19.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.996 -1.065 . . . . 0.0 108.997 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.58 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.1 m-85 -154.63 96.98 1.94 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.674 -1.266 . . . . 0.0 108.918 179.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.84 ' HG2' HG22 ' A' ' 16' ' ' THR . 6.6 mtmm -103.15 160.28 26.65 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.266 -0.897 . . . . 0.0 109.806 -179.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.536 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.1 Cg_endo . . . . . 0 C--O 1.215 -0.656 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.974 HG22 ' HG2' ' A' ' 36' ' ' ARG . 6.2 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -109.63 121.65 45.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.546 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 10.3 p -129.28 141.4 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.353 -0.842 . . . . 0.0 109.427 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.442 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 67.9 p -141.58 145.79 35.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.139 -0.976 . . . . 0.0 109.721 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.63 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.0 m-85 -118.63 143.72 46.63 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 31' ' ' ASP . 63.7 m -137.87 128.07 26.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.109 -0.995 . . . . 0.0 109.283 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 ' CD2' ' A' ' 30' ' ' LEU . 15.7 t -76.05 128.63 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.27 -0.893 . . . . 0.0 109.425 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.417 ' O ' HD12 ' A' ' 100' ' ' ILE . 89.9 mm-40 -91.26 -178.39 5.13 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.551 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 20.2 mttt -79.91 70.14 6.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.18 25.84 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.423 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 1.5 t -73.97 140.34 45.45 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.748 -1.442 . . . . 0.0 108.831 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.53 173.74 5.45 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.011 -1.056 . . . . 0.0 109.809 -179.532 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 52.1 Cg_endo -71.8 -32.18 11.9 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.719 2.279 . . . . 0.0 111.909 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -116.95 5.63 12.92 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.012 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.508 ' CD ' ' HE2' ' A' ' 67' ' ' LYS . 79.6 tttt -142.37 133.36 25.85 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.997 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -125.15 131.08 53.3 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.077 -1.014 . . . . 0.0 109.619 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 1.059 HG13 ' HG2' ' A' ' 65' ' ' GLU . 3.1 t -121.45 124.39 71.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.997 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.5 143.5 31.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.029 -1.044 . . . . 0.0 109.999 -179.487 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HA ' HG12 ' A' ' 63' ' ' VAL . 60.1 t0 -83.99 135.16 34.55 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.577 HG21 ' CE2' ' A' ' 80' ' ' PHE . 78.3 mt -119.4 130.11 74.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.541 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 8.5 ttmm -111.19 120.39 42.13 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.6 ' CE2' ' HB2' ' A' ' 36' ' ' ARG . 87.3 t80 -120.32 119.87 34.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.391 -0.818 . . . . 0.0 109.519 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 31.1 m -122.31 115.55 22.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.298 -0.876 . . . . 0.0 109.751 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.974 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -133.59 136.86 27.61 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.525 -0.734 . . . . 0.0 109.03 179.768 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 48.1 Cg_endo -69.93 104.49 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.676 2.251 . . . . 0.0 111.95 -179.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.31 3.38 87.06 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.562 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 4.2 t0 -136.38 175.05 9.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.155 -1.203 . . . . 0.0 109.758 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.511 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 p -153.05 161.02 43.0 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.337 -0.852 . . . . 0.0 109.372 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.803 HD21 ' CG2' ' A' ' 44' ' ' VAL . 8.1 tp -72.08 132.74 44.63 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.789 ' N ' HD12 ' A' ' 41' ' ' LEU . . . -117.26 -41.63 2.97 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 109.741 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -141.76 150.12 41.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.181 -0.949 . . . . 0.0 109.992 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.803 ' CG2' HD21 ' A' ' 41' ' ' LEU . 2.6 t -138.52 135.98 43.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.439 -0.788 . . . . 0.0 109.365 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.451 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 78.4 mt-10 -127.81 149.78 50.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.911 -1.118 . . . . 0.0 109.21 179.432 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.889 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.0 tt -120.28 139.69 52.34 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.335 -0.853 . . . . 0.0 109.89 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.883 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.3 ttp180 -126.82 120.12 28.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.875 . . . . 0.0 108.82 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.511 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 32.0 mt-30 -64.39 145.05 56.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.141 -179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.552 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 49.1 t60 -55.82 145.41 24.59 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.454 -0.779 . . . . 0.0 109.243 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.51 1.22 51.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.419 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 9.6 t -111.44 152.75 27.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.1 -1.235 . . . . 0.0 109.316 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 -119.0 7.32 11.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -104.89 97.9 7.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.543 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 51.5 m95 -63.11 132.07 50.62 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 109.779 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -105.3 136.97 19.14 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 109.391 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD22 ' A' ' 57' ' ' LEU . 50.9 Cg_endo -70.88 151.82 62.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.752 2.301 . . . . 0.0 112.201 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.744 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.3 OUTLIER -110.2 154.03 23.94 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 179.6 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' TRP . 7.0 m -110.21 126.4 54.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.833 -1.167 . . . . 0.0 108.808 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 tttm -74.31 105.73 5.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.087 -1.008 . . . . 0.0 109.283 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.77 ' O ' HG22 ' A' ' 63' ' ' VAL . 16.4 mttp -120.47 142.86 48.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.819 -1.176 . . . . 0.0 110.249 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.84 35.96 1.67 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 7.9 m-20 78.06 10.82 2.01 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.061 -1.258 . . . . 0.0 110.469 179.158 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 60' ' ' LYS . 15.6 m -128.59 -177.96 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.977 -1.077 . . . . 0.0 108.776 179.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 66.1 m95 -123.07 141.07 52.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.05 -1.032 . . . . 0.0 109.927 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 1.059 ' HG2' HG13 ' A' ' 29' ' ' VAL . 92.1 mt-10 -127.96 142.37 51.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.473 -0.767 . . . . 0.0 109.105 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.744 ' HB ' HD13 ' A' ' 57' ' ' LEU . 1.9 p -139.39 137.53 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.227 -0.92 . . . . 0.0 109.377 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.508 ' HE2' ' CD ' ' A' ' 27' ' ' LYS . 28.7 mttt -122.71 134.15 54.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.463 -0.773 . . . . 0.0 109.632 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.511 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.7 t -117.46 145.3 44.26 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.488 -0.758 . . . . 0.0 109.18 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 49.5 m -68.77 -16.5 63.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.16 -0.962 . . . . 0.0 109.289 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.557 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.73 176.4 1.53 Allowed Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.557 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.8 Cg_endo -70.03 136.64 32.77 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.684 2.256 . . . . 0.0 111.726 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.946 HD13 HD12 ' A' ' 28' ' ' LEU . 6.4 mt -68.64 136.57 53.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.9 t -126.06 125.56 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.491 -0.756 . . . . 0.0 109.472 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.529 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -93.66 166.25 27.68 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.64 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.73 146.12 78.93 Favored 'Cis proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.843 -1.732 . . . . 0.0 111.99 0.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.9 m-85 -90.09 148.39 23.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.482 -0.761 . . . . 0.0 110.425 -179.201 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.455 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 18.9 m-80 -110.52 144.37 39.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.387 -0.821 . . . . 0.0 108.829 179.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.889 ' CE2' HD12 ' A' ' 46' ' ' LEU . 61.8 m-85 -135.81 125.38 25.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.89 -1.131 . . . . 0.0 110.25 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.955 ' HG3' HG22 ' A' ' 89' ' ' VAL . 15.2 ttp180 -105.85 141.38 37.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -0.96 . . . . 0.0 108.451 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.766 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.0 m-85 -122.11 142.23 50.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 111.082 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -125.5 123.97 40.33 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.603 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.4 p -74.43 144.19 44.38 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.386 -0.821 . . . . 0.0 110.352 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.774 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 46.5 mttp -46.39 -44.76 17.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.429 -0.795 . . . . 0.0 108.946 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.47 -3.42 0.63 Allowed Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.462 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.05 24.36 20.0 Favored Glycine 0 N--CA 1.49 2.27 0 O-C-N 120.992 -1.299 . . . . 0.0 110.124 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.603 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.0 mtm -98.34 150.12 21.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.994 -1.298 . . . . 0.0 108.516 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.597 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 22.7 mtm-85 -125.58 141.59 51.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.845 -1.16 . . . . 0.0 110.636 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . 23.7 m120 -137.03 141.37 42.48 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.955 HG22 ' HG3' ' A' ' 79' ' ' ARG . 10.5 t -122.63 136.87 58.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.882 -1.136 . . . . 0.0 110.447 -178.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.557 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.7 m-85 -123.57 121.65 36.15 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.54 146.59 25.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.778 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.64 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 51.8 tt0 53.7 51.54 14.82 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.431 -0.793 . . . . 0.0 110.424 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.453 HG21 ' HB2' ' A' ' 90' ' ' PHE . 72.5 t -82.33 -34.18 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.88 -1.138 . . . . 0.0 108.992 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.4 HG12 ' HB3' ' A' ' 104' ' ' TYR . 12.2 mt -135.82 127.13 17.19 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.258 -0.902 . . . . 0.0 109.162 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.48 161.13 47.12 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.552 2.168 . . . . 0.0 112.007 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.529 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 28.0 m -52.04 -45.15 64.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.744 -179.717 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.82 102.41 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.429 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 47.1 p90 -111.1 151.75 27.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.128 -0.982 . . . . 0.0 109.504 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 33.2 m -106.36 163.11 13.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.909 . . . . 0.0 109.467 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.531 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.1 mm -98.16 137.4 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.376 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.4 7.47 58.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.9 tptt -121.1 143.56 49.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.134 -1.215 . . . . 0.0 109.362 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.7 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.2 m -79.29 178.79 7.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 108.764 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.7 ' H ' HG22 ' A' ' 103' ' ' THR . 25.3 m-85 -164.36 94.57 0.72 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.659 -1.275 . . . . 0.0 109.112 179.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -106.26 163.73 16.42 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.375 -0.828 . . . . 0.0 109.596 -179.481 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 48.5 Cg_endo . . . . . 0 C--O 1.216 -0.62 0 C-N-CA 122.496 2.13 . . . . 0.0 111.723 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.81 HG22 ' CG ' ' A' ' 36' ' ' ARG . 47.8 t . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 74.5 mt-30 -107.53 119.43 39.41 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.123 -0.985 . . . . 0.0 109.122 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.661 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.8 p -128.66 139.43 51.91 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.21 -0.931 . . . . 0.0 110.051 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.513 HG22 ' HG2' ' A' ' 105' ' ' LYS . 30.4 p -141.21 145.12 35.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.304 -0.873 . . . . 0.0 109.41 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.602 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.8 m-85 -117.16 136.23 53.18 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 52.3 m -131.27 127.21 37.31 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.968 -1.083 . . . . 0.0 109.326 179.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.96 HG22 ' CD2' ' A' ' 30' ' ' LEU . 9.0 t -75.38 128.37 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.283 -0.886 . . . . 0.0 109.274 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.414 ' O ' HG12 ' A' ' 100' ' ' ILE . 88.6 mm-40 -89.35 -178.25 5.57 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.061 -1.024 . . . . 0.0 109.843 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.2 mttp -80.23 65.38 5.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.437 -0.789 . . . . 0.0 109.975 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.28 25.9 0.08 OUTLIER Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.496 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.608 ' HB3' ' CZ ' ' A' ' 98' ' ' PHE . 3.2 m -79.72 144.04 34.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.079 -1.248 . . . . 0.0 109.337 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.4 172.06 7.48 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.121 -0.987 . . . . 0.0 109.579 -179.766 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -70.67 -28.2 21.16 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.667 2.244 . . . . 0.0 111.809 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.44 ' HB3' ' O ' ' A' ' 68' ' ' SER . 80.4 mttt -116.4 5.57 13.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.087 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 61.4 mttm -141.55 132.86 26.57 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.682 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.11 123.21 41.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.978 -1.076 . . . . 0.0 109.71 -179.6 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.787 HG22 ' HG3' ' A' ' 65' ' ' GLU . 13.6 t -119.58 125.09 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.96 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -145.14 146.04 31.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.926 -1.109 . . . . 0.0 110.125 -179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.469 ' HA ' HG12 ' A' ' 63' ' ' VAL . 62.6 t0 -86.06 136.82 33.08 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.068 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.869 HG21 ' HE2' ' A' ' 80' ' ' PHE . 78.6 mt -121.05 130.82 74.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 C-N-CA 118.825 -1.15 . . . . 0.0 110.661 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.661 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 29.0 tttm -110.43 120.75 43.45 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.533 ' CE1' HG11 ' A' ' 13' ' ' VAL . 88.5 t80 -120.93 111.33 17.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.328 -0.857 . . . . 0.0 109.528 -179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 19.9 m -113.66 114.72 26.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 109.772 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.81 ' CG ' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -152.58 113.01 2.78 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.515 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.06 128.91 17.39 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.704 2.269 . . . . 0.0 112.165 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.61 -22.46 40.42 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.82 -178.76 5.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -1.144 . . . . 0.0 109.807 -179.817 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.561 ' O ' ' HA ' ' A' ' 82' ' ' SER . 57.9 m -154.37 161.68 41.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.324 -0.86 . . . . 0.0 109.331 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.51 130.19 40.64 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.255 -0.903 . . . . 0.0 109.736 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.937 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.4 -41.22 3.14 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.222 -0.924 . . . . 0.0 109.839 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -141.19 149.48 41.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.466 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.638 ' CG2' HD11 ' A' ' 41' ' ' LEU . 95.2 t -138.72 136.94 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -128.67 149.68 50.57 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.832 -1.168 . . . . 0.0 109.551 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.006 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.3 tt -119.4 135.73 54.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.443 -0.786 . . . . 0.0 109.852 -179.288 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 1.006 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.3 ttp180 -122.37 129.79 52.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -0.883 . . . . 0.0 109.051 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.465 HE21 HD23 ' A' ' 72' ' ' LEU . 58.8 mt-30 -72.11 145.83 47.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.751 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.593 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 38.4 t60 -64.42 112.09 2.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 109.358 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.48 1.26 24.71 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 11.0 t -114.27 153.91 28.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -1.2 . . . . 0.0 109.421 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -110.73 6.92 21.92 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.3 mt-10 -118.04 104.14 10.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.593 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 33.6 m95 -61.8 142.16 57.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.415 -0.803 . . . . 0.0 109.746 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -106.0 136.15 19.34 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.361 -0.837 . . . . 0.0 109.293 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.8 Cg_endo -71.59 147.14 50.85 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.634 2.223 . . . . 0.0 112.198 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.81 HD11 ' HB2' ' A' ' 46' ' ' LEU . 9.0 mp -108.14 148.54 29.72 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.267 -0.896 . . . . 0.0 108.775 179.461 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 61.4 m -96.29 125.63 40.93 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.876 -1.14 . . . . 0.0 109.161 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.441 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 55.4 tttt -70.15 111.19 5.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.144 -0.972 . . . . 0.0 109.072 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.438 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.5 mttt -111.78 107.71 16.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.957 -1.089 . . . . 0.0 109.608 -179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.9 -93.15 0.12 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -134.75 20.01 3.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.206 -1.173 . . . . 0.0 109.339 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.469 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.7 m -130.86 -172.81 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.362 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.441 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 69.2 m95 -135.45 125.21 25.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.885 . . . . 0.0 109.122 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.787 ' HG3' HG22 ' A' ' 29' ' ' VAL . 60.9 tt0 -114.99 149.99 36.52 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 109.748 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.677 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 14.5 p -141.57 137.54 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.412 -0.805 . . . . 0.0 109.456 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -119.91 129.33 54.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.491 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.44 ' O ' ' HB3' ' A' ' 26' ' ' LYS . 35.6 t -118.3 131.83 56.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.602 -0.687 . . . . 0.0 109.51 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.5 t -61.26 -14.02 23.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.911 . . . . 0.0 108.973 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -116.1 167.55 10.12 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.35 -0.844 . . . . 0.0 109.208 179.9 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 46.4 Cg_endo -68.14 129.64 19.81 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.54 2.16 . . . . 0.0 111.792 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.617 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -63.41 142.5 58.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.374 -0.829 . . . . 0.0 109.648 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.03 124.25 68.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.332 -0.855 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.523 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.77 164.31 27.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.67 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.3 Cg_endo -69.0 147.31 82.79 Favored 'Cis proline' 0 C--O 1.214 -0.713 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.935 0.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.617 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -91.26 147.6 22.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.536 -0.728 . . . . 0.0 110.353 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -108.32 143.77 36.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.354 -0.841 . . . . 0.0 108.736 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.697 ' CE2' HD12 ' A' ' 46' ' ' LEU . 85.3 m-85 -134.17 125.66 28.35 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.062 -1.024 . . . . 0.0 109.906 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.943 ' HG3' HG22 ' A' ' 89' ' ' VAL . 44.2 ttt180 -108.21 142.34 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.962 -1.086 . . . . 0.0 108.834 179.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.869 ' HE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -124.4 143.28 50.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.881 . . . . 0.0 111.154 -178.202 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.65 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.2 ttm -126.2 125.69 42.85 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.568 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 20.5 p -73.99 145.85 44.29 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.284 -0.885 . . . . 0.0 110.26 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.937 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 18.8 mttm -50.55 -42.88 55.92 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.342 -0.849 . . . . 0.0 108.771 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.94 -4.5 0.72 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.89 27.21 11.42 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 8.8 mtm -103.32 153.86 19.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.04 -1.27 . . . . 0.0 108.802 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.65 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 32.7 mtt180 -128.29 142.18 51.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.812 -1.18 . . . . 0.0 110.786 -178.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.5 m120 -134.81 140.09 45.6 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.943 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.9 t -122.63 137.04 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.958 -1.089 . . . . 0.0 110.498 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 56.8 m-85 -124.93 122.52 37.58 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 35.2 p-10 -98.85 147.62 24.74 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.15 -0.969 . . . . 0.0 109.645 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.67 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 32.8 mt-10 53.0 52.44 13.85 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.84 . . . . 0.0 110.277 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.413 HG21 ' HB2' ' A' ' 90' ' ' PHE . 45.2 t -83.23 -34.41 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.789 -1.194 . . . . 0.0 109.094 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.406 HG13 HG12 ' A' ' 93' ' ' VAL . 13.4 mt -138.32 125.25 13.23 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.325 -0.859 . . . . 0.0 109.032 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.04 162.79 40.26 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.611 2.207 . . . . 0.0 111.97 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.523 HG23 ' H ' ' A' ' 74' ' ' GLY . 12.3 m -54.01 -37.51 64.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.41 -0.806 . . . . 0.0 109.899 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.14 101.29 12.92 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.004 -1.06 . . . . 0.0 109.714 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.608 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 40.4 p90 -109.58 149.56 29.49 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 109.279 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ILE . 1.4 m -118.77 104.22 10.38 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.731 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.525 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 8.7 mt -43.29 139.96 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 105.0 -3.09 41.05 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.9 tptt -122.29 142.76 50.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -1.174 . . . . 0.0 109.226 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.612 HG22 ' H ' ' A' ' 104' ' ' TYR . 10.9 m -79.18 175.0 10.99 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.117 -0.99 . . . . 0.0 108.619 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.612 ' H ' HG22 ' A' ' 103' ' ' THR . 26.8 m-85 -159.94 96.7 1.24 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.675 -1.265 . . . . 0.0 109.119 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.517 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 7.9 mtmt -97.8 163.2 20.0 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.441 -0.787 . . . . 0.0 109.635 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 48.1 Cg_endo . . . . . 0 C--O 1.216 -0.602 0 C-N-CA 122.69 2.26 . . . . 0.0 112.024 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.777 HG13 ' HB2' ' A' ' 36' ' ' ARG . 4.6 t . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 88.4 mm-40 -102.81 121.31 42.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.227 -0.92 . . . . 0.0 109.251 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 7.0 p -129.81 141.15 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.279 -0.888 . . . . 0.0 109.691 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.486 ' HA ' ' HB3' ' A' ' 105' ' ' LYS . 21.4 p -141.88 145.78 35.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.562 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.7 m-85 -117.0 150.83 37.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.436 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 42.3 m -144.48 127.26 16.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.999 -1.063 . . . . 0.0 109.373 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.919 HG22 ' CD2' ' A' ' 30' ' ' LEU . 12.2 t -75.84 135.63 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.4 mm-40 -114.62 155.18 27.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.049 -1.032 . . . . 0.0 109.885 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -47.23 109.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.495 -0.753 . . . . 0.0 109.853 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.68 -5.76 1.36 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.669 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 98' ' ' PHE . 7.3 p -62.39 142.94 57.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.801 -1.411 . . . . 0.0 109.361 -179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.535 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.43 173.83 5.15 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.6 Cg_endo -70.79 -28.75 19.9 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.667 2.245 . . . . 0.0 111.954 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -116.24 7.22 13.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.068 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.491 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 33.1 mttp -142.7 133.68 25.7 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.687 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.48 123.16 40.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.929 -1.107 . . . . 0.0 109.613 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.549 HG22 ' HG3' ' A' ' 65' ' ' GLU . 9.0 t -120.2 125.59 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 179.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.919 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -144.87 144.95 31.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.893 -1.129 . . . . 0.0 110.226 -179.369 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.562 ' HA ' HG12 ' A' ' 63' ' ' VAL . 16.2 t70 -82.4 134.43 35.24 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.625 HG21 ' CE2' ' A' ' 80' ' ' PHE . 74.9 mt -119.96 130.64 73.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.779 -1.201 . . . . 0.0 110.74 -178.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 62.8 mttm -111.49 120.15 41.16 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 178.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.545 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 90.1 t80 -120.53 112.86 19.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.425 -0.797 . . . . 0.0 109.501 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 33.8 m -115.22 115.24 26.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 0.0 109.688 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.777 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -147.6 117.55 4.36 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.462 -0.774 . . . . 0.0 109.066 179.897 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.29 123.65 10.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.94 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.37 59.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.572 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -142.71 -176.39 4.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -1.201 . . . . 0.0 109.864 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.6 m -155.83 162.69 40.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.332 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.759 HD21 HG21 ' A' ' 44' ' ' VAL . 48.6 tp -69.32 126.38 29.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.964 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.855 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.83 -44.51 2.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.854 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.433 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 27.0 mt-10 -137.19 146.85 45.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.158 -0.964 . . . . 0.0 110.262 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 HD21 ' A' ' 41' ' ' LEU . 98.2 t -139.93 137.39 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.476 -0.765 . . . . 0.0 109.252 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.432 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 94.5 mt-10 -127.79 150.69 49.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.822 -1.174 . . . . 0.0 109.231 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.035 HD23 HG11 ' A' ' 66' ' ' VAL . 12.1 tp -120.42 132.24 55.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 110.393 -178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.647 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.4 OUTLIER -113.19 124.88 53.56 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.292 -0.88 . . . . 0.0 108.995 179.178 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.576 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 61.1 mt-30 -65.24 159.14 24.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.252 -0.905 . . . . 0.0 109.087 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.583 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 11.4 t-80 -75.95 108.15 8.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.17 7.09 21.66 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 23.1 t -115.88 154.16 30.23 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.047 -1.267 . . . . 0.0 109.514 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mt-10 -104.9 -22.44 13.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.274 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -87.67 129.03 35.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.62 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 9.4 m95 -86.92 141.68 28.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.632 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.41 ' OE2' ' O ' ' A' ' 67' ' ' LYS . 45.4 tt0 -107.98 133.75 20.38 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.351 -0.843 . . . . 0.0 109.481 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.7 Cg_endo -70.78 151.0 62.93 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.693 2.262 . . . . 0.0 111.783 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.809 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.8 mp -109.16 143.84 38.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.206 -0.934 . . . . 0.0 109.11 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.7 m -92.7 127.44 38.2 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.99 -1.069 . . . . 0.0 109.136 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -70.49 109.99 5.13 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.164 -0.96 . . . . 0.0 109.11 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -109.4 115.77 30.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.945 -1.097 . . . . 0.0 109.586 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 53.18 -97.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -128.12 16.58 6.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.216 -1.167 . . . . 0.0 109.466 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.562 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.3 m -131.04 -176.94 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.32 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.477 ' CD1' HD12 ' A' ' 32' ' ' ILE . 57.9 m95 -128.33 130.35 47.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.112 -0.993 . . . . 0.0 109.332 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.2 tt0 -111.69 135.97 51.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.645 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 1.035 HG11 HD23 ' A' ' 46' ' ' LEU . 5.3 p -130.67 129.67 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.426 -0.797 . . . . 0.0 109.012 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.449 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 19.4 mtmm -121.43 133.3 55.07 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.04 -1.038 . . . . 0.0 109.692 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.576 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.1 t -118.38 153.08 34.63 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.422 -0.799 . . . . 0.0 109.305 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.1 m -78.6 -2.36 38.57 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.151 -0.968 . . . . 0.0 109.148 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.561 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 3.5 mttt -128.81 177.02 2.34 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.339 -0.851 . . . . 0.0 109.164 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.6 Cg_endo -68.54 150.3 75.02 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.495 2.13 . . . . 0.0 111.856 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.579 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 14.9 mt -85.58 137.46 32.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.33 -0.856 . . . . 0.0 109.682 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.557 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 28.9 t -127.02 125.86 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.46 -0.775 . . . . 0.0 109.475 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.522 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.94 169.19 28.03 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.664 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.2 Cg_endo -67.98 146.92 78.86 Favored 'Cis proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.912 -1.703 . . . . 0.0 112.002 0.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 86.6 m-85 -89.69 149.77 22.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.589 -0.695 . . . . 0.0 110.343 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.809 ' O ' HD12 ' A' ' 46' ' ' LEU . 3.0 m-80 -112.06 142.74 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.78 ' CE1' HD13 ' A' ' 46' ' ' LEU . 96.5 m-85 -134.85 134.84 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.999 -1.063 . . . . 0.0 109.381 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.536 ' NH1' ' CZ ' ' A' ' 87' ' ' ARG . 64.5 ttt180 -116.8 144.07 44.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.943 -1.098 . . . . 0.0 108.864 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.732 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.6 m-85 -122.89 140.79 52.6 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.157 -0.965 . . . . 0.0 111.238 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.624 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.1 ttm -123.45 124.02 41.96 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 18.8 p -72.37 142.41 48.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.455 -0.778 . . . . 0.0 110.475 -178.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.855 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 56.4 mttt -46.64 -44.18 18.18 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 108.821 178.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -57.09 -5.85 1.65 Allowed Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 97.3 25.36 11.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 55.4 mtp -99.67 152.52 19.97 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.108 -1.23 . . . . 0.0 108.473 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.624 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 33.5 mtm180 -128.39 142.13 51.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.617 -1.302 . . . . 0.0 110.918 -178.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.535 ' N ' ' O ' ' A' ' 80' ' ' PHE . 29.9 m120 -135.69 140.73 44.67 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.3 t -122.79 136.72 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.863 -1.148 . . . . 0.0 110.387 -179.026 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.548 ' CD1' ' CB ' ' A' ' 106' ' ' PRO . 55.5 m-85 -124.16 122.41 37.75 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -99.53 147.37 25.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.209 -0.932 . . . . 0.0 109.716 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.664 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 81.3 mt-10 53.99 51.18 15.15 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.505 -0.747 . . . . 0.0 110.344 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 94' ' ' ILE . 43.5 t -81.96 -34.89 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.864 -1.148 . . . . 0.0 108.938 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 93' ' ' VAL . 13.0 mt -135.8 125.07 16.02 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.473 -0.767 . . . . 0.0 108.974 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.28 161.61 45.19 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.569 2.179 . . . . 0.0 111.977 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.522 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 29.1 m -50.09 -45.68 52.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.373 -0.83 . . . . 0.0 109.726 -179.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.06 101.18 13.89 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.053 -1.029 . . . . 0.0 109.5 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.509 ' CE1' HG11 ' A' ' 19' ' ' VAL . 44.8 p90 -108.26 154.12 22.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 69.4 m -110.43 170.87 7.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.39 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 23.2 mm -105.19 136.71 37.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 109.312 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.72 6.28 59.56 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 46.7 tttt -119.03 143.43 47.1 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.095 -1.238 . . . . 0.0 109.225 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.622 HG22 ' H ' ' A' ' 104' ' ' TYR . 15.5 m -80.8 174.74 11.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.161 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.622 ' H ' HG22 ' A' ' 103' ' ' THR . 35.1 m-85 -160.36 102.25 1.39 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.765 -1.209 . . . . 0.0 108.772 179.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.597 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 1.7 ptpp? -114.16 166.36 11.66 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.201 -0.937 . . . . 0.0 109.776 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.597 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 48.7 Cg_endo . . . . . 0 C--O 1.216 -0.617 0 C-N-CA 122.587 2.191 . . . . 0.0 111.811 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.624 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 10.9 t . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -113.31 120.96 42.95 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.6 HG22 ' CD1' ' A' ' 34' ' ' TYR . 2.7 t -127.67 137.89 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.257 -0.902 . . . . 0.0 109.823 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 32.4 p -142.31 146.09 34.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.39 -0.819 . . . . 0.0 109.231 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.603 ' O ' ' N ' ' A' ' 104' ' ' TYR . 8.7 m-85 -119.41 151.85 37.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.106 -0.996 . . . . 0.0 110.02 -179.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 27.7 m -143.18 158.86 43.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 108.71 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.845 HG22 HD23 ' A' ' 30' ' ' LEU . 4.3 t -107.75 127.96 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.087 -1.008 . . . . 0.0 109.433 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -101.47 149.8 23.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.897 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -44.01 114.09 0.62 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.498 -0.752 . . . . 0.0 109.94 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.16 2.19 1.4 Allowed Glycine 0 N--CA 1.49 2.264 0 C-N-CA 119.272 -1.442 . . . . 0.0 110.907 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.0 m -61.18 142.38 56.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.667 -1.49 . . . . 0.0 109.054 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.82 171.94 7.59 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.094 -1.004 . . . . 0.0 109.616 -179.627 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.7 Cg_endo -70.68 -29.02 20.09 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.729 2.286 . . . . 0.0 111.829 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -118.03 3.4 12.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.009 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 21.1 mttt -141.83 133.15 26.51 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.049 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.07 133.78 50.39 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.018 -1.051 . . . . 0.0 110.17 -179.374 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.492 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.3 t -121.62 124.05 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.049 HD11 HD22 ' A' ' 28' ' ' LEU . 1.3 mt -140.94 141.14 34.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.01 -1.056 . . . . 0.0 110.093 -179.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.72 ' CG ' HG12 ' A' ' 63' ' ' VAL . 18.2 t0 -85.55 134.51 34.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.654 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -116.12 126.89 73.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 118.922 -1.111 . . . . 0.0 110.893 -179.105 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 13.7 tttm -107.28 115.07 29.52 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.01 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.624 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.2 t80 -124.93 111.88 15.96 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.345 0.593 . . . . 0.0 109.634 -178.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.3 m -113.85 119.77 38.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.94 . . . . 0.0 109.691 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.488 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 29.7 ttt85 -140.91 119.58 8.2 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.7 119.29 6.26 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.714 2.276 . . . . 0.0 111.821 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.14 -14.52 60.52 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.488 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 6.2 m-20 -136.43 175.18 9.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.181 -1.188 . . . . 0.0 109.644 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 m -154.41 161.6 41.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.297 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.718 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.4 OUTLIER -71.21 130.87 42.53 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.257 -0.902 . . . . 0.0 109.385 179.947 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.93 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -112.4 -41.03 3.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.466 ' O ' HD21 ' A' ' 41' ' ' LEU . 90.4 mt-10 -143.18 151.27 40.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 0.0 110.187 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.693 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.1 t -138.9 136.32 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.5 mt-10 -126.77 149.24 49.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.697 -1.252 . . . . 0.0 109.547 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.908 HD13 ' CE2' ' A' ' 78' ' ' PHE . 10.4 tp -122.18 131.24 53.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.479 -0.763 . . . . 0.0 109.929 -179.106 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.646 ' N ' HD12 ' A' ' 46' ' ' LEU . 41.8 ttp180 -118.92 135.04 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.088 179.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.603 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 78.7 mt-30 -75.05 150.72 38.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 110.034 -179.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 4.2 t-80 -67.4 112.55 4.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.41 -0.806 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.63 0.63 30.73 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.464 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 4.0 t -113.67 155.54 25.35 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.206 -1.173 . . . . 0.0 109.32 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -108.33 -14.31 14.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.243 -0.911 . . . . 0.0 109.404 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -93.17 117.92 30.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.223 -0.923 . . . . 0.0 109.736 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.631 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 25.3 m95 -75.94 140.29 42.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.419 -0.801 . . . . 0.0 109.638 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.469 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.8 OUTLIER -106.59 127.35 28.31 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.472 -0.768 . . . . 0.0 109.095 179.757 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.617 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.6 Cg_endo -69.67 150.42 68.71 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.586 2.191 . . . . 0.0 112.19 -179.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.8 mp -107.47 141.85 38.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 108.847 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 43.5 m -92.91 127.26 38.36 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.923 -1.11 . . . . 0.0 109.06 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tttm -73.49 109.86 7.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 109.717 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.0 mttm -109.88 110.93 22.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.998 -1.064 . . . . 0.0 109.752 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.46 -90.02 0.07 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.431 ' OD1' HG13 ' A' ' 63' ' ' VAL . 49.5 p-10 -139.04 18.45 2.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.288 -1.124 . . . . 0.0 109.281 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.72 HG12 ' CG ' ' A' ' 31' ' ' ASP . 16.2 m -130.66 173.4 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.283 -0.886 . . . . 0.0 109.249 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.434 ' CD1' HG13 ' A' ' 32' ' ' ILE . 66.5 m95 -123.17 128.64 50.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 109.317 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.461 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.7 tt0 -117.85 151.38 37.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.627 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.882 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -145.38 140.9 22.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.329 -0.857 . . . . 0.0 109.308 179.784 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 34.9 mttp -122.15 132.97 54.73 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.717 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.603 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 38.8 t -116.71 121.52 41.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.454 -0.779 . . . . 0.0 109.349 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 58.8 m -49.16 -22.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.571 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -109.65 177.25 1.28 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.318 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.571 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -68.86 152.69 73.67 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.504 2.136 . . . . 0.0 111.657 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.732 HD13 HD12 ' A' ' 28' ' ' LEU . 1.5 mt -90.28 138.05 31.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 35.4 t -126.34 125.28 67.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.422 -0.798 . . . . 0.0 109.605 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA3' ' N ' ' A' ' 96' ' ' THR . . . -94.39 167.29 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.713 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.1 Cg_endo -68.15 147.43 80.46 Favored 'Cis proline' 0 C--O 1.213 -0.735 0 C-N-CA 122.937 -1.693 . . . . 0.0 112.034 0.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.604 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.1 m-85 -91.23 150.82 21.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.441 -0.787 . . . . 0.0 110.448 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.784 ' O ' HD12 ' A' ' 46' ' ' LEU . 23.3 m-80 -111.12 142.08 43.77 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.908 ' CE2' HD13 ' A' ' 46' ' ' LEU . 41.9 m-85 -135.95 128.3 30.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.918 -1.114 . . . . 0.0 110.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.875 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.2 ttt180 -108.56 142.23 39.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 108.643 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.654 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.3 m-85 -123.49 143.6 50.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.213 -0.93 . . . . 0.0 111.411 -178.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.621 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.6 ttm -127.44 125.67 40.97 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.2 p -77.39 144.94 37.54 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.89 . . . . 0.0 110.246 -178.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.93 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 60.0 mttm -47.78 -43.14 27.28 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.4 -2.71 0.74 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.37 23.98 22.87 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.8 mmm -98.64 148.39 23.86 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -1.231 . . . . 0.0 108.681 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 77.8 mtm-85 -126.84 142.58 51.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.78 -1.2 . . . . 0.0 110.586 -178.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.413 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.2 m120 -136.97 141.17 42.59 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.875 HG22 ' HG3' ' A' ' 79' ' ' ARG . 2.9 t -121.43 136.32 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 71.8 m-85 -124.56 122.39 37.44 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.267 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -100.06 148.62 24.36 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.244 -0.91 . . . . 0.0 109.644 -179.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.713 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 88.6 mt-10 53.28 51.87 14.66 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.369 -0.832 . . . . 0.0 110.278 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.648 HG22 ' HB3' ' A' ' 106' ' ' PRO . 97.6 t -84.08 -34.33 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.856 -1.153 . . . . 0.0 109.188 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.2 mt -137.53 125.56 14.33 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.325 -0.859 . . . . 0.0 109.127 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.71 163.02 39.8 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.577 2.185 . . . . 0.0 112.07 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.535 ' N ' ' HA3' ' A' ' 74' ' ' GLY . 32.3 m -54.13 -44.09 71.06 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.414 -0.804 . . . . 0.0 109.918 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.39 99.41 11.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.054 -1.029 . . . . 0.0 109.363 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -107.85 147.09 31.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 109.722 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 70.4 m -107.08 167.86 9.6 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -0.862 . . . . 0.0 109.169 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.502 HD13 ' CG1' ' A' ' 19' ' ' VAL . 29.8 mm -104.16 136.78 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 109.408 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.73 2.66 61.26 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.1 tptt -116.15 142.55 46.67 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.09 -1.241 . . . . 0.0 109.176 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.573 HG22 ' H ' ' A' ' 104' ' ' TYR . 18.6 m -78.39 173.51 12.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.075 -1.016 . . . . 0.0 108.966 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.603 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -156.16 105.83 2.35 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.765 -1.209 . . . . 0.0 108.831 179.187 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 105' ' ' LYS . 1.3 ptmt -103.67 157.41 33.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.724 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.648 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.744 2.296 . . . . 0.0 111.734 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.959 HG22 ' HG2' ' A' ' 36' ' ' ARG . 40.5 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 97.2 mm-40 -109.4 120.35 42.24 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 109.118 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.9 p -128.35 140.53 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.314 -0.866 . . . . 0.0 109.499 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.49 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 32.0 p -143.09 146.32 33.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.187 -0.945 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.606 ' CD2' HG12 ' A' ' 32' ' ' ILE . 7.4 m-85 -117.01 148.41 41.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.251 -0.905 . . . . 0.0 109.286 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 36.0 m -143.6 128.63 18.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.929 -1.107 . . . . 0.0 109.621 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.935 HG22 HD21 ' A' ' 30' ' ' LEU . 3.5 t -76.7 138.52 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.157 -0.964 . . . . 0.0 109.364 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.7 mm-40 -118.66 155.66 30.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.02 -1.05 . . . . 0.0 109.612 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -47.51 112.73 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.82 . . . . 0.0 110.009 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.73 -7.96 1.99 Allowed Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.71 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 4.5 p -60.18 141.76 55.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.805 -1.409 . . . . 0.0 109.435 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.584 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.14 177.27 2.25 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.165 -0.959 . . . . 0.0 109.693 -179.594 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.584 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.8 Cg_endo -71.2 -33.93 10.77 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.784 2.322 . . . . 0.0 112.015 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.443 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -115.54 2.82 13.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 108.894 179.509 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 27.2 mtmt -139.19 132.29 29.64 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 1.116 HD21 ' CD1' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -127.68 132.99 49.6 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.001 -1.062 . . . . 0.0 110.211 -179.086 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.854 HG13 ' HG2' ' A' ' 65' ' ' GLU . 13.6 t -119.56 122.76 69.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.116 ' CD1' HD21 ' A' ' 28' ' ' LEU . 16.8 mt -137.66 136.72 37.7 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.046 -1.034 . . . . 0.0 110.324 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.563 ' HA ' HG12 ' A' ' 63' ' ' VAL . 37.7 t70 -84.2 136.22 34.05 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 177.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.854 HD12 ' CD1' ' A' ' 64' ' ' TRP . 88.1 mt -121.62 131.11 73.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.688 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.589 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 44.3 tttt -110.32 119.46 39.28 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 83.5 t80 -121.44 118.15 28.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.456 -0.777 . . . . 0.0 109.355 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 17.1 m -121.16 117.81 28.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.268 -0.895 . . . . 0.0 109.923 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.959 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -124.24 168.52 12.7 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.832 . . . . 0.0 109.345 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.582 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -70.07 76.96 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.634 2.223 . . . . 0.0 111.726 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.43 -5.92 75.28 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.44 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -97.26 179.38 4.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 109.498 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.0 m -151.08 158.37 43.97 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.302 -0.874 . . . . 0.0 109.527 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.847 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.79 136.4 47.06 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.659 -0.65 . . . . 0.0 109.342 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.928 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.58 -43.13 3.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.11 -0.994 . . . . 0.0 110.238 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -139.83 148.81 42.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.004 -1.06 . . . . 0.0 110.659 -179.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.615 HG13 ' CE1' ' A' ' 80' ' ' PHE . 14.6 t -139.0 136.3 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.541 -0.725 . . . . 0.0 109.33 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.508 ' HA ' HD13 ' A' ' 57' ' ' LEU . 95.2 mt-10 -128.75 150.89 50.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.953 -1.092 . . . . 0.0 109.255 179.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.95 HD12 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tt -121.61 147.32 46.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.27 -0.893 . . . . 0.0 110.045 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.799 ' N ' HD23 ' A' ' 46' ' ' LEU . 13.4 ttp180 -131.95 128.56 38.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.87 . . . . 0.0 108.808 179.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.414 ' NE2' HD23 ' A' ' 72' ' ' LEU . 36.0 mt-30 -69.7 153.02 43.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 0.0 109.942 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.573 ' CG ' ' HD2' ' A' ' 75' ' ' PRO . 66.1 t60 -67.45 119.29 12.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.41 -0.806 . . . . 0.0 109.682 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.91 4.35 54.41 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.452 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 39.4 t -114.24 154.49 27.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.453 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 87.5 mt-10 -117.78 15.69 14.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.375 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -119.02 97.6 5.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.903 . . . . 0.0 109.687 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -55.84 134.56 51.91 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.36 -0.838 . . . . 0.0 109.657 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -104.26 134.79 19.51 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.348 -0.845 . . . . 0.0 109.316 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.606 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.1 Cg_endo -70.61 145.35 52.01 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.627 2.218 . . . . 0.0 112.095 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.631 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.6 mp -110.0 151.2 27.45 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 108.871 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.1 m -100.66 125.51 47.09 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.865 -1.147 . . . . 0.0 108.851 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -72.13 108.83 5.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.202 -0.936 . . . . 0.0 109.091 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.513 ' O ' ' N ' ' A' ' 62' ' ' ASN . 15.2 mttm -107.48 126.26 52.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.986 -1.071 . . . . 0.0 109.542 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 48.67 -92.68 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 60' ' ' LYS . 31.6 p-10 -136.73 19.5 3.07 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.282 -1.128 . . . . 0.0 109.344 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.563 HG12 ' HA ' ' A' ' 31' ' ' ASP . 20.6 m -131.72 173.57 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.334 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.854 ' CD1' HD12 ' A' ' 32' ' ' ILE . 71.1 m95 -117.35 127.44 54.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.94 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.854 ' HG2' HG13 ' A' ' 29' ' ' VAL . 80.3 mt-10 -113.43 141.07 47.53 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.29 -0.881 . . . . 0.0 109.892 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.631 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 7.7 p -135.56 132.69 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.284 -0.885 . . . . 0.0 109.066 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.457 ' HG3' ' HG2' ' A' ' 27' ' ' LYS . 41.3 tttm -120.32 132.42 55.29 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 0.0 109.686 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 69' ' ' SER . 23.2 t -121.66 124.08 43.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.5 -0.75 . . . . 0.0 109.316 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 68' ' ' SER . 44.7 m -44.2 -29.86 0.7 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.011 -1.056 . . . . 0.0 108.461 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.713 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 0.1 OUTLIER -105.72 170.53 5.77 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.37 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.713 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.3 Cg_endo -66.6 172.18 9.67 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.115 1.876 . . . . 0.0 111.687 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.609 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.9 mt -100.59 144.53 29.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 110.122 -179.486 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.87 125.34 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.453 -0.779 . . . . 0.0 109.295 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -96.47 170.35 26.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.602 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.2 Cg_endo -68.62 146.6 79.94 Favored 'Cis proline' 0 C--O 1.213 -0.739 0 C-N-CA 122.837 -1.734 . . . . 0.0 111.859 -0.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 84.5 m-85 -92.48 147.22 23.07 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.447 -0.783 . . . . 0.0 110.669 -179.104 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.529 ' C ' ' CD1' ' A' ' 78' ' ' PHE . 20.5 m-80 -108.75 144.99 35.83 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.95 ' CE2' HD12 ' A' ' 46' ' ' LEU . 3.8 m-85 -136.99 122.56 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.855 -1.153 . . . . 0.0 110.319 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 89' ' ' VAL . 54.2 ttt180 -101.89 142.19 33.58 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.818 ' CD2' HD11 ' A' ' 41' ' ' LEU . 8.8 m-85 -123.91 143.79 50.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 111.267 -177.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.3 ttt -126.14 124.5 40.68 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.519 ' OG ' ' HB2' ' A' ' 86' ' ' MET . 13.4 p -77.53 145.6 36.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.846 . . . . 0.0 110.157 -178.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.928 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -44.96 -47.28 11.39 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.156 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.52 -6.92 5.14 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 97.01 34.41 5.68 Favored Glycine 0 N--CA 1.489 2.185 0 O-C-N 121.141 -1.211 . . . . 0.0 110.111 179.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.519 ' HB2' ' OG ' ' A' ' 82' ' ' SER . 55.8 mtp -105.36 110.46 22.82 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.028 -1.278 . . . . 0.0 109.127 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 26.6 mtm180 -90.4 140.6 29.56 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 110.668 -179.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.1 m120 -137.61 141.84 41.26 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.1 t -121.24 135.57 60.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.916 -1.115 . . . . 0.0 110.299 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.515 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 13.4 m-85 -124.2 122.31 37.45 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -98.44 146.98 25.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.208 -0.933 . . . . 0.0 109.546 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.602 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 49.1 tt0 52.92 52.64 13.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.438 -0.789 . . . . 0.0 110.162 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 94' ' ' ILE . 42.4 t -80.34 -33.38 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.882 -1.136 . . . . 0.0 108.933 179.447 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.484 HG13 HG12 ' A' ' 93' ' ' VAL . 14.0 mt -138.55 127.53 14.34 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.381 -0.824 . . . . 0.0 108.882 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.06 160.64 49.1 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.559 2.173 . . . . 0.0 112.099 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.474 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 58.6 m -50.96 -36.49 39.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.83 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.15 103.23 12.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.11 -0.994 . . . . 0.0 109.522 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.481 ' CE1' HG11 ' A' ' 19' ' ' VAL . 48.7 p90 -110.9 155.01 23.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.87 . . . . 0.0 109.219 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.5 m -105.99 172.39 6.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.145 -0.972 . . . . 0.0 109.418 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.433 HD13 ' CG1' ' A' ' 19' ' ' VAL . 28.2 mm -104.61 135.21 43.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.264 -0.898 . . . . 0.0 109.152 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 99.36 2.8 56.65 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.6 tttp -117.77 142.74 46.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.967 -1.313 . . . . 0.0 109.159 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.642 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.3 m -81.74 176.45 9.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.119 -0.988 . . . . 0.0 109.091 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.642 ' H ' HG22 ' A' ' 103' ' ' THR . 26.9 m-85 -160.69 98.4 1.22 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.8 -1.188 . . . . 0.0 109.064 179.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.53 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 0.2 OUTLIER -100.35 164.94 15.34 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.265 -0.897 . . . . 0.0 109.797 -179.423 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.53 ' HD2' ' HB3' ' A' ' 105' ' ' LYS . 50.5 Cg_endo . . . . . 0 C--O 1.215 -0.626 0 C-N-CA 122.712 2.274 . . . . 0.0 111.81 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.646 ' CG1' ' CE1' ' A' ' 34' ' ' TYR . 5.0 t . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -112.23 121.58 45.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.052 -1.03 . . . . 0.0 109.625 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.753 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.7 t -128.19 138.59 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.606 HG22 ' HB3' ' A' ' 105' ' ' LYS . 68.6 p -141.85 146.5 35.89 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.775 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.715 ' CD1' HG11 ' A' ' 93' ' ' VAL . 88.8 m-85 -119.35 118.79 32.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.3 -0.875 . . . . 0.0 109.734 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 21.9 m -108.36 158.51 17.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.922 -1.111 . . . . 0.0 108.979 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.702 ' CG1' HD13 ' A' ' 100' ' ' ILE . 8.5 t -107.8 126.68 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' HD12 ' A' ' 100' ' ' ILE . 1.7 mp0 -92.66 -173.52 3.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.146 -0.971 . . . . 0.0 109.605 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -83.65 66.01 8.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.385 -0.822 . . . . 0.0 109.937 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -172.33 22.01 0.07 OUTLIER Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.055 -1.545 . . . . 0.0 110.924 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.54 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 50.3 m -74.21 142.34 45.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.766 -1.432 . . . . 0.0 109.058 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.9 173.31 5.81 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.055 -1.028 . . . . 0.0 109.875 -179.634 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.8 Cg_endo -71.66 -30.56 14.52 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.793 2.329 . . . . 0.0 111.836 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -115.88 5.26 14.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 108.731 179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 72.8 mttt -142.17 133.11 25.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.949 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -127.87 135.34 49.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.067 -1.021 . . . . 0.0 110.099 -179.321 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.92 ' O ' HD13 ' A' ' 30' ' ' LEU . 4.1 t -119.39 119.05 59.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.949 HD11 HD22 ' A' ' 28' ' ' LEU . 0.4 OUTLIER -126.85 127.11 44.46 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.217 -0.927 . . . . 0.0 110.282 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.58 ' CB ' HG12 ' A' ' 63' ' ' VAL . 63.6 t0 -77.99 132.02 37.64 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.722 HG21 ' CE2' ' A' ' 80' ' ' PHE . 52.4 mt -118.3 128.56 75.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.157 -178.125 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.637 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 33.5 mttt -109.41 119.98 41.12 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.753 ' CD1' HG22 ' A' ' 15' ' ' VAL . 71.7 t80 -121.21 120.77 36.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.302 -0.874 . . . . 0.0 109.837 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -123.66 116.95 23.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.399 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CG ' ' HB2' ' A' ' 39' ' ' ASP . 38.0 ttt85 -139.72 131.94 14.96 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.452 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.44 107.85 2.08 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.814 2.343 . . . . 0.0 111.992 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.99 -5.29 84.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.556 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 31.6 m-20 -134.71 174.28 10.74 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -1.201 . . . . 0.0 109.682 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 82' ' ' SER . 14.7 m -155.42 162.65 40.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.74 HD13 ' HD2' ' A' ' 80' ' ' PHE . 26.8 tp -71.87 129.73 39.32 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.27 -0.894 . . . . 0.0 109.649 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.787 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -116.1 -40.29 3.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -0.934 . . . . 0.0 109.479 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -143.74 152.2 40.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.915 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.829 HG13 ' CE1' ' A' ' 80' ' ' PHE . 46.5 t -139.71 137.14 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.445 -0.785 . . . . 0.0 109.406 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.509 ' HA ' HD13 ' A' ' 57' ' ' LEU . 75.4 mt-10 -128.89 150.48 50.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.904 -1.123 . . . . 0.0 109.433 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.989 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.03 142.22 48.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.434 -0.791 . . . . 0.0 109.805 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.989 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.5 ttp180 -128.03 130.02 47.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.374 -0.829 . . . . 0.0 108.812 179.216 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.453 ' HA ' ' OE1' ' A' ' 48' ' ' GLN . 57.6 mm-40 -72.14 152.42 42.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 110.218 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.574 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 13.0 t-80 -68.07 131.0 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.513 -0.742 . . . . 0.0 109.461 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 87.8 3.36 80.42 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.8 t -112.23 153.04 27.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.178 -1.19 . . . . 0.0 109.189 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -113.75 21.56 14.86 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.387 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.35 124.59 43.28 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.236 -0.915 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.452 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 64.6 m95 -85.06 129.94 34.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.432 -0.793 . . . . 0.0 109.415 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.4 134.62 19.66 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.369 -0.832 . . . . 0.0 109.342 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.663 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.3 Cg_endo -71.8 146.88 49.15 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.642 2.228 . . . . 0.0 112.164 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.676 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -106.8 158.04 17.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 108.621 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 52.3 m -108.87 127.04 53.7 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.846 -1.159 . . . . 0.0 109.116 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 37.5 tttm -65.35 120.95 13.73 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 63' ' ' VAL . 2.8 mttm -109.92 -152.7 0.5 Allowed 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.167 -0.958 . . . . 0.0 109.377 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 62' ' ' ASN . . . -58.72 81.2 0.01 OUTLIER Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.518 ' N ' ' O ' ' A' ' 60' ' ' LYS . 39.2 t30 63.97 10.54 5.4 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.243 -1.151 . . . . 0.0 110.086 179.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.582 HG23 ' HB2' ' A' ' 60' ' ' LYS . 5.3 m -132.05 179.12 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.092 -1.005 . . . . 0.0 109.717 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.507 ' CD1' HD12 ' A' ' 32' ' ' ILE . 63.0 m95 -127.15 126.75 43.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.067 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.443 ' HG2' ' N ' ' A' ' 66' ' ' VAL . 62.1 tt0 -119.25 154.58 33.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.17 -0.956 . . . . 0.0 109.706 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.627 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.0 p -146.17 141.42 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.405 -0.81 . . . . 0.0 109.244 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -119.81 129.01 54.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -0.941 . . . . 0.0 109.723 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.2 t -118.6 130.36 55.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.57 -0.706 . . . . 0.0 109.578 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.0 p -61.24 -21.35 63.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.149 -0.969 . . . . 0.0 108.922 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 15.0 ptmt -106.95 166.86 10.34 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.445 -0.784 . . . . 0.0 109.332 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.633 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 45.6 Cg_endo -67.74 141.39 54.34 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.478 2.118 . . . . 0.0 111.721 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.92 HD13 HD12 ' A' ' 28' ' ' LEU . 10.6 mt -76.49 141.04 41.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.343 -0.848 . . . . 0.0 109.84 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 124.72 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.366 -0.834 . . . . 0.0 109.378 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.505 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.99 165.33 26.69 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.75 147.41 82.24 Favored 'Cis proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.892 -1.712 . . . . 0.0 112.077 -0.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.558 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.1 m-85 -90.9 148.03 22.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.411 -0.806 . . . . 0.0 110.339 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.469 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 26.9 m-80 -109.91 144.54 38.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.379 -0.826 . . . . 0.0 108.928 179.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.864 ' CE2' HD12 ' A' ' 46' ' ' LEU . 82.9 m-85 -135.13 129.23 33.56 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.029 -1.044 . . . . 0.0 110.049 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.618 ' HG3' HG22 ' A' ' 89' ' ' VAL . 20.3 ttt85 -110.27 141.79 42.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.061 -1.025 . . . . 0.0 108.528 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.829 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.6 m-85 -125.31 143.34 51.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 111.396 -178.116 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.8 124.57 42.4 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.591 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.9 p -72.68 145.45 47.21 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.36 -0.838 . . . . 0.0 110.145 -178.472 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.787 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 90.6 mttt -47.6 -45.53 27.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 109.145 179.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.16 -5.06 0.58 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.47 25.99 12.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.591 ' O ' ' N ' ' A' ' 82' ' ' SER . 45.6 mtp -98.99 150.7 21.7 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -1.18 . . . . 0.0 108.727 179.468 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 62.3 mtm-85 -123.78 138.82 54.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.888 -1.132 . . . . 0.0 110.575 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 31.1 m120 -135.69 140.6 44.57 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.618 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.9 t -124.04 137.73 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.95 -1.094 . . . . 0.0 110.637 -178.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.529 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.3 m-85 -123.53 121.54 35.91 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 178.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -98.11 147.05 24.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.164 -0.96 . . . . 0.0 109.58 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 65.8 tt0 53.47 52.84 12.61 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.4 -0.812 . . . . 0.0 110.03 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.715 HG11 ' CD1' ' A' ' 17' ' ' PHE . 70.4 t -81.51 -34.43 13.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.906 -1.121 . . . . 0.0 109.26 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.483 HG12 ' HB3' ' A' ' 104' ' ' TYR . 13.4 mt -136.91 126.43 15.57 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.149 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.26 160.88 48.12 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.603 2.202 . . . . 0.0 111.986 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.505 HG23 ' H ' ' A' ' 74' ' ' GLY . 9.2 m -52.0 -43.13 63.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.382 -0.824 . . . . 0.0 110.192 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.0 103.64 15.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.025 -1.047 . . . . 0.0 109.83 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.414 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 52.4 p90 -111.68 152.09 28.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 28.2 m -102.11 164.72 11.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.423 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.702 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.4 mm -98.52 137.43 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.972 . . . . 0.0 109.381 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.44 62.74 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -121.24 146.49 46.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -1.182 . . . . 0.0 109.338 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.6 m -79.77 164.15 23.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.111 -0.993 . . . . 0.0 109.321 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.543 ' N ' ' O ' ' A' ' 17' ' ' PHE . 18.0 m-85 -150.06 92.21 1.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.74 -1.225 . . . . 0.0 109.064 179.089 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.606 ' HB3' HG22 ' A' ' 16' ' ' THR . 0.0 OUTLIER -108.88 164.31 15.0 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.4 -0.813 . . . . 0.0 109.867 -179.477 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.529 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 47.7 Cg_endo . . . . . 0 C--O 1.215 -0.675 0 C-N-CA 122.843 2.362 . . . . 0.0 111.617 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 36' ' ' ARG . 15.7 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 70.6 mt-30 -111.95 122.35 47.54 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.12 -0.988 . . . . 0.0 109.424 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 6.2 t -129.01 139.51 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 0.0 109.721 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.452 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 19.9 p -141.26 145.91 36.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.885 . . . . 0.0 109.237 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.624 ' CD2' HG12 ' A' ' 32' ' ' ILE . 3.9 m-85 -120.22 141.93 49.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.104 -0.998 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 23.9 m -134.37 127.3 31.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.915 . . . . 0.0 108.963 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.0 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.7 t -76.0 134.32 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.146 -0.971 . . . . 0.0 109.243 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.7 mm-40 -115.29 153.29 31.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.004 -1.06 . . . . 0.0 109.897 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 57.3 mttp -44.15 113.17 0.49 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.458 -0.776 . . . . 0.0 109.988 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.12 -5.86 1.96 Allowed Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.251 -1.452 . . . . 0.0 110.771 179.186 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.572 ' OG ' ' CE1' ' A' ' 98' ' ' PHE . 26.8 t -64.24 144.35 57.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.737 -1.449 . . . . 0.0 109.635 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.539 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -138.54 174.15 4.52 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.332 -0.855 . . . . 0.0 109.561 -179.907 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.57 ' O ' ' N ' ' A' ' 72' ' ' LEU . 50.0 Cg_endo -69.89 -28.84 24.11 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.837 2.358 . . . . 0.0 112.072 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -116.35 6.22 13.68 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.087 -1.008 . . . . 0.0 109.045 179.611 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.448 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 5.9 mtpm? -142.29 133.4 26.04 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.24 40.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.084 -1.01 . . . . 0.0 109.51 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 1.015 HG13 ' HG2' ' A' ' 65' ' ' GLU . 46.3 t -118.49 124.57 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.193 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.0 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.19 146.22 31.65 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.014 -1.054 . . . . 0.0 110.37 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.543 ' OD1' HG12 ' A' ' 63' ' ' VAL . 48.4 t0 -86.04 138.19 32.14 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.99 HG21 ' CE2' ' A' ' 80' ' ' PHE . 57.8 mt -123.39 132.27 71.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.817 -1.177 . . . . 0.0 110.644 -178.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 59.5 mttm -109.85 118.07 35.51 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 178.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.645 ' CD1' HG22 ' A' ' 15' ' ' VAL . 73.1 t80 -121.69 109.04 14.25 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.505 -0.747 . . . . 0.0 109.619 -179.038 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 83.5 m -111.45 116.11 30.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.272 -0.892 . . . . 0.0 109.562 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -141.83 121.61 8.19 Favored Pre-proline 0 N--CA 1.488 1.473 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.812 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.7 117.6 5.18 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.458 2.105 . . . . 0.0 112.014 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.74 -11.31 68.28 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.544 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.27 -179.94 6.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.894 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 82' ' ' SER . 15.4 m -155.68 162.96 40.48 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.356 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.485 HD21 HG21 ' A' ' 44' ' ' VAL . 17.5 tp -70.5 127.91 34.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.266 -0.896 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.853 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.52 -41.65 3.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.218 -0.926 . . . . 0.0 109.734 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -147.15 155.11 41.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.169 -0.957 . . . . 0.0 110.176 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.57 HG22 ' CD2' ' A' ' 80' ' ' PHE . 21.4 t -142.39 141.15 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.442 -0.786 . . . . 0.0 109.33 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.435 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 88.6 mt-10 -127.61 150.52 49.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.767 -1.208 . . . . 0.0 109.434 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.955 HD12 ' O ' ' A' ' 77' ' ' ASN . 21.7 tp -122.2 144.21 49.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.408 -178.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.627 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.1 OUTLIER -126.17 127.85 46.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.383 -0.823 . . . . 0.0 109.012 179.243 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.474 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 74.0 mt-30 -71.06 149.77 46.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 109.315 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.592 ' CD2' ' HD2' ' A' ' 75' ' ' PRO . 47.3 t60 -64.84 109.03 1.93 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.559 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.37 2.99 24.41 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.518 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 18.1 t -114.91 154.97 27.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.013 -1.287 . . . . 0.0 109.566 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.429 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 54.7 mp0 -112.02 -12.27 13.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.187 -0.946 . . . . 0.0 109.313 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -95.43 99.7 11.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.323 -0.861 . . . . 0.0 109.559 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.627 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 24.9 m95 -59.32 141.5 54.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.302 -0.874 . . . . 0.0 109.707 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -106.63 137.0 19.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.502 -0.749 . . . . 0.0 109.599 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.435 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 53.1 Cg_endo -72.46 144.41 40.55 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.592 2.195 . . . . 0.0 111.776 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.704 HD11 ' CB ' ' A' ' 46' ' ' LEU . 7.5 mp -106.95 146.37 31.14 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.17 -0.956 . . . . 0.0 108.863 179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 88.4 m -103.11 126.22 50.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.936 -1.103 . . . . 0.0 108.905 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 9.4 tttm -68.82 112.81 5.76 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.189 -0.944 . . . . 0.0 108.904 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mttm -120.07 80.37 1.59 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.004 -1.06 . . . . 0.0 110.702 -178.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.31 60.39 1.31 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.369 179.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 60.03 10.37 2.18 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.148 -1.207 . . . . 0.0 110.16 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 59' ' ' LYS . 13.6 m -129.51 -172.64 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.161 -0.962 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.409 ' CD1' HD12 ' A' ' 32' ' ' ILE . 78.4 m95 -139.13 125.52 20.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.924 . . . . 0.0 109.553 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 1.015 ' HG2' HG13 ' A' ' 29' ' ' VAL . 27.0 mt-10 -115.08 152.08 33.14 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.856 . . . . 0.0 109.596 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.704 HG11 HD23 ' A' ' 46' ' ' LEU . 3.1 p -138.22 134.91 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.439 -0.788 . . . . 0.0 109.304 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 26.5 mttp -120.89 133.99 55.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.346 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.474 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 9.5 t -120.66 126.84 51.26 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.37 -0.831 . . . . 0.0 109.308 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' SER . 73.4 p -45.28 -26.69 0.54 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.007 -1.058 . . . . 0.0 108.514 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -115.26 178.33 0.99 Allowed Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.1 Cg_endo -67.81 178.94 2.98 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.332 2.022 . . . . 0.0 111.846 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.583 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -112.09 143.48 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.199 -0.938 . . . . 0.0 109.786 -179.577 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 6.4 t -120.8 123.71 70.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.367 -0.833 . . . . 0.0 109.31 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.729 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.41 166.21 29.24 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.4 Cg_endo -69.62 146.76 82.78 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.783 -1.757 . . . . 0.0 112.082 0.045 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 46' ' ' LEU . 72.1 m-85 -91.54 153.6 19.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.627 -0.671 . . . . 0.0 110.494 -179.249 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.955 ' O ' HD12 ' A' ' 46' ' ' LEU . 1.8 m-80 -112.5 141.03 46.73 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.91 ' CE1' HD13 ' A' ' 46' ' ' LEU . 84.4 m-85 -132.27 128.41 37.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.997 -1.065 . . . . 0.0 109.894 -179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.772 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.3 ttt180 -112.41 143.68 43.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.019 -1.051 . . . . 0.0 108.732 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.99 ' CE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -125.37 144.42 50.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.269 -0.894 . . . . 0.0 111.611 -177.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.8 ttt -127.15 126.19 42.47 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.552 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.8 p -79.06 148.87 32.31 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.284 -0.885 . . . . 0.0 110.18 -178.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.853 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 23.3 mttt -47.0 -46.51 21.76 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.244 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.422 ' HA3' ' OD1' ' A' ' 39' ' ' ASP . . . -59.83 -8.48 8.0 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.3 34.13 5.44 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 51.6 mmm -102.97 109.18 20.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.107 -1.231 . . . . 0.0 109.065 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 87.7 mtm-85 -91.48 141.52 28.65 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.125 -0.984 . . . . 0.0 110.704 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.565 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.1 m120 -135.88 140.08 43.85 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.772 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -120.57 136.48 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.022 -1.049 . . . . 0.0 110.358 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.55 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 31.6 m-85 -125.96 122.23 35.35 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -98.17 147.33 24.7 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.946 . . . . 0.0 109.655 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 41.3 mt-10 53.31 52.88 12.67 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.346 -0.846 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.687 HG12 HG13 ' A' ' 94' ' ' ILE . 40.2 t -82.94 -34.35 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.986 -1.071 . . . . 0.0 109.3 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.687 HG13 HG12 ' A' ' 93' ' ' VAL . 65.8 mt -136.83 125.15 14.89 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.347 -0.845 . . . . 0.0 109.134 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.08 162.58 41.16 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.548 2.165 . . . . 0.0 111.887 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.729 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.7 m -52.87 -37.11 59.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.469 -0.77 . . . . 0.0 110.016 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.74 98.34 9.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.029 -1.044 . . . . 0.0 109.717 -179.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.572 ' CE1' ' OG ' ' A' ' 23' ' ' SER . 35.4 p90 -107.0 146.61 30.89 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.125 -0.985 . . . . 0.0 109.366 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.2 m -114.53 118.37 33.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.918 . . . . 0.0 109.554 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.576 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 4.8 mt -56.76 139.37 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.392 -0.817 . . . . 0.0 109.721 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.08 5.52 54.68 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 26.4 tttt -124.13 143.46 50.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.991 -1.299 . . . . 0.0 109.379 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.4 m -78.11 158.77 28.99 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.187 -0.946 . . . . 0.0 108.908 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.8 m-85 -146.58 97.49 2.93 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.491 -1.381 . . . . 0.0 108.953 179.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.54 157.9 32.81 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 110.059 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.55 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.7 Cg_endo . . . . . 0 C--O 1.215 -0.649 0 C-N-CA 122.825 2.35 . . . . 0.0 111.822 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.778 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 4.2 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.408 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 82.7 mt-30 -106.99 120.84 43.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.183 -0.948 . . . . 0.0 109.172 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.619 HG11 ' HG3' ' A' ' 106' ' ' PRO . 11.4 p -129.57 141.65 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.253 -0.904 . . . . 0.0 109.747 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.498 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 60.5 p -140.77 144.6 35.57 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.071 -1.018 . . . . 0.0 109.481 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 104' ' ' TYR . 49.7 m-85 -114.24 147.41 39.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.246 -0.909 . . . . 0.0 109.253 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 29.1 m -145.98 127.34 14.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.994 -1.066 . . . . 0.0 109.483 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.91 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.8 t -75.88 136.52 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.392 -0.818 . . . . 0.0 109.209 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.16 158.22 19.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.985 -1.072 . . . . 0.0 109.835 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -51.43 113.11 0.87 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.865 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.77 -6.91 2.68 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.516 179.384 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.523 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 10.8 m -57.46 143.51 40.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.892 -1.358 . . . . 0.0 109.39 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.553 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.69 171.45 8.83 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.707 -179.818 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.3 Cg_endo -70.22 -31.27 18.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.861 2.374 . . . . 0.0 111.891 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.455 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 2.5 pttt -112.82 7.27 18.38 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.222 -0.923 . . . . 0.0 108.938 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.487 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 29.8 mttm -141.83 132.93 26.18 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.709 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.1 121.48 37.97 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.999 -1.063 . . . . 0.0 109.406 -179.87 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 1.025 HG22 ' HG3' ' A' ' 65' ' ' GLU . 11.9 t -119.72 125.69 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.91 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -145.27 145.37 31.24 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.983 -1.073 . . . . 0.0 110.024 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.508 ' HA ' HG12 ' A' ' 63' ' ' VAL . 67.7 t0 -84.54 137.57 33.25 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.665 HG21 ' HE2' ' A' ' 80' ' ' PHE . 53.9 mt -120.49 130.09 74.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.752 -1.217 . . . . 0.0 110.557 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.7 tttt -110.36 119.57 39.64 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.472 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.778 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 66.2 t80 -121.85 121.01 36.19 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.563 -0.711 . . . . 0.0 109.259 -179.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 91.7 m -122.75 115.82 22.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.128 -0.983 . . . . 0.0 110.162 -179.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.623 ' HG3' HG22 ' A' ' 13' ' ' VAL . 20.5 ttt85 -135.64 137.48 25.92 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.534 -0.729 . . . . 0.0 109.065 179.434 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.48 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.5 Cg_endo -69.66 99.4 0.73 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.648 2.232 . . . . 0.0 111.904 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.14 -38.0 3.25 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.565 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 53.5 m-20 -96.28 176.16 6.17 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.228 -1.16 . . . . 0.0 109.798 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -154.74 162.22 41.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.378 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.789 HD21 HG21 ' A' ' 44' ' ' VAL . 31.8 tp -68.11 128.74 37.66 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.061 -1.024 . . . . 0.0 109.109 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.837 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.37 -45.0 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.132 -0.98 . . . . 0.0 110.274 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.473 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 81.5 mt-10 -135.55 144.56 46.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.043 -1.036 . . . . 0.0 110.392 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.789 HG21 HD21 ' A' ' 41' ' ' LEU . 99.7 t -137.97 135.59 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.474 -0.766 . . . . 0.0 109.147 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -127.91 150.03 50.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.964 -1.085 . . . . 0.0 109.162 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.96 HD13 ' CE2' ' A' ' 78' ' ' PHE . 13.5 tp -121.38 133.2 55.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.798 . . . . 0.0 110.176 -178.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.618 ' N ' HD12 ' A' ' 46' ' ' LEU . 40.8 ttp180 -119.46 129.04 54.55 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 108.788 179.134 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.597 ' NE2' HD23 ' A' ' 72' ' ' LEU . 55.0 mt-30 -71.01 160.74 32.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.276 -0.89 . . . . 0.0 110.161 -179.216 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.8 t60 -70.59 145.66 50.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.42 -0.8 . . . . 0.0 109.438 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.54 2.66 44.43 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.462 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.8 t -112.83 154.25 26.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.102 -1.234 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -121.17 14.18 11.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.889 . . . . 0.0 109.417 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -111.66 98.66 7.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.344 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.541 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 65.4 m95 -59.88 134.38 56.98 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.281 -0.887 . . . . 0.0 109.737 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -111.54 130.93 22.61 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.468 -0.77 . . . . 0.0 109.095 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.506 ' C ' HD12 ' A' ' 57' ' ' LEU . 48.5 Cg_endo -69.62 141.53 46.06 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.502 2.135 . . . . 0.0 111.978 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.804 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.9 mp -97.16 143.06 28.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 108.534 179.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -81.38 125.91 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.902 -1.123 . . . . 0.0 109.13 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -72.22 108.22 5.27 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.16 -0.962 . . . . 0.0 109.379 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.449 ' O ' ' C ' ' A' ' 61' ' ' GLY . 22.7 mttm -113.76 132.78 55.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.995 -1.065 . . . . 0.0 109.469 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 60' ' ' LYS . . . 43.17 -100.24 0.02 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.443 ' N ' ' O ' ' A' ' 60' ' ' LYS . 23.9 p-10 -130.5 24.98 5.12 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -1.148 . . . . 0.0 109.187 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.508 HG12 ' HA ' ' A' ' 31' ' ' ASP . 35.9 m -131.62 -170.08 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.568 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.566 ' CD1' HD12 ' A' ' 32' ' ' ILE . 44.6 m95 -140.99 124.69 16.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.03 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 1.025 ' HG3' HG22 ' A' ' 29' ' ' VAL . 69.8 tt0 -115.36 151.96 33.69 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 109.71 -179.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.92 HG11 HD23 ' A' ' 46' ' ' LEU . 2.0 p -141.19 138.46 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.367 -0.833 . . . . 0.0 109.191 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.441 ' CD ' ' HD3' ' A' ' 27' ' ' LYS . 84.4 mttt -122.14 134.78 54.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.278 -0.889 . . . . 0.0 109.6 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' SER . 8.8 t -120.18 126.21 50.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.343 -0.848 . . . . 0.0 109.188 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 68' ' ' SER . 6.0 m -44.1 -29.03 0.55 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.084 -1.01 . . . . 0.0 108.83 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.567 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -112.55 178.35 0.99 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.431 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.8 Cg_endo -68.79 166.34 26.59 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.382 2.055 . . . . 0.0 111.618 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.597 HD23 ' NE2' ' A' ' 48' ' ' GLN . 1.8 mt -97.34 143.29 28.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.117 -0.989 . . . . 0.0 109.816 -179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.419 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 22.9 t -119.89 124.79 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.81 . . . . 0.0 109.307 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.763 ' H ' HG23 ' A' ' 96' ' ' THR . . . -95.51 169.09 27.15 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.615 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.5 Cg_endo -67.99 146.34 77.5 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.838 -1.734 . . . . 0.0 111.85 0.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.611 ' HB3' HD11 ' A' ' 46' ' ' LEU . 74.2 m-85 -91.34 149.84 21.56 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.532 -0.73 . . . . 0.0 110.37 -179.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.874 ' O ' HD12 ' A' ' 46' ' ' LEU . 18.9 m-80 -111.99 143.67 42.6 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 179.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.96 ' CE2' HD13 ' A' ' 46' ' ' LEU . 96.1 m-85 -134.84 120.36 19.24 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.056 -1.028 . . . . 0.0 109.515 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.934 ' HG3' HG22 ' A' ' 89' ' ' VAL . 63.3 ttt180 -100.55 141.94 32.7 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.955 -1.091 . . . . 0.0 108.653 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.74 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.3 m-85 -124.96 142.95 51.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.907 . . . . 0.0 111.317 -178.256 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.67 124.2 41.68 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.157 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.615 ' N ' ' O ' ' A' ' 86' ' ' MET . 13.6 p -72.16 144.85 48.43 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.408 -0.808 . . . . 0.0 110.097 -178.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.837 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.2 OUTLIER -50.24 -44.45 53.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -0.917 . . . . 0.0 108.777 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.04 -2.18 0.19 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.32 25.7 18.11 Favored Glycine 0 N--CA 1.491 2.35 0 O-C-N 121.068 -1.254 . . . . 0.0 109.978 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.615 ' O ' ' N ' ' A' ' 82' ' ' SER . 39.2 mtp -100.85 149.06 24.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.109 -1.23 . . . . 0.0 108.864 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 7.6 mtt85 -120.15 135.97 54.78 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.332 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -134.57 139.91 45.72 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.934 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -123.1 136.2 60.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.043 -1.036 . . . . 0.0 110.294 -178.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.653 ' CG ' ' CB ' ' A' ' 106' ' ' PRO . 11.3 m-85 -122.45 121.04 35.67 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.59 147.62 24.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.21 -0.931 . . . . 0.0 109.707 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.615 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 48.2 mt-10 53.69 49.64 18.86 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.412 -0.805 . . . . 0.0 110.2 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.611 HG12 HG13 ' A' ' 94' ' ' ILE . 54.3 t -77.91 -33.71 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.867 -1.146 . . . . 0.0 108.885 179.333 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.611 HG13 HG12 ' A' ' 93' ' ' VAL . 69.8 mt -138.83 124.71 12.33 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.321 -0.862 . . . . 0.0 108.959 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -67.72 162.83 37.69 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.647 2.232 . . . . 0.0 112.161 -179.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.763 HG23 ' H ' ' A' ' 74' ' ' GLY . 8.1 m -50.56 -43.87 56.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.41 -0.806 . . . . 0.0 109.829 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.03 103.77 15.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.039 -1.038 . . . . 0.0 109.528 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.582 ' CE2' HG11 ' A' ' 19' ' ' VAL . 43.0 p90 -111.25 158.86 18.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 109.157 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.4 m -107.92 172.48 6.81 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.256 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.6 mm -104.56 135.93 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.877 . . . . 0.0 109.253 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.75 6.77 58.1 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -117.08 141.74 47.88 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.064 -1.256 . . . . 0.0 109.337 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.57 HG22 ' N ' ' A' ' 104' ' ' TYR . 34.5 m -81.95 170.1 16.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.09 -1.007 . . . . 0.0 109.026 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.575 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.4 m-85 -151.23 99.37 2.65 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.771 -1.205 . . . . 0.0 109.261 179.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.571 ' HG2' ' O ' ' A' ' 15' ' ' VAL . 1.9 mtmt -84.43 148.95 53.75 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.467 -0.77 . . . . 0.0 109.66 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.653 ' CB ' ' CG ' ' A' ' 90' ' ' PHE . 51.1 Cg_endo . . . . . 0 C--O 1.215 -0.65 0 C-N-CA 122.254 1.969 . . . . 0.0 111.569 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 36' ' ' ARG . 17.1 t . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.457 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 36.1 mt-30 -109.31 121.35 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.094 -1.004 . . . . 0.0 109.814 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 9.5 p -128.87 140.39 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.35 -0.844 . . . . 0.0 109.439 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.484 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 27.9 p -142.08 146.16 35.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.06 -1.025 . . . . 0.0 109.606 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.0 m-85 -118.51 143.68 46.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.581 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 1.005 HG23 ' O ' ' A' ' 102' ' ' LYS . 69.0 m -139.67 129.05 24.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.067 -1.02 . . . . 0.0 109.245 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.904 HG22 HD23 ' A' ' 30' ' ' LEU . 42.6 t -75.91 132.67 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.225 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -105.17 159.78 15.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.109 -0.994 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -54.35 115.22 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.388 -0.82 . . . . 0.0 109.782 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 24' ' ' ASP . . . 139.5 -0.59 2.24 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.279 179.476 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.432 ' C ' ' OD1' ' A' ' 24' ' ' ASP . 34.1 t -66.85 142.17 57.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.976 -1.308 . . . . 0.0 109.394 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.648 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -134.56 174.48 4.59 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.205 -0.935 . . . . 0.0 109.31 -179.833 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.648 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 49.3 Cg_endo -70.36 -28.71 22.05 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.612 2.208 . . . . 0.0 111.985 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.3 mttm -114.51 9.37 16.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.935 . . . . 0.0 109.127 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.505 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 31.9 mttt -142.98 133.47 24.91 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.731 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.5 122.5 39.86 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.997 -1.064 . . . . 0.0 109.571 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.647 HG22 ' CG ' ' A' ' 65' ' ' GLU . 22.2 t -120.2 125.6 74.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.904 HD23 HG22 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -144.89 145.69 31.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.883 -1.136 . . . . 0.0 110.248 -179.419 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.494 ' HA ' HG12 ' A' ' 63' ' ' VAL . 17.9 t70 -86.22 138.52 31.81 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.824 HG21 ' HE2' ' A' ' 80' ' ' PHE . 70.5 mt -120.2 130.34 74.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.859 -178.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 25.1 tptt -110.55 120.26 41.83 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.115 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.504 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 79.6 t80 -121.77 123.64 42.31 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.395 -0.815 . . . . 0.0 109.915 -178.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.457 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 56.8 m -125.11 115.13 19.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 109.484 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 13' ' ' VAL . 29.8 ttt85 -139.79 135.37 16.6 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.448 -0.782 . . . . 0.0 109.199 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.481 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.8 Cg_endo -70.96 108.01 2.21 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.778 2.318 . . . . 0.0 112.182 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.02 -1.9 86.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.56 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.8 m-20 -134.36 173.92 11.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.075 -1.25 . . . . 0.0 109.655 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -153.45 160.85 42.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.81 HD11 ' CG2' ' A' ' 44' ' ' VAL . 7.8 tp -68.65 123.3 20.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.913 . . . . 0.0 109.212 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.794 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.36 -44.89 2.95 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.469 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 69.5 mt-10 -135.18 144.46 47.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.162 -0.961 . . . . 0.0 110.217 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.81 ' CG2' HD11 ' A' ' 41' ' ' LEU . 12.6 t -138.36 135.96 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.445 -0.784 . . . . 0.0 109.273 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -128.96 150.02 50.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.878 -1.139 . . . . 0.0 109.537 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.942 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.2 143.3 47.34 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.453 -0.779 . . . . 0.0 109.857 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.942 ' N ' HD23 ' A' ' 46' ' ' LEU . 35.8 ttp180 -131.33 126.36 35.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 108.821 179.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.589 ' NE2' HD23 ' A' ' 72' ' ' LEU . 56.1 mt-30 -66.39 156.11 35.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.159 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.59 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 8.3 t-80 -71.9 117.15 13.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 109.629 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 103.53 4.07 46.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.486 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 10.1 t -114.37 159.82 19.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.28 -1.13 . . . . 0.0 109.342 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.65 14.97 9.46 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -116.36 91.45 3.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.443 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -52.79 134.37 36.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -106.78 135.16 19.57 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.313 -0.867 . . . . 0.0 109.434 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.485 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.5 Cg_endo -70.15 145.78 55.84 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.677 2.251 . . . . 0.0 111.733 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.682 HD11 ' CB ' ' A' ' 46' ' ' LEU . 8.2 mp -110.41 150.78 28.33 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.168 -0.958 . . . . 0.0 109.052 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 m -102.36 126.74 49.47 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.993 -1.067 . . . . 0.0 109.141 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.7 tttt -77.46 101.56 6.48 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.071 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.565 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.7 mttt -115.4 150.39 36.46 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.866 -1.146 . . . . 0.0 110.083 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 43.38 32.23 1.75 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 1.5 m120 76.79 12.73 2.34 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.244 . . . . 0.0 110.126 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 3.0 m -130.17 176.9 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.136 -0.978 . . . . 0.0 108.805 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 64' ' ' TRP . 37.8 m95 -120.5 144.35 48.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.926 -1.108 . . . . 0.0 109.796 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.647 ' CG ' HG22 ' A' ' 29' ' ' VAL . 51.3 tt0 -136.5 151.97 50.01 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.376 -0.827 . . . . 0.0 109.445 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.813 HG11 HD13 ' A' ' 46' ' ' LEU . 9.8 p -137.11 133.77 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.387 -0.821 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' NZ ' ' A' ' 27' ' ' LYS . 21.4 mttt -119.72 131.21 55.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.934 . . . . 0.0 109.398 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t -118.24 165.96 13.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.381 -0.824 . . . . 0.0 109.522 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 50.2 m -88.74 2.98 52.47 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.249 -0.907 . . . . 0.0 109.052 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.558 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.2 OUTLIER -142.14 176.78 2.18 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.476 -0.765 . . . . 0.0 109.18 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.558 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.5 Cg_endo -68.55 139.31 44.37 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.506 2.137 . . . . 0.0 111.721 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.589 HD23 ' NE2' ' A' ' 48' ' ' GLN . 8.8 mt -73.88 143.08 45.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.261 -0.899 . . . . 0.0 109.627 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.424 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 31.2 t -119.42 123.3 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.249 -0.907 . . . . 0.0 109.31 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.532 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -92.05 164.7 28.76 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.701 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.55 147.87 85.07 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.775 -1.761 . . . . 0.0 112.035 -0.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 58.9 m-85 -89.52 151.1 22.15 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.505 -0.747 . . . . 0.0 110.149 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.432 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 39.2 m-80 -112.68 142.9 44.75 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.823 . . . . 0.0 109.051 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.874 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.9 m-85 -135.12 123.5 23.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 109.773 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.999 ' HG3' HG22 ' A' ' 89' ' ' VAL . 38.4 ttt180 -103.86 141.69 35.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.985 -1.072 . . . . 0.0 108.514 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.824 ' HE2' HG21 ' A' ' 32' ' ' ILE . 13.3 m-85 -125.17 142.8 51.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 111.497 -178.06 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.5 ttm -124.46 123.75 40.82 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.621 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.6 p -70.45 143.45 51.78 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.367 -0.833 . . . . 0.0 110.302 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.794 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -48.39 -45.2 35.57 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.356 -0.84 . . . . 0.0 108.83 178.924 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.42 -2.13 0.25 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.499 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.34 24.99 20.28 Favored Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.083 -1.246 . . . . 0.0 110.025 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.621 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.6 mmm -98.95 149.17 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.011 -1.288 . . . . 0.0 108.786 179.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.538 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 19.6 mtm105 -120.33 135.81 54.9 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.969 -1.082 . . . . 0.0 110.401 -179.013 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -134.32 139.44 45.67 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.999 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.7 t -122.82 136.42 59.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.112 -0.992 . . . . 0.0 110.316 -179.026 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 15' ' ' VAL . 27.7 m-85 -123.28 121.83 36.85 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.517 -0.919 . . . . 0.0 108.517 179.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -99.35 147.49 25.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.272 -0.893 . . . . 0.0 109.643 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.701 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 25.7 mt-10 53.48 52.2 13.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.392 -0.818 . . . . 0.0 110.201 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.3 t -83.04 -34.87 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 120.889 -1.132 . . . . 0.0 109.085 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -133.63 123.78 17.54 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.334 -0.854 . . . . 0.0 109.197 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.33 161.74 44.92 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.549 2.166 . . . . 0.0 111.79 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.532 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 32.6 m -54.29 -36.07 63.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.414 -0.804 . . . . 0.0 110.055 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.43 79.19 5.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.936 -1.102 . . . . 0.0 109.702 -179.513 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -89.02 145.05 25.73 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.314 -0.866 . . . . 0.0 109.408 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.59 116.48 26.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.321 -0.862 . . . . 0.0 109.67 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.59 HG12 HG12 ' A' ' 19' ' ' VAL . 11.1 mt -56.82 139.95 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.292 -0.88 . . . . 0.0 109.656 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.14 5.95 54.17 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 1.005 ' O ' HG23 ' A' ' 18' ' ' THR . 20.3 mttm -120.23 -165.82 1.23 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.009 -1.289 . . . . 0.0 109.183 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 8.7 m -131.06 165.22 23.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.07 -1.019 . . . . 0.0 108.517 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.7 m-85 -155.53 93.45 1.49 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.428 -1.42 . . . . 0.0 109.169 179.138 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 6.8 pttm -105.11 164.43 15.14 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.409 -0.807 . . . . 0.0 109.393 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 50.2 Cg_endo . . . . . 0 C--O 1.216 -0.601 0 C-N-CA 122.494 2.129 . . . . 0.0 111.739 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.645 HG22 ' HG3' ' A' ' 36' ' ' ARG . 20.1 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -111.65 121.37 44.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.157 -0.964 . . . . 0.0 109.313 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.2 t -128.16 138.09 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.814 -179.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.472 HG22 ' HD3' ' A' ' 105' ' ' LYS . 28.1 p -142.17 146.21 35.04 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.352 -0.842 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.594 ' O ' ' N ' ' A' ' 104' ' ' TYR . 34.1 m-85 -118.31 142.42 47.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.673 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 61.1 m -138.18 129.2 27.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.058 -1.027 . . . . 0.0 109.329 179.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.901 HG22 ' CD2' ' A' ' 30' ' ' LEU . 24.0 t -77.29 138.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.882 . . . . 0.0 109.39 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -106.15 -177.11 3.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.107 -0.995 . . . . 0.0 109.508 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 43.0 mttt -77.67 110.29 12.38 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.369 -0.832 . . . . 0.0 109.698 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.61 -0.32 1.66 Allowed Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.558 -1.306 . . . . 0.0 110.481 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.0 t -56.4 144.82 29.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.875 -1.368 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.5 168.99 14.62 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.167 -0.958 . . . . 0.0 109.636 -179.833 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.527 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 48.3 Cg_endo -69.76 -27.64 26.24 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.854 2.369 . . . . 0.0 111.859 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -114.65 8.61 16.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.164 -0.96 . . . . 0.0 109.01 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.443 ' C ' HD11 ' A' ' 72' ' ' LEU . 56.4 mttp -143.99 134.15 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 108.98 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.91 123.02 40.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.927 -1.108 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.735 HG13 ' HG2' ' A' ' 65' ' ' GLU . 5.0 t -120.36 126.07 74.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.901 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.35 145.48 31.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.842 -1.161 . . . . 0.0 110.2 -179.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.423 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.2 t0 -83.88 135.01 34.66 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 178.044 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.633 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -115.53 127.07 73.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.779 -1.201 . . . . 0.0 111.154 -178.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 10.2 ttpt -108.12 115.19 29.67 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 177.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.514 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 76.7 t80 -124.05 108.16 12.06 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.682 -0.637 . . . . 0.0 109.84 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.0 m -109.6 117.56 34.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.351 -0.843 . . . . 0.0 109.446 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.645 ' HG3' HG22 ' A' ' 13' ' ' VAL . 9.4 ttt85 -144.65 114.49 5.14 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.405 -0.81 . . . . 0.0 109.354 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.41 120.7 7.5 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.704 2.269 . . . . 0.0 111.809 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.06 -19.54 54.38 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.531 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 5.0 m-20 -140.75 -179.09 5.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -1.126 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.412 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 18.6 m -155.75 162.86 40.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.86 . . . . 0.0 109.535 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.778 HD21 ' CG2' ' A' ' 44' ' ' VAL . 25.1 tp -69.97 129.19 38.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.294 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.884 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.12 3.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -138.95 147.6 42.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.189 -0.944 . . . . 0.0 110.246 -179.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.778 ' CG2' HD21 ' A' ' 41' ' ' LEU . 77.6 t -138.18 136.01 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.488 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.3 mt-10 -129.76 151.63 50.13 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.88 -1.137 . . . . 0.0 109.775 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.943 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.9 tt -120.99 140.23 52.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 109.636 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . 0.943 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.8 ttp180 -125.73 128.13 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.135 179.301 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.469 ' NE2' HD23 ' A' ' 72' ' ' LEU . 28.2 mt-30 -69.58 145.5 52.51 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.594 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' HIS . . . . . 0.609 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 22.4 t60 -63.85 113.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.842 . . . . 0.0 109.421 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.78 1.97 30.49 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.425 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 29.1 t -114.02 154.92 26.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.241 . . . . 0.0 109.418 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -118.25 22.35 12.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.444 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 83.0 mt-10 -127.43 81.2 2.0 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.535 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.612 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 43.8 m95 -43.38 136.53 3.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -0.907 . . . . 0.0 109.698 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -104.91 138.48 19.52 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.84 . . . . 0.0 109.311 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.497 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.7 Cg_endo -71.74 147.84 51.43 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.649 2.233 . . . . 0.0 112.113 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.62 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -111.48 155.78 22.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 108.958 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 m -109.7 127.14 54.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.813 -1.179 . . . . 0.0 109.078 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 41.6 tttm -71.72 110.64 6.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.145 -0.972 . . . . 0.0 109.344 -179.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.965 ' O ' HG22 ' A' ' 63' ' ' VAL . 20.8 mttt -119.63 141.1 49.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.815 -1.178 . . . . 0.0 109.812 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.584 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.52 31.08 0.97 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.584 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER 81.88 15.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.306 -1.114 . . . . 0.0 110.362 179.292 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.1 m -129.86 173.42 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.986 -1.071 . . . . 0.0 108.838 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 69.3 m95 -118.96 122.75 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.875 -1.141 . . . . 0.0 109.666 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.735 ' HG2' HG13 ' A' ' 29' ' ' VAL . 5.5 mt-10 -115.88 153.71 31.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.438 -0.789 . . . . 0.0 109.511 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.736 HG11 HD13 ' A' ' 46' ' ' LEU . 2.9 p -138.73 135.57 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.486 -0.759 . . . . 0.0 109.432 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.3 mttm -119.8 131.36 55.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -118.41 160.28 21.98 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.466 -0.771 . . . . 0.0 109.25 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 71.1 m -80.25 -13.87 58.87 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.145 -0.972 . . . . 0.0 109.148 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.556 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.0 OUTLIER -124.09 177.2 1.85 Allowed Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.369 -0.832 . . . . 0.0 109.031 179.791 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.556 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.5 Cg_endo -69.41 138.84 39.93 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.42 2.08 . . . . 0.0 111.678 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.675 HD13 ' HB2' ' A' ' 28' ' ' LEU . 16.2 mt -69.9 140.38 53.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.328 -0.858 . . . . 0.0 109.858 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.1 t -121.55 124.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.416 -0.803 . . . . 0.0 109.213 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.52 168.64 28.17 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.611 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.08 146.1 79.78 Favored 'Cis proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.822 -1.741 . . . . 0.0 112.025 -0.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 73.0 m-85 -91.14 147.76 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -0.832 . . . . 0.0 110.422 -179.179 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.418 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 30.2 m-80 -108.38 142.88 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.414 -0.804 . . . . 0.0 108.91 179.103 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.872 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.1 m-85 -133.93 122.29 22.91 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.041 -1.037 . . . . 0.0 109.77 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.584 ' HG3' HG22 ' A' ' 89' ' ' VAL . 57.9 ttp180 -106.33 144.1 33.5 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.089 -1.007 . . . . 0.0 108.937 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.633 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -124.69 142.76 51.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.14 -0.975 . . . . 0.0 111.502 -178.142 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.568 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.8 ttt -125.13 124.78 42.55 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' SER . . . . . 0.662 ' N ' ' O ' ' A' ' 86' ' ' MET . 21.0 p -73.59 144.43 45.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.325 -0.86 . . . . 0.0 110.544 -178.284 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' LYS . . . . . 0.884 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 47.3 mttm -47.17 -45.18 22.63 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.414 -0.804 . . . . 0.0 109.033 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.64 -5.02 1.65 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 96.61 24.72 13.11 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.662 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.1 mmm -95.96 147.62 23.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.045 -1.268 . . . . 0.0 108.503 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 24.5 mtm180 -123.29 138.39 54.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.686 -1.259 . . . . 0.0 110.794 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.428 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.1 m120 -134.97 139.94 45.3 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.584 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.7 t -123.01 137.34 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 120.877 -1.139 . . . . 0.0 110.461 -178.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.561 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 75.1 m-85 -124.91 123.51 40.06 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -99.8 146.73 26.25 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.805 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.611 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 79.1 tt0 53.67 53.93 10.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.411 -0.806 . . . . 0.0 110.652 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.606 HG22 ' HB3' ' A' ' 106' ' ' PRO . 45.5 t -83.81 -33.92 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.866 -1.146 . . . . 0.0 109.04 179.366 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 12.5 mt -135.98 125.24 15.92 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.412 -0.805 . . . . 0.0 109.017 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.78 161.98 43.83 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.563 2.175 . . . . 0.0 112.101 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.52 HG23 ' H ' ' A' ' 74' ' ' GLY . 23.7 m -50.49 -46.33 56.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.451 -0.781 . . . . 0.0 109.966 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.72 102.61 15.22 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.006 . . . . 0.0 109.627 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 53.7 p90 -109.85 154.36 23.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 109.353 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 73.1 p -107.97 171.96 7.1 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.545 HD13 ' CG1' ' A' ' 19' ' ' VAL . 20.9 mm -106.26 136.77 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.266 -0.897 . . . . 0.0 109.347 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 93.25 8.13 61.61 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -119.25 143.69 47.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.243 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -77.32 174.95 10.21 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.016 -1.052 . . . . 0.0 108.827 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' TYR . . . . . 0.616 ' H ' HG22 ' A' ' 103' ' ' THR . 26.6 m-85 -159.49 94.65 1.18 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.737 -1.227 . . . . 0.0 109.165 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' LYS . . . . . 0.472 ' HD3' HG22 ' A' ' 16' ' ' THR . 11.8 mtmm -91.72 155.33 43.72 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.341 -0.849 . . . . 0.0 109.665 -179.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.606 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.7 Cg_endo . . . . . 0 C--O 1.215 -0.626 0 C-N-CA 122.783 2.322 . . . . 0.0 111.649 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 17.8 mtt85 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -66.64 95.08 0.25 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.6 p -75.6 155.27 36.08 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.243 -1.151 . . . . 0.0 109.529 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -106.09 92.29 4.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.437 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 55.3 p-80 -93.83 8.54 40.77 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.262 -0.899 . . . . 0.0 109.539 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -50.23 -34.26 22.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.282 -0.886 . . . . 0.0 109.462 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -63.85 -32.23 73.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.467 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 33.1 t-80 -58.32 -43.17 88.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 51.6 m80 -50.18 -34.23 21.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.25 -127.29 8.86 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -118.29 157.34 27.24 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -1.14 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -148.95 150.22 32.52 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.757 HG13 ' HG3' ' A' ' 36' ' ' ARG . 2.1 t -125.71 135.58 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -112.18 120.4 41.64 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.011 -1.056 . . . . 0.0 109.539 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.8 t -128.19 139.1 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 109.75 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.442 ' HA ' ' HG3' ' A' ' 105' ' ' LYS . 70.7 p -141.52 145.62 35.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.225 -0.922 . . . . 0.0 109.697 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.803 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.9 m-85 -117.05 128.97 55.69 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.248 -0.907 . . . . 0.0 109.786 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.462 ' O ' ' N ' ' A' ' 31' ' ' ASP . 41.3 m -128.03 128.64 45.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.162 -0.961 . . . . 0.0 109.157 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.848 HG22 HD23 ' A' ' 30' ' ' LEU . 21.3 t -76.18 139.44 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.357 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.16 157.23 21.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.117 -0.989 . . . . 0.0 109.72 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -51.3 114.39 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.444 -0.785 . . . . 0.0 109.977 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.16 -1.43 2.19 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.523 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.1 t -60.01 141.24 56.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.925 -1.338 . . . . 0.0 109.175 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.57 176.13 3.02 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.121 -0.987 . . . . 0.0 109.664 -179.639 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.6 Cg_endo -71.77 -30.56 14.19 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.606 2.204 . . . . 0.0 111.816 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.4 mttm -117.21 4.99 12.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -0.886 . . . . 0.0 109.091 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.488 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 41.6 mttt -142.17 133.43 26.28 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.15 HD12 HD13 ' A' ' 72' ' ' LEU . 0.3 OUTLIER -127.18 133.78 50.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.034 -1.042 . . . . 0.0 110.21 -179.445 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 2.8 t -122.99 124.84 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.038 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -141.16 141.31 34.13 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.034 -1.041 . . . . 0.0 110.041 -179.526 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.602 ' CB ' HG12 ' A' ' 63' ' ' VAL . 59.7 t0 -86.11 137.34 32.74 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.575 HG12 ' CD2' ' A' ' 17' ' ' PHE . 82.1 mt -122.23 131.14 73.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 120.865 -1.147 . . . . 0.0 110.523 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 66.2 mttm -110.54 120.29 41.94 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.604 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.5 t80 -122.49 114.19 20.35 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.415 -0.803 . . . . 0.0 109.541 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.9 m -116.99 117.96 31.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.784 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.757 ' HG3' HG13 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -135.22 132.0 19.9 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.432 -0.793 . . . . 0.0 109.21 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.453 ' HD2' ' HG2' ' A' ' 36' ' ' ARG . 49.9 Cg_endo -70.2 105.89 1.64 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.67 2.246 . . . . 0.0 112.078 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.93 -2.12 87.02 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.523 ' HB3' ' HD2' ' A' ' 36' ' ' ARG . 1.7 m-20 -135.44 173.7 11.43 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.114 -1.227 . . . . 0.0 109.673 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 82' ' ' SER . 20.6 m -153.89 161.34 42.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.439 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.735 HD11 ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -71.5 132.98 45.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.947 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.47 -42.47 3.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.18 -0.95 . . . . 0.0 109.499 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -142.84 151.24 40.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.065 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.735 ' CG2' HD11 ' A' ' 41' ' ' LEU . 65.1 t -139.86 137.6 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.1 mt-10 -126.22 148.73 49.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.784 -1.198 . . . . 0.0 109.432 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.017 HD13 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tp -121.44 129.58 53.07 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.491 -0.756 . . . . 0.0 110.184 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.688 ' N ' HD12 ' A' ' 46' ' ' LEU . 12.1 ttp180 -115.63 131.97 56.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.199 -0.938 . . . . 0.0 108.875 179.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.588 HE21 HD23 ' A' ' 72' ' ' LEU . 44.5 mt-30 -73.47 155.15 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.315 -0.865 . . . . 0.0 110.021 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.1 t60 -67.29 147.83 52.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.446 -0.783 . . . . 0.0 109.357 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.83 2.12 35.67 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 32.5 t -113.21 152.46 29.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -1.214 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -117.81 17.88 14.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -0.907 . . . . 0.0 109.316 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -116.39 104.35 11.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.0 109.454 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.58 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 45.8 m95 -66.59 134.72 52.92 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.338 -0.851 . . . . 0.0 109.673 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.486 ' HG2' ' HD2' ' A' ' 56' ' ' PRO . 0.9 OUTLIER -108.71 134.27 20.37 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.345 179.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.535 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.5 Cg_endo -70.45 144.51 50.53 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.625 2.217 . . . . 0.0 111.961 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.73 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -103.88 148.36 26.23 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 108.823 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 63.0 m -97.5 125.78 42.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 108.947 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 12.9 tttm -70.93 111.64 6.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.236 -0.915 . . . . 0.0 109.269 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -109.77 105.54 14.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.054 -1.029 . . . . 0.0 109.461 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.79 -96.24 0.25 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -131.04 18.83 4.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.256 -1.144 . . . . 0.0 109.451 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.602 HG12 ' CB ' ' A' ' 31' ' ' ASP . 22.5 m -132.43 177.42 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.265 -0.897 . . . . 0.0 109.437 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.572 ' CD1' HD12 ' A' ' 32' ' ' ILE . 74.5 m95 -122.58 142.67 50.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 108.961 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -129.73 145.16 51.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.805 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.977 HG11 HD23 ' A' ' 46' ' ' LEU . 3.6 p -137.62 134.11 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.351 -0.843 . . . . 0.0 109.033 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -121.17 133.4 55.19 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.227 -0.92 . . . . 0.0 109.56 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.6 t -118.04 163.88 15.94 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.445 -0.784 . . . . 0.0 109.452 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 65.1 m -87.14 -5.96 58.82 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.191 -0.943 . . . . 0.0 109.152 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.9 OUTLIER -131.99 178.44 1.75 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.385 -0.822 . . . . 0.0 109.126 179.866 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -69.18 139.52 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.395 2.063 . . . . 0.0 111.577 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.15 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -75.38 141.19 43.31 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.25 -0.906 . . . . 0.0 109.935 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 42.9 t -123.86 124.92 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.465 -0.772 . . . . 0.0 109.155 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.585 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.67 170.18 30.67 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.63 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.8 Cg_endo -69.8 147.57 85.0 Favored 'Cis proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.836 -1.735 . . . . 0.0 111.833 0.037 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.591 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.7 m-85 -91.92 151.38 20.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.473 -0.767 . . . . 0.0 110.599 -179.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.746 ' O ' HD12 ' A' ' 46' ' ' LEU . 34.9 m-80 -112.15 143.45 43.17 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 1.017 ' CE2' HD13 ' A' ' 46' ' ' LEU . 95.7 m-85 -136.33 130.76 33.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.947 -1.096 . . . . 0.0 109.972 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.993 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.3 ttp180 -110.31 141.49 43.25 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.058 -1.026 . . . . 0.0 108.627 179.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.568 ' CE2' HG21 ' A' ' 32' ' ' ILE . 5.8 m-85 -120.93 142.78 49.4 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 111.021 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.591 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -127.77 125.35 39.74 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.701 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.629 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.1 p -78.0 144.48 36.66 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 110.416 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.947 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 30.8 mttm -46.21 -43.79 15.63 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.14 -2.96 0.69 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.12 22.94 26.17 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.629 ' O ' ' N ' ' A' ' 82' ' ' SER . 1.6 mmm -96.34 146.45 24.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.123 -1.221 . . . . 0.0 108.604 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 42.8 mtm180 -124.36 141.35 52.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.826 -1.172 . . . . 0.0 110.535 -178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.432 ' N ' ' O ' ' A' ' 80' ' ' PHE . 24.2 m120 -136.48 140.91 43.41 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.993 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.0 t -121.49 135.95 59.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 110.354 -179.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.552 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 41.9 m-85 -124.59 122.53 37.81 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -99.55 148.94 23.76 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.202 -0.936 . . . . 0.0 109.753 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.63 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 10.5 mt-10 51.7 51.03 17.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.53 -0.731 . . . . 0.0 110.371 179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.803 HG11 ' CE1' ' A' ' 17' ' ' PHE . 39.7 t -82.83 -33.54 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.911 -1.118 . . . . 0.0 109.255 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 9.1 mt -131.62 124.3 19.88 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.113 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -71.54 161.04 46.65 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.494 2.129 . . . . 0.0 111.916 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.585 HG23 ' H ' ' A' ' 74' ' ' GLY . 7.7 m -53.54 -43.96 68.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.341 -0.849 . . . . 0.0 109.95 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.4 99.84 12.75 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.105 -0.997 . . . . 0.0 109.568 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.73 146.06 34.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.627 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 16.2 m -106.54 156.68 18.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.395 -0.816 . . . . 0.0 109.183 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.575 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.2 mm -92.21 136.39 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.134 -0.979 . . . . 0.0 109.441 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.04 2.2 62.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -115.56 143.04 45.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.174 -1.192 . . . . 0.0 109.097 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.456 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.0 m -79.7 169.66 17.65 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.068 -1.02 . . . . 0.0 108.995 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.7 m-85 -154.57 100.32 2.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.714 -1.241 . . . . 0.0 109.032 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.524 ' CD ' ' N ' ' A' ' 105' ' ' LYS . 0.5 OUTLIER -95.25 158.2 35.12 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.718 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo -71.58 135.98 27.36 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.743 2.296 . . . . 0.0 111.808 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -90.04 161.92 15.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.31 -0.868 . . . . 0.0 109.494 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 71.2 mm-40 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.995 -1.003 . . . . 0.0 109.47 -179.95 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 54.2 mtm180 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.26 137.28 47.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 52.4 m -51.61 -31.69 26.06 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.191 -1.182 . . . . 0.0 109.465 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 -121.69 139.34 53.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.489 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.3 p-80 -90.95 31.46 1.08 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.421 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.524 ' HA ' ' CE1' ' A' ' 9' ' ' HIS . 7.8 m-70 62.07 70.44 0.58 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.294 -0.879 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 29.2 t60 -55.12 -55.92 25.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.4 p-80 -170.42 37.17 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.418 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.524 ' CE1' ' HA ' ' A' ' 6' ' ' HIS . 72.5 m80 -49.32 -40.04 33.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.213 -0.929 . . . . 0.0 109.471 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.71 165.6 27.22 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.1 m -119.33 134.24 55.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -1.154 . . . . 0.0 109.476 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 59.47 -147.58 0.48 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.252 -0.905 . . . . 0.0 109.51 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.734 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 16.6 t -127.14 138.36 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -0.943 . . . . 0.0 109.37 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -110.1 120.77 43.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.363 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.517 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.4 t -127.94 138.17 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.346 -0.846 . . . . 0.0 109.632 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 34.0 p -141.53 145.83 35.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.25 -0.906 . . . . 0.0 109.418 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.621 ' CD2' HG12 ' A' ' 32' ' ' ILE . 15.0 m-85 -118.46 143.98 46.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.21 -0.931 . . . . 0.0 109.781 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 21.4 m -139.39 128.05 23.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 0.0 109.136 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.829 HG22 ' CD2' ' A' ' 30' ' ' LEU . 16.7 t -76.21 130.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -108.57 152.76 24.32 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.076 -1.015 . . . . 0.0 109.695 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -45.41 114.81 0.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.416 -0.802 . . . . 0.0 109.978 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.34 -2.92 1.84 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.834 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 34.9 m -63.71 141.09 58.89 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.703 -1.469 . . . . 0.0 109.277 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.534 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.64 175.49 3.55 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.128 -0.983 . . . . 0.0 109.593 -179.697 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.0 Cg_endo -71.54 -30.82 14.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.566 2.177 . . . . 0.0 111.845 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.2 mttp -117.33 4.78 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 0.0 109.053 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.426 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 35.4 mttp -142.27 133.64 26.42 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.074 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.12 132.25 50.63 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.948 -1.095 . . . . 0.0 110.347 -179.253 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.614 HG13 ' HG2' ' A' ' 65' ' ' GLU . 8.8 t -121.91 125.41 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.074 HD11 HD22 ' A' ' 28' ' ' LEU . 1.4 mt -141.88 141.49 33.05 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.942 -1.099 . . . . 0.0 110.142 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.438 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.0 t0 -86.36 137.56 32.48 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.742 HG21 ' CE2' ' A' ' 80' ' ' PHE . 88.2 mt -122.74 131.56 73.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 120.856 -1.153 . . . . 0.0 110.437 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 23.4 mttt -109.9 119.22 38.65 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.734 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.2 t80 -122.99 110.69 15.68 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.511 -0.743 . . . . 0.0 109.482 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.0 m -113.21 118.17 33.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.88 . . . . 0.0 109.68 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.551 ' CG ' ' HD2' ' A' ' 37' ' ' PRO . 1.4 ttt85 -130.15 141.81 43.22 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.277 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.12 89.29 0.46 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.572 2.181 . . . . 0.0 112.001 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.03 -32.19 6.62 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.492 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 21.1 m-20 -95.11 175.74 6.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -1.188 . . . . 0.0 109.705 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 82' ' ' SER . 51.1 m -155.01 162.56 41.04 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.404 -0.81 . . . . 0.0 109.337 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.739 HD11 ' CD2' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -71.52 133.92 46.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.274 179.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.917 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.45 3.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.24 -0.912 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -140.62 149.42 42.28 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 0.0 110.205 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' CG2' HD11 ' A' ' 41' ' ' LEU . 21.6 t -139.14 136.32 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.408 -0.808 . . . . 0.0 109.455 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -129.59 152.02 49.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.903 -1.123 . . . . 0.0 109.385 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.88 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.3 tt -121.75 141.39 51.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.301 -0.875 . . . . 0.0 109.928 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.878 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.5 ttp180 -124.23 129.61 51.08 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.311 -0.868 . . . . 0.0 109.022 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' HD23 ' A' ' 72' ' ' LEU . 37.1 mt-30 -70.69 150.42 45.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.357 -0.839 . . . . 0.0 109.878 -179.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.521 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 54.9 t60 -68.06 118.3 11.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.577 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.77 4.09 52.05 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.4 t -114.48 160.63 18.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.332 -1.099 . . . . 0.0 109.468 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 72.9 tt0 -124.56 15.23 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -0.924 . . . . 0.0 109.371 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 64.9 tt0 -118.11 81.4 1.67 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.445 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.563 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 40.8 m95 -43.28 138.86 2.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.34 -0.85 . . . . 0.0 109.778 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.28 136.68 20.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.48 -0.762 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.27 145.13 47.85 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.797 2.331 . . . . 0.0 111.898 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.839 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.3 mp -112.05 155.22 24.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.235 -0.916 . . . . 0.0 109.009 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.9 m -109.67 126.92 54.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.952 -1.092 . . . . 0.0 109.32 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 31.9 tttm -73.2 110.4 7.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.061 -1.024 . . . . 0.0 109.312 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.837 ' O ' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -119.31 142.83 47.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.904 -1.122 . . . . 0.0 110.126 -179.469 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.8 32.46 0.93 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 3.6 t-20 81.49 12.84 0.68 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.231 -1.158 . . . . 0.0 110.478 179.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.837 HG22 ' O ' ' A' ' 60' ' ' LYS . 16.6 m -129.47 176.71 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.029 -1.044 . . . . 0.0 108.872 179.386 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.719 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.3 m95 -116.5 138.09 51.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 0.0 109.56 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.614 ' HG2' HG13 ' A' ' 29' ' ' VAL . 38.3 mt-10 -124.29 139.69 53.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.343 -0.848 . . . . 0.0 109.418 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 46' ' ' LEU . 10.1 p -133.57 130.85 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.311 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -120.34 131.98 55.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.114 -0.991 . . . . 0.0 109.517 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t -118.52 145.99 44.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.502 -0.749 . . . . 0.0 109.421 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.4 m -72.3 -5.17 34.23 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.098 -1.001 . . . . 0.0 109.114 179.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.577 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.3 mtmt -130.18 177.82 2.01 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.368 -0.833 . . . . 0.0 109.11 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.5 Cg_endo -68.96 145.93 63.46 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.498 2.132 . . . . 0.0 111.765 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.99 HD13 HD12 ' A' ' 28' ' ' LEU . 3.6 mt -83.63 138.69 33.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.797 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.0 t -123.4 124.9 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.385 -0.822 . . . . 0.0 109.484 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -94.03 169.64 29.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.51 147.52 81.73 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.903 -1.707 . . . . 0.0 112.019 -0.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.8 m-85 -91.19 151.38 20.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.556 -0.715 . . . . 0.0 110.561 -179.232 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.445 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 9.2 m-80 -112.59 143.5 43.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.342 -0.848 . . . . 0.0 108.778 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.88 ' CE2' HD12 ' A' ' 46' ' ' LEU . 49.7 m-85 -137.28 128.45 27.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.925 -1.109 . . . . 0.0 110.257 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.609 ' HG3' HG22 ' A' ' 89' ' ' VAL . 9.1 ttp180 -108.13 142.72 37.91 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.742 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -123.16 144.04 49.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.155 -0.965 . . . . 0.0 111.373 -178.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' O ' ' A' ' 86' ' ' MET . 10.0 ttm -127.94 126.12 40.85 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -79.8 144.17 33.78 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 110.323 -178.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.917 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 68.6 mttm -44.71 -43.56 8.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.27 -3.11 0.78 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.454 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.67 23.43 26.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 35.6 mtp -97.59 147.25 24.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.101 -1.235 . . . . 0.0 108.716 179.433 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.6 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 20.7 mtm180 -125.53 142.78 51.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.819 -1.176 . . . . 0.0 110.505 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.0 m120 -137.38 141.52 41.74 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 79' ' ' ARG . 7.4 t -121.45 136.28 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.924 -1.11 . . . . 0.0 110.252 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.512 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 43.9 m-85 -124.94 122.55 37.67 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -98.42 147.28 24.88 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 18.3 mt-10 52.83 51.9 15.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.439 -0.788 . . . . 0.0 110.284 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.444 HG21 ' HB2' ' A' ' 90' ' ' PHE . 58.4 t -80.74 -33.32 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.804 -1.185 . . . . 0.0 109.159 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.474 HG12 ' HB3' ' A' ' 104' ' ' TYR . 65.2 mt -138.47 126.27 13.7 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.089 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.24 162.81 40.32 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.563 2.175 . . . . 0.0 111.981 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.488 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 54.4 m -53.6 -39.76 65.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.359 -0.838 . . . . 0.0 109.924 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -92.16 99.44 12.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.064 -1.022 . . . . 0.0 109.651 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -108.28 148.01 30.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.562 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.8 t -107.24 168.96 8.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.234 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.616 HD13 ' CG1' ' A' ' 19' ' ' VAL . 16.3 mm -104.29 136.18 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.182 -0.949 . . . . 0.0 109.237 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.84 3.45 59.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -117.67 142.76 46.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.109 -1.23 . . . . 0.0 109.172 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.1 m -78.58 175.23 10.56 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 108.914 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.611 ' H ' HG22 ' A' ' 103' ' ' THR . 25.0 m-85 -159.66 97.21 1.3 Allowed 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.703 -1.248 . . . . 0.0 108.972 179.267 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -97.84 159.31 31.22 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.423 -0.798 . . . . 0.0 109.787 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.512 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo -71.25 159.1 52.91 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.778 2.319 . . . . 0.0 111.681 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -138.66 156.14 47.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.492 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.487 -179.956 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 81.8 mtm180 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.85 149.72 45.1 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -60.95 -32.69 72.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.208 -1.172 . . . . 0.0 109.386 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -104.04 167.34 9.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.422 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.559 ' O ' ' CB ' ' A' ' 6' ' ' HIS . 36.0 m80 -121.53 175.47 6.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.545 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.576 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 7.1 m80 79.78 -6.11 1.81 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.399 -0.813 . . . . 0.0 109.639 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.576 ' CG ' ' O ' ' A' ' 6' ' ' HIS . 98.5 m-70 -159.32 118.61 2.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.561 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -73.27 -18.59 61.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.392 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -62.77 -47.13 84.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.31 -0.869 . . . . 0.0 109.422 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.43 11.18 61.21 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -132.63 152.47 51.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -1.164 . . . . 0.0 109.528 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -146.26 142.09 28.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.23 -0.919 . . . . 0.0 109.469 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.81 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 9.9 t -127.11 137.09 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.94 . . . . 0.0 109.548 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -109.78 120.93 44.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.079 -1.013 . . . . 0.0 109.456 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.564 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -129.14 140.52 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.752 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 105' ' ' LYS . 34.7 p -141.44 145.24 35.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.215 -0.928 . . . . 0.0 109.549 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.596 ' CD2' HG12 ' A' ' 32' ' ' ILE . 91.2 m-85 -116.37 135.26 54.02 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.196 -0.94 . . . . 0.0 109.609 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.428 ' O ' ' N ' ' A' ' 31' ' ' ASP . 25.9 m -134.84 129.02 33.83 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 109.412 179.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 HD23 ' A' ' 30' ' ' LEU . 39.2 t -76.47 135.84 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 109.353 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -111.46 157.18 20.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.708 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 25.7 mtpt -50.86 113.91 1.03 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.822 . . . . 0.0 109.924 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 142.49 -3.92 1.92 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.58 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.476 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 40.8 m -60.68 140.28 57.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.896 -1.355 . . . . 0.0 109.258 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.562 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.24 177.09 2.4 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.195 -0.941 . . . . 0.0 109.57 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -71.22 -31.66 14.1 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.59 2.193 . . . . 0.0 111.814 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -117.14 5.11 12.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.033 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.473 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 47.0 mttp -141.37 132.98 27.06 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.041 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.56 132.18 51.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.069 -1.02 . . . . 0.0 110.084 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.533 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 4.7 t -121.43 124.68 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.041 HD11 HD22 ' A' ' 28' ' ' LEU . 0.8 OUTLIER -140.87 141.07 34.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.948 -1.095 . . . . 0.0 110.124 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.428 ' N ' ' O ' ' A' ' 18' ' ' THR . 63.6 t0 -85.9 136.34 33.33 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 178.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.672 HD13 ' HZ ' ' A' ' 80' ' ' PHE . 82.4 mt -121.71 131.12 73.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 120.932 -1.105 . . . . 0.0 110.236 -179.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 47.4 mttm -110.36 119.53 39.5 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.81 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 59.0 t80 -122.85 115.76 22.51 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.536 -0.727 . . . . 0.0 109.324 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.5 m -119.32 119.59 34.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.527 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 14.0 ttt85 -137.5 138.8 25.54 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.246 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.507 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 49.0 Cg_endo -69.74 103.05 1.1 Allowed 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.754 2.303 . . . . 0.0 112.06 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.75 2.86 86.42 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.527 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 26.2 m-20 -137.87 175.99 9.09 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -1.194 . . . . 0.0 109.693 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.9 m -156.25 163.84 39.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.466 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.74 HD21 HG21 ' A' ' 44' ' ' VAL . 23.4 tp -69.18 130.16 41.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.204 -0.935 . . . . 0.0 109.229 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.641 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -113.75 -45.69 3.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 110.148 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 77.9 mt-10 -137.34 147.18 45.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.102 -0.998 . . . . 0.0 110.264 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.74 HG21 HD21 ' A' ' 41' ' ' LEU . 94.2 t -139.35 136.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.531 -0.731 . . . . 0.0 109.334 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.531 ' O ' ' HA ' ' A' ' 78' ' ' PHE . 35.1 mt-10 -128.87 151.38 49.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.415 179.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.04 HD23 ' N ' ' A' ' 47' ' ' ARG . 7.0 tt -120.83 144.35 48.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.377 -0.827 . . . . 0.0 109.865 -179.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 1.04 ' N ' HD23 ' A' ' 46' ' ' LEU . 19.5 ttp180 -126.86 108.86 11.39 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 109.037 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.484 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 39.8 mt-30 -51.97 156.1 1.63 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.858 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB3' HG12 ' A' ' 73' ' ' VAL . 86.4 t60 -69.31 118.5 12.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.472 -0.768 . . . . 0.0 109.6 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.47 3.44 55.33 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -113.76 153.27 29.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -1.156 . . . . 0.0 109.467 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.48 ' HA ' ' HD2' ' A' ' 47' ' ' ARG . 85.3 tt0 -115.66 -3.47 12.29 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.273 -0.892 . . . . 0.0 109.393 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.0 tt0 -97.25 112.34 24.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -0.908 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.539 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 78.5 m95 -74.33 129.12 37.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.326 -0.859 . . . . 0.0 109.549 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -101.66 137.19 19.51 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.874 . . . . 0.0 109.364 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -71.4 144.85 46.55 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.694 2.262 . . . . 0.0 111.937 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.575 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.1 mp -107.89 148.24 29.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 108.949 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.418 HG21 ' NZ ' ' A' ' 60' ' ' LYS . 85.6 m -102.31 127.22 49.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.894 -1.129 . . . . 0.0 109.27 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.605 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 41.2 tttm -72.44 110.05 6.57 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.243 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.905 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.8 mmtt -118.43 140.66 49.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.907 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.583 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.85 31.74 0.84 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.583 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 9.4 m-20 82.66 13.67 0.46 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.239 -1.154 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.905 HG22 ' O ' ' A' ' 60' ' ' LYS . 21.0 m -128.43 173.36 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.014 -1.054 . . . . 0.0 108.761 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.605 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 62.3 m95 -120.2 124.98 47.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.98 -1.075 . . . . 0.0 109.657 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -114.15 150.2 34.51 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.45 -0.782 . . . . 0.0 109.491 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.575 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 9.4 p -137.23 134.04 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.492 -0.755 . . . . 0.0 109.248 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -120.32 131.58 54.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.167 -0.958 . . . . 0.0 109.444 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.484 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 20.2 t -117.85 157.72 26.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.416 -0.802 . . . . 0.0 109.52 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.7 t -83.94 5.83 24.06 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.256 -0.903 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -139.09 176.2 2.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.295 -0.878 . . . . 0.0 109.214 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.4 Cg_endo -70.17 126.15 12.73 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.499 2.132 . . . . 0.0 111.791 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.938 HD13 HD12 ' A' ' 28' ' ' LEU . 2.0 mt -60.63 136.93 58.21 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.243 -0.91 . . . . 0.0 109.787 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.594 HG12 ' HB3' ' A' ' 49' ' ' HIS . 95.7 t -124.23 125.44 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.444 -0.785 . . . . 0.0 109.461 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.9 168.74 27.73 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.6 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.73 146.87 81.02 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.83 -1.737 . . . . 0.0 112.011 0.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 90.9 m-85 -91.09 149.6 21.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.506 -0.746 . . . . 0.0 110.356 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 47' ' ' ARG . 3.4 m-80 -111.99 144.57 41.11 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.845 ' CE2' HD12 ' A' ' 46' ' ' LEU . 18.2 m-85 -135.84 126.06 26.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.925 -1.109 . . . . 0.0 110.127 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.986 ' HG3' HG22 ' A' ' 89' ' ' VAL . 18.8 ttt180 -105.81 141.34 37.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.133 -0.979 . . . . 0.0 108.662 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.734 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.9 m-85 -123.7 143.03 50.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.924 . . . . 0.0 111.402 -178.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.638 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.5 ttt -125.93 124.47 40.87 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.0 p -72.46 144.59 48.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.385 -0.822 . . . . 0.0 109.968 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.641 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 86.4 mttt -47.19 -44.74 22.49 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.402 -0.811 . . . . 0.0 108.975 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.8 -3.7 0.77 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.71 24.53 15.4 Favored Glycine 0 N--CA 1.491 2.307 0 O-C-N 120.988 -1.301 . . . . 0.0 110.257 179.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.638 ' O ' ' HA ' ' A' ' 81' ' ' MET . 15.4 mmm -96.72 148.31 23.02 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.114 -1.227 . . . . 0.0 108.633 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.582 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 72.8 mtp180 -124.12 140.03 53.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.885 -1.134 . . . . 0.0 110.416 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 28.2 m120 -136.42 141.25 43.59 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.986 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.3 t -122.15 136.14 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.183 -179.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.565 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 13.3 m-85 -123.77 122.6 38.48 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 63.9 t0 -98.66 145.1 27.22 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.6 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 64.5 tt0 54.76 52.54 11.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.481 -0.762 . . . . 0.0 110.377 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 ' CD1' ' A' ' 17' ' ' PHE . 88.8 t -81.14 -34.75 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.939 -1.101 . . . . 0.0 109.006 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 46.6 mt -135.42 129.4 18.63 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 121.353 -0.842 . . . . 0.0 108.95 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.88 159.52 50.25 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.483 2.122 . . . . 0.0 112.009 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.541 HG23 ' H ' ' A' ' 74' ' ' GLY . 31.9 m -50.17 -36.66 31.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.677 -179.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.63 101.66 11.81 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.071 -1.018 . . . . 0.0 109.518 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.5 ' CE1' HG11 ' A' ' 19' ' ' VAL . 50.9 p90 -109.49 150.84 27.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.159 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.79 168.83 8.88 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 ' CG1' ' A' ' 19' ' ' VAL . 17.8 mm -101.01 136.37 32.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.226 -0.921 . . . . 0.0 109.177 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 94.69 0.79 64.16 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 15.9 mttm -114.27 144.96 42.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.245 . . . . 0.0 109.157 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.683 HG22 ' H ' ' A' ' 104' ' ' TYR . 4.2 m -82.65 178.37 8.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.294 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.683 ' H ' HG22 ' A' ' 103' ' ' THR . 16.3 m-85 -161.81 92.65 0.87 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.863 -1.148 . . . . 0.0 108.859 179.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.488 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.2 OUTLIER -81.39 155.07 71.86 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.245 -0.909 . . . . 0.0 109.783 -179.415 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.565 ' CB ' ' HB3' ' A' ' 90' ' ' PHE . 50.0 Cg_endo -69.83 149.84 66.98 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.741 2.294 . . . . 0.0 111.886 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.433 ' O ' ' O ' ' A' ' 108' ' ' GLU . 90.5 mt-10 -81.97 138.15 34.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.228 -0.92 . . . . 0.0 109.545 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.433 ' O ' ' O ' ' A' ' 107' ' ' GLU . 94.1 mt-10 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.98 -8.53 73.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.2 m -62.88 -31.13 72.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.193 -1.181 . . . . 0.0 109.601 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 55.0 m80 -129.25 151.47 49.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.25 -0.907 . . . . 0.0 109.484 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -56.89 -39.57 74.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.29 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -106.47 -179.71 4.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.362 -0.836 . . . . 0.0 109.449 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -117.79 132.64 56.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 72.7 m-70 -109.28 100.9 9.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.414 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -131.31 149.18 52.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 109.44 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 11' ' ' SER . . . 106.5 25.41 6.32 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 10' ' ' GLY . 27.1 m -43.48 -63.61 0.8 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -1.18 . . . . 0.0 109.348 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.46 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -82.03 -154.41 0.12 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.863 . . . . 0.0 109.331 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.932 HG22 ' HG2' ' A' ' 36' ' ' ARG . 4.0 t -120.79 119.62 60.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.14 -0.975 . . . . 0.0 109.582 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.418 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 91.5 mt-30 -109.65 121.36 45.03 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.384 -0.823 . . . . 0.0 109.167 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.7 p -128.84 139.92 50.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.207 -0.933 . . . . 0.0 109.836 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.764 HG22 ' HD2' ' A' ' 105' ' ' LYS . 29.3 p -142.02 145.99 35.02 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.406 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.8 m-85 -118.31 147.48 43.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 31' ' ' ASP . 29.9 m -141.84 127.93 19.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.112 -0.993 . . . . 0.0 109.202 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.938 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.8 t -76.33 135.9 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.106 -0.996 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.418 ' O ' HD12 ' A' ' 100' ' ' ILE . 76.1 mm-40 -101.44 -174.83 2.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.107 -0.996 . . . . 0.0 109.531 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.4 mttt -81.6 67.42 7.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.369 -0.832 . . . . 0.0 109.983 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -174.96 22.97 0.06 OUTLIER Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.755 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.557 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 48.9 m -75.44 142.58 42.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.777 -1.425 . . . . 0.0 109.109 179.638 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.574 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.14 171.96 7.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 109.856 -179.552 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.574 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.92 -31.05 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.869 2.38 . . . . 0.0 111.984 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -115.57 6.8 14.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.235 -0.916 . . . . 0.0 108.984 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.525 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 2.5 ttpm? -142.96 133.91 25.57 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.76 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.56 124.27 43.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.934 -1.104 . . . . 0.0 109.398 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.563 ' O ' ' HG ' ' A' ' 30' ' ' LEU . 10.7 t -120.06 124.81 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.938 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.23 145.88 31.48 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.027 -1.046 . . . . 0.0 110.147 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.714 ' HA ' HG12 ' A' ' 63' ' ' VAL . 59.2 t0 -83.86 134.92 34.67 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.777 HG21 ' CE2' ' A' ' 80' ' ' PHE . 82.5 mt -121.86 131.82 72.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 120.825 -1.172 . . . . 0.0 110.723 -178.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 24.7 mmtp -110.44 119.28 38.67 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.471 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 81.2 t80 -120.42 124.67 46.04 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.411 -0.806 . . . . 0.0 109.568 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 5.2 m -128.64 118.74 23.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.847 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.932 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -128.54 167.0 20.68 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.708 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.1 Cg_endo -70.55 79.06 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.716 2.277 . . . . 0.0 111.876 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.14 -9.63 69.0 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.531 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -96.84 179.0 5.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.175 . . . . 0.0 109.422 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.503 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 12.4 m -153.02 160.68 43.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.147 -0.971 . . . . 0.0 109.712 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.815 HD21 HG21 ' A' ' 44' ' ' VAL . 22.4 tp -69.97 130.18 41.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.471 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.795 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.44 -45.65 2.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.232 -0.918 . . . . 0.0 110.127 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.468 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 43.8 mt-10 -134.66 144.57 47.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.116 -0.99 . . . . 0.0 110.335 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.815 HG21 HD21 ' A' ' 41' ' ' LEU . 93.8 t -137.99 135.48 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.492 -0.755 . . . . 0.0 109.217 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.48 ' HA ' ' CD1' ' A' ' 57' ' ' LEU . 25.7 mt-10 -129.04 151.05 50.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.985 -1.072 . . . . 0.0 109.395 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.945 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.4 tt -119.4 132.61 55.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.447 -0.783 . . . . 0.0 109.913 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.945 ' N ' HD23 ' A' ' 46' ' ' LEU . 27.0 ttp180 -118.53 128.21 54.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.225 -0.922 . . . . 0.0 108.761 179.118 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -73.13 152.24 41.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 110.195 -179.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.527 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 55.1 t-80 -63.02 147.48 50.56 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.408 -0.808 . . . . 0.0 109.137 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.92 1.0 54.57 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.6 t -112.45 150.31 31.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -1.144 . . . . 0.0 109.316 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -116.59 8.46 13.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.924 . . . . 0.0 109.517 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 64.0 mm-40 -107.01 115.42 30.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.401 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 58.3 m95 -76.08 129.03 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.326 -0.859 . . . . 0.0 109.715 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -99.94 133.38 21.68 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.432 -0.793 . . . . 0.0 109.193 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.62 149.03 67.25 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.689 2.259 . . . . 0.0 111.803 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.673 HD11 ' HB2' ' A' ' 46' ' ' LEU . 6.1 mp -111.98 158.58 19.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.194 -0.941 . . . . 0.0 109.354 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 91.2 m -107.48 127.72 53.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.954 -1.091 . . . . 0.0 109.279 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 47.3 tttt -70.84 112.89 7.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -0.896 . . . . 0.0 109.242 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.451 ' HE3' ' HB3' ' A' ' 65' ' ' GLU . 40.2 mttt -113.64 125.66 54.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.953 -1.092 . . . . 0.0 109.595 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 44.68 -109.54 0.29 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -117.11 17.44 14.84 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.258 -1.142 . . . . 0.0 109.564 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 31' ' ' ASP . 10.9 m -131.93 -175.82 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.451 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -127.33 139.82 52.62 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 67' ' ' LYS . 19.1 tt0 -121.21 135.01 55.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.215 -0.928 . . . . 0.0 109.753 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.603 HG12 ' HB3' ' A' ' 28' ' ' LEU . 4.6 p -131.09 129.36 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.274 -0.891 . . . . 0.0 109.304 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG2' ' CD ' ' A' ' 27' ' ' LYS . 88.3 mttt -120.05 131.58 55.15 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.094 -1.004 . . . . 0.0 109.529 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.5 t -117.6 138.91 51.63 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.526 -0.734 . . . . 0.0 109.288 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 79.3 p -65.56 -11.3 42.72 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.154 -0.966 . . . . 0.0 109.232 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -121.12 176.34 1.95 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.68 164.57 32.66 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.602 2.201 . . . . 0.0 111.811 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.626 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 16.1 mt -100.59 141.56 33.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.258 -0.901 . . . . 0.0 109.849 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 50.2 t -127.86 125.2 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.547 -0.72 . . . . 0.0 109.319 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.671 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.76 164.74 26.64 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.614 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.9 Cg_endo -68.84 148.15 83.97 Favored 'Cis proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.984 0.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.626 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.4 m-85 -92.58 149.87 21.08 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.442 -0.786 . . . . 0.0 110.476 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.495 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 14.6 m-80 -110.51 143.33 41.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.358 -0.839 . . . . 0.0 108.769 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 46' ' ' LEU . 83.1 m-85 -134.69 126.84 29.87 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.014 -1.054 . . . . 0.0 109.737 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 89' ' ' VAL . 53.1 ttt180 -108.35 142.51 38.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.04 -1.038 . . . . 0.0 108.753 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.777 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.1 m-85 -124.6 143.42 50.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 111.551 -178.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' MET . 6.6 ttm -126.38 125.95 43.06 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 178.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.632 ' N ' ' O ' ' A' ' 86' ' ' MET . 15.9 p -74.0 145.92 44.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 110.204 -178.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.795 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 78.7 mttt -48.37 -44.22 34.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.272 -0.893 . . . . 0.0 108.934 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.44 -3.69 0.68 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.53 25.05 16.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.632 ' O ' ' N ' ' A' ' 82' ' ' SER . 13.0 mmm -97.39 148.36 23.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.172 -1.193 . . . . 0.0 108.575 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 21.6 mtm180 -124.31 140.03 53.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.843 -1.16 . . . . 0.0 110.68 -178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . 34.7 m120 -135.42 140.08 44.65 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.1 t -122.03 136.9 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.037 -1.039 . . . . 0.0 110.409 -179.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.541 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 15.9 m-85 -125.52 122.98 38.13 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -99.57 147.84 24.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 95.8 mt-10 53.45 51.4 15.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.338 -0.851 . . . . 0.0 110.044 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.536 HG12 HG13 ' A' ' 94' ' ' ILE . 44.1 t -81.03 -33.98 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.821 -1.174 . . . . 0.0 109.26 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 93' ' ' VAL . 43.7 mt -138.13 125.75 13.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.139 -0.976 . . . . 0.0 109.057 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.12 161.78 44.43 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.533 2.155 . . . . 0.0 111.882 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.671 HG23 ' H ' ' A' ' 74' ' ' GLY . 2.6 m -57.08 -39.46 75.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.376 -0.827 . . . . 0.0 109.923 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.45 70.31 9.89 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.081 -1.012 . . . . 0.0 109.492 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -81.2 148.52 29.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.936 . . . . 0.0 109.656 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 43.3 m -109.82 168.8 9.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.317 -0.865 . . . . 0.0 109.186 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.521 HD13 ' CG1' ' A' ' 19' ' ' VAL . 35.6 mm -103.4 135.71 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.137 -0.977 . . . . 0.0 109.284 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 97.01 5.88 58.17 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.471 ' HD3' ' CZ ' ' A' ' 104' ' ' TYR . 43.7 tttp -119.73 143.17 47.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.25 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.652 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.7 m -79.88 176.51 9.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 109.018 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.652 ' H ' HG22 ' A' ' 103' ' ' THR . 32.5 m-85 -162.7 95.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.875 -1.141 . . . . 0.0 108.937 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.764 ' HD2' HG22 ' A' ' 16' ' ' THR . 0.3 OUTLIER -103.0 166.33 12.05 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.873 . . . . 0.0 109.793 -179.405 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 50.6 Cg_endo -71.11 140.93 38.68 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.588 2.192 . . . . 0.0 111.727 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.09 -31.22 72.32 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.403 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 12.8 mp0 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.464 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.4 ptm180 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -153.69 176.65 31.58 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.9 m -137.92 156.0 48.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -1.13 . . . . 0.0 109.452 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -112.01 173.2 6.47 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.273 -0.892 . . . . 0.0 109.359 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -68.32 153.64 43.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.394 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 44.1 m80 -91.54 140.39 29.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.289 -0.882 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 55.0 t60 -56.69 -47.29 80.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.497 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -160.15 91.96 0.97 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.228 -0.92 . . . . 0.0 109.522 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 -64.48 -50.41 67.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.221 -0.925 . . . . 0.0 109.47 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -100.97 122.46 7.6 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.511 ' HB3' ' HG3' ' A' ' 37' ' ' PRO . 22.9 t -132.9 -158.65 0.9 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -1.116 . . . . 0.0 109.463 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.66 162.75 12.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.547 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.954 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 3.6 t -129.48 145.85 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.877 . . . . 0.0 109.539 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -111.47 121.64 45.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.896 . . . . 0.0 109.244 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.4 t -128.95 139.68 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.202 -0.936 . . . . 0.0 109.817 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.0 p -141.99 146.15 35.26 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.328 -0.857 . . . . 0.0 109.474 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CE1' HG11 ' A' ' 93' ' ' VAL . 91.7 m-85 -118.38 123.65 45.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.425 ' O ' ' N ' ' A' ' 31' ' ' ASP . 34.8 m -120.05 128.37 53.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.03 -1.044 . . . . 0.0 109.063 179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' CD2' ' A' ' 30' ' ' LEU . 11.9 t -76.04 132.57 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 37.7 mm-40 -107.3 156.35 18.98 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.8 mttt -50.08 114.55 1.12 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.432 -0.793 . . . . 0.0 109.909 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.95 1.98 1.96 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 65.9 p -62.85 142.32 58.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.762 -1.434 . . . . 0.0 109.185 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.43 174.12 4.71 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.133 -0.98 . . . . 0.0 109.664 -179.626 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.9 Cg_endo -71.01 -29.86 17.31 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.683 2.255 . . . . 0.0 111.86 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -118.18 4.18 11.98 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.32 -0.862 . . . . 0.0 109.041 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.47 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 52.7 mttt -143.01 134.13 25.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.994 HD12 HD13 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -128.01 134.25 49.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.984 -1.073 . . . . 0.0 110.401 -179.332 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.528 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 8.6 t -121.95 123.73 69.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.966 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.68 144.51 31.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 109.914 -179.352 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 18' ' ' THR . 57.0 t0 -86.3 136.13 33.27 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.334 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.701 HG21 ' CE2' ' A' ' 80' ' ' PHE . 80.1 mt -120.68 131.63 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 120.881 -1.137 . . . . 0.0 110.324 -179.163 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 mttm -111.09 118.69 36.71 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.954 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 67.6 t80 -121.26 109.33 14.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.489 -0.757 . . . . 0.0 109.339 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.1 m -112.62 117.32 31.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.89 . . . . 0.0 109.89 -179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.625 ' HG3' HG22 ' A' ' 13' ' ' VAL . 37.8 ttt-85 -136.83 139.73 29.75 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.368 -0.833 . . . . 0.0 109.179 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.525 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 48.3 Cg_endo -69.75 109.35 2.29 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 112.069 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.05 4.44 88.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.561 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 4.9 m-20 -134.52 173.21 11.91 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -1.22 . . . . 0.0 109.772 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.9 m -155.53 162.61 40.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.341 -0.849 . . . . 0.0 109.502 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.701 HD21 ' CG2' ' A' ' 44' ' ' VAL . 10.7 tp -70.55 129.56 39.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.846 . . . . 0.0 109.501 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.741 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -115.83 -42.74 3.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.161 -0.962 . . . . 0.0 109.839 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -142.62 151.09 41.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.138 -0.976 . . . . 0.0 110.002 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.701 ' CG2' HD21 ' A' ' 41' ' ' LEU . 21.4 t -139.9 137.27 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.435 -0.791 . . . . 0.0 109.465 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 56' ' ' PRO . 61.4 mt-10 -127.78 150.55 49.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.873 -1.142 . . . . 0.0 109.215 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.776 HD12 ' O ' ' A' ' 77' ' ' ASN . 10.9 tp -120.87 133.0 55.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.333 -0.855 . . . . 0.0 110.243 -178.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.693 ' N ' HD12 ' A' ' 46' ' ' LEU . 47.8 ttp85 -113.53 127.98 56.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.099 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -71.91 152.35 42.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.512 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 37.6 t-80 -69.31 111.3 5.12 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.382 -0.824 . . . . 0.0 109.554 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.82 2.1 36.75 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.511 ' O ' ' NH1' ' A' ' 47' ' ' ARG . 33.5 t -113.47 154.37 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.195 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 37.9 mm-40 -113.22 16.14 19.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.333 -0.854 . . . . 0.0 109.394 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -113.88 114.19 25.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.528 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.594 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.6 m95 -80.13 120.09 23.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.267 -0.895 . . . . 0.0 109.655 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.445 ' O ' ' N ' ' A' ' 46' ' ' LEU . 11.6 mm-40 -95.95 129.99 32.63 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.445 -0.784 . . . . 0.0 109.344 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 48.2 Cg_endo -69.32 149.48 69.74 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.561 2.174 . . . . 0.0 111.879 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.618 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -101.6 149.52 24.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.149 -0.97 . . . . 0.0 108.576 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -102.46 126.54 49.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 108.941 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -70.41 109.47 4.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.168 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.877 ' O ' HG22 ' A' ' 63' ' ' VAL . 37.2 mttp -121.74 139.53 53.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.797 -1.189 . . . . 0.0 109.975 -179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.531 ' O ' ' HB2' ' A' ' 62' ' ' ASN . . . 38.39 48.25 2.21 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.531 ' HB2' ' O ' ' A' ' 61' ' ' GLY . 54.3 m-20 68.48 11.46 8.36 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.169 -1.195 . . . . 0.0 110.956 178.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.9 m -128.88 -178.61 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.858 -1.151 . . . . 0.0 108.997 179.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.506 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 71.1 m95 -122.8 141.27 52.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.082 . . . . 0.0 109.632 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 62.5 tt0 -128.42 142.22 51.17 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.815 . . . . 0.0 109.212 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.645 HG11 HD23 ' A' ' 46' ' ' LEU . 1.8 p -136.37 135.18 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.24 -0.913 . . . . 0.0 109.145 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.433 ' HD2' ' HE2' ' A' ' 27' ' ' LYS . 6.1 ttpm? -122.54 133.73 54.56 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.851 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.8 t -117.86 148.13 42.41 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.456 -0.778 . . . . 0.0 109.153 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 85.5 p -72.77 -4.43 31.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.988 . . . . 0.0 109.354 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.552 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -131.5 176.19 3.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.243 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.552 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.6 Cg_endo -68.44 140.52 48.25 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.482 2.121 . . . . 0.0 111.714 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.994 HD13 HD12 ' A' ' 28' ' ' LEU . 10.5 mt -74.76 137.89 42.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.826 -179.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.9 t -123.37 125.12 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.469 -0.769 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.665 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.3 165.47 27.67 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.642 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 50.5 Cg_endo -70.01 145.66 80.6 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.806 -1.747 . . . . 0.0 111.883 0.03 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.667 ' HB3' HD11 ' A' ' 46' ' ' LEU . 76.8 m-85 -91.46 151.18 20.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.523 -0.736 . . . . 0.0 110.367 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.776 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.4 m-80 -110.77 142.43 42.75 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 178.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.767 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.0 m-85 -133.24 127.3 33.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.913 -1.117 . . . . 0.0 109.971 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.686 ' HG3' HG22 ' A' ' 89' ' ' VAL . 41.4 ttt180 -110.62 143.12 41.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.006 -1.059 . . . . 0.0 108.627 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.701 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.0 m-85 -124.86 143.81 50.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.218 -0.926 . . . . 0.0 111.632 -177.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 1.2 ttt -125.85 124.4 40.82 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.537 ' CB ' ' HB2' ' A' ' 86' ' ' MET . 24.2 p -77.39 147.7 35.92 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.206 -0.934 . . . . 0.0 110.043 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.741 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 32.9 mttt -46.65 -46.0 19.6 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.32 -8.19 8.65 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.41 34.53 5.28 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.537 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 44.3 mmm -103.24 110.61 22.64 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.987 -1.302 . . . . 0.0 109.011 179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 61.0 mtt180 -91.71 139.49 30.63 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.199 -0.938 . . . . 0.0 110.472 -179.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.4 m120 -137.25 141.69 42.02 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.686 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.2 t -122.06 136.5 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.865 -1.147 . . . . 0.0 110.471 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.567 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 55.0 m-85 -124.44 122.36 37.42 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -97.13 145.27 26.17 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.18 -0.95 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.642 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 12.8 mt-10 53.96 54.26 9.99 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.491 -0.756 . . . . 0.0 110.335 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.779 HG11 ' CE1' ' A' ' 17' ' ' PHE . 75.8 t -82.26 -34.18 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 109.074 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.464 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.7 mt -135.44 124.4 16.0 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.201 -0.937 . . . . 0.0 109.132 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.42 162.13 43.12 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.608 2.205 . . . . 0.0 111.968 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.665 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.3 m -53.3 -44.7 68.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 109.976 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.84 99.72 12.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.046 -1.034 . . . . 0.0 109.502 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -109.45 147.83 32.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.94 . . . . 0.0 109.715 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.8 m -106.09 171.15 7.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.212 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.552 HD13 ' CG1' ' A' ' 19' ' ' VAL . 27.2 mm -106.73 137.83 35.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.42 9.62 61.49 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 4.6 tptp -120.57 144.18 48.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.495 HG22 ' H ' ' A' ' 104' ' ' TYR . 8.6 m -77.81 170.97 15.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.038 -1.039 . . . . 0.0 108.706 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.593 ' N ' ' O ' ' A' ' 17' ' ' PHE . 24.0 m-85 -157.62 97.94 1.63 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.607 -1.308 . . . . 0.0 109.151 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.529 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -104.93 161.53 22.49 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.277 -0.889 . . . . 0.0 109.767 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.2 Cg_endo -69.08 143.2 53.27 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.718 2.279 . . . . 0.0 111.663 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -52.97 -30.97 38.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.546 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.417 ' HA ' ' OE1' ' A' ' 108' ' ' GLU . 62.3 mm-40 . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.439 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -76.78 -16.69 80.55 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.0 m -118.72 147.66 43.6 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.316 -1.108 . . . . 0.0 109.466 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -132.08 164.33 26.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 109.508 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -126.66 164.19 21.81 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.448 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.1 m80 -78.95 -12.72 60.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.507 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -53.55 -26.96 23.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.422 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 t60 -58.06 -34.5 70.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -99.87 144.17 29.24 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.397 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.27 -152.98 17.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 91.9 p -114.09 146.76 39.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.294 -1.121 . . . . 0.0 109.483 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.506 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -140.66 153.32 45.95 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.488 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.989 HG22 ' HG3' ' A' ' 36' ' ' ARG . 30.3 t -125.37 130.32 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.295 -0.878 . . . . 0.0 109.567 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.47 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 77.9 mm-40 -106.01 120.24 41.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.027 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.601 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 11.1 p -128.92 139.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.232 -0.917 . . . . 0.0 110.049 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 73.1 p -141.25 145.42 35.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.334 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.646 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.8 m-85 -118.24 136.22 53.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.176 -0.953 . . . . 0.0 109.717 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 88.5 m -131.34 127.77 38.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.903 -1.123 . . . . 0.0 109.302 179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.898 HG22 ' CD2' ' A' ' 30' ' ' LEU . 30.6 t -75.02 134.01 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.216 -0.928 . . . . 0.0 109.173 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.468 ' OE1' ' O ' ' A' ' 19' ' ' VAL . 4.9 mm100 -106.57 156.34 18.69 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.174 -0.954 . . . . 0.0 109.975 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.5 mttt -51.34 115.87 1.79 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.51 -0.743 . . . . 0.0 109.947 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 137.26 -1.52 3.05 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.447 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 p -60.29 144.15 51.14 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.911 -1.347 . . . . 0.0 109.403 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.19 169.79 12.62 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.288 -0.882 . . . . 0.0 109.71 -179.779 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.4 Cg_endo -70.73 -29.34 19.39 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.806 2.337 . . . . 0.0 111.88 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -113.02 7.09 17.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.165 -0.959 . . . . 0.0 108.819 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -142.74 133.55 25.45 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.72 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.35 122.84 40.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.965 -1.085 . . . . 0.0 109.337 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.549 HG13 ' HG2' ' A' ' 65' ' ' GLU . 51.4 t -118.72 124.35 73.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.898 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -144.33 144.76 31.61 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.977 -1.077 . . . . 0.0 110.253 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.635 ' OD1' HG12 ' A' ' 63' ' ' VAL . 20.9 t70 -85.39 137.04 33.2 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 177.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.897 HG21 ' CE2' ' A' ' 80' ' ' PHE . 75.7 mt -120.71 130.98 73.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 C-N-CA 118.667 -1.213 . . . . 0.0 110.786 -179.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.601 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 22.1 tttm -110.61 120.38 42.23 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.094 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.51 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 78.6 t80 -120.15 112.77 19.52 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.343 -0.848 . . . . 0.0 109.567 -178.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 31.2 m -115.71 115.79 26.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -0.851 . . . . 0.0 109.677 -179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.989 ' HG3' HG22 ' A' ' 13' ' ' VAL . 28.0 ttt85 -138.68 136.29 18.62 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.526 -0.734 . . . . 0.0 109.208 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 12' ' ' ALA . 49.2 Cg_endo -69.88 112.57 3.13 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.1 0.69 83.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.563 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.2 m-20 -133.92 172.26 13.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.966 -1.314 . . . . 0.0 109.87 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 82' ' ' SER . 13.6 m -153.98 161.61 41.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.408 -0.807 . . . . 0.0 109.341 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.864 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.7 OUTLIER -72.28 131.27 42.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.279 -0.888 . . . . 0.0 109.845 -179.588 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.936 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -114.93 -40.24 3.54 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.619 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.45 150.41 40.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.124 -0.985 . . . . 0.0 110.187 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.679 ' CG2' HD11 ' A' ' 41' ' ' LEU . 5.9 t -139.21 136.88 41.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.581 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -129.63 150.81 50.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.935 -1.103 . . . . 0.0 109.394 179.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.0 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -118.72 140.61 49.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.892 . . . . 0.0 109.715 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 1.0 ' N ' HD23 ' A' ' 46' ' ' LEU . 28.3 ttp180 -126.74 129.54 48.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.293 -0.879 . . . . 0.0 109.072 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.588 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 47.8 mt-30 -72.6 144.8 47.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.343 -0.848 . . . . 0.0 109.863 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.537 ' ND1' ' HD2' ' A' ' 75' ' ' PRO . 2.0 t-160 -61.36 115.81 4.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.35 -0.844 . . . . 0.0 109.442 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.42 2.75 35.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.417 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 25.6 t -113.7 155.71 25.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -1.188 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 69.7 tt0 -116.05 1.03 13.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.583 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -108.83 92.48 4.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.602 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 46.0 m95 -51.55 138.64 22.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.356 -0.84 . . . . 0.0 109.599 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -105.05 135.19 19.33 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.375 -0.828 . . . . 0.0 109.32 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.83 145.51 51.11 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.617 2.211 . . . . 0.0 111.891 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.869 HD11 ' HB2' ' A' ' 46' ' ' LEU . 5.4 mp -107.17 146.14 31.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.032 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.2 m -94.41 126.92 39.97 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.956 -1.09 . . . . 0.0 109.176 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -70.6 111.18 5.91 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.408 -0.808 . . . . 0.0 109.033 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -111.77 113.04 25.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.982 -1.074 . . . . 0.0 109.571 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 57.15 -103.72 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -123.76 17.36 9.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -1.146 . . . . 0.0 109.398 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.635 HG12 ' OD1' ' A' ' 31' ' ' ASP . 17.8 m -130.82 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.328 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 60.9 m95 -134.1 142.06 47.38 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.155 -0.966 . . . . 0.0 109.466 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG2' HG13 ' A' ' 29' ' ' VAL . 30.2 mt-10 -122.48 134.79 54.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.214 -0.929 . . . . 0.0 109.766 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.855 HG11 HD13 ' A' ' 46' ' ' LEU . 4.8 p -130.83 130.35 64.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -0.903 . . . . 0.0 109.217 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.7 tttm -122.17 133.85 54.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.064 -1.023 . . . . 0.0 109.75 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.588 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.3 t -117.63 154.77 31.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.437 -0.789 . . . . 0.0 109.239 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 20.4 m -80.15 -4.36 52.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.288 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.546 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.1 mttm -128.33 176.05 3.03 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.5 Cg_endo -69.52 124.19 10.94 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.508 2.138 . . . . 0.0 111.735 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.598 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.3 mt -58.53 139.67 55.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.354 -0.842 . . . . 0.0 109.79 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 46.4 t -125.14 124.68 67.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.378 -0.826 . . . . 0.0 109.543 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -95.3 166.78 25.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 45.4 Cg_endo -66.61 146.53 73.86 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 123.043 -1.649 . . . . 0.0 112.087 0.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 75.5 m-85 -90.72 150.53 21.6 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.607 -0.683 . . . . 0.0 110.405 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.41 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 10.0 m-80 -111.91 143.16 43.33 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.805 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.3 m-85 -134.77 122.16 21.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.01 -1.056 . . . . 0.0 109.704 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.571 ' HG3' HG22 ' A' ' 89' ' ' VAL . 51.9 ttp180 -103.3 141.91 35.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.96 -1.087 . . . . 0.0 108.609 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.897 ' CE2' HG21 ' A' ' 32' ' ' ILE . 31.7 m-85 -125.51 143.91 50.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.187 -0.946 . . . . 0.0 111.595 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.588 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.8 ttm -126.65 126.82 44.19 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.3 p -77.52 145.62 36.85 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.203 -0.936 . . . . 0.0 110.412 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.936 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.6 mttt -48.7 -44.56 38.15 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.61 -6.24 6.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.26 34.34 5.9 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.537 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 15.8 mmm -106.07 108.78 20.47 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.075 -1.25 . . . . 0.0 109.001 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.588 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 82.5 mtm180 -85.86 134.98 33.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.199 -0.938 . . . . 0.0 110.634 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.446 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -134.3 139.49 45.74 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.571 HG22 ' HG3' ' A' ' 79' ' ' ARG . 37.2 t -122.84 136.82 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.036 -1.04 . . . . 0.0 110.587 -178.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.532 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 61.2 m-85 -124.16 122.09 36.88 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 21.0 p-10 -100.11 148.96 24.01 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.346 -0.846 . . . . 0.0 109.744 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 40.1 tt0 52.98 51.19 16.33 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.323 -0.86 . . . . 0.0 110.002 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 94' ' ' ILE . 61.6 t -81.76 -33.87 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.924 -1.11 . . . . 0.0 109.116 179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.5 HG13 HG12 ' A' ' 93' ' ' VAL . 67.1 mt -138.83 127.67 14.09 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.312 -0.868 . . . . 0.0 109.074 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.45 161.37 46.14 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.611 2.208 . . . . 0.0 111.982 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.52 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 87.4 m -51.2 -45.44 61.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.394 -0.816 . . . . 0.0 109.916 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -93.07 104.01 16.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.113 -0.992 . . . . 0.0 109.688 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -111.09 151.57 27.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.359 -0.838 . . . . 0.0 109.33 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.0 m -102.64 170.18 8.18 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 30.6 mm -103.23 136.06 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.182 -0.948 . . . . 0.0 109.306 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.8 57.7 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -121.28 143.39 49.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.974 -1.309 . . . . 0.0 109.306 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.667 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -79.15 177.2 9.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.076 -1.015 . . . . 0.0 108.919 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.667 ' H ' HG22 ' A' ' 103' ' ' THR . 27.5 m-85 -162.23 96.27 0.97 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.769 -1.207 . . . . 0.0 109.107 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.521 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -102.51 164.54 15.45 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.362 -0.836 . . . . 0.0 109.724 -179.584 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.532 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 47.5 Cg_endo -68.68 174.89 7.88 Favored 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.675 2.25 . . . . 0.0 111.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 37.5 tt0 -88.59 -22.04 23.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.355 -0.841 . . . . 0.0 109.511 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.3 mt-10 . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.506 179.972 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 73.39 -125.67 9.58 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 65.3 p -139.63 168.48 19.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -1.154 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -106.58 99.64 9.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -0.955 . . . . 0.0 109.479 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 82.0 t60 -62.45 -41.47 98.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.903 . . . . 0.0 109.481 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -86.05 139.96 30.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.201 -0.937 . . . . 0.0 109.484 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 40.6 t-80 -64.61 -42.05 95.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.439 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.3 p80 -127.52 141.03 51.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.451 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 74.1 m80 -54.37 -35.59 62.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.287 -0.883 . . . . 0.0 109.565 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.86 -159.38 26.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.2 t -120.29 116.54 25.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -1.154 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.474 ' O ' ' HD2' ' A' ' 37' ' ' PRO . . . -149.57 176.89 10.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.278 -0.889 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 36' ' ' ARG . 60.7 t -121.58 123.95 70.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.533 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.498 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 94.7 mt-30 -112.96 121.78 45.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.274 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.639 HG11 ' CE2' ' A' ' 90' ' ' PHE . 12.5 p -128.79 139.99 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.258 -0.902 . . . . 0.0 109.668 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.469 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 17.0 p -141.6 145.72 35.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.155 -0.965 . . . . 0.0 109.515 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.576 ' O ' ' N ' ' A' ' 104' ' ' TYR . 6.7 m-85 -117.49 150.44 38.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.234 -0.916 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.973 HG23 ' O ' ' A' ' 102' ' ' LYS . 92.2 m -144.81 127.7 16.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.069 -1.02 . . . . 0.0 109.378 179.097 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.813 HG22 ' CD2' ' A' ' 30' ' ' LEU . 4.5 t -76.29 129.1 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.885 . . . . 0.0 109.377 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.49 ' O ' HD12 ' A' ' 100' ' ' ILE . 91.2 mm-40 -92.97 -175.25 3.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.609 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.0 mttm -81.94 62.16 5.59 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.962 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -169.05 24.49 0.1 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.71 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.537 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 26.2 m -79.95 143.64 34.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.778 -1.425 . . . . 0.0 109.252 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.632 ' O ' HD12 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -137.71 174.19 4.6 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.101 -0.999 . . . . 0.0 109.605 -179.726 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.546 ' O ' ' N ' ' A' ' 72' ' ' LEU . 48.7 Cg_endo -70.76 -30.39 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.67 2.247 . . . . 0.0 112.045 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 88.8 mttt -115.17 5.7 14.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.067 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.42 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 81.8 mttt -142.18 133.38 26.21 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.31 40.95 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.042 -1.036 . . . . 0.0 109.466 -179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.609 HG22 ' HG3' ' A' ' 65' ' ' GLU . 21.9 t -118.74 124.62 73.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.813 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.0 OUTLIER -144.65 145.76 31.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.978 -1.076 . . . . 0.0 110.169 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -85.63 137.36 32.9 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.787 HG21 ' CE2' ' A' ' 80' ' ' PHE . 77.0 mt -120.78 130.13 74.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.755 -1.215 . . . . 0.0 110.688 -178.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.55 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.5 tttm -109.66 119.95 40.98 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 72.3 t80 -122.0 124.27 43.6 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.334 -0.853 . . . . 0.0 109.716 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 16.2 m -126.74 116.93 21.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.301 -0.874 . . . . 0.0 109.737 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.606 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.5 OUTLIER -151.27 116.66 3.19 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.416 -0.803 . . . . 0.0 109.139 179.804 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.474 ' HD2' ' O ' ' A' ' 12' ' ' ALA . 48.3 Cg_endo -68.95 126.21 13.56 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.73 2.286 . . . . 0.0 111.95 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.54 -19.48 54.5 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 1.5 m-20 -142.95 -176.35 4.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.209 -1.171 . . . . 0.0 109.814 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' LYS . 5.9 m -156.17 163.31 39.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.36 -0.838 . . . . 0.0 109.367 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.672 HD11 HG22 ' A' ' 44' ' ' VAL . 29.4 tp -70.52 129.02 38.12 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.342 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.893 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.65 -42.35 2.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.418 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 86.6 mt-10 -139.59 147.89 41.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.176 -0.953 . . . . 0.0 110.218 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.672 HG22 HD11 ' A' ' 41' ' ' LEU . 8.9 t -138.6 136.99 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 108.965 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.406 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 72.5 mt-10 -128.15 149.22 50.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.821 -1.174 . . . . 0.0 109.56 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.099 HD23 HG11 ' A' ' 66' ' ' VAL . 11.2 tp -120.18 131.64 55.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.418 -0.801 . . . . 0.0 109.96 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.65 ' N ' HD12 ' A' ' 46' ' ' LEU . 7.5 ttp180 -119.82 131.94 55.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.076 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.487 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 43.2 mt-30 -72.27 149.95 44.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.738 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 10.2 t60 -68.54 113.94 6.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.746 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.48 2.42 27.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.45 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 28.1 t -115.01 154.92 27.93 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -1.172 . . . . 0.0 109.406 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -111.22 15.59 21.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.291 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -121.97 121.43 37.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.541 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.506 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 43.1 m95 -83.34 132.94 34.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.4 -0.812 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.431 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.0 OUTLIER -100.76 135.11 20.14 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.335 -0.853 . . . . 0.0 109.422 179.975 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.431 ' HD2' ' HG3' ' A' ' 55' ' ' GLU . 52.3 Cg_endo -71.11 149.49 58.39 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.606 2.204 . . . . 0.0 111.96 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.623 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 5.6 mp -108.4 138.46 44.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.213 -0.929 . . . . 0.0 109.07 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.3 m -90.17 127.48 36.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.99 -1.069 . . . . 0.0 109.014 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 22.7 tttt -74.48 105.68 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.265 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -108.3 110.63 22.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.006 -1.059 . . . . 0.0 109.551 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.11 -107.73 1.93 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 35.0 p-10 -121.99 16.24 10.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.282 -1.128 . . . . 0.0 109.345 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.2 m -132.08 170.09 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.947 . . . . 0.0 109.424 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.445 ' CD1' HD12 ' A' ' 32' ' ' ILE . 55.9 m95 -116.11 142.82 46.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.169 -0.957 . . . . 0.0 109.216 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 29' ' ' VAL . 75.7 tt0 -123.67 136.57 54.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 109.921 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 1.099 HG11 HD23 ' A' ' 46' ' ' LEU . 11.9 p -131.07 130.25 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.361 -0.837 . . . . 0.0 109.118 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.424 ' HE2' ' OE2' ' A' ' 65' ' ' GLU . 25.1 mttt -120.75 132.34 55.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.148 -0.97 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.487 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 8.4 t -118.56 145.55 45.27 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.447 -0.783 . . . . 0.0 109.217 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.3 m -66.55 -11.28 52.19 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.092 -1.005 . . . . 0.0 109.165 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.55 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -123.28 176.55 2.1 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.387 -0.821 . . . . 0.0 109.278 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.4 Cg_endo -69.74 157.62 59.8 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.454 2.102 . . . . 0.0 111.63 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.632 HD12 ' O ' ' A' ' 24' ' ' ASP . 5.3 mt -87.58 138.65 31.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.798 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 73.5 t -124.85 125.26 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.416 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.542 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.3 164.96 26.08 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.93 146.48 80.48 Favored 'Cis proline' 0 C--O 1.214 -0.704 0 C-N-CA 122.761 -1.766 . . . . 0.0 111.8 0.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.615 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 76.1 m-85 -91.02 152.4 20.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.515 -0.741 . . . . 0.0 110.544 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.773 ' O ' HD12 ' A' ' 46' ' ' LEU . 37.8 m-80 -112.68 141.67 46.2 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.856 ' CE1' HD13 ' A' ' 46' ' ' LEU . 86.9 m-85 -134.77 122.18 21.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.102 -0.999 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.987 ' HG3' HG22 ' A' ' 89' ' ' VAL . 70.6 ttt180 -104.2 143.32 33.1 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.997 -1.064 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.787 ' CE2' HG21 ' A' ' 32' ' ' ILE . 11.0 m-85 -125.29 143.15 51.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.196 -0.94 . . . . 0.0 111.402 -178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.559 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.5 ttt -125.23 125.03 42.96 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.594 ' N ' ' O ' ' A' ' 86' ' ' MET . 14.8 p -73.7 147.12 43.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 110.267 -178.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.893 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 42.1 mttp -50.03 -44.78 51.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.468 -0.77 . . . . 0.0 109.134 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.65 -4.31 0.61 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.86 27.06 11.64 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.594 ' O ' ' N ' ' A' ' 82' ' ' SER . 46.4 mtp -99.89 149.07 23.79 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.187 -1.184 . . . . 0.0 108.627 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.559 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 17.8 mtt180 -121.87 136.92 54.95 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.871 -1.143 . . . . 0.0 110.457 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -134.1 139.79 46.17 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.987 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.4 t -123.2 136.97 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 120.952 -1.093 . . . . 0.0 110.315 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.639 ' CE2' HG11 ' A' ' 15' ' ' VAL . 18.2 m-85 -123.62 121.65 36.11 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -98.96 147.35 25.08 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.262 -0.899 . . . . 0.0 109.803 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 63.1 tt0 53.88 51.41 14.87 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.5 -0.75 . . . . 0.0 110.338 179.512 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.563 HG12 HG13 ' A' ' 94' ' ' ILE . 42.0 t -81.13 -34.37 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.889 -1.132 . . . . 0.0 108.905 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.563 HG13 HG12 ' A' ' 93' ' ' VAL . 40.9 mt -136.45 125.32 15.42 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.326 -0.859 . . . . 0.0 109.121 179.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.85 162.71 41.09 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.565 2.177 . . . . 0.0 112.024 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.542 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 32.2 m -49.96 -38.39 36.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.373 -0.829 . . . . 0.0 110.007 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.49 102.8 13.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.006 -1.059 . . . . 0.0 109.72 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CE1' HG11 ' A' ' 19' ' ' VAL . 42.8 p90 -110.33 154.13 23.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.905 . . . . 0.0 109.163 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.9 t -104.32 167.51 9.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 20' ' ' GLN . 28.6 mm -103.41 138.9 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -0.864 . . . . 0.0 109.29 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 90.35 16.0 56.2 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.973 ' O ' HG23 ' A' ' 18' ' ' THR . 18.9 mttm -119.21 -165.97 1.21 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 109.071 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.6 m -131.61 163.41 28.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.977 -1.077 . . . . 0.0 108.665 179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.576 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.8 m-85 -151.6 94.03 1.95 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.44 -1.412 . . . . 0.0 109.147 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.54 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -99.66 162.13 22.2 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.584 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.548 ' CD ' HG13 ' A' ' 15' ' ' VAL . 49.3 Cg_endo -69.57 146.02 60.06 Favored 'Trans proline' 0 C--O 1.217 -0.555 0 C-N-CA 122.554 2.169 . . . . 0.0 111.83 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -75.33 -32.44 60.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.511 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.421 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.71 26.4 72.04 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.4 m -60.84 -26.11 67.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -1.127 . . . . 0.0 109.463 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -67.1 -42.58 84.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.286 -0.884 . . . . 0.0 109.532 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 41.5 m-70 -118.77 120.2 36.66 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.506 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -82.37 -8.6 59.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.295 -0.878 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 80.8 m80 56.5 -177.69 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.193 -0.942 . . . . 0.0 109.431 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 20.8 m-70 -119.62 137.19 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.6 p-80 -56.83 -18.8 14.3 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.282 -0.886 . . . . 0.0 109.412 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.02 -162.87 36.16 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HG3' ' A' ' 37' ' ' PRO . 3.4 m -145.88 131.55 18.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.26 -1.141 . . . . 0.0 109.505 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.5 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -98.92 140.42 33.11 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.424 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 36' ' ' ARG . 47.5 t -121.46 124.18 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.115 -0.991 . . . . 0.0 109.537 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -111.93 121.4 44.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.611 HG22 ' CD1' ' A' ' 34' ' ' TYR . 5.1 t -128.3 138.44 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.878 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.41 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 36.7 p -141.44 145.5 35.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.346 -0.846 . . . . 0.0 109.146 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.587 ' CD2' HG12 ' A' ' 32' ' ' ILE . 13.6 m-85 -119.06 142.68 47.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.927 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.7 m -137.85 127.79 25.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.247 -0.908 . . . . 0.0 109.189 179.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.876 HG22 ' CD2' ' A' ' 30' ' ' LEU . 27.9 t -75.74 136.09 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.289 -0.882 . . . . 0.0 109.173 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -114.14 156.24 24.57 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.083 -1.011 . . . . 0.0 109.926 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 34.6 mttt -48.35 111.98 0.53 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.497 -0.752 . . . . 0.0 109.955 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.15 -6.39 1.53 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.283 -1.437 . . . . 0.0 110.784 179.251 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.452 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 3.3 m -61.41 140.26 58.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.842 -1.387 . . . . 0.0 109.192 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.57 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.95 177.47 2.2 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.207 -0.933 . . . . 0.0 109.53 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.57 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 50.3 Cg_endo -70.88 -31.34 15.69 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.614 2.209 . . . . 0.0 111.903 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -117.93 5.26 12.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 108.931 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.472 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 44.3 mttt -142.35 133.8 26.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.039 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.25 133.71 50.17 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 120.988 -1.07 . . . . 0.0 110.222 -179.511 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.972 HG13 ' HG2' ' A' ' 65' ' ' GLU . 21.2 t -122.4 124.64 71.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.039 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -142.22 142.22 32.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.057 -1.027 . . . . 0.0 110.047 -179.372 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -86.15 136.62 33.13 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.849 HG21 ' CE2' ' A' ' 80' ' ' PHE . 87.8 mt -121.3 131.02 74.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.339 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 60.3 tttt -109.99 118.38 36.28 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.611 ' CD1' HG22 ' A' ' 15' ' ' VAL . 77.2 t80 -122.26 111.16 16.59 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.54 -0.725 . . . . 0.0 109.341 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 47.5 m -115.08 120.33 39.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.215 -0.928 . . . . 0.0 109.804 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 34' ' ' TYR . 2.9 mtt-85 -123.21 163.34 34.45 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.609 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.502 ' HG3' ' CB ' ' A' ' 11' ' ' SER . 51.9 Cg_endo -72.57 50.65 1.7 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.73 2.287 . . . . 0.0 111.864 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 117.94 -12.89 13.01 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.433 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.5 OUTLIER -96.83 178.78 5.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -1.169 . . . . 0.0 109.308 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.8 p -150.95 159.25 44.68 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.204 -0.935 . . . . 0.0 109.708 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.955 HD23 ' N ' ' A' ' 42' ' ' ALA . 2.2 tt -71.81 134.27 46.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.955 ' N ' HD23 ' A' ' 41' ' ' LEU . . . -114.74 -42.35 3.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.178 -0.952 . . . . 0.0 109.848 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -144.02 152.4 40.97 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.065 -1.022 . . . . 0.0 110.431 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.498 HG13 ' CE1' ' A' ' 80' ' ' PHE . 3.5 t -140.39 138.07 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.441 -0.787 . . . . 0.0 109.345 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.424 ' OE2' ' HB3' ' A' ' 56' ' ' PRO . 5.7 mm-40 -127.08 150.91 49.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 109.352 179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.724 HD23 HG11 ' A' ' 66' ' ' VAL . 5.9 tp -122.99 123.82 41.76 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.321 -0.862 . . . . 0.0 110.56 -178.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.709 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.6 OUTLIER -106.25 129.41 54.29 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.935 . . . . 0.0 109.006 178.838 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.59 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 27.7 mt-30 -71.64 151.17 43.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.291 -0.881 . . . . 0.0 109.306 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.608 ' CE1' ' HG2' ' A' ' 75' ' ' PRO . 30.0 t60 -67.49 110.33 3.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.188 -0.945 . . . . 0.0 109.44 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 106.28 1.03 38.17 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 27.2 t -112.77 153.11 28.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.246 . . . . 0.0 109.397 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 61.8 tt0 -116.22 14.23 15.82 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.25 -0.906 . . . . 0.0 109.34 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -112.45 86.9 2.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.282 -0.886 . . . . 0.0 109.465 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.628 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 22.5 m95 -53.84 138.72 35.36 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.424 -0.798 . . . . 0.0 109.841 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.07 131.61 23.44 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.454 -0.779 . . . . 0.0 108.911 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.424 ' HB3' ' OE2' ' A' ' 45' ' ' GLU . 49.1 Cg_endo -69.91 150.09 66.84 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.56 2.173 . . . . 0.0 112.027 -179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.712 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -100.92 148.43 25.0 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.469 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 69.7 m -98.12 126.69 43.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.742 -1.224 . . . . 0.0 109.051 179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -71.38 107.58 4.4 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.26 -0.9 . . . . 0.0 109.204 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.426 ' HD3' ' HA ' ' A' ' 60' ' ' LYS . 6.6 mmtp -111.75 106.79 15.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.969 -1.082 . . . . 0.0 109.581 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 65.35 -95.46 0.21 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -134.18 17.19 3.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -1.144 . . . . 0.0 109.453 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.01 169.85 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.305 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.459 ' HE3' ' CB ' ' A' ' 57' ' ' LEU . 70.3 m95 -116.41 131.04 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.177 -0.952 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.972 ' HG2' HG13 ' A' ' 29' ' ' VAL . 91.1 mt-10 -117.89 144.69 45.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.596 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.724 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -141.34 138.47 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -122.44 132.42 54.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 0.0 110.0 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.59 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 48.4 t -118.88 116.55 26.73 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.467 -0.771 . . . . 0.0 109.479 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 68' ' ' SER . 50.0 m -43.37 -37.71 2.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.143 -0.973 . . . . 0.0 109.085 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.618 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 5.2 ptpp? -94.72 168.44 11.28 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.159 179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.618 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.6 146.68 80.17 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.443 2.095 . . . . 0.0 111.743 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.006 HD13 HD12 ' A' ' 28' ' ' LEU . 1.6 mt -80.06 139.66 36.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.307 -0.871 . . . . 0.0 109.913 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.1 t -124.4 125.06 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.467 -0.771 . . . . 0.0 109.273 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.495 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.45 166.41 26.72 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.608 ' HG2' ' CE1' ' A' ' 49' ' ' HIS . 47.9 Cg_endo -68.65 145.13 76.04 Favored 'Cis proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.846 -1.731 . . . . 0.0 112.045 0.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.1 m-85 -91.19 153.1 20.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.588 -0.695 . . . . 0.0 110.49 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.477 ' O ' HD12 ' A' ' 46' ' ' LEU . 2.7 m-80 -111.72 140.91 45.97 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 46' ' ' LEU . 91.6 m-85 -131.65 135.76 47.18 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.886 -1.134 . . . . 0.0 109.772 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.442 ' N ' ' HZ3' ' A' ' 54' ' ' TRP . 53.3 ttt-85 -119.97 142.86 48.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.192 -0.943 . . . . 0.0 108.609 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.849 ' CE2' HG21 ' A' ' 32' ' ' ILE . 15.3 m-85 -124.77 144.18 50.39 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.183 -0.948 . . . . 0.0 111.721 -177.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.654 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.4 ttt -126.65 124.16 39.22 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 178.315 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.53 ' OG ' ' CB ' ' A' ' 86' ' ' MET . 20.8 p -77.76 141.87 39.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.325 -0.859 . . . . 0.0 109.867 -178.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.804 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 19.9 mttm -44.3 -44.02 7.81 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.21 -4.31 8.09 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 96.03 30.63 7.76 Favored Glycine 0 N--CA 1.491 2.319 0 O-C-N 121.256 -1.144 . . . . 0.0 110.33 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.53 ' CB ' ' OG ' ' A' ' 82' ' ' SER . 37.0 mmm -103.45 107.85 18.86 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.02 -1.282 . . . . 0.0 108.854 179.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 35.7 mtm-85 -92.29 142.21 27.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 110.923 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.54 ' N ' ' O ' ' A' ' 80' ' ' PHE . 30.0 m120 -137.25 141.33 42.01 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 t -121.33 136.8 57.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.998 -1.064 . . . . 0.0 110.202 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 82.2 m-85 -125.05 121.65 34.97 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 92' ' ' GLU . 55.1 t0 -97.51 147.96 23.73 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.097 -1.002 . . . . 0.0 109.662 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.599 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 35.8 mt-10 51.77 54.52 10.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.449 -0.782 . . . . 0.0 109.947 179.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' A' ' 106' ' ' PRO . 75.1 t -83.63 -32.89 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.954 -1.091 . . . . 0.0 109.261 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.45 HG12 ' HB3' ' A' ' 104' ' ' TYR . 34.8 mt -138.55 126.49 13.73 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.33 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.19 163.82 37.21 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.553 2.169 . . . . 0.0 111.8 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.495 HG23 ' H ' ' A' ' 74' ' ' GLY . 5.7 m -54.38 -37.31 64.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.309 -0.87 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.49 96.2 10.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.008 . . . . 0.0 109.836 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -104.95 143.94 32.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.488 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 88.0 p -116.66 124.07 48.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.211 -0.931 . . . . 0.0 109.665 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.567 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 5.9 mt -64.04 138.65 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.528 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.45 -4.19 50.88 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 37.8 tttp -118.19 142.86 47.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.108 -1.23 . . . . 0.0 109.264 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.562 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.3 m -76.81 173.61 11.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.033 -1.042 . . . . 0.0 108.476 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.568 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.0 m-85 -158.13 96.45 1.45 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 120.64 -1.288 . . . . 0.0 109.004 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.57 158.61 33.42 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.322 -0.861 . . . . 0.0 109.833 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HB3' HG22 ' A' ' 93' ' ' VAL . 49.5 Cg_endo -70.95 149.07 58.66 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.734 2.289 . . . . 0.0 111.663 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -60.84 -37.72 83.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.17 -0.956 . . . . 0.0 109.539 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 61.9 tt0 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.488 -179.914 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . 0.428 ' O ' ' HG2' ' A' ' 1' ' ' ARG . 37.1 ttp180 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -93.05 20.22 47.25 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 84.1 p -63.56 -16.63 61.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -1.146 . . . . 0.0 109.392 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -65.99 -12.36 54.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 57.52 16.96 3.59 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -128.36 122.5 31.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 109.486 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -140.15 139.94 35.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -58.06 -21.52 45.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -107.18 141.14 38.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.461 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.03 169.81 16.17 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HB2' ' A' ' 12' ' ' ALA . 15.7 m -109.76 166.09 11.19 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.41 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 11' ' ' SER . . . 176.05 173.21 0.35 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.213 -0.929 . . . . 0.0 109.344 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 36' ' ' ARG . 3.0 t -123.47 128.09 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -111.49 120.88 43.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.145 -0.972 . . . . 0.0 109.189 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.58 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.0 t -127.77 137.06 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.89 . . . . 0.0 109.874 -179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.495 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 18.1 p -143.75 147.27 33.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.409 -0.807 . . . . 0.0 109.259 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.626 ' O ' ' N ' ' A' ' 104' ' ' TYR . 21.6 m-85 -118.55 145.46 45.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 109.786 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 62.6 m -139.59 128.12 22.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.112 -0.993 . . . . 0.0 109.201 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 HD23 ' A' ' 30' ' ' LEU . 5.2 t -76.4 133.36 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.222 -0.924 . . . . 0.0 109.53 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.3 mm-40 -109.83 156.27 20.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.526 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -49.32 113.56 0.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.39 -4.13 1.72 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.39 -1.386 . . . . 0.0 110.727 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.496 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 66.4 m -63.94 140.57 58.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.835 -1.391 . . . . 0.0 109.34 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.58 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.65 177.81 2.05 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.195 -0.941 . . . . 0.0 109.497 -179.571 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 49.9 Cg_endo -70.77 -31.08 16.63 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.516 2.144 . . . . 0.0 111.827 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -116.68 6.25 13.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.016 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 19.8 mttp -142.41 133.56 26.05 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.084 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -126.29 132.28 51.69 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.964 -1.085 . . . . 0.0 110.002 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.929 HG13 ' HG2' ' A' ' 65' ' ' GLU . 45.7 t -121.8 124.25 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.084 HD11 HD22 ' A' ' 28' ' ' LEU . 1.0 OUTLIER -141.55 142.02 33.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.947 -1.095 . . . . 0.0 110.285 -179.456 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD2' HG12 ' A' ' 63' ' ' VAL . 10.4 t70 -86.51 136.9 32.91 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.599 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.2 mt -117.06 127.96 74.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 120.712 -1.243 . . . . 0.0 111.122 -178.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 31.1 mtpt -108.06 114.97 29.28 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.58 ' CD1' HG22 ' A' ' 15' ' ' VAL . 84.4 t80 -124.3 108.2 11.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.71 -0.618 . . . . 0.0 109.817 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.9 m -109.52 117.3 33.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.38 -0.825 . . . . 0.0 109.523 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.554 ' CD ' ' HB2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -139.89 121.72 9.79 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.406 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 50.4 Cg_endo -70.52 119.39 6.3 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.72 2.28 . . . . 0.0 111.929 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.39 -12.44 68.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -141.25 -178.63 5.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.141 -1.211 . . . . 0.0 109.646 -179.906 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.9 m -156.32 163.45 39.5 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.748 HD13 ' HD2' ' A' ' 80' ' ' PHE . 51.0 tp -68.96 125.94 28.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.228 -0.92 . . . . 0.0 109.195 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.828 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -113.97 -44.24 3.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 109.9 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -138.55 147.56 43.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.17 -0.956 . . . . 0.0 110.22 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.738 HG22 HD11 ' A' ' 41' ' ' LEU . 43.4 t -138.83 136.75 43.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.458 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 93.0 mt-10 -127.75 149.8 50.08 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.813 -1.179 . . . . 0.0 109.726 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.984 HD13 ' N ' ' A' ' 47' ' ' ARG . 3.2 tm? -118.73 142.72 47.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.529 -0.732 . . . . 0.0 109.642 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.984 ' N ' HD13 ' A' ' 46' ' ' LEU . 13.7 ttp180 -127.48 124.65 38.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -0.86 . . . . 0.0 108.885 179.217 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.454 ' NE2' ' OG ' ' A' ' 68' ' ' SER . 39.4 mt-30 -63.87 155.44 30.62 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.25 -0.906 . . . . 0.0 109.895 -179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.569 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 44.1 t60 -73.19 119.19 17.08 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.348 -0.845 . . . . 0.0 109.586 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 101.34 6.79 50.44 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.402 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.4 t -115.52 156.28 26.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -1.136 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -114.73 14.63 17.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.266 -0.896 . . . . 0.0 109.332 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -120.62 111.93 18.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.335 -0.853 . . . . 0.0 109.629 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.4 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 44.6 m95 -70.05 135.82 49.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -105.28 133.89 19.94 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.439 -0.788 . . . . 0.0 109.427 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.557 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.5 Cg_endo -72.16 144.63 42.43 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.653 2.235 . . . . 0.0 112.084 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.717 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.5 mp -102.28 154.63 18.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.123 -0.986 . . . . 0.0 108.669 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 96.8 m -99.89 127.64 46.05 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.855 -1.153 . . . . 0.0 109.208 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.4 tttm -69.72 109.69 4.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.14 -0.975 . . . . 0.0 109.099 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 62' ' ' ASN . 21.5 mttp -108.96 119.15 38.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.983 -1.073 . . . . 0.0 109.725 -179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 47.8 -92.94 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 60' ' ' LYS . 4.8 m120 -131.8 17.05 4.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -1.131 . . . . 0.0 109.422 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.487 HG12 ' OD2' ' A' ' 31' ' ' ASP . 27.1 m -130.61 178.16 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.413 ' CD1' HG13 ' A' ' 32' ' ' ILE . 59.0 m95 -124.98 125.19 43.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.34 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.929 ' HG2' HG13 ' A' ' 29' ' ' VAL . 62.4 mt-10 -115.77 150.71 36.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.57 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 2.1 p -144.53 140.11 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.85 . . . . 0.0 109.265 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -121.87 132.88 54.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.185 -0.947 . . . . 0.0 109.606 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.454 ' OG ' ' NE2' ' A' ' 48' ' ' GLN . 8.0 t -116.92 133.9 55.44 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.421 -0.8 . . . . 0.0 109.214 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.9 m -59.94 -18.94 49.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.169 -0.957 . . . . 0.0 109.31 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.573 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.4 178.22 1.02 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.573 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 50.7 Cg_endo -70.85 141.18 40.2 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.573 2.182 . . . . 0.0 111.846 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.956 HD13 HD12 ' A' ' 28' ' ' LEU . 4.5 mt -76.39 139.05 40.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.475 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 20.8 t -125.01 125.12 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.465 -0.772 . . . . 0.0 109.53 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.438 ' HA2' ' C ' ' A' ' 75' ' ' PRO . . . -94.72 169.28 28.41 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.646 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.6 Cg_endo -68.37 146.09 77.89 Favored 'Cis proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.826 -1.739 . . . . 0.0 112.021 0.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.835 ' HB3' HD21 ' A' ' 46' ' ' LEU . 83.4 m-85 -89.67 146.37 24.58 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.465 -0.772 . . . . 0.0 110.355 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.943 ' O ' HD22 ' A' ' 46' ' ' LEU . 7.1 m-80 -107.14 142.07 37.41 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 178.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.833 ' CE2' HD23 ' A' ' 46' ' ' LEU . 45.6 m-85 -131.7 119.48 21.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.843 -1.161 . . . . 0.0 110.205 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.99 ' HG3' HG22 ' A' ' 89' ' ' VAL . 33.0 ttm180 -102.13 141.14 35.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.097 -1.002 . . . . 0.0 108.51 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.748 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.3 m-85 -123.01 142.6 50.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 111.403 -178.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' O ' ' A' ' 86' ' ' MET . 0.0 OUTLIER -125.92 124.86 41.75 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.194 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.613 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.8 p -74.06 145.63 44.3 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 110.174 -178.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.828 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 94.5 mttt -48.14 -44.5 32.29 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.393 -0.817 . . . . 0.0 108.959 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.443 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -56.78 -3.19 0.64 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.72 24.34 18.22 Favored Glycine 0 N--CA 1.489 2.173 0 O-C-N 121.062 -1.258 . . . . 0.0 110.003 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.613 ' O ' ' N ' ' A' ' 82' ' ' SER . 15.0 mmm -96.37 146.75 24.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.071 -1.252 . . . . 0.0 108.634 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 52.9 mtm-85 -122.94 139.42 54.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.855 -1.153 . . . . 0.0 110.55 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.0 m120 -136.31 141.02 43.77 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.99 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.6 t -122.07 136.52 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.982 -1.074 . . . . 0.0 110.195 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.547 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 72.9 m-85 -124.23 122.58 38.15 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.16 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -100.42 147.75 25.5 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.262 -0.899 . . . . 0.0 109.775 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 78.9 mt-10 53.19 52.62 13.3 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 110.276 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.459 ' HB ' ' CD1' ' A' ' 78' ' ' PHE . 57.8 t -84.68 -34.44 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 109.332 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.429 HG13 HG12 ' A' ' 93' ' ' VAL . 44.9 mt -136.58 125.88 15.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.228 -0.92 . . . . 0.0 109.146 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.26 161.96 44.07 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.509 2.139 . . . . 0.0 111.887 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.6 m -52.89 -43.05 65.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.901 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.13 99.75 12.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.107 -0.996 . . . . 0.0 109.655 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -108.27 150.72 26.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.124 -0.985 . . . . 0.0 109.478 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 87.6 p -109.73 170.31 8.15 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.346 -0.847 . . . . 0.0 109.34 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.493 HD13 ' CG1' ' A' ' 19' ' ' VAL . 32.1 mm -104.99 136.12 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.276 -0.89 . . . . 0.0 109.254 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.07 4.66 59.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -118.87 144.27 46.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.104 -1.233 . . . . 0.0 109.362 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.634 HG22 ' H ' ' A' ' 104' ' ' TYR . 3.5 m -78.73 177.15 8.89 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.115 -0.991 . . . . 0.0 109.193 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.634 ' H ' HG22 ' A' ' 103' ' ' THR . 30.7 m-85 -163.73 100.08 0.89 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.859 -1.151 . . . . 0.0 108.926 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.0 OUTLIER -112.86 164.88 14.32 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.118 -0.989 . . . . 0.0 109.887 -179.448 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.547 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.6 Cg_endo -70.44 167.1 26.29 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.9 2.4 . . . . 0.0 111.771 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 69.7 mm-40 -102.64 142.01 34.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.368 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.978 -1.011 . . . . 0.0 109.448 -179.998 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 91.4 mtt180 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 87.99 -163.98 33.63 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 92.3 p -123.97 163.42 21.4 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -1.143 . . . . 0.0 109.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 16.7 m-70 -86.65 136.82 32.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.929 . . . . 0.0 109.457 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 86.3 m-70 -80.13 -40.01 28.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -82.37 -9.76 59.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -0.877 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 36.6 t60 -128.43 153.95 46.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.257 -0.902 . . . . 0.0 109.51 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -133.55 143.38 48.68 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.47 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 47.4 m80 -93.53 1.38 56.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.229 -0.919 . . . . 0.0 109.549 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -50.84 113.6 2.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -108.67 162.81 13.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.236 -1.155 . . . . 0.0 109.477 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.479 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . -93.96 -146.84 0.25 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.755 HG22 ' HG2' ' A' ' 36' ' ' ARG . 15.4 t -123.04 127.99 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.906 . . . . 0.0 109.259 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -109.81 120.02 41.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.44 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 34' ' ' TYR . 3.8 t -126.28 135.6 63.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.917 . . . . 0.0 109.71 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.84 HG22 ' HG2' ' A' ' 105' ' ' LYS . 61.0 p -141.59 146.48 36.32 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.476 -0.765 . . . . 0.0 109.279 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.58 ' O ' ' N ' ' A' ' 104' ' ' TYR . 4.0 m-85 -119.41 141.16 49.34 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 0.0 109.939 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.4 m -136.97 128.52 28.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.17 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.909 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.0 t -76.27 144.68 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.142 -0.974 . . . . 0.0 109.377 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -115.78 159.84 20.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.997 . . . . 0.0 109.584 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 50.6 mttt -53.61 114.3 1.48 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.926 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.7 -3.61 2.62 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.446 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -58.33 141.89 49.76 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.87 -1.371 . . . . 0.0 109.232 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.551 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.19 171.84 8.36 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.223 -0.923 . . . . 0.0 109.689 -179.705 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.0 Cg_endo -70.79 -30.8 16.98 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.808 2.339 . . . . 0.0 111.998 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.1 mttt -112.76 8.82 18.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.077 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.453 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 16.9 mttp -142.17 132.82 25.43 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.612 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.1 OUTLIER -120.88 123.05 41.59 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.979 -1.076 . . . . 0.0 109.362 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.985 HG13 ' HG2' ' A' ' 65' ' ' GLU . 25.1 t -120.42 125.99 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.909 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.9 mt -144.7 144.29 31.14 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.046 -1.034 . . . . 0.0 110.165 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.76 138.91 31.23 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.936 HG21 ' CE2' ' A' ' 80' ' ' PHE . 69.0 mt -122.28 131.46 73.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.489 -179.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 54.7 tttp -109.8 119.01 38.01 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.575 ' CD1' HG22 ' A' ' 15' ' ' VAL . 78.7 t80 -122.7 113.25 18.97 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.46 -0.775 . . . . 0.0 109.748 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.9 m -115.99 118.38 32.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.32 -0.863 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.755 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -132.91 150.75 76.53 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.459 179.984 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.88 88.61 0.66 Allowed 'Trans proline' 0 C--O 1.214 -0.691 0 C-N-CA 122.642 2.228 . . . . 0.0 112.081 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.43 -27.73 8.29 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.951 -1.259 . . . . 0.0 109.951 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.56 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -91.17 171.98 8.87 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.116 -1.226 . . . . 0.0 109.619 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.534 ' O ' ' HA ' ' A' ' 82' ' ' SER . 18.2 m -153.66 161.33 42.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.545 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.901 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.4 tt -72.56 132.84 44.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.365 -0.835 . . . . 0.0 109.695 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.952 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.14 -40.06 3.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.197 -0.939 . . . . 0.0 109.899 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 87.7 mt-10 -142.45 150.56 40.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.156 -0.965 . . . . 0.0 110.197 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.491 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.8 t -138.44 136.13 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 109.319 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.59 150.51 50.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.002 HD23 HG11 ' A' ' 66' ' ' VAL . 16.7 tp -120.25 135.36 55.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.411 -0.806 . . . . 0.0 109.888 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.598 ' H ' HD12 ' A' ' 46' ' ' LEU . 4.0 ttp180 -121.58 130.27 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.837 . . . . 0.0 108.845 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 57.0 mt-30 -74.72 150.54 39.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.13 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.567 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 51.6 t-80 -64.45 117.75 7.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.37 1.34 44.06 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.455 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 38.3 t -113.33 153.14 28.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.188 -1.183 . . . . 0.0 109.439 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 58.0 mt-10 -118.3 20.48 13.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.321 -0.862 . . . . 0.0 109.318 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -124.23 94.08 4.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.873 . . . . 0.0 109.456 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.427 ' CZ3' ' N ' ' A' ' 79' ' ' ARG . 66.3 m95 -54.22 132.06 42.64 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 109.774 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.4 mm-40 -101.05 138.22 19.93 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.799 . . . . 0.0 109.273 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.87 143.78 46.42 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.709 2.273 . . . . 0.0 112.04 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.785 HD11 ' CB ' ' A' ' 46' ' ' LEU . 6.8 mp -110.63 149.85 29.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.194 -0.941 . . . . 0.0 108.931 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 11.3 m -103.31 125.33 49.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.923 -1.11 . . . . 0.0 109.154 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 12.9 tttm -73.58 109.85 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.135 -0.978 . . . . 0.0 109.275 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.898 ' O ' HG22 ' A' ' 63' ' ' VAL . 66.8 mttt -120.23 144.23 47.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.906 -1.121 . . . . 0.0 110.068 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.59 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.76 29.96 0.87 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.59 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 8.0 t30 81.99 14.73 0.51 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.239 -1.153 . . . . 0.0 110.376 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.898 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.6 m -129.52 170.26 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.099 -1.0 . . . . 0.0 109.021 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.678 ' CD1' HD12 ' A' ' 32' ' ' ILE . 81.6 m95 -114.51 122.67 47.29 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.908 -1.12 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.985 ' HG2' HG13 ' A' ' 29' ' ' VAL . 43.1 mt-10 -112.39 147.18 36.96 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.402 -0.811 . . . . 0.0 109.445 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 1.002 HG11 HD23 ' A' ' 46' ' ' LEU . 9.7 p -136.21 132.65 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.502 -0.749 . . . . 0.0 109.121 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.0 mttp -119.2 130.51 55.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.099 -1.001 . . . . 0.0 109.482 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.4 t -118.54 144.7 45.89 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 1.2 p -71.4 -4.18 24.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.072 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 16.2 mmtt -132.86 169.7 13.3 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.386 -0.821 . . . . 0.0 109.105 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 43.9 Cg_endo -66.02 133.18 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.519 2.146 . . . . 0.0 111.776 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.605 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -68.13 146.53 53.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.346 -0.846 . . . . 0.0 109.777 -179.607 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.84 123.65 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.404 -0.81 . . . . 0.0 109.198 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -92.82 165.39 28.24 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.653 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.5 Cg_endo -68.78 145.17 76.46 Favored 'Cis proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.922 -1.699 . . . . 0.0 111.985 0.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.605 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -89.35 149.07 23.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.578 -0.701 . . . . 0.0 110.432 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.861 ' O ' HD12 ' A' ' 46' ' ' LEU . 36.2 m-80 -109.52 141.82 41.45 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.875 ' CE1' HD13 ' A' ' 46' ' ' LEU . 87.1 m-85 -133.38 121.09 21.8 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.958 -1.089 . . . . 0.0 109.748 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.646 ' HG3' HG22 ' A' ' 89' ' ' VAL . 27.8 ttm180 -104.12 143.31 33.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.07 -1.019 . . . . 0.0 108.944 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.936 ' CE2' HG21 ' A' ' 32' ' ' ILE . 22.6 m-85 -125.53 144.22 50.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 111.676 -178.013 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.637 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -127.04 126.37 42.97 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.611 ' N ' ' O ' ' A' ' 86' ' ' MET . 25.9 p -76.33 145.98 39.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.215 -0.928 . . . . 0.0 110.387 -178.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.952 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 58.5 mttt -50.08 -42.96 51.1 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.15 -2.57 0.41 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 92.84 25.88 18.71 Favored Glycine 0 N--CA 1.489 2.22 0 O-C-N 121.082 -1.246 . . . . 0.0 109.991 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.611 ' O ' ' N ' ' A' ' 82' ' ' SER . 12.8 mtm -102.17 151.24 22.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.084 -1.245 . . . . 0.0 108.769 179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.637 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 67.8 mtp180 -125.47 140.89 52.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.92 -1.112 . . . . 0.0 110.567 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 80' ' ' PHE . 11.9 m120 -135.23 139.95 44.88 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 79' ' ' ARG . 26.3 t -122.39 137.45 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.999 -1.063 . . . . 0.0 110.364 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.536 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 95.4 m-85 -125.37 122.71 37.57 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.26 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -99.81 148.34 24.52 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 98.9 mt-10 52.76 54.06 11.14 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.408 -0.808 . . . . 0.0 110.393 179.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 106' ' ' PRO . 77.8 t -85.37 -34.07 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 120.903 -1.123 . . . . 0.0 109.093 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.456 HG12 ' HB3' ' A' ' 104' ' ' TYR . 22.0 mt -136.57 125.21 15.21 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.879 . . . . 0.0 108.979 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.53 162.4 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.453 2.102 . . . . 0.0 111.871 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.525 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 39.5 m -51.48 -44.99 62.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.31 -0.869 . . . . 0.0 109.815 -179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.01 101.7 14.46 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.126 -0.983 . . . . 0.0 109.365 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -109.26 151.53 26.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.266 -0.897 . . . . 0.0 109.405 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 53.5 p -105.63 170.41 7.91 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.276 -0.89 . . . . 0.0 109.23 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 18.6 mm -105.13 136.35 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.192 -0.942 . . . . 0.0 109.374 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 92.26 9.46 61.88 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 52.5 tttt -118.42 143.14 46.89 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -1.197 . . . . 0.0 109.18 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.513 HG22 ' N ' ' A' ' 104' ' ' TYR . 23.2 m -77.28 168.61 19.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.996 -1.065 . . . . 0.0 108.997 -179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.58 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.1 m-85 -154.63 96.98 1.94 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.674 -1.266 . . . . 0.0 108.918 179.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.84 ' HG2' HG22 ' A' ' 16' ' ' THR . 6.6 mtmm -103.15 160.28 26.65 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.266 -0.897 . . . . 0.0 109.806 -179.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.536 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.1 Cg_endo -70.07 146.16 57.46 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -57.59 -63.38 1.26 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 109.485 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.6 mt-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.063 -0.97 . . . . 0.0 109.375 -179.948 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.56 -12.28 58.14 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.0 t -59.59 -29.63 68.1 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -1.169 . . . . 0.0 109.498 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 58.3 t60 -125.02 144.18 50.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -97.74 173.55 7.06 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.875 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -118.58 148.88 42.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -57.17 -32.38 66.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.33 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 14.2 m-70 -50.61 -49.74 55.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.432 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -70.51 -54.79 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.407 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.26 -160.67 19.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.494 ' OG ' ' HG2' ' A' ' 37' ' ' PRO . 79.6 p -114.01 -170.24 1.67 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.312 -1.11 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.43 152.37 31.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.885 . . . . 0.0 109.61 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.974 HG22 ' HG2' ' A' ' 36' ' ' ARG . 6.2 t -126.65 136.91 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.238 -0.914 . . . . 0.0 109.507 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -109.63 121.65 45.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.546 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 10.3 p -129.28 141.4 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.353 -0.842 . . . . 0.0 109.427 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.442 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 67.9 p -141.58 145.79 35.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.139 -0.976 . . . . 0.0 109.721 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.63 ' O ' ' N ' ' A' ' 104' ' ' TYR . 7.0 m-85 -118.63 143.72 46.63 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 31' ' ' ASP . 63.7 m -137.87 128.07 26.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.109 -0.995 . . . . 0.0 109.283 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.821 HG22 ' CD2' ' A' ' 30' ' ' LEU . 15.7 t -76.05 128.63 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.27 -0.893 . . . . 0.0 109.425 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.417 ' O ' HD12 ' A' ' 100' ' ' ILE . 89.9 mm-40 -91.26 -178.39 5.13 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.551 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 20.2 mttt -79.91 70.14 6.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.18 25.84 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.423 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 1.5 t -73.97 140.34 45.45 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.748 -1.442 . . . . 0.0 108.831 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -134.53 173.74 5.45 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.011 -1.056 . . . . 0.0 109.809 -179.532 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 52.1 Cg_endo -71.8 -32.18 11.9 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.719 2.279 . . . . 0.0 111.909 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.0 mttp -116.95 5.63 12.92 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.012 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.508 ' CD ' ' HE2' ' A' ' 67' ' ' LYS . 79.6 tttt -142.37 133.36 25.85 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.997 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -125.15 131.08 53.3 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.077 -1.014 . . . . 0.0 109.619 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 1.059 HG13 ' HG2' ' A' ' 65' ' ' GLU . 3.1 t -121.45 124.39 71.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.997 HD11 HD22 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -143.5 143.5 31.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.029 -1.044 . . . . 0.0 109.999 -179.487 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HA ' HG12 ' A' ' 63' ' ' VAL . 60.1 t0 -83.99 135.16 34.55 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.577 HG21 ' CE2' ' A' ' 80' ' ' PHE . 78.3 mt -119.4 130.11 74.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.541 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 8.5 ttmm -111.19 120.39 42.13 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.6 ' CE2' ' HB2' ' A' ' 36' ' ' ARG . 87.3 t80 -120.32 119.87 34.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.391 -0.818 . . . . 0.0 109.519 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 31.1 m -122.31 115.55 22.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.298 -0.876 . . . . 0.0 109.751 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.974 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -133.59 136.86 27.61 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.525 -0.734 . . . . 0.0 109.03 179.768 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.494 ' HG2' ' OG ' ' A' ' 11' ' ' SER . 48.1 Cg_endo -69.93 104.49 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.676 2.251 . . . . 0.0 111.95 -179.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.31 3.38 87.06 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.562 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 4.2 t0 -136.38 175.05 9.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.155 -1.203 . . . . 0.0 109.758 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.511 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 p -153.05 161.02 43.0 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.337 -0.852 . . . . 0.0 109.372 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.803 HD21 ' CG2' ' A' ' 44' ' ' VAL . 8.1 tp -72.08 132.74 44.63 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.789 ' N ' HD12 ' A' ' 41' ' ' LEU . . . -117.26 -41.63 2.97 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 109.741 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -141.76 150.12 41.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.181 -0.949 . . . . 0.0 109.992 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.803 ' CG2' HD21 ' A' ' 41' ' ' LEU . 2.6 t -138.52 135.98 43.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.439 -0.788 . . . . 0.0 109.365 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.451 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 78.4 mt-10 -127.81 149.78 50.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.911 -1.118 . . . . 0.0 109.21 179.432 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.889 HD12 ' CE2' ' A' ' 78' ' ' PHE . 7.0 tt -120.28 139.69 52.34 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.335 -0.853 . . . . 0.0 109.89 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.883 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.3 ttp180 -126.82 120.12 28.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.875 . . . . 0.0 108.82 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.511 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 32.0 mt-30 -64.39 145.05 56.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.141 -179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.552 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 49.1 t60 -55.82 145.41 24.59 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.454 -0.779 . . . . 0.0 109.243 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.51 1.22 51.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.419 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 9.6 t -111.44 152.75 27.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.1 -1.235 . . . . 0.0 109.316 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 -119.0 7.32 11.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -104.89 97.9 7.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.543 ' NE1' ' HD3' ' A' ' 47' ' ' ARG . 51.5 m95 -63.11 132.07 50.62 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 109.779 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -105.3 136.97 19.14 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 109.391 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD22 ' A' ' 57' ' ' LEU . 50.9 Cg_endo -70.88 151.82 62.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.752 2.301 . . . . 0.0 112.201 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.744 HD13 ' HB ' ' A' ' 66' ' ' VAL . 0.3 OUTLIER -110.2 154.03 23.94 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 179.6 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 64' ' ' TRP . 7.0 m -110.21 126.4 54.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.833 -1.167 . . . . 0.0 108.808 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 tttm -74.31 105.73 5.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.087 -1.008 . . . . 0.0 109.283 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.77 ' O ' HG22 ' A' ' 63' ' ' VAL . 16.4 mttp -120.47 142.86 48.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.819 -1.176 . . . . 0.0 110.249 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 41.84 35.96 1.67 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 7.9 m-20 78.06 10.82 2.01 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.061 -1.258 . . . . 0.0 110.469 179.158 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 60' ' ' LYS . 15.6 m -128.59 -177.96 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.977 -1.077 . . . . 0.0 108.776 179.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 57' ' ' LEU . 66.1 m95 -123.07 141.07 52.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.05 -1.032 . . . . 0.0 109.927 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 1.059 ' HG2' HG13 ' A' ' 29' ' ' VAL . 92.1 mt-10 -127.96 142.37 51.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.473 -0.767 . . . . 0.0 109.105 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.744 ' HB ' HD13 ' A' ' 57' ' ' LEU . 1.9 p -139.39 137.53 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.227 -0.92 . . . . 0.0 109.377 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.508 ' HE2' ' CD ' ' A' ' 27' ' ' LYS . 28.7 mttt -122.71 134.15 54.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.463 -0.773 . . . . 0.0 109.632 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.511 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.7 t -117.46 145.3 44.26 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.488 -0.758 . . . . 0.0 109.18 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 49.5 m -68.77 -16.5 63.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.16 -0.962 . . . . 0.0 109.289 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.557 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -115.73 176.4 1.53 Allowed Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.557 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 49.8 Cg_endo -70.03 136.64 32.77 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.684 2.256 . . . . 0.0 111.726 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.946 HD13 HD12 ' A' ' 28' ' ' LEU . 6.4 mt -68.64 136.57 53.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.9 t -126.06 125.56 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.491 -0.756 . . . . 0.0 109.472 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -93.66 166.25 27.68 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.64 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.8 Cg_endo -68.73 146.12 78.93 Favored 'Cis proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.843 -1.732 . . . . 0.0 111.99 0.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 80.9 m-85 -90.09 148.39 23.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.482 -0.761 . . . . 0.0 110.425 -179.201 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.455 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 18.9 m-80 -110.52 144.37 39.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.387 -0.821 . . . . 0.0 108.829 179.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.889 ' CE2' HD12 ' A' ' 46' ' ' LEU . 61.8 m-85 -135.81 125.38 25.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.89 -1.131 . . . . 0.0 110.25 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.955 ' HG3' HG22 ' A' ' 89' ' ' VAL . 15.2 ttp180 -105.85 141.38 37.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -0.96 . . . . 0.0 108.451 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.766 ' CE1' HG13 ' A' ' 44' ' ' VAL . 6.0 m-85 -122.11 142.23 50.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 111.082 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 6.2 ttm -125.5 123.97 40.33 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.603 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.4 p -74.43 144.19 44.38 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.386 -0.821 . . . . 0.0 110.352 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.774 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 46.5 mttp -46.39 -44.76 17.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.429 -0.795 . . . . 0.0 108.946 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -56.47 -3.42 0.63 Allowed Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.462 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.05 24.36 20.0 Favored Glycine 0 N--CA 1.49 2.27 0 O-C-N 120.992 -1.299 . . . . 0.0 110.124 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.603 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.0 mtm -98.34 150.12 21.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.994 -1.298 . . . . 0.0 108.516 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.597 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 22.7 mtm-85 -125.58 141.59 51.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.845 -1.16 . . . . 0.0 110.636 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . 23.7 m120 -137.03 141.37 42.48 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.955 HG22 ' HG3' ' A' ' 79' ' ' ARG . 10.5 t -122.63 136.87 58.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.882 -1.136 . . . . 0.0 110.447 -178.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.557 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.7 m-85 -123.57 121.65 36.15 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.54 146.59 25.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.778 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.64 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 51.8 tt0 53.7 51.54 14.82 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.431 -0.793 . . . . 0.0 110.424 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.453 HG21 ' HB2' ' A' ' 90' ' ' PHE . 72.5 t -82.33 -34.18 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.88 -1.138 . . . . 0.0 108.992 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.4 HG12 ' HB3' ' A' ' 104' ' ' TYR . 12.2 mt -135.82 127.13 17.19 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.258 -0.902 . . . . 0.0 109.162 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.48 161.13 47.12 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.552 2.168 . . . . 0.0 112.007 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.529 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 28.0 m -52.04 -45.15 64.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.744 -179.717 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.82 102.41 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.429 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 47.1 p90 -111.1 151.75 27.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.128 -0.982 . . . . 0.0 109.504 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 33.2 m -106.36 163.11 13.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.909 . . . . 0.0 109.467 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.531 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.1 mm -98.16 137.4 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.376 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.4 7.47 58.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.9 tptt -121.1 143.56 49.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.134 -1.215 . . . . 0.0 109.362 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.7 HG22 ' H ' ' A' ' 104' ' ' TYR . 7.2 m -79.29 178.79 7.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 108.764 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.7 ' H ' HG22 ' A' ' 103' ' ' THR . 25.3 m-85 -164.36 94.57 0.72 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.659 -1.275 . . . . 0.0 109.112 179.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 0.1 OUTLIER -106.26 163.73 16.42 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.375 -0.828 . . . . 0.0 109.596 -179.481 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 48.5 Cg_endo -69.89 143.99 51.95 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.496 2.13 . . . . 0.0 111.723 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.2 mm-40 -52.95 -40.73 63.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.31 -0.868 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.02 -0.99 . . . . 0.0 109.459 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -100.87 2.54 55.59 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.1 t 57.34 79.52 0.19 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -1.167 . . . . 0.0 109.431 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -91.05 146.2 24.05 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.234 -0.916 . . . . 0.0 109.425 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 76.7 t60 -62.87 -20.11 64.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.268 -0.895 . . . . 0.0 109.426 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t60 -65.06 -12.63 52.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.469 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -57.11 -16.86 8.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.536 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 59.76 55.02 4.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.277 -0.89 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -132.74 125.74 30.87 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.925 . . . . 0.0 109.543 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.52 -174.09 46.38 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.0 p -135.43 168.48 19.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.29 -1.123 . . . . 0.0 109.421 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -151.43 152.03 32.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.424 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.81 HG22 ' CG ' ' A' ' 36' ' ' ARG . 47.8 t -125.05 130.84 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 74.5 mt-30 -107.53 119.43 39.41 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.123 -0.985 . . . . 0.0 109.122 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.661 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.8 p -128.66 139.43 51.91 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.21 -0.931 . . . . 0.0 110.051 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.513 HG22 ' HG2' ' A' ' 105' ' ' LYS . 30.4 p -141.21 145.12 35.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.304 -0.873 . . . . 0.0 109.41 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.602 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.8 m-85 -117.16 136.23 53.18 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.253 -0.904 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 52.3 m -131.27 127.21 37.31 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.968 -1.083 . . . . 0.0 109.326 179.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.96 HG22 ' CD2' ' A' ' 30' ' ' LEU . 9.0 t -75.38 128.37 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.283 -0.886 . . . . 0.0 109.274 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.414 ' O ' HG12 ' A' ' 100' ' ' ILE . 88.6 mm-40 -89.35 -178.25 5.57 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.061 -1.024 . . . . 0.0 109.843 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.2 mttp -80.23 65.38 5.37 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.437 -0.789 . . . . 0.0 109.975 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.28 25.9 0.08 OUTLIER Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.275 -1.441 . . . . 0.0 110.496 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.608 ' HB3' ' CZ ' ' A' ' 98' ' ' PHE . 3.2 m -79.72 144.04 34.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.079 -1.248 . . . . 0.0 109.337 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.4 172.06 7.48 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.121 -0.987 . . . . 0.0 109.579 -179.766 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.0 Cg_endo -70.67 -28.2 21.16 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.667 2.244 . . . . 0.0 111.809 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.44 ' HB3' ' O ' ' A' ' 68' ' ' SER . 80.4 mttt -116.4 5.57 13.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.087 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 61.4 mttm -141.55 132.86 26.57 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.682 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.11 123.21 41.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.978 -1.076 . . . . 0.0 109.71 -179.6 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.787 HG22 ' HG3' ' A' ' 65' ' ' GLU . 13.6 t -119.58 125.09 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.96 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -145.14 146.04 31.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.926 -1.109 . . . . 0.0 110.125 -179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.469 ' HA ' HG12 ' A' ' 63' ' ' VAL . 62.6 t0 -86.06 136.82 33.08 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.068 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.869 HG21 ' HE2' ' A' ' 80' ' ' PHE . 78.6 mt -121.05 130.82 74.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 C-N-CA 118.825 -1.15 . . . . 0.0 110.661 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.661 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 29.0 tttm -110.43 120.75 43.45 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.533 ' CE1' HG11 ' A' ' 13' ' ' VAL . 88.5 t80 -120.93 111.33 17.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.328 -0.857 . . . . 0.0 109.528 -179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 19.9 m -113.66 114.72 26.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 109.772 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.81 ' CG ' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -152.58 113.01 2.78 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.515 ' O ' ' NH1' ' A' ' 36' ' ' ARG . 48.6 Cg_endo -69.06 128.91 17.39 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.704 2.269 . . . . 0.0 112.165 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.61 -22.46 40.42 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.82 -178.76 5.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -1.144 . . . . 0.0 109.807 -179.817 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.561 ' O ' ' HA ' ' A' ' 82' ' ' SER . 57.9 m -154.37 161.68 41.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.324 -0.86 . . . . 0.0 109.331 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.51 130.19 40.64 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.255 -0.903 . . . . 0.0 109.736 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.937 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -116.4 -41.22 3.14 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.222 -0.924 . . . . 0.0 109.839 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -141.19 149.48 41.48 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.466 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.638 ' CG2' HD11 ' A' ' 41' ' ' LEU . 95.2 t -138.72 136.94 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -128.67 149.68 50.57 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.832 -1.168 . . . . 0.0 109.551 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.006 HD23 ' N ' ' A' ' 47' ' ' ARG . 5.3 tt -119.4 135.73 54.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.443 -0.786 . . . . 0.0 109.852 -179.288 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 1.006 ' N ' HD23 ' A' ' 46' ' ' LEU . 5.3 ttp180 -122.37 129.79 52.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -0.883 . . . . 0.0 109.051 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.465 HE21 HD23 ' A' ' 72' ' ' LEU . 58.8 mt-30 -72.11 145.83 47.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.751 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.593 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 38.4 t60 -64.42 112.09 2.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 109.358 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.48 1.26 24.71 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 11.0 t -114.27 153.91 28.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -1.2 . . . . 0.0 109.421 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -110.73 6.92 21.92 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.257 -0.902 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.3 mt-10 -118.04 104.14 10.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.593 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 33.6 m95 -61.8 142.16 57.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.415 -0.803 . . . . 0.0 109.746 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -106.0 136.15 19.34 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.361 -0.837 . . . . 0.0 109.293 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.459 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.8 Cg_endo -71.59 147.14 50.85 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.634 2.223 . . . . 0.0 112.198 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.81 HD11 ' HB2' ' A' ' 46' ' ' LEU . 9.0 mp -108.14 148.54 29.72 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.267 -0.896 . . . . 0.0 108.775 179.461 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 61.4 m -96.29 125.63 40.93 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.876 -1.14 . . . . 0.0 109.161 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.441 ' HD2' ' CZ2' ' A' ' 64' ' ' TRP . 55.4 tttt -70.15 111.19 5.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.144 -0.972 . . . . 0.0 109.072 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.438 ' O ' HG22 ' A' ' 63' ' ' VAL . 17.5 mttt -111.78 107.71 16.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.957 -1.089 . . . . 0.0 109.608 -179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.9 -93.15 0.12 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -134.75 20.01 3.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.206 -1.173 . . . . 0.0 109.339 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.469 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.7 m -130.86 -172.81 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.362 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.441 ' CZ2' ' HD2' ' A' ' 59' ' ' LYS . 69.2 m95 -135.45 125.21 25.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.885 . . . . 0.0 109.122 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.787 ' HG3' HG22 ' A' ' 29' ' ' VAL . 60.9 tt0 -114.99 149.99 36.52 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 109.748 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.677 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 14.5 p -141.57 137.54 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.412 -0.805 . . . . 0.0 109.456 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -119.91 129.33 54.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.491 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.44 ' O ' ' HB3' ' A' ' 26' ' ' LYS . 35.6 t -118.3 131.83 56.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.602 -0.687 . . . . 0.0 109.51 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 32.5 t -61.26 -14.02 23.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.911 . . . . 0.0 108.973 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HB3' ' HD2' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -116.1 167.55 10.12 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.35 -0.844 . . . . 0.0 109.208 179.9 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 70' ' ' LYS . 46.4 Cg_endo -68.14 129.64 19.81 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.54 2.16 . . . . 0.0 111.792 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.617 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 3.6 mt -63.41 142.5 58.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.374 -0.829 . . . . 0.0 109.648 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.03 124.25 68.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.332 -0.855 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.77 164.31 27.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.67 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.3 Cg_endo -69.0 147.31 82.79 Favored 'Cis proline' 0 C--O 1.214 -0.713 0 C-N-CA 122.892 -1.712 . . . . 0.0 111.935 0.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.617 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 67.1 m-85 -91.26 147.6 22.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.536 -0.728 . . . . 0.0 110.353 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -108.32 143.77 36.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.354 -0.841 . . . . 0.0 108.736 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.697 ' CE2' HD12 ' A' ' 46' ' ' LEU . 85.3 m-85 -134.17 125.66 28.35 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.062 -1.024 . . . . 0.0 109.906 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.943 ' HG3' HG22 ' A' ' 89' ' ' VAL . 44.2 ttt180 -108.21 142.34 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.962 -1.086 . . . . 0.0 108.834 179.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.869 ' HE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -124.4 143.28 50.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.881 . . . . 0.0 111.154 -178.202 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.65 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.2 ttm -126.2 125.69 42.85 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.568 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.623 ' N ' ' O ' ' A' ' 86' ' ' MET . 20.5 p -73.99 145.85 44.29 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.284 -0.885 . . . . 0.0 110.26 -178.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.937 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 18.8 mttm -50.55 -42.88 55.92 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.342 -0.849 . . . . 0.0 108.771 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.94 -4.5 0.72 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 94.89 27.21 11.42 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.623 ' O ' ' N ' ' A' ' 82' ' ' SER . 8.8 mtm -103.32 153.86 19.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.04 -1.27 . . . . 0.0 108.802 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.65 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 32.7 mtt180 -128.29 142.18 51.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.812 -1.18 . . . . 0.0 110.786 -178.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.5 m120 -134.81 140.09 45.6 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.943 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.9 t -122.63 137.04 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.958 -1.089 . . . . 0.0 110.498 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 56.8 m-85 -124.93 122.52 37.58 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 35.2 p-10 -98.85 147.62 24.74 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.15 -0.969 . . . . 0.0 109.645 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.67 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 32.8 mt-10 53.0 52.44 13.85 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.84 . . . . 0.0 110.277 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.413 HG21 ' HB2' ' A' ' 90' ' ' PHE . 45.2 t -83.23 -34.41 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.789 -1.194 . . . . 0.0 109.094 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.406 HG13 HG12 ' A' ' 93' ' ' VAL . 13.4 mt -138.32 125.25 13.23 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.325 -0.859 . . . . 0.0 109.032 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.04 162.79 40.26 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.611 2.207 . . . . 0.0 111.97 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.523 HG23 ' H ' ' A' ' 74' ' ' GLY . 12.3 m -54.01 -37.51 64.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.41 -0.806 . . . . 0.0 109.899 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.14 101.29 12.92 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.004 -1.06 . . . . 0.0 109.714 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.608 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 40.4 p90 -109.58 149.56 29.49 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 109.279 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ILE . 1.4 m -118.77 104.22 10.38 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.731 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.525 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 8.7 mt -43.29 139.96 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 105.0 -3.09 41.05 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.9 tptt -122.29 142.76 50.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -1.174 . . . . 0.0 109.226 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.612 HG22 ' H ' ' A' ' 104' ' ' TYR . 10.9 m -79.18 175.0 10.99 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.117 -0.99 . . . . 0.0 108.619 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.612 ' H ' HG22 ' A' ' 103' ' ' THR . 26.8 m-85 -159.94 96.7 1.24 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.675 -1.265 . . . . 0.0 109.119 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.517 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 7.9 mtmt -97.8 163.2 20.0 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.441 -0.787 . . . . 0.0 109.635 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.557 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 48.1 Cg_endo -68.41 144.48 61.74 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.69 2.26 . . . . 0.0 112.024 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.469 ' O ' ' HB2' ' A' ' 108' ' ' GLU . 96.7 mt-10 -52.5 -19.36 2.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.243 -0.911 . . . . 0.0 109.563 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 107' ' ' GLU . 79.9 mt-10 . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.536 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 48.2 mtm180 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.221 0.534 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.471 ' O ' ' CE1' ' A' ' 4' ' ' HIS . . . 94.69 7.45 60.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 83.6 p -61.68 -25.61 67.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -1.15 . . . . 0.0 109.472 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . 0.471 ' CE1' ' O ' ' A' ' 2' ' ' GLY . 9.1 m-70 64.58 22.6 12.69 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.306 -0.871 . . . . 0.0 109.465 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 58.3 m-70 -121.67 125.5 46.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.425 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.8 m80 -96.16 -10.38 28.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 65.4 m-70 -124.45 136.39 54.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 82.8 t60 -61.47 -38.09 85.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.253 -0.904 . . . . 0.0 109.348 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -49.32 -29.1 5.56 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.179 -0.951 . . . . 0.0 109.401 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.8 -175.83 6.03 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HG2' ' A' ' 37' ' ' PRO . 2.3 t -158.62 157.88 32.77 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -1.204 . . . . 0.0 109.534 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -112.53 156.42 22.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.47 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.777 HG13 ' HB2' ' A' ' 36' ' ' ARG . 4.6 t -125.14 126.23 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.471 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 88.4 mm-40 -102.81 121.31 42.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.227 -0.92 . . . . 0.0 109.251 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 7.0 p -129.81 141.15 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.279 -0.888 . . . . 0.0 109.691 -179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.486 ' HA ' ' HB3' ' A' ' 105' ' ' LYS . 21.4 p -141.88 145.78 35.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.562 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' A' ' 104' ' ' TYR . 2.7 m-85 -117.0 150.83 37.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.436 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 42.3 m -144.48 127.26 16.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.999 -1.063 . . . . 0.0 109.373 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.919 HG22 ' CD2' ' A' ' 30' ' ' LEU . 12.2 t -75.84 135.63 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.4 mm-40 -114.62 155.18 27.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.049 -1.032 . . . . 0.0 109.885 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -47.23 109.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.495 -0.753 . . . . 0.0 109.853 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.68 -5.76 1.36 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.669 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 98' ' ' PHE . 7.3 p -62.39 142.94 57.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.801 -1.411 . . . . 0.0 109.361 -179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.535 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.43 173.83 5.15 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.6 Cg_endo -70.79 -28.75 19.9 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.667 2.245 . . . . 0.0 111.954 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -116.24 7.22 13.99 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.068 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.491 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 33.1 mttp -142.7 133.68 25.7 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.687 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.48 123.16 40.62 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.929 -1.107 . . . . 0.0 109.613 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.549 HG22 ' HG3' ' A' ' 65' ' ' GLU . 9.0 t -120.2 125.59 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 179.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.919 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.3 mt -144.87 144.95 31.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.893 -1.129 . . . . 0.0 110.226 -179.369 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.562 ' HA ' HG12 ' A' ' 63' ' ' VAL . 16.2 t70 -82.4 134.43 35.24 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.625 HG21 ' CE2' ' A' ' 80' ' ' PHE . 74.9 mt -119.96 130.64 73.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.779 -1.201 . . . . 0.0 110.74 -178.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 62.8 mttm -111.49 120.15 41.16 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 178.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.545 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 90.1 t80 -120.53 112.86 19.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.425 -0.797 . . . . 0.0 109.501 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 33.8 m -115.22 115.24 26.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 0.0 109.688 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.777 ' HB2' HG13 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -147.6 117.55 4.36 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.462 -0.774 . . . . 0.0 109.066 179.897 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.489 ' HG2' ' OG ' ' A' ' 11' ' ' SER . 49.1 Cg_endo -69.29 123.65 10.48 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.94 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.37 59.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.572 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -142.71 -176.39 4.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -1.201 . . . . 0.0 109.864 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 82' ' ' SER . 5.6 m -155.83 162.69 40.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.332 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.759 HD21 HG21 ' A' ' 44' ' ' VAL . 48.6 tp -69.32 126.38 29.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.964 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.855 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.83 -44.51 2.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.854 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.433 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 27.0 mt-10 -137.19 146.85 45.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.158 -0.964 . . . . 0.0 110.262 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 HD21 ' A' ' 41' ' ' LEU . 98.2 t -139.93 137.39 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.476 -0.765 . . . . 0.0 109.252 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.432 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 94.5 mt-10 -127.79 150.69 49.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.822 -1.174 . . . . 0.0 109.231 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.035 HD23 HG11 ' A' ' 66' ' ' VAL . 12.1 tp -120.42 132.24 55.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 110.393 -178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.647 ' N ' HD12 ' A' ' 46' ' ' LEU . 0.4 OUTLIER -113.19 124.88 53.56 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.292 -0.88 . . . . 0.0 108.995 179.178 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.576 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 61.1 mt-30 -65.24 159.14 24.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.252 -0.905 . . . . 0.0 109.087 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.583 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 11.4 t-80 -75.95 108.15 8.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.17 7.09 21.66 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 23.1 t -115.88 154.16 30.23 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.047 -1.267 . . . . 0.0 109.514 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 76.6 mt-10 -104.9 -22.44 13.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.274 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -87.67 129.03 35.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.62 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 9.4 m95 -86.92 141.68 28.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.632 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.41 ' OE2' ' O ' ' A' ' 67' ' ' LYS . 45.4 tt0 -107.98 133.75 20.38 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.351 -0.843 . . . . 0.0 109.481 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 50.7 Cg_endo -70.78 151.0 62.93 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.693 2.262 . . . . 0.0 111.783 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.809 HD11 ' CB ' ' A' ' 46' ' ' LEU . 5.8 mp -109.16 143.84 38.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.206 -0.934 . . . . 0.0 109.11 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 83.7 m -92.7 127.44 38.2 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.99 -1.069 . . . . 0.0 109.136 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -70.49 109.99 5.13 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.164 -0.96 . . . . 0.0 109.11 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -109.4 115.77 30.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.945 -1.097 . . . . 0.0 109.586 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 53.18 -97.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -128.12 16.58 6.71 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.216 -1.167 . . . . 0.0 109.466 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.562 HG12 ' HA ' ' A' ' 31' ' ' ASP . 27.3 m -131.04 -176.94 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.32 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.477 ' CD1' HD12 ' A' ' 32' ' ' ILE . 57.9 m95 -128.33 130.35 47.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.112 -0.993 . . . . 0.0 109.332 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.2 tt0 -111.69 135.97 51.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.645 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 1.035 HG11 HD23 ' A' ' 46' ' ' LEU . 5.3 p -130.67 129.67 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.426 -0.797 . . . . 0.0 109.012 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.449 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 19.4 mtmm -121.43 133.3 55.07 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.04 -1.038 . . . . 0.0 109.692 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.576 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 3.1 t -118.38 153.08 34.63 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.422 -0.799 . . . . 0.0 109.305 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 51.1 m -78.6 -2.36 38.57 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.151 -0.968 . . . . 0.0 109.148 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.561 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 3.5 mttt -128.81 177.02 2.34 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.339 -0.851 . . . . 0.0 109.164 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.6 Cg_endo -68.54 150.3 75.02 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.495 2.13 . . . . 0.0 111.856 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.579 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 14.9 mt -85.58 137.46 32.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.33 -0.856 . . . . 0.0 109.682 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.557 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 28.9 t -127.02 125.86 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.46 -0.775 . . . . 0.0 109.475 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.522 ' HA3' ' CA ' ' A' ' 96' ' ' THR . . . -94.94 169.19 28.03 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.664 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 46.2 Cg_endo -67.98 146.92 78.86 Favored 'Cis proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.912 -1.703 . . . . 0.0 112.002 0.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 86.6 m-85 -89.69 149.77 22.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.589 -0.695 . . . . 0.0 110.343 -179.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.809 ' O ' HD12 ' A' ' 46' ' ' LEU . 3.0 m-80 -112.06 142.74 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.78 ' CE1' HD13 ' A' ' 46' ' ' LEU . 96.5 m-85 -134.85 134.84 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.999 -1.063 . . . . 0.0 109.381 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.536 ' NH1' ' CZ ' ' A' ' 87' ' ' ARG . 64.5 ttt180 -116.8 144.07 44.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.943 -1.098 . . . . 0.0 108.864 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.732 ' HD2' HD13 ' A' ' 41' ' ' LEU . 6.6 m-85 -122.89 140.79 52.6 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.157 -0.965 . . . . 0.0 111.238 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.624 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.1 ttm -123.45 124.02 41.96 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 18.8 p -72.37 142.41 48.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.455 -0.778 . . . . 0.0 110.475 -178.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.855 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 56.4 mttt -46.64 -44.18 18.18 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 108.821 178.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' A' ' 39' ' ' ASP . . . -57.09 -5.85 1.65 Allowed Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 97.3 25.36 11.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 55.4 mtp -99.67 152.52 19.97 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.108 -1.23 . . . . 0.0 108.473 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.624 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 33.5 mtm180 -128.39 142.13 51.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.617 -1.302 . . . . 0.0 110.918 -178.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.535 ' N ' ' O ' ' A' ' 80' ' ' PHE . 29.9 m120 -135.69 140.73 44.67 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.3 t -122.79 136.72 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.863 -1.148 . . . . 0.0 110.387 -179.026 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.548 ' CD1' ' CB ' ' A' ' 106' ' ' PRO . 55.5 m-85 -124.16 122.41 37.75 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -99.53 147.37 25.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.209 -0.932 . . . . 0.0 109.716 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.664 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 81.3 mt-10 53.99 51.18 15.15 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.505 -0.747 . . . . 0.0 110.344 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 94' ' ' ILE . 43.5 t -81.96 -34.89 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.864 -1.148 . . . . 0.0 108.938 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 93' ' ' VAL . 13.0 mt -135.8 125.07 16.02 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.473 -0.767 . . . . 0.0 108.974 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.28 161.61 45.19 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.569 2.179 . . . . 0.0 111.977 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.522 ' CA ' ' HA3' ' A' ' 74' ' ' GLY . 29.1 m -50.09 -45.68 52.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.373 -0.83 . . . . 0.0 109.726 -179.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -90.06 101.18 13.89 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.053 -1.029 . . . . 0.0 109.5 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.509 ' CE1' HG11 ' A' ' 19' ' ' VAL . 44.8 p90 -108.26 154.12 22.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 69.4 m -110.43 170.87 7.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.39 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 23.2 mm -105.19 136.71 37.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 109.312 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.72 6.28 59.56 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 46.7 tttt -119.03 143.43 47.1 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.095 -1.238 . . . . 0.0 109.225 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.622 HG22 ' H ' ' A' ' 104' ' ' TYR . 15.5 m -80.8 174.74 11.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.161 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.622 ' H ' HG22 ' A' ' 103' ' ' THR . 35.1 m-85 -160.36 102.25 1.39 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.765 -1.209 . . . . 0.0 108.772 179.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.597 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 1.7 ptpp? -114.16 166.36 11.66 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.201 -0.937 . . . . 0.0 109.776 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.597 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 48.7 Cg_endo -69.91 -169.56 0.34 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.587 2.191 . . . . 0.0 111.811 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -123.61 154.05 39.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.485 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.464 ' HB3' ' NE2' ' A' ' 4' ' ' HIS . 88.0 mt-10 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.521 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 72.5 mtt85 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.1 164.71 37.7 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.7 p -150.2 133.84 16.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -1.165 . . . . 0.0 109.451 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -132.95 18.75 4.13 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.204 -0.935 . . . . 0.0 109.492 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -75.15 -44.7 45.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.484 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 75.3 t60 -145.14 141.47 28.78 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.223 -0.923 . . . . 0.0 109.554 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.45 ' CE1' ' O ' ' A' ' 10' ' ' GLY . 86.4 t60 -111.38 114.17 27.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.244 -0.91 . . . . 0.0 109.393 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -141.34 154.52 45.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 0.0 109.592 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 62.11 29.13 17.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.216 -0.927 . . . . 0.0 109.462 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.45 ' O ' ' CE1' ' A' ' 7' ' ' HIS . . . 56.03 -123.51 31.21 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -59.15 -172.14 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -1.132 . . . . 0.0 109.548 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -143.26 165.63 26.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 109.517 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.624 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 10.9 t -127.66 141.27 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.34 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -113.31 120.96 42.95 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.6 HG22 ' CD1' ' A' ' 34' ' ' TYR . 2.7 t -127.67 137.89 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.257 -0.902 . . . . 0.0 109.823 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 32.4 p -142.31 146.09 34.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.39 -0.819 . . . . 0.0 109.231 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.603 ' O ' ' N ' ' A' ' 104' ' ' TYR . 8.7 m-85 -119.41 151.85 37.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.106 -0.996 . . . . 0.0 110.02 -179.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 27.7 m -143.18 158.86 43.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 108.71 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.845 HG22 HD23 ' A' ' 30' ' ' LEU . 4.3 t -107.75 127.96 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.087 -1.008 . . . . 0.0 109.433 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -101.47 149.8 23.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.897 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -44.01 114.09 0.62 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.498 -0.752 . . . . 0.0 109.94 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.16 2.19 1.4 Allowed Glycine 0 N--CA 1.49 2.264 0 C-N-CA 119.272 -1.442 . . . . 0.0 110.907 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.0 m -61.18 142.38 56.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.667 -1.49 . . . . 0.0 109.054 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.82 171.94 7.59 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.094 -1.004 . . . . 0.0 109.616 -179.627 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 50.7 Cg_endo -70.68 -29.02 20.09 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.729 2.286 . . . . 0.0 111.829 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -118.03 3.4 12.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.009 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 67' ' ' LYS . 21.1 mttt -141.83 133.15 26.51 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.049 HD22 HD11 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -127.07 133.78 50.39 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.018 -1.051 . . . . 0.0 110.17 -179.374 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.492 ' C ' ' HG ' ' A' ' 30' ' ' LEU . 3.3 t -121.62 124.05 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.049 HD11 HD22 ' A' ' 28' ' ' LEU . 1.3 mt -140.94 141.14 34.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.01 -1.056 . . . . 0.0 110.093 -179.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.72 ' CG ' HG12 ' A' ' 63' ' ' VAL . 18.2 t0 -85.55 134.51 34.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.654 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -116.12 126.89 73.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 118.922 -1.111 . . . . 0.0 110.893 -179.105 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 13.7 tttm -107.28 115.07 29.52 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.01 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.624 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 77.2 t80 -124.93 111.88 15.96 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.345 0.593 . . . . 0.0 109.634 -178.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.3 m -113.85 119.77 38.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.94 . . . . 0.0 109.691 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.488 ' NE ' ' HB2' ' A' ' 39' ' ' ASP . 29.7 ttt85 -140.91 119.58 8.2 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.7 119.29 6.26 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.714 2.276 . . . . 0.0 111.821 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.14 -14.52 60.52 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.488 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 6.2 m-20 -136.43 175.18 9.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.181 -1.188 . . . . 0.0 109.644 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 82' ' ' SER . 10.2 m -154.41 161.6 41.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.297 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.718 HD23 ' N ' ' A' ' 42' ' ' ALA . 0.4 OUTLIER -71.21 130.87 42.53 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.257 -0.902 . . . . 0.0 109.385 179.947 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.93 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -112.4 -41.03 3.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.466 ' O ' HD21 ' A' ' 41' ' ' LEU . 90.4 mt-10 -143.18 151.27 40.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 0.0 110.187 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.693 ' CG2' HD11 ' A' ' 41' ' ' LEU . 11.1 t -138.9 136.32 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.5 mt-10 -126.77 149.24 49.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.697 -1.252 . . . . 0.0 109.547 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.908 HD13 ' CE2' ' A' ' 78' ' ' PHE . 10.4 tp -122.18 131.24 53.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.479 -0.763 . . . . 0.0 109.929 -179.106 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.646 ' N ' HD12 ' A' ' 46' ' ' LEU . 41.8 ttp180 -118.92 135.04 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.088 179.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.603 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 78.7 mt-30 -75.05 150.72 38.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 110.034 -179.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.594 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 4.2 t-80 -67.4 112.55 4.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.41 -0.806 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.63 0.63 30.73 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.464 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 4.0 t -113.67 155.54 25.35 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.206 -1.173 . . . . 0.0 109.32 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -108.33 -14.31 14.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.243 -0.911 . . . . 0.0 109.404 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -93.17 117.92 30.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.223 -0.923 . . . . 0.0 109.736 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.631 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 25.3 m95 -75.94 140.29 42.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.419 -0.801 . . . . 0.0 109.638 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.469 ' HG3' ' HD2' ' A' ' 56' ' ' PRO . 0.8 OUTLIER -106.59 127.35 28.31 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.472 -0.768 . . . . 0.0 109.095 179.757 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.617 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.6 Cg_endo -69.67 150.42 68.71 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.586 2.191 . . . . 0.0 112.19 -179.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.8 mp -107.47 141.85 38.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 108.847 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 43.5 m -92.91 127.26 38.36 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.923 -1.11 . . . . 0.0 109.06 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tttm -73.49 109.86 7.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 109.717 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.0 mttm -109.88 110.93 22.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.998 -1.064 . . . . 0.0 109.752 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 63.46 -90.02 0.07 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.431 ' OD1' HG13 ' A' ' 63' ' ' VAL . 49.5 p-10 -139.04 18.45 2.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.288 -1.124 . . . . 0.0 109.281 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.72 HG12 ' CG ' ' A' ' 31' ' ' ASP . 16.2 m -130.66 173.4 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.283 -0.886 . . . . 0.0 109.249 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.434 ' CD1' HG13 ' A' ' 32' ' ' ILE . 66.5 m95 -123.17 128.64 50.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.173 -0.954 . . . . 0.0 109.317 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.461 ' HG3' HG22 ' A' ' 29' ' ' VAL . 78.7 tt0 -117.85 151.38 37.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.627 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.882 HG11 HD23 ' A' ' 46' ' ' LEU . 2.2 p -145.38 140.9 22.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.329 -0.857 . . . . 0.0 109.308 179.784 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.402 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 34.9 mttp -122.15 132.97 54.73 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.183 -0.948 . . . . 0.0 109.717 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.603 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 38.8 t -116.71 121.52 41.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.454 -0.779 . . . . 0.0 109.349 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 58.8 m -49.16 -22.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.571 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -109.65 177.25 1.28 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.318 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.571 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.6 Cg_endo -68.86 152.69 73.67 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.504 2.136 . . . . 0.0 111.657 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.732 HD13 HD12 ' A' ' 28' ' ' LEU . 1.5 mt -90.28 138.05 31.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 35.4 t -126.34 125.28 67.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.422 -0.798 . . . . 0.0 109.605 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA3' ' N ' ' A' ' 96' ' ' THR . . . -94.39 167.29 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.713 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.1 Cg_endo -68.15 147.43 80.46 Favored 'Cis proline' 0 C--O 1.213 -0.735 0 C-N-CA 122.937 -1.693 . . . . 0.0 112.034 0.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.604 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 83.1 m-85 -91.23 150.82 21.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.441 -0.787 . . . . 0.0 110.448 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.784 ' O ' HD12 ' A' ' 46' ' ' LEU . 23.3 m-80 -111.12 142.08 43.77 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.908 ' CE2' HD13 ' A' ' 46' ' ' LEU . 41.9 m-85 -135.95 128.3 30.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.918 -1.114 . . . . 0.0 110.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.875 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.2 ttt180 -108.56 142.23 39.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 108.643 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.654 ' CE2' HG21 ' A' ' 32' ' ' ILE . 9.3 m-85 -123.49 143.6 50.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.213 -0.93 . . . . 0.0 111.411 -178.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.621 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 7.6 ttm -127.44 125.67 40.97 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 86' ' ' MET . 32.2 p -77.39 144.94 37.54 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.89 . . . . 0.0 110.246 -178.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.93 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 60.0 mttm -47.78 -43.14 27.28 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.4 -2.71 0.74 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.37 23.98 22.87 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.65 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.8 mmm -98.64 148.39 23.86 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -1.231 . . . . 0.0 108.681 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 77.8 mtm-85 -126.84 142.58 51.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.78 -1.2 . . . . 0.0 110.586 -178.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.413 ' N ' ' O ' ' A' ' 80' ' ' PHE . 4.2 m120 -136.97 141.17 42.59 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.875 HG22 ' HG3' ' A' ' 79' ' ' ARG . 2.9 t -121.43 136.32 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 71.8 m-85 -124.56 122.39 37.44 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.267 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -100.06 148.62 24.36 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.244 -0.91 . . . . 0.0 109.644 -179.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.713 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 88.6 mt-10 53.28 51.87 14.66 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.369 -0.832 . . . . 0.0 110.278 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.648 HG22 ' HB3' ' A' ' 106' ' ' PRO . 97.6 t -84.08 -34.33 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.856 -1.153 . . . . 0.0 109.188 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.2 mt -137.53 125.56 14.33 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.325 -0.859 . . . . 0.0 109.127 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.71 163.02 39.8 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.577 2.185 . . . . 0.0 112.07 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.535 ' N ' ' HA3' ' A' ' 74' ' ' GLY . 32.3 m -54.13 -44.09 71.06 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.414 -0.804 . . . . 0.0 109.918 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.39 99.41 11.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.054 -1.029 . . . . 0.0 109.363 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -107.85 147.09 31.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 109.722 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 70.4 m -107.08 167.86 9.6 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -0.862 . . . . 0.0 109.169 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.502 HD13 ' CG1' ' A' ' 19' ' ' VAL . 29.8 mm -104.16 136.78 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 109.408 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 95.73 2.66 61.26 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.1 tptt -116.15 142.55 46.67 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.09 -1.241 . . . . 0.0 109.176 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.573 HG22 ' H ' ' A' ' 104' ' ' TYR . 18.6 m -78.39 173.51 12.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.075 -1.016 . . . . 0.0 108.966 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.603 ' N ' ' O ' ' A' ' 17' ' ' PHE . 32.5 m-85 -156.16 105.83 2.35 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.765 -1.209 . . . . 0.0 108.831 179.187 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 105' ' ' LYS . 1.3 ptmt -103.67 157.41 33.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.724 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.648 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.2 Cg_endo -70.47 151.79 65.26 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.744 2.296 . . . . 0.0 111.734 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 63.5 tt0 -56.49 -20.63 21.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.216 -0.927 . . . . 0.0 109.458 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.489 179.929 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 45.5 mtt85 . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.92 -179.43 51.11 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 82.7 p -79.11 -8.96 59.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.228 -1.16 . . . . 0.0 109.501 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' A' ' 6' ' ' HIS . 19.4 m-70 -48.46 -41.85 30.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.464 ' CG ' ' O ' ' A' ' 5' ' ' HIS . 74.5 t60 46.12 32.89 1.54 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.229 -0.92 . . . . 0.0 109.427 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.456 ' CE1' ' O ' ' A' ' 4' ' ' HIS . 36.6 m80 -109.75 126.27 53.56 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -0.904 . . . . 0.0 109.454 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.34 -40.37 90.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.308 -0.87 . . . . 0.0 109.367 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 30.6 m80 -132.8 150.45 52.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.528 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -60.54 -29.62 69.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.69 -153.41 28.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.9 m -114.39 159.41 20.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.253 -1.146 . . . . 0.0 109.316 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -148.39 145.02 27.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.959 HG22 ' HG2' ' A' ' 36' ' ' ARG . 40.5 t -124.45 129.01 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.407 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 97.2 mm-40 -109.4 120.35 42.24 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 109.118 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 12.9 p -128.35 140.53 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.314 -0.866 . . . . 0.0 109.499 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.49 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 32.0 p -143.09 146.32 33.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.187 -0.945 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.606 ' CD2' HG12 ' A' ' 32' ' ' ILE . 7.4 m-85 -117.01 148.41 41.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.251 -0.905 . . . . 0.0 109.286 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.416 ' HB ' ' HB3' ' A' ' 31' ' ' ASP . 36.0 m -143.6 128.63 18.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.929 -1.107 . . . . 0.0 109.621 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.935 HG22 HD21 ' A' ' 30' ' ' LEU . 3.5 t -76.7 138.52 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.157 -0.964 . . . . 0.0 109.364 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.7 mm-40 -118.66 155.66 30.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.02 -1.05 . . . . 0.0 109.612 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 91.4 mttt -47.51 112.73 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.82 . . . . 0.0 110.009 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.73 -7.96 1.99 Allowed Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.71 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 4.5 p -60.18 141.76 55.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.805 -1.409 . . . . 0.0 109.435 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.584 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -137.14 177.27 2.25 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.165 -0.959 . . . . 0.0 109.693 -179.594 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.584 ' HD2' ' CB ' ' A' ' 24' ' ' ASP . 52.8 Cg_endo -71.2 -33.93 10.77 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.784 2.322 . . . . 0.0 112.015 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.443 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -115.54 2.82 13.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 108.894 179.509 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 27.2 mtmt -139.19 132.29 29.64 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 1.116 HD21 ' CD1' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -127.68 132.99 49.6 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.001 -1.062 . . . . 0.0 110.211 -179.086 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.854 HG13 ' HG2' ' A' ' 65' ' ' GLU . 13.6 t -119.56 122.76 69.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.116 ' CD1' HD21 ' A' ' 28' ' ' LEU . 16.8 mt -137.66 136.72 37.7 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.046 -1.034 . . . . 0.0 110.324 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.563 ' HA ' HG12 ' A' ' 63' ' ' VAL . 37.7 t70 -84.2 136.22 34.05 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 177.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.854 HD12 ' CD1' ' A' ' 64' ' ' TRP . 88.1 mt -121.62 131.11 73.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.688 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.589 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 44.3 tttt -110.32 119.46 39.28 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.482 ' OH ' ' HG3' ' A' ' 36' ' ' ARG . 83.5 t80 -121.44 118.15 28.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.456 -0.777 . . . . 0.0 109.355 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.407 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 17.1 m -121.16 117.81 28.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.268 -0.895 . . . . 0.0 109.923 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.959 ' HG2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -124.24 168.52 12.7 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.832 . . . . 0.0 109.345 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.582 ' HD2' ' CG ' ' A' ' 36' ' ' ARG . 49.2 Cg_endo -70.07 76.96 1.22 Allowed 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.634 2.223 . . . . 0.0 111.726 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.43 -5.92 75.28 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.44 ' HB2' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -97.26 179.38 4.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 109.498 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.0 m -151.08 158.37 43.97 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.302 -0.874 . . . . 0.0 109.527 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.847 HD23 ' N ' ' A' ' 42' ' ' ALA . 1.2 tt -71.79 136.4 47.06 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.659 -0.65 . . . . 0.0 109.342 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.928 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.58 -43.13 3.06 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.11 -0.994 . . . . 0.0 110.238 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -139.83 148.81 42.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.004 -1.06 . . . . 0.0 110.659 -179.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.615 HG13 ' CE1' ' A' ' 80' ' ' PHE . 14.6 t -139.0 136.3 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.541 -0.725 . . . . 0.0 109.33 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.508 ' HA ' HD13 ' A' ' 57' ' ' LEU . 95.2 mt-10 -128.75 150.89 50.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.953 -1.092 . . . . 0.0 109.255 179.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.95 HD12 ' CE2' ' A' ' 78' ' ' PHE . 9.6 tt -121.61 147.32 46.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.27 -0.893 . . . . 0.0 110.045 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.799 ' N ' HD23 ' A' ' 46' ' ' LEU . 13.4 ttp180 -131.95 128.56 38.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.87 . . . . 0.0 108.808 179.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' NE2' HD23 ' A' ' 72' ' ' LEU . 36.0 mt-30 -69.7 153.02 43.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 0.0 109.942 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.573 ' CG ' ' HD2' ' A' ' 75' ' ' PRO . 66.1 t60 -67.45 119.29 12.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.41 -0.806 . . . . 0.0 109.682 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.91 4.35 54.41 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.452 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 39.4 t -114.24 154.49 27.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.453 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 87.5 mt-10 -117.78 15.69 14.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.375 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -119.02 97.6 5.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.903 . . . . 0.0 109.687 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -55.84 134.56 51.91 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.36 -0.838 . . . . 0.0 109.657 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -104.26 134.79 19.51 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.348 -0.845 . . . . 0.0 109.316 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.606 ' C ' HD12 ' A' ' 57' ' ' LEU . 50.1 Cg_endo -70.61 145.35 52.01 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.627 2.218 . . . . 0.0 112.095 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.631 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 9.6 mp -110.0 151.2 27.45 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 108.871 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.1 m -100.66 125.51 47.09 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.865 -1.147 . . . . 0.0 108.851 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -72.13 108.83 5.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.202 -0.936 . . . . 0.0 109.091 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.513 ' O ' ' N ' ' A' ' 62' ' ' ASN . 15.2 mttm -107.48 126.26 52.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.986 -1.071 . . . . 0.0 109.542 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 48.67 -92.68 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 60' ' ' LYS . 31.6 p-10 -136.73 19.5 3.07 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.282 -1.128 . . . . 0.0 109.344 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.563 HG12 ' HA ' ' A' ' 31' ' ' ASP . 20.6 m -131.72 173.57 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.334 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.854 ' CD1' HD12 ' A' ' 32' ' ' ILE . 71.1 m95 -117.35 127.44 54.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.94 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.854 ' HG2' HG13 ' A' ' 29' ' ' VAL . 80.3 mt-10 -113.43 141.07 47.53 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.29 -0.881 . . . . 0.0 109.892 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.631 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 7.7 p -135.56 132.69 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.284 -0.885 . . . . 0.0 109.066 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.457 ' HG3' ' HG2' ' A' ' 27' ' ' LYS . 41.3 tttm -120.32 132.42 55.29 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 0.0 109.686 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 69' ' ' SER . 23.2 t -121.66 124.08 43.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.5 -0.75 . . . . 0.0 109.316 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 68' ' ' SER . 44.7 m -44.2 -29.86 0.7 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.011 -1.056 . . . . 0.0 108.461 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.713 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 0.1 OUTLIER -105.72 170.53 5.77 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.37 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.713 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 43.3 Cg_endo -66.6 172.18 9.67 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.115 1.876 . . . . 0.0 111.687 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.609 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 12.9 mt -100.59 144.53 29.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 110.122 -179.486 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.87 125.34 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.453 -0.779 . . . . 0.0 109.295 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 96' ' ' THR . . . -96.47 170.35 26.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.602 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.2 Cg_endo -68.62 146.6 79.94 Favored 'Cis proline' 0 C--O 1.213 -0.739 0 C-N-CA 122.837 -1.734 . . . . 0.0 111.859 -0.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 84.5 m-85 -92.48 147.22 23.07 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.447 -0.783 . . . . 0.0 110.669 -179.104 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.529 ' C ' ' CD1' ' A' ' 78' ' ' PHE . 20.5 m-80 -108.75 144.99 35.83 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.95 ' CE2' HD12 ' A' ' 46' ' ' LEU . 3.8 m-85 -136.99 122.56 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.855 -1.153 . . . . 0.0 110.319 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 89' ' ' VAL . 54.2 ttt180 -101.89 142.19 33.58 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.818 ' CD2' HD11 ' A' ' 41' ' ' LEU . 8.8 m-85 -123.91 143.79 50.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 111.267 -177.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.604 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.3 ttt -126.14 124.5 40.68 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.519 ' OG ' ' HB2' ' A' ' 86' ' ' MET . 13.4 p -77.53 145.6 36.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.846 . . . . 0.0 110.157 -178.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.928 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -44.96 -47.28 11.39 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.156 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.52 -6.92 5.14 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 97.01 34.41 5.68 Favored Glycine 0 N--CA 1.489 2.185 0 O-C-N 121.141 -1.211 . . . . 0.0 110.111 179.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.519 ' HB2' ' OG ' ' A' ' 82' ' ' SER . 55.8 mtp -105.36 110.46 22.82 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.028 -1.278 . . . . 0.0 109.127 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 26.6 mtm180 -90.4 140.6 29.56 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 110.668 -179.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 80' ' ' PHE . 14.1 m120 -137.61 141.84 41.26 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 79' ' ' ARG . 3.1 t -121.24 135.57 60.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.916 -1.115 . . . . 0.0 110.299 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.515 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 13.4 m-85 -124.2 122.31 37.45 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -98.44 146.98 25.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.208 -0.933 . . . . 0.0 109.546 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.602 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 49.1 tt0 52.92 52.64 13.49 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.438 -0.789 . . . . 0.0 110.162 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 94' ' ' ILE . 42.4 t -80.34 -33.38 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.882 -1.136 . . . . 0.0 108.933 179.447 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.484 HG13 HG12 ' A' ' 93' ' ' VAL . 14.0 mt -138.55 127.53 14.34 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.381 -0.824 . . . . 0.0 108.882 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.06 160.64 49.1 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.559 2.173 . . . . 0.0 112.099 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.474 ' HA ' ' HA3' ' A' ' 74' ' ' GLY . 58.6 m -50.96 -36.49 39.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.83 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.15 103.23 12.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.11 -0.994 . . . . 0.0 109.522 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.481 ' CE1' HG11 ' A' ' 19' ' ' VAL . 48.7 p90 -110.9 155.01 23.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.87 . . . . 0.0 109.219 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.5 m -105.99 172.39 6.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.145 -0.972 . . . . 0.0 109.418 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.433 HD13 ' CG1' ' A' ' 19' ' ' VAL . 28.2 mm -104.61 135.21 43.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.264 -0.898 . . . . 0.0 109.152 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 99.36 2.8 56.65 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.6 tttp -117.77 142.74 46.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.967 -1.313 . . . . 0.0 109.159 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.642 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.3 m -81.74 176.45 9.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.119 -0.988 . . . . 0.0 109.091 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.642 ' H ' HG22 ' A' ' 103' ' ' THR . 26.9 m-85 -160.69 98.4 1.22 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.8 -1.188 . . . . 0.0 109.064 179.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.53 ' HB3' ' HD2' ' A' ' 106' ' ' PRO . 0.2 OUTLIER -100.35 164.94 15.34 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.265 -0.897 . . . . 0.0 109.797 -179.423 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.53 ' HD2' ' HB3' ' A' ' 105' ' ' LYS . 50.5 Cg_endo -69.91 164.93 32.86 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.712 2.274 . . . . 0.0 111.81 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 108' ' ' GLU . 80.5 tt0 -56.36 -26.78 53.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.536 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 107' ' ' GLU . 36.4 tp10 . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.441 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 110.71 34.35 2.25 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.8 p -73.78 -8.46 56.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -1.164 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -109.47 128.56 55.25 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.39 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 87.5 m-70 -121.93 123.6 42.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.21 -0.931 . . . . 0.0 109.614 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -133.2 167.87 19.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.297 -0.877 . . . . 0.0 109.409 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 81.3 m-70 -123.1 90.46 3.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -52.35 -24.88 8.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.457 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -130.85 144.09 51.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.551 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.44 ' O ' ' HD3' ' A' ' 37' ' ' PRO . . . 119.81 -16.96 10.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -63.46 -11.44 23.6 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.203 -1.175 . . . . 0.0 109.436 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -116.71 -146.97 0.41 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.646 ' CG1' ' CE1' ' A' ' 34' ' ' TYR . 5.0 t -122.64 128.45 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.255 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -112.23 121.58 45.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.052 -1.03 . . . . 0.0 109.625 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.753 HG22 ' CD1' ' A' ' 34' ' ' TYR . 14.7 t -128.19 138.59 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.606 HG22 ' HB3' ' A' ' 105' ' ' LYS . 68.6 p -141.85 146.5 35.89 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.775 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.715 ' CD1' HG11 ' A' ' 93' ' ' VAL . 88.8 m-85 -119.35 118.79 32.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.3 -0.875 . . . . 0.0 109.734 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 30' ' ' LEU . 21.9 m -108.36 158.51 17.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.922 -1.111 . . . . 0.0 108.979 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.702 ' CG1' HD13 ' A' ' 100' ' ' ILE . 8.5 t -107.8 126.68 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' HD12 ' A' ' 100' ' ' ILE . 1.7 mp0 -92.66 -173.52 3.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.146 -0.971 . . . . 0.0 109.605 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -83.65 66.01 8.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.385 -0.822 . . . . 0.0 109.937 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -172.33 22.01 0.07 OUTLIER Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.055 -1.545 . . . . 0.0 110.924 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.54 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 50.3 m -74.21 142.34 45.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.766 -1.432 . . . . 0.0 109.058 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.9 173.31 5.81 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.055 -1.028 . . . . 0.0 109.875 -179.634 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.8 Cg_endo -71.66 -30.56 14.52 Favored 'Trans proline' 0 C--O 1.216 -0.576 0 C-N-CA 122.793 2.329 . . . . 0.0 111.836 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -115.88 5.26 14.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 108.731 179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.492 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 72.8 mttt -142.17 133.11 25.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.949 HD22 HD11 ' A' ' 30' ' ' LEU . 0.3 OUTLIER -127.87 135.34 49.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.067 -1.021 . . . . 0.0 110.099 -179.321 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.92 ' O ' HD13 ' A' ' 30' ' ' LEU . 4.1 t -119.39 119.05 59.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.949 HD11 HD22 ' A' ' 28' ' ' LEU . 0.4 OUTLIER -126.85 127.11 44.46 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.217 -0.927 . . . . 0.0 110.282 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.58 ' CB ' HG12 ' A' ' 63' ' ' VAL . 63.6 t0 -77.99 132.02 37.64 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.722 HG21 ' CE2' ' A' ' 80' ' ' PHE . 52.4 mt -118.3 128.56 75.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.157 -178.125 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.637 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 33.5 mttt -109.41 119.98 41.12 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.753 ' CD1' HG22 ' A' ' 15' ' ' VAL . 71.7 t80 -121.21 120.77 36.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.302 -0.874 . . . . 0.0 109.837 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -123.66 116.95 23.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.399 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CG ' ' HB2' ' A' ' 39' ' ' ASP . 38.0 ttt85 -139.72 131.94 14.96 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.452 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.3 Cg_endo -70.44 107.85 2.08 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.814 2.343 . . . . 0.0 111.992 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.99 -5.29 84.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.556 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 31.6 m-20 -134.71 174.28 10.74 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -1.201 . . . . 0.0 109.682 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 82' ' ' SER . 14.7 m -155.42 162.65 40.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.74 HD13 ' HD2' ' A' ' 80' ' ' PHE . 26.8 tp -71.87 129.73 39.32 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.27 -0.894 . . . . 0.0 109.649 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.787 ' HB2' ' CA ' ' A' ' 83' ' ' LYS . . . -116.1 -40.29 3.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -0.934 . . . . 0.0 109.479 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -143.74 152.2 40.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.915 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.829 HG13 ' CE1' ' A' ' 80' ' ' PHE . 46.5 t -139.71 137.14 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.445 -0.785 . . . . 0.0 109.406 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.509 ' HA ' HD13 ' A' ' 57' ' ' LEU . 75.4 mt-10 -128.89 150.48 50.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.904 -1.123 . . . . 0.0 109.433 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.989 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.03 142.22 48.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.434 -0.791 . . . . 0.0 109.805 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.989 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.5 ttp180 -128.03 130.02 47.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.374 -0.829 . . . . 0.0 108.812 179.216 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.453 ' HA ' ' OE1' ' A' ' 48' ' ' GLN . 57.6 mm-40 -72.14 152.42 42.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 110.218 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.574 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 13.0 t-80 -68.07 131.0 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.513 -0.742 . . . . 0.0 109.461 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 87.8 3.36 80.42 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 22.8 t -112.23 153.04 27.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.178 -1.19 . . . . 0.0 109.189 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -113.75 21.56 14.86 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.387 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.35 124.59 43.28 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.236 -0.915 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.452 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 64.6 m95 -85.06 129.94 34.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.432 -0.793 . . . . 0.0 109.415 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.4 134.62 19.66 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.369 -0.832 . . . . 0.0 109.342 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.663 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.3 Cg_endo -71.8 146.88 49.15 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.642 2.228 . . . . 0.0 112.164 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.676 ' N ' HD12 ' A' ' 57' ' ' LEU . 7.3 mp -106.8 158.04 17.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 108.621 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 52.3 m -108.87 127.04 53.7 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.846 -1.159 . . . . 0.0 109.116 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 37.5 tttm -65.35 120.95 13.73 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 63' ' ' VAL . 2.8 mttm -109.92 -152.7 0.5 Allowed 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.167 -0.958 . . . . 0.0 109.377 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 62' ' ' ASN . . . -58.72 81.2 0.01 OUTLIER Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.518 ' N ' ' O ' ' A' ' 60' ' ' LYS . 39.2 t30 63.97 10.54 5.4 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.243 -1.151 . . . . 0.0 110.086 179.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.582 HG23 ' HB2' ' A' ' 60' ' ' LYS . 5.3 m -132.05 179.12 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.092 -1.005 . . . . 0.0 109.717 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.507 ' CD1' HD12 ' A' ' 32' ' ' ILE . 63.0 m95 -127.15 126.75 43.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.067 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.443 ' HG2' ' N ' ' A' ' 66' ' ' VAL . 62.1 tt0 -119.25 154.58 33.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.17 -0.956 . . . . 0.0 109.706 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.627 ' HB ' ' HG ' ' A' ' 57' ' ' LEU . 11.0 p -146.17 141.42 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.405 -0.81 . . . . 0.0 109.244 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -119.81 129.01 54.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -0.941 . . . . 0.0 109.723 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.2 t -118.6 130.36 55.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.57 -0.706 . . . . 0.0 109.578 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 60.0 p -61.24 -21.35 63.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.149 -0.969 . . . . 0.0 108.922 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . 15.0 ptmt -106.95 166.86 10.34 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.445 -0.784 . . . . 0.0 109.332 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.633 ' HD2' ' HB2' ' A' ' 70' ' ' LYS . 45.6 Cg_endo -67.74 141.39 54.34 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.478 2.118 . . . . 0.0 111.721 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.92 HD13 HD12 ' A' ' 28' ' ' LEU . 10.6 mt -76.49 141.04 41.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.343 -0.848 . . . . 0.0 109.84 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 124.72 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.366 -0.834 . . . . 0.0 109.378 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.505 ' H ' HG23 ' A' ' 96' ' ' THR . . . -93.99 165.33 26.69 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.636 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 47.6 Cg_endo -68.75 147.41 82.24 Favored 'Cis proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.892 -1.712 . . . . 0.0 112.077 -0.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.558 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 77.1 m-85 -90.9 148.03 22.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.411 -0.806 . . . . 0.0 110.339 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.469 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 26.9 m-80 -109.91 144.54 38.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.379 -0.826 . . . . 0.0 108.928 179.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.864 ' CE2' HD12 ' A' ' 46' ' ' LEU . 82.9 m-85 -135.13 129.23 33.56 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.029 -1.044 . . . . 0.0 110.049 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.618 ' HG3' HG22 ' A' ' 89' ' ' VAL . 20.3 ttt85 -110.27 141.79 42.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.061 -1.025 . . . . 0.0 108.528 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.829 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.6 m-85 -125.31 143.34 51.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 111.396 -178.116 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.585 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.8 124.57 42.4 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.591 ' N ' ' O ' ' A' ' 86' ' ' MET . 16.9 p -72.68 145.45 47.21 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.36 -0.838 . . . . 0.0 110.145 -178.472 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.787 ' CA ' ' HB2' ' A' ' 42' ' ' ALA . 90.6 mttt -47.6 -45.53 27.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 109.145 179.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.16 -5.06 0.58 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 95.47 25.99 12.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.591 ' O ' ' N ' ' A' ' 82' ' ' SER . 45.6 mtp -98.99 150.7 21.7 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -1.18 . . . . 0.0 108.727 179.468 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 62.3 mtm-85 -123.78 138.82 54.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.888 -1.132 . . . . 0.0 110.575 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.437 ' N ' ' O ' ' A' ' 80' ' ' PHE . 31.1 m120 -135.69 140.6 44.57 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.618 HG22 ' HG3' ' A' ' 79' ' ' ARG . 59.9 t -124.04 137.73 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.95 -1.094 . . . . 0.0 110.637 -178.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.529 ' CD2' ' HG3' ' A' ' 106' ' ' PRO . 36.3 m-85 -123.53 121.54 35.91 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 178.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -98.11 147.05 24.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.164 -0.96 . . . . 0.0 109.58 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.636 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 65.8 tt0 53.47 52.84 12.61 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.4 -0.812 . . . . 0.0 110.03 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.715 HG11 ' CD1' ' A' ' 17' ' ' PHE . 70.4 t -81.51 -34.43 13.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.906 -1.121 . . . . 0.0 109.26 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.483 HG12 ' HB3' ' A' ' 104' ' ' TYR . 13.4 mt -136.91 126.43 15.57 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.149 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.26 160.88 48.12 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.603 2.202 . . . . 0.0 111.986 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.505 HG23 ' H ' ' A' ' 74' ' ' GLY . 9.2 m -52.0 -43.13 63.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.382 -0.824 . . . . 0.0 110.192 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -96.0 103.64 15.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.025 -1.047 . . . . 0.0 109.83 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.414 ' CZ ' ' HB3' ' A' ' 23' ' ' SER . 52.4 p90 -111.68 152.09 28.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 28.2 m -102.11 164.72 11.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.423 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.702 HD13 ' CG1' ' A' ' 19' ' ' VAL . 18.4 mm -98.52 137.43 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.972 . . . . 0.0 109.381 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.44 62.74 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -121.24 146.49 46.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -1.182 . . . . 0.0 109.338 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.6 m -79.77 164.15 23.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.111 -0.993 . . . . 0.0 109.321 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.543 ' N ' ' O ' ' A' ' 17' ' ' PHE . 18.0 m-85 -150.06 92.21 1.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.74 -1.225 . . . . 0.0 109.064 179.089 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.606 ' HB3' HG22 ' A' ' 16' ' ' THR . 0.0 OUTLIER -108.88 164.31 15.0 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.4 -0.813 . . . . 0.0 109.867 -179.477 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.529 ' HG3' ' CD2' ' A' ' 90' ' ' PHE . 47.7 Cg_endo -69.16 174.88 8.35 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 122.843 2.362 . . . . 0.0 111.617 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -127.4 138.79 53.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.632 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.503 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 83.4 mtp180 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.44 -176.49 38.79 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.8 m -53.55 141.04 26.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 109.415 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -46.41 -69.0 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.466 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 16.0 p-80 -172.07 62.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.508 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -159.59 143.8 14.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.258 -0.901 . . . . 0.0 109.482 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 38.2 m170 -100.86 159.9 14.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.384 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 53.9 m80 -120.82 134.43 55.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.18 -0.95 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -117.24 125.16 50.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.223 -0.923 . . . . 0.0 109.353 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.71 121.86 0.6 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.2 t -111.31 169.37 8.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.224 -1.162 . . . . 0.0 109.482 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.79 139.67 58.35 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.896 HG22 ' HG3' ' A' ' 36' ' ' ARG . 15.7 t -126.27 135.63 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 70.6 mt-30 -111.95 122.35 47.54 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.12 -0.988 . . . . 0.0 109.424 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.645 HG22 ' CD1' ' A' ' 34' ' ' TYR . 6.2 t -129.01 139.51 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 0.0 109.721 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.452 ' OG1' ' HB2' ' A' ' 33' ' ' LYS . 19.9 p -141.26 145.91 36.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.885 . . . . 0.0 109.237 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.624 ' CD2' HG12 ' A' ' 32' ' ' ILE . 3.9 m-85 -120.22 141.93 49.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.104 -0.998 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 23.9 m -134.37 127.3 31.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.915 . . . . 0.0 108.963 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.0 HG22 ' CD2' ' A' ' 30' ' ' LEU . 21.7 t -76.0 134.32 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.146 -0.971 . . . . 0.0 109.243 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.7 mm-40 -115.29 153.29 31.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.004 -1.06 . . . . 0.0 109.897 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 57.3 mttp -44.15 113.17 0.49 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.458 -0.776 . . . . 0.0 109.988 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.12 -5.86 1.96 Allowed Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.251 -1.452 . . . . 0.0 110.771 179.186 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.572 ' OG ' ' CE1' ' A' ' 98' ' ' PHE . 26.8 t -64.24 144.35 57.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.737 -1.449 . . . . 0.0 109.635 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.539 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -138.54 174.15 4.52 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.332 -0.855 . . . . 0.0 109.561 -179.907 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.57 ' O ' ' N ' ' A' ' 72' ' ' LEU . 50.0 Cg_endo -69.89 -28.84 24.11 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.837 2.358 . . . . 0.0 112.072 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -116.35 6.22 13.68 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.087 -1.008 . . . . 0.0 109.045 179.611 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.448 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 5.9 mtpm? -142.29 133.4 26.04 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.723 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -122.53 123.24 40.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.084 -1.01 . . . . 0.0 109.51 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 1.015 HG13 ' HG2' ' A' ' 65' ' ' GLU . 46.3 t -118.49 124.57 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.193 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.0 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.19 146.22 31.65 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.014 -1.054 . . . . 0.0 110.37 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.543 ' OD1' HG12 ' A' ' 63' ' ' VAL . 48.4 t0 -86.04 138.19 32.14 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.99 HG21 ' CE2' ' A' ' 80' ' ' PHE . 57.8 mt -123.39 132.27 71.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.817 -1.177 . . . . 0.0 110.644 -178.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 59.5 mttm -109.85 118.07 35.51 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 178.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.645 ' CD1' HG22 ' A' ' 15' ' ' VAL . 73.1 t80 -121.69 109.04 14.25 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.505 -0.747 . . . . 0.0 109.619 -179.038 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 83.5 m -111.45 116.11 30.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.272 -0.892 . . . . 0.0 109.562 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.896 ' HG3' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -141.83 121.61 8.19 Favored Pre-proline 0 N--CA 1.488 1.473 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.812 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.7 117.6 5.18 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.458 2.105 . . . . 0.0 112.014 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.74 -11.31 68.28 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.544 ' CB ' ' HD3' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -140.27 -179.94 6.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.894 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 82' ' ' SER . 15.4 m -155.68 162.96 40.48 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.356 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.485 HD21 HG21 ' A' ' 44' ' ' VAL . 17.5 tp -70.5 127.91 34.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.266 -0.896 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.853 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.52 -41.65 3.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.218 -0.926 . . . . 0.0 109.734 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -147.15 155.11 41.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.169 -0.957 . . . . 0.0 110.176 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.57 HG22 ' CD2' ' A' ' 80' ' ' PHE . 21.4 t -142.39 141.15 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.442 -0.786 . . . . 0.0 109.33 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.435 ' HG2' ' HA ' ' A' ' 56' ' ' PRO . 88.6 mt-10 -127.61 150.52 49.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.767 -1.208 . . . . 0.0 109.434 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.955 HD12 ' O ' ' A' ' 77' ' ' ASN . 21.7 tp -122.2 144.21 49.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.408 -178.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.627 ' HB2' ' CD2' ' A' ' 54' ' ' TRP . 0.1 OUTLIER -126.17 127.85 46.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.383 -0.823 . . . . 0.0 109.012 179.243 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.474 ' NE2' ' CB ' ' A' ' 68' ' ' SER . 74.0 mt-30 -71.06 149.77 46.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 109.315 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.592 ' CD2' ' HD2' ' A' ' 75' ' ' PRO . 47.3 t60 -64.84 109.03 1.93 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.559 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.37 2.99 24.41 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.518 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 18.1 t -114.91 154.97 27.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.013 -1.287 . . . . 0.0 109.566 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.429 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 54.7 mp0 -112.02 -12.27 13.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.187 -0.946 . . . . 0.0 109.313 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -95.43 99.7 11.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.323 -0.861 . . . . 0.0 109.559 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.627 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 24.9 m95 -59.32 141.5 54.32 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.302 -0.874 . . . . 0.0 109.707 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -106.63 137.0 19.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.502 -0.749 . . . . 0.0 109.599 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.435 ' HA ' ' HG2' ' A' ' 45' ' ' GLU . 53.1 Cg_endo -72.46 144.41 40.55 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.592 2.195 . . . . 0.0 111.776 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.704 HD11 ' CB ' ' A' ' 46' ' ' LEU . 7.5 mp -106.95 146.37 31.14 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.17 -0.956 . . . . 0.0 108.863 179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 88.4 m -103.11 126.22 50.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.936 -1.103 . . . . 0.0 108.905 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 9.4 tttm -68.82 112.81 5.76 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.189 -0.944 . . . . 0.0 108.904 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mttm -120.07 80.37 1.59 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.004 -1.06 . . . . 0.0 110.702 -178.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.31 60.39 1.31 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.369 179.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 60.03 10.37 2.18 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.148 -1.207 . . . . 0.0 110.16 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 59' ' ' LYS . 13.6 m -129.51 -172.64 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.161 -0.962 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.409 ' CD1' HD12 ' A' ' 32' ' ' ILE . 78.4 m95 -139.13 125.52 20.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.221 -0.924 . . . . 0.0 109.553 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 1.015 ' HG2' HG13 ' A' ' 29' ' ' VAL . 27.0 mt-10 -115.08 152.08 33.14 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.856 . . . . 0.0 109.596 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.704 HG11 HD23 ' A' ' 46' ' ' LEU . 3.1 p -138.22 134.91 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.439 -0.788 . . . . 0.0 109.304 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HG2' ' HG2' ' A' ' 27' ' ' LYS . 26.5 mttp -120.89 133.99 55.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.346 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.474 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . 9.5 t -120.66 126.84 51.26 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.37 -0.831 . . . . 0.0 109.308 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' SER . 73.4 p -45.28 -26.69 0.54 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.007 -1.058 . . . . 0.0 108.514 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.58 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -115.26 178.33 0.99 Allowed Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.1 Cg_endo -67.81 178.94 2.98 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.332 2.022 . . . . 0.0 111.846 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.583 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -112.09 143.48 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.199 -0.938 . . . . 0.0 109.786 -179.577 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 6.4 t -120.8 123.71 70.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.367 -0.833 . . . . 0.0 109.31 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.729 ' H ' HG23 ' A' ' 96' ' ' THR . . . -92.41 166.21 29.24 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.628 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.4 Cg_endo -69.62 146.76 82.78 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.783 -1.757 . . . . 0.0 112.082 0.045 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 46' ' ' LEU . 72.1 m-85 -91.54 153.6 19.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.627 -0.671 . . . . 0.0 110.494 -179.249 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.955 ' O ' HD12 ' A' ' 46' ' ' LEU . 1.8 m-80 -112.5 141.03 46.73 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.91 ' CE1' HD13 ' A' ' 46' ' ' LEU . 84.4 m-85 -132.27 128.41 37.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.997 -1.065 . . . . 0.0 109.894 -179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.772 ' HG3' HG22 ' A' ' 89' ' ' VAL . 16.3 ttt180 -112.41 143.68 43.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.019 -1.051 . . . . 0.0 108.732 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.99 ' CE2' HG21 ' A' ' 32' ' ' ILE . 24.5 m-85 -125.37 144.42 50.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.269 -0.894 . . . . 0.0 111.611 -177.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 2.8 ttt -127.15 126.19 42.47 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.552 ' HA ' ' O ' ' A' ' 40' ' ' SER . 19.8 p -79.06 148.87 32.31 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.284 -0.885 . . . . 0.0 110.18 -178.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.853 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 23.3 mttt -47.0 -46.51 21.76 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.244 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.422 ' HA3' ' OD1' ' A' ' 39' ' ' ASP . . . -59.83 -8.48 8.0 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 82' ' ' SER . . . 98.3 34.13 5.44 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 82' ' ' SER . 51.6 mmm -102.97 109.18 20.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.107 -1.231 . . . . 0.0 109.065 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 87.7 mtm-85 -91.48 141.52 28.65 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.125 -0.984 . . . . 0.0 110.704 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.565 ' N ' ' O ' ' A' ' 80' ' ' PHE . 26.1 m120 -135.88 140.08 43.85 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.772 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -120.57 136.48 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.022 -1.049 . . . . 0.0 110.358 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.55 ' HB3' ' HB3' ' A' ' 106' ' ' PRO . 31.6 m-85 -125.96 122.23 35.35 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -98.17 147.33 24.7 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.946 . . . . 0.0 109.655 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.628 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 41.3 mt-10 53.31 52.88 12.67 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.346 -0.846 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.687 HG12 HG13 ' A' ' 94' ' ' ILE . 40.2 t -82.94 -34.35 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.986 -1.071 . . . . 0.0 109.3 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.687 HG13 HG12 ' A' ' 93' ' ' VAL . 65.8 mt -136.83 125.15 14.89 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.347 -0.845 . . . . 0.0 109.134 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.08 162.58 41.16 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.548 2.165 . . . . 0.0 111.887 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.729 HG23 ' H ' ' A' ' 74' ' ' GLY . 3.7 m -52.87 -37.11 59.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.469 -0.77 . . . . 0.0 110.016 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.74 98.34 9.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.029 -1.044 . . . . 0.0 109.717 -179.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.572 ' CE1' ' OG ' ' A' ' 23' ' ' SER . 35.4 p90 -107.0 146.61 30.89 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.125 -0.985 . . . . 0.0 109.366 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.2 m -114.53 118.37 33.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.918 . . . . 0.0 109.554 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.576 ' HA ' ' HB ' ' A' ' 19' ' ' VAL . 4.8 mt -56.76 139.37 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.392 -0.817 . . . . 0.0 109.721 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.08 5.52 54.68 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 26.4 tttt -124.13 143.46 50.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.991 -1.299 . . . . 0.0 109.379 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.4 m -78.11 158.77 28.99 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.187 -0.946 . . . . 0.0 108.908 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.538 ' N ' ' O ' ' A' ' 17' ' ' PHE . 29.8 m-85 -146.58 97.49 2.93 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.491 -1.381 . . . . 0.0 108.953 179.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.54 157.9 32.81 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 110.059 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.55 ' HB3' ' HB3' ' A' ' 90' ' ' PHE . 49.7 Cg_endo -70.72 174.58 10.13 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.825 2.35 . . . . 0.0 111.822 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.406 ' O ' ' CB ' ' A' ' 108' ' ' GLU . 96.8 mt-10 -87.51 161.11 17.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.527 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 107' ' ' GLU . 36.7 tt0 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.415 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 25.9 mtm180 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 121.283 0.563 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.33 -48.25 2.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 92.1 p -126.61 131.2 51.55 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.468 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -56.49 -43.56 79.81 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.288 -0.883 . . . . 0.0 109.56 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.581 ' HB2' ' CE1' ' A' ' 7' ' ' HIS . 48.4 m80 -126.04 175.21 7.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.292 -0.88 . . . . 0.0 109.529 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 49.9 t-80 -84.72 -15.44 45.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.581 ' CE1' ' HB2' ' A' ' 5' ' ' HIS . 2.2 p-80 -56.87 121.94 11.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.294 -0.879 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 9' ' ' HIS . 88.1 m-70 -90.37 -10.4 44.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.267 -0.895 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER -55.05 -167.02 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.32 -0.862 . . . . 0.0 109.547 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.494 ' O ' ' HG3' ' A' ' 37' ' ' PRO . . . 97.15 0.39 59.92 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -93.63 18.72 9.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.47 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -82.94 149.13 27.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.334 -0.854 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.778 HG11 ' CZ ' ' A' ' 34' ' ' TYR . 4.2 t -127.23 137.25 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.848 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.408 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 82.7 mt-30 -106.99 120.84 43.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.183 -0.948 . . . . 0.0 109.172 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.619 HG11 ' HG3' ' A' ' 106' ' ' PRO . 11.4 p -129.57 141.65 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.253 -0.904 . . . . 0.0 109.747 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.498 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 60.5 p -140.77 144.6 35.57 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.071 -1.018 . . . . 0.0 109.481 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 104' ' ' TYR . 49.7 m-85 -114.24 147.41 39.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.246 -0.909 . . . . 0.0 109.253 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 29.1 m -145.98 127.34 14.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.994 -1.066 . . . . 0.0 109.483 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.91 HG22 ' CD2' ' A' ' 30' ' ' LEU . 3.8 t -75.88 136.52 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.392 -0.818 . . . . 0.0 109.209 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.16 158.22 19.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.985 -1.072 . . . . 0.0 109.835 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -51.43 113.11 0.87 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.865 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 140.77 -6.91 2.68 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.516 179.384 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.523 ' OG ' ' CG1' ' A' ' 19' ' ' VAL . 10.8 m -57.46 143.51 40.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.892 -1.358 . . . . 0.0 109.39 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.553 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -135.69 171.45 8.83 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.707 -179.818 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 51.3 Cg_endo -70.22 -31.27 18.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.861 2.374 . . . . 0.0 111.891 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.455 ' HG3' ' HG3' ' A' ' 27' ' ' LYS . 2.5 pttt -112.82 7.27 18.38 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.222 -0.923 . . . . 0.0 108.938 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.487 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 29.8 mttm -141.83 132.93 26.18 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.709 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.1 121.48 37.97 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.999 -1.063 . . . . 0.0 109.406 -179.87 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 1.025 HG22 ' HG3' ' A' ' 65' ' ' GLU . 11.9 t -119.72 125.69 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.91 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.2 mt -145.27 145.37 31.24 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.983 -1.073 . . . . 0.0 110.024 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.508 ' HA ' HG12 ' A' ' 63' ' ' VAL . 67.7 t0 -84.54 137.57 33.25 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.665 HG21 ' HE2' ' A' ' 80' ' ' PHE . 53.9 mt -120.49 130.09 74.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.752 -1.217 . . . . 0.0 110.557 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 58.7 tttt -110.36 119.57 39.64 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.472 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.778 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 66.2 t80 -121.85 121.01 36.19 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.563 -0.711 . . . . 0.0 109.259 -179.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 91.7 m -122.75 115.82 22.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.128 -0.983 . . . . 0.0 110.162 -179.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.623 ' HG3' HG22 ' A' ' 13' ' ' VAL . 20.5 ttt85 -135.64 137.48 25.92 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.534 -0.729 . . . . 0.0 109.065 179.434 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.494 ' HG3' ' O ' ' A' ' 10' ' ' GLY . 48.5 Cg_endo -69.66 99.4 0.73 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.648 2.232 . . . . 0.0 111.904 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.14 -38.0 3.25 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.565 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 53.5 m-20 -96.28 176.16 6.17 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.228 -1.16 . . . . 0.0 109.798 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -154.74 162.22 41.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.378 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.789 HD21 HG21 ' A' ' 44' ' ' VAL . 31.8 tp -68.11 128.74 37.66 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.061 -1.024 . . . . 0.0 109.109 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.837 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.37 -45.0 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.132 -0.98 . . . . 0.0 110.274 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.473 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 81.5 mt-10 -135.55 144.56 46.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.043 -1.036 . . . . 0.0 110.392 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.789 HG21 HD21 ' A' ' 41' ' ' LEU . 99.7 t -137.97 135.59 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.474 -0.766 . . . . 0.0 109.147 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -127.91 150.03 50.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.964 -1.085 . . . . 0.0 109.162 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.96 HD13 ' CE2' ' A' ' 78' ' ' PHE . 13.5 tp -121.38 133.2 55.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.798 . . . . 0.0 110.176 -178.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.618 ' N ' HD12 ' A' ' 46' ' ' LEU . 40.8 ttp180 -119.46 129.04 54.55 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 108.788 179.134 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.597 ' NE2' HD23 ' A' ' 72' ' ' LEU . 55.0 mt-30 -71.01 160.74 32.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.276 -0.89 . . . . 0.0 110.161 -179.216 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 77.8 t60 -70.59 145.66 50.59 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.42 -0.8 . . . . 0.0 109.438 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.54 2.66 44.43 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.462 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 32.8 t -112.83 154.25 26.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.102 -1.234 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -121.17 14.18 11.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.889 . . . . 0.0 109.417 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -111.66 98.66 7.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.344 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.541 ' CD2' ' HB2' ' A' ' 47' ' ' ARG . 65.4 m95 -59.88 134.38 56.98 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.281 -0.887 . . . . 0.0 109.737 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -111.54 130.93 22.61 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.468 -0.77 . . . . 0.0 109.095 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.506 ' C ' HD12 ' A' ' 57' ' ' LEU . 48.5 Cg_endo -69.62 141.53 46.06 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.502 2.135 . . . . 0.0 111.978 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.804 ' N ' HD12 ' A' ' 57' ' ' LEU . 5.9 mp -97.16 143.06 28.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 108.534 179.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -81.38 125.91 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.902 -1.123 . . . . 0.0 109.13 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -72.22 108.22 5.27 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.16 -0.962 . . . . 0.0 109.379 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.449 ' O ' ' C ' ' A' ' 61' ' ' GLY . 22.7 mttm -113.76 132.78 55.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.995 -1.065 . . . . 0.0 109.469 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 60' ' ' LYS . . . 43.17 -100.24 0.02 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.443 ' N ' ' O ' ' A' ' 60' ' ' LYS . 23.9 p-10 -130.5 24.98 5.12 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.249 -1.148 . . . . 0.0 109.187 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.508 HG12 ' HA ' ' A' ' 31' ' ' ASP . 35.9 m -131.62 -170.08 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.568 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.566 ' CD1' HD12 ' A' ' 32' ' ' ILE . 44.6 m95 -140.99 124.69 16.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.03 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 1.025 ' HG3' HG22 ' A' ' 29' ' ' VAL . 69.8 tt0 -115.36 151.96 33.69 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 109.71 -179.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.92 HG11 HD23 ' A' ' 46' ' ' LEU . 2.0 p -141.19 138.46 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.367 -0.833 . . . . 0.0 109.191 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.441 ' CD ' ' HD3' ' A' ' 27' ' ' LYS . 84.4 mttt -122.14 134.78 54.74 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.278 -0.889 . . . . 0.0 109.6 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' SER . 8.8 t -120.18 126.21 50.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.343 -0.848 . . . . 0.0 109.188 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 68' ' ' SER . 6.0 m -44.1 -29.03 0.55 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.084 -1.01 . . . . 0.0 108.83 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.567 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.0 OUTLIER -112.55 178.35 0.99 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.431 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 47.8 Cg_endo -68.79 166.34 26.59 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.382 2.055 . . . . 0.0 111.618 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.597 HD23 ' NE2' ' A' ' 48' ' ' GLN . 1.8 mt -97.34 143.29 28.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.117 -0.989 . . . . 0.0 109.816 -179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.419 ' O ' ' HB3' ' A' ' 49' ' ' HIS . 22.9 t -119.89 124.79 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.81 . . . . 0.0 109.307 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.763 ' H ' HG23 ' A' ' 96' ' ' THR . . . -95.51 169.09 27.15 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.615 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 48.5 Cg_endo -67.99 146.34 77.5 Favored 'Cis proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.838 -1.734 . . . . 0.0 111.85 0.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.611 ' HB3' HD11 ' A' ' 46' ' ' LEU . 74.2 m-85 -91.34 149.84 21.56 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.532 -0.73 . . . . 0.0 110.37 -179.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.874 ' O ' HD12 ' A' ' 46' ' ' LEU . 18.9 m-80 -111.99 143.67 42.6 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 179.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.96 ' CE2' HD13 ' A' ' 46' ' ' LEU . 96.1 m-85 -134.84 120.36 19.24 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.056 -1.028 . . . . 0.0 109.515 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.934 ' HG3' HG22 ' A' ' 89' ' ' VAL . 63.3 ttt180 -100.55 141.94 32.7 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.955 -1.091 . . . . 0.0 108.653 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.74 ' CE1' HG13 ' A' ' 44' ' ' VAL . 7.3 m-85 -124.96 142.95 51.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.907 . . . . 0.0 111.317 -178.256 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 4.7 ttm -124.67 124.2 41.68 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.157 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.615 ' N ' ' O ' ' A' ' 86' ' ' MET . 13.6 p -72.16 144.85 48.43 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.408 -0.808 . . . . 0.0 110.097 -178.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.837 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.2 OUTLIER -50.24 -44.45 53.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -0.917 . . . . 0.0 108.777 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.04 -2.18 0.19 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.32 25.7 18.11 Favored Glycine 0 N--CA 1.491 2.35 0 O-C-N 121.068 -1.254 . . . . 0.0 109.978 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.615 ' O ' ' N ' ' A' ' 82' ' ' SER . 39.2 mtp -100.85 149.06 24.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.109 -1.23 . . . . 0.0 108.864 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 7.6 mtt85 -120.15 135.97 54.78 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.332 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -134.57 139.91 45.72 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.934 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.5 t -123.1 136.2 60.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.043 -1.036 . . . . 0.0 110.294 -178.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.653 ' CG ' ' CB ' ' A' ' 106' ' ' PRO . 11.3 m-85 -122.45 121.04 35.67 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.59 147.62 24.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.21 -0.931 . . . . 0.0 109.707 -179.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.615 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 48.2 mt-10 53.69 49.64 18.86 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.412 -0.805 . . . . 0.0 110.2 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.611 HG12 HG13 ' A' ' 94' ' ' ILE . 54.3 t -77.91 -33.71 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.867 -1.146 . . . . 0.0 108.885 179.333 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.611 HG13 HG12 ' A' ' 93' ' ' VAL . 69.8 mt -138.83 124.71 12.33 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.321 -0.862 . . . . 0.0 108.959 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -67.72 162.83 37.69 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.647 2.232 . . . . 0.0 112.161 -179.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.763 HG23 ' H ' ' A' ' 74' ' ' GLY . 8.1 m -50.56 -43.87 56.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.41 -0.806 . . . . 0.0 109.829 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.03 103.77 15.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.039 -1.038 . . . . 0.0 109.528 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.582 ' CE2' HG11 ' A' ' 19' ' ' VAL . 43.0 p90 -111.25 158.86 18.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 109.157 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 7.4 m -107.92 172.48 6.81 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.256 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.6 mm -104.56 135.93 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.877 . . . . 0.0 109.253 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 96.75 6.77 58.1 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -117.08 141.74 47.88 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.064 -1.256 . . . . 0.0 109.337 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.57 HG22 ' N ' ' A' ' 104' ' ' TYR . 34.5 m -81.95 170.1 16.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.09 -1.007 . . . . 0.0 109.026 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.575 ' N ' ' O ' ' A' ' 17' ' ' PHE . 21.4 m-85 -151.23 99.37 2.65 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.771 -1.205 . . . . 0.0 109.261 179.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.571 ' HG2' ' O ' ' A' ' 15' ' ' VAL . 1.9 mtmt -84.43 148.95 53.75 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.467 -0.77 . . . . 0.0 109.66 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.653 ' CB ' ' CG ' ' A' ' 90' ' ' PHE . 51.1 Cg_endo -72.22 120.4 6.76 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.254 1.969 . . . . 0.0 111.569 179.635 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.16 -76.83 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.242 -0.911 . . . . 0.0 109.584 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 90' ' ' PHE . 32.8 tt0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.522 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 29.8 mtm180 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.17 138.32 45.73 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.3 t -80.41 152.37 28.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -1.169 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 37.3 p-80 -117.62 8.19 12.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 36.0 t60 -53.75 -48.85 69.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.189 -0.945 . . . . 0.0 109.427 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 63.9 m80 -55.1 -29.32 57.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.423 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.543 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 74.1 t60 -113.76 22.0 14.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.447 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -98.29 144.53 27.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.922 . . . . 0.0 109.505 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -138.97 168.6 19.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.891 . . . . 0.0 109.499 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -164.35 169.76 39.28 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.453 ' O ' ' HB2' ' A' ' 12' ' ' ALA . 69.0 m -100.9 151.09 22.15 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.262 -1.14 . . . . 0.0 109.328 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.453 ' HB2' ' O ' ' A' ' 11' ' ' SER . . . 177.81 -142.3 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.195 -0.941 . . . . 0.0 109.602 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.904 HG22 ' HG3' ' A' ' 36' ' ' ARG . 17.1 t -123.89 132.76 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 108.855 179.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.457 ' HB2' ' HB ' ' A' ' 35' ' ' THR . 36.1 mt-30 -109.31 121.35 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.094 -1.004 . . . . 0.0 109.814 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 9.5 p -128.87 140.39 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.35 -0.844 . . . . 0.0 109.439 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.484 ' OG1' ' HB3' ' A' ' 33' ' ' LYS . 27.9 p -142.08 146.16 35.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.06 -1.025 . . . . 0.0 109.606 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.583 ' O ' ' N ' ' A' ' 104' ' ' TYR . 5.0 m-85 -118.51 143.68 46.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.581 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 1.005 HG23 ' O ' ' A' ' 102' ' ' LYS . 69.0 m -139.67 129.05 24.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.067 -1.02 . . . . 0.0 109.245 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.904 HG22 HD23 ' A' ' 30' ' ' LEU . 42.6 t -75.91 132.67 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.225 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -105.17 159.78 15.59 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.109 -0.994 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -54.35 115.22 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.388 -0.82 . . . . 0.0 109.782 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 24' ' ' ASP . . . 139.5 -0.59 2.24 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.279 179.476 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.432 ' C ' ' OD1' ' A' ' 24' ' ' ASP . 34.1 t -66.85 142.17 57.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.976 -1.308 . . . . 0.0 109.394 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.648 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -134.56 174.48 4.59 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.205 -0.935 . . . . 0.0 109.31 -179.833 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.648 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 49.3 Cg_endo -70.36 -28.71 22.05 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.612 2.208 . . . . 0.0 111.985 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.3 mttm -114.51 9.37 16.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.935 . . . . 0.0 109.127 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.505 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 31.9 mttt -142.98 133.47 24.91 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.731 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.5 122.5 39.86 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.997 -1.064 . . . . 0.0 109.571 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.647 HG22 ' CG ' ' A' ' 65' ' ' GLU . 22.2 t -120.2 125.6 74.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.904 HD23 HG22 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -144.89 145.69 31.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.883 -1.136 . . . . 0.0 110.248 -179.419 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.494 ' HA ' HG12 ' A' ' 63' ' ' VAL . 17.9 t70 -86.22 138.52 31.81 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.824 HG21 ' HE2' ' A' ' 80' ' ' PHE . 70.5 mt -120.2 130.34 74.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.859 -178.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 25.1 tptt -110.55 120.26 41.83 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.115 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.504 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 79.6 t80 -121.77 123.64 42.31 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.395 -0.815 . . . . 0.0 109.915 -178.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.457 ' HB ' ' HB2' ' A' ' 14' ' ' GLN . 56.8 m -125.11 115.13 19.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 109.484 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.904 ' HG3' HG22 ' A' ' 13' ' ' VAL . 29.8 ttt85 -139.79 135.37 16.6 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.448 -0.782 . . . . 0.0 109.199 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.481 ' HD2' ' HG3' ' A' ' 36' ' ' ARG . 50.8 Cg_endo -70.96 108.01 2.21 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.778 2.318 . . . . 0.0 112.182 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.02 -1.9 86.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.56 ' HB2' ' CD ' ' A' ' 36' ' ' ARG . 66.8 m-20 -134.36 173.92 11.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.075 -1.25 . . . . 0.0 109.655 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -153.45 160.85 42.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.81 HD11 ' CG2' ' A' ' 44' ' ' VAL . 7.8 tp -68.65 123.3 20.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.913 . . . . 0.0 109.212 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.794 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.36 -44.89 2.95 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.469 ' HB2' ' HB3' ' A' ' 81' ' ' MET . 69.5 mt-10 -135.18 144.46 47.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.162 -0.961 . . . . 0.0 110.217 -179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.81 ' CG2' HD11 ' A' ' 41' ' ' LEU . 12.6 t -138.36 135.96 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.445 -0.784 . . . . 0.0 109.273 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -128.96 150.02 50.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.878 -1.139 . . . . 0.0 109.537 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.942 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.7 tt -119.2 143.3 47.34 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.453 -0.779 . . . . 0.0 109.857 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.942 ' N ' HD23 ' A' ' 46' ' ' LEU . 35.8 ttp180 -131.33 126.36 35.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 108.821 179.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.589 ' NE2' HD23 ' A' ' 72' ' ' LEU . 56.1 mt-30 -66.39 156.11 35.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.159 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.59 ' CE1' ' HD2' ' A' ' 75' ' ' PRO . 8.3 t-80 -71.9 117.15 13.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 109.629 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 103.53 4.07 46.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.486 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 10.1 t -114.37 159.82 19.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.28 -1.13 . . . . 0.0 109.342 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.65 14.97 9.46 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -116.36 91.45 3.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.443 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -52.79 134.37 36.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -106.78 135.16 19.57 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.313 -0.867 . . . . 0.0 109.434 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.485 ' C ' HD12 ' A' ' 57' ' ' LEU . 49.5 Cg_endo -70.15 145.78 55.84 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.677 2.251 . . . . 0.0 111.733 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.682 HD11 ' CB ' ' A' ' 46' ' ' LEU . 8.2 mp -110.41 150.78 28.33 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.168 -0.958 . . . . 0.0 109.052 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.7 m -102.36 126.74 49.47 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.993 -1.067 . . . . 0.0 109.141 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.7 tttt -77.46 101.56 6.48 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.071 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.565 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 20.7 mttt -115.4 150.39 36.46 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.866 -1.146 . . . . 0.0 110.083 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 43.38 32.23 1.75 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 1.5 m120 76.79 12.73 2.34 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.244 . . . . 0.0 110.126 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 60' ' ' LYS . 3.0 m -130.17 176.9 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.136 -0.978 . . . . 0.0 108.805 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 64' ' ' TRP . 37.8 m95 -120.5 144.35 48.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.926 -1.108 . . . . 0.0 109.796 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.647 ' CG ' HG22 ' A' ' 29' ' ' VAL . 51.3 tt0 -136.5 151.97 50.01 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.376 -0.827 . . . . 0.0 109.445 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.813 HG11 HD13 ' A' ' 46' ' ' LEU . 9.8 p -137.11 133.77 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.387 -0.821 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' NZ ' ' A' ' 27' ' ' LYS . 21.4 mttt -119.72 131.21 55.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.934 . . . . 0.0 109.398 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t -118.24 165.96 13.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.381 -0.824 . . . . 0.0 109.522 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 50.2 m -88.74 2.98 52.47 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.249 -0.907 . . . . 0.0 109.052 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.558 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 0.2 OUTLIER -142.14 176.78 2.18 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.476 -0.765 . . . . 0.0 109.18 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.558 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 46.5 Cg_endo -68.55 139.31 44.37 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.506 2.137 . . . . 0.0 111.721 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.589 HD23 ' NE2' ' A' ' 48' ' ' GLN . 8.8 mt -73.88 143.08 45.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.261 -0.899 . . . . 0.0 109.627 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.424 ' O ' ' CB ' ' A' ' 49' ' ' HIS . 31.2 t -119.42 123.3 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.249 -0.907 . . . . 0.0 109.31 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.532 ' CA ' ' OG1' ' A' ' 96' ' ' THR . . . -92.05 164.7 28.76 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.701 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.55 147.87 85.07 Favored 'Cis proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.775 -1.761 . . . . 0.0 112.035 -0.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 58.9 m-85 -89.52 151.1 22.15 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.505 -0.747 . . . . 0.0 110.149 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.432 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 39.2 m-80 -112.68 142.9 44.75 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.823 . . . . 0.0 109.051 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.874 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.9 m-85 -135.12 123.5 23.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 109.773 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.999 ' HG3' HG22 ' A' ' 89' ' ' VAL . 38.4 ttt180 -103.86 141.69 35.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.985 -1.072 . . . . 0.0 108.514 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.824 ' HE2' HG21 ' A' ' 32' ' ' ILE . 13.3 m-85 -125.17 142.8 51.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 111.497 -178.06 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ARG . 3.5 ttm -124.46 123.75 40.82 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.621 ' N ' ' O ' ' A' ' 86' ' ' MET . 17.6 p -70.45 143.45 51.78 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.367 -0.833 . . . . 0.0 110.302 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.794 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 0.0 OUTLIER -48.39 -45.2 35.57 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.356 -0.84 . . . . 0.0 108.83 178.924 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.42 -2.13 0.25 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.499 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 93.34 24.99 20.28 Favored Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.083 -1.246 . . . . 0.0 110.025 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.621 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.6 mmm -98.95 149.17 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.011 -1.288 . . . . 0.0 108.786 179.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.538 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 19.6 mtm105 -120.33 135.81 54.9 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.969 -1.082 . . . . 0.0 110.401 -179.013 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -134.32 139.44 45.67 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.999 HG22 ' HG3' ' A' ' 79' ' ' ARG . 6.7 t -122.82 136.42 59.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.112 -0.992 . . . . 0.0 110.316 -179.026 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 15' ' ' VAL . 27.7 m-85 -123.28 121.83 36.85 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.517 -0.919 . . . . 0.0 108.517 179.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -99.35 147.49 25.16 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.272 -0.893 . . . . 0.0 109.643 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.701 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 25.7 mt-10 53.48 52.2 13.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.392 -0.818 . . . . 0.0 110.201 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.3 t -83.04 -34.87 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 120.889 -1.132 . . . . 0.0 109.085 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -133.63 123.78 17.54 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.334 -0.854 . . . . 0.0 109.197 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.33 161.74 44.92 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.549 2.166 . . . . 0.0 111.79 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.532 ' OG1' ' CA ' ' A' ' 74' ' ' GLY . 32.6 m -54.29 -36.07 63.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.414 -0.804 . . . . 0.0 110.055 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.43 79.19 5.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.936 -1.102 . . . . 0.0 109.702 -179.513 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -89.02 145.05 25.73 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.314 -0.866 . . . . 0.0 109.408 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.59 116.48 26.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.321 -0.862 . . . . 0.0 109.67 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.59 HG12 HG12 ' A' ' 19' ' ' VAL . 11.1 mt -56.82 139.95 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.292 -0.88 . . . . 0.0 109.656 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 100.14 5.95 54.17 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 1.005 ' O ' HG23 ' A' ' 18' ' ' THR . 20.3 mttm -120.23 -165.82 1.23 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.009 -1.289 . . . . 0.0 109.183 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 104' ' ' TYR . 8.7 m -131.06 165.22 23.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.07 -1.019 . . . . 0.0 108.517 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' PHE . 20.7 m-85 -155.53 93.45 1.49 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.428 -1.42 . . . . 0.0 109.169 179.138 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.553 ' HB2' ' HD2' ' A' ' 106' ' ' PRO . 6.8 pttm -105.11 164.43 15.14 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.409 -0.807 . . . . 0.0 109.393 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.553 ' HD2' ' HB2' ' A' ' 105' ' ' LYS . 50.2 Cg_endo -71.28 147.72 53.89 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.494 2.129 . . . . 0.0 111.739 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.427 ' OE1' ' HA ' ' A' ' 107' ' ' GLU . 69.5 mm-40 -91.93 145.67 24.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.212 -0.93 . . . . 0.0 109.458 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.457 179.961 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -51.8 114.1 2.9 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.99 -44.11 96.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.231 -1.158 . . . . 0.0 109.433 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . 0.453 ' HA ' ' HB2' ' A' ' 7' ' ' HIS . 1.6 m80 -54.41 -33.15 58.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 69.6 t60 -54.49 -33.38 59.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.396 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -98.74 -34.7 10.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.313 -0.867 . . . . 0.0 109.465 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.453 ' HB2' ' HA ' ' A' ' 4' ' ' HIS . 65.6 m-70 -65.9 -38.32 88.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.951 . . . . 0.0 109.478 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.5 m-70 -119.04 140.27 50.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.382 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 -103.66 -7.43 20.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.567 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 72.57 -167.27 53.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.9 t -103.14 153.68 20.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.233 -1.157 . . . . 0.0 109.527 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -137.46 138.92 40.26 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.396 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.645 HG22 ' HG3' ' A' ' 36' ' ' ARG . 20.1 t -124.35 129.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.286 -0.884 . . . . 0.0 109.655 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -111.65 121.37 44.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.157 -0.964 . . . . 0.0 109.313 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' LYS . 2.2 t -128.16 138.09 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.814 -179.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.472 HG22 ' HD3' ' A' ' 105' ' ' LYS . 28.1 p -142.17 146.21 35.04 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.352 -0.842 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.594 ' O ' ' N ' ' A' ' 104' ' ' TYR . 34.1 m-85 -118.31 142.42 47.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.673 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 61.1 m -138.18 129.2 27.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.058 -1.027 . . . . 0.0 109.329 179.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.901 HG22 ' CD2' ' A' ' 30' ' ' LEU . 24.0 t -77.29 138.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.882 . . . . 0.0 109.39 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -106.15 -177.11 3.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.107 -0.995 . . . . 0.0 109.508 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 43.0 mttt -77.67 110.29 12.38 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.369 -0.832 . . . . 0.0 109.698 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 141.61 -0.32 1.66 Allowed Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.558 -1.306 . . . . 0.0 110.481 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' CZ ' ' A' ' 98' ' ' PHE . 8.0 t -56.4 144.82 29.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.875 -1.368 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.5 168.99 14.62 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.167 -0.958 . . . . 0.0 109.636 -179.833 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.527 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 48.3 Cg_endo -69.76 -27.64 26.24 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.854 2.369 . . . . 0.0 111.859 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -114.65 8.61 16.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.164 -0.96 . . . . 0.0 109.01 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.443 ' C ' HD11 ' A' ' 72' ' ' LEU . 56.4 mttp -143.99 134.15 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.452 -0.78 . . . . 0.0 108.98 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 30' ' ' LEU . 0.1 OUTLIER -121.91 123.02 40.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.927 -1.108 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.735 HG13 ' HG2' ' A' ' 65' ' ' GLU . 5.0 t -120.36 126.07 74.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.901 ' CD2' HG22 ' A' ' 19' ' ' VAL . 1.1 mt -145.35 145.48 31.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.842 -1.161 . . . . 0.0 110.2 -179.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.423 ' HA ' HG12 ' A' ' 63' ' ' VAL . 64.2 t0 -83.88 135.01 34.66 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 178.044 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.633 HG21 ' CE2' ' A' ' 80' ' ' PHE . 1.4 mt -115.53 127.07 73.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.779 -1.201 . . . . 0.0 111.154 -178.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 15' ' ' VAL . 10.2 ttpt -108.12 115.19 29.67 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 177.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.514 ' OH ' ' HD2' ' A' ' 36' ' ' ARG . 76.7 t80 -124.05 108.16 12.06 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.682 -0.637 . . . . 0.0 109.84 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 91.0 m -109.6 117.56 34.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.351 -0.843 . . . . 0.0 109.446 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.645 ' HG3' HG22 ' A' ' 13' ' ' VAL . 9.4 ttt85 -144.65 114.49 5.14 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.405 -0.81 . . . . 0.0 109.354 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.41 120.7 7.5 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.704 2.269 . . . . 0.0 111.809 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.06 -19.54 54.38 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.531 ' HB2' ' NE ' ' A' ' 36' ' ' ARG . 5.0 m-20 -140.75 -179.09 5.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -1.126 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.412 ' HB2' ' HD2' ' A' ' 83' ' ' LYS . 18.6 m -155.75 162.86 40.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.86 . . . . 0.0 109.535 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.778 HD21 ' CG2' ' A' ' 44' ' ' VAL . 25.1 tp -69.97 129.19 38.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.294 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.884 ' HB2' ' HA ' ' A' ' 83' ' ' LYS . . . -115.35 -42.12 3.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 78.0 mt-10 -138.95 147.6 42.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.189 -0.944 . . . . 0.0 110.246 -179.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.778 ' CG2' HD21 ' A' ' 41' ' ' LEU . 77.6 t -138.18 136.01 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.488 ' HA ' HD13 ' A' ' 57' ' ' LEU . 94.3 mt-10 -129.76 151.63 50.13 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.88 -1.137 . . . . 0.0 109.775 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.943 HD23 ' N ' ' A' ' 47' ' ' ARG . 6.9 tt -120.99 140.23 52.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 109.636 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.943 ' N ' HD23 ' A' ' 46' ' ' LEU . 17.8 ttp180 -125.73 128.13 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.135 179.301 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.469 ' NE2' HD23 ' A' ' 72' ' ' LEU . 28.2 mt-30 -69.58 145.5 52.51 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.594 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' HIS . . . . . 0.609 ' HB2' ' O ' ' A' ' 75' ' ' PRO . 22.4 t60 -63.85 113.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.842 . . . . 0.0 109.421 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 109.78 1.97 30.49 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.425 ' O ' ' HD2' ' A' ' 47' ' ' ARG . 29.1 t -114.02 154.92 26.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.241 . . . . 0.0 109.418 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -118.25 22.35 12.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.444 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.421 ' O ' ' C ' ' A' ' 54' ' ' TRP . 83.0 mt-10 -127.43 81.2 2.0 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.535 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.612 ' CD1' ' HD3' ' A' ' 47' ' ' ARG . 43.8 m95 -43.38 136.53 3.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -0.907 . . . . 0.0 109.698 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -104.91 138.48 19.52 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.84 . . . . 0.0 109.311 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.497 ' C ' HD12 ' A' ' 57' ' ' LEU . 52.7 Cg_endo -71.74 147.84 51.43 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.649 2.233 . . . . 0.0 112.113 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.62 ' HG ' ' HB ' ' A' ' 66' ' ' VAL . 8.2 mp -111.48 155.78 22.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 108.958 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 m -109.7 127.14 54.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.813 -1.179 . . . . 0.0 109.078 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 41.6 tttm -71.72 110.64 6.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.145 -0.972 . . . . 0.0 109.344 -179.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.965 ' O ' HG22 ' A' ' 63' ' ' VAL . 20.8 mttt -119.63 141.1 49.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.815 -1.178 . . . . 0.0 109.812 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.584 ' O ' ' CB ' ' A' ' 62' ' ' ASN . . . 42.52 31.08 0.97 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.584 ' CB ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER 81.88 15.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.306 -1.114 . . . . 0.0 110.362 179.292 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 60' ' ' LYS . 27.1 m -129.86 173.42 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.986 -1.071 . . . . 0.0 108.838 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 69.3 m95 -118.96 122.75 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.875 -1.141 . . . . 0.0 109.666 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.735 ' HG2' HG13 ' A' ' 29' ' ' VAL . 5.5 mt-10 -115.88 153.71 31.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.438 -0.789 . . . . 0.0 109.511 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.736 HG11 HD13 ' A' ' 46' ' ' LEU . 2.9 p -138.73 135.57 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.486 -0.759 . . . . 0.0 109.432 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.3 mttm -119.8 131.36 55.3 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 8.3 t -118.41 160.28 21.98 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.466 -0.771 . . . . 0.0 109.25 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 71.1 m -80.25 -13.87 58.87 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.145 -0.972 . . . . 0.0 109.148 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.556 ' CB ' ' HD2' ' A' ' 71' ' ' PRO . 1.0 OUTLIER -124.09 177.2 1.85 Allowed Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.369 -0.832 . . . . 0.0 109.031 179.791 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.556 ' HD2' ' CB ' ' A' ' 70' ' ' LYS . 48.5 Cg_endo -69.41 138.84 39.93 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.42 2.08 . . . . 0.0 111.678 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.675 HD13 ' HB2' ' A' ' 28' ' ' LEU . 16.2 mt -69.9 140.38 53.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.328 -0.858 . . . . 0.0 109.858 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.1 t -121.55 124.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.416 -0.803 . . . . 0.0 109.213 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' H ' HG23 ' A' ' 96' ' ' THR . . . -94.52 168.64 28.17 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.611 ' HB2' ' HA ' ' A' ' 92' ' ' GLU . 49.3 Cg_endo -69.08 146.1 79.78 Favored 'Cis proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.822 -1.741 . . . . 0.0 112.025 -0.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.624 ' CE1' ' HB3' ' A' ' 72' ' ' LEU . 73.0 m-85 -91.14 147.76 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -0.832 . . . . 0.0 110.422 -179.179 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.418 ' HB2' ' HB3' ' A' ' 47' ' ' ARG . 30.2 m-80 -108.38 142.88 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.414 -0.804 . . . . 0.0 108.91 179.103 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.872 ' CE2' HD12 ' A' ' 46' ' ' LEU . 89.1 m-85 -133.93 122.29 22.91 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.041 -1.037 . . . . 0.0 109.77 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.584 ' HG3' HG22 ' A' ' 89' ' ' VAL . 57.9 ttp180 -106.33 144.1 33.5 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.089 -1.007 . . . . 0.0 108.937 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.633 ' CE2' HG21 ' A' ' 32' ' ' ILE . 8.3 m-85 -124.69 142.76 51.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.14 -0.975 . . . . 0.0 111.502 -178.142 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.568 ' HA ' ' O ' ' A' ' 86' ' ' MET . 1.8 ttt -125.13 124.78 42.55 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' SER . . . . . 0.662 ' N ' ' O ' ' A' ' 86' ' ' MET . 21.0 p -73.59 144.43 45.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.325 -0.86 . . . . 0.0 110.544 -178.284 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.884 ' HA ' ' HB2' ' A' ' 42' ' ' ALA . 47.3 mttm -47.17 -45.18 22.63 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.414 -0.804 . . . . 0.0 109.033 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -57.64 -5.02 1.65 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 83' ' ' LYS . . . 96.61 24.72 13.11 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.662 ' O ' ' N ' ' A' ' 82' ' ' SER . 2.1 mmm -95.96 147.62 23.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.045 -1.268 . . . . 0.0 108.503 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 81' ' ' MET . 24.5 mtm180 -123.29 138.39 54.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.686 -1.259 . . . . 0.0 110.794 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.428 ' N ' ' O ' ' A' ' 80' ' ' PHE . 21.1 m120 -134.97 139.94 45.3 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.584 HG22 ' HG3' ' A' ' 79' ' ' ARG . 4.7 t -123.01 137.34 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 120.877 -1.139 . . . . 0.0 110.461 -178.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.561 ' HB3' ' CB ' ' A' ' 106' ' ' PRO . 75.1 m-85 -124.91 123.51 40.06 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -99.8 146.73 26.25 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.805 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.611 ' HA ' ' HB2' ' A' ' 75' ' ' PRO . 79.1 tt0 53.67 53.93 10.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.411 -0.806 . . . . 0.0 110.652 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.606 HG22 ' HB3' ' A' ' 106' ' ' PRO . 45.5 t -83.81 -33.92 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.866 -1.146 . . . . 0.0 109.04 179.366 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 12.5 mt -135.98 125.24 15.92 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.412 -0.805 . . . . 0.0 109.017 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.78 161.98 43.83 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.563 2.175 . . . . 0.0 112.101 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.52 HG23 ' H ' ' A' ' 74' ' ' GLY . 23.7 m -50.49 -46.33 56.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.451 -0.781 . . . . 0.0 109.966 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.72 102.61 15.22 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.09 -1.006 . . . . 0.0 109.627 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.513 ' CZ ' ' OG ' ' A' ' 23' ' ' SER . 53.7 p90 -109.85 154.36 23.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 109.353 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 73.1 p -107.97 171.96 7.1 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.545 HD13 ' CG1' ' A' ' 19' ' ' VAL . 20.9 mm -106.26 136.77 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.266 -0.897 . . . . 0.0 109.347 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 93.25 8.13 61.61 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -119.25 143.69 47.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.243 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 104' ' ' TYR . 6.9 m -77.32 174.95 10.21 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.016 -1.052 . . . . 0.0 108.827 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.616 ' H ' HG22 ' A' ' 103' ' ' THR . 26.6 m-85 -159.49 94.65 1.18 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.737 -1.227 . . . . 0.0 109.165 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.472 ' HD3' HG22 ' A' ' 16' ' ' THR . 11.8 mtmm -91.72 155.33 43.72 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.341 -0.849 . . . . 0.0 109.665 -179.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.606 ' HB3' HG22 ' A' ' 93' ' ' VAL . 51.7 Cg_endo -71.83 52.02 1.67 Allowed 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.783 2.322 . . . . 0.0 111.649 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 108' ' ' GLU . 35.7 tt0 -96.3 -51.97 4.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 107' ' ' GLU . 77.0 tt0 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.493 -179.961 . . . . . . . . 1 1 . 1 stop_ save_